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The developments in molecular medicine are leading to important insights with 
regard to lung diseases. Leading clinicians and scientists in the world have brought 
their considerable knowledge and experience, and focused research in their 
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advances in a variety of lung diseases that will enable them to better understand 
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Airway Smooth Muscle in Asthma Symptoms: 
Culprit but Maybe Innocent 
Ynuk Bossé1, Peter D. Paré1 and Yohan Bossé2 
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2Institut Universitaire de Cardiologie et de Pneumologie de Québec and 
Department of Molecular Medicine, Laval University, Quebec City 
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1. Introduction 
The main function of smooth muscle found in either the airways or in other hollow organs is 
to contract. Once stimulated to contract, the smooth muscle strives to shorten. In turn, 
smooth muscle shortening narrows the lumen of the organ it surrounds. Contraction usually 
serves a physiological purpose, such as increasing arterial tension for vascular smooth 
muscle, micturition for the detrusor muscle or parturition for the uterus muscle. However, 
for the airway smooth muscle (ASM), the shortening narrows the airway lumen, which 
concomitantly increases the resistance to airflow. So it seems that every time ASM manifests 
its function it causes respiratory distress. This had raised the question of whether its 
existence is the problem (65, 162)? 
One common respiratory disorder in which the symptoms are greatly engendered by ASM 
contraction is asthma. In fact, a proper asthma diagnosis involved testing the reversibility of 
airway obstruction with a bronchodilator, a drug relaxing ASM (usually a 2-adrenoceptor 
agonist). A positive test is indicated by complete or partial reversibility, which 
simultaneously confirms the implication of ASM shortening in asthma symptoms. However, 
we know that a judge will never blame the gun for a murder. She/he would rather blame 
the assassin that pulled the trigger. Thus, the ASM could simply be an obeisant effector 
tissue that responds to external cues that are asking it to contract. So despite being culprit in 
the elaboration of asthma symptoms it may still be ‘innocent’.  
Hence, for asthma symptoms (at least the one mediated by airway narrowing) to be 
provoked, contractile stimuli need to be present. There is no doubt about the increased 
expression of spasmogens (i.e., contractile agonists) into asthmatic airways. Histamine (251), 
leukotrienes (125), endothelin-1 (148), prostaglandin D2 (170), thromboxane A2 (249), 
adenosine (61), bradykinin (136), anaphylatoxin C3a and C5a (121), substance P (231) and 
others, are all inflammatory mediators capable of stimulating ASM contraction and were all 
shown to be overexpressed in asthmatic lungs. These spasmogens are secreted/synthesized 
following exposure to environmental asthma triggers, such as allergens, viruses, bacteria, 
fungi, air pollutants, exercise, aspirin and/or cold dry air. The nature of the environmental 
trigger involved obviously varies among asthmatics but all of them ultimately lead to a type 
of airway inflammation with inflammation-derived spasmogens. However, not everyone 
who gets inflammation into her/his airways because of a cold, because they are exposed to 
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an allergen to which they are sensitized (atopic), because they do exercise, etc… gets asthma 
symptoms. So it might not be enough to have airway inflammation to get asthma 
symptoms. If you try to kill a moose with a pellet gun, you may have the gun and you may 
pull the trigger, but you are more likely to have no responsiveness. Saying that it may also 
be necessary to be responsive, or maybe hyperresponsive, to these inflammation-derived 
spasmogens to get asthma symptoms.  
In fact, one of the pathognomonic feature of asthma is airway hyperresponsiveness (AHR). 
AHR is defined as an increased sensitivity and maximal narrowing in response to an 
inhalational challenge with a spasmogen (methacholine is the most commonly used). 
Whether AHR is a prerequisite to suffer from asthma or whether asthma is the cause of 
AHR is a contemporaneous debate and will be slightly addressed in this chapter. Some can 
argue that asthma can affect the degree of airway responsiveness and others would be just 
as right by arguing that AHR is a predisposing factor to be diagnosed with asthma. What is 
clear is that the degree of responsiveness is a good surrogate for the airway narrowing that 
will take place in vivo in response to endogenously produced spasmogens that are released 
either in normal state or during asthma exacerbation.  
In a syndrome like asthma, understanding the factors involved in AHR may give important 
clues concerning the pathogenesis of asthma and the generation of asthmatic symptoms. As 
aforementioned, this is because the symptoms of asthma are caused, to a great extent, by 
airway narrowing induced by ASM shortening. Due to its unequivocal role in airway 
responsiveness, it is clear that the ASM plays an important role in AHR; without 
responsiveness there would be no hyperresponsiveness. However, whether the ASM is 
intrinsically different in asthma and responsible for AHR is still unclear. Several ASM 
dysfunctions, but also many other defects in non-muscle factors have been suggested to play a 
role in the manifestation of AHR. Whether these defects are genetically inherited or acquired 
as a result of disease processes is also a question of great interest. This chapter is an attempt to 
outline the current state of comprehension regarding the alterations in muscle and non-muscle 
factors that may contribute to the hyperresponsive phenotype seen in asthmatics. 
2. Muscle factors  
Studying ASM mechanics involves more than measuring its force-generating capacity. 
Many other ASM contractile properties may play a role in determining the degree of airway 
responsiveness in vivo, such as shortening amount and velocity, stiffness, ability to relax and 
to tolerate and/or recover from the decline in contractility induced by length perturbations. 
The term ‘contractility’ in this chapter is vague and refers to any contractile properties. So a 
hypercontractile ASM phenotype can mean one or all of the following: the muscle is 
stronger (increased force-generating capacity), it shortens more and/or shortens faster, it is 
stiffer, it has an attenuated ability to relax either spontaneously or in response to 
bronchodilators, or has an increased ability to tolerate and/or to recover from a drop in 
contractility caused by length perturbations. In the following section, these contractile 
properties are discussed individually and the rationale for their respective involvement in 
determining the degree of airway responsiveness in vivo is described. The published 
evidences suggesting that alterations to some of these contractile properties contribute to 
AHR in asthma are also briefly reviewed. The premise, here, is that AHR would be due to 
an inherited ASM hypercontractility; not one that would be acquired due to defects in non-
muscle factors. Some of the factors discussed were addressed in a previous review (24). 
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It is worth-mentionning that the ASM has also been shown to proliferate, to migrate, to 
express adhesion molecules and receptors interacting with immune cells, as well as to 
synthesize extracellular matrix components, cytokines and chemokines. Most of these ASM 
functions were studied in monolayers of ASM cells in culture. More evidences are eagerly 
needed to confirm the existence of these ASM functions in vivo. However, if they happen in 
vivo, their relevance to asthma pathogenesis is unquestionable. These subjects have been 
reviewed lately and will not be addressed in the present chapter (18, 50, 72). 
2.1 Force 
The load impeding ASM shortening is auxotonic; i.e., it increases progressively as the 
muscle shortens. It is thus logical that greater force would lead to more shortening and 
concomitantly more airway narrowing. That is the reason why the force-generating capacity 
of ASM is such an important determinant of airway responsiveness.  
The force-generating capacity also matters because it influences other ASM contractile 
properties. The relationship between the load and the velocity can be fitted with an 
exponential decay equation; so that increasing the load decreases the shortening velocity 
exponentially. This implies that a stronger muscle would counteract a given load faster and 
would thus shorten faster. In a context where the muscle is subjected to contract under a 
progressively increasing load, as it occurs in vivo, a stronger muscle would also shorten 
further. This is because a muscle able to produce more force at any given length would 
allow the shortening to progress further before reaching a load equal to its force. A stronger 
muscle would also increase ASM stiffness, which, as discussed below (subsection 2.2), can 
have an important impact on in vivo airway responsiveness.  
The force or stress, which is the force per cross-sectional area, produced by the ASM 
depends on the potency and the concentration of the contractile stimulus involved. The 
relationship between spasmogen concentration and ASM-force can be described by a 
sigmoidal equation. So, in vivo, the amount of spasmogen reaching the ASM is one of the 
main determinants of the force produced by the muscle. The force produced by the ASM is 
also dictated by its length. Longer muscle generally generates more force in response to a 
given contractile stimulus (86, 154, 259, 261). In fact, the decrease in ASM-force caused by 
length reduction is proportional to he magnitude of the length change (103). Hence, in situ 
factors affecting the operating length of the ASM can be of considerable importance in the 
understanding of AHR, but that will be discussed later in this chapter (subsection 4.1.5).  
Regardless of the aforementioned factors, the force can also be determined by the muscle’s 
intrinsic capacity to generate force. So for a given concentration of a chosen spasmogen and 
a given length, the stress produced by the muscle can be different. This has led some to 
suggest that ASM derived from asthmatics may produce more stress than ASM derived 
from non-asthmatics, and that might be the cause of AHR. This hypothesis has been tested 
by several groups now and, although still debatable, the bulk of evidence suggests that the 
stress-generating capacity of asthmatic and non-asthmatic ASM is the same (reviewed in 
(153)). Taken together, the force-generating capacity of the ASM is certainly an important 
determinant of airway responsiveness, but no data published thus far convincingly 
demonstrate that this contractile property is altered in asthma. 
2.2 Stiffness 
In the field of ASM the term ‘stiffness’ certainly has different connotations. By definition 
stiffness is the amount of force required to cause a given change in length. The stiffness of 
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ASM can be either passive or active depending on whether the resistance to stretch stems 
from relaxed or activated components of ASM, respectively. Passive stiffness relies 
predominantly on the cell cytoskeleton. In fact, ablation of the cytoskeleton protein vimentin 
was shown to reduce passive stiffness by 3-fold (243). However, it came to experts’ attention 
that the ASM is relatively compliant. The resting tension observed along the range of in situ 
operating lengths, even when the ASM is stretched to a level comparable to the one 
observed in a lung inflated to total lung capacity (TLC), is almost neglectable. On the other 
hand, the amount of tension generated by the same stretch in the presence of an active tone 
(i.e., in the presence of spasmogens) is disproportionally greater. For this reason, we focus 
here on ASM active stiffness, since it would be the principal component affecting airway 
responsiveness. Passive stiffness can also have a broader connotation if one considers the 
other components of the airway wall and the extracellular matrix (ECM) surrounding the 
ASM cells. These other passive elements obviously impact the overall stiffness of the airway 
wall and will be addressed later in this chapter (subsections 4.1.4 and 4.1.6).  
Active stiffness is related to the level of ASM activation by spasmogenic stimuli. Its 
magnitude has always been thought to be dictated by the number of myosin heads bound to 
the actin filaments (i.e., number of cross-bridges). However, an emerging field in ASM 
suggests that other factors might play a part in active siffness. That is the level of 
interconnectivity between the ECM, the plasma membrane and the cell’s cytoskeleton. These 
points of junction are excessively important for mechanotransduction efficiency; i.e., the 
transfer of individual resistive forces to the overall stiffness of the tissue during a stretch. 
Once considered as passive, recent studies rather suggested that the structures responsible 
for this interconnectivity can rearrange extensively upon ASM cell activation (reviewed in 
(264)). For example, Zhang and coworkers (263) have shown that -actinin translocates to 
the plasmalemma and binds to 1-integrin early after acetylcholine (ACh) activation, and 
blocking this interaction reduces active tension in response to ACh (263). This and other 
recent findings (105, 188, 265) confirmed that this interconnectivity between intracellular 
proteins, the plasma membrane proteins (integrins) and the ECM relies on dynamic 
processes that are activated by spasmogens. We shall henceforth consider this level of 
interconnectivity as an integral part of the active stiffness component of ASM.  
ASM stiffness has captured the eyes of many scientists in the field recently because of its 
influence on airway responsiveness. To understand the link between stiffness and airway 
responsiveness, it is important to emphasize that ASM operates in a dynamic environment. 
The swings in transpulmonary pressure required for ventilation cause oscillating stresses on 
the airway wall, which, in turn, cause continuous variations of airway caliber. The effects of 
these oscillating strains (a strain is a change in length caused by a change in stress) on ASM 
mechanics are not small (Fredberg). In fact, in was predicted that the bronchodilating effect 
of oscillating strains at an amplitude that is thought to prevail in vivo due to tidal breathing 
is just as potent as high concentrations of a 2-adrenoceptor agonist (isoproterenol) to 
reverse airway constriction induced by different contractile stimuli (84). In fact, a single 
stretch of the airway wall at greater amplitude seems to be sufficient. Stretching the airway 
wall by taking a deep inspiration (DI) has been recognized as a powerful way to induce 
bronchodilatation and bronchoprotection (171, 222). Inversely, refraining from taking 
regular DIs has been shown to increase AHR in normal (i.e., non-asthmatic) subjects (117, 
118, 221). In the same vein, cessation of tidal breathing during breath-holding caused a 
decrease in tracheal and central bronchial diameter (165). This later observation suggests 
that the bronchodilating effect of breathing is omnipresent in vivo, and that removing the 
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oscillating airway wall strains caused by breathing allows the baseline level of ASM 
activation (tone) to constrict the airways. Finally, breathing at low lung volume has been 
shown to increase airway responsiveness (56), suggesting that not only the presence but also 
the amplitude of the airway wall strains induced by breathing impacts on the subsequent 
degree of airway narrowing provoked by a given spasmogenic challenge. Therefore, 
identifying the factors decreasing airway lumen expansion during a DI, or the factors 
limiting fluctuating strains of the airway wall during tidal breathing, such as passive and 
active ASM stiffness, are relevant to the understanding of airway narrowing and AHR. 
The decrease in airway responsiveness induced by a DI has also been mimicked ex vivo on 
isolated porcine (178) and human (177) airways. In these studies, the liquid-filled airways 
were subjected to luminal volume changes reproducing the changes in transmural pressure 
occurring during tidal breathing (from 5 to 10 cmH2O) and DIs (from 5 to 30 cmH2O). The 
authors showed that the presence of DI simulations reduces the active pressure or the 
decrease in luminal volume produced by ASM in response to different concentrations of 
ACh. 
Oscillations of airway caliber by breathing maneuvers seem to have a bronchodilating effect 
because they stretch the ASM. It was estimated that tidal breathing, sigh and DI, stretch the 
relaxed ASM by 4, 12 and 25% of its initial length, respectively (66). This is probably an 
overestimation since it was calculated based on changes in lung volume occurring during 
these breathing maneuvers while considering the lungs as isotropic material. Nevertheless, 
these length oscillations are known to decrease ASM stiffness, even during supra-maximal 
activation with ACh (66, 84, 128, 198). Importantly, the maximal force-generating capacity of 
ASM during or immediately following these oscillations is also reduced (66, 84, 85, 128, 186, 
198, 242). The decline in isometric force that ensues length oscillations has been shown to be 
proportional to the amplitude and the duration of the stretch, but not to the frequency (242). 
These results demonstrated that the force produced by ASM in response to a given stimulus 
is greater in a static environment than a dynamic environment.  
Oscillating strains at amplitude that is thought to prevail in vivo during breathing 
maneuvers also caused elongation of the contracted muscle (128, 130, 160). This later 
phenomenon is now referred to as force fluctuation-induced relengthening (FFIR). It also 
occurred in experimental settings more closely mimicking the in situ environment, where 
the ASM was subjected to an auxotonic load (186). Therefore, oscillating strains not only 
reduce the stiffness and the force-generating capacity of ASM in response to a given 
stimulus but also cause ASM relengthening. In vivo, this ASM relengthening will be 
translated into airway dilatation. The mechanisms underlying FFIR are not well understood 
but the length of the actin filaments seems to play a role (160).  
Collectively, these studies have shown that the force (66, 84, 85, 128, 186, 198, 242) and the 
stiffness (66, 84, 128, 198) of ASM, as well as the length of the contracted ASM (128, 130, 160, 
186), are affected by length oscillations (66, 84, 85, 128, 130, 160, 186, 198, 242) or simply by 
an acute stretch (242). Considering these phenomena together, one can envision the 
following in vivo vicious cycle. With exposure to spasmogens and the development of stiffer 
ASM, the same fluctuating stresses of breathing will cause less airway wall strains. This will 
allow the muscle to operate in a more static environment, where it will be able to produce 
more force and will be subjected to less FFIR. By producing more force, the muscle becomes 
stiffer, which further decreases the airway wall strains induced by breathing, and so on. 
Because the load impeding muscle shortening increases with the amount of airway 
narrowing, ASM shortening will eventually stop (when the force generated by the muscle is 
 
Lung Diseases – Selected State of the Art Reviews 
 
8 
equal to the load opposing its contraction). However, the repetitive sequence of events 
described above allows greater ASM shortening and consequently greater airway narrowing 
for any level of ASM activation. The link between stiffer ASM and AHR is thus indirect and 
explained by the fact that stiffening of ASM reduces the magnitude of airway wall strains 
(i.e., ASM stretches) caused by breathing maneuvers. In conjunction, these studies also 
suggest that the bronchodilating and bronchoprotective effect of breathing maneuvers seen 
in vivo may be due to he fact that ASM contractile properties are malleable and affected by 
straining forces.  
Having said that, the bronchodilating effect of tidal breathing does not make unanimity 
(reviewed in (176)). In systems that more closely imitate the in vivo situation, such as in a 
liquid-filled airway segment subjected to transmural pressure oscillations mimicking the 
swings in transpulmonary pressure occurring in vivo due to breathing maneuvers, only the DI 
(but not tidal breathing) was shown to attenuate the increase in pressure (178) or the reduction 
in luminal volume (177) caused by ACh stimulation. Nevertheless, it will be important to 
determine whether the stiffness of the ASM is different between asthmatics and non-
asthmatics. So far, the only evidence to support the conjecture that an increased ASM stiffness 
causes AHR comes from a study using animal cells. The ASM cells derived from the inherently 
hyperresponsive Fisher rats were shown to exhibit a higher stiffening response to a panel of 
spasmogens compared to the cells derived from the hyporesponsive Lewis rats (6).  
2.3 Tolerance to oscillating stretches and rate of recovery following length 
perturbations  
In the previous subsection, we have seen that length perturbations can greatly affect ASM 
contractility. From now on, by length perturbations we meant any of the following: a length 
change, either elongation or length reduction; a single stretch or release with an immediate 
return to the initial length; oscillating strains (length oscillations); or oscillating stresses 
(force oscillations) that is sufficient to modulate ASM length. The ability to tolerate and 
recover from these length perturbations are thus important ASM contractile properties that 
may influence the degree of airway responsiveness. The ASM’s ability to maintain its force-
generating capacity during shortening could also be important in determining the degree of 
airway narrowing. It is well-known that the ASM becomes ‘weaker’ as it shortens. So that 
the instantaneous capacity to produce force during (or immediately after a) length reduction 
is inversely proportional to the magnitude of the length change (103). This suggests that the 
force-generating capacity of ASM at shorter lengths is an important factor determining the 
extent of airway narrowing; simply because it dictates the remaining force available to 
counteract the loads which limit further airway narrowing at these new shorter lengths. 
There is currently no data comparing the decline in force caused by given reductions of 
ASM length between asthmatics and non-asthmatics. 
Since we just came to realize the potentially important role of these contractile properties in 
airway responsiveness, it is not surprising that not enough comparisons were made between 
asthmatic and non-asthmatic tissues. The only evidence that we are aware of comes from our 
group (Leslie et al., accepted in the European Respiratory Journal). In that study, tracheal 
ASM strips derived from asthmatics and non-asthmatics were isolated and their ability to 
tolerate length perturbations and to recover from them was studied ex vivo. We found that the 
decline in force caused by length perturbations was attenuated in asthmatic tissues. The length 
perturbations used were a 60% length oscillations for 10 min, which are way beyond the 
length changes that would occur in vivo. The physiologic meaning of this finding may thus be 
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questioned. However, since all tissues were exposed to the same oscillating strains, it still 
means that there is an intrinsic difference between asthmatic and non-asthmatic ASM tissues 
in their ability to tolerate length oscillations. Interestingly, other ASM contractile properties 
were also compared in that study, such as the stress-generating capacity in response to 
electrical field stimulation (EFS), the velocity of shortening, the amount of shortening and the 
ability to relax. Among all the contractile properties tested, only the ability to tolerate length 
oscillations was clearly different between asthmatic and non-asthmatic ASM. These results 
suggested that the influence of disparate ASM in determining the different degree of airway 
responsiveness observed between asthmatics and non-asthmatics would only be manifested in 
certain circumstances… such as in a human that is breathing?? These results would need to be 
confirmed by other investigators. 
The speed and the extent of force recovery following an initial decline in force induced by 
length perturbations could also contribute to the manifestation of AHR. In the  aforementioned 
study using human tracheal ASM strips (Leslie et al., accepted in the European Respiratory 
Journal), no difference in the rate and extent of recovery was observed between asthmatic and 
non-asthmatic tissues. Since the decline in force induced by length oscillations was greater in 
non-asthmatic ASM, this implies that the force produced by the non-asthmatic ASM was lower 
during the entire recovery period (which was measured for 30 min). Also worth-mentioning is 
that this time period was sufficient for the asthmatic ASM to come back to its force before 
oscillations, which was not the case for non-asthmatic tissues. Other studies have used animal 
models to study the recovery of ASM-force following length oscillations. Wang and coworkers 
(241) measured the effect of length oscillations on isometric force-generating capacity of 
tracheal ASM strips from guinea pigs of different age groups. The force was assessed before 
and immediately after length oscillations, as well as at 6-min intervals thereafter to follow both 
the change and the recovery of force following oscillations. All age groups showed a similar 
decline in force immediately following length oscillations. However, whereas the force 
produced by tissues from older animals (3 week-old and adult) recovered to pre-oscillations 
levels over a time course of ~30 min, the force produced by the tissues from the youngest 
animals (1 week-old) rapidly rose above baseline (i.e., force before oscillations) and remained 
at this higher value for the entire time-window over which force recovery was measured. The 
increase in force over baseline induced by length oscillations was called ‘force potentiation’. 
The molecular mechanisms underlying force potentiation are not well understood, but 
differential synthesis of prostaglandins seems to explain this age-dependent phenomenon in 
the guinea pig (44)). 
A phenomenon closely related to force potentiation, which was dubbed the ‘myogenic 
response’, has also been suggested as a possible contributor to AHR in humans. Marthan 
and Woolcock (144) studied asthmatic patients in whom a DI induced a decrease in specific 
airway conductance. As discussed earlier, this paradoxical response is not uncommon in 
severe asthmatics and is an indicator of marked AHR (134). They found that nifedipine, a L-
type calcium channel blocker, prevented the decrease in specific airway conductance 
induced by the DI (144). They suggested that the stretch of the ASM caused by the DI 
provoked a calcium-dependent bronchoconstriction (myogenic response).  
Taken together, it seems clear that the tolerance to the decrease in contractility induced by 
length perturbations and the ability to recover from them may play a role in determining the 
degree of airway responsiveness. However, more data are warranted to confirm that these 
contractile properties can discriminate normo-responsiveness from AHR. Studying these 
contractile properties also unveiled other phenomena, such as force potentiation and the 
myogenic response, which can also be significant in the understanding of AHR.  
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2.4 Amount of shortening and velocity of shortening  
The amount of ASM shortening is of major importance because it ultimately determines the 
amount of airway narrowing. As discussed earlier, the amount (as well as the velocity) of 
shortening depends on the ASM-force relative to the load. Therefore, all the factors influencing 
ASM-force, such as the potency and the concentration of the contractile stimulus involved, the 
quantity of spasmogens reaching the ASM, the muscle’s intrinsic capacity to generate force, 
and its length, as well as all the factors influencing the load impeding muscle shortening affect 
the amount and velocity of shortening. However, the intrinsic ability to shorten may also be 
different between asthmatics and non-asthmatics. So that under the same load and despite 
producing the same stress, the amount of shortening achieved may be different. Interestingly, 
this has been shown in isolated ASM cells (140). In that study, the authors showed that 
unloaded ASM cells derived from asthmatics shorten more at room temperature in response to 
EFS. However, this observation, which now has a decade old, still awaits confirmation. The 
underlying mechanisms involved are also unclear but decreased resistance to shortening due 
to reduction in either internal resistive load (214, 226) or stiffness (44) has been proposed. 
The shortening velocity of ASM could also be a critical determinant of the amount of airway 
narrowing. Again, to comprehend the potential implication of ASM shortening velocity in 
determining the degree of airway responsiveness, it is important to understand that ASM 
operates in a dynamic environment. The load impeding its shortening is continuously 
fluctuating due to swings in transpulmonary pressure caused by ventilatory maneuvers 
(e.g., tidal breathing and DI). The amount of ASM shortening in vivo is determined by a 
balance between the rate of cross-bridge cycling on the actin filaments causing muscle 
shortening versus the rate and the magnitude of stretch-induced disruption of cross-bridges 
causing muscle elongation (67). A faster cycling rate of the cross-bridges with a 
commensurate increased velocity of shortening would lead to more shortening during 
exhalation, when the load opposing muscle shortening is lowering. A faster rate of cycling 
would also lead to more cross-bridges being attached at the end of expiration, rendering the 
ASM and the entire airway wall stiffer. In turn, the stiffer airway wall would be less 
vulnerable to the stress imposed by the subsequent inspiration; i.e., the airway wall would 
be exposed to the same stress of breathing but the strain of the airway wall and, 
consequently, the stretch of the ASM would be attenuated in an airway with stiffer ASM. 
The combination of more shortening and more cross-bridge attachments during exhalation 
with less stretch and less cross-bridge detachments during inhalation means that the ASM 
with an increased shortening velocity would eventually reach a new equilibrium where the 
size of the airway lumen would be smaller than with a slower ASM. In addition, the airway 
wall that has reached this equilibrium becomes more static. Since ASM operating in a static 
environment produces more force in response to the same stimulus (as discussed above), it 
is possible that a faster muscle would not only cause more shortening and more cross-
bridges during exhalation, but would also becomes stronger (i.e. able to produce more force 
for the same level of activation). By acquiring more force the ASM would then be able to 
narrow the airway further during the next exhalation and… the cycle can perpetuate itself. 
This vicious cycle is likely to happen in airways possessing ASM with faster shortening 
velocity and this is the rationale behind the idea that the speed of ASM contraction could be 
the cause of AHR. 
Experimental evidences exist to support the hypothesis that a faster ASM velocity of 
shortening can contribute to AHR. The velocity of ASM shortening was shown to be greater 
in animal models in which there is innate AHR (reviewed in (132)). Similarly, there is 
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greater maximal shortening velocity in human ASM cells derived from asthmatics (140). 
Whether this increased velocity of shortening is innate or acquired due to asthma in humans 
remains to be determined. Two mechanisms have been suggested to be responsible for the 
observed increased velocity of shortening in asthmatic ASM: 1-The increased expression of 
myosin light chain kinase (MLCK) (3, 16, 133); and 2-a preponderant expression of the faster 
cycling smooth muscle myosin heavy chain (smMHC) isoform B over the slower cycling 
smMHC isoform A (reviewed in (132)).  
MLCK is a enzyme capable of phosphorylating the regulatory myosin light chain (rMLC), 
which is a necessary step required for actin-activation of myosin ATPase activity and the 
subsequent binding and pivotal of the cross-bridges on the actin filaments. The rationale is that 
faster rMLC phosphorylation caused by the increased amount of MLCK would lead to the 
activation of more cross-bridges and a faster onset and velocity of shortening at early time-
points following ASM stimulation. However, increased expression of MLCK in asthma is not a 
unanimous finding (147, 256). An alternate explanation for the increased velocity of shortening 
of asthmatic ASM is a differential expression of smMHC isoforms. The so called B isoform (also 
called the (+) insert isoform because of the presence of a 7-amino acid insert in the loop 1 of the 
protein) shows a greater rate of cross-bridge cycling in vitro (129). Its preponderant expression 
over the A isoform would likely increase the velocity of ASM shortening and, therefore, 
contributes to AHR. In accordance to this assertion, the ratio of the isoforms correlates with the 
level of airway responsiveness in rats; i.e., hyperresponsive animals expressed more of the B 
than the normo-responsive animals (73). The mRNA expression of the B isoform is also 
overexpressed in human asthmatics (133). Taken together, the amount and the velocity of 
shortening are potentially important factors determining the level of airway responsiveness. 
However, more data are needed to confirm that derangements in these contractile properties 
are involved in the manifestation of asthmatic AHR. 
2.5 Ability to relax 
ASM relaxation can also affect airway luminal diameter and the degree of airway 
responsiveness (reviewed in (69) and (44)). Just as stiffness, relaxation can have different 
connotations. It could refer to the relaxation either during or following the removal of the 
spasmogenic stimulation, as well as the relaxation induced by a relaxing agonist 
(bronchodilator). The time of onset, the rate and the extent of relaxation following 
stimulation with a relaxing agonist, or during or after the removal of the spasmogen, can 
also impact airway patency. The potential implication of impaired relaxation in asthma is 
clear. Incomplete or slower relaxation could keep the airways narrowed and, thus, prolong 
the respiratory distress experienced by asthmatics during an asthma attack. However, the 
mechanism by which impaired relaxation could contribute to AHR is not as obvious. It 
relies on the assumption that spontaneous relaxation occurs rapidly following airway 
narrowing induced by inhalational challenge with a spasmogen. Increased time for the 
muscle to relax following a spasmogenic stimulation certainly means that the airway 
luminal size will remain smaller for an extended period of time following a 
bronchoprovocative challenge and, consequently, will limit airflow during a forced 
expiratory maneuver (which is often used to assess airway responsiveness).  
The following studies provide some evidences that impaired relaxation may play a role in 
determining the degree of airway responsiveness. Altered relaxation of ASM has been 
proposed to play a role in determining inherent differences in the degree of airway 
responsiveness observed between guinea pigs of different ages (reviewed in (44)). The 
absence or presence of spontaneous relaxation in response to continuous EFS has also been 
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proposed to be a factor explaining innate differences of airway responsiveness seen in 
different strains of mice (44). The role of impaired relaxation of ASM in AHR seen in human 
asthmatics needs further investigations.  
To reiterate, contractility is defined here as a vague term that may imply different contractile 
properties. So a hypercontractile ASM phenotype may imply one or all of the following: the 
muscle may be stronger (increased force-generating capacity), it may shorten more and/or 
shorten faster, it may be stiffer, it may have an attenuated ability to relax either 
spontaneously or in response to bronchodilators, or it may have an increased ability to 
tolerate or recover from a drop in force caused by length perturbations. As seen in this last 
chapter’s section, there are currently evidences suggesting that some intrinsic defects of 
ASM can contribute to asthmatic AHR. This also suggests that being hyperresponsive could 
be a prerequisite, or at least a predisposing factor, to be diagnosed with athma. However, 
whether these intrinsic defects are genetically inherited or acquired as a result of other 
defects seen in asthmatics is still unknown. One might expect that if asthmatic AHR is due 
to inherited ASM hypercontractility, it should be encrypted into the genome? The next 
section shall explore this question. 
3. Interrogating the genome for asthma susceptibility genes 
Genetics has evolved tremendously in the last decades and is now endowed with powerful 
tools to ask questions on the etiology of complex human traits (77). Asthma and the degree 
of airway responsiveness are irrefutably complex traits. Based on genetic epidemiology 
studies, the heritability of asthma was estimated to be 40 to 60% (22). However, finding 
genes and genetic variants responsible for this important genetic component is still very 
challenging. Not only asthma is a complex trait because of its heterogeneous nature, but also 
because its manifestation relies on the exposure of an (or many) environmental trigger(s). 
Thus, a lot of noise in genetic analyses of asthma may stand from the fact that some non-
asthmatics (control cohort) are carriers of susceptibility alleles, but are not asthmatics 
because they never encountered the environmental trigger(s). In addition, maybe more than 
a single complex trait is required to develop clinical manifestations of asthma. For example, 
both AHR and airway inflammation may be required to suffer from asthma. If true, the 
noise in genetic analyses may arise from people with airway inflammation (e.g., atopy) that 
are protected from asthma symptoms because they are normo- or hypo-responsive. In fact, 
~50% of the population is atopic but most of the affected individuals are non-asthmatics. On 
the other hand, some people may be carrier of alleles that confer susceptibility to AHR, 
which also confer susceptibility to asthma, but will always be free of asthma symptoms 
because they will never develop airway inflammation. In fact, it is estimated that roughly 
15% of the population is hyperresponsive. Some of these people are asymptomatic, will 
never be diagnosed with asthma, and are counted in the control (non-asthmatic) group in 
most genetic studies despite being carriers of alleles conferring susceptibility to asthma. 
Despite these challenges, recent progress in genetics of asthma was made by genome-wide 
association studies (GWAS). These studies consist of testing hundreds of thousands of single-
nucleotide polymorphisms (SNPs) distributed across the human genome for association with a 
disease in hundreds or thousands of individuals. This genomic approach was particularly 
successful to identify robustly replicated genetic variants involved in complex diseases and 
biological traits (142). Asthma and asthma-related phenotypes are no exception and a number 
of GWAS were performed in the field (83, 104, 163, 164, 223). 
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Before the era of GWAS, more than 100 genes have been associated with asthma and related 
phenotypes (22, 183). Figure 1 shows these genes classified by their most likely 
pathobiological implication in asthma. Most of these genes were found using a candidate 
gene strategy (in blue), while fewer were found using genome-wide linkage studies (in 
green). Eleven genes were specifically studied for their possible involvement in 
bronchoconstriction and it is suspected that the risk conferred by genetic variants in these 
genes may act directly through ASM. However, for all these genes the functional 




Fig. 1. Overview of asthma susceptibility genes. Genes illustrated are reported to be 
associated with asthma or asthma-related phenotypes in at least one published study. Each 
gene is categorized according to what we believe is its major role in the pathogenesis of 
asthma. In blue and green are genes identified using candidate gene and genome-wide 
linkage studies, respectively. The latest and more robust asthma susceptibility genes are 
illustrated in red and identified using a genome-wide association approach. Complete 
references for genes in blue and green can be found in Ober & Hoffjan (183). References for 
genes in red are in the text (see section 3). The shapes and subcellular localizations are taken 
from the Ingenuity System (http://www.ingenuity.com). Genes are labeled with official 
Entrez Gene symbols, and common alias names are shown in parentheses for some genes. 
The figure is updated from Bossé & Hudson (Annu Rev Med 2007; 58: 171-84). 
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inconsistency and genetic associations illustrated in Figure 1 require validation in large 
population samples.  
In contrast to candidate gene studies, susceptibility genes derived from GWAS on asthma 
were confirmed in multiple and larger set of samples. These genes include ORMDL3, 
GSDMB, IL33, TSLP, IL18R1, IL1RL1, IL2RB, RAD50, MYB, SMAD3, CHI3L1, PDE4D, and 
DENND1B (illustrated in red in Figure 1). The specific cells and tissues that are molecularly 
altered by the risk variant in these genes are still unknown. Most of these genes are not 
known as regulators of airway responsiveness, suggesting that the genetic predisposition to 
suffer from asthma do not originate from genes altering ASM function. In fact, most of the 
GWAS-nominated asthma genes are expressed in the airway epithelium or in inflammatory 
cells, which is consistent with the growing body of evidences that asthma originates in 
subjects whose epithelium has altered response to environmental triggers and whose 
immune system is susceptible to the development of inflammation. The exception is the 
PDE4D gene found to be associated with asthma in multiple white and Hispanic 
populations (104). PDE4D is expressed in ASM and can potentially alter ASM contractile 
function, suggesting that this tissue, in addition to the epithelium and inflammatory cells, 
may influence susceptibility to asthma. 
It should be noted that we cannot rule out the contribution of other GWAS-nominated genes 
acting on ASM. We know from our previous whole-genome gene expression experiment in 
bronchial smooth muscle cells (23) that approximately half of the genes in the human 
genome are expressed in non-stimulated ASM cells (nearly 10,000 genes). Obviously other 
genes might be inducible and expressed only in a ‘sick’ environment. However, at baseline, 
in a monolayer of ASM cells, many GWAS-nominated asthma genes are expressed including 
ORMDL3, GSDMB, IL33, TSLP, RAD50, SMAD3, CHI3L1, and DENND1B. Although what 
is known about the biological functions of these genes is not pointing toward ASM as the 
primary pathobiological target, their expression in this tissue suggests that they may play a 
role. The characterization of asthma susceptibility genes derived from GWAS is currently a 
priority in the field of genetics of asthma (182). The functions of these genes in ASM, if any, 
will need to be investigated, as are the consequences of the risk variants on these functions. 
4. Non-muscle factors  
In contrast to the above, AHR may also be secondary to the asthmatic syndrome. In fact, many 
causes of AHR in asthma are attributed to alterations in the lung environment; implying that 
the ASM can be absolutely normal but would lead to AHR upon activation because it operates 
in a ‘bad’ environment. Two scenarios here are envisaged: First, AHR may develop in 
asthmatic individuals because inflammatory or remodeling changes alter ASM contractile 
properties. In those instances, AHR still relies on a defect in ASM contractile properties, as 
discussed in section 2, but they are acquired as a result of an altered environment. 
Parenthetically, the phenomena that lead to an acquired increase in contractility will be called 
here an ‘ASM behavior’ (see Figure 2). Thus, a behavior is a normal ASM’s ability to adapt to 
its surrounding environment. Some ASM behaviors are addressed in the non-muscle factors 
section of this chapter because their appearance is attributable to lung defects. This didactic 
distinction between ASM contractile properties and behaviors would become clearer along the 
remaining of this chapter. In the second scenario, certain causes of AHR are unrelated to 
genetically or acquired abnormalities of ASM but are rather due, exclusively, to lung 
alterations. In those instances, the abnormal milieu is sufficient to cause AHR in a setting 
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where none of the ASM contractile properties are altered. In the following section, we will 
describe the non-muscle factors that are potentially involved in asthmatic AHR by affecting, or 
not, the contractile properties of ASM. Four broad themes will be discussed; that is 
remodeling, airway inflammation, ASM-tone and ventilation heterogeneity. Some of the 
factors discussed below were addressed in previous reviews (24, 26).    
 
 
Fig. 2. Muscle and non-muscle mechanisms potentially involved in airway 
hyperresponsiveness (AHR) seen in asthmatic patients. Any alterations in airway smooth 
muscle (ASM) contractile properties, which can be innate or acquired as a result of lung 
defects, may participate in the development and manifestation of AHR. Lung defects can 
also contribute to AHR either directly or by fostering normal ASM behaviors, such as force 
adaptation. See text for further details. 
4.1 Remodeling 
The term ‘remodeling’ refers to any structural changes occurring in the lungs. It could be any 
alteration in the quantity, the distribution and the composition of the molecular, cellular and 
tissular constituents of the lungs. It can affect, or not, the physical and mechanical properties of 
the lung constituents. The term ‘remodeling’ is also usually reserved for structural changes that 
are permanent or fixed (relatively), such as the deposition of extra ECM components. So even if 
edema and inflammatory cell infiltrates fit into the definition of remodeling given above, these 
changes are not usually perceived as remodeling changes. They are rather the results of 
inflammatory processes that are transient and reversible in nature. Generally speaking, 
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remodeling can designate any or all of the following: epithelial metaplasia, such as zone of 
denudation, deciliated areas and goblet cell hyperplasia; fibrosis of all the airway wall layers 
but especially the lamina reticularis (the third layer of the basal lamina); vascular alterations, such 
as vessel enlargement and angiogenesis; thickening of all the layers of the airway wall including 
the epithelium, the basal lamina, the lamina propria, the ASM and the adventitia; and 
parenchymal changes, such as emphysema and breaks of alveolar attachments on the outer 
edge of the airway wall (Figure 3). Lung remodeling, especially airway remodeling, has been 
reviewed by many in the past (25). In the present chapter, we focus on the structural changes 
that have been shown or suggested to alter the level of airway responsiveness.  
 
 
Fig. 3. A cartoon of an airway half normal (on the left) and half asthmatic (on the right) to 
illustrate the various features of airway remodeling in asthma. Airway responsiveness can 
be influenced by (1) an increase in volume of mucus and/or cellular debris in the airway 
lumen, (2) fewer but deeper folds in the mucosal membrane, (3) increased volume or altered 
surface tension of the liquid layer, (4) thickening and stiffening of the basement membrane 
(BM), (5) increased ASM mass embedded in an increased fibrous network, (6) decreased 
integrity and/or (7) decreased number of alveolar tethers to the adventitia contributing to 
decreased elastic recoil, (8) increased thickness of the lamina propria, (9) increased goblet 
cell number, (10) increased vascularity and/or vascular dilatation in the lamina propria and 
adventitia, (11) increased thickness of the adventitia, and (12) increased inflammatory cell 
infiltration throughout the airway wall. From Bossé et al. Annu Rev Physiol 2010; 72: 437-62. 
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4.1.1 Epithelium integrity 
Researchers working with isolated airway segments ex vivo have long recognized that the 
concentration of spasmogens required for a given response is orders of magnitude greater 
(30 to 300-fold) when a chosen spasmogen is delivered on the mucosal side (within the 
lumen) compared to when it is delivered on the adventitial side (179). Mechanical removal 
of the epithelium in bronchial segments of dogs has also been shown to increase ACh 
sensitivity by 100 to 716-fold (159, 187). These observations suggested that the epithelium 
acts as a cellular barrier and establishes a large concentration gradient across the airway 
wall. A breach in the integrity of the epithelium would disrupt its barrier function and, 
consequently, increases airway responsiveness by facilitating the delivery of spasmogens to 
the ASM. In fact, association between epithelial permeability and airway responsiveness in 
humans has been previously reported (108); albeit this finding is not unanimous (197). 
Increased leakiness of the epithelium can be due to cellular damage and desquamation, 
which can be induced, for example, by eosinophil mobilization and activation into the 
airways. Disruption of cell-cell connectivity, by interrupting E-cadherin adhesion for 
example, can equally facilitate the delivery of spasmogens to the ASM by increasing the 
paracellular conductance (254). Many asthma stressors, such as allergens, ozone, particulate 
matters, smoke and occupational triggers have been shown to affect airway epithelial 
integrity, which may underlie their link with AHR. Alterations in epithelium integrity by 
these asthma stressors can be mediated directly, or indirectly by fostering inflammatory cell 
infiltration into the epithelium or by increasing the release of endogenous proteases (187).  
In addition to act as a physical barrier, the airway epithelium can also play a direct role in 
controlling ASM contractility. The airway epithelium has been shown to produce several 
bronchoactive substances, such as lipooxygenase and cyclooxygenase products as well as 
nitric oxide. This subject was reviewed in the past (225) and will not be discussed in detail 
here. Briefly, the combined effect of these mediators seems to be bronchodilatory and may 
thus play a protective role against airway narrowing. Collectively, these observations 
suggest that any alteration in the lungs affecting the integrity of the epithelium or the release 
of epithelium-derived bronchoactive substances may influence airway responsiveness. 
4.1.2 Vascular remodeling 
The number and size of blood vessels, as well as the vascular area, are increased in 
asthmatic airways (reviewed in (55)). Signs of dilation, congestion, endothelium leakiness 
and abnormal wall thickness of the airway vessels have also been noted, which all alter by 
different manner and different extent the normal function of these vessels. The space 
occupied by the vessels conspicuously increases airway wall thickness, but may also do so 
by changing its turgidity. It may also modify the mechanical properties of the airway wall 
and affect the pattern of airway wall folding during airway narrowing. The detrimental 
effects of these structural changes are discussed in the following subsections (4.1.3 and 
4.1.4).  
Chronic vascular alterations also have the potential to exacerbate edematous changes 
occurring in the face of inflammation (discussed in section 4.2.2). It may also alter the 
clearance of spasmogens into the airways, which can greatly affect the degree of airway 
responsiveness (151). Taken together, these results suggest that changes in number, size, 
structure and integrity of the vascular bed interwinding the airway wall can have direct or 
indirect repercussions on airway responsiveness.  
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4.1.3 Increased amount of material inner the ASM layer 
As aforementioned, all the layers of the airway wall were shown to be thicker in asthma. An 
increased amount of material inner the ASM layer amplifies the luminal airway narrowing 
for any given degree of ASM shortening. This is because of a geometrical effect. Airway 
resistance is inversely related to the luminal radius at the fourth power. So small decreases 
in radius can cause huge increases in airflow resistance. This effect is more pronounced 
when the thickening encroaches the lumen (inwardly-directed remodeling) prior 
constriction. This is because the airway lumen will be smaller to begin with. Thus, the same 
amount of ASM shortening (or the same decrease in luminal radius) would increase further 
the resistance to airflow. However, this geometric effect would also occur if the thickening 
does not encroach the lumen (outwardly-directed remodeling) prior constriction. This is 
because the luminal area decreases as the ASM shortens, but the area of the material inner 
the ASM does not; assuming that this material is uncompressible. With a greater fraction of 
the total area occupied by uncompressible material to begin with, a thicker airway wall 
would exaggerate the changes in the luminal area during ASM shortening. In other words, 
for a given change in total area (i.e., area inner the ASM layer), if more area is occupied by 
uncompressible material, more changes in the compressible area (i.e., lumen) would have to 
occur. Importantly, filling the airway lumen by inflammatory cells, mucus accumulation or 
by plasma extravasation would have the same detrimental consequence. 
In vivo, even if the material inner the ASM would be somewhat compressible, an increased 
amount of material inner the ASM layer would still contribute to AHR, unless the 
compressibility of this material is severely affected in asthma. Computation models of the 
human bronchial tree confirmed that thicker airway wall inner the ASM increases airflow 
resistance caused by any given degree of ASM activation (126). This effect may not be small. 
Wagers and coworkers have developed a computational model based on morphometric and 
functional data derived from a mouse model of allergic airway inflammation to address this 
question. They predicted that thickening of the airway wall combined with an increased 
propensity for airway closure (discussed later in subsection 4.4.2) in the ‘asthmatic’ mice 
were sufficient to explain entirely AHR, without the need of increasing ASM shortening 
(237). Taken together, any lung defect that increase the volume of material inner the ASM 
layer leads to more luminal narrowing for any given degree of ASM shortening. This is a 
good example showing that AHR may be present despite normal ASM contractility.  
4.1.4 Reduced ASM-load due to remodeling 
The load impeding muscle shortening is just as important as the force-generating capacity of 
the ASM. A weaker load will allow the ASM to shorten more but also to shorter faster for 
the same reasons as a stronger ASM would shorten more and faster against a given load 
(discussed in subsection 2.1).  
The loads impeding ASM shortening originate from different airway wall and lung 
elements. One of the most important load is the parenchymal recoil; i.e., the radial tethering 
force offered by the parenchymal attachments on the outer edge (adventitia) of the airway 
wall. In fact, this load seems to be crucial for the maintenance of intraparenchymal airway 
patency. In condition where the ASM would be fully relaxed, this load is totally 
counterbalanced by the circumferential tension of the airway wall; an inwardly-directed force 
equal to the force of recoil but acting in opposite direction. To overcome a greater recoil, more 
strain within the airway wall would be required to reach a circumferential tension equal but 
opposite to the recoil, which would mean more airway dilatation. Therefore, greater 
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parenchymal recoil leads to greater airway caliber. The extent of the recoil depends on lung 
volume, the elasticity of the parenchymal tissue and the strength of the connection between 
the airway wall and the parenchyma (the later is sometimes called the force of 
interdependence). Any lung defect affecting these parameters may influence the strength of 
the recoil at a given lung volume and, concomitantly, change airway caliber. The parenchymal 
recoil also offers an additional load during airway narrowing because the lung parenchyma is 
progressively distorted as the ASM shortens. This load can be calculated from the shear 
modulus () of the lung parenchyma, which was estimated to be 0.7 time the transpulmonary 
pressure (124), and the changes in adventitial diameter during airway narrowing, which is 
geometrically related to the changes in ASM length during shortening (126). So in addition to 
keep the intraparenchymal airways patent prior constriction, the lung recoil imposes an after-
load that further limits airway narrowing once the ASM begins to shorten. Lung defects 
previously observed in asthma, such as alveolar breaks (149) and adventitial thickening (190), 
were shown to decouple the airways from the parenchyma and affect the extent of both the 
pre- and the after-load offered by the recoil. These lung defects may contribute to AHR. 
The ECM within and surrounding the ASM bundle also affects the after-load impeding 
muscle shortening. In conditions where the muscle is fully relaxed, the circumferential 
tension (which is carrying the load of the recoil) would be born from the passive elements of 
the airway wall, including the resting tension of the ASM. However, during narrowing 
induced by ASM shortening, the load carried by the parallel elastic elements is 
progressively transferred to the ASM. This transfer proceeds until these parallel elastic 
elements are no longer in tension but in compression. At that time, they become a direct 
load impeding muscle shortening. So whether these parallel elastic elements are in tension 
and progressively transfer the load to the ASM during airway narrowing or whether they 
pass the transition from being in tension to become in compression, they still limit ASM 
shortening by increasing the after-load. If this material is stiffer for example, it would be 
carrying more load for less strain (i.e., for a given lung recoil pressure there will be less 
airway dilatation). In those conditions, while the ASM begins to shorten upon activation, a 
greater load would be transferred to the ASM for a given amount of airway narrowing. It 
will also be harder to compress this material if airway narrowing proceeds until the parallel 
elastic elements are no longer in tension but in compression. In addition, when a cell or a 
bundle of ASM shortens, its center tempts to bulge. Anything that would prevent the 
modification of cell shape required for shortening may limit airway narrowing. This load 
has been called radial constraint (190). Together, this suggests that the quantity and the 
mechanical properties of the ECM, but also any other wall constituents, within and 
surrounding the ASM cells or bundles may affect the degree of airway narrowing. In 
support of this contention, pre-treatment of airway wall strips with collagenase was shown 
to increase ASM shortening in response to a given contractile stimulus (29). This result 
suggested that degradation of the collagenous matrix in the airway wall reduces the load, 
allowing the ASM to shorten further in response to a given level of activation. 
Epithelial buckling pressure and airway wall corrugation that occur during airway 
narrowing are also believed to provide an after-load hampering ASM shortening. The 
number of mucosal folds developing during narrowing seems to be of major importance. 
The number of folds, in turn, may be determined by the flexibility, stiffness and thickness of 
the airway wall, by the stiffness and thickness ratios of the different layers composing the 
airway wall, or by structural features such as longitudinal elastic bundles (37) or blood and 
lymphatic vessels (239), which could dictate the location of the folds. More studies are 
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warranted to establish a consensus concerning the factors influencing the pattern of mucosal 
folding and how it affects ASM-load. Current evidences suggested that the number of folds 
is not different between asthmatic and non-asthmatic airways (37). 
The load impeding ASM shortening may either decrease or increase due to airway 
remodeling. Thickening and/or fibrosis of the airway wall, for instance, may protect against 
airway narrowing. Accordingly, airway reactivity was shown to correlate negatively with 
airway wall thickness in humans with asthma (155, 175). Similar observations were made in 
a mouse model of asthma (2). Therefore, even if thickening due to fibrosis can theoretically 
increase airway narrowing in response to spasmogens because of geometrical effects, airway 
wall stiffening due to thicker or more fibrotic wall may well protect against AHR. Clearly, it 
is not just the geometric effects of wall thickening that influence airway narrowing (189). 
The mechanical properties of the material that causes the thickening are also important since 
ASM has to deform this material to narrow the lumen. The composition of the ECM may 
also affect the ASM phenotype (discussed in subsection 4.1.6). 
Taken together, we have seen that the caliber of the airways embedded in the parenchyma is 
determined by the dilating force of the lung elastic recoil and the stiffness of the airway 
wall. Anything affecting the parenchymal recoil, the airway-parenchymal interdependence, 
the parallel elastic elements, the radial constraint and the pattern of mucosal folding may 
reduce (or augment) the load and, consequently, causes more (or less) ASM shortening for 
any given degree of ASM activation.  
4.1.5 Length adaptation 
A decrease in airway caliber caused by any lung defect attenuating the pre-load would 
cause a reduction in ASM length. Because the force-generating capacity of the ASM is 
proportional to its length, decreasing ASM length simultaneously decreases its force-
generating capacity. However, the ASM is endowed with an intrinsic ability to adapt to 
length changes (reviewed in (27)). This phenomenon was called length adaptation and is 
defined as the recovery of ASM force-generating capacity that was loss following length 
perturbations. Adaptation of ASM to a shorter length is particularly relevant to the 
understanding of AHR. This is because a muscle adapted to shorten length is able to 
generate more force at any given length during shortening comparatively to a muscle 
adapted to a longer length. In contradistinction, adaptation to longer length would have a 
protective effect in terms of airway responsiveness. This is a good example to show how a 
normal ASM behavior (i.e., length adaptation), may contribute to AHR by increasing a 
contractile property of the ASM (herein force).  
Length adaptation is likely to occur in different situations. Emphysema, for example, 
decreases airway caliber by reducing lung recoil, which will allow the ASM to adapt to 
shorter length. Other factors reducing lung volume such as recumbent posture (247), high 
spinal cord injury (201) and obesity could have a similar effect. However, a recent review on 
obesity and AHR (206) rather concludes that obesity has little direct effect on airway caliber 
despite reducing functional residual capacity (FRC) and expiratory reserve volume. Based on 
the authors, the expiratory flow limitation observed in individuals with low lung volume (like 
the obese) is due to an increased propensity for airway closure (discussed in subsection 4.4.2). 
That may also apply to other conditions affecting lung volume. 
Another contractile property that is affected by length adaptation is the ASM-passive 
stiffness. It was shown that the passive stiffness initially declines following a length 
reduction but slowly re-develops over time (28). However, since the contribution of ASM-
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passive stiffness to the overall stiffness of the airway wall is neglectable, it is insignificant to 
the understanding of AHR in asthma.  
4.1.6 Alterations in the composition to the ECM  
It was suggested that the phenotype of ASM cells can be switched around from a contractile 
phenotype to a synthetic/proliferative phenotype (95). ECM components are thought to 
play an important role in determining ASM phenotypes. Laminin, for example, was shown 
to be required for the transformation of ASM cells into a more contractile phenotype (233). 
The existing interplay between ECM and ASM phenotypes and functions has been the 
subject of other reviews (232). It is known that the composition of the ECM is altered in 
asthma due to either a change in the rate of ECM component synthesis or a change in the 
rate of their degradation, the later being controlled by a balance between proteases and their 
inhibitors. Taken together, this suggests that a fine balance of ECM components is required 
to keep the ASM phenotype in check. Any alteration in this balance may affect ASM 
contractility and airway responsiveness.  
4.1.7 Enlargement of ASM mass 
We came to realize that the mass of ASM is increased in asthmatic airways almost a century 
ago (106). This structural change was one of the first hypothesis advanced to explain AHR in 
asthma and has not been refuted yet. Although a recent study suggested that the increased 
ASM mass is related predominantly to cellular hyperplasia rather than hypertrophy (199), 
the exact origin of ASM enlargement is still a matter of debate. In addition to the 
possibilities of cellular hyperplasia and hypertrophy, alternative hypotheses have been 
proposed, such as myositis (i.e., inflammation of the ASM) and increased ECM deposition. 
The origin of hyperplasia is also unclear but could stem from increased proliferation, 
decreased rate of apoptosis and/or migration of ASM progenitors into the ASM bundle with 
their subsequent differentiation into ASM cells (reviewed in (25)). The role of proliferation in 
ASM hyperplasia has gained credibility recently when Hassan and coworkers (100) 
provided data suggestive of an increased rate of ASM cell proliferation in humans with 
severe asthma. Irrespective of the mechanism of ASM thickening, the increased mass could 
lead to a greater total force generation for any given level of ASM activation; assuming that 
the ASM from asthmatics produce the same stress (force per cross-sectional area) as non-
asthmatic ASM. In vivo, that would be translated into increased airway narrowing for any 
given dose of inhaled spasmogen and, therefore, AHR. 
To reiterate, asthmatic remodeling is characterized by relatively permanent changes in the 
architecture of the airways, the lung parenchyma and their interconnection. Many of these 
changes can affect, positively or negatively, the degree of airway responsiveness. The 
integrity of the epithelium and vascular remodeling may influence the delivery and the 
clearance of spasmogens toward and away from the ASM, respectively. Increased amount of 
material inner the ASM layer can increase airway narrowing by a geometrical effect. 
Decremented load impeding ASM shortening can cause more ASM shortening for any given 
degree of ASM activation. Remodeling can also promote ASM hypercontractility by 
fostering normal ASM behaviors such as length adaptation or phenotype switching. Finally, 
factors fostering the growing of the ASM mass encircling the airways may increase ASM-
force per unit of airway length. Those are all different ways by which a normal ASM may 
account for AHR in a remodeled environment. 
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4.2 Airway inflammation  
Airway inflammation is a hallmark of asthma. The use of the term ‘airway inflammation’ is 
vague though. Asthma can be characterized by different types of inflammation, which may 
be useful to distinguish for diagnosis purposes and to offer patients the optimal therapeutic 
strategy (248). There is clearly a link between airway inflammation and AHR. Interventions 
altering airway inflammation are effective in changing the degree of airway responsiveness. 
For example, AHR can be increased in asthmatics following the induction of acute 
inflammation by inhalation of allergens (47, 143) or IL-5 (218). On the other hand, reducing 
inflammation by the use of glucocorticoids attenuates AHR (reviewed in (30)).  
Airway inflammation can affect airway responsiveness by many means. It is sometime hard 
to dissociate the effect of inflammatory changes from remodeling changes, since both can 
affect features of the airway wall, such as its thickness, that participate to AHR. It is also 
hard to dissociate because of the interplay that exists between inflammation and 
remodeling. Many believe that inflammation is the cause of remodeling, as the damage 
caused by inflammation may lead to impaired repair, scaring and loss of function. For the 
sake of this chapter, we considered inflammation as the transient and potentially reversible 
changes occurring in the lungs of asthmatics following exposure to the triggering agent. We 
also consider the direct influence of asthma triggers and inflammation-derived molecules on 
ASM contractile properties.  
4.2.1 Mucus accumulation 
Any encroachment of the airway lumen, whether it is provoked by narrowing or by filling 
the lumen, causes airway obstruction, increases airway resistance and contributes to AHR. 
The mucus layer is required for normal lung homeostasis. It is recognized as a physical and 
immunological barrier protecting the host against inhaled pathogens, particulates and 
pollutants. However, its hyper-secretion can encroach the lumen and causes airway 
obstruction. Goblet cell hyperplasia (1), as well as enlargement and hyperplasia of the 
submucosal glands (16), can contribute to mucus hyper-secretion. These are remodeling 
changes but their contribution to lung dysfunction is only manifested upon exposure to 
airway stresses. In the extreme cases, mucus can also cause complete occlusion by forming 
mucus plugs, which contain, in addition to mucus, proteinaceous exudate, inflammatory 
cells and isolated epithelial cells and creola bodies (123). Complete occlusion of some 
airways severely compromises airflow into the lungs, and may thus be an important player 
in the manifestation of AHR. It also has severe repercussions on ventilation.  
The accumulation of mucus can also originate from improper clearance. Mucociliary 
clearance was shown to be slower in asthmatics (108). The cephalad transport of mucus into 
the lungs is motored by a synchronized rotational beating of the epithelial cils and by cough 
when necessary. It also relies on the integrity of a low-viscosity solution lying atop the 
epithelial cells called the periciliary liquid layer (PCL), which prevents the shear friction 
between the epithelial surface glycocalyx and the mucus layer (120). Any alteration in 
mucus clearance, such as cil diskinesia, changes in mucus consistency, overly thin PCL and 
problems associated with cough reflex can all lead to mucus accumulation and airway 
obstruction. In addition, stagnant mucus can increase the risk of infection (120).  
Mucus accumulation also increases the surface tension. It was estimated that replacing the 
normal fluid lining the epithelium of peripheral airways by mucus would increase surface 
tension by 5 folds (141). Surface tension is sometime overlook but can play an important role 
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in determining the degree of airway responsiveness. This was well demonstrated when we 
came to realize that the pressure required to achieve a given lung volume is significantly 
higher when the lung is inflated with a gas compare to when it is filled with a liquid. In 
addition to its great impact on airway resistance, surface tension also increases the 
propensity for airway closure.  In fact, a 5-fold increase in surface tension was predicted to 
be sufficient to cause airway instability and collapse (141). The influence of airway closure in 
airway responsiveness is discussed further in subsection 4.4.2. The role of surfactant in 
controlling surface tension is thus of major importance. Any alteration in surfactant caused 
by allergen exposure (51) or plasma exudation (238) is likely to affect surface tension and, 
concomitantly, lung functions (257). Finally, combined with ASM constriction, the baseline 
airway obstruction induced by mucus accumulation can synergistically increase airway 
responsiveness for geometric reasons mentioned in section 4.1.3. 
4.2.2 Edema 
Edema is a characteristic feature of inflammation. It is due to an increased permeability of 
the vessels. This increased leakiness of the vascular endothelium swells the tissue by 
fostering extravasation of inflammatory cells, as well as plasmatic fluid and proteins, into 
the interstitial tissue. It may also encroach the airway lumen. Plasma exudation onto the 
epithelial lining is increased in asthma and the extent of it is associated with the level of 
airway responsiveness (235). Many inflammatory molecules that are overexpressed in 
asthma were shown to increase vascular permeability, such as substance P, histamine and 
many others. Newly formed blood vessels are also more permeable than the existing vessels 
(10). Angiogenic remodeling seen in asthma may thus render the airways more prone to 
tumefaction.  
Edema can alter the degree of airway responsiveness by many means. Plasma exudation 
induced experimentally by infusion of saline in dogs was shown to increase airway wall 
thickness and to decrease the caliber of the airway lumen over the level achieved simply by 
increasing the vascular pressure (35). This model of airway edema suggested that both the 
airway wall thickness and the size of the lumen are affected at baseline by airway turgidity. 
These changes in lumen and airway wall geometry can severely increase the degree of 
airway responsiveness as discussed in section 4.1.3. In fact, using this dog model of airway 
engorgement by saline infusion, it was shown that airway responsiveness to histamine 
increases for the same level of ASM shortening (34). Leakage of plasma protein in the 
epithelial lining fluid can also be detrimental for airway narrowing and closure. Fibrin, for 
example, inactivates the surfactant and can increase airway responsiveness by increasing the 
surface tension (238).  
4.2.3 Inflammatory cells and molecules 
In addition to mucus accumulation and edema, which increase airway responsiveness 
mainly by changing the luminal and airway wall geometry, other inflammatory changes 
may increase directly ASM contractility.  
At the cellular level, mast cells have been linked to increased ASM contractility. The number 
of mast cells has been shown to be elevated in ASM tissues of asthmatics compared to non-
asthmatic subjects with or without other inflammatory disorders (31). The participation of 
mast cells in AHR has been suggested based on correlations observed between the 
percentage of mast cells recovered in the bronchoalveolar lavage fluid (BALF) (64) or 
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interspersed in the ASM tissue (113) and the degree of airway responsiveness. Interestingly, 
the later correlation was even stronger when the mast cells with a fibroblastoid phenotype, 
which spontaneously produce more histamine, were counted (113). It was also 
demonstrated using immunohistological sections of human airways that ASM cells that 
localized in vicinity of mast cells express higher levels of -smooth muscle actin (-SMA), 
suggesting a paracrine influence of mast cells that increases ASM contractility (255). Taken 
together, these results suggest that the release of mast cell-derived mediators or direct mast 
cell-ASM contact could contribute to AHR by making the ASM stronger.  
An earlier study also suggested that a short period of mast cell activation alone is sufficient 
to induce AHR in mice. In that study, it was shown that acute activation of mast cells by an 
anti-IgE antibody 20 min prior to methacholine (MCh) challenge increases airway 
responsiveness in wild-type naïve (i.e., non-sensitized and challenged) animals but not in 
mast cell-deficient naïve animals (146). Apart from histamine, mast cells can release a 
plethora of inflammatory mediators upon activation. As it is the case for histamine, some of 
these mediators increase ASM-tone directly by triggering ASM contraction, such as 
prostaglandin D2 and leukotrienes. It would be a hard task to distinguish the effect of 
inflammation from the effect of increased ASM-tone on airway responsiveness. This is 
because a lot of molecules that are part of the asthmatic inflammatory processes are 
spasmogens. The increase ASM-tone caused by inflammation-derived spasmogens will be 
discussed separately in a following subsection (4.3). In the present subsection, the focus is on 
the inflammatory mediators that are not spasmogenic but have been shown to increase ASM 
contractility. 
At the molecular level, several asthma triggers have been shown to increase ASM 
contractility ex vivo. For example, ASM contractility has been shown to be enhanced 
following prolong (at least 16 h) incubation with atopic serum (15, 19, 78, 89, 91, 161, 211, 
245, 246), IgE immune complex (80, 89, 250) and exogenous asthma triggers such as the 
house dust mite allergen Der p 1 (82), the bacterial endotoxin lipopolysaccharide (LPS) (8, 
166, 216, 220) and the rhinovirus (serotype 16) (78, 81) or the virus mimetic toll-like receptor 
(TLR)3 ligand polyinosinic polycytidylic acid (poly-IC) (8). Most of these studies assessed 
ASM contractility by measuring its force-generating capacity. However, some studies also 
reported that some of these inflammatory insults change the velocity and amount of 
shortening of the ASM in response to a spasmogen (161), as well as its ability to relax in 
response to bronchodilators (8, 15, 78, 81, 89, 216). The half-time of relaxation after short 
EFS-induced tetani has also been shown to increase (double) in ASM strips derived from 
dogs sensitized to ragweed (109).  
The effect of asthma triggers on ex vivo ASM contractility can be indirect; i.e., due to an 
autocrine loop of mediators that are produced by the ASM in response to asthma triggers 
(79, 80, 91, 166). In vivo, the paracrine influence of other cells that are responsive to asthma 
triggers can also impact ASM contractility. Ultimately, all the inflammatory mediators 
overexpressed in asthma, whether they originate from other cells or from the ASM itself, can 
contribute individually or in combination to ASM hypercontractility and AHR. Supports for 
this contention are accumulating. Cytokines such as interleukin (IL)-1 (11, 92, 200, 250), 
tumor necrosis factor (TNF) (4, 7, 167, 168, 172, 191, 193, 200, 227), the combination of 
TNF and IL-1 (90, 92), IL-13 (41, 62, 80, 228), IL-5 (93, 250), IL-10 (79), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (94), interferon (IFN) (5), leukemia 
inhibitory factor (LIF) (63, 119) and transforming growth factor (TGF) (75, 255), as well as 
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the protease -tryptase (212, 255) were shown to increase ASM contractility. In turn, the 
effect of these mediators is not always direct. For example, the potentiating effect of IL-1 on 
bradykinin-induced contraction is due to a greater release of thromboxane (Tx)A2 in response 
to bradykinin (166). As for the asthma triggers, most of these studies assessed ASM 
contractility by measuring its force-generating capacity. However, inflammatory mediators 
found in asthmatic airways can also impair ASM relaxation. For example TNF (90, 92), IL-1 
(90, 92), IL-13 (127), IL-10 (79), IL-5 (79) and lysophosphatidic acid (LPA) (230) have all been 
shown to attenuate ASM relaxation elicited by 2-adrenoceptor agonists. In addition, TNF (9, 
92) and IL-1 (92) were shown to attenuate the relaxant effect of prostaglandin (PG)E2.  
The molecular mechanisms governing the transformation of ASM into a hypercontractile 
phenotype may differ from one inflammatory mediator to another. In the case of TGF, 
increased expression of the contractile protein -SMA and actin filamentogenesis have been 
proposed (75, 76). On the other hand, many inflammatory mediators increase ASM 
contractility through shared mechanisms related to alterations in calcium handling; either 
by Ca2+ sensitization via the Rho-ROCK pathway or by increasing the intracellular 
mobilization of Ca2+ via the CD38/cADPR/RyR pathway (both briefly described below and 
illustrated in Figure 4).  
Ca2+ sensitization is a phenomenon that allows the ASM to produce more force in response 
to a given mobilization of intracellular calcium concentration ([Ca2+]i). Ca2+ sensitization 
seems to rely mainly on a signaling pathway running in parallel to canonical Ca2+ signaling 
pathways (inositol 3-phosphate receptor (IP3R)-dependent and entry from the extracellular 
compartment). The pathway is referred to as the Rho-Rho-associated, coiled coil-containing 
kinase (ROCK) pathway and is activated by certain G protein-coupled receptors (GPCRs) 
following ligation with their cognate spasmogen (see Figure 4). Rho is a small G (GTPase) 
protein activated by the exchange of GDP for GTP. The identity of the guanine exchange 
factor (GEF) that is activated by the GPCR and involved in Rho activation is unclear, and is 
probably receptor specific. However, one of the downstream signals mediated by Rho that 
leads to Ca2+ sensitization is well characterized. GTP-bound (active) Rho initially activates 
ROCK, which then inhibits myosin light chain (MLC) phosphatase (MLCP) both directly, via 
phosphorylation of the myosin phosphatase-targeting subunit 1 (MYPT1) of MLCP, and 
indirectly, via CPI-17 (17-kDa PKC-potentiated inhibitory protein of PP1; PP1 stands for 
protein phosphatase 1, which is the catalytic subunit of the heterotrimeric MLCP). Since the 
level of MLC phosphorylation depends on a balance between its phosphorylation by MLCK 
and its dephosphorylation by MLCP, direct or indirect inhibition of MLCP by ROCK causes 
more MLC phosphorylation for the same degree of MLCK activation. Therefore, when the 
Rho-ROCK pathway is activated, the same degree of MLCK activation induced by a given 
sarcoplasmic Ca2+ mobilization leads to more MLC phosphorylation and sequentially more 
activated cross-bridges and more force.  
AHR in animal models of airway inflammation has been attributed to an increased ASM-
sensitivity to Ca2+ (40, 43). Ca2+ sensitization is more typically triggered by inflammation-
derived spasmogens (discussed in section 4.3.1), which bind to GPCRs capable of activating 
the Rho-ROCK pathway. However, non-spasmogenic inflammatory mediators such as 
TNF have also been shown to potentiate ASM-force by fostering Ca2+ sensitization (107, 
172, 191). In addition, the extent of Ca2+ sensitization can be regulated by mediators affecting 
the levels of expression or activation of key regulatory proteins involved in the Rho-ROCK 
pathway. For example, IL-13 (41) increases the level of RhoA expression in ASM, which 
consequently increases the proficiency of Rho-ROCK signaling pathway to induce Ca2+   
 







Fig. 4. Pathways transducing the extracellular signal of the spasmogens from their cognate 
cell-surface receptor to the contractile apparatus. See text for descriptions and abbreviations. 
The green and red dots represent Ca2+ and Na+, respectively. The reverse mode of the 
Na+/Ca2+ exchanger (NCX) is shown. Reproduced with permission from: Bossé and Paré. 
Airway smooth muscle responsiveness: The origin of airway hyperresponsiveness in 
asthma? Current Respiratory Medicine Reviews. 7(4): 289-301, 2011. 
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sensitization. On the other hand, mediators capable of reducing the expression/activity of 
intermediate proteins involved in this pathway may have therapeutic potential for 
diminishing Ca2+ sensitization and AHR. One example is the effect of glucocorticoids in 
reducing the expression of RhoA, which concomitantly attenuates antigen-induced ASM 
hyperresponsiveness in a rat model of allergic airway inflammation (40). 
In addition to canonical Ca2+ signaling pathways, at least one other Ca2+ signaling pathway 
contributes to the release of Ca2+ into the sarcoplasm (see Figure 4). This pathway is referred 
to as the CD38/cyclic adenosine-5'-diphosphate (ADP) ribose (cADPR) signaling pathway 
and has received significant attention recently in regard to its potential role in AHR. CD38 is 
a type II transmembrane protein of 45-kDa with dual ecto-enzymatic activity. It possesses an 
ADP-ribosyl cyclase activity, converting -NAD into cADPR and a cADPR hydrolase 
activity, converting the cADPR into ADPR. The product of the ADP-ribosyl cyclase activity, 
cADPR, sensitizes the ryanodine receptor (RyR) for Ca2+ release and, more specifically, 
potentiates Ca2+-induced Ca2+ release (CICR) (70). Whether cADPR binds directly to RyR or 
requires other intermediates to open the RyR channel is still a matter of debate (54). What is 
sure is that cADPR increases the open probability of the RyR, liberating more Ca2+ from the 
sarcoplasmic reticulum (SR) (196). As is the case for IP3R-dependent Ca2+ release, the CD38 
pathway is also activated by binding of specific spasmogens to their cognate receptors (252). 
Thus, this pathway acts in parallel with the canonical Ca2+ signaling pathways to amplify 
the mobilization of Ca2+ into the sarcoplasm following spasmogenic stimulation.  
The amplitude of Ca2+ release by the CD38/cADPR/RyR pathway, as well as its 
contribution in ASM-force generation, is influenced by CD38 expression. CD38 expression 
and/or activity were shown to be upregulated by many of the pro-inflammatory cytokines 
present in asthmatic airways, such as IFN (229), IFN (53), TNF (53, 229), IL-1 (53) and 
IL-13 (52). Therefore, in the presence of inflammation, the proficiency of this signaling 
pathway to liberate the Ca2+ from the internal stores may be enhanced. Consequently, 
higher force generation would be attained for a given contractile stimulus since more Ca2+ 
would be released. The influence of inflammatory mediators on the CD38/cADPR/RyR 
pathway may thus play a role in AHR seen in asthma.  
Taken together, these results suggested that the contractile properties of ASM are not fixed 
but rather plastic; i.e., they can change rapidly in the face of external (inflammatory) cues. So 
in an inflammatory lung disorder such as asthma, the ASM may be stronger or faster, for 
example, because of the ‘bad’ environment in which it is embedded. This increased 
contractility may only be present in vivo when the muscle is exposed to inflammation-
derived mediators, but might be lost once the muscle is removed from the airways and 
washed repetitively before being studied ex vivo. These results may offer an explanation for 
the failure of ex vivo studies to show an increased strength of ASM from asthmatics 
(reviewed in (153)). The ability of ASM to rapidly change its contractile capacity in response 
to inflammatory molecules can also contribute to changes in airway responsiveness 
observed in response to interventions altering airway inflammation (30, 47, 143, 218). Those 
are all different ways by which a normal ASM may account for AHR in an inflamed 
environment. Another way by which inflammation can increase airway responsiveness is by 
producing spasmogens, which increases ASM-tone. 
4.3 Increased ASM-tone 
The responsiveness of asthmatics to bronchodilators, together with more direct evidence 
(165), indicate that ASM-tone is increased in asthmatic airways. The origin of this 
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augmented ASM-tone is not clear and likely varies between asthmatic individuals. 
Nonetheless, asthmatic lungs are characterized by the overexpression of inflammation-
derived spasmogens. These spasmogens trigger sustained ASM contraction and, acting 
individually or collectively, are a likely cause of increased ASM-tone in asthma. In the 
present subsection, we discuss the mechanisms by which inflammation-derived 
spasmogens, together with the attendant increase in ASM-tone, can contribute to AHR.  
The rationale is that the amount of airway narrowing in response to a given concentration of 
a chosen spasmogen (e.g., MCh) is due to the combined effect of this extrinsically delivered 
spasmogen plus the baseline tone, which is caused by the endogenous spasmogens already 
present. In other words, it is the cooperative effect of all the spasmogens present at the time 
of the challenge that determines the total level of ASM activation and, ultimately, the 
amount of airway narrowing achieved. In addition, one of the causes of AHR can be the 
contractile synergistic interactions that are often observed when different spasmogens are 
used in combination. In this regard, a sizable literature exists documenting contractile 
synergisms between different spasmogens (Table 1). The mechanisms involved in these 
synergistic interactions have been debated in the last few decades and it is now clear that all 
the mechanisms that may be involved are not mutually exclusive. The nature of these 
interplays can give us important clues regarding the role of baseline airway tone in 
determining the degree of airway responsiveness.   
4.3.1 Interactive synergisms between spasmogens  
Initial studies in that area begin in the late 1970s and have started by looking at the 
combined effect of spasmogens on different measures of lung function in animals (45, 46, 57, 
99, 102, 112, 131, 152, 180, 181, 192, 208, 209, 224, 244), as well as in humans (49, 68, 97, 101, 
110, 156, 158, 194, 202, 240). Apart from an interactive synergism at the level of ASM 
contraction, many other factors can account for these in vivo interactive synergisms. In fact, 
although these synergistic interactions can be extremely relevant to the understanding of 
AHR, the mechanisms involved are sometime impossible to delineate.  
First, the interactions between spasmogens were assessed in vivo by measuring airway 
resistance (or conductance) and/or flow parameters (flow rate at different lung volumes, 
forced expiratory volume in 1 sec (FEV1), etc...). All of these measurements are geometry-
dependent. As mentioned earlier, airway resistance is inversely proportional to the luminal 
radius at the 4th power. The potentiation of the effect of one spasmogen by another 
spasmogen (or an increased baseline tone) might be related to a geometrical effect more than 
a true synergistic interaction of spasmogens on ASM-force. In other words, an additive 
effect at the level of muscle activation that may result in an additive effect in terms of ASM-
force generation and shortening can be perceived as a synergistic effect when looking at 
airway resistance.  
To circumvent these limitations, others have used in situ preparations allowing the 
assessment of tracheal smooth muscle-isometric force (12, 33, 131) or have measured airway 
caliber using tantalum bronchography (17). Some of these studies confirmed the synergistic 
effect of spasmogens on airway narrowing and ASM-force generation. However, these 
results are also confounded by the acute effect of some spasmogens on vessels and nerves, 
or by the effect of some spasmogens on airway inflammation and the epithelium. In regard 
to the vessels, many airway spasmogens also have vasoactive properties. Both 
vasoconstrictors and vasodilators have significant impact on the degree of airway   
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Mediators in vivo ex vivo in vitro 
ET-1 CCh (180) in sheep;  




MCh or CCh) 
HIST (158) in humans; 
HIST (131) and 
NE (33) in dogs 
HIST (71), 5-HT (71) and NE (87, 
185) in canine tracheal SM strips  
 
HIST MCh (158) and HIST (97) 
in humans  
MCh (131), ACh (33) and 
NE (12, 33, 131) in dogs 
MCh (71), ACh (87), 5HT (87) and 
NE (12, 87) in canine tracheal SM 
strips;  
CCh (135) in bovine tracheal 
strips 
 
AII MCh (156) in humans;  
MCh (244) in guinea pigs 
 
MCh (156) in human bronchi;  
ET-1 (32, 173, 174, 195) in bovine 
bronchi;  
CCh (203, 204), K* (204) and NaF 
(204) in rat bronchial rings  
 
5-HT NE (12, 33), HIST (57), 
ACh (57) in dogs 
 
MCh (71), ACh (87) and NE (12, 
87) in canine tracheal SM strips;  
CCh (135) in bovine tracheal strips 
 




HIST (131) in dogs;  
HIST (208) and bombesin 
(208) in guinea pigs 
  
ATP  MCh (184) in guinea pig tracheal 
strips 
 
Adenosine HIST (224) in guinea pigs   
Dopamine HIST (208) and bombesin 
(208) in guinea pigs 
  
TXA2 (or its 
pharmacological 
analog U46619) 
MCh (110) in humans   
PGD2 HIST (68, 97) and MCh 
(68) in humans 
  
PGE2  CCh (38) in bovine tracheal strips  
PGF2 HIST (101, 240) in 
humans 
CCh (38) in bovine tracheal  
8-isoprostanes MCh (102) in mice K+ (38), CCh (38, 135) and 





MCh (49, 202) in humans; 
LTD4 (192) in rhesus 
monkeys; 
ACh (46) in dogs;  
HIST (45) in sheep;  
HIST (152) and bombesin 
(209) in guinea pigs  
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Mediators in vivo ex vivo in vitro 
LTB4 ACh (181) in dogs   
Cys-LTs HIST (194) and PGD2 
(194) in humans;  
PAF (192) in rhesus 
monkeys 
K+ (215) and CCh (215) in porcine 
tracheal strips;  
ET-1 (195) in bovine bronchial 
rings;  
ACh (48) and HIST (48) in guinea 
pig tracheal rings 
 
S1P  MCh (122) in guinea pig tracheal 
strips;  
K+ in bronchial rings from normal 
but not antigen-challenged mice 
(42) 
 
LPA  MCh (230), 5-HT (230), SP (230) in 
rabbit tracheal rings;  
MCh (230) in cat tracheal rings;  









PA  MCh (230) in rabbit tracheal rings  
Abbreviations in the table: AII, angiotensin II; ACh, acetylcholine; ATP, adenosine triphosphate; BK, 
bradykinin; CCh, carbachol; Cys-LTs, cysteinyl-leukotrienes; ET-1, endothelin-1; HIST, histamine; 5-HT, 
5-hydroxytryptamine (also called serotonine); K+, potassium; LPA, lysophosphatidic acid; LTB4, 
leukotriene B4; MCh, methacholine; NaF, sodium fluoride; NE, norepinephrine; PA, phosphatidic acid; 
PAF, platelet activating factor; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF2, prostaglandin 
F2; SM, smooth muscle; SP, substance P; S1P, sphingosine-1-phosphate; TXA2, thromboxane A2. 
Table 1. Interactions between spasmogens increasing ASM contractility 
responsiveness (151). The potentiating effect of histamine on the responsiveness to 
muscarinic agonists (33, 131), for example, can likely be due to its vasodilating effect, 
especially when the drugs are administered intravenously or via the tracheal vasculature. 
This is because vasodilatation facilitates the delivery of the bronchoactive substance (ACh) 
to the ASM. Histamine also increases airway epithelium permeability by altering E-
cadherin-based adhesions (262). The effect of a second inhaled spasmogen may thus be 
potentiated by histamine pre-treatment because the second spasmogen will have easier 
access to the ASM. 
In regard to the nerves, many studies have shown synergistic interactions between 
spasmogens and electrical stimulation of the vagal nerves (17, 33, 57, 88, 114, 137, 217, 258). 
Similarly, a decrease in responsiveness to spasmogens (other than ACh (88)) was observed 
following vagotomy (59, 137, 157, 258), cooling of the vagal nerves (58, 88), or treatments 
with either atropine (59, 219), tetrodotoxin (219) or hexamethonium (59). These results 
suggest that the basal cholinergic tone synergistically interacts with the exogenously 
delivered spasmogen. These studies are not included in Table 1 because it is not clear 
whether the potentiating effect is due to a true synergistic effect at the level of ASM-force 
generation or due to the ability of the spasmogens to either trigger a vagal reflex (36, 58, 74, 
157) or to increase cholinergic neurotransmission and/or synaptic transmission at the 
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ganglia (217). These latter phenomena would lead to more ACh release and concomitantly 
higher ASM activation for the same neural input. On the other hand, the 
bronchoconstricting effect of spasmogens is known to decrease the vagal tone (13, 210). This 
is because of their indirect effect on the slowly adapting stretch receptors (SARs), which, 
upon an enhanced discharge, relax the ASM by reducing parasympathetic tone to the 
airways. However, other spasmogens, such as bradykinin, would synergize with the effect 
of these mechanoreceptors via C-fibers activation to initiate the bronconconstricting reflex 
(150). Together, the influence of the nervous system is intricate and certainly a major 
confounding factor in vivo when one tries to elucidate the synergistic interaction between 
spasmogens.  
Finally, thickening of the airway wall by edema and inflammatory infiltrates, encroachment 
of the airway lumen by mucus hypersecretion and cellular debris, and reduction in the 
forces of interdependence between the airway wall and the lung parenchyma by the 
accumulation of inflammatory exudates in the adventitial layer are all means by which 
airway inflammation can increase airway responsiveness without affecting ASM-force 
(reviewed in (26)). Therefore, the hyperresponsiveness observed in response to the second 
spasmogen, when the first spasmogen is administered hours before the second spasmogen 
(180), may be due to the inflammation provoked by the initial spasmogen.  
To avoid these confounding factors and to investigate whether the synergistic action of two 
spasmogens on airway responsiveness relies on mechanisms operating at the level of ASM, 
the only solution is to study the ASM tissue in isolation. Many investigators have focused on 
this strategy. Most studies were performed using freshly dissected ASM strips or bronchial 
rings from which isometric force was measured ex vivo (12, 32, 38, 48, 71, 87, 98, 122, 135, 
156, 173, 174, 184, 185, 195, 203, 204, 215, 230). In vitro preparations (i.e., cell culture) have 
also been used on occasions (205). These reported synergisms are also enumerated inTable 1.  
The molecular mechanisms involved in contractile synergisms observed between different 
pairs of spasmogens have been extensively studied. The synergisms involve the co-activation 
of ASM by two spasmogens acting on two distinct GPCRs. The activation of two distinct 
GPCRs can lead to intracellular signaling synergisms that ultimately potentiate ASM-force. 
The more commonly discussed mechanism is Ca2+ sensitization, defined as an increased ASM-
force generation in response to a given amount of intracellular Ca2+ mobilization (as discussed 
in subsection 4.2.3). Many spasmogenic mediators, such as leukotriene C4 (215), isoprostanes 
(135), ATP (184), endothelin-1 (260), LPA (205), TxA2 (167) and S1P (122), have been shown to 
increase the responsiveness of the contractile apparatus to Ca2+.  
However, these synergisms in terms of force generation can also be related to an additive 
effect in terms of ASM activation, especially when the concentrations of spasmogens used 
are low. This is because the dose-response curve to any spasmogen is sigmoidal, regardless 
of whether the response is measured in terms of ASM-force or shortening. That means that 
initially, a threshold concentration is needed before any response can be measured, but then 
there is a progressive increase toward a steeper, relatively linear slope followed by a 
progressive decrease in slope to reach a plateau. When two different spasmogens are used 
in combination, their additive effect on ASM-activation could be erroneously interpreted as 
being synergistic because sub-threshold concentrations of two spasmogens could have a 
measurable effect on ASM-force or shortening. Similarly, if one uses a concentration just 
above the response threshold, the subsequent addition of a different or the same spasmogen 
will have more effect simply because it is now acting on the steeper part of the dose-
response curve. In fact, many of the previously documented examples of ‘synergism’ 
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performed either in vivo (110, 112, 131, 158, 244) or ex vivo (38, 71, 87, 135) were involving 
low concentrations of spasmogens, and were unable to demonstrate a synergism at higher 
concentrations for at least some of the reported spasmogenic interactions (71, 87, 131). So the 
level of basal tone, even if low, can seemingly synergize with the extrinsically delivered 
spamogen to cause AHR simply by an additive effect at the level of ASM activation 
Collectively, the force potentiation of one spasmogen (or baseline tone) on another 
spasmogen can be due to many factors such as: 1-use of sub-threshold or barely active 
concentrations of spasmogens, which simply act additively in terms of ASM activation but 
will be perceived as being synergistic in terms of ASM-force, ASM shortening, airway 
narrowing or airway resistance; 2-use of geometry-dependent measurements such as airway 
resistance; so that the effect of the second spasmogen is augmented by the reduced airway 
caliber caused by the first spasmogen; 3-a synergistic effect due to the contribution of 
vascular, neural or inflammatory effects when tested in vivo or in situ, which can be 
observed when the spasmogens used have vasoactive and inflammatory activities or when 
they can trigger either a vagal reflex and/or an increase in the efferent cholinergic traffic; 
and 4-a true synergistic effect on myosin cross-bridge cycling due to the convergence of 
intracellular signaling pathways that are activated by the ligation of two distinct GPCRs 
(such as Ca2+ sensitization).  
4.3.2 Force adaptation 
There is an additional, more subtle way by which the tone can contribute to AHR. Recent 
studies from our laboratory have demonstrated that a short period (~30 min) of increased 
ASM-tone augments ASM strength over time (20, 21). Specifically, ASM was exposed to 
ACh and ASM-force generation in response to EFS was monitored both before and after the 
induction of the ACh-induced tone. The first EFS in the presence of tone was given 1 min 
post ACh administration and then at 5-min intervals thereafter. Addition of ACh 
immediately increased the total force (ACh-induced tone + EFS-induced force), suggesting 
that ASM generates more force in response to two sub-maximal stimuli (ACh + EFS) 
compared with EFS alone. More surprisingly, while the EFS-induced force decreased 
immediately following the administration of ACh, it recovered significantly over time. Since 
the tone produced by the exogenous ACh remained relatively constant, the total force 
increased over time. We termed this phenomenon ‘force adaptation’ (20). The potential 
significance of force adaptation on airway narrowing based on a computational model has 
been demonstrated recently (Bossé et al., in press in the journal of Respiratory Physiology & 
Neurobiology).  
Force adaptation is distinct from the synergisms in force that were attributed to the 
convergence of intracellular signaling pathways described above, which occur as a result of 
activation of two distinct GPCRs. This form of synergism cannot occur when ACh is 
combined with activation of the ASM by EFS, which was the experimental setting that was 
used to describe force adaptation. This is because EFS triggers ASM contraction by releasing 
ACh from the nerve endings (145), which, in turn, binds on the same M3 receptor as the 
exogenously administered ACh. In fact, all studies investigating the acute effect of a 
muscarinic agonist on EFS-induced force have failed to show a synergistic effect (57, 114). 
Therefore, despite abundant literature reporting synergistic effects between spasmogens on 
ASM strength, force adaptation is a phenomenon with no precedent.  
The molecular mechanisms involved in force adaptation are also likely to be different from 
those described above because it occurs over minutes. This time-course would be too fast for 
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de novo gene expression; so it is not likely due to transcriptional activation of genes involved 
in ASM contraction induced by the initial tone. On the other hand, if it was due to 
biochemical events such as increased phosphorylation of MLC due MLCP deactivation 
leading to Ca2+ sensitization (as described in subsection 4.2.3), the potentiating effect would 
be very fast and seen at the first EFS following ACh administration (1 min). Taken together, 
the kinetic of force adaptation is too slow to be explained by fast biochemical reactions, such 
as protein phosphorylation, but too fast for de novo gene expression. We thus suggest that 
this time-dependent increase in ASM-force is due to post-translational mechanisms. All the 
necessary machinery responsible for this increased ASM-force might be present within the 
cell prior to activation, but it is only upon stimulation (i.e., induction of tone) that this 
protein machinery re-organizes to optimize generation of force. Processes such as actin (264) 
or myosin (213) filamentogenesis and/or re-arrangement of the cytoskeleton and its 
connectivity with the contractile apparatus, the plasmalemma and the ECM (264) are likely 
possibilities. However, these remain pure speculations as the mechanisms underlying force 
adaptation have never been investigated. 
4.3.3 Increased tone on airway wall stiffness 
Apart from ASM-force, increased ASM-tone can also impact other ASM contractile properties. 
For instance, stiffness is greatly enhanced upon ASM activation. By increasing ASM stiffness, 
an increased tone would reduce the strains experienced by the airway wall due to the cyclical 
stresses of breathing. Interestingly, Noble and coworkers (178) have demonstrated that the 
amount of airway wall strain induced by a DI is proportional to its bronchodilating effect 
(178). They also showed that the main factor limiting the strain was the magnitude of ASM-
tone, which was controlled by delivering different concentrations of ACh. These observations 
suggested that the ASM needs not only to be stressed but to be stretched for a DI to be effective 
in reducing ASM contractility. They concluded by saying that a stiffer airway caused by an 
increased ASM-tone reduces the strain induced by the dynamic load associated with DI and, 
for this reason, reduces the bronchodilating effect of a DI.  
Taken all together, these observations suggest that baseline tone is of crucial importance in 
determining the degree of airway responsiveness to an inhalational challenge with a 
spasmogen. The increased tone observed in asthma can be from inflammatory and/or vagal 
origin. In both cases, this increased tone acts additively with the extrinsically delivered 
spamogen in terms of ASM activation, force generation, ASM shortening and airway 
diameter narrowing. This can also be translated into a synergistic effect when geometry-
dependent measurements are taken, such as airway cross-sectional area of the lumen or 
airflow resistance (or other measurements relying on it, such as peak expiratory flow (PEF), 
FEV1, …). In cases where the increased tone is mediated by inflammation-derived 
spasmogens, the potentiating effect of increased tone on airway responsiveness can also be 
due to a vascular effect, a neural effect, an inflammatory effect and/or an increase in ASM-
force caused by either Ca2+ sensitization or force adaptation. Finally, augmented tone also 
increases ASM stiffness and, concomitantly, airway wall stiffness, which can further 
enhance airway responsiveness by many ways as discussed in subsections 2.2 and 2.3. 
4.4 Heterogeneity 
To assess airway responsiveness airway resistance is measured at the mouth using the 
forced oscillation technique or, alternatively, flow parameters are measured using standard 
spirometry. These measurements take into account airway resistance but also lung tissue 
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and chest wall resistance. Since chest wall resistance does not change during 
bronchoprovocation, and lung tissue resistance does not change by much, the progressive 
increase of resistance occurring in response to increasing doses of a spasmogen is thought to 
reflect changes of airway caliber. In other words, the change of resistance along the course of 
a challenge is viewed as being due to airway narrowing caused by ASM shortening. 
However, even this change of resistance is intricate. This is because this resistance 
represents represents the combined resistance of all generations of airways arranged in 
series and in parallel. Therefore, simply looking at the factors affecting resistance in a single 
airway, as we have done since the beginning of this chapter, may not be sufficient to 
understand the full nature of airway responsiveness.  
4.4.1 Mathematical link between airway narrowing heterogeneity and airway 
responsiveness  
The link between heterogeneity and AHR was initially though as being simply due to 
geometric considerations. As aforementioned, the relationship between airway luminal 
radius and resistance to airflow is not linear. A decrease in radius causes an exponential 
increase in airway resistance. For this reason, even if the total cross sectional area within a 
given airway generation is the same, inhomogeneous airway caliber increases airway 
resistance. In other words, the increase in resistance caused by narrowing of some airways is 
not compensated for by the decrease in resistance caused by dilation of other airways. 
Airway narrowing heterogeneity upon a bronchoprovocative challenge with a spasmogen 
will have the same consequence. So that the increases in resistance caused by augmented 
narrowing in some airways are not compensated for by the attenuated increases in 
resistance caused by reduced narrowing happening in other airways.  
The consequences of baseline heterogeneity on baseline resistance and of non-homogeneous 
airway narrowing on airway responsiveness were predicted based on computational 
models. Bates (14) was one of the first to address the issue of heterogeneity. He developed a 
stochastic model of the airway tree in which the values of airway radii within every airway 
generation were chosen randomly according to a probability distribution function. The 
mean values were based on realistic values (morphometric data of human lungs). He found 
that, while the mean values were kept the same, increasing the standard deviations 
progressively leads to greater airway resistance. This suggested that the simple presence of 
heterogeneity increases airway resistance. The model further predicted that, upon ASM 
activation, both baseline airway caliber heterogeneity and ASM shortening heterogeneity 
increase airway responsiveness. Obviously, this is only true if one assumes that the flow is 
not redistributed into more patent airways.  
More sophisticated computational models have then been developed and brought 
additional insights about the origin of this increased resistance evoked by baseline or airway 
narrowing heterogeneity. The main contributor to this increased resistance comes from 
nearly closed peripheral airways, especially when resistance is measured at frequency near 
the breathing frequency (138). These airway closures (or near closed) ultimately lead to 
ventilation defects and attendant flow limitation. They might be the link between ventilation 
heterogeneity and AHR.  
4.4.2 Non-uniform ventilation with air trapping and AHR  
Using the forced oscillation technique, several groups noticed that the frequency-
dependence of resistance and elastance was increased at baseline in asthmatics (139) and 
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upon MCh challenge in both asthmatics and non-asthmatics (111, 139). In accordance to the 
computational models discussed above, this is indicative of a heterogenous pattern of 
constriction that includes randomly distributed airway closures or near closures (138). These 
observations are supported by ventilation imaging studies such as hyperpolarized 3He MRI 
(39, 207, 234), single-photon emission computed tomography (116) and positron emission 
tomography (169). These studies showed that asthmatics have increased ventilation 
heterogeneity at baseline and, even if heterogeneous airway response to a spamogen is also 
observed in non-asthmatics, the level of ventilation heterogeneity achieved is greater in 
asthmatics (39, 207, 234). This heterogeneous pattern of ventilation is characterized by 
relatively large zone of non-ventilated area, which supports the presence of airway closure. 
These ventilations defects represent zones of air trapping, which are characteristic of 
obstructive diseases and known to contribute to airflow limitation. Ventilation heterogeneity 
can thus be one of the sources of AHR seen in asthmatics. This is consistent with recent 
reports showing that baseline ventilation heterogeneity measured by nitrogen washouts 
correlates with the severity of AHR in both younger (60) and older (96) asthmatic subjects.  
The increase in ventilation heterogeneity in response to a spasmogenic challenge may 
simply be due to an amplifying effect over the baseline heterogeneity. However, upon 
induced bronchoconstriction, airway narrowing heterogeneity can also contribute to 
ventilation heterogenetity. King and coworkers (115) have used high resolution computed 
tomography (HRCT) to measure the heterogeneity of airway narrowing in response to MCh 
challenge in human subjects. The heterogeneity was measured by the standard deviations of 
the changes in luminal airway caliber caused by MCh. They showed that in airways of  2 
mm of diameter that the variability of airway narrowing was greater than the measure of 
repeatability (the variability in the changes in luminal airway caliber when two pre-MCh 
scans were compared), suggesting that airways narrow heterogeneously. They also shown 
that for the same level of bronchoconstriction achieved, asthmatic airways narrowed more 
heterogeneously than non-asthmatics. Together, these observations suggest that the larger 
and more numerous ventilation defects observed in asthmatics during a spasmogenic 
challenge are due to both greater baseline heterogeneity and greater airway narrowing 
heterogeneity. 
4.4.3 Mechanistic link between airway narrowing heterogeneity and airway 
responsiveness  
As aforementioned, the emergence of ventilation defects during bronchoconstriction is 
essentially the link between ventilation heterogeneity and AHR. In other words, simple 
heterogeneity without airway closure (or near closure) does not seem to cause AHR. It is 
true that for the same mean level of bronchoconstriction, heterogeneity would increase 
resistance but only if the flow is still evenly distributed among the different airways. 
However, during heterogeneous constriction, the flow is more likely to be redirected into 
more conductant (patent) airways and correspondingly less flow would be redirected into 
more resistant (constricted) airways. Consequently, the overall resistance would rather 
decrease with heterogeneity. On the other hand, when the airways are closed (or nearly), the 
volume of air subtended by these airways is trapped and will not be able to be expelled (at 
least not as fast) upon maximal expiratory flow maneuvers and that would be the cause of 
AHR. 
It is also unlikely that the ventilation defects are due to random closure of single peripheral 
airways. Based on the size of these ventilation defects, they are more likely due to clustering 
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of constricted peripheral airways. In a computational model developed by Venegas and 
coworkers (236, 253), it was shown that airway closure occurs in cluster. In their model, the 
bronchial tree branches dichotomously, where every bifurcation is composed of one parent 
airway and two daughter airways with slight heterogeneity between them. During 
bronchoconstriction, the flow is redistributed according to divergence of patency among 
daughter airways. The model predicted that all the airways shorten uniformly when the 
level of ASM activation is low. However, passed a certain threshold of ASM activation, 
daughter airways develop a dichotomic response. Whereas one constricts excessively the 
other one dilates. This is because the initial heterogeneity between the two daughter airways 
fosters the redistribution of flow into the more conductant airway. The insufflation pressure 
thus rises in the hyperventilated areas subtended by this airway, which increases the load 
impeding ASM shortening. In fact, the model predicted that this airway dilates despite the 
rise in ASM activation. On contrary, diminution of flow in the other daughter airway causes 
regional lung deflation and loss of parenchymal tethering recoil. The load impeding muscle 
shortening thus decreases and, for the same level of ASM activation, more narrowing 
occurs. Because of axial interdependence of pathways in series, all the smaller airways 
downstream of the excessively closed airways are also affected. The size of the ventilation 
defects depends on the first airway generation afflicted by this dichotomic response. Since 
more ASM activation is required to close larger airways, this dichotomic response begins in 
more peripheral airways. But as the ASM activation progressively rises, the model predicted 
that larger and larger airways are affected and larger and larger patches of lung become 
non-ventilated.  
Taken together, Venegas and colleagues suggested that only a slight degree of heterogeneity at 
baseline can trigger a self-perpetuating feedback loop when a certain level of ASM activation is 
achieved; such that the redistribution of flow in slightly more patent airways, makes the other 
airways and their downstream pathways unstable because of the loss of elastic recoil. This 
ultimately leads to clustering of peripheral airway constriction and the emergence of large 
ventilation defects, which, in turn, cause flow limitation. The chase for the factors determining 
this baseline heterogeneity, which was heretofore ignored, is now on. 
4.4.4 Factors potentially involved in determining baseline heterogeneity 
The amplifying effect described by Venegas and coworkers (236), which can lead to large 
ventilation defects and attendant AHR, relies on subtle structural and/or functional changes 
that were already present prior the inhalation of the spasmogen. Therefore, the identification 
of factors responsible for this baseline airway wall heterogeneity is of major interest.  
Remodeling can certainly impact heterogeneity and can potentially discriminate the 
different levels of heterogeneity observed between asthmatics and non-asthmatics. 
Remodeling occurs non-uniformly throughout the tracheobronchial tree. The occurrence of 
epithelium desquamation or inflammatory infiltrates for example is patchy in nature. The 
extent of subepithelial fibrosis, ASM enlargement, and other structural changes present in 
asthmatic lungs could also vary at different locations in the lung. Together, these disparities 
alter the mechanical properties of the airway wall non-uniformly along the bronchial tree. It 
can also modify airway geometry and sometimes lead to the formation of bottlenecks, a 
characteristic feature found in terminal bronchioles of chronic obstructive pulmonary disease 
(COPD) patients (McDonough et al., provisionally accepted in the New England Journal of 
Medicine). The effect of a bottleneck is treacherous because not only it increases the resistance 
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to airflow in an airway that otherwise may look normal but also because it reduces ventilation 
in the parenchymal tissue subtended by this airway. This ultimately fosters the development 
of a ventilation defect due to a decrease in the force of airway-parenchymal interdependence. 
Greater ventilation defects at baseline seen in asthmatics can thus be attributed to remodeling. 
However, ventilation heterogeneity is mainly attributable to the fact that airways narrow 
heterogeneously. So, it is upon bronchoconstriction that the functional consequences of 
these disparities (localized remodeling changes) along the length of a pathway are 
exacerbated. For example, remodeling heterogeneity can affect locally the initial geometry, 
which has a huge influence on airway responsiveness (as discussed in subsection 4.1.3). It 
can also modify locally the after-load impeding ASM shortening. Another example would 
be the patchiness of ASM mass enlargement, which can potentially amplify regional 
differences in airway narrowing upon ASM activation.  
Gain in contractile properties (e.g., force-generating capacity) due to ASM behaviors could 
also be patchy within the lungs. For example, acquisition of supplemental force by length 
adaptation can occur in an area where the airway caliber is smaller because of a localized 
decrease in the force of airway-parenchymal interdependence. The baseline ASM-tone also 
likely differs in different areas of the lung. Its magnitude may be spatially correlated with 
zones of inflammation, where inflammation-derived spasmogens are produced/released. 
That would also lead to force adaptation and the attendant gain in force-generating capacity 
in those areas. All these factors can affect ASM contractile properties in a localized manner 
and contribute to narrowing heterogeneity and AHR.  
Hence, remodeling and inflammatory changes seen in asthmatic lungs can give rise to a 
greater baseline level of airway wall heterogeneity. It can also cause inhomogeneity of 
narrowing upon a bronchoprovocative challenge with a spasmogen by changing the load 
impeding ASM shortening or by fostering the development of increased ASM contractility. 
Together with the strong interplay between the parenchymal tethering and airway patency, 
this increased level of heterogeneity can be sufficient to trigger a self-perpetuating loop 
leading to patches of hypo- or non-ventilated area and the appearance of AHR in 
asthmatics.   
5. Conclusion  
Despite abundant evidence implicating the ASM as the culprit of AHR in asthma, the latest 
genetic studies are relatively weak to support the role of asthma susceptibility gene risk 
variants in causing ASM dysfunction. The more reliable genetic analyses performed to date 
have instead suggested that the well-recognized genetic predisposition to suffer from 
asthma may be related to polymorphisms in genes that are predominately involved in 
immunology and/or epithelial integrity and functions. Even if we cannot rule out the 
contribution of genetic alterations affecting the ASM in AHR at the present time, the bulk of 
evidence rather suggests that if alterations in ASM mechanics contribute to AHR, these 
alterations are acquired as a result of inflammatory mediators and/or extracellular matrix 
remodeling that are present in asthmatic lungs. For example, lung defects can foster the 
appearance of normal ASM behaviors that render the muscle hypercontractile, such as 
length adaptation, force adaptation and changes in ASM cell’s phenotype. These ASM 
behaviors are the testimony that he contractile properties of the ASM are not fixed but rather 
plastic (adaptable).  
On the other hand, alterations in ASM contractile properties are not necessarily a 
prerequisite to suffer from AHR. Many lung defects are sufficient alone (i.e., without the 
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need of increased ASM contractility) to cause AHR. These include but are not restricted to: 
1-alterations in epithelial integrity, which increase the bioavailability of the inhaled 
spasmogen onto the ASM; 2-increased ASM-tone (due to the preponderance of 
inflammation-derived spasmogens, an augmented vagal input and/or decreased expression 
of relaxant factors), which acts additively with the extrinsically-delivered spasmogen in 
terms of ASM activation and ASM shortening, and synergistically in terms of narrowing of 
the cross-sectional area of the lumen and airway resistance; 3-obstruction of the vessels 
irrigating the ASM, which prevents clearance of the spasmogens into the circulation and 
concomitantly sequesters the spasmogens in the vicinity of ASM; 4-increased mass of the 
material inner the ASM layer, which increases airway narrowing for any given degree of 
ASM shortening; 5-decreased ASM-load (due to adventitial thickening, detachment of the 
parenchymal tethers from the outer edge of the airway wall, decrease in lung recoil, 
reduction in lung volume, diminution of the radial constraint limiting ASM bulging during 
shortening, other changes in ECM constitution which may change the mechanical properties 
of the airway wall to make it easier to compress by affecting, or not, its pattern of folding), 
which increases ASM shortening for any given degree of ASM activation; and 6-ventilation 
heterogeneity with airway closure, which affects flow measurements (such as FEV1, PEF and 
others) because of air trapping. For all of these reasons, some asthmatics can be 
hypperresponsive even when their ASM operates as normal. In conclusion, we think that 
the ASM is often ‘blamed’ for the AHR seen in asthma simply because of its unequivocal 
role in airway responsiveness. We would like to propose that without further or more 
convincing proofs to incriminate ASM in AHR, this obeisant tissue should still be 
considered ‘innocent’. 
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1. Introduction  
The last two decades efforts have been made in investigation of genes that encode proteins 
involved in pathogenesis of emphysema and chronic obstructive pulmonary disease 
(COPD). So far, SERPINA1 gene which encodes protein alpha-1-antitrypsin (A1AT) is the 
only defined genetic risk factor associated with early development of emphysema.  
The A1AT is dominant protein of 1 electrophoretic fraction of serum proteins, whose main 
physiological role is to inhibit neutrophil elastase (NE) in the lower respiratory tract, and 
protect pulmonary connective tissue from NE released from triggered neutrophiles. 
Neutrophil elastase is serine protease that degrades elastin of the alveolar walls as well 
other structural proteins of a variety of tissues.  
Hereditary alpha-1-antitrypsin deficiency (A1ATD) is associated with retention of mutant 
A1AT polymers in hepatocytes which leads to decrease of circulating A1AT with less than 
15% of normal level in A1ATD homozygotes. Since the integrity of lung alveoli is 
maintained by proper circulating level of A1AT, severe deficiency of this protein was 
identified as genetic risk factor for emphysema and COPD. Clinical manifestation of 
emphysema in patients with A1ATD occurs in 3th decade in smokers and in the 5th decade 
in non-smokers (Larsson, 1978; Janus et al., 1985) and requires replacement therapy with 
purified A1AT pooled from donor plasma.  
Genetic epidemiologic studies show that A1ATD may affect 1 in about 1,500 individuals in 
Europe (De Serres, 2002). Approximately 3.4 million individuals of all racial subgroups are 
affected by A1ATD worldwide (De Serres, 2002). 
Liver disease in early childhood is second clinically significant consequence resulting from 
retention of mutant A1AT polymers in hepatocytes (Eriksson, 1986; Sveger, 1976). Clinically 
it is presents as neonatal cholestasis which may progress to juvenile chirosis or slowly 
progress to the liver disease in adults (Mahadeva and Lomas, 1998).  
In the early sixties of the last century, Laurell and Eriksson discovered that the absence of 
the electrophoretic 1-globulin pattern of serum is associated with A1AT deficiency (Laurell 
and Eriksson, 1963). At the same time was discovered an association between A1ATD and 
emphysema in relatively young patients in fourth decade of life (Eriksson, 1964; Lieberman, 
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1969). These observations suggested a significant role of A1ATD in pathogenesis of 
emphysema. The proteinase-antiproteinase hypothesis, established by Janoff (Janoff, 1985) 
still remains central in our understanding of the pathogenesis of lung disease. According to 
this hypothesis, emphysema in A1ATD arises from an imbalance of neutrophil elastase and 
A1AT as antielastase, which leads to inappropriate antielastase defense and the relatively 
excessive activity of neutrophil elastase and consequent degradation of elastin and other 
extracellular matrix components of the lower respiratory tract.  
However, only 1% of patients with COPD are A1ATD (Lieberman, et al., 1986), indicating 
that A1ATD alone is not sufficient to induce emphysema (Silverman, et al., 1989). The 
additional factor which may induce emphysema in A1ATD is inflammation, when elastin 
repair mechanisms are overwhelmed by a massive attack of elastase from triggered 
neutrophils and cigarette smoke. Studies of the genetic and environmental factors have 
shown a difference in the reduction of pulmonary function in A1ATD, indicating that 
additional genetic factors (modifier genes) may influence the pulmonary function in A1ATD 
subjects (Silverman et al., 1990). Also, the single-nucleotide polymorphisms (SNPs) were 
identified in the six haplotypes of the SERPINA1 gene, which controls synthesis of A1AT 
(Chappell, et al., 2006). Several environmental factors that accelerate the onset of symptoms 
in A1ATD patients, such as personal and second hand exposure to tobacco smoke in 
childhood, respiratory infections (Mayer et al., 2006), and higher exposures to ozone (Wood 
et al., 2009) have been also identified.  
In addition to the low circulating levels of A1AT in hereditary A1ATD, the risk of 
emphysema includes reduced antielastase activity. Functional inactivation of A1AT by 
oxidants present in cigarette smoke could impair antielastase defence in lower respiratory 
tract, and represent acquired A1AT inactivation. Furthermore, in hereditary A1ATD 
smoking could impair the function of A1AT both quantitatively and qualitatively. 
2. Alpha-1-antitrypsin 
Alpha-1-antitrypsine (A1AT) is the archetype of the serpin family of proteins. SERPINs 
(SERine Proteinase INhibitors) are the superfamily of structurally related proteins that control 
many physiological processes. A1AT is a highly polymorphic, acute-phase glycoprotein, 
synthesised in hepatocytes (Koj et al., 1978) and subsequently secreted into the plasma. 
Hepatic synthesis of this acute phase protein by SERPINA1 gene is under control of different 
cytokines, such as interleukin-1 (IL-1), tumour necrosis factors  (TNF) and most effectively 
the interleukin-6 family of cytokines (interleukin-6, leukaemia inhibitory factor, oncostatin M) 
(Richards and Gauldie, 1991). Besides liver, the small quantities of A1AT are produced by 
alveolar macrophages, circulating monocytes and intestinal, renal and lung-derived epithelial 
cells (Mornex et al., 1986; Carlson et al., 1988; Molmenti et al., 1993; Cichy et al., 1997; Mulgrew 
et al., 2004). Extra hepatic synthesis of A1AT is important in preventing tissue damage in the 
site of inflammation or injury. For instance, synthesis of A1AT in monocytes is up-regulated 
by inflammatory mediators such as IL-1 and TNF in lung tissue (Knoell et al., 1998). Serum 
level of A1AT is elevated in inflammation, trauma, and pregnancy.  
Healthy individuals produce 34 mg of A1AT per kilogram of body weight per day (Jones, 
1978). Normal reference interval for antigenic concentration of serum A1AT measured by 
nephelometry is 15-40 M (0.83-2.20 g/L) (ATS/ERS Statement, 2003). The threshold level of 
11 M (0.59 g/L) provides relevant antielastase protection of lower respiratory tract (WHO 
Meeting, 1996.). As a relatively small protein (52 kD), the mature A1AT is capable to diffuse 
into many organs. The concentration of A1AT in organs is lower than in plasma. Thus, 
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Olsen et al. (Olsen et al., 1975) reported that A1AT level in a bronchoalveolar lavage fluid of 
non-smokers is 7% of serum level, with a higher value (11%) in smokers. Also, total amount 
of A1AT in the lavage fluid of smokers was significantly greater than in non-smokers. The 
same authors reported about five times higher A1AT concentration in pulmonary alveolar 
macrophages in smokers in comparison to non-smokers. All these results suggest an 
increased A1AT concentration in the air spaces of the cigarette smokers.   
2.1 Structure and function of alpha-1-antitrypsin 
The mature A1AT protein is a single chain composed of 394 amino acids. The main 
characteristics of the protein are: Met358 residue at the active site, isoelectric point ranging 
from 4.4 to 4.6, and a total molecular weight of 52 kDa. Crystalographic analysis of the 
mature protein reveals that A1AT is a globular protein with tree N asparigynil-linked 
carbohydrate side chains on the external surface of the one end of the molecule 
(Loebermann et al., 1984). The side chains are composed of N-acetylglukosamine, mannose, 
galactose and sialic acid and they are N-linked to amino acids Asn46, Asn83 and Asn247. 
These carbohidrate side chains are on the outside surface of one-half of the elongated 
structure. The difference in carbohydrate side chains at position of Asn83 is responsible for 
the two major bands of A1AT when serum focused at pH 4-4.9 on thin-layer polyacrilamide 
gel. The internal structure of A1AT is highly ordered with 30 percent -helices and 40 
percent -pleated sheets. There are nine -helices (AI) and three -sheets (AI).  
Similar to other inhibitory serpins, A1AT is „suicide” or „single use” inhibitor that employs 
a unique and extensive conformational change in the process of inhibition of target 
proteases (Figure 1.). The hallmark of serpins is the reactive centre loop (RCL) that presents 
the key P1-P’1 methionine–serine bond as a pseudosubstrate for the cognate proteinase, 
neutrophil elastase (Johnson and Travis, 1978). The reactive centre loop of A1AT is highly 
stressed external loop protruding from the molecule with Met358-Ser359 in the active center. 
Inhibitory process begins by docking of the serpin and the protease, and formation of 
Michaelis complex. Like the other inhibitory serpins, the structure of the RCL is crucial for 
the ability of the inhibitor to undergo a „stressed to relaxed” (S→R) conformational change. 
The active A1AT is in metastable or „stressed form”, which is essential for inhibition of 
proteases. During the process of inhibition, A1AT is like mousetrap with spring-like shift 
from a metastable to a hyperstable state (Hunington et al., 2000; Carrell and Lomas, 2002). 
After the formation of Michaelis complex there are two possible different ending of the 
reaction. One is inactivation of protease, where serpin has undergone the S → R transition, 
and the protease hangs distorted at the base of the molecule. The other possibility is A1AT 
substrate-like behavior, where RCL forms the fourth -sheet, providing the opportunity for 
the protease to escape the conformational trap, leaving active protease and inactive cleaved 
serpin. Thus, in vivo, A1AT can exist in: native inhibitory conformation with an exposed 
RCL, latent conformation with a partially inserted RCL and non-inhibitory conformation. 
Non-inhibitory conformation of A1AT occurs in certain circumstances: when A1AT is in 
complex with neutrophil elastase, when the reactive center loop of A1AT is cleaved by non-
target proteinases, when reactive oxygen species oxidized A1AT, and when A1ATD variants 
form polymers.  
Moreover, A1AT non-inhibitory conformations show other biological effects. For instance, 
oxidized A1AT and the cleaved peptide fragment of A1AT stimulate monocyte activation, 
and A1AT-elastase complexes and polymeric A1AT are chemotactic for neutrophils (Banda 
et al., 1988; Dabbagh et al., 2001; Moraga and Janciauskiene, 2000; Moraga et al., 2001). 
 




Fig. 1. Structure of alpha-1antitrypsin and reaction with target protease (modified from Law, 
et al., 2006) 
2.2 Physiological roles of alpha-1-antitrypsin 
The main physiological role of A1AT is protection of lower respiratory tract by inhibiting 
proteases released from triggered neutrophiles including neutrophil elastase, cathepsin G, 
and proteinase-3 (Carrell, 1986). The target proteases of A1AT derive from azurophilic 
granules of polymorphonuclear neutrophils which participate in lysosomal bacterial 
digestion and neutrophil migration through the extracellular matrix at the sites of 
inflammation. This protective role of A1AT occurs primarily extracellular. A1AT enters the 
lung from the circulation by passive diffusion (Stockley, 1984). Besides direct inhibition of 
NE, there are evidences that A1AT exhibits anti-inflammatory properties to suppress 
cigarette smoke induced production of tumor necrosis factor  (TNF) and matrix 
metalloproteinase 12 (MMP12) by alveolar macrophages, and subsequent inflammatory cell 
infiltration (Churg et al., 2007). Furthermore, studies have shown that native A1AT 
modulates function of immune cells, such as neutrophils (Bergin et al., 2010), monocytes 
(Janciauskiene et al., 2007), and T cells (Lu et al., 2006). Ex vivo and in vitro experiments have 
shown that endogenous A1AT in blood contributes to the suppression of proinflammatory 
cytokine synthesis (Pott et al., 2009). Thus, A1AT is an endogenous inhibitor of 
proinflammatory cytokine production in whole blood, and may participate in innate 
immune response to an inflammation-inducing stimulus. The recently discovered role of 
A1AT in prevention of emphysema is the inhibition of lung endothelial cell apoptosis due to 
inactivation of intracellular caspase-3 (Petrache et al., 2006a; Petrache et al., 2006b). 
Antiapoptotic role of A1AT in the lung in vivo and in vitro in micro vascular endothelial cells 
is associated with intracellular presence of A1AT. Lung endothelial cells don’t produce 
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A1AT and they take it. Sohrab et al. (Sohrab et al., 2009) showed that clathrin-mediated 
endocytosis predominantly regulates A1AT intracellular function in the lung endothelium, 
and might represent an important determinant of the serpin’s protection against 
development of cigarette smoke-induced emphysema. The uptake is severely affected by 
exposure to cigarette smoke extract in vitro and in vivo, probably directly influencing 
clathrin-mediated endocytosis. Furthermore, polymers of A1AT exhibit a marked decrease 
in lung endothelial cell uptake. Inhibition of A1AT uptake by cigarette smoke may further 
weaken the A1AT protective role in the lung. 
In the last decade other physiological roles of A1AT have been discovered, such as roles in 
atherogenesis (Talmud et al., 2003), angiogenesis (Huang et al., 2004), fibroblast 
proliferation, and procollagen synthesis (Dabbagh et al., 2001). 
2.3 Genetics of alpha-1-antitrypsin 
The alpha-1-antitrypsin is encoded by SERPINA1 gene (serpin peptidase inhibitor, clade A) 
located in proteinase inhibitor (Pi) locus on the long arm of chromosome 14q32.1 (Schroeder 
et al., 1985; Billingsley et al., 1993). The Pi locus is 12.2 kb long and consists of 4 coding 
exons, 3 non-coding exons and 6 introns (Figure 2.). At the 5 region of the SERPINA1 gene 
there are three non-protein coding exons (IA, IB, IC) which control gene transcription. Exons 
referred as exons II-V are coding and containing the sequence information that defines the 
protein itself. The start codon (ATG) for translational of the mRNA and the signal peptide 
are in exon II, and the stop codon (TAA) is in exon V, followed by the polyadenilatyon 
signal (ATTAA). The carbohydrate attachmnent site (Asn46, Asn83, Asn247) are coded for in 
exon II and III. The region coding for the reactive loop with the active inhibitory centre 
Met358 is within exon V.  
Following transcription, A1AT mRNA is translated on ribosome bound to the the rough 
endoplasmatic reticulum, producing a preprotein of 418 amino acids. The signal peptide of 
24 residues is removed during secretion into the cisterne of the rough endoplasmatic 
reticulum where the protein is glycosylated with high-mannose type carbohydrates, and 
folds into appropriate globular tree-dimensional configuration. Complete protein 
maturation is accomplished within the Golgi apparatus and protein is secreted.  
 
 
Fig. 2. Structure of the SERPINA1 gene (Crystal et al., 1989) 
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Hepatocytes and monocytes have two different promotors (Perlino et al., 1987) that operate 
via different mechanisms. The SERPINA1 gene in macrophages is transcribed from a 
macrophags-specific promoter located about 2,000 bp upstream of the hepatocyte-specific 
promoter. Transcription from the two SERPINA1 promoters is mutually exclusive; the 
macrophage promoter is silent in hepatocytes, and the hepatocyte promoter is silent in 
macrophages. In macrophages, two distinct mRNAs are generated by alternative splicing. In 
addition, Hafeez et al. (Hafeez et al., 1992) demonstrated that the SERPINA1 gene has 3 
monocyte-specific transcriptional initiation sites upstream from a single hepatocyte-specific 
transcriptional initiation site. Macrophages use these sites during basal and modulated 
expression. Hepatoma cells use the hepatocyte-specific transcriptional initiation site during 
basal and modulated expression, but also switch to transcription from the upstream 
macrophage transcriptional initiation sites during modulation by the acute phase mediator 
interleukin-6 (IL-6). 
2.4 Polymorphism of alpha-1-antitrypsin  
The A1AT coding gene SERPINA1 is a highly polimorphic, with more than 125 SNPs 
reported in public SNP databases (Entrez SNP). Protein variants of A1AT are classified by 
the Pi (Protese inhibitor) system and each variant is identified by migration on agarose gel 
electrophoresis. These differences in migration relate to variations in protein charge 
resulting from amino acid alterations (Fagerhol and Laurell, 1970; Cox, 1978). Isoelectric 
focusing in the narrow range of pH (4.2-4.9) has enabled identification of more A1AT 
variants then in agarose gel electrophoresis. The alleles were given symbols according to the 
relative electrophoretic mobility of the allele product, so anodal variants are marked with 
the first letters, and cathodal with last letters. All A1AT variants are categorized according 
to the serum level and functional activity as normal, deficient, null and dysfunctional.  
2.4.1 Normal A1AT variants 
Normal A1AT variants have normal serum level and functional activity to inhibit neutrophil 
elastase. More than 95% of normal variants are the „common” M1 (Ala213), M1 (Val213), M2 
and M3. Among Caucasians, M1 (Val213) is the most common, and M1 (Ala213), M2 and M3 
are less frequent. The „rare” normal variants with frequencies less than 1% are: M4, Balhambra, 
F, PStAlbans and XChirstchurch. Usually, rare variants are named by the birthplace of the oldest 
individual tested in pedegree. PiM homozygotes and heterozygotes are characterized by 
normal serum level of A1AT (20-50 M) and normal functional activity (ATS/ERS 
Statement, 2003).  
2.4.2 Deficient A1AT variants 
Deficient variants are associated with lower serum level of A1AT than normal variants. 
Several mutations associated with A1ATD have been identified, and the most common are Z 
and S alleles. Rare A1ATD variants are MMalton, MMineralSprings, MNichinan, MProcida, PLowell, SIiyama 
and others.  
Gene-mapping studies have shown that the PiZ allele probably arose in Northern Europe 
(Cox et al., 1985). Age estimates of A1AT variants based on microsatellite variation, suggest 
that the Z deficiency allele appeared 107 to 135 generations ago and could have been spread 
in neolithic times. Frequency of the Z allele shows a large variation in Caucasians, but is rare 
or absent in Asians and Africans (De Croo et al., 1991; Hutchison, 1998.). 
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The PiS deficiency allele has an older 279-generation to 470-generation age and from its high 
incidence on the Iberia peninsula it has been suggested that it could have originated in this 
region (Seixas et al., 2001).  
2.4.2.1 Z variant 
The Z variant represents a „classic“A1ATD variant and derives from M1 (Ala213) following a 
point mutation which is the same for the all Z individuals who are probably descendants of 
a single ancestral progenitor. The result of mutation is the substitution of a GAG that codes 
for Glu342 with an AAG that code for Lys342 (Nukiwa et al., 1987). The Z mutation perturbs 
the folding (Yu et al., 1995.) and structure of the protein (Lomas et al., 1993a). It distorts the 
relationship between the reactive centre loop and -sheet A, and the consequent 
perturbation in structure allows opening of -sheet A to favor partial loop insertion and 
formation of an unstable intermediate (M*) (Figure 3.). Then the patent -sheet A accepts the 
loop of another A1AT molecule to form a dimer (D) which then extends to form chains of 
loop-sheet polymer (P) (Lomas, et al., 1992; Elliott et al., 1996a; Lomas, 2000).  
 
 
Fig. 3. Formation of Z polymers (Lomas, 2005) 
Process of polymerization depends on concentration and temperature. Abnormality in 
posttranslational modification of protein causes accumulation of the A1AT polymers in the 
cisterna of the rough endoplsmatic reticulum with a drastic reduction in secretion rates. The 
abnormal protein accumulates in hepatocytes and forms inclusion bodies (aggregates) that 
are positive to diastase-resistant periodic acid Schiff (PAS-D) staining and visible on 
microscopy. The retained A1AT polymers are cytotoxic for hepatocytes and can cause a 
diverse liver damages, ranging from neonatal hepatitis to juvenile cirrhosis, and 
hepatocellular carcinoma in adults (Eriksson, et al., 1986). As a consequence of polymer 
accumulation, hepatocytes of PiZZ homozygote secrete only 10–15 % of normal quantity. 
PiMZ heterozygotes have about 50 % of normal A1AT circulating level. 
Besides low circulation level, the Z protein also less efficiently inhibits elastase (Ogushi, et 
al., 1987). Consequently, in PiZZ individuals, quantitative and qualitative defects of A1AT 
lead to early-onset COPD including emphysema and chronic bronchitis.  
A similar form of loop-sheet polymers in vivo with hepatic inclusions and plasma deficiency 
was found in two other variants, MMalton (Phe52 deleted) (Lomas et al., 1995) and SIiyama 
(Ser53→Phe) (Lomas et al., 1993b.), that are common in Sardinia and Japan, respectively. 
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A1AT polymers were also detected in bronchoalveolar lavage fluid (BALF) from PiZ 
homozygotes with emphysema. This conformational transition may further reduce the 
levels of functional proteinase inhibitor in the lungs, and consequently exacerbate lung 
tissue damage (Elliott et al., 1998).   
Studies of Parmar et al. (Parmar et al., 2002) and Mulgrew et al. (Mulgrew et al., 2004) 
showed that Z A1AT locally produced on the epithelial surface of the lung polymerizes and 
A1AT polymers demonstrate proapoptotic and proinflammatory effects. These studies also 
revealed that unlike M A1AT protein, Z A1AT protein polymerized at body temperature, 
and in addition of being an ineffective antiprotease inhibitor, might become a strong 
neutrophil chemoattractant, thus representing an ongoing source of inflammation in the 
lungs of individuals with A1ATD. Thus, polymerization of locally produced ZA1AT is a 
contributory factor to the lung inflammation experienced by those with A1AT deficiency 
and that standard antiprotease therapies may not address this problem. Other studies 
reported that even PiZZ patients with near-normal lung function had high concentrations of 
neutrophils on respiratory epithelial surfaces (Rouhani et al., 2000). Neutrophil burden in 
PiZZ and in PiMZ (on a lesser extent) is attributed to leukotriene B4 or IL-8 released from 
neutrophils or epithelial cells (Woolhouse et al., 2002; Malerba et al., 2006). Neutrophil 
accumulation in the lung of PiZZ deficient individuals is multifactorial and chemoattraction 
due to polymerized Z protein represents another potential cause of neutrophil dominated 
inflammation. These findings suggest a novel mechanism in pathogenesis of emphysema 
associated with Z antitrypsin deficiency. 
Lomas (Lomas, 2006) highlighted a possible role of Z mutant in systemic response to 
infection. In the case of invasion of pathogens, organism initiates a systemic inflammatory 
response that results in increased secretion of Z A1AT as acute phase protein, by 
hepatocytes. Factors such as: elevation of body temperature, increased concentration of 
mutant Z A1AT, and lower pH at the site of bacterial invasion of lung (Stockley and Burnett, 
1979) favor polymerization of mutant Z A1AT. Polymers possess chemotactic properties, 
which in turn amplify inflammatory response and enhance the recruitment of neutrophils. 
Excessive burden of neutrophils may cause increase of proinflamatory and proxidative 
factors.   
Therefore, a rational approach in therapy of A1ATD would be to inhibit the polymerization 
of the Z protein (intracellularly and extracellularly), accompanied by standard 
augmentation therapy. It is clear that in addition to increased level of A1AT above a 
putative therapeutic threshold, it is necessary to increase the secretion of active non-
polymerized form of Z protein. This approach could potentially ameliorate the liver disease, 
and defend respiratory epithelial surface, providing antielastase protection and avoiding the 
proinflammatory effects of polymerized Z A1AT.  
Currently, there is some progress in development of synthetic peptide designed to 
selectively inhibit Z polymerisation (Mahadeva et al., 2002; Parfrey et al., 2004; Chang et al., 
2006; Mallya et al., 2007; Chang et al., 2009).       
2.4.2.2 S variant 
In contrast to the Z allele, S causes only mild plasma deficiency. The genetic sequence of the S 
variant derives from M1 (Val213) as a result of a mutation which cause substitution of GAA that 
codes for Glu264 with an GTA that codes for Val264 (Owen et al., 1976; Yoshida et al., 1977).  
The single mutation of the S variant leads to spontaneous polymer formation, but slower 
than the Z variant, without affecting the ability to inhibit neutrophil elastase (Elliott, et al., 
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1996b; Mahadeva et al., 1999; Dafforn et al., 1999). The slower polymerization causes less 
retention of S variant in the liver, and hence the plasma levels are 60% of the normal M 
allele. Thus, carriers of S allele (PiSS, PiSZ and PiMS) have levels of 52%, 32% and 75% of 
normal level, respectively. Furthermore, Z A1AT forms heteropolymers with S A1AT 
(Mahadeva et al., 1999), which explains cases of hepatic cirrhosis in PiSZ patients (Cruz et 
al., 1975; Campra et al., 1973; Craig et al., 1975.). Also, PiSZ smokers are at significant risk of 
the development of COPD, while in nonsmoking individuals the PiSZ phenotype may 
confer little or no risk to develop COPD (Turino et al., 1996).  
2.4.2.3 Null A1AT variants 
Null variants are characterized by the modification of an important part of the gene with no 
detectable mRNA. Although extremely rare, they have been found in all populations. 
Frequencies of null variants among Caucasians are estimated to be less than 0.1%. Null-
allelic variants are denoted as Q0 rather than Pi. The Null mutations do not result in 
secreted protein or the formation of polymers. Subjects with Null mutations show 
significantly lower lung function values than PiSZ and PiZZ individuals, and they are at 
particularly high risk to develop emphysema (Cox and Levison, 1988; Fregonese et al., 2008). 
Early detection of Null carriers is important for preventive and therapeutic interventions. 
The PiNullBellingham differs from the normal M1 (Val213) gene by the mutation in exon II, 
where the codon for Lys217 (AAG) is altered to Stop codon (TAG) (Satoh et al., 1988). 
Homozygotes for PiNullBellingham have complete absence of A1AT, and develop premature 
emphysema much earlier than more common PiZZ individuals (Cook et al., 1994). The 
Nullisola di procida is caused by complete deletion of exons II-V of SERPINA1 gene (Takahashi 
and Crystal, 1990). The Nullgranite falls allele derives from the M1 (Ala213) by the deletion of a 
single base in exon II in the codon for Tyr160 (TAC) with deletion of the C. Consequently, 
there is 5' frame shift of the downstream nucleotides, moving the G form the next codon, 
Val161 GTC in place of the normal Tyr160 (Holmes et al., 1989). 
The Nullmattawa allele is a consequence of the insertion of a single nucleotide within the 
coding region of exon V, causing a 3' frameshift with generation of a premature stop signal 
(Curiel et al., 1989).   
Prins et al. (Prins et al., 2008) performed genotyping by direct sequencing of the SERPINA1 
gene coding region in patients with A1AT concentrations ≤1.0 g/L, and this approach 
allowed them to discover Q0soest and Q0amersfoort null alleles.  
2.4.2.4 Dysfunctional variants 
Dysfunctional A1AT variants are synthesized in normal quantities, but have altered protein 
function. The PiPittsburgh allele is a mutation which occurs at the A1AT active site, and 
represents an example of a mutation responsible for altered function of the gene product. 
A1AT becomes a potent inhibitor of thrombin and factor XI rather than of elastase, which 
results in a bleeding disorder (Lewis et al., 1978; Owen et al., 1983). 
3. Hereditary alpha-1-antitrypsin deficiency and emphysema 
The risk of developing early-onset emphysema caused by hereditary A1ATD is inversely 
correlated with the serum A1AT level (ATS/ERS Statement, 2003). Only PiZ homozygotes 
with severe decreased A1AT serum level, or carriers of M-like or Null alleles are at 
significant risk to develop panlobular emphysema with typical dilatation or destruction of 
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all lower lobules. However, the risk of COPD in PiMZ individuals is still controversial. 
Heterozygous, PiMZ individuals have moderately reduced serum levels A1AT, but whether 
they have increased risk of COPD is uncertain. Tarjan et al. (Tarjan et al., 1994) in 
longitudinal lung function study in heterozygous PiMZ subjects observed a decrease in 
elasticity and deterioration lung function parameters in comparison to those without 
A1ATD, which supports the concept of PiMZ phenotype being a risk factor for pulmonary 
emphysema development at a younger age. Dahl et al. (Dahl et al., 2002) found that PiMZ 
heterozygotes had a slightly greater rate of decrease in FEV1. Meta analysis by Hersh et al. 
(Hersh et al., 2004) has shown an increased odd of COPD in PiMZ individuals with 
suggestion that variability in study design and quality limits interpretation. Recent study 
(Sørheim et al., 2010) suggests that PiMZ individuals may be slightly more susceptible to the 
development of the airflow obstruction than PiMM individuals. 
3.1 Epidemiology of A1ATD 
The majority of the data regarding frequency and geographical distribution of severe 
A1ATD genotypes refer to the most frequent deficient variants PiZZ and PiSZ. Considering 
that severe A1ATD predisposes the development of emphysema that requires expensive 
diagnostic methods and treatment, it would be very useful to determine prevalence of 
severe A1ATD in every population.  
The most comprehensive study that has been performed on 200,000 Swedish newborns 
revealed the prevalence rate of PiZZ phenotype of approximately 1 in 1,600 newborns 
(Sveger, 1976). Despite the lack of reliable epidemiological studies and marked differences 
between countries, Blanco et al. (Blanco et al., 2006) estimated numbers of individuals 
carrying two most common deficiency alleles, Z and S in Europe. Highest prevalence of the 
PiZZ phenotype is in the Scandinavian Peninsula, Latvia and Denmark and progressively 
decreases towards the South and the East of Europe. While the highest prevalence of the 
PiSZ is in the Iberian Peninsula and it gradually decreases towards the North, South and 
East of the continent. Prevalence of the moderate PiMZ is highest in the South of the 
Scandinavian Peninsula, Baltic Republics, Denmark and the UK, and progressively 
decreases towards the East, South and North of the continent. The estimated prevalence of 
PiZZ, PiSZ and PiMZ in European adults was 1/4727, 1/1051 and 1/36 respectively, with 
large variation in different countries. In this regard, it was estimated that there are 124,594 
PiZZ, 560,515 PiSZ, and even 16 million PiMZ individuals in all Europe. Globally, A1ATD 
affects all major racial subgroups, and there are at least 116 million carriers (PiMZ and 
PiMS) and 3.4 million deficiency allele’s combinations (PiSS, PiSZ and PiZZ) worldwide (De 
Serres, 2002). According to these data, frequency of the Z allele is lowest in Far East Asia  
(0.04%), and highest in Northern Europe (1.53%), while the S allele is lowest in Far East Asia 
(0.07%), and highest in Southern Europe (5.64%).  
Although the epidemiological data indicate a large of number of A1ATD individuals 
worldwide, this condition is largely undiagnosed and exact prevalence of A1ATD in most 
population remains unknown. Owing to data from international registry of A1ATD, 
established in several countries, it was estimated that only 0.35% of severe A1ATD (PiZZ 
and PiSZ) are actually recognized (Luisetti and Seersholm, 2004). One of the reasons may be 
significantly delayed onset of symptoms. In 1994 Stoller at al. (Stoller et al., 1994) reported a 
mean interval of 7.2 years between initial symptom and first diagnosis.  A decade later, a 
decrement in the overall diagnostics of 5.6 years was noted (Stoller et al., 2005a), which was 
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attributed to the better education of physicians about recognising A1ATD. Authors 
concluded that despite this decrement in the overall diagnostics, underrecognition of 
individuals with A1ATD persisted. Under-recognition of A1ATD may be a part of a larger 
phenomenon of under-recognition of individuals with COPD. The second reason could be a 
low penetrance of the PiZ gene, so that the relationship between genotype and clinical 
phenotype is not strong. 
There are many benefits of early detection of A1ATD, such as avoidance of exposures to 
cigarette smoke and air pollution in prevention of pulmonary emphysema. Also, measure of 
prevention is protection from pneumonia, which is frequently reported in medical history of 
A1ATD patients with emphysema (McElvaney et al., 1997). In A1ATD patients, pulmonary 
infection further increases the risk of developing emphysema. Pulmonary infection favors 
increasing of elastase activity with subsequent destruction of lung due to compromised 
antiprotease defenses, and promotion of A1AT polymers due to elevated body temperature 
in inflammation. In this regard, it is very important to protect lung function of A1ATD 
individuals trough aggressive treatment of pulmonary infections and by vaccination with 
pneumococcal and influenza A vaccines. 
Data concerning genetic epidemiology of the rare A1ATD variants are incomplete, and 
therefore raise a suspicion that the prevalence of these variants might be higher than 2-4%, 
as previously considered, due to misclassification as Z variant (Luisetti and Seersholm, 
2004). Phenotyping by isoelectric focusing is often used to characterize 1AT deficiency, but 
this method may lead to misdiagnosis (e.g., by missing null alleles). Zorzetto et al. (Zorzetto 
et al., 2008) sequenced exons II, III, IV, and V of subjects whose are negative for Z and S 
alleles, and detected even 7% rare A1ATD alleles. Moreover, Prins et al. (Prins et al., 2008) 
have analyzed patients with A1ATD by sequencing of exons II, III, and V of the SERPINE1 
gene and reported that up to 22% of deficiency variants were missed by conventional 
diagnostic methods. 
3.2 Emphysema caused by A1ATD  
The main lung manifestations of severe A1ATD are emphysema and COPD (ATS/ERS 
Statement, 2003). In A1ATD-smokers, the first symptoms usually occur between 32 and 41 
years, with considerable variability in the time of onset of symptoms (Larsson, 1978; Tobin 
et al., 1983). 
Panlobular emphysema is dominant clinical manifestation in A1ATD patients, and affects 
the lower half of the lungs. Pulmonary vessels of the emphysematous lung appear fewer 
and smaller than normal (Stein et al., 1971). In severe A1ATD changes at the level of 
bronchioli such as bronchiolitis obliterans, bronchiolectasia, acute and chronic bronchiolitis 
and bronchiolitis with organizing pneumonia are more frequent than in emphysema 
without A1ATD (Theegarten et al., 1998).  
First representative study that included 124 patients with A1ATD and symptomatic 
emphysema (Brantly et al., 1988) showed predominance of male gender, ex-smoke status, 
levels of A1AT ≤ 5.5 M (0.3 g/L), and abnormalities in a lower zone distribution. About 
one third of patients had pulmonary hypertension. The lung function tests were typical for 
emphysema: the FEV1 and DLCO were dramatically reduced, and their annual rate of decline 
was greater than in general population. The cumulative probability of survival of the 
patients indicated a significantly shortened lifespan with a mean survival of 16% at 60 yr of 
age compared with 85% for normal persons.  
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The largest study ever conducted has been included 1,129 patients who participated in the 
National Heart, Lung, and Blood Institute (NHLBI) Registry of Individuals with Severe 
Deficiency of A1AT (McElvaney et al., 1997). Most frequent were PiZZ (97%), and very few 
PiSZ (1%), and rare variants (2%). Pulmonary function test results were consistent with 
emphysema. The pulmonary function impairment was moderate to severe, frequently 
associated with a bronchodilator response, but generally with preservation of the PaCO2 
until the development of severe airway obstruction. Medical history of lung function 
revealed that initial diagnoses included asthma (in 35% of participants), respiratory tract 
allergies (28%), pneumonia (43%), and chronic bronchitis (36%). The most frequent 
symptoms in A1ATD patients were dyspnea on exertion (in 84% of participants), self-
reported wheezing during respiratory tract infections (76%), and wheezing independent of 
infections (65%), usual cough (45%), and „annual” cough in phlegm episodes (52%). 
Significant number of patients who initially diagnosed as asthma had symptoms that 
suggest airway hyper-responsiveness such as cough and wheezing, responded to aerosol 
bronchodilator moderately (Eden et al., 1997).  It is interesting that a subgroup of 
individuals in the Registry with relatively normal lung function was younger, more likely to 
have never smoked and more likely to have come to medical attention owing to a family 
history of A1ATD.  
Cigarette smoking is associated with more accelerated decline of lung function and early 
development of emphysema in PiZZ individuals leading to a considerably reduced life 
expectancy (Larsson, 1978). A mortality study showed that emphysema was a major 
determinant of mortality in population of severe A1ATD patients (Stoller et al., 2005b). 
Negative impact of smoking on survival of A1ATD patients was demonstrated in two 
recently published studies. Tanassh et al. (Tanash et al., 2008) reported that PiZZ individuals 
who have never smoked and have been identified trough screening do not have an 
increased mortality risk in comparison to general Swedish population. Larger study which 
included 1,349 PiZZ individuals selected from the Swedish National AATD Registry 
showed that smokers with severe A1ATD had a significantly higher mortality risk than the 
general Swedish population (Tanash et al., 2010). The pulmonary emphysema has been 
more common in PiZZ smokers (78%) than in PiZZ never smokers (47%), and respiratory 
diseases have been main cause of death among PiZZ smokers (58%).   
3.3 Laboratory diagnosis of hereditary A1ATD   
Although being one of the most prevalent and potentially severe hereditary disorders, 
A1ATD still remains under-recognized. Affected individuals often visit several physicians 
before obtaining the correct diagnosis. The main reason is generally low knowledge about 
A1ATD among internists and respiratory therapists (Taliercio et al., 2010). Clinically 
relevant A1ATD is often caused by homozygous inheritance of the Z allele, but A1ATD can 
also be due to the combination of other rare deficient or null alleles at the Pi locus. Even 
moderate A1ATD in PiMZ heterozygote is associated with reduced pulmonary functions in 
individuals with clinically established COPD (Dahl et al., 2001). 
The guidelines of the American Thoracic Society and the European Respiratory Society 
(ATS/ERS Statement, 2003) recommend quantitative and qualitative laboratory testing for 
A1ATD for all patients with COPD, asthma, unexplained liver disease, and necrotizing 
panniculitis, as well as for asymptomatic subjects with persistent airflow limitation and 
siblings of A1ATD individuals. Laboratory testing of suspected A1ATD individuals involve 
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analysis of A1AT concentrations in serum and identification of specific alleles by 
genotyping or phenotyping. Therefore it is important to identify appropriate cutoff that 
balances costs of testing identification of deficiency alleles in the general population. 
Diagnostic algorithms for laboratory testing of the A1AT deficiency that were proposed 
(Snyder et al., 2006; Bornhorst et al., 2007; Miravitlles et al., 2010) should lead to improve 
diagnostics of A1ATD (Figure 4.). Initial testing involves quantification of A1AT 
concentrations and genotyping. Quantification of A1AT alone is not sufficient to diagnose 
genetic causes of A1ATD due to secondary causes of reduced concentration of A1AT in 
severe liver diseases, protein-losing enteropathies or nephrotic syndrome which may cause 
a general decrease of serum proteins. If serum level of A1AT lay in the expected range for 
the certain genotype, than the results and interpretation should be reported to physician. 
Qualitative analyses of A1ATD include two complementary methods, genotyping and 
phenotyping, each with advantages and disadvantages. Using conventional phenotyping of 
the A1AT by isoelectic focusing (IEF) necessarily leads to misdiagnoses of the null alleles 
(Klaassen et al., 2001). Therefore, the replacement of IEF with direct sequencing of the 
relevant parts of the SERPINA1 gene enables an efficient and reliable approach to reveal 
A1ATD patient. Direct sequencing of exons II, III and V of the SERPINA1 gene is the 
preferred method in initial phase of diagnostic algorithm for laboratory testing of A1ATD 
(Prins et al., 2008), as it allows detection of disease-associated A1AT allele combinations, 
including null alleles.  
However if quantitative result are in discrepancy with obtained genotype, laboratory should 
perform phenotype assay. Determination of phenotypes serve as complementary to the 
genetic assay, in order to clarify cases that cannot be detected by genotyping. Besides 
phenotyping, other techniques that can be considered as complementary include whole-
gene sequencing and the addition of other alleles to the melting curve genotype assay 
(Rodriguez et al., 2002).  
There are two approaches to assess the complementarity between serum level of A1AT and 
genotype result. Previously, the estimate was based on established threshold of A1AT 
serum levels for the most frequent A1AT phenotypes/genotypes in the general population. 
The various ranges for A1AT serum level of the most common phenotypes, which can be 
found in the literature, are results of different methods of quantification, different 
commercially available standards of A1AT, and samples size. (Brantly et al., 1991; Lee et al., 
2002; ATS/ERS Statement, 2003). Additional difficulty is the estimation of the ranges for 
rare phenotypes because it is difficult to collect a representative number of samples in a 
given population.  
In the context of these concerns, particular problem is the presence of inflammation in 
examined population. The A1AT is an acute phase protein and its production and secretion 
increases with inflammation. Thus, serum levels might be „falsely elevated” and are not 
reflecting the genotype, especially in moderate A1ATD. This was confirmed in a recent 
study which found that PiMZ individuals with a higher level of C-reactive protein (CRP, a 
sensitive marker of inflammation) had  higher level of A1AT than those with lower level of 
CRP (Zorzetto et al., 2008). Also, we should bear in mind that in healthy blood donors only 
26% of the variance of circulating A1AT level is explained by known SERPINA1 gene 
variants (Oakeshott et al., 1985). Recently, large population-based study on the Swiss 
SAPALDIA cohort (Senn et al., 2008) revealed that female gender, hormone intake, systolic 
blood pressure, age in men and in postmenopausal women, as well active and passive 
smoking were positively, whereas alcohol intake and body mass index (BMI) were  
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inversely correlated with serum A1AT levels, independent of CRP adjustment. The results 
of this study reflect a complexity of relationship between tobacco exposures, gender, 
circulating A1AT, systemic inflammatory status and lung function.   
Nowadays, the efforts are directed towards determination of the cut-off values with high 
specificity and sensitivity, in order to separate normal from deficient phenotypes. The value 
of A1AT serum level of 22 M (1, 2 g/L) has been determined as a reliable cut-off able to 
identify A1ATD with a specificity of 73% and a sensitivity of 97% (Corda et al., 2006). The 
lower value of 18.5 M (1.00 g/L) was able to detect heterozygous A1ATD (Simsek et al., 
2011), while cut-off value of 14.7 M (0.8 g/L) was proposed for detection of all patients 
who are at risk of A1ATD (Prins et al., 2008).    
  
 
Fig. 4. Alpha-1-antitrypsin deficiency−testing algorithm (Snyder et al., 2006) 
4. Oxidation of alpha-1-antitrypsin and emphysema 
Cigarette smoke and lung inflammation leads to proteolytic destruction of the lung 
parenchyma with characteristic loss of alveolar integrity and an enlargement of alveolar 
space (reviewed in: Sharafkhaneh et al., 2008). Oxidative stress, as a result of an imbalance 
between oxidants and antioxidants, plays a critical role in the pathogenesis of emphysema 
(Rahman, 2005; Janoff et al., 1983). There are two main significant sources of oxidants: 
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exogenous from cigarette smoke or air pollutants and endogenous from activated 
neutrophils and macrophages.  
Oxidative stress caused by cigarette smoke and airway inflammation together form a 
vicious circle. It has been shown that cigarette smoke-mediated oxidative stress induces the 
release of proinflammatory cytokine by activation of NF-kappaB and posttranslational 
modifications of histone deacetylase in macrophages (Yang et al., 2006). Chronic 
inflammation that persists in emphysema leads to the activation of macrophages and 
neutrophils (Finkelstein et al., 1995), which are a significant source of reactive oxygen 
species (ROS). When ROS overwhelm lung antioxidant defenses, the oxidative stress arises. 
Thus, cigarette smoke and activated macrophages/neutrophils represent considerable 
source of reactive oxygen species in emphysema. 
Cigarette smoke contains free radicals with tremendous oxidative power which serve as 
direct damaging agents and/or precursor of the other damaging substances. The main free 
radicals in cigarette smoke are superoxide (O2-•), hydroxyl radical (•OH), and hydrogen 
peroxide (H2O2) (Pryor, 1997).   
Harmful effects of oxidative stress are numerous: inactivation of antiproteases, disregulation 
of cell proliferation, induction of apoptosis, modulation the immune system, direct damages 
of proteins, lipids, and nucleic acids. The products of lipid peroxidation, protein oxidation, 
and nucleic acid oxidation have been shown in emphysema (Mohsenin, 1991; Sahin et al., 
2001; Hackett et al., 2010; Torres-Ramos et al., 2009; Deslee et al., 2009; Deslee et al., 2010).  
4.1 Oxidation of A1AT - structural and functional consequences  
A1AT is a protein susceptible to oxidation, and its exposure to pro-oxidative enzymes and 
chemicals results in their oxidation. Exposure of one A1AT molecule to oxidants results in 
oxidation of Met358 and Met351 residues to methionine sulfoxide (Johnson and Travis, 1979). 
Oxidation of both Met358 and Met351 significantly reduces the ability of A1AT to inhibit 
neutrophil elastase (Beatty et al., 1980; Taggart et al., 2000). Oxidation of Cys232 is far more 
likely to occur in oxidizing environments comparing with oxidation of exposed and reactive 
methionine residues (Griffiths et al., 2002). The structural and biological aspects of Cys232 
oxidation are still unknown.  
Methionine residues can be oxidized by cigarette smoke-derived oxidants (Pryor et al., 1984), 
produced in vivo  such as peroxide, hydroxyl radicals, chloramines, hypochloride, inducible 
nitric oxide, and peroxynitrite (Vogt, 1995), or with mineral dust (coal, amosite asbestos, silica, 
or titanium dioxide) (Li et al., 1997). Thus the oxidation of A1AT by cigarette smoke or free 
radicals in vivo could lead to a functional deficiency of A1AT and has been suggested as a 
mechanism contributing to the development of emphysema in non-deficient PiM individuals. 
Cigarette smoke-mediated oxidation of the Z mutant accelerates process of  polymerization, 
which further reduces defense of lung, increases neutrophil influx into the lungs (Alam et al., 
2011), and contributes to premature emphysema in PiZZ homozygotes who smoke.  
It has been reported that cigarette smoke oxidize A1AT (oxyA1AT), and reduces inhibitory 
activity of A1AT against elastase (Janoff et al., 1979) and caspase-3 (Petrache et al., 2006a). 
Substantial constituents of cigarette smoke that oxidise and inactivate A1AT include 
hydrogen peroxyde, nitrogen dioxide, transition metals, and products of lipid peroxidation 
initiated by cigarette smoke (reviewed in: Evans and Pryor, 1994). Inactivation of 
antielastase activity of A1AT is reversible and phenolic antioxidants prevented the 
suppression of serum elastase-inhibition by cigarette smoke (Carp and Janoff, 1978).  
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Another mechanism of A1AT oxidation is its oxidative inactivation in the microenvironment 
of inflammatory cells, at sites of acute or chronic inflammation. The lower airways of 
smokers are infiltrated with phagocitic cells. Induced neutrophils and alveolar macrophage 
release a spectrum of oxidants and pro-oxidative enzymes that may inactivate A1AT in their 
local environment. Increased release of proteases from triggered phagocytes and reduced 
antiprotease defense leads to damage of lung tissue (Carp and Janoff, 1980). 
Myeloperoxidase-dependent production of oxidants from neutrophils is increased in 
inflammation, and can cause significant damage of A1AT. Myeloperoxidase (MPO) is 
located in the azurophilic granules of the neutrophils, and plays an important role in the 
human immune system by killing bacteria and invading pathogen. Under certain 
circumstances, a MPO can be released into the extracellular space. In the presence of 
hydrogen peroxide and chloride ions, MPO produces hypochlorous acid (HOCl), the major 
strong oxidant which reacts readily with free amino groups to form N-chloramines. In vitro 
studies show that MPO inactivates purified A1AT trough oxidation of two methionine 
residues (Matheson et al., 1979; Summers et al., 2008). Hydrogen peroxide released from 
macrophages in the small airways of smokers synergistically with hydrogen peroxide from 
tobacco may contribute to the oxidative inhibition of A1AT (Cohen and James, 1982). 
Moreover, A1AT oxidized by the myeloperoxidase-hydrogen peroxide system (MPO-H2O2), 
in inflammation, promotes the formation of IgA-A1AT complexes, and consequently the 
elastase inhibitory activity of A1AT is reduced (Scott et al., 1999). 
Recent studies have shown that although oxyA1AT loses antielastase activity it gets new 
biological properties that may be important in the pathogenesis of certain diseases. Several 
studies have shown that oxyA1AT behaves as a proinflammatory stimulus. Moraga et al. 
(Moraga and Janciauskiene, 2000) revealed that oxyA1AT activates monocytes, which is 
reflected in significant elevation in monocyte chemoattractant protein-1, cytokine IL-6, and 
TNF expression, as well in increased activity of NADPH oxidase. Furthermore, oxyA1AT 
by activation of pro-oxidative NADPH oxidase may promote its own formation and thereby 
contributes to inflammation. OxyA1AT generated in the airway interacts directly with 
epithelial cells to release chemokines IL-8 and MCP-1, which in turn attracts macrophages 
and neutrophils into the airways (Li et al., 2009). The release of oxidants by these 
inflammatory cells could oxidize A1AT, perpetuating the cycle and potentially contributing 
to the pathogenesis of COPD.  
4.2 Oxidation of A1AT - clinical aspects  
Centrolobular emphysema in smokers as a clinical manifestation is strongly associated with 
functional deficiency caused by oxidation of A1AT. Several studies supported the 
mechanism by which tobacco smoke increased the risk of developing emphysema. 
According to this mechanism, cigarette smoke reduces protease inhibitory capacity, causing 
the increase of the lung vulnerability to elastolytic destruction and thereby increasing the 
risk for the development of emphysema (Carp et al., 1982; Janoff et al., 1983; Ogushi et al., 
1991). By losing the antiprotease ability and becoming pro-inflammatory stimulus, the 
oxyA1AT favors the development of clinical emphysema.  
OxyA1AT has a potential clinical significance in atherogenesis. Mashiba et al. (Mashiba et 
al., 2001) have revealed that A1AT produced and oxidized by macrophages, attaches to low 
density lipoprotein (LDL) in the intima of the arterial wall and contributes to the lipid 
accumulation in arterial wall cells in the early stage of atherogenesis. 
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In addition, reduction of antielastase activity was observed in hemodialysis patients 
(Hashemi et al., 2009). Furthermore, Honda et al. (Honda, et al., 2009) reported that serum 
levels of oxyA1AT positively correlated with myeloperoxidase in patients on hemodialysis, 
and could represent a useful marker for the estimation of the increasing carotid intima-
media thickness. They also found that oxyA1AT might be an independent predictor of 
protein-energy wasting in patients on hemodialysis. Oxidized A1AT was also detected in 
patients with Alzheimer's disease, heart failure, and in premature rupture of the fetal 
membrane (Choi et al., 2002; Banfi et al., 2008; Izumi-Yoneda et al., 2009). 
4.3 Perspective of the determination of oxidized A1AT 
Determination of oxyA1AT as biomarker is not used in routine practice, although it may be 
useful in assessment of pulmonary emphysema risk, and other pathological conditions 
associated with oxidative stress and inflammation. Our knowledge of the clinical 
significance of oxyA1AT is still insufficient, as well the optimal quantification of oxyA1AT.  
Previously used method for quantification of oxyA1AT was based on determination of 
elastase- (EIC) and trypsin inhibitory capacity (TIC) (Beatty et al., 1982). As oxyA1AT loses 
its ability to inhibit porcine elastase but retains antitrypsin activity, the increased TIC/EIC 
ratio correlates with degree of A1AT oxidation. Progress in oxyA1AT methodology includes 
development of immunochemical method (Ueda et al., 2002).  
Advanced methodology of quantification of oxyA1AT should be developed as a sensitive, 
specific method which would be suitable for routine practice. 
5. Conclusion  
The only proven genetic risk factor in pathogenesis of emphysema is severe alpha-1-
antitrypsin deficiency. However, several known and unknown genetic and environmental 
factors contribute to the differences in the susceptibility of A1ATD individuals to develop 
lung disease. Among the most important are cigarette smoke and air pollutants that could 
provoke oxidative stress and inflammatory response.  
So far, a lot of attention and efforts in A1ATD research was given to the deficient A1AT 
variants and A1AT polymerization, while the oxidation of A1AT protein has been generally 
overlooked. Non-deficient, heavy smokers may have normal serum level of A1AT, but with 
reduced functional activity due to functional deficiency caused by oxidation. The 
physiological role of oxyA1AT could be particularly important regarding growing evidence 
of different biological functions of A1AT that go beyond those usually linked to its 
antiprotease activities. Future studies will elucidate the role of A1AT oxidation in 
modulation of inflammation and tissue destruction which represent landmarks of 
emphysema, as well in modulation of augmentation therapy. 
The early recognition and diagnostics of A1ATD is the most important in terms of 
prevention and delay of the onset of symptoms of emphysema. The optimal approach in 
therapy of A1ATD would be to inhibit the polymerization of the Z protein (intracellular and 
extracellular) and prevent oxidative stress, accompanied by standard augmentation therapy.  
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1. Introduction  
Human alpha-1-proteinase inhibitor (1-PI) is a well-characterized multifunctional protease 
inhibitor, the major physiological role of which is inhibition of neutrophil elastase (NE) in 
the lungs. The importance of1-PI is underlined by its deficiency which is characterized by 
low levels of 1-PI in the circulation. Under such conditions, lower levels of 1-PI are 
transported to tissues, including the fragile alveoli of the lungs. 1-PI deficiency (with levels 
of 1-PI in blood below 11 M, insufficient for inhibition of proteolytic enzymes in the 
lungs) is a common genetic condition predisposing 1-PI-deficient individuals to the 
development of chronic obstructive pulmonary disease (COPD). Hereditary1-PI deficiency 
is classically associated with the development of premature, ultimately fatal, panacinar 
emphysema. To slow down the progression of emphysema, several licensed 1-PI 
concentrate preparations derived from pooled human plasma are currently available for 
intravenous augmentation therapy for patients with congenital 1-PI deficiency and 
clinically evident emphysema. In addition, and as an alternative to the plasma-derived 1-PI 
products, multiple efforts have been made to develop recombinant versions of human 1-PI 
over the last three decades. This review describes the recent advances in the research and 
development of human 1-PI for therapetic use and covers the following: characterization of 
human 1-PI; epidemiology of 1-PI deficiency and currently licensed treatment; summary 
of the manufacturing and recent quality improvements of the 1-PI plasma-derived 
products; safety and efficacy of 1-PI intravenous augmentation and alternative routes; 
development of recombinant versions of human 1-PI; conditions other than emphysema 
that are associated with 1-PI; and some other aspects related to the research and 
development of 1-PI for therapeutic use.  
                                                 
 The findings and conclusions in this article have not been  formally disseminated by the Food  
and Drug Administration and should not be construed to represent any Agency determination or  
policy  
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2. Human 1-PI and 1-PI deficiency  
2.1 Structure and function of 1-PI  
Human alpha-1-proteinase inhibitor (α1−PI), also known as alpha-1-antitrypsin, is the most 
abundant inhibitor of serine proteases in plasma. It is predominantly synthesized in 
hepatocytes, but is also produced, to a lower extent, by alveolar macrophages, neutrophils, 
and some other cells (White et al., 1981; Carlson et al., 1988; Paakko et al., 1996). In healthy 
individuals, the concentration of α1−PI in blood normally varies from 20 µM to 53 µM (1.04-
2.76 g/L) (Brantly et al., 1988; Brantly et al., 1991) with a half-life in the circulation of about 
3-5 days (Crystal, 1989; Kalsheker et al., 2002). Though α1−PI has a wide range of inhibitory 
activities, its main physiological role is known to be the inhibition of polymorphonuclear 
leukocyte (neutrophil) elastase (NE) in the lungs (Travis, 1988). In the lower respiratory tract 
of healthy lungs, 1–PI provides more than 90% of the anti–neutrophil elastase protection 
(Crystal, 1991; Crystal et al., 1989). Hereditary α1−PI deficiency (with levels of α1−PI in 
blood below 11 µM, insufficient for inhibition of NE) is classically associated with 
development of early-onset pulmonary emphysema, a hallmark of α1−PI deficiency (Crystal 
et al., 1989; Snider, 1992). Smoking is known to be the biggest risk factor for developing 
emphysema; in smokers with α1−PI deficiency a severe lung impairment is usually observed 
in their fourth decade of life. 
α1-PI is encoded by a single 12.2 kb gene (Pi) located on the long arm of chromosome 14 
(Long et al., 1984; Rabin et al., 1986). Over 120 alleles of α1−PI have been identified with 
approximately 35 of them being associated with α1−PI deficiency, including Z-allele, which 
is the most common cause of the deficiency when inherited in a homozygous fashion. Due 
to a single mutation in the mobile domain (Glu342Lys), the α1−PI Z-mutant undergoes 
aberrant conformational transitions that prompts the protein to aggregate. This results in 
retention of polymerized α1−PI Z mutant within hepatocytes, thus inducing disease 
conditions in the liver and causing α1−PI deficiency in the circulation (Ekeowa et al., 2011; 
Lomas, 2005; Volpert et al., 2000). The prevalence of three major α1−PI variants (PiM, PiS, 
and PiZ) defines the number of carriers (PiMZ and PiMS) and individuals with deficiency 
phenotypes ( PiZZ, PiSZ, and PiSS). The epidemiology of α1−PI deficiency and its clinical 
manifestations, including lung diseases and liver diseases, has been described in detail 
(Ekeowa et al., 2011; Luisetti & Seersholm, 2004; Needham & Stockley, 2004; Gooptu & 
Lomas, 2009). Based on the α1−PI serum concentration, a common classification to define 
α1−PI deficiency includes the four major categories: (1) normal (with α1−PI serum levels not 
lower than 20 M); (2) deficient (with α1−PI concentrations in serum lower than 20 M); (3) 
dysfunctional (with normal α1−PI level, but lost or lower inhibitory activity); and (4) null 
(with α1−PI serum concentrations below the detectable level). 
α1−PI is a 52 kDa glycoprotein belonging to the serine protease inhibitor (serpin) 
superfamily, which in addition to α1-PI also includes 1-antichymotrypsin, antithrombin, 
plasminogen activator inhibitor, C1 esterase inhibitor, and many others (Stein & Carrell, 
1995; Silverman et al., 2001). A single polypeptide chain of  α1-PI is comprised of 394 amino 
acid residues, including one cysteine, 2 tryptophanes, and 9 methionine residues (Carp et 
al., 1982; Johnson & Travis, 1979). Three N-linked glycans attached to asparagine residues 
46, 83, and 247 represent ~12% of α1−PI by molecular weight (Mega et al., 1980a,b;  
Carrell et al., 1981, 1982). The carbohydrate moiety is comprised of biantennary N-glycans, 
but also triantennary and traces of tetraantennary structures grounded on the mannose fork 
core and containing N-acetyl glucosamine, galactose, and terminal negatively-charged sialic 
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(N-acetylneuraminic) acid (Mega et al., 1980b; Travis & Salvesen, 1983; Kolarich et al., 
2006a). The glycosylation pattern is a major cause of the iso-electric focusing (IEF) pattern 
typical for α1−PI with major isoforms M2, M4, M6, and also M7 and M8 due to the N-
terminal truncation (Jeppsson et al., 1985; Kolarich et al., 2006a,b). Some characteristics of 
human α1−PI are listed in Table 1. Like the majority of other native glycoproteins, α1-PI is 
intrinsically a highly heterogeneous moiety, mainly due to variably trimmed glycosylation 
and an N-terminal pentapeptide that can be absent (Hercz, 1985; Krasnewich et al., 1995; 
Vaughan et al., 1982). 
 
Characteristics Description 
Synonyms  alpha-1-proteinase inhibitor, alpha-1-antitrypsin 
Common abbreviations α1−PI, alpha-1-PI, α1−AT, alpha-1-AT, A1AT, ATT, AT 
Classification Serine proteinase inhibitor (serpin) 
Substrates Neutrophil elastase, trypsin, chymotrypsin 
Molecular weight 52,000 Da (50,300 Da by mass spectrometric analysis) 
Glycosylation Three N-attached carbohydrates (12% w/w) 
Polypeptide Single polypeptide chain of 394 amino acid residues 
Heterogeneity Highly heterogeneous protein 
Major isoforms M2, M4, M6, M7 and M8 
Half-life in circulation 3-5 days (for native plasma α1−PI) 
Concentration in blood Acute-phase plasma protein, concentration normally 
varies from 20 µM to 53 µM (1.04-2.76 g/L) 
Major biological activities Inhibitory anti-serine proteinase activity 
Multiple non-inhibitory activities 
Aggregation α1−PI Z mutant is naturally prone to aggregation 
α1−PI S mutant aggregates to a lower degree 
Physiologically important 
phenotypes 
PiMM (normal); PiSS, PiSZ & PiZZ (deficiency 
phenotypes); PiZZ, PiSS & PiNull (the most abnormal) 
Diagnostic α1-PI variants 
(serum concentrations) 
Normal (NLTa 20 M); Deficient (lower than 20 M; 
Dysfunctional (NLT 20 M, inactive); Null (n.d.b level) 
Diseases related to α1−PI 
deficiency and aggregation 
Pulmonary and liver diseases 
Other rare diseases (putative)c 
a NLT, not lower than; b n.d., non-detectable; c See Table 3 
Table 1. Characteristics of human α1-PI 
Figure 1 shows a crystal structure of α1-PI, typical for serpins, which features 9 α-helices, 3 
β-sheets (A, B, and C), and a mobile 15-residue reactive center loop (RCL) exposed for 
interaction with the target serine protease (Johnson & Travis, 1979; Lomas, 2005).  Protease 
attack of the RCL results in cleavage at Met358-Ser359, formation of a covalent α1-PI-
protease complex with the amino-terminal polypeptide inserted into the A β-sheet, and an 
overall dramatic conformational change (Huntington et al., 2000; Ludeman et al., 2001; 
Stratikos & Gettins, 1999; Wilczynska et al., 1997).  
Unlike the majority of proteins, α1−PI is naturally folded in a metastable structure which is 
essential for its function. This is not the most thermodynamically stable form, and thus, α1-
PI is prone to a variety of conformational transitions and modifications (Lomas, 2005; Lomas 
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et al., 1995). Much like other serpins, α1-PI can intramolecularly convert into a more stable 
latent form, which is inactive, but the biological activity can be restored via denaturation 
and refolding (Lomas et al., 1995; Silverman et al., 2001).   
 
 
Fig. 1. Crystal structure of α1-PI (PDB 1HP7) in two projections. (A) Front view at the α1-PI    
structure in respect to -sheet A, and (B) Side view obtained by 90o clockwise rotation of the 
molecule. The images were obtained using PyMOL (the PyMOL Molecular Graphics 
System, Version 1.1r1, Schrödinger, LLC). 
In addition to its inhibitory antiprotease function, α1−PI exhibits a broad spectrum of non-
inhibitory activities (Brantly, 2002; Janciauskiene et al., 2011; Nita et al., 2005). Because of  
the nine methionine residues in α1−PI molecule, its plausible role as a putative antioxidant 
has been suggested (e.g., Levine et al., 1999, 2000).  
Due to the abundance of α1−PI in human plasma and its conservative tertiary structure with 
hydrophobic cavities (Elliott et al., 2000; Lee et al., 2001; Parfrey et al., 2003), α1−PI has the 
capacity to bind small hydrophobic molecules. This property has been explored mainly with 
respect to the peptides and small molecules that may prevent the aggregation of the α1−PI Z 
mutant (Mahadeva et al. 2002; Mallya et al., 2007; Chang et al. 2009).  
2.2 The 1-PI deficiency and 1-PI replacement therapy 
There are approximately 60,000-100,000 severely deficient individuals in the United States 
which define α1-PI deficiency as a rare disease. However, according to several publications, 
α1-PI deficiency is widely under- and mis-diagnosed (e.g., de Serres, 2003; Bals et al., 2007). 
As reported by the World Health Organization (WHO, 1997), only 4% of  the individuals 
with α1-PI deficiency cases are identified, and only a portion of them are receiving 
treatment. Currently licensed treatment of the patients with α1-PI deficiency and 
manifestation of pulmonary emphysema involves intravenous infusion of plasma-derived 
α1-PI preparations with the recommended dose of 60 mg of active α1-PI per kg of body 
weight administered once weekly. To maintain a threshold level of α1-PI (11µM), α1−PI- 
deficient patients should receive augmentation therapy for the duration of their lives, to 
slow the progression of emphysema. This nadir level has been determined based on α1-PI 
 
RCL A B RCL 
-sheet A 
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levels observed in the plasma of individuals who are heterozygous for Z-mutant α1−PI and 
who do not develop emphysema. Evaluation of the efficacy of α1-PI products used in clinical 
studies is based on surrogate markers: the infusion of α1-PI must elevate the circulating 
serum level of α1−PI above an epidemiologically established ‘protective threshold’ and the 
protein must be detectable in bronchoalveolar lavage fluid (Juvelekian & Stoller, 2004; 
Sandhaus, 2009). However, the ability of α1-PI augmentation therapy to reduce the 
progression of emphysema still remains to be proven. Safety and efficacy of intravenous α1-
PI augmentation are considered in section 3.3.1. For other disease conditions that may 
possibly benefit from α1-PI therapy see section 3.3.3.  
3. Research and development of 1-PI for therapeutic use 
3.1 Plasma-derived 1-PI products  
3.1.1 Currently approved 1-PI products  
Currently there are six commercial plasma-derived α1-PI products (Table 2) licensed by the 
US FDA for intravenous treatment of patients with hereditary α1-PI deficiency who show 
evidence of emphysema. Prolastin® (registered trade name of Bayer Corporation since 1987) 
was the first α1-PI product to be approved. Since 2005, when Bayer Corporation was 
acquired by Talecris Biotherapeutics (Research Triangle Park, NC, USA; www.talecris.com), 
the product has been manufactured by Talecris. Aralast® (initially registered trademark of 
Alpha Therapeutic Corporation) was approved in 2003, and has been manufactured under 
the direction of Baxter Healthcare Corporation since then (Baxter, Westlake Village, CA, USA 
www.baxter.com). Zemaira® (registered trade name of Aventis Behring since 2003), another 
available product, is now manufactured by CSL Behring LLC (Kankakee, IL, USA; 
www.cslbehring-us.com). In 2007, the US FDA approved another of Baxter’s preparations of 
α1-PI concentrate - Aralast NP® - that has the same formulation as its predecessor, but differs 
from the earlier approved product by having a significantly lower content of C-terminal 
lysine-truncated α1-PI (approximately 2% vs. 67%). In 2009, the US FDA approved Prolastin 
C®, the updated version  of the earlier Talecris product that had been on the market for more 
than two decades. Due to more sophisticated purification and pathogen reduction steps, 
including  two dedicated viral inactivation steps instead of heat treatment, the specific activity 
of Prolastin C® (above 0.7 mg of functional α1-PI per mg of total protein) is twice higher than 
that of Prolastin®, which means that lower volumes and shorter transfusion time are needed. 
Most recently, in July 2010, the FDA approved GlassiaTM (formerly Respira), a product 
manufactured by Kamada (Weizmann Science Park, Ness Ziona, Israel; www.kamada.com) 
and commercially launched by Baxter in the United States and some other countries. GlassiaTM 
is another highly purified α1-PI (with specific activity above 0.7 mg of active α1-PI per mg of 
total protein) and the only α1-PI product that is available in a ready-to-use liquid form with a 
shelf-life stability of two years under refrigerated conditions.  
α1−PI products are manufactured as part of a complex plasma fractionation scheme which 
was originally developed for large-scale production of albumin, but now also yields many 
other plasma therapeutics. Since products are made from pooled human plasma, they may   
                                                 









Date of  
licensure Product form 
Major steps of viral 
inactivation/removal  
Prolastin® Talecris Biotherapeutics 12/2/1987 
Lyophilized  
powderb 
Depth Filtration Heat 
Treatment 





Zemaira® CSL Behring 7/8/2003 Lyophilized  powder 
Heat Treatment  & 
Ultrafiltration 










 GlassiaTM Kamada 7/1/2010 Ready-to-use liquid 
Solvent/Detergent & 
Nanofiltration 
a Based on recent publications including (Stockley, 2010; Tonelli & Brantly, 2010)  
b Reconstitution using Sterile Water for Injection is required  
c  Aralast®, previously known as Respitin, contains approximately 67% of α1-PI with the truncated  
C-terminal lysine (Lys394)  
d Aralast NP® contains approximately 2% of α1-PI with truncation of C-terminal lysine residue 
Table 2. The plasma-derived α1-PI therapeutic products approved by the US FDA for   
chronic augmentation and maintenance therapy in adults with congenital α1-PI deficiency 
and clinically evident emphysemaa 
carry the risk of transmitting human infectious agents, e.g., some viruses, and theoretically, 
the Creutzfeldt-Jakob disease (CJD) agent or disease variant agents, as well as emerging or 
unknown infectious agents. To reduce the potential risk of transmitting infectious agents, 
the α1-PI preparations are manufactured using a number of viral inactivation and removal 
steps. Currently approved α1−PI products differ in the procedures used for pathogen 
reduction. For instance, the heat treatment procedure used in manufacturing of Prolastin 
was one of the reasons for higher content of inactive and aggregated α1−PI in the product. 
The manufacturing procedures of the later products (Table 2) include two dedicated steps 
that are specifically designed for inactivation and removal of viruses (Hotta et al., 2010). 
Thus, solvent/detergent treatment and nanofiltration are used as the dedicated pathogen 
reduction steps in the manufacturing of recently approved Prolastin C®, GlassiaTM  and both 
Aralast products. Overall, the manufacturing history of plasma-derived α1-PI therapeutic 
products reflects a trend of continous improvement of product quality.  
3.1.2 Heterogeneity of α1-PI products  
Heterogeneity of α1-PI therapeutic preparations is a complex phenomenon. First of all,  
heterogeneous nature of plasma α1-PI is an intrinsic property of the native glycoproten (see 
2.1). Second, the presence of variously processed α1-PI forms including latent, cleaved, 
complexed or aggregated α1-PI species, is barely avoidable. However, it must be kept 
minimal as the inactive protein species have a direct influence on the product’s specific 
activity. Third, α1-PI products purified from pooled human plasma contain certain 
impurities of other plasma proteins, including albumin, haptoglobin, α1-antichymotrypsin, 
α1-lipoprotein, antithrombin III, C1-esterase inhibitor, etc. The human origin of these 
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impurities ensures their tolerability, however, the level of these plasma proteins in α1-PI 
concentrate may significantly increase the non-therapeutic protein load in the α1-PI 
preparation intended for transfusion. In addition to all that, multistep manufacturing 
procedures are known to induce various protein alterations, such as aggregation and 
chemical modifications (e.g., deamidation, cysteinylation, and C-terminal truncation). Some 
modifications can be observed by IEF and other techniques (Cowden et al., 2005; Kolarich et 
al., 2006a, 2006b) and reflected in the product specifications. Currently there are no data that 
would demonstrate whether these alterations affect the in vivo activity, safety, efficacy or 
immunogenicity of α1-PI therapeutic preparations. In general, commercial plasma-derived 
α1-PI products differ in terms of their purity, specific activity, modifications, and excipients 
(Lomas et al., 1997; Cowden et al., 2005; Stockley, 2010; Tonelli & Brantly, 2010).    
3.2 Research and development of the recombinant versions of human 1-PI  
3.2.1 Advances in the development of recombinant α1-PI  
The plasma supply per se is a limited source and appears to be insufficient to meet 
anticipated clinical demand. Moreover, despite effective viral inactivation/removal  steps in 
the manufacturing of plasma proteins (Cai et al., 2005; Hotta et al., 2010), the risk of 
contamination with new and unknown pathogens may still exist. Therefore, recombinant 
technology has been widely explored as an alternative approach for the production of 
human α1-PI since the pioneering works of the early 1980s (Bollen et al., 1983; Cabezon et al., 
1984; Rosenberg et al., 1984). As evident from numerous reports, both from academic 
research and industry, the human gene for α1-PI has been expressed in virtually all available 
hosts (E. coli, various yeasts, fungi, insect cells, CHO cells, human neuronal cells, and 
produced in transgenic plants and animals). For more details on  research and development 
of recombinant α1-PI (r-α1-PI) in different systems and advances and limitations of the 
recombinant approach for production of stable and biologically active α1-PI, see our 
comprehensive 2006 review (Karnaukhova et al., 2006). More recently, the human gene for 
α1-PI has been expressed in filamentous fungi (Chill et al., 2009; Karnaukhova et al., 2007), 
transgenic tomato plants (Agarwal et al., 2009), tobacco cell cultures (Huang et al., 2009; 
Nadai et al., 2009), and human neuronal cell lines (Blanchard et al., 2011). Nevertheless, no r-
α1-PI  is available as a licensed therapeutic treatment. In general, the essential criteria for the 
development of therapeutics for human use are safety, optimal clinical efficacy, and 
maximum cost-effectiveness. Among many efforts to develop r-α1-PI of therapeutic quality 
(see Karnaukhova et al., 2006), there appear to be only two examples of the r-α1-PIs for 
which development went far enough to get to clinical trials. The first was r-α1-PI produced 
in the yeasts Saccromyces cerevisiae and manufactured by Arriva Pharmaceuticals Inc. 
(Arriva) for several indications. A nebulized formulation of  this non-glycosylated r-α1-PI 
preparation has been intended for the treatment of respiratory disorders including 
emphysema and COPD (phase II clinical trials), and asthma (pre-clinical studies) (Brown, 
2006a). Although animal studies have been considered  to be successful (Pemberton et al., 
2006), human trials have not been recommended (see review by Stokley, 2010). A topical gel 
formulation of r-α1-PI has been intended for the treatment of dermatitis and other severe 
dermatological disorders in phase II clinical trials (see Brown, 2006b).  
The second example of the advanced development of recombinant human α1-PI is large 
scale production performed in transgenic dairy animals (t-α1-PI): sheep [by PPL 
Therapeutics (UK) in partnership with Bayer Biologicals (USA), (Dalrymple & Garner, 1998;  
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Wright et al., 1991)], and goats [by Genzyme Transgenics Corporation (USA), (Ziomek, 
1998)]. The transgenic α1-PI  recovered from sheep milk was purified to 99.9% purity.  Even 
so, sheep native α1-PI and sheep α1-antichymotrypsin were major impurities, at 6.7-18.7 
mg/L and 60.3-75.8 parts per million, respectively. Two sequential clinical studies were 
performed to evaluate the safety and immunogenicity of aerosolized transgenic human α1-
PI. None of the subjects had an antibody response to human t-α1-PI (Tebbutt, 2000; Spencer 
et al., 2005); however, antibody responses were observed to sheep α1-PI and to sheep α1-
antichymotrypsin (Spencer et al., 2005).  Four patients withdrew from the study due to the 
development of dyspnea and a decline in lung function, and the later product development 
was terminated.   
3.2.2 Pitfalls in the development of r-α1-PI for therapeutic use  
The general regulatory requirements for biologicals intended for therapeutic use, including 
r-α1-PI, are purity, safety, and efficacy. In order to be effective, therapeutic proteins have to 
be stable in vivo and in vitro (Karnaukhova et al., 2006). Reviewing the work performed over 
the last two decades to produce stable and biologically active r-α1-PI of therapeutic quality, 
one can see basically two major factors that were impeding the progress: (1) impurities that 
could induce antibody responses and cause adverse reactions in patients, and (2) lower 
stability than that of plasma counterpart, mainly caused by the lack of glycosylation or non-
human type of glycosylation (the latter may also induce immune responses). Although 
presently the first reason can be technically better solved, removal of trace amounts of non-
human native proteins derived from the host, e.g., sheep α1-PI, from the human r-α1-PI to 
exclude further adverse reactions, requires a much higher level of purification than was 
possible at the time of that development. As for the second reason, indeed, glycosylation is 
considered to be a cause of rapid clearance of r-α1-PI from the circulation (Casolaro et al., 
1987; Cantin et al., 2002a). Aberrant glycosylation (or lack of glycans) does not neccessarily 
affect biological activity of the recombinant protein, but it is important for its stability. 
According to recently published data, glycosylation of α1-PI does not interfere with the 
serpin native state flexibility (or instability) essential for its efficient function, though it may 
confer resistance to degradation by proteases and thus extend its half-life in the circulation 
(Sarkar & Wintrode,  2011). Extensive work performed over decades for the development of 
viable r-α1-PI of therapeutic quality and lessons learned from these experiences truly paved 
the way for other protein therapeutics. It is worthwhile to mention two serpins produced in  
transgenic animals that were recently approved. In 2009, the US FDA approved recombinant 
antithrombin (ATryn®) produced in the milk of transgenic goats (Fyfe & Tait, 2009). In 2010, 
another serpin, recombinant human C1-esterase inhibitor (Ruconest®) produced in the milk 
of transgenic rabbits was granted European marketing authorization (Varga & Farkas, 2011). 
Both pharmaceutical proteins show a faster clearance, yet it may not be an issue depending 
on the intended use. For instance, Ruconest® was approved for the treatment of acute 
attacks of hereditary angioedema, and therefore there is no need to maintain its higher level 
in blood longer than its action is required. Given a shorter in vivo half-life of recombinant α1-
PI, it has been considered for other administration routes and applications, such as 
inhalation for the treatment of emphysematous condition, and topical application for 
various skin diseases. However, a convincing proof of the recombinant product efficacy and 
safety in appropriate clinical trials is as problematic as it is for plasma-derived α1-PI; large 
clinical trials in the cases of rare diseases are difficult to perform because of small 
geographically dispersed patient populations. In addition, a limited population means a 
Recent Advances in the Research  
and Development of Alpha-1 Proteinase Inhibitor for Therapeutic Use 
 
91 
limited market, which is less attractive for large investments. No doubt, these reasons 
markedly slow down the development of r-α1-PI. 
3.31-PI –based therapies 
3.3.1 Safety and efficacy of intravenous 1-PI augmentation  
The intravenous augmentation of α1-PI was shown to be safe and well tolerated over a long 
history of the replacement therapy. However, its impact on disease progression and 
mortality still remains to be convincingly proven. α1-PI augmentation is assumed to slow 
down the rate of emphysema development and progression and, thus, to improve the life 
quality and duration of α1-PI deficient patients, yet the essential proof of efficacy is missing. 
According to Hubbard & Crystal (1990), only approximately 2-3% of infused α1−PI actually 
reaches the lungs; and the effictiveness of α1-PI replacement therapy has been evaluated 
mainly on the bases of biochemical (not clinical) criteria (Tonelli & Brantly, 2010). For 
recently approved α1-PI products, their pharmacokinetic equivalence and comparable safety 
profile to Prolastin were demonstrated (e.g., Stocks et al., 2010). α1-PI  therapy is a life-long 
and very expensive treatment that may cost up to $150,000 (Silverman, 2009) in the United 
States. Whether this therapy decreases mortality also remains unknown, as there are no 
reliable data on mortality, as well as morbidity and survival (Gøtzsche & Johansen, 2010a). 
Some observational studies support the idea that augmentation therapy may help to slow 
the decline in lung function (Seersholm et al., 1997; Wencker et al., 2001; Kueppers, 2011). 
But there are also more critical evaluations including the opinion that α1-PI augmentation 
therapy cannot be recommended due to lack of evidence of clinical benefit and the cost of 
treatment (Gøtzsche & Johansen, 2010a, 2010b). It is currently widely admitted that the 
efficacy of α1-PI augmentation therapy has never been persuasively demonstrated and must 
be proven in a proper clinical trial. Due to the widespread and small clusters of patients all 
over the country, conducting a prospective, randomized, placebo-controlled clinical trial is 
challenging. In addition, the development of emphysema proceeds slowly, creating the 
additional difficulties of monitoring lung function decline and mortality data (Hutchinson & 
Hughes, 1997; Schluchter et al., 2000).   
3.3.2 Alternative routes of administration of 1-PI products 
Due to the inconvenience of life-time intravenous augmentation therapy and low levels of 
α1−PI reaching lungs, the inhalation of aerosolized α1-PI has been suggested as a less 
invasive and more efficient way to deliver large amounts of α1-PI directly to the lungs where 
it is most needed (Hubbard et al., 1989; McElvaney et al., 1991; Cockett, 1999). Although 
strategies for aerosol therapy of α1-PI deficiency has been proposed two decades ago 
(Hubbard et al., 1989; Hubbard & Crystal, 1990), there is still no α1-PI aerosolized treatment 
approved. Several studies examined efficiency of the α1-PI inhalation therapy in animals 
and in humans (Kropp et al., 2001; Siekmeier, 2010). It was demonstrated (Kropp et al., 2001) 
that significantly more α1-PI was deposited in the lungs through the inhalational route than 
via intravenous infusion (14.6% vs. 2%). Although the inhalation route seems attractive, 
nevertheless, enabling the inhaled material to reach the lung interstitium, the most 
important to the emphysematous process region, is still problematic. With regards to 
recombinant versions of α1-PI, it is generally assumed that products directly delivered to the 
lungs may not require the same degree of stability as α1-PI given intravenously. However, 
as mentioned above, human studies using r-α1-PI from transgenic sheep were associated 
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with adverse reactions due to impurities derived from the host (Spenser et al., 2005). Thus, 
higher levels of purification and more clinical studies are required.  
3.3.3 Other 1-PI applications 
Currently, α1-PI therapeutic preparations are licensed exclusively for one indication, i.e., 
chronic augmentation and maintenance therapy in individuals with emphysema due to 
congenital α1-PI deficiency. Previously unrecognized inherited disorder, α1-PI deficiency 
was first described in 1963 (Laurell & Eriksson, 1963) based on the serum electrophoretic 
analysis that revealed five individuals deficient of α1–fraction; three of those patients had 
developed emphysematous conditions. Six years later, in 1969, cirrosis associated with α1-PI 
deficiency was described (Sharp et al., 1969). These findings initiated a concept of linkage 
between α1-PI deficiency and pulmonary and liver diseases. As evident from the available 
literature, due to the multiple biological activities of α1-PI, it has been associated with other 
lung diseases (first of all, cystic fibrosis) and many non-pulmonary diseases (Table 3).  Some 
of these conditions may possibly benefit from α1-PI augmentation therapy (see recent 
reviewes by Blanco et al., 2011 and Janciauskiene et al., 2011).  
According to Blanco et al. (2011), α1-PI therapy has proven remarkable efficacy in small 
cohorts of α1-PI-deficient patients who also suffer from fibromyalgia, systemic vasculitis, 
relapsing panniculitis and bronchial asthma. Although the putative benefits of α1-PI therapy 
for treatment of additional rare diseases (some are listed in Table 3) requires much more 
clinical data than are currently available to support clinical efficacy and safety of α1-PI 
treatment, in general it indicates a clear potential for additional α1-PI supply to satisfy the 
anticipated clinical demand in near future. Because of controversy related to the additional 
clinical implications of 1-PI deficiency, more clinical data are needed to verify whether the 
reported links between 1-PI deficiency and other rare diseases are real or accidental.  
As a potent anti-inflammatory agent, 1-PI has been investigated in clinical studies for 
treatment of cystic fibrosis (Jones & Helm, 2009). Whereas patients with emphysematous 
conditions suffer from the hereditary 1-PI deficiency and, thus, insufficient levels of the 
protease inhibitor in the lungs due to impaired 1-PI synthesis in hepatocytes, patients with 
cystic fibrosis may have normal synthesis of 1-PI and suffer from severe pulmonary 
inflammation due to high excess of NE in the lungs, leading to a progressive loss of lung 
function (Allen, 1996; Siekmeier, 2010). Therefore, it has been proposed that both groups of 
patients may benefit from 1-PI augmentation therapy to prevent the deleterious effect of 
free protease (Allen, 1996; Birrer, 1995; Birrer et al, 1996) However, intravenous 
administration of 1-PI did not result in a suppression of the respiratory neutrophil elastase 
burden (McElvaney et al, 1991). Several studies have been conducted using inhalation of an 
aerosolized 1-PI in cystic fibrosis and 1-PI deficiency (Hubbard et al., 1989; Griese et al, 
2001, 2007; Martin et al, 2006; Brand et al, 2009). 
Whereas several studies that investigated the efficacy of treatment with an aerosolized 1-PI 
both in patients with cystic fibrosis and in those with 1-PI deficiency came to positive 
conclusions regarding deposition of inhaled 1-PI in the lungs and its anti-elastase activity 
(see review by Siekmeier, 2010), the conclusion from other studies was that treatment with 
1-PI did not demonstrate any clinical improvements (Martin, 2006). If further clinical 
studies support the safety and efficacy of an aerosolized1-PI, and it is approved for 
treatment of cystic fibrosis, the demand for therapeutic 1-PI preparations could be 
significantly increased.  
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Vasculitis Dowd et al., 1995; Esnault, 1997; Griffith et al., 1996 
Panniculitis Chowdhury et al., 2002;  Gross et al., 2009; Kjus et al., 2002; Smith et al., 1987; Valverde et al., 2008 
Fibromyalgia Ablin et al., 2009; Blanco et al., 2004; Blanco et al., 2010 
Asthma Blanco et al., 2008; Blanco et al., 2011; Eden et al., 1997 
Pancreatitis Rabassa et al., 1995; Needlham & Stockley, 2004 
Renal  Szönyi et al., 2006; Ting et., 2008 
Diabetes Kalis et al., 2010; Lisowska-Myjak et al., 2006; 
Cancer Li et al., 2011; Lindor et al., 2010; Topic et al., 2011 
Rheumatoid arthritis Grimstein et al., 2010; Grimstein et al., 2011 
Atherosclerosis Stakisaitis et al., 2001; Talmud et al., 2003; 
Acute anterior uveitis Fearnley et al., 1988; Saari et al., 1986 
Chronic rhinosinusitis Kilty et al., 2008, 2010; Maune et al., 1995 
Table 3. Conditions other than emphysema and liver disease possibly associated with α1-PI 
3.3.4 Research toward the enhancement of 1-PI-therapies 
During last decade various approaches have been considered for the enhancement of 1-PI-
based therapies. For instance, to prolong a short half-life of r-1-PI in the circulation, Cantin 
and co-workers hypothesized that conjugation of r-1-PI with polyethylene glycol (PEG) at 
Cys232 could extend the in vivo half-life of recombinant protein in blood and lung (Cantin et 
al., 2002b). According to their data, the site-specific conjugation with either 20 or 40 kD PEG at 
Cys232 of nonglycosylated r-1-PI (human) results in an active inhibitor with extended in vivo 
stability. Moreover, 72 h later after airway instillation, the PEG-r-1-PI seemed to be significantly 
better than glycosylated 1-PI at protecting the lung against elastase–induced lung hemorrhage.  
As an example of the in vitro biochemical evaluation of the concept, α1−PI has been considered 
for its affinity to various small ligands and drugs for different reasons. Mainly this approach 
has been explored with respect to the peptides and small molecules in order to prevent the 
aggregation of Z mutant (e.g., Mallya et al., 2007; Chang et al. 2009). In the meantime, the 
protein’s potential for binding small ligands of pharmaceutical interest has been proposed as a 
promising approach that is directed at, and may ultimately enhance, currently existing α1−PI 
therapies (Karnaukhova et al., 2010). For instance, α1−PI’s affinity to retinoic acid, which is 
known for a wide range of physiological activities including alveolar repair and regrowth 
(Roche clinical studies, see Stockley, 2010; Massaro & Massaro, 1996, 1997) and tissue 
rejuvenation in various dermatologic diseases, has been convincingly demonstrated in 
biochemical experiments in vitro (Karnaukhova et al., 2010). As α1−PI augmentation therapy 
cannot cure, but may only slow down, the progression of emphysema, its complexation with 
retinoic acid could be more efficient for treatment than α1−PI alone. It is noteworthy that the 
interactions of α1−PI with several other physiologically active ligands (including porphyrins) 
may reveal additional properties of this multifunctional serpin. 
4. Conclusions  
Since 1-PI deficiency was first described by Carl-Bertil Laurell and Sten Eriksson (Laurell & 
Eriksson, 1963) as a condition that could lead to the development of severe obstructive 
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pulmonary disease, our knowledge about 1-PI structure-function relationships and clinical 
manifestations of 1-PI deficiency has increased tremendously. Moreover, multi-disciplinary 
research efforts prompted the development of 1-PI-based augmentation therapy to 
maintain the inhibitor level above the protective threshold. Since 1987, several 1-PI 
products derived from pooled human plasma have been approved and are currently 
available to slow down the progression of emphysematous conditions in 1-PI-deficient 
patients. In addition, due to its multiple physiological activities, 1-PI has been identified for 
its putative involvement in several other rare diseases, the treatment of which may possibly 
benefit from 1-PI-based therapies. As an alternative to intravenous administration that may 
improve the efficacy of1-PI treatment, the inhalation of aerosolized 1-PI preparations has 
been in clinical trials. Recombinant versions of human 1-PI have been produced in all 
available hosts and in several transgenic animals. These efforts made a remarkable impact 
on the research realm of recombinant protein therapeutics, but did not yet bring any viable 
version of recombinant 1-PI to the treatment. In regards to therapeutic preparations and 
their use, there are several questions to be addressed when looking to the future. Keeping in 
mind the long history of replacement therapy using currently approved plasma-derived 1-
PI products, it is essential that the efficacy of 1-PI replacement therapy be clearly 
demonstrated in prospective, randomized, placebo-controlled trials. Will the efficacy of 
inhalation therapy using aerosolized 1-PI preparations be proven to be superior to that of 
the intravenous route? Will the recombinant/transgenic versions of human 1-PI be 
optimized to meet the requirements for protein therapeutics? Will other rare diseases 
currently implicated in association with 1-PI and 1-PI deficiency be clearly proven to 
benefit from 1-PI treatment? From the standpoint of product quality, safety and efficacy, 
the current state of research and development of 1-PI for therapeutic use demonstrates a 
symbiosis of the recent achievements and controversies, hopefully typical of our progress. 
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Tissue remodeling is a common pathology in many diseases. The reparative processes of 
wound healing result in an increase in extracellular matrix (ECM) generation, serving to 
restore barrier protection and normal tissue architecture. However in the lung, increased 
formation of ECM results in decreased lung compliance and impaired gas exchange. The 
chronic lung diseases COPD (chronic obstructive pulmonary disease) and IPF (idiopathic 
pulmonary fibrosis) both exhibit increased extracellular matrix (ECM) deposition within the 
lung due to increased stromal cell number and activation. The chronic nature of the disease 
is hypothesized to correlate with the extent of scarring and remodeling, with greater 
evidence being available for COPD rather than IPF. The potential underlying causes of both 
diseases are numerous, including direct insults to the lung such as cigarette smoke or 
exhaust particles; as well as underlying autoimmune conditions such as scleroderma or 
collagen vascular disease. Moreover, a correlation between COPD and smoking is well 
established; however, any causes for IPF, apart from a familial link, are currently not 
understood. To date there are no approved anti-fibrotic therapies that target the underlying 
remodeling in either disease. In order to treat this pathology, understanding the 
mechanisms promoting continual ECM deposition may elucidate novel therapeutic 
approaches that could provide clinical benefit to patients suffering from these debilitating 
diseases. This Chapter will focus on the cellular mechanisms and interactions within the 
fibrotic lung including resident fibroblast-epithelial cells as well as the cross-talk between 
fibroblasts and recruited bone marrow derived cells such as fibrocytes and monocytes. Also, 
the soluble mediators that have been associated with disease and how these can directly and 
indirectly modulate stromal cell activation will be discussed. 
2. COPD and IPF disease pathogenesis  
One of the common features between COPD and IPF is the heterogeneous pathology 
observed in the lung at the macroscopic level in both disease settings. Both diseases exhibit 
patchy areas of pathology, consisting of ECM proteins or inflammatory infiltrates, with 
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fibrotic regions being juxtaposed to regions of normal alveolar tissue or areas with 
interstitial leukocyte accumulation. Grossly, COPD contains regions dense in bronchiolar 
inflammation and consolidated lung tissue, as well as emphysematous areas, due to alveolar 
destruction 1,2. In IPF, salient hallmarks of disease included profound collagen deposition, as 
well as regions of honeycombed lung due to a collapse of alveolar walls 3. COPD has been 
clinically separated into distinct GOLD (Global initiative for chronic Obstructive Lung 
Disease) Stages based primarily on a key parameter of lung function, Forced Expiratory 
Volume in one second (FEV1). Here, patients with more significant impairment in FEV1 have 
a higher GOLD Stage status. Supporting these changes in lung function analysis of the 
underlying pathologies of patients within each GOLD Stage has also highlighted that, as the 
disease progresses, there is an increase in airway wall thickness 4. Even though the GOLD 
staging system is universally recognized, there are efforts underway to also separate COPD 
patients in to fast decliners and slow decliners based on lung function parameters. Extensive 
work is currently underway to try and stage IPF in an equivalent manner. In this disease, 
retrospective analysis of patient survival has indicated that there is both a rapidly 
progressing phenotype and a more slowly progressing phenotype of IPF patients. In the 
‘rapid’ IPF progressors, approximately 50% of patients will die within 6-8 months, whereas 
this is greatly extended in slow progressors 5,6.  
Chronic remodeling is a common feature between IPF and COPD. In order to understand 
the mechanisms underlying the maintenance, progression and staging of disease, this Book 
Chapter will focus on the similarities and differences between stromal cells in these patients. 
We will focus on the phenotypic differences in fibroblasts and myofibroblasts as well as how 
these cell types interact within the lung (Fig. 1). We will also describe some of the key 
families of mediators that are found to be elevated in disease and how their mechanism may 
be directly promoting chronic lung disease. Lastly, we will discuss the potential therapeutic 
approaches to targeting stromal cells clinically. 
3. Profibrotic role of fibroblasts  
Fibroblasts play a myriad of important roles in normal tissue function. In the lung they 
coordinate organogenesis and budding of the lung from the foregut through intimate bi-
directional communication with adjacent epithelial cells. Myofibroblasts are “smooth 
muscle-like cells” that are morphologically similar to fibroblasts, but also express alpha-
smooth muscle actin (-SMA) 7. Fibroblasts and myofibroblasts are also key cells in the 
production and homeostatic maintenance of the ECM of the tissue or organ in which they 
reside. They are metabolically active cells, capable of synthesizing and secreting ECM 
components such as collagens and proteoglycans. Fibroblasts continually synthesize ECM 
proteins although the amount they secrete is tightly regulated, with up to 90% of all 
procollagen molecules being degraded intracellularly prior to secretion, depending on tissue 
and age. Further, fibroblasts generate both matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases, thus controlling homeostatic tissue architecture.  
Myofibroblasts were first described by Gabbiani and colleagues as cells central to wound 
healing 8. The actin filaments result in myofibroblasts having contractile properties, which, 
at sites of wound healing serve to close the wound. However, the presence of contractile 
myofibroblasts in the interstitium of the lung may cause a retraction of parenchymal tissue 
resulting in alveolar collapse giving the characteristic honeycombing as observed in the 
lungs of IPF patients, or add to the increase in alveolar size, which is characteristic of COPD 9.  
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Fig. 1. Cellular Pathways in Lung Fibrosis: Multi-Faceted Aberrant Response 
Chronic lung remodelling is hypothesized to occur following repeated trauma or injury to 
the lung. Multiple cellular pathways and interactions which can all promote ECM 
deposition have been described in lung fibrosis which promote fibroblast and myofibroblast 
activation, proliferation and survival. Following injury to the epithelium, apoptotic and 
necrotic signals stimulate collagen producing cells. These resident epithelial cells can also 
differentiate into a collagen-producing phenotype during EMT. The immune response in the 
lung is also altered in chronic lung diseases, with pro-fibrotic M2 macrophages and type 2 T 
cells predominating. These cells generate soluble mediators such as TGF, CCL2 and IL13 
which directly activates collagen producing cells. 
Key: EMT: epithelial to mesenchymal transition; Mac: Macrophage; Treg: regulatory T cell 
Under normal conditions, myofibroblasts sequentially perpetuate and then dampen 
inflammation via the secretion of chemokines, cytokines, arachidonic acid metabolites and 
protease inhibitors. When activated, they express cell surface adhesion molecules allowing 
specific interactions with immune and inflammatory cells, including lymphocytes, mast 
cells and neutrophils. If these processes become dysregulated, fibrosis may ensue with 
catastrophic consequences for lung function. 
Most insight into the potential role of fibroblasts at driving pulmonary remodeling, as well 
as phenotypic differences in fibroblasts found in fibrotic regions versus those located in 
normal tissue has been garnered from in vitro studies using fibroblasts isolated from IPF 
lungs and animal models. Fibroblasts isolated from fibrotic environments are 
phenotypically different than non-fibrotic fibroblasts 10-12. Fibroblasts from a profibrotic 
environment exhibit altered responsiveness to growth factors, express enhanced receptor 
levels for chemokines, which has also been observed in murine models of pulmonary 
remodeling. These studies suggest a distinct heterogeneity in fibroblast function and 
phenotype in the fibrotic lung.  
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We and other investigators have reported that fibroblasts derived from IPF lungs proliferate 
faster than cells derived from normal lung tissue. In contrast, others have shown that the 
growth rate of IPF fibroblasts was significantly slower than normal fibroblasts. This 
discrepancy may be due to the site in the lung from which fibroblasts are harvested, since 
the magnitude of inflammation and fibrosis are heterogeneous in distribution. Thus, areas of 
active fibrosis may yield hyperproliferative fibroblasts compared to areas of established 
fibrosis in which cells may be hypoproliferative. 
To begin to address this diversity, recent studies have used microarray technologies to 
profile global gene expression in pulmonary fibrosis in man and mouse models. These 
studies have showed expression of almost 500 genes are increased more than two- fold in 
fibrotic lungs, including many genes related to cytoskeletal reorganization, ECM, cellular 
metabolism and protein biosynthesis, signaling, proliferation and survival 13,14. There was 
excellent concordance between gene expression in human and experimental models, giving 
us some confidence in the value of our efforts to model human disease. Studies examining 
human lung fibroblast global gene expression in response to TGF1 have shown almost 150 
genes upregulated, representing several functional categories described above. This 
included 80 genes that were not previously known to be TGF -responsive.  
The progression and severity of many lung diseases, most notably IPF, are tightly associated 
with regions of fibroblast accumulation and proliferation, to the extent that these regions have 
become a reliable indicator of survival. The increased number of (myo)fibroblasts seen in these 
diseases, implies that they are either hyper-proliferative and/or resistant to apoptosis. 
However, most studies suggest that these cells proliferate faster than normal 10,15,16 
4. Sources and fates of fibroblasts and myofibroblasts  
As remodeling of the lung is associated with accumulation and activation of fibroblasts and 
myofibroblasts, the derivation of both cell types is currently under examination. Reports 
indicate that there may be multiple pathways through which fibroblasts and myofibroblasts 
are derived 17. Fibroblasts isolated from human or murine fibrotic tissue exhibit enhanced 
basal proliferation. Therefore an increase in the fibroblast pool could be due to local 
proliferation. Myofibroblasts express a panel of markers and these markers have been 
correlated with site of derivation. For example, myofibroblasts found in the peripheral and 
subpleural regions of fibrosis express -SMA, vimentin and desmin, whereas cells found in 
other regions of the lung do not express desmin 18.  
4.1 Epithelial to mesenchymal transition 
Another potential source of fibroblasts is by a process called epithelial to mesenchymal 
transition (EMT). EMT is a dynamic process by which epithelial cells undergo phenotypic 
transition to fully differentiated motile mesenchymal cells, such as fibroblasts and 
myofibroblasts. This process occurs normally during early fetal development where there is 
seamless plasticity between epithelial and mesenchymal cells 19. Furthermore, this 
phenomenon is well accepted in cancer as a key mechanism that supports tumor metastases 20. 
However, the process of EMT in development and cancer differ greatly in that, unlike 
developmental EMT, the tumorigenic EMT process is poorly regulated 21. During the process 
of EMT, the downregulation of epithelial and tight junction proteins is associated with a 
concomitant increase in mesenchymal cell markers 22,23. In chronic lung diseases, the dual 
expression of epithelial and mesenchymal markers in the same cells has led investigators to 
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postulate that EMT is a mechanism resulting in more ECM-generating mesenchymal cells in 
the lung  24,25. The differentiation of airway epithelial cells has been previously described, for 
example, type I pneumocytes transitioning into goblet cells 26-29. However, the switching of an 
epithelial cell into a phenotype that moves beyond the original cell’s embryonic lineage, has 
only recently been suggested to be a causative factor in fibrosis 23,30,31.  
The initial events of EMT include the loss of cell polarity and the induction of matrix 
metalloproteinases (MMPs) that promote basement membrane degradation and cell 
detachment. The cells also undergo cytoskeletal changes, as well as altered expression of 
surface molecules which allow for the migration and transition of these cells to a mesenchymal 
phenotype 32,33. The majority of the work evaluating EMT has been performed in vitro; 
however the full extent of this pathogenic pathway in vivo is currently being evaluated. In 
animal models of kidney fibrosis, it has been estimated that up to 20% of the fibroblasts found 
in the fibrotic lesions were derived from the epithelium through EMT 30,34-37.  
The idea of EMT promoting the fibrosis observed in COPD and IPF is rapidly beginning to 
evolve 29. Several recent studies have also shown that EMT occurs in lung epithelial cells 
both in vitro and in vivo, supporting the concept of EMT contributing to the fibrosis observed 
in IPF 29,38,39. Moreover, we have recently published an alteration in the microRNA 
regulation of genes associated with EMT in IPF40. The potential of EMT promoting COPD 
requires further investigation. Nevertheless, there is an emerging link between COPD and 
lung cancer, thus increasing the likelihood of EMT being present in the COPD lung. The link 
between smoking, lung cancer and COPD is also apparent, in that smoking is a risk factor 
for COPD and also for lung cancer 41,42. An underlying response to cigarette smoke is 
generating an altered inflammatory environment in the lung 43, which can then be 
susceptible to either COPD or lung cancer development 44. Therefore, future work 
correlating the timecourse of EMT induction with COPD and IPF disease staging will be 
insightful to determine the extent of contribution mediated by this process.  
4.2 Circulating progenitor mesenchymal cells 
Along with the epithelium, studies have also highlighted a role for bone marrow-derived 
circulating progenitor mesenchymal cells, or fibrocytes, in promoting lung fibrosis by 
differentiating into fibroblasts or myofibroblasts 45,46,47 (Fig. 1). Fibrocytes have been 
observed at sites of active fibrosis and increased numbers of these cells in the circulation 
correlate with mortality in IPF 5. They are induced by pro-fibrotic mediators such as TGF1 
and Th2 cytokines 48; and the cell markers include leukocyte markers (CD45, CD34), 
mesenchymal markers (collagen I, fibronectin) and chemokine receptors (CCR3, CCR5, 
CCR7 and CXCR4) 49. Human and mouse studies have demonstrated that fibrocytes from 
peripheral blood migrate to skin wound chambers 49-51 and bronchial mucosa after antigen 
challenge 52. Furthermore, these cells have been reported in disease states with fibrotic 
pathologies including hypertrophic scars, asthma and IPF 52-55.  
Fibrocytes are pleiotropic and may contribute to fibrogenesis by directly producing collagen, 
as well as inflammatory cytokines, hematopoietic growth factors, and chemokines 54-58 (Fig. 
2). In a study performed in collaboration between AstraZeneca and Malmö University 
Hospital, increased fibrocyte numbers were observed in the circulation of COPD patients, 
where patients with mild COPD had the most elevated number of fibrocytes in comparison 
to moderate COPD, severe COPD or healthy patients 59. Although there was no correlation of 
fibrocyte number with any lung function parameter, inhaled glucocorticosteroid use  
 






Fig. 2. Overlapping Differentiation Pathways and Functions of Fibroblasts, Fibrocytes and 
Macrophages 
Fibroblasts, fibrocytes and macrophages share many in vitro and in vivo functions such as 
mediator production, host defence and extracellular matrix deposition. Monocytes can 
differentiate into fibrocytes or macrophages depending on the environment and the nature 
of the stimulus. In vitro studies have highlighted a role for various mediators such as 
cytokines, TLR signals, cellular debris and cell function at promoting differentiation. 
However, it is likely a combination of these pathways in situ which dictates the fate of the 
monocyte. Fibrocytes have been shown to differentiate into fibroblasts, in part through 
losing CD45 expression but retaining collagen I expression. Moreover in vitro, fibrocytes 
stimulated with TGF or ET-1 can promote fibrocyte to fibroblast differentiation. Recent 
evidence has indicated that fibroblasts can differentiate into haematopoietic cells when 
stimulated with appropriate growth factors.  
Key: TGF: transforming growth factor ; GM-CSF: granulocyte macrophage colony-
stimulating factor; M-CSF: macrophage colony-stimulating factor; TLR: toll-like receptors; 
ET-1: endothelin-1; OCT4: octamer-binding transcription factor 4); ECM: extracellular 
matrix; SMA: -smooth muscle actin. 
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significantly inhibited circulating fibrocyte numbers, corroborating the pro-inflammatory 
association of fibrocytes 59. While it was originally thought that fibrocytes promote fibrosis 
through production of ECM components, it is becoming increasingly hypothesized that their 
primary role in tissue remodelling may be through secretion of soluble factors. 
Fibrocytes have pleuripotent potential to differentiate into other cell lineages, as has been 
demonstrated with fibrocyte-derived adipocytes 60. Furthermore, the extreme plasticity of 
these cells in vitro, makes both the derivation and characterization of these cells difficult. 
Exposure of fibrocytes to TGF1 in vitro results in the cells transitioning into a myofibroblast 
phenotype that expresses both fibronectin and type III collagen 52. Using an adoptive 
transfer model of bone marrow cells from green fluorescent protein (GFP) transgenic mice 
into mice challenged with intratracheal bleomycin to initiate lung injury, recruited GFP+ 
fibrocytes were shown to differentiate into fibroblasts while resident lung fibroblasts 
differentiated into myofibroblasts 56.  
At sites of normal wound healing, once sufficient ECM has been deposited, fibroblasts and 
myofibroblasts undergo apoptosis 61,62. This serves to limit the excessive deposition of ECM 
and also dampen the pro-inflammatory and pro-fibrotic milieu. However, myofibroblasts 
persist in fibrotic conditions. Moreover, IPF fibroblasts are relatively resistant to apoptosis in 
vitro, with IPF cells inducing a different pattern of pro-apoptotic enzymes in response to 
Fas-L stimulation compared to normal fibroblasts 63. 
A recently described study showed an alternate potential fate of fibroblasts in that they can 
de-differentiation or transition into haematopoietic cells64. Here the investigators showed 
that, in the presence of haematopoietic transcription factors, fibroblasts can convert into 
haematopoietic progenitor cells, indicating a stem-like potential of cells that have 
traditionally thought to be resident to the lung 64. Therefore, expanding our understanding 
on the pathways that control fibroblast to myofibroblast fate, as well as fibroblast to non-
fibroblast cell fate, particularly in disease, will greatly expand our understanding of disease.  
5. Fibroblast cell: Cell interactions  
In the lung, fibroblasts are found in the greatest number in the subepithelial layer of the 
conducting airways and the interstitium of the lung parenchyma (Fig. 1). Here they are in a 
prime location to interact with the epithelial and endothelial cells, as well as leukocytes in 
the airspaces, interstitium and vasculature. One of the key inflammatory cells that is found 
in the lung, and one that is becoming more associated with the maintenance and 
progression of fibrosis, is the alternatively activated (M2) macrophage. The M2 macrophage 
is the predominant macrophage found in the lungs of IPF patients 65. Moreover, M2 
macrophages have been associated with COPD 66,67. In healthy tissue, alveolar macrophages 
are known to remove apoptotic and necrotic debris and pathogens via phagocytosis in a 
non-phlogistic mechanism, in that downstream inflammation is limited and the 
inflammatory process is attenuated 68.  
In chronic lung disease, the predominant M2 macrophage phenotype is inefficient at 
clearing debris. M2 macrophages are defective in phagocytosis and do not dampen the 
inflammatory response 69. These macrophages are capable of synthesizing pro-fibrotic 
mediators, which supports their role in wound healing, yet this cell type is inefficient at 
supporting host defense 69. This may explain why COPD and IPF patients are susceptible to 
repeated bouts of pulmonary infections or exacerbation of disease. These cells express 
elevated levels of scavenger receptors such as macrophage scavenger receptor (MSR) and 
 
Lung Diseases – Selected State of the Art Reviews 
 
112 
mannose receptor C (MRC/ CD206) 69,70. Assessing circulating primary cells from IPF 
patients, we have determined an elevation of CD163+CD14+ cells and M2-associated soluble 
mediators in the circulation, which was more pronounced in progressive IPF patients, 
suggestive of an overall elevated M2 background in these patients 71. We have also shown 
that peripheral blood monocytes from patients with scleroderma-related lung disease 
display a pro-fibrotic phenotype, characterized by increased CD163 expression and CCL18 
production 72. Interestingly, macrophages in the lungs of COPD patients, as well as smokers 
with or without COPD, also demonstrate a skewing towards an M2 phenotype, with a 
deactivated M1 phenotype 73,74. Moreover in vitro, cigarette smoke induces a M2-type 
phenotype and this result was also seen in an in vivo cigarette smoke model in mice 73. In 
vitro, macrophage polarization to an M2 phenotype has only been shown robustly with 
mouse cells. Here the differentiation of a monocyte to an M2 phenotype requires a cocktail 
of cytokines including IL13 and CCL17/TARC75. Therefore the Th2 cytokine profile 
observed in remodeled lungs contributes to the appearance of M2 macrophages.  
Studies of bleomycin-induced fibrosis have assessed either M2 macrophage or fibrocyte 
number 71,76. It is increasingly recognized that there is some overlap between these cell subsets 
in terms of both function and markers 76. However, although both fibrocytes and M2 
macrophages can be derived from monocytes, they are not completely redundant in function. 
Recently, using a lung-specific TGF1 over-expression model of lung fibrosis, we determined 
that depletion of lung monocyte/macrophages using liposomal clodronate reduced collagen 
accumulation, but this had no effect on the TGF-induced fibrocyte recruitment 77. Therefore, 
for novel therapeutic approaches such as cell depletion or specific targeting, the M2 
macrophage may be a more compelling target for chronic lung remodeling.  
In COPD, alveolar macrophages have been hypothesized to have reduced anti-inflammatory 
properties, as well as a reduced capacity to turn over matrix 78. However a recent study 
looking at macrophage number, MMP expression and emphysema determined a correlation 
between a greater infiltration of macrophage to the lung and emphysema in COPD patients 79. 
Ex vivo, cigarette smoke induces a wide array of changes in the inflammatory profile and the 
host defence potential of COPD alveolar macrophages 80. Moreover, microarray analysis 
indicated a correlation between alveolar macrophage gene expression, circulating monocyte 
gene expression and lung function 81. The investigators hypothesized that there is a “COPD-
related gene expression pattern” as many genes differentially expressed in COPD alveolar 
macrophages were also expressed in COPD circulating monocytes 81. 
6. Activators of fibroblasts/ mesenchymal cells  
Fibroblasts are activated by numerous signals including: mechanical forces such as those 
imposed during bronchoconstriction; matrix interactions; hypoxia and resultant changes in 
pH levels; and soluble mediators (Fig. 1). The large variety of soluble mediators capable of 
activating mesenchymal cells are produced by many different cell types found in fibrotic 
regions. Furthermore, proteases of the coagulation cascade and other serum factors also 
promote fibroblast proliferation, collagen synthesis, migration and differentiation.  
6.1 Growth factors 
Growth factors are the most recognized mediators that activate mesenchymal cells. 
Transforming growth factor β (TGFβ) is one of the most potent profibrotic mediators in vitro 
and is a central driver in the remodeling process. TGF1 regulates numerous biologic 
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activities such as proliferation, apoptosis, and differentiation 82,83. TGF1 is upregulated in 
the lungs of IPF patients and patients with other chronic lung diseases 84-89. Interestingly, 
expression of TGF1 is nearly absent in the bronchial epithelial cells but is highly expressed 
in inflammatory cells beneath the basement membrane where subepithelial fibrosis 
predominates 90. In COPD, TGF has also been reported to be produced by circulating and 
interstitial T cells and monocytes 91. Polymorphisms in the promoter region of TGF1 have 
been reported in COPD patients 92. However, TGF SNPs have been associated with 
protection in COPD 93 or have been linked to COPD but not related to worsening of disease 94.  
Transient overexpression of TGF1, or pulmonary delivery of this cytokine to mouse lungs, 
induces a pronounced interstitial fibrosis mediated by excess ECM generation and 
deposition, as well as the presence of myofibroblasts95. Using a transgenic mouse model of 
SMAD-3 deficiency, TGF/SMAD-3 signaling has been shown to be required for alveolar 
integrity and ECM homeostasis and that this pathway is involved in pathogenic 
mechanisms mediating both tissue destruction and fibrogenesis.  
Due to TGF1 being such a potent growth factor, the release and activation of this growth 
factor is tightly regulated. TGF is released in a latent complex, associated with LAP 
(latency activated peptide) and LTBP. There are several mechanisms by which TGF is then 
activated and these include integrin-mediated cell cytoskeletal rearrangement in the case of 
integrin v696; cell membrane MMP recruitment for enzymatic cleavage in the case of 
integrin v897 and other protease-related mechanisms exhibited by components of the 
coagulation cascade98 (discussed later). The integrin v6 is upregulated in IPF99 and 
neutralization of this integrin in vivo reduces fibrosis in various experimental models 99-101.  
There are also endogenous inhibitors of TGF, the largest being the BMP (bone 
morphogenic protein) family. The BMP family is structurally and functionally related to the 
TGF superfamily 102. BMPs inhibit TGF signaling through either inhibiting Smad 2/3 
phosphorylation or competing for Smad 4 or both 103,104. Recombinant BMP7 has been 
shown to inhibit TGF-induced EMT in vitro, as well as reducing renal fibrosis 105. However, 
we have shown that BMP7 had no anti-fibrotic effect in models of lung fibrosis, nor were 
there effects on lung epithelial cells in vitro 106. 
6.2 Th2-associated mediators 
Interleukin 13 (IL13) and IL4 are two pleiotropic, Th2-associated cytokines, with numerous 
distinct and overlapping functions. They share overlapping roles due to the shared IL13R1 
receptor subunit. However they also have unique subunits that confer the distinct functions. 
IL13 activates epithelial cells and goblet cells causing mucous production, goblet cell 
hyperplasia and EMT 107,108. Various animal models of pulmonary fibrosis have indicated a 
more pro-fibrotic role for IL13 than IL4. Indeed it has been hypothesized that IL4 is involved 
in the initiation of fibrosis whereas IL13 is central to the maintenance of the fibrotic 
response.  
We have published that IL-13 is elevated in the lungs of IPF patients 71 and this protein is 
associated with fibrotic pathologies and aberrant remodeling at various tissue sites 65,109. 
There is also elevated expression of the two IL13 receptor subunits IL13R1 and IL13R2 
which are prominant on fibroblasts 110,111. More recently we have shown that IPF fibroblasts 
are hyper-responsive to IL13 in comparison to non-fibrotic fibroblasts58. It was originally 
hypothesized that IL13R2 is a decoy receptor as it has a short cytoplasmic tail and although 
it is the higher affinity receptor subunit, it is found at high levels in a soluble form, but only 
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in murine models of fibrosis112 and not in humans113. However, recent data has suggested 
that signaling of IL13 through IL13R2 is pro-fibrotic, resulting in TGF1 production 114.  
Lung-specific over-expression of IL13 in mice results in remodeling and emphysema 115. 
Moreover, various MMPs and cathepsins that are associated with COPD1 are also induced in 
the IL13-transgenic lung 116. However robust detection of IL13 has not been consistently 
reported. IL13 producing macrophages and NKT cells have been detected in the COPD lung 
117. Also, the presence of the cytokine and IL13 positive cells have been shown in the bronchial 
epithelium of smokers with chronic bronchitis 118. In contrast, decreased IL13 has been 
measured in emphysema compared to non-emphysematous lungs 119. An inverse correlation 
between plasma IL13 and the lung diffusion capacity for carbon monoxide (DLCO) parameter, 
used to determine the efficiency  of gas exchange in COPD has been reported 120. 
Another Th2-associated mediator that is being actively researched in fibrosis is the chemokine 
CCL18/ PARC. In IPF, CCL18 has been associated with poor outcome, namely, patients with 
CCL18 levels greater than 150ng/ml in the circulation will typically have more progressive 
disease, compared to those with CCL18 levels below 150ng/ml 6. CCL18 expression is also a 
marker for M2 macrophages 121, therefore linking the profibrotic cell phenotype with IPF 
progression. In the recent ECLISPE study, elevated CCL18 levels in COPD patients has been 
associated with increased chance of COPD exacerbation 122. This association of CCL18 with 
COPD exacerbations was in stark contrast to TNF, IL6 or CXCL8/ IL8 levels, or the number 
of pack years of smoking 122. These observations may change the understanding of the 
pleiotropic nature of the underlying mechanisms for COPD, as CCL18 is not associated with 
smoking or with neutrophil accumulation and activation.  
6.3 Coagulation cascade 
Thrombin is a serine protease generated during activation of the coagulation pathway 123. 
Thrombin has been implicated in a number of pulmonary fibrotic diseases such as acute 
lung injury (ALI) 124,125 acute respiratory distress syndrome (ARDS) 126, interstitial lung 
disease (ILD) 127,128  and IPF 127,129-132 and IPF BAL fluid thrombin has been shown to 
promote fibroblast proliferation  131. In COPD, elevated procoagulant activity has been 
observed in the serum of patients with moderate to severe disease 133. Animal models of 
fibrosis have strengthened the connection between thrombin and fibrosis. Increased 
thrombin is found in the lungs of mice challenged with bleomycin and pharmacological 
inhibition of thrombin significantly reduced the collagen deposition 130.  
At the cellular level, thrombin has numerous biologic effects that are in addition to its role as a 
coagulation pathway proteinase. It has been shown to promote inflammation and fibrosis 
through inducing chemokine and growth factor production from fibroblasts. Many of the cell-
based activities of thrombin are mediated through a family of receptors termed proteinase-
activated receptors (PARs). PARs are G-protein coupled receptors (GPCR), with 4 known 
subtypes identified to date. A defining feature of these receptors is that they are activated by 
proteases that cleave a portion of the extracellular amino terminus to unmask a new N-
terminal sequence, which then functions as a tethered ligand that autoactivates the receptor. 
PAR-1-deficient mice are protected from bleomycin induced lung fibrosis 134. Further, PAR-2-
deficient mice had decreased eotaxin/CCL11 and reduced eosinophilia in the lungs following 
antigen challenge in an allergen sensitization and challenge model of asthma 135,136. 
Furthermore, thrombin and other PAR1 agonists promote the integrin-mediated activation 
latent TGF in a model of acute lung injury 98 . Thus, the local activation of TGF at sites of 
fibrosis may be enhanced by the coagulation cascade in both IPF and COPD.  
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Pentraxins comprise a highly conserved superfamily of cyclic pentameric proteins. These 
proteins interact with numerous ligands, including selected pathogens and apoptotic 
cells137, and are recognized by macrophages via mannose 6P and Fc gamma () receptors, 
ultimately leading to complement activation, pathogen recognition, and apoptotic cell 
clearance 138-140. Pentraxins are subdivided into the short pentraxins that include C-reactive 
protein (CRP) and serum amyloid P component (SAP, PTX2), and the long pentraxin 3 
(PTX3) 141,142. SAP appears to be uniquely involved in the resolution or repair phase of tissue 
injury via its modulator effects on resident and bone marrow derived collagen producing 
cells 76,143. SAP binds to Fc receptors144 and the anti-fibrotic activities of SAP have been 
shown to be mediated through Fc receptors143 which affect peripheral blood monocyte 
differentiation and activation states.  
SAP promotes the differentiation of M1 classically activated macrophages in a tuberculosis 
model of lung infection 145. We have recently demonstrated that SAP has prominent 
immunomodulatory effects on mouse macrophages, thereby providing a mechanism for its 
ability to prevent the development and reverse established experimental fungal airway disease 
75. Moreover, human SAP has been shown to potently inhibit the differentiation of monocytes 
into fibrocytes146 and it has consequently been used therapeutically in animal models to inhibit 
lung fibrosis and fibrosis in a number of organ sites. In addition, SAP causes an inhibition of 
the differentiation of peripheral blood mononuclear cells into CD45+/collagen I+ cells called 
fibrocytes76,146,147, as well as reducing M2 macrophage number 75,77.  
6.5 Matrix Metalloproteinases and Chitinases 
Active remodeling of the ECM is dependent on the coordinated activities of proteases and 
protease inhibitors 148,149. Fibroblasts generate metalloproteinases (MMPs), which are 
elevated in asthma and COPD (reviewed in 150). MMPs are a family of proteins that exert 
proteolytic activities on various proteins including ECM components and are thus central to 
ECM formation and organization 150. Tissue inhibitors of metalloproteinases (TIMP)s are 
endogenous inhibitors of MMPs that bind to the catalytic site on these proteinases 151. In IPF, 
MMP1, 2 and 9 were co-localized to the epithelium surrounding fibrotic lesions, whereas 
increased TIMP2 was also observed suggesting that the MMP activity may be inhibited and 
that the fibrotic region not degraded 152.  
Another family of enzymes associated with fibrosis and remodeling is the chitinase family. 
Chitinases are proteolytic enzymes that bind, but do not cleave chitin 153. Chitin is the main 
component of the insect exoskeleton, thought to be absent in human tissue. However, these 
proteins are postulated to play important, yet currently undefined roles in biology. The 
prototypic chitinase-like protein is derived from the chitinase 3 like 1 (Ch3l1) gene, called 
YKL40 in humans and BRP39 in mice. YKL40/BRP39 is a circulating regulator of apoptosis, 
and shown to have a role in M2 macrophage activation, TGF1 induction and tissue fibrosis 
154. An early report in asthmatics indicated that YKL40 is elevated in the circulation and is 
associated with asthma severity 155. Chitinolytic activity has also been demonstrated in COPD 
patients 156,157, as well as in models of cigarette smoke induced emphysema 157. Interestingly, 
BRP39 gene deficient mice have increased epithelial cell apoptosis and alveolar destruction in 
response to cigarette smoke, but worsened pathology in hyperoxia-induced lung injury which 
is a more acute ARDS-like model 157,158. Increased YKL40 has also been detected in the lungs 
and circulation of IPF patients, with levels correlating with survival 159,160. Thus, there is clear 
disease association with chitinase activity, however because of discrepancies in the different 
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animal models, whether these chitinases are promoting disease or uniquely serve as a marker 
of disease activity still requires further elucidation. 
7. Therapeutic options for targeting pro-fibrotic cells  
IPF is a disease that is driven by continual parenchymal ECM deposition, which reduces 
lung compliance and effective gas exchange. The fibrosis observed in the lungs of COPD 
patients predominates around small airways4,161 and may not be the main driving factor 
causing the loss in lung function and death. Emphysema and lung tissue destruction is often 
observed in COPD patients and honeycombing is a salient feature in IPF patient lungs 162. 
Overall this suggests an imbalance in repair processes within the lung and targeting the 
underlying pro-fibrotic mechanisms may impact COPD and IPF in a positive way. In IPF, 
the capacity of the lungs (FVC, forced vital capacity); as well as the efficiency of gas 
exchange (DLCO) may improve with a reduction in fibrosis. Both of these parameters are 
used clinically in IPF patients to measure lung function and monitor disease progression162. 
In COPD, anti-fibrotic strategies directed at the same cells and/or mediators may attenuate 
the obstructive nature in the airways and this may be the most discernible improvement in 
lung function. This would translate to an improvement in forced expiratory volume in a 
short time frame (FEV1). Again, FEV1 is commonly used in COPD patient management and 
is used to segregate patients into the various GOLD stages of disease4.  
As has been highlighted in this Chapter, monocytes and mesenchymal cells express a 
variety of receptor that can promote recruitment, proliferation or activation, as well as 
differentiation into other phenotypes (Fig. 2). In experimental mouse models of lung 
fibrosis, blocking fibrocyte recruitment through chemokine ligand/ receptor blockade 
significantly attenuated ECM deposition 54-56,163. However, these chemokine receptors are 
not uniquely expressed on fibrocytes164, so the anti-fibrotic effects observed following 
blockade of these G-protein coupled receptors might extend beyond impaired fibrocyte 
recruitment. Also, we have demonstrated that depletion of lung monocyte/ macrophages 
inhibits TGF-induced lung fibrosis, but has no effect on lung fibrocyte number, suggesting 
a redundant role for fibrocyte recruitment in promoting TGF-induced lung fibrosis 77.  
One other mechanism to consider in any therapeutic approach in pulmonary fibrosis is 
fibrocyte activation. A prototypic activator of fibrocytes, fibroblasts and myofibroblasts is 
TGF. Adenoviral-mediated over-expression of TGF in the lungs of mice or rats, or lung-
specific transgenic over-expression in mice induces significant lung pathology95,165,166. In the 
lung specific TGF over expression, active TGF is expressed by airway epithelial cells. At 
early timepoints following over-expression, apoptosis is observed, following by interstitial 
leukocyte accumulation and then increased collagen deposition, predominating around the 
airways and then gradually increasing in the parenchyma77,165,167. At later stages of lung-
specific TGF over-expression, alveolar collapse is observed77 whereas adenoviral TGF 
expression results in a prolonged, severe fibrosis95. These apparent chronic differences may 
be due to the initial extent of acute lung injury immediately following TGF over-
expression, in that transgenic mediated TGF induces extensive apoptosis, whereby 
blocking apoptosis inhibits subsequent fibrosis165. Blockade of TGF in experimental models 
of lung fibrosis through either antibody neutralization, receptor inhibition of TGF 
activation has been shown to attenuate lung remodelling 99,100,168-170. However, TGF1 gene 
deficient mice die within 3-4 weeks of age and demonstrate significant autoimmune 
pathologies, potentially due to the lack of immunoregulation in the absence of TGF 171,172. 
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Therefore direct neutralization of this target might have significant safety concerns in IPF or 
COPD patients.  
Other factors that work in concert with TGF- include IL4 and IL13. In order to examine the 
role of IL4- and IL13-responsive cells in pulmonary fibrosis, we have conducted preclinical 
studies using IL13 conjugated to a Pseudomonas exotoxin, IL13-PE173, which targets cells 
expressing the type 2 IL4 receptor and IL13R2. This protein-toxin conjugate selectively 
targets IPF fibroblasts because they express these receptor subunits, resulting in specific cell 
death. Moreover, in vivo use in a murine model of bleomycin-induced lung fibrosis showed 
that selective targeting of fibroblasts at the end stages or maintenance phase of fibrosis, 
attenuated remodelling. In contrast, IL13-PE delivered to the lung during the onset or 
initiation of disease had no therapeutic benefit173. This suggests that targeting these cells in 
established disease may allow for the resolution of lung pathology that is observed in 
chronic lung disease patients.  
Taken together, targeting stromal cells to dampen the extent of activation and the amount of 
ECM deposition, regardless of disease, or region within the lung may have an impact in 
lung function that can either halt disease progression or promote resolution and restoration 
of lung function. 
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1. Introduction 
The cancer stem cell model for tumor progression is the first model of its type to suggest 
that only one subpopulation of cancer cells is capable of proliferating indefinitely. These 
cells resemble normal stem cells in their capacity for self-renewal and multi-potential 
differentiation, and can both initiate and maintain tumors. The prevailing names for these 
cells are “cancer stem cells (CSCs)” and “cancer initiating cells (CICs).” The CSC model 
implies a hierarchical organization within the tumor in which a limited number of CSCs 
represents the apex of the hierarchy. CSCs are chemo-resistant, radio-resistant, and 
quiescent, and have been shown to cause both metastasis and relapse. 
CSCs were first described in patients with acute myeloid leukemia (AML) by Dick et al. 
(Lapidot et al., 1994). As to be expected from leukemia stem cells, these CSCs exhibited the 
properties of self-renewal, proliferation and multipotency. The frequency of these leukemia-
initiating cells in the peripheral blood of those AML patients was one engraftment unit in 
250,000 cells. Dick et al. identified the leukemia-initiating cells as CD34+CD38-. 
 In the years since, CSCs have been identified in cancers of the breast(Al-Hajj et al., 2003), 
brain (Singh et al., 2003) and prostate, pancreas and lung (Eramo et al., 2008). In this chapter 
we review CSCs in lung cancer. 
2. Overview of CSCs in lung cancer 
2.1 Concept of CSCs 
Two major models have been described for tumor propagation: the clonal evolution model, 
which involves a stochastic component, and the CSC model, which is defined as 
hierarchical. According to the clonal evolution model, a neoplasm arises from a single cell of 
origin, whereupon an acquired genetic variability within the original clone allows a 
sequential selection to more aggressive clones, thereby allowing the tumor to progress. 
According to the CSC model, tumor cells are heterogeneous, and only the CSC subset has 
the ability to proliferate extensively and form new tumors (Wicha et al., 2006). Yet neither 
model alone can adequately explain the complex biology of tumor progression, resistance, 
and metastasis. Fig. 1 describes a new CSC hypothesis model that encompasses both the 
CSC hierarchical and clonal evolution components, a model in which pre-existing CSCs can 
transform into secondary CSCs (Takebe & Ivy, 2003). 
 




Fig. 1. CSC development. 
A combination of DNA hits and niche microenvironmental factors can transform normal 
stem cells into primary CSCs or more differentiated cancer progenitor cells. Primary tumors 
are formed mostly from bulk tumor cells together with a small percentage of CSCs. The 
accumulation of additional DNA hits plus an altered niche microenvironment may drive 
primary CSCs to evolve into a genetically distinct population of secondary CSCs. Metastatic 
CSCs have the potential to proliferate and form metastatic tumors at distant sites composed 
mostly of bulk tumor cells together with a minority of metastatic CSCs (Takebe & Ivy, 2003). 
2.2 Origins of CSCs 
It remains uncertain whether CSCs originate from normal (somatic) stem cells that acquire 
oncogenic mutations or from non-stem cells of more differentiated forms that dedifferentiate 
and acquire stem-cell-like properties through mutation and reprogramming. CSCs can 
convert into differentiated cells, (Fig. 2) and evidence has suggested that these differentiated 
cells can acquire stem-cell-like properties via exogenous circumstances (including the niche), 
with plasticity. (Fig. 2) Cancer stem cells, for example, might be supplied from cancer cells 
of a non-metastatic epithelial form through a process referred to as “epithelial–
mesenchymal transition” (EMT). Besides tissue stem cells, bone marrow-derived cells 
(BMDCs) may also represent a potential source of malignancy (Fig. 2). Houghton et al. 
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showed that chronic infection of C57BL/6 mice with Helicobacter, a known carcinogen, 
repopulated the stomach with BMDCs (Houghton et al., 2004). Not long after, these cells 
progressed through metaplasia and dysplasia to intraepithelial cancer. These findings have 
broad implications for the multistep model of cancer progression, as they suggest that 
epithelial cancers can originate from bone-marrow-derived sources. The BMDCs may also 
be the precursors to CSCs in lung cancer. 
 
Fig. 2. Origins of CSCs 
2.3 How CSCs can be identified? 
Cancer stem cells are difficult to isolate in solid cancers, though several possible 
methodologies for attempting isolation are available. The process can be attempted with a 
surface marker (CD44 or CD133), or with non-adherent cells cultured in a specific condition 
(sphere-forming), or with side population (SP) cells identified by efflux of dye and an 
intracellular enzyme activity (aldehyde dehydrogenase, ALDH). As yet, there is no apparent 
consensus about the ‘best marker’ by which to identify CSCs. The gold standard assay in 
vivo, the assessment that isolates what most closely fits the definition of CSCs, may be serial 
transplantation in animal models. 
2.3.1 Surface marker 
CD44 or CD133 have served as CSC markers in many solid cancers. In a lung cancer study 
by Eramo et al., some tumors contained a rare population of CD133+ cancer stem-like cells 
that could both self-renew and generate an unlimited progeny of non-tumorigenic cells 
(Eramo et al., 2008). Eramo’s group found that the tumorigenic cells in small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC) consisted of rare populations of 
undifferentiated cells expressing CD133, an antigen present in the cell membrane of normal 
and cancer-primitive cells of the hematopoietic, neural, endothelial and epithelial lineages. 
In their cultures, lung cancer CD133+ cells were able to grow indefinitely as ‘tumor spheres.’ 
Meanwhile, Bertolini et al. independently reported similar findings using CD133+ cells 
isolated from 60 samples of human lung cancer (Bertolini et al., 2009). In their experiments, a 
CD133+ population was increased in primary NSCLC compared with normal lung tissue. 
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Importantly, the expression of CD133 in tumors was linked to shorter progression-free 
survival of NSCLC patients treated with platinum-based regimens. The proliferative 
potential, invasiveness, and chemoresistance of CD133+ cells isolated from human lung 
tumors are reported to depend on the expression of Oct-4 (Chen et al., 2008), a protein 
important in embryonic stem cell development. Lung cancer CD133+ cells have higher Oct-4 
expression, can self-renew, and robustly resist both chemotherapy agents and radiotherapy. 
Leung et al. found that stem cell-like properties are enriched in CD44+ subpopulations of 
some lung cancer cell lines, while most cancer cell lines showed no significant CD133 
expression (Leung et al., 2010). 
Urokinase plasminogen activator (uPA) and its receptor (uPAR/CD87) are major regulators 
of extracellular matrix degradation. Both take part in cell migration and invasion under 
physiological and pathological conditions. uPAR/CD87 was identified as one of the 
candidate CSC markers in SCLC (Gutova et al., 2007). uPAR+ cells exhibited multi-drug 
resistance, high clonogenic activity, and co-expression of the putative cancer stem cell 
markers CD44 and MDR1 in all of the SCLC cell lines examined. 
2.3.2 Sphere formation in culture 
Primary cancer cells can be propagated in spheroid cultures (Reynolds & Weiss, 1992 ), and 
doing so may allow extensive CSC characterization in vitro. The cells are grown in vitro as 
tumor spheres under nonadherent conditions using a serum-free medium supplemented 
with growth factors. Once cultured by this technique, they exhibit high clonogenic potential 
and readily renew themselves, generate differentiated progeny, and generate tumors in vivo 
(Singh et al., 2003; Ricci-Vitiani et al., 2007). From the major subtypes of lung cancer, ‘tumor 
spheres’ were found to possess CSC properties, both in vitro (expression of the CSC marker 
CD133, unlimited proliferative potential, extended abilities to self-renew and differentiate ) 
and in vivo (high tumorigenic potential, capacity to recapitulate tumor heterogeneity and 
mimic the histology of the specific tumor subtype from which CSCs were derived). Lung 
cancer ‘spheres’ are also extremely resistant to most conventional drugs currently used to 
treat lung cancer patients. This spheroid culture method serves adequately in isolating CSCs 
from clinical samples. 
2.3.3 Side population (SP) on flow cytometry 
SP cells are a subpopulation of cells rich in stem-cell-like characteristics. This subpopulation 
was first identified by flow-cytometer-based cell sorting defined by Hoechst 33342 dye 
exclusion (Goodell et al., 1996). Hoechst low cells are described as side population (SP) cells 
by virtue of their typical profiles in Hoechst red versus Hoechst blue bivariate fluorescent-
activated cell sorting dot plots. This test is based on ABCG2 transporter, the second member 
of the G subfamily of ATP binding cassette (ABC) transporters. ABCG2 is one of the most 
important multidrug-resistance transporters, and its substrates include Hoeschst 33342 
(Ding et al., 1996). SP cells were isolated from several solid cancers and certified to have 
stemness. Regarding the lung, SP cells isolated from six lung cancer cell lines exhibited 
higher invasiveness, higher resistance to chemotherapeutic drugs, and higher 
tumorigenicity in vivo compared with non-SP cells (Ho et al., 2007). Most of the SP fraction 
appeared to be in the G(0) quiescent state. Several SCLC cell lines examined by Salcido et al. 
contained a consistent SP fraction comprising <1% of the bulk population. SP cells had 
higher proliferative capacity in vitro, were able to efficiently self-renew, and exhibited 
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reduced cell surface expression of differentiation markers. These cells also over-expressed 
many genes associated with cancer stem cells, drug resistance, and angiogenesis (Salcido et 
al., 2010). 
2.3.4 ALDH activity 
Aldehyde dehydrogenase (ALDH) is a detoxifying enzyme known for its role in the 
oxidation of intracellular aldehydes and for its contribution to the oxidation of retinol to 
retinoic acid in early stem cell differentiation (Jiang et al., 2009). Class 1 of the ALDH family 
(ALDH1) is the predominant ALDH isoform in mammals, and ALDH1 activity might serve 
as a common marker for both normal and malignant stem cell populations. Jiang et al. used 
the Aldefluor assay and fluorescence-activated cell sorting (FACS) analysis to isolate 
ALDH1-positive cells from human lung cancer cell lines. The ALDH1-positive cancer cells 
they isolated exhibited several of the important CSC properties: self-renewal, differentiation, 
multidrug resistance and expression of stem cell marker in vitro; tumor initiation and 
occurrence of a heterogeneous population of cancer cells in vivo. Jiang et al. also found that 
relatively high ALDH1 protein levels were positively associated with the stage and grade of 
the tumors, and inversely related to patient survival. 
2.3.5 Surface marker may vary even when the cells originate from the same tumor 
subtype 
The marked heterogeneity within CSC sub-populations underlines the need to find more 
specific single markers or to define new marker combinations for the prospective isolation 
of CSCs in solid tumors. CD133 is generally considered a stem cell marker, but CD133- 
tumors also contain cells with CSC activity. Independent studies have shown that CD133- 
glioblastoma cells can establish tumors in recipient mice with efficiencies comparable to 
those of CD133+ cells (Beier et al., 2007). In a study by Meng et al., CD133+ and CD133- 
subpopulations in lung cancer cells exhibited similar levels of colony formation, self-
renewal, proliferation, differentiation, and invasion, as well as similar resistance to 
chemotherapy drugs (Meng et al., 2009). As such, these CD133+ and CD133- subpopulations 
can be assumed to have contained similar numbers of cancer stem cells. In some cases, 
CD133 is undetectable among lung cancer samples. In a study by Tirino et al., for example, 
CD133+ was found in only 72% of 89 fresh specimens (Tirino et al., 2009). As to be expected 
from heterogeneous populations, the CSC phenotype is less than uniform, even when the 
cells originate from the same tumor subtype. Primary tumors with different genotypes at 
just one locus can have tumor-propagating cell populations with distinct markers. Fig. 3 
(Curtis et al., 2010) 
Transgenic mice carrying mutant Kras (left), mutant Kras with p53 deficiency (center), and 
mutant EGFR (right) all develop lung adenocarcinomas that harbor similar proportions of 
cells expressing the mouse stem cell marker Sca-1 (blue cells). The tumor-propagating 
capacity of Sca-1+ and Sca-1- cells from each primary tumor genotype was tested by 
implanting small numbers of sorted cells into the lungs of recipient mice. When isolated 
from primary Kras tumors, both Sca-1+ and Sca-1- cells generated secondary tumors that 
recapitulated the Sca-1 cell heterogeneity found in the primary tumor (left). Yet in tumors 
with the mutant Kras and p53 deficiency, Sca-1+ cells were better able to form secondary 
tumors (represented as larger tumors) than Sca-1- cells (center). Further, the secondary 
tumors derived from Sca-1+ cells harbored Sca-1+ cells in a proportion comparable to the  
 




Fig. 3. Tumor Propagating Capacity of Sca-1+ Lung Cancer Cells 
primary tumor, whereas the few small tumors derived from Sca-1- cells had no detectable 
Sca-1+ population. These data suggest that the Sca-1+ cells in this tumor genotype are 
enriched in lung cancer stem cells. The opposite appears to be true in mutant EGFR 
adenocarcinomas, in which Sca-1- cells exhibited a greater capacity for generating secondary 
tumors (right). The distribution of Sca-1+ cells in secondary mutant EGFR tumors remains 
undetermined. Adapted with permission from Sullivan JP, Minna JD. Tumor oncogenotypes 
and lung cancer stem cell identity. Cell Stem Cell. 2010 Jul 2;7(1):2-4. 
2.4 Serial transplantation is the gold standard to validate CSCs 
Serial transplantation in animal models has been the gold standard to certify stemness, but 
animal models fail to mimic the human tumor microenvironment as closely as desired. This 
can be overcome, however, by orthotopic transplantation of candidate cancer-initiating cells 
back into their normal microenvironment. When working with putative lung cancer-
initiating cells, this can be achieved by intratracheal delivery into the lung cavity using a 
methodology employed for the delivery of an adeno-Cre virus in sporadic murine models of 
human lung cancer (Meuwissen et al., 2001, 2003). In serial transplantation in animal 
models, the presence of residual immune effector cells in recipient mice may influence the 
efficiency of human cell engraftment in NOD/SCID mice. Shultz et al. showed that NOD-
scid IL2Rγnull (NSG) mice engrafted with human hemopoietic stem cells generate a 6-fold 
higher percentage of human CD45+ cells in host bone marrow compared to similarly treated 
NOD-scid mice (Shultz et al., 2005). 
2.5 How do we overcome obstacles of researching CSCs? 
It would be impossible to extensively investigate CSCs without expanding the cell 
populations in vitro. Given the low frequency of lung CSCs within primary tumor tissues, 
we have difficulty in finding agents which can kill CSCs with strong selective toxicity. There 
are two methods to surmount this obstacle.  
2.5.1 Sphere formation is the best way to obtain CSCs from patients 
This experimental strategy is the best approach so far developed to obtain the unlimited 
expansion of a tumorigenic lung cancer cell population from primary patients. As such, it 
 
Cancer Stem Cells (CSCs) in Lung Cancer 
 
135 
serves as a powerful enabler for extensive studies on these cells. Yet CSC spheres are 
difficult to establish from epithelial tumors, particularly in the case of lung cancer. Indeed, 
only a few specialized laboratories in the world are able to use CSC spheroids from primary 
tumors. And as another potential limiting factor, CSCs constitute 5 - 30% of the cells in an 
average tumor sphere (Eramo et al., 2008). 
2.5.2 Inducing CSCs by EMT 
Another potential solution is the generation of ‘induced’ CSCs (iCSC). The induction of an 
epithelial-mesenchymal transition (EMT) in normal or neoplastic mammary epithelial cell 
populations has been shown to enrich the cells with stem-like properties. Gupta et al. 
demonstrated that normal and cancer cell populations experimentally induced into an EMT 
also exhibited an increased resistance to chemotherapy drug treatment. When cancer cell 
populations are induced to pass through an EMT, the proportion of CSCs could increase 
(Gupta et al., 2009). 
2.6 Lung stem cells and lung cancer stem cells  
The lung is a complex organ made up of regionally and functionally distinct cell 
phenotypes. A diverse class of lung stem cells drives the development and turnover of these 
populations. The epithelium of the adult airways consists of three distinct compartments 
arranged along a proximal-distal axis. One factor impeding efforts to demonstrate the 
existence of adult lung stem cells has been the slow turnover rates in the adult epithelium. 
Yet in spite of this factor, findings from new studies on pollutant- and pathogen-induced 
injuries leading to massive lung cell proliferation suggest that adult stem cells are present in 
each of the epithelial compartments. These different tumor subclasses may arise from distinct 
cells of origin localized within a defined regional compartment/microenvironment. (Fig. 4) 
 
 
Fig. 4. Airway stem cell microenvironments and associated human carcinomas. 
 
Lung Diseases – Selected State of the Art Reviews 
 
136 
A schematic diagram of the mouse lung highlighting the spatially distinct cellular 
environments shown to harbour airway stem/progenitor cells. Candidate epithelial niches 
(depicted on the right hand side) have been identified and found to exist in spatially defined 
regions: the tracheal submucosal gland ducts, neuroendocrine bodies (NEB) of the 
bronchi/bronchioles, and the broncholalveolar duct junction (BADJ). Adapted with 
permission from Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol. 2010 
Oct;4(5):398. 
2.6.1 Adenocarcinoma 
The distal airways are composed of respiratory bronchioles and alveoli lined with cuboidal 
epithelium. The bronchioalveolar duct junction (BADJ) has been identified as a 
microenvironment harboring airway stem cells (Giangreco et al., 2002). With regard to 
tumorigenicity, Jackson et al. reported that lung tumors were suggested to initiate by oncogenic 
K-Ras activation appeared to be derived from targeted cells located in the BAD (Fig. 5A) 
(Jackson et al., 2001). Kim et al. have isolated bronchioalveolar stem cells (BASCs), a regional 
pulmonary stem cell population, in BADJ, and have identified the candidate origins of CSCs in 
lung adenocarcinomas (Kim et al., 2005). The BASCs in their experiments resisted bronchiolar 
and alveolar damage and proliferated during epithelial cell renewal in vivo. The BASCs also 
exhibited self-renewal capability and multipotent properties in clonal assays, and expanded in 
response to oncogenic K-ras in culture and developed to the lung tumor precursors in vivo. 
2.6.2 Squamaous carcinoma 
The histopathology and gene expression patterns of mouse lung SCC-like lesions frequently 
resemble those of tracheal basal cell progenitors. This presents the appealing prospect that 
these are the target cells of origin in this subclass of lung cancer (Fig. 5C). Keratin (K) 5/14-
expressing basal cells are located at the submucosal gland duct junctions or 
intracartilaginous boundaries and are capable of self-renewal, proliferation, and 
multipotency (Borthwick et al., 2001; Hong et al., 2004a, 2004b; Rawlins et al., 2008; Rock et 
al., 2009). As such, K 5/14-expressing cells are the putative major airway stem cells. But the 
clear relationship between basal progenitors and lung SCC has not been established yet. 
2.6.3 Small cell carcinoma 
The specific cell population that gives rise, upon genetic alteration, to SCLC remains to be 
identified. Human and mouse SCLC predominately localize to the midlevel bronchioles and 
typically express a range of neuroendocrine markers, including calcitonin-gene related 
peptide (CGRP) and other neuropeptides normally expressed within pulmonary 
neuroendocrine cells (PNECs) (Meuwissen et al., 2003). Some investigators have 
hypothesized, based on these observations, that a rare population of PNECs are the 
progenitors of SCLC. (Fig. 5B) In the mouse lung, microenvironments found in close 
proximity to  neuroepithelial bodies (NEB) have been shown to maintain putative stem cell 
populations containing both PNECs and variant CCSP-expressing (vCE) cells (Reynolds et 
al., 2000a). These may be the CSCs of small cell carcinoma. 
2.6.4 Human lung stem cells 
Kajstura et al. recently identified a set of potential stem cells in the human lung (Kajstura et 
al., 2011). These cells were self renewing, clonogenic and multipotent in vitro. And when  
 






Fig. 5. Schematic overview of the putative role of normal tissue stem/progenitor cells in 
lung cancer. 
(A) BADJ contains a rare cell population that expresses both Clara-specific and alveolar-
specific markers. These cells are BASCs. K-Ras activation enhances the proliferation of 
BASCs. (B) Two hypotheses on the origin of lung NE tumors. NEBs in the epithelial lining of 
the bronchi harbor PNECs associated with vCEs. The first hypothesis proposes that (i) NE 
tumors arise from these PNECs. The second hypothesis proposes (ii) that NE hyperplasia 
and SCLC arise from a less-differentiated progenitor-like cell (for example vCE). (C) Given 
the basal-like phenotype of SCC, one could hypothesize that squamous cell tumors arise 
from these basal stem cells. Adapted with permission from Sutherland KD, Berns A. Cell of 
origin of lung cancer. Mol Oncol. 2010 Oct;4(5):397-403. 
injected into a mouse model of lung injury, they regenerated bronchioles, alveoli, smooth 
muscle, pulmonary vessels and many other lung components. The experiments were 
performed using c-kit as a stem cell marker. These results are exciting, though rigorous 
validation will be required. CSCs of the human lung with the potential to differentiate into 
NSCLCs and SCLCs may originate from not only regional lung stem cells, but also 
multipotent stem cells. 
2.6.5 Analysis of important molecules and pathways of CSCs in the mouse model 
Several papers have reported analyses of important molecules related with CSCs in mouse 
models. 
 




Bmi1 is requisite for K-ras–induced tumorigenesis in the mouse model (Dovey et al., 2008). 
Loss of Bmi1 in K-ras transgenic mice decreased the prevalence and progression of lung 
tumors and impaired BADJ stem cell proliferation and self-renewal in vivo and in vitro. 
2.6.5.2 PI3K/PTEN/Akt 
The phosphoinositide 3-kinases (PI3K)/phosphatase and tensin homolog (PTEN)/protein 
kinase B (Akt) pathway is requisite for normal stem cell function. The tumor suppressor 
PTEN encodes a lipid phosphatase that negatively regulates the PI3K /Akt cell survival 
pathway. In NSCLC, loss of PTEN protein expression occurs frequently (Marsit et al., 2005). 
 
 
Fig. 6. Loss of PTEN function results in accumulation of PIP3, which activates a cascade of 
signaling molecules. 
AKT activation inhibits pro-apoptotic factors and stimulates cell cycle progression. The loss 
of PTEN function leads to increased cell survival and proliferation. RTK, receptor tyrosine 
kinase. Adapted with permission from Hill R, Wu H. PTEN, stem cells, and cancer stem 
cells. J Biol Chem. 2009 May 1;284(18):11755-9. 
Recent work has linked the PI3K/PTEN/Akt pathway to lung cancer stem cells and to the 
suppression of K-ras mutations. (Fig. 6) Spontaneous lung adenocarcinomas develop in 
transgenic mice with an inducible loss of PTEN expression in bronchioalveolar cells (Yanagi 
et al., 2007). Interestingly, a loss of PTEN expression resulted in K-ras mutations in 33% of 
mice and developed spontaneous adenocarcinomas. A loss of PTEN expression and PI3K 
activation may elicit increases in BADJ stem cells, side-population (SP) cells, and the 
frequency of K-ras mutations, and thereby initiate the development of lung adenocarcinoma 
over time. 
2.6.5.3 Hedgehog 
The Hedgehog (Hh) signaling pathway acts as an important regulator of stem cell fates 
during embryonic development and has been linked to SCLC (Watkins et al., 2003a, 2003b). 
The observation that intraepithelial Hh signaling is increased after naphthalene-induced 
airway injury suggests that progenitor cells activate Hh signaling in response to injury. 
Increased Hh signaling is also observed in the lungs of PTEN-deficient mice that develop 
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spontaneous lung adenocarcinomas in conjunction with BADJ stem cell expansion, and thus 
may play a causal role in this process (Yanagi et al., 2007). 
2.6.5.4 Wnt 
The Wnt developmental pathway is an another critical regulator of embryonic lung stem 
cells (Reynolds et al., 2008; Zhang et al., 2008). In adult mice, conditional deletion of p38+, a 
known downstream target of noncanonical Wnt signaling (Ma & Wang, 2007), leads to an 
expansion of CCSP+SP-C+ stem cells, hyperproliferation, and increased sensitization to K-
ras–induced tumorigenesis (Ventura et al., 2007). 
2.7 Therapeutic strategy against CSCs 
CSCs are thought to be responsible for disease relapse or metastasis, and also for resistance 
to radiation or conventional chemotherapy. CSCs showed increased quiescence in vivo and 
in vitro, which suggests that they may respond poorly to conventional treatments designed 
to mainly kill the proliferating cells or terminally differentiated cells forming the bulk of 
tumors (Guan et al., 2003). Several therapies against CSCs have been considered, but none 
have been fully developed for lung cancer CSCs. The remainder of this chapter will discuss 
strategies for targeting CSCs in various organs. 
2.7.1 Targeting the key molecule (stem cell marker), key gene & key signaling 
pathways 
Given that CSCs share many of the same features as normal stem cells, there is a potential 
risk of killing normal stem cells while targeting CSCs. It thus becomes important to further 
characterize the similarities and differences between these two types of stem cells. New 
therapeutic approaches to selectively target CSC-specific markers, genes, and pathways are 
needed. 
2.7.1.1 Antibody-based treatment against surface markers 
One recently introduced therapeutic approach for human AML employs an activating mAb 
directed to the adhesion molecule CD44, a known CSC marker of AML (Jin et al., 2006). The 
in vivo administration of this Ab to NOD/SCID mice transplanted with human AML 
markedly reduced leukemic repopulation. Mechanistically, CD44-specific Ab treatment 
induced differentiation to a more mature cancer cell progeny that were unable to establish 
robust leukemia upon xenotransplantation. For solid tumors, CD13, a CSC marker of 
hepatocellular carcinoma, is expected to become a target of CSC therapy (Haraguchi et al., 
2010). 
2.7.1.2 Inhibition of essential pathways in the CSCs function 
The eventual goal is to generate targeted therapeutics that inhibit essential pathways in the 
CSC fraction. It will probably be complicated to target these pathways, as the same 
pathways are also pivotal in normal stem cell function. The Wnt pathway, hedgehog 
pathway, and notch pathway are all reportedly essential for maintaining stemness. The 
blocking of these pathways thus holds promise as a therapeutic approach. Many reports and 
target drugs have been published and developed in pursuit of such a therapy, but only few 
of these reports have touched upon lung cancer CSCs. The hedgehog pathway may play an 
important role in lung CSCs, as the pharmacological inhibition of this pathway reduced the 
growth of lung tumor cells in xenograft models (Watkins et al., 2003a). Suppression of the 
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Notch pathway by treatment with either a -secretase inhibitor or stable expression of 
shRNA against NOTCH3 significantly decreased ALDH+ lung cancer cells, and 
commensurate reductions in tumor cell proliferation and clonogenicity were observed 
(Sullivan et al., 2010). Notch signaling thus appears to take part in lung cancer stem cell 
maintenance. 
2.7.1.3 Blocking of the stemness gene 
CD133+ cells in lung cancer exhibit higher Oct-4 expression. Oct-4 plays a crucial role in 
maintaining the self-renewing, cancer stem-like, and chemoradioresistant properties of 
CD133+ cells. Knock-down of Oct-4 expression can significantly inhibit the abilities of tumor 
invasion and colony formation, increase apoptotic activities, and enhance the treatment 
effect of chemoradiotherapy (Chen et al., 2008). The downregulation of transcription factor 
SOX in lung CSCs reportedly suppresses growth and metastasis (Xiang et al., 2011), and the 
blocking of the SCF/c-kit signaling pathway inhibits CSC proliferation and survival after 
chemotherapy exposure in human lung cancer cell lines (Levina et al., 2010). Cisplatin 
treatment eliminated most of the tumor cells, but unlike the blocking of c-kit, it was 
unsuccessful in eliminating CSCs. A combination treatment with cisplatin and c-kit blocking 
prevented the growth of both tumor cell subpopulations. 
2.7.2 Regulation of micro RNA 
Micro RNAs can affect the signaling pathways that influence stem cell self-renewal. A lack 
of let-7 is required for self renewal in vitro and for tumorigenicity in vivo. In other words, an 
overexpression of let-7a reduces self renewal and proliferative capacity and converts highly 
malignant and metastasizing CSCs into less malignant cells (Yu et al., 2007). 
2.7.3 Induction of diffentiation of CSCs 
Differentiation therapy aims at converting tumorigenic CSCs in their non-tumorigenic 
progeny. Treatment with bone morphogenic protein 4 (BMP4) reduced the tumor-initiating 
cell pool in a glioma model and markedly slowed down tumor growth in vivo without toxic 
side effects (Piccirillo et al., 2006). 
2.7.4 Altering the CSCs’ environment (niche) 
The stem cell niche plays an important role in maintaining CSCs and apparently enhances 
the therapy resistance of CSCs by sheltering the cells from diverse insults (Folkins et al., 
2007). Perivascular, hypoxic, premetastatic and stromal myofibroblast niches have all been 
reported. The perivascular niche in brain tumors has been shown to contribute directly to 
the generation of CSCs and tumor growth. Anti-angiogenic therapy using vascular 
endothelial growth factor inhibitors not only depleted tumor vascularization, but also 
ablated CSCs in the xenograft (Calabrese et al., 2007). While some stem cells are 
perivascular, others may occupy hypoxic niches and be regulated by O2 gradients (Parmar 
et al., 2007). However, the underlying mechanisms are still unclear. O2 availability may have 
a direct role in stem cell regulation through the HIF-1 modulation of Wnt/-catenin 
signaling (Mazumdar et al., 2010). These niches are expected to become targets of CSC 
therapy. In experiments with colon adenocarcinomas, Vermeulen et al. found that 
hepatocyte growth factor and other myofibroblast-secreted factors activate CSC 
clonogenicity (Vermeulen et al., 2010). More significantly, myofibroblast-secreted factors 
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restored the CSC phenotype in more differentiated tumor cells both in vitro and in vivo. 
Vermeulen’s group therefore propose that the stemness of colon cancer cells is in part 
orchestrated by the microenvironment. 
2.7.5 Activation of reactive oxygen species (ROS) 
CSCs have the ability to keep ROS levels low. Subsets of CSCs in some tumors contain lower 
ROS levels and enhanced ROS defenses compared to their non-tumorigenic progeny. This 
may contribute to tumor radioresistance. Overcoming low ROS levels within CSCs may be a 
useful method for improving local and systemic oncologic therapies (Diehn et al., 2009). 
Haraguchi et al. found that CD13 is a marker for semiquiescent CSCs in human liver cancer 
cell lines and clinical samples. Mechanistically, CD13 reduced ROS-induced DNA damage 
after genotoxic chemo/radiation stress and protected cells from apoptosis. In mouse 
xenograft models, a combination of a CD13 inhibitor and the genotoxic chemotherapeutic 
fluorouracil (5-FU) drastically reduced tumor volume compared with either agent alone. 
Thus, the combination of a CD13 inhibitor with a ROS-inducing chemo/radiation therapy 
may improve the treatment of liver cancer (Haraguchi et al., 2010). CD44 is an adhesion 
molecule expressed in cancer stem-like cells in gastric cancer. Ishimoto et al. showed that a 
CD44 variant (CD44v) interacts with xCT, a glutamate-cystine transporter, and controls the 
intracellular level of reduced glutathione (GSH) (Ishimoto et al., 2011). Human 
gastrointestinal cancer cells with strong CD44 expression showed an enhanced capacity for 
GSH synthesis and defense against ROS. Ablation of CD44 induced a loss of xCT from the 
cell surface and suppressed tumor growth in a transgenic mouse model of gastric cancer. 
The activation of ROS may be viable as another target therapy for CSCs. 
2.7.6 Overcoming of chemoresistance and radioresistance in CSCs 
Reversing chemoresistance in CSC populations can be achieved through a specific blockade 
of multidrug resistance ABC transporters (Frank et al., 2005). Enhanced drug efflux 
mediated by ABCB1 P-glycoprotein and related ATP-binding cassette transporters is one of 
several mechanisms of multidrug resistance thought to impair chemotherapeutic success in 
human cancers. In CD133+ CSC in malignant melanoma, ABCB5, a novel human ABC 
transporter, mediates melanoma resistance to the chemotherapeutic agent doxorubicin, and 
this effect is reversible by both mAb-mediated inhibition of ABCB5-dependent drug efflux. 
In addition, ABCB5 gene silencing substantially increases the sensitivity of human 
melanoma cells to the anticancer chemotherapeutics 5-fluorouracil (5-FU) and camptothecin 
(Huang et al., 2004). CSC-targeted therapeutic approaches might also include strategies 
directed at reversal of radioresistance. Bao et al. reported that CD133+ human glioma CSCs 
contributed to tumor radioresistance by preferentially activating the DNA damage 
checkpoint response and enhancing the DNA repair capacity (Bao et al., 2006). An inhibition 
of the Chk1 and Chk2 checkpoint kinases reversed the radioresistance of CD133+ glioma 
CSCs in their experiments. 
2.7.7 Supressing EMT and inducing MET 
EMT in carcinoma seems to be associated with the acquisition of a CSC phenotype endowed 
with a more invasive and metastatic phenotype. As such, a new drug to suppress EMT is 
expected as a target therapy for CSCs. Metastatic progression might involve the 
dissemination of CSCs at tumor margins that have undergone EMT. Thus, the 
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mesenchymal-epithelial transition (MET) seems to hold promise as a therapy. Gupta et al. 
identified small molecules (salinomycin) that specifically inhibit cancer stem cell 
proliferation through the induction of MET (Gupta et al., 2009). 
3. Conclusion 
Though targeted therapies have been developed, we have witnessed only limited 
improvement in the prognosis of lung cancer patients. Ultimately, patient cure will require 
the eradication of all cells within a cancer. From this standpoint, combination therapies 
targeting both CSCs and bulk cancer populations hold promise. In the coming years we 
must clarify the origin of CSCs, find more specific CSC markers, elucidate the CSC niche, 
and develop more effective innovative agents against resistant tumorigenic lung CSCs. 
CSCs may vary in different lung cancers, so personalized CSC therapy may be needed. 
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1. Introduction 
Small cell lung cancer (SCLC) makes up almost 15% of all cases of lung cancer and occurs 
almost exclusively in individuals with a history of smoking (Blackhall & Faivre-Finn, 2011; 
Meyerson et al., 2004; Tamasi and Muller, 2011; Walenkamp et al., 2009). However, SCLCs 
differ significantly from NSCLCs in specific genetic alterations that occur. Moreover, 
smoking-damaged bronchial epithelia accompanying SCLCs appears to have undergone 
significantly more acquired genetic damage than is frequently found in NSCLCs. Two 
subtypes of SCLC exist: homogeneous small cell carcinoma and combined SCLC (mixture of 
any non-small cell type) (Meyerson et al., 2004; Tamasi and Muller, 2011). SCLC in its 
advanced stage has an aggressive clinical course and is commonly accompanied by 
paraneoplastic syndromes. Autocrine growth factors, such as neuroendocrine regulatory 
peptides (e.g. bombesin/gastrin-releasing peptide), are prominent in SCLC.  
SCLC is categorized as limited stage disease (LS) when confined to the ipsilateral hemithorax 
and within a single radiation port, while extensive stage disease (ES) includes metastatic 
disease outside the ipsilateral hemithorax (Blackhall & Faivre-Finn, 2011; Meyerson et al., 2004; 
Tamasi and Muller, 2011; Walenkamp et al., 2009). SCLC is sensitive to chemotherapy; 
response rates to front-line agents are often in the range of 60%, with approximately 10% of 
patients achieving a complete response, even in the setting of metastatic disease (Brambilla et 
al., 2009 Jemal et al., 2006). Despite this, the relapse rates are quite high and survival with 
currently available salvage therapy is quite modest. With current therapy, patients with LS-
SCLC have a median survival of 17 months and a 5-year overall survival rate of 12% , while 
patients with ES-SCLC have a median survival of 8.9 months, and a 5-year survival rate of 
approximately 2%. (Brambilla et al., 2009 Jemal et al., 2006; Tamasi and Muller, 2011). This 
article will review the molecular targeted agents, the genetic abnormalities, and therapeutic 
efficacy in SCLC.  
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2. Trp53 gene 
The p53 gene located on chromosome 17p13.1 encodes a nuclear protein that acts as a 
transcription factor and causes cell cycle arrest or apoptosis. Mutations of this gene lead to 
the loss of tumor suppressor function, thereby promoting cellular proliferation. The majority 
of the mutations seen in lung cancers are G to T transversions on the non-transcribed strand, 
suggesting mutagenesis secondary to tobacco smoke. Wild-type p53 protein is present in 
very low levels in normal cells, whereas mutant p53 is present in much greater quantities in 
tumor cells due to its prolonged half-life. In fact, 40–70% of SCLC express abnormal p53 
protein (Wistuba et al., 2001). Inactivating mutations of p53, seen in approximately 90% of 
SCLC, are typically missense mutations in the DNA binding domain and, to a lesser degree, 
homozygous deletions (Demirhan et al., 2010). Preclinical studies have shown that a vaccine 
composed of dendritic cells transduced with a human wild-type P53 containing 
recombinant adenovirus (DC-Ad-p53) causes an antitumor response (Ishihda et al., 1999). 
The differential expression of the mutant P53 gene between normal and tumor cells could 
provide a basis for vaccine therapy.  
Antonia et al. (2006) treated 29 patients with relapsed/refractory ES-SCLC with a vaccine 
consisting of dendritic cells transduced with the full-length wild-type P53 gene delivered 
via an adenoviral vector. Only one patient showed a clinical response to the vaccine therapy. 
Interestingly, there was a high rate of objective clinical responses to chemotherapy (61.9%) 
that immediately followed vaccination. This clinical response to subsequent chemotherapy 
was closely associated with induction of immunologic response to vaccination. Hence, it is 
likely that vaccine therapy could serve as an adjunct to chemotherapy, rather than a primary 
treatment modality. Using this rationale, a current phase I/II trial is evaluating an 
autologous dendritic cell-adenovirus p53 vaccine following standard platinum-etoposide 
chemotherapy in patients with ES- SCLC (Horn et al., 2011). Another approach towards 
vaccination therapy is to target the ganglioside GD3, a cell surface glycosphingolipid 
antigen that is typically expressed on cells of neuroectodermal origin and a subset of T-
lymphocytes (Grant et al., 1999). Studies using SCLC cell lines suggest that these cell lines 
express significant levels of GD3. The anti-idiotypic antibody BEC-2, which mimics the 
structure of the GD3 ganglioside, showed promising results in a pilot study (Grant et al., 
1999). Based on these results, the European Organization for Research and Treatment of 
Cancer (EORTC) performed a randomized phase III study in 515 patients with LS-SCLC 
who were randomized to receive BEC-2 or not as a maintenance treatment following 
standard induction chemotherapy (Giaccone et al., 2005). Although there was no 
improvement in overall survival, progression-free survival, or quality of life in the 
vaccination arm, there was a trend toward prolonged survival in patients who had a 
humoral response. The authors concluded that vaccination strategies may be warranted 
with vaccines that were better able to induce a humoral immune response. 
Yang et al. (2011) evaluated the role of genetic P53 polymorphism in radiation-induced 
pneumonitis (RP), a common dose-limiting toxicity of radiotherapy. In a cohort comprised 
of 253 (188 NSCLC and 65 SCLC) lung cancer patients receiving thoracic irradiation, the P53 
72Arg/Arg genotype was associated with increased radiation-induced pneumonitis risk 
compared with the 72Pro/Pro genotype. Furthermore, the P53 Arg72Pro and ATM-111G>A 
polymorphisms displayed an additive effect in intensifying the risk of developing RP. The 
cross-validation test showed that 63.2% of RP cases could be identified by P53 and ATM 
genotypes. Thus, genotyping P53 and ATM polymorphisms might help proactively identify 
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patients susceptible to developing RP when receiving radiotherapy. A recent report by 
Garcia and co-workers (2010) describe the association of SCLC with ovarian metastases. A 
54-year-old woman with SCLC presented with a left ovarian mass, 4.8 cm in diameter, the 
microscopic appearance of which was identical to the previous bronchoscopic biopsy. 
Molecular analysis of P53 demonstrated an identical point mutation (S215) in both tumor 
sites. Moreover, a P53 DNA polymorphism (P52R) was identified in normal tissue, but 
present in homozygosity in both tumor sites. 
3. Retinoblastoma (RB) gene 
The RB gene, located on chromosome 13q14.11, has been implicated in the regulation of cell 
cycle progression, particularly the G1 to S-phase transition, in part, through inactivation of 
members of the E2F transcription factor family (Modi et al., 2000; Schaffer et al., 2010; 
Wikman et al., 2006). Hypophosphorylated RB is the growth suppressing form that controls 
the transcription factors E2F1, E2F2 and E2F3, which are necessary for the G1/S transition. 
(Modi et al., 2000; Wikman et al., 2006). When bound to hypophosphorylated RB, E2F is in 
its inactive form, causing cell arrest in the G1 phase. The cyclin D1/CDK4 complex 
phosphorylates RB, which in turn releases E2F, allowing its activation and promoting entry 
into S phase. During S phase, cyclin E and CDK2 assert control over the phosphorylation of 
RB (Wikman et al., 2006; Xue et al., 2003). Inactivation of pRB by gross structural alterations 
or point mutations in the RB-1 gene has been described in >90% of all SCLC (Wikman et al., 
2006; Xue et al., 2003). The types of mutations that occur in the RB gene include deletions, 
nonsense mutations and splicing abnormalities. Phosphorylated RB suppresses apoptosis by 
repressing other pro-apoptotic target genes, including apoptotic protease activating factor-1 
(Apaf-1) and caspases.   
There have been numerous reports of RB protein expression in lung cancer (Wikman & 
Kettunen, 2006). Similar to human tumor entities in general, different lung cancer types 
show extensively varying expression patterns:  SCLC and large cell neuroendocrine 
carcinomas (LCNEC) are mostly characterized by loss of RB expression (~90%). Conversely, 
altered expression of RB is rare (~25%) in squamous cell carcinoma (SCC) and 
adenocarcinoma (AC), which comprise most cases of NSCLC (Leversha et al., 2003; Gouyer  
et al., 1998). Rather, NSCLC is attributed to p16INK4a loss or CCND1 overexpression (Schauer 
et al., 1994). Interestingly, a few cases of SCLC display p16INK4a alterations, but retain normal 
RB. Preinvasive bronchial lesions and carcinoid tumors also rarely exhibit abnormal RB 
expression. It is thought that SCLC and other neuroendocrine lung tumors originate from 
the progenitor neural crest that is similar to the origin of RB.  
RB is altered by mutations (20–30%) or small deletions and chromosomal loss (80–90%) in 
SCLC (Mori et al., 1990; Kashii et al., 1994). Even though 58% of neuroendocrine lung 
tumors show low or absent mRNA levels, no hypermethylation has been observed in these 
tumors. In NSCLC, some reports have detected no RB DNA alterations, whereas others, 
somewhat controversially, have found frequent loss of heterozygosity (LOH) (up to 75%) 
and mutations (33%) of RB in SCC (Gouyer et al., 1998; Leversha et al., 2003). DNA 
Alterations of RB have rarely bee described in AC (Sachse et al., 1994). In summary, 
complete loss of RB or a mutant form of RB are present in greater than 90% of SCLC cases 
(Modi et al., 2000). As all normal cells express functional RB, drugs that target cells with 
inactived or deleted RB would be appropriate candidates for testing in patients with SCLC. 
Such drugs include heat shock protein-90 (Hsp90) inhibitors (Rodina et al., 2007). 
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4. BCL2 gene 
BCL2 is an oncogene that plays a major role in suppressing apoptosis and thus in treatment 
resistance (Ilievska et al., 2008; Tudor et al., 2000). Therefore, suppression of BCL2 may 
increase therapeutic efficacy (Ilievska et al., 2008; Lawson et al., 2010; Ziegler et al., 1997). 
Since BCL2 is expressed in the vast majority of SCLC cases, it represents a potential 
therapeutic target in this disease. G3139 (oblimersen) is an 18-base antisense 
phosphorothioate oligonucleotide complementary to the BCL2 mRNA in the region 
encoding the first six amino acids (Reed et al., 1990). Preclinical and clinical studies have 
demonstrated that intravenous administration of G3139 reduces BCL2 protein production 
(Waters et al., 2000). The combination of oblimersen and paclitaxel was evaluated in a phase 
II trial of 12 patients with chemo-refractory SCLC (Rudin et al., 2002). There were no 
objective responses, but four patients had stable disease. The low yield of this small study 
was attributed to the relatively low doses of both agents; the dose of oblimersen chosen may 
have been insufficient to suppress expression of the target gene BCL2, while paclitaxel had 
to be given at a dose clearly below that routinely used. Also, since inhibition of BCL2 
expression may increase therapeutic efficacy of cytotoxic agents, this strategy may be more 
beneficial in patients who responded positively to chemotherapy. In order to test this 
hypothesis, Rudin et al. (2004) combined oblimersen with etoposide and carboplatin in 16 
patients with newly diagnosed extensive stage SCLC. This combination yielded promising 
results with reasonable toxicity and is currently being studied in a randomized phase III 
trial to define an exact role for this molecule. Additionally, a small molecule BCL2 inhibitor, 
AT101, is currently being evaluated in combination with topotecan in patients with 
relapsed/refractory SCLC. ABT-263 has also been identified as a Bcl-2 inhibitor in numerous 
SCLC and leukemia/lymphoma cell lines in vitro and in vivo (Tahir et al., 2010). In another 
study, Knoefel et al. (2011) studied the single-nucleotide polymorphism C-938A to assess the 
potential impact as a genetic marker for response to chemotherapy and outcome prediction 
in 188 Caucasian SCLC patients. Patients carrying the BCL2-938CC genotype showed 
significantly worse time to progression and overall survival than those with the BCL2-
938AA genotype. This genetic marker might particularly impact on treatment strategies 
using BCL2 antisense approaches. 
5. MYC genes 
c-MYC, N-MYC and L-MYC are proto-oncogenes that code for proteins involved in the 
regulation of proliferation, differentiation, and apoptosis (Komiya et al., 2011; Paulson et al., 
2009; Xion et al., 2011). Amplification of the c-MYC oncogene has been observed in various 
human malignancies (Komiya et al., 2011). Studies in small cell lung cancer have suggested 
that although amplification of the MYC family genes is seen in only about 10% of patients 
with newly diagnosed SCLC, this proportion increases following treatment (Komiya et al., 
2011; Paulson et al., 2009; Xion et al., 2011 ; Barr et al., 1998), suggesting that MYC 
expression increases with resistance of SCLC to therapy. Other studies have suggested that 
higher levels of expression of the MYC gene family may play a significant role in the 
carcinogenesis of SCLC (Kumimoto et al., 2002). Protein overexpression is seen with MYC 
activation by gene amplification or transcriptional dysregulation (Komiya et al., 2011). In 
addition, amplification of these genes may have a predictive value, since  tumors with N-
MYC amplification have been associated with poor response to chemotherapy, rapid tumor 
growth, and short survival (Komiya et al., 2011). 
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6. c-KIT receptor 
c-Kit is a tyrosine kinase receptor that, when activated by its ligand stem cell factor (SCF), 
enhances the growth and survival of hematopoietic cells (Reber et al., 2006; Schneider et al., 
2010). Preclinical studies have demonstrated the expression of c-KIT and SCF on almost 70% 
of SCLC cell lines (Reber et al., 2006), suggesting a possible role in the autocrine/paracrine 
stimulation of tumor growth. Almost a third of patients with ES-SCLC  show evidence of c-
kit overexpression by immunohistochemistry (IHC) (Potti et al., 2003; 2005). In a phase II 
study of imatinib in SCLC, Johnson et al. (2003) enrolled 19 patients with extensive disease 
who were either treatment-naïve or had a chemo-sensitive relapse. No activity for imatinib 
was reported, with only one patient showing disease stabilization. A major drawback of this 
study was that 79% of the enrolled patients lacked c-KIT expression. In an attempt to 
improve on these findings, the Cancer and Leukemia Group B (CALGB) refined the study 
design and conducted a similar trial (Dy et al., 2005) in patients with c-KIT overexpression. 
Despite this, the results were similar to those seen in the previous study, with no observed 
responses and only one patient with stable disease for 31 weeks. In a third study, imatinib 
was used as maintenance therapy following cisplatin and irinotecan in patients with ES-
SCLC and c-KIT overexpression in tumor tissue (Schneider et al., 2010). Patients who 
received imatinib did not have any improvement in the progression-free survival, and thus, 
this strategy did not warrant further investigation. One of the reasons for the inactivity of 
imatinib in SCLC may be that the putative cells of origin of SCLC are not developmentally 
dependent on c-KIT (Heinrich et al., 2002), as opposed to hematopoietic stem cells. Another 
reason could be the absence of activating mutations in patients with SCLC in c-KIT exon 11 
that predict for imatinib activity in gastrointestinal stromal tumors (Burger et al., 2003). 
7. Vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) 
The vascular endothelial growth factor (VEGF) family is comprised of VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and VEGF-E growth factors and their three VEGF receptors (VEGFR 1-3) 
(Tanno et al., 2004; Wójcik et. al., 2010). The VEGF signaling pathway leads to increased 
proliferation, migration, and invasion of endothelial cells, thus mediating tumor 
angiogenesis (Tanno et al., 2004; Sattler & Salgia, 2003). VEGF is a key factor in the 
development of new blood vessels that increases the permeability of microvessels (Thomas 
et al., 2003). High levels of VEGF have been reported in patients with SCLC, which are 
associated with tumor stage, disease progression, resistance to chemotherapy and poorer 
outcomes (Fischer et al., 2007). Studies affecting angiogenesis in SCLC have involved: (1) 
External inhibitors of angiogenesis, chiefly targeting VEGF and its receptor, (2) Endogenous 
inhibitors such as interferons, and, (3) Miscellaneous agents, e.g., thalidomide. SCLCs 
express VEGFR1-3 and VEGFR-2, which are actively involved in tumor growth and invasion 
(Tanno et al., 2004). The VEGF/VEGFR autocrine signaling pathway mediates proliferation 
and metastasis, which can be inhibited with the use of monoclonal antibodies against 
VEGFR-2 and VEGFR-3 in SCLC (Tanno et al., 2004). SU6668, which inhibits VEGFR, c-KIT 
and FGFR, blocks proliferation and angiogenesis in human lung tumor xenografts (Laird et 
al., 2000). In a study of 87 patients with SCLC who underwent primary resection followed 
by adjuvant therapy, microvessel count and expression of VEGF significantly affected 
survival, thereby establishing a role for angiogenesis in SCLC (Lucchi et al., 2002). Another 
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preclinical trial demonstrated that ZD6474, a VEGFR-2 and EGFR kinase inhibitor, 
successfully interfered with VEGF signaling and angiogenesis, leading to decreased 
proliferation and increased apoptosis in SCLC xenographs. Bevacizumab is a recombinant 
humanized monoclonal antibody against VEGF that has been approved by the US Food and 
Drug Administration (FDA) for the treatment of metastatic colon cancer and NSCLC. 
Preliminary reports of bevacizumab following carboplatin and irinotecan treatment in 
patients with LS-SCLC have demonstrated response rates, 1- and 2-year survival rates and a 
safety profile comparable to standard therapy (Raefsky et al., 2005). However, whether the 
addition of bevacizumab increases progression-free and overall survival is currently unclear 
and needs to be studied in a randomized phase III trial. VEGF-tyrosine kinase (VEGF-TK) 
inhibitors have been shown to inhibit downstream signaling pathways that are activated 
following ligand binding to the VEGF receptor. Multiple agents with VEGF-TK inhibitory 
activity are being tested for their utility in therapy of various malignancies. A number of 
small molecules that inhibit VEGFTKs are currently in development, including ZD6474, 
PTK787/ ZKI222584 (vatalanib), AZD2171, BAY 43-9006 (sorafenib), SU11248 (sunitinib), 
and AMG706 (Herbst et al., 2005; Morabito et al., 2009). Trials incorporating SU11248 
(sunitinib), a multi-targeted TK inhibitor, are being planned in SCLC.  
The interferons are a family of naturally-occurring cytokines that have anticancer activity 
through immunomodulatory and antiangiogenic properties (Blackhall & Shepherd, 2004). 
Interferons affect endothelial cells by blocking production of basic fibroblast growth factor 
(bFGF). Patients who achieved a response to chemotherapy were randomized to either 
interferon maintenance or placebo in different randomized trials. In each of those trials, 
administration of interferon was associated with considerable toxicity, although two studies 
showed a trend towards improved survival with interferon treatment (Lebeau et al., 1999). 
Current trials are investigating the role of interferon either as a vaccine or in combination with 
cytotoxic chemotherapy in SCLC. Initial reports of maintenance therapy with thalidomide 
following induction with platinum - etoposide in patients with ES-SCLC have been promising 
(Conney et al., 2005; Ustuner et al., 2008). This approach needs evaluation in the future. 
8. Epidermal growth factor receptor (EGFR) 
Although EGFR expression has been reported to be low in SCLC, gefitinib, an oral EGFR 
tyrosine kinase inhibitor, has been shown to inhibit EGFR signaling in SCLC cell lines 
(Schmid et al., 2010; Tanno et al., 2004). Anecdotal evidence has suggested tumor regression 
in patients with advanced stage SCLC following treatment with gefitinib (Araki et al., 2005; 
Okamoto et al., 2006). This suggests a potential role for gefitinib and other agents targeting 
the EGFR pathway in this disease. Sequist et al. (2011) performed systematic genetic and 
histological analyses of tumor biopsies from 37 patients with drug-resistant NSCLCs 
carrying EGFR mutations. All drug-resistant tumors retained their original activating EGFR 
mutations, and some acquired known mechanisms of resistance including, the EGFR T790M 
mutation or MET gene amplification. Furthermore, some resistant cancers showed 
unexpected genetic changes, such as EGFR amplification and mutations in the PIK3CA gene, 
whereas others underwent a pronounced epithelial-to-mesenchymal transition. 
Surprisingly, five resistant tumors (14%) transformed from NSCLC into SCLC, and were 
sensitive to standard SCLC treatments. Serial biopsies in three patients revealed that genetic 
mechanisms of resistance were lost in the absence of the continued selective pressure of 
EGFR inhibitor treatment, and were sensitive to a second round of treatment with EGFR 
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inhibitors (Sequist et al., 2011). Collectively, these results deepen our understanding of 
resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers 
throughout the course of the disease. 
HER2/neu expression in SCLC has been less well studied. Studies have demonstrated 
overexpression of HER2/neu by immunohistochemistry in approximately 13–30% of 
patients with advanced stage SCLC (Micke et al., 2001; Potti et al., 2002, 2003). These studies 
also found that HER2/neu expression was associated with a poor prognosis for patients 
with advanced disease. Based on these findings, the anti-HER2/neu monoclonal antibody 
trastuzumab may be useful as a therapeutic agent in SCLC. 
9. Matrix metalloproteinase (MMP) inhibitors 
Matrix metalloproteinases are involved in extracellular matrix (ECM) degradation (Stetler-
Stevenson et al., 1993), a key process in metastasis. Use of protease inhibitors to limit 
extracellular matrix proteolysis by cancer cells, thereby interfering with tumor cell invasion, 
would thus be an attractive therapeutic target. In a retrospective analysis, elevated MMP 
expression was identified as a negative predictor of survival in SCLC (Michael et al., 1999). 
60 to 70% of tumor cells stained positive by IHC for MMP-1 and -9, while positive signals 
for MMP-11, -13, and -14 were observed in 70 to 100% of tumor cells. Expression of MMP-11 
and MMP-14 was determined to be an independent negative prognostic factor for 
Marimastat, a synthetic, orally administrated, broad spectrum MMPI with activity against 
collagenases, gelatinases, and stromolysins (Brown & Giavazzi 1995). The National Cancer 
Institute of Canada-Clinical Trials Group (NCIC-CTG) and EORTC conducted a randomized 
placebo-controlled trial of marimastat following induction chemotherapy in 532 patients 
with sensitive SCLC (Shepherd et al., 2002). The addition of marimastat after induction 
chemotherapy did not result in improved survival and also had a negative impact on 
quality of life. These disappointing results may be due to patient selection, as MMP 
expression was not studied in these patients. The proteinases MMP11 and MMP14 were 
expressed, a more selective MMPI-targeting these two proteins would arguably be more 
beneficial. In another study, Jumper et al. (2004) evaluated the relationship between 
circulating MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP-1). Thirty one 
male and female patients with either stage III or IV NSCLC and 17 with either stage III or IV 
SCLC were compared to 117 age-matched non-smoking controls of both sexes. Prior to any 
treatment of the patient, a baseline serum sample was obtained from each of the patients for 
the determination of circulating MMP-9 and TIMP-1. The results indicate that both MMP-9 
and TIMP-1 were elevated in the serum of patients with SCLC or NSCLC when compared to 
the controls. However, the mean values for both MMP-9 and TIMP-1 in the two tumors did 
not differ. The natural physiological relationship between MMP-9 and the inhibitor TIMP-1 
was lost in both SCLC and NSCLC, indicative of abnormal alterations by the tumor. This 
study suggests that advanced lung cancer alters the normal circulatory pattern of MMP-9 
and TIMP-1 a finding that could aid in the understanding of tumor invasion and/or 
metastasis. 
10. Sonic hedgehog pathway 
The hedgehog (HH) signaling pathway is important during embryonic development and 
may be involved in development and progression of several human malignancies (Datta & 
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Datta, 2006; Watkins & Peacock, 2004). In vitro studies have demonstrated extensive 
activation of this pathway in a subset of SCLC cell lines (Watkins et al., 2003). The 
Hedgehog (Hh) pathway is essential in early lung formation and development through 
epithelial-mesenchymal interactions (Peacock & Watkins, 2008; Watkins et al., 2003). The 
signaling cascade is initiated by Hh binding to the Patched-1 receptor (Ptch-1), a twelve 
transmembrane protein. In the absence of Hh ligand, Ptch-1 constitutively inhibits the seven 
transmembrane protein Smoothened (Smo), and renders the pathway inactive. However, 
binding of Hh ligand to Ptch-1 causes the inhibition of Smo to be relieved, which then 
activates a protein complex and downstream transcription of Hh targets in the nucleus, 
including Gli-1 and Ptch-1. Present at low levels in the basal layer of bronchial epithelium in 
the adult, active Hedgehog signaling results in expansion of an intraepithelial cell 
population during airway regeneration induced by naphthalene injury. In SCLC, there is 
ligand-dependent activation of the Hedgehog pathway in a juxtacrine fashion, with adjacent 
cells expressing Sonic hedgehog (Peacock & Watkins, 2008; Watkins et al., 2003). Further, in 
vitro and in vivo studies have demonstrated that SCLC can be inhibited by the steroidal 
alkaloid Hedgehog antagonist, cyclopamine (Watkins et al., 2003; Vestergaard et al., 2006). 
These data support the presence of a progenitor cell in SCLC that remains chemotherapy-
resistant and relies on the Hedgehog developmental pathway, which can be targeted. Gene 
expression analysis on members of this pathway showed that although the key transcription 
factor of this pathway, GL1, was only weakly expressed in cell lines, it was expressed on 
most SCLC tumors studied, thereby suggesting an important role for this pathway for 
tumor growth in vivo (Vestergaard et al., 2006). Thus, the data support the idea that the HH 
pathway may be an ideal therapeutic target in SCLC. Agents that inhibit this pathway, 
cyclopamine and its analog KAAD cyclopamine, will soon be in clinical trials. 
11. mTOR pathway 
Mammalian target of rapamycin (mTOR), a downstream mediator in the PI3K/Akt 
signaling pathway, plays a critical role in the regulation of cell proliferation, survival, 
mobility and angiogenesis (Schmid et al., 2010). Inhibition of this pathway leads to 
inhibition of downstream signaling elements, thereby resulting in cell cycle arrest in the G1 
phase (Chan 2004). Temsirolimus (CCI-779), an inhibitor of mTOR, is being investigated in a 
phase II trial in patients with ES-SCLC in remission following platinum-based 
chemotherapy. Genome-wide gene expression profiling revealed that mutant NRF2 affects 
diverse molecular pathways including the mTOR pathway. Mutant NRF2 upregulates 
RagD, a small G-protein activator of the mTOR pathway, which was also overexpressed in 
primary lung cancer (Shibata et al., 2010). Preliminary results show a prolongation of 
progression-free survival, thereby suggesting significant activity for this agent in SCLC 
(Pandya et al., 2005). Another agent from this class, everolimus (RAD-001), is currently 
being tested in a phase II trial for patients with relapsed SCLC (Schmid et al., 2010). 
12. CD56 (NCAM) 
The neural cell adhesion molecule (NCAM, CD56) is associated with the immunoglobulin 
family and modulates neuroendocrine cell growth, migration, and differentiation (Jensen & 
Berthold, 2007; Kim and Kwon, 2010). CD56 is an isoform encoded by the NCAM gene. 
NCAM is found in almost 100% of SCLC and is also expressed on natural killer cells, 
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neuroendocrine glands, cardiomyocytes, and in the central and peripheral nervous system 
(Kim and Kwon, 2010). Since malignant cells can be influenced by NCAM signaling, it has 
been investigated as a target for anti-cancer therapy (Jensen & Berthold, 2007). N901 is an 
anti-CD56 monoclonal antibody covalently linked to a blocked ricin molecule binds to SCLC 
tumors and cell lines (Lynch, 1993). Initial studies showed promising activity, but were 
hampered by the immune response that developed against the murine monoclonal antibody 
and the ricin molecule, leading to potentially fatal side effects (Fidias et al., 2002). In order to 
overcome this, a humanized version of this antibody covalently bound to the maytasinoid 
(microtubule- depolymerizing compound) effector molecule DM-1 has now been made 
available (BB-10901 or huN901-DM1). Initial studies of this compound have shown evidence 
of efficacy and safety (Fossella et al., 2005) and a phase II trial is currently underway. 
13. Chromosomal alterations 
In SCLC and other epithelial tumors, multiple chromosomal aberrations are found, 
reflecting genomic instability (Balsara& Testa, 2002; Sato et al., 2007.). Loss of the short arm 
of chromosome 3 has been consistently seen in SCLC (Balsara & Testa, 2002). The deletion of 
3p leads to inactivation of three putative tumor-suppressor genes. The majority of SCLCs 
have deletions affecting multiple chromosomal sites, with recurrent losses at 3p, 5q, 13q and 
17p, which are loci with tumor suppressor genes including p53 (Balsara& Testa, 2002). 
Comparative genomic hybridization analyses have revealed that a large number of SCLCs 
harbor gains of 1p, 2p, 3q, 5p, 8q and 19p, regions which encode well-known oncogenes, 
such as MYC and KRAS. SCLC cell lines found to have amplifications of 1p, 2p and 3q, and 
deletion of 18q display a more aggressive phenotype of the disease (Balsara & Testa, 2002). 
Allele loss on chromosome 3p occurs with a frequency greater than 90% in SCLC and is 
believed to be an early event found in lung carcinogenesis (Sato et al., 2007). The loss of the 
fragile histidine triad (FHIT) gene results in the accumulation of diadenosine 
tetraphosphate, stimulating DNA synthesis and proliferation (Sozzi et al., 1996). This gene 
has been localized to 3p14.2 and is believed to be an important tumor suppressor gene 
involved in the pathogenesis of lung cancer (Sozzi et al., 1996; Wistuba et al., 2001). The 
second tumor suppressor gene is believed to be RASSF1A, which is located within a 120 
kilobase region of chromosome 3p21.3 which also contains the FUS1, SEMA3B and SEMA3F 
loci. RASSF1A encodes a protein similar to RAS effector proteins and is inactivated by 
tumor-acquired promoter hypermethylation in 90-100% of SCLC samples (Burbee et al., 
2001; Dammann et al., 2000). ASSF1 is involved in cell cycle pathways, apoptosis and 
microtubule stability (Agathanggelou et al., 2005).  
FUS1 is a novel tumor suppressor gene identified in the human chromosome 3p21.3 region 
where allele losses and genetic alterations occur early and frequently for many human 
cancers. Expression of FUS1 protein is absent or reduced in the majority of lung cancers and 
premalignant lung lesions. Specificially, expression of the FUS1 protein is lost in 100% of 
SCLC cases. Interestingly, restoration of wild-type FUS1 function in 3p21.3-deficient non-
small cell lung carcinoma cells significantly inhibited tumor cell growth by induction of 
apoptosis and alteration of cell cycle kinetics (Ji & Ross, 2008). They report that FUS1 
induces apoptosis through the activation of the intrinsic mitochondrial-dependent and 
Apaf-1-associated pathways and inhibits the function of protein tyrosine kinases including 
EGFR, PDGFR, AKT, c-Abl, and c-Kit. Moreover, intravenous administration of a 
nanoparticle encapsulated FUS1 expression plasmid effectively delivered FUS1 to distant 
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tumor sites and mediated an antitumor effect in orthotopic human lung cancer xenograft 
models (Ji & Ross, 2008). This approach is the rationale for an ongoing FUS1-nanoparticle-
mediated gene delivery clinical trial for the treatment of lung cancer. 
Deletion of a third gene, TGFBR2, located at 3p21.3.22, that encodes the transforming 
growth factor β (TGF-β) type II receptor, has also been described in SCLC (Hougaard et al., 
1999). This nonsense mutation results in the synthesis of a truncated receptor and has been 
linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. The gene coding for 
Retinoic Acid Receptor Beta (RAR-β) is located on chromosome 3p24 (Mattei et al., 1991). 
Retinoic acid plays an important role in lung development and differentiation, acting 
primarily via nuclear receptors. Loss of heterozygosity of RAR-B2 and RAR-B4 isoforms is 
seen in almost all cases of SCLC. Methylation of the promoter region of these two isoforms 
may be responsible for the silencing of their expression in SCLC (Virmani et al., 2000). 
14. Telomerase 
Telomeres are genetic elements present at the ends of linear chromosomes that play an 
important role in stabilizing chromosomes from degradation and cell death (Counter et al., 
1992; Hyer & Silvestri, 2000). Telomerase is a ribonucleoenzyme that compensates for 
telomere shortening during cell division by synthesizing hexameric TTAGGG repeats at the 
end of the chromosomes. The functional unit of this enzyme consists of an RNA component 
hTR, and a catalytic component hTERT. Repression of telomerase in the somatic tissues of 
humans seems to have evolved as a powerful protective barrier against carcinogenesis 
(Newbold, 2002). Studies in patients with neuroendocrine lung tumors have demonstrated 
upregulation of the RNA component of telomerase in 98% of human SCLC (Sarvesvaran et 
al., 1999). Similar studies assessing telomerase activity in small cell lung cancer showed 
increased activity in all specimens analyzed (Hiyama et al., 1995). Zaffaroni et al. (2003) 
studied telomerase activity by the telomeric repeat amplification protocol (TRAP) assay in 
38 neuroendocrine (NE) lung tumors. A positive TRAP signal was observed in 14 of 15 
(93%) SCLCs, 7 of 8 (87%) large-cell NE carcinomas, and only 1 of 15 (7%) typical carcinoid 
tumors. When telomerase activity was correlated with the gene product-based 
immunophenotypic profile of individual tumors, the absence of telomerase activity was 
associated with a lack of BCL-2, P53, c-KIT, and CDK4 expression and presence of RB. Such 
a phenotype was appreciable in most of the carcinoid tumors. Conversely, telomerase-
positive tumors generally showed an immunophenotype consistent with gene product 
alterations (including high expression of BCL-2, P53, and c-KIT, and loss of RB) and were 
characterized by a high proliferative index. These data support the previously reported 
evidence for two genetically unrelated groups of NE lung tumors that have distinct 
phenotypic profiles (Zaffaroni et al., 2003). 
15. Knockout Mouse Models for SCLC 
Contrary to NSCLC, neuroendocrine carcinomas are virtually never found in spontaneous 
or chemically induced murine lung cancer. One reason for this could be that in these murine 
models, a combination of both p53 and Rb mutations is almost never found, unlike most 
human SCLCs. To address this issue, a Cre/lox based deletion of both conditional alleles for 
Rb and p53 was performed by intratracheal instillation with Adeno-Cre (Meuwissen et al., 
2003). After 3 months, foci of neuroendocrine hyperplasia developed through the proximal 
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as well as distal bronchi. After a further 3 months, these early lesions progressed into 
massive lung tumors with histological features typical of SCLC. Interestingly, some early 
type lesions remained even in the presence of extensive SCLC. Consequently, it was of 
importance to determine if the early neuroendocrine lesions are indeed precursors for SCLC 
and, if so, which additional epigenetic events are then needed for progression. 
Immunohistological characterization of the full-blown tumors revealed that they indeed 
shared neuroendocrine features with human SCLC. As in human SCLC all neuroendocrine 
differentiation markers, such as calcitonin gene-related protein (CGRP), neuron-specific 
enolase, synaptophysin, neural cell adhesion molecule, and achaete-scute homolog-1 (ASH-
1) were not expressed. Furthermore, the murine SCLC readily metastasized towards similar 
organs as found with human SCLC (Meuwissen et al., 2003). All primary SCLC, as well as 
their metastases, had all Rb and p53 alleles inactivated. Tumors that retained one WT Rb 
allele were all invariably adenocarcinomas without any neuroendocrine features. Therefore, 
the status of Rb most likely determines if tumors occur with mixed SCLC and NSCLC 
phenotypes, as has been observed in some patients (Brambilla et al., 2000). No lung tumors 
were found in RbF/F mice, which suggested that loss of Rb alone is not enough to initiate lung 
tumorigenesis (Meuwissen et al., 2003) and the additional loss of p53 is needed.  
Not only does Rb loss require additional genetic events to initiate lung tumorigenesis, the 
nature of these complementary lesions also determines which type of lung cancer will 
develop. For instance, RB inactivation and KRas mutations are almost never found together 
in the same human lung cancer. Moreover, the overall mutation rate of RB in human NSCLC 
is very low (Wistuba & Gazdar, 2003). As noted, Adeno-Cre dependent activation of Kras in 
a broad range of lung epithelial cells leads exclusively to the onset of NSCLC. However, 
when LSLKrasG12D transgenes were combined with RbF/F and Rb family p130F/F alleles for 
Adeno-Cre-dependent lung tumor induction, much more advanced adenocarcinomas of 
KrasG12D; Rb-/-; p130-/- genotypes resulted compared to single KrasG12D (Ho et al., 2009). Loss of 
both Rb and p130, albeit to a lesser extent, contributed to Kras dependent NSCLC. Clearly, in 
this genetic context KrasG12D overrules any effect of Rb loss on neuroendocrine 
differentiation.  
Another intriguing observation came from CC10-rtTA; tetO7-Cre; RbF/F mice administered 
doxycycline during early embryogenesis, causing a complete Rb ablation in all bronchial 
Clara cells. However, only increased hypercellular neuroendocrine lesions were detected in 
these mice, and no effect on Clara cell homeostasis could be observed. Alternatively, when 
all three Rb family proteins (Rb, p107 and p130) were inactivated by a truncated SV40 large 
T-antigen oncoprotein (T121) in CC10-T121 mice, severe bronchial hyperplasia with 
complete dedifferentiation of all Clara cells occurred. These results suggest that Rb might be 
specifically required for determining neuroendocrine cell fate, but only in a strict cellular 
and genetic context. The combined evidence from mouse models indicate it is unlikely that 
NSCLC and SCLC develop from similar target cells. It would be more plausible that 
separate, non-identical target cells can develop into different lung cancers, although each 
still depends on specific major genetic pathways.  
Apart from the somatic RbF/F; p53F/F model for SCLC, two other lung cancer models have 
also been associated with pulmonary neuroendocrine tumors. One model made use of 
bitransgenic CC10-hASH1; CC10-SV40 large T system in which progressive neuroendocrine 
dysplasia and aggressive lung adenocarcinoma developed with both focal neuroendocrine 
differentiation (through expression of pro-neural ASH-1 transcription factor) and CC10 
expression (Linnoila et al., 2000). These adenocarcinomas closely resembled human NSCLC 
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with neuroendocrine differentiation (Linnoila et al., 1994). In the other model, the cyclin 
dependent kinase inhibitor p18Ink4c and Men1, a tumor suppressor gene deleted in human 
multiple endocrine neoplasia, were both inactivated. To determine how p18 and p27 
genetically interact with Men1, Pei et al. (2007) characterized p18-Men1 and p27-Men1 
double mutant mice and showed that p18, but not p27, functionally collaborates with Men1 
in suppressing lung tumorigenesis. Lung tumors developed in both Men1+/- and p18-/-; 
Men1+/- mice at a high penetrance and contained both neuroendocrine and non-
neuroendocrine cells. The remaining wild-type Men1 allele was lost in most lung tumors 
from Men1+/- mice, but was retained in most tumors from p18-/-;Men1+/- mice, showing a 
functional collaboration between p18 and Men1 in lung tumor suppression (Pei et al., 2007). 
Phosphorylation of Rb protein at both Cdk2 and Cdk4/Cdk6 sites were significantly 
increased in normal bronchial epithelia and tumor cells derived from p18-/-;Men1+/- mice 
compared to those from single p18-/- or Men1+/- mice. Lung tumors developed in p18-/-;Men1+/- 
mice were multifocal, more heterogeneous, and highly invasive compared to those in either 
p18-/- or Men1+/- mice. These results revealed a previously unrecognized function of p18 in 
lung tumor suppression through collaboration with Men1 to control lung stem cell 
proliferation. To investigate the cellular origin(s) of this cancer, Sutherland et al. (2011) 
assessed the effect of Trp53 and Rb1 inactivation in distinct cell types in the adult lung using 
adenoviral vectors that target Cre recombinase to Clara, neuroendocrine (NE), and alveolar 
type 2 (SPC-expressing) cells. Using these cell type-restricted Adeno-Cre viruses, loss of 
Trp53 and Rb1 efficiently transformed NE and SPC-expressing cells, leading to SCLC, albeit 
SPC-expressing cells were transformed less efficiently (Sutherland et al., 2011). In contrast, 
Clara cells were largely resistant to transformation. Their results indicate that although NE 
cells serve as the predominant cell of origin of SCLC, a subset of SPC-expressing cells are 
also endowed with this ability. 
Increasingly, it is realized that during tumorigenesis a variety of cells are recruited into the 
tumor to provide a range of functions that are associated with tumor progression (Calbo et 
al., 2011). Karnoub and colleagues (2007) showed that mesenchymal stem cells recruited into 
the stroma of breast cancer promote metastasis through CCL5-mediated paracrine signaling, 
thereby emphasizing the relevance of the interactions between tumor cells and the 
surrounding microenvironment. Using the mouse model for simultaneous Rb and p53 
inactivation, Calbo et al. (2011) established primary cultures from 21 murine NSCLCs. They 
found mouse SCLC primary cultures attached to the dishes in 9 of 21 cases, consistent with 
cell culture derived from human SCLC. They seeded single-cell suspensions from 15 mouse 
SCLC cultures in soft agar-containing medium, and isolated individual colonies and 
expanded separately. Most of the obtained clones grew as suspending aggregates of very 
small cells. These cells expressed neuroendocrine protein markers such as synaptophysin, 
achaete-scute complex homolog 1, and neural cell adhesion molecule. They also obtained 
clones grew as a cellular monolayer composed of larger cells with visible cytoplasm and 
spindle-like membrane extensions, spreading on the substrate (mesenchymal cells). This is 
consistent with human SCLC that are often composed of phenotypically different cells with 
either a neuroendocrine or a mesenchymal marker profile. Importantly, these two types of 
cells had a common origin because they shared specific genomic aberrations as 
demonstrated by SKY analysis. Calbo et al. also showed that the transition from 
neuroendocrine to mesenchymal phenotype could be achieved by the ectopic expression of 
oncogenic RasV12 in the former (Calbo et al., 2011). When engrafted as a mixed population, 
the mesenchymal cells endowed the neuroendocrine cells with metastatic capacity, 
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illustrating the potential relevance of tumor cell heterogeneity in dictating tumor properties 
(Calbo et al., 2011). In short, they showed a specific type of tumor heterogeneity of SCLC, in 
which the interaction between clonally derived but diversified subclones alters the behavior 
of the tumor as a whole (Calbo et al., 2011). One outcome was a substantially increased 
metastatic potential, a feature with important clinical ramifications in human SCLC. Tumor 
cell behavior then not only depended on the interactions with stromal cells, but was also 
influenced by interactions with tumor cell variants that fulfill a distinct role in the tumor 
tissue. This study provides a unique system, whereby the mesenchymal compartment of the 
tumor was generated from a separate subclone of SCLC during the tumorigenic process, 
providing the tumor cell population as a whole with new capabilities such as metastatic 
potential. 
16. Xenograft models for SCLC 
For the past three decades, the mainstay of preclinical cancer therapeutic research has been 
the use of human cancer cells lines cultured in vitro and of xenografts derived from these cell 
lines grown in vivo in immunodeficient mice. However, neither model consistently 
predicted the efficacy in clinical trials, resulting in two major barriers to the successful 
translation of new cancer therapeutics. First, resources are expended on drug development 
based on these models that ultimately fail in clinical trials. Second, many potentially useful 
therapies that might be beneficial in humans are discarded because the animal models fail to 
demonstrate efficacy in conventional cell culture and xenograft models. Emerging evidence 
suggests that the process of establishing conventional cell lines from human cancers results 
in distinct and irreversible loss of important biological properties. These include (a) gain or 
loss of gene amplification, (b) the ability to migrate and metastasize, (c) the maintenance of a 
distinct stem cell population, and (d) the preservation of dependency on embryonic 
signaling pathways. These properties are not restored when these conventional cell lines are 
grown as heterotopic or orthotopic xenografts.  
Because SCLC is usually diagnosed by endobronchial biopsy or fine-needle aspiration 
cytology, substantial quantities of fresh or frozen tissues are typically lacking in most tumor 
banks. For this reason, most SCLC researches rely on conventional cell lines, which are often 
chemoresistant because they were derived from patients who had received cytotoxic 
chemotherapy (Phelps et al., 1996). In addition, all of these cell lines have experimental 
limitations and lack the three-dimensional tumor-stromal interactions, which seem to 
significantly affect the response of these cells to chemotherapy (Hodkinson et al., 2007). To 
establish better models for the study of SCLC, Daniel et al. (2009) generated and 
characterized a series of primary xenograft models derived from chemo-naive patients to 
more accurately model SCLC in mice. In parallel, cell lines grown in conventional tissue 
culture conditions were derived from each xenograft line, passaged for 6 months, and then 
reimplanted to generate secondary xenografts. When compared with normal lung, primary 
tumors, xenografts, and cell lines displayed a gene expression signature specific for SCLC 
(Daniel et al., 2009). Comparison of gene expression within the xenograft model identified a 
group of tumor-specific genes expressed in primary SCLC and xenografts that was lost 
during the transition to SCLC cell lines; these genes were not regained when the tumors 
were re-established as secondary xenografts. Such changes in gene expression may be a 
common feature of many cancer cell culture systems, with functional implications for the 
use of such models for preclinical drug development. 
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Bcl-2 is a central regulator of cell survival that is overexpressed in most SCLC tumors and 
contributes to both malignant transformation and therapeutic resistance. Hann et al. (2008) 
compared primary SCLC xenografts prepared from de novo human tumors with standard 
cell line–based xenografts to evaluate a novel and highly potent small molecule inhibitor of 
Bcl-2, ABT-737. ABT-737 induced dramatic regressions in tumors derived from some SCLC 
cell lines. In contrast, only one of three primary xenograft SCLC tumors showed significant 
growth inhibition with ABT-737. Explanations for this apparent difference may include 
relatively low expression of Bcl-2 in the primary xenografts or inherent differences in the 
model systems. The addition of etoposide to ABT-737 in the primary xenografts resulted in 
significantly decreased tumor growth, underscoring the clinical potential of ABT-737 in 
combination therapy. To identify factors that may contribute to resistance to ABT-737 and 
related inhibitors, they isolated resistant derivatives of an initially sensitive cell line–based 
xenograft. Acquired resistance in this model was associated with decreases in the expression 
of the primary target Bcl-2, of proapoptotic partners of Bcl-2 (Bax and Bim), and of Bcl-2:Bim 
heterodimers. Expression profiling revealed 85 candidate genes demonstrating consistent 
changes in gene expression with acquired resistance. These data have specific implications 
for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the 
testing of novel anticancer strategies in relevant preclinical models.  
17. Conclusions 
There are many distinct genetic pathways present in SCLC, leading to its unique biology 
and clinical features. A better understanding of these basic molecular and cellular changes 
will allow for the development of novel therapeutic strategies. Multiple molecularly 
targeted agents are actively being studied pre-clinically and clinically, with the hope of 
ultimately improving survival of patients with SCLC. Development of targeted therapy in 
small cell lung cancer has significantly lagged behind that of non-small cell lung cancer. 
Etoposide and cisplatin remain the mainstays of first-line SCLC treatment. Although the 
decreasing prevalence of smoking in industrialized countries will lead to decreased 
incidence of SCLC, the burden of disease is shifting to developing countries. Further 
investment in research for this disease is, therefore, warranted. Many phase 1 and 2 studies 
of drugs with potential activity in SCLC and phase 2 and 3 trials to improve radiotherapy 
are underway. Inclusion of patients with SCLC in such trials should be encouraged, 
especially otherwise healthy patients with relapsing or refractory SCLC, for whom 
treatment options are limited. A new, effective, and active combination for extensive-stage 
SCLC would be quickly moved up as a treatment priority.  
SCLC remains a therapeutic challenge despite high initial responses to chemotherapy and 
radiotherapy. The fact that several promising molecularly targeted agents have not shown 
adequate activity in clinical trials does not mean the end of novel targeted therapies for 
SCLC. Nevertheless, a better understanding of SCLC biology and better preclinical models 
of SCLC are needed to improve available therapies.  
The mouse model presented in the study by Meuwissen et al. clearly showed that somatic 
inactivation of both Rb1 and Trp53 alleles in lung epithelial cells readily leads to formation 
of small cell NE tumors. Their histopathologic characteristics and metastasizing capacity 
were strikingly similar to human SCLCs. Their mouse model will prove a valuable tool for 
(1) comparing genotype-phenotype similarities between human SCLC and MSCLC, (2) the 
identification of precursor lesions, and (3) additional factors involved in tumor progression, 
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and (4) ultimately, testing of targeted, novel tumor intervention strategies and 
chemoprevention.  
The identification of specific cell type(s) from which SCLC originates is critical in the 
development of methods for early diagnosis and treatment. By using cell type-restricted 
Adeno-Cre vectors in directing Trp53 and Rb1 loss to distinct cell populations in the adult 
mouse lung, Sutherland et al. showed that NE cells are the predominant cells of origin of 
SCLC. Their study provides additional tools to address questions related to the cell of origin 
of lung cancer, and highlights the importance of specifically targeting NE cells for the 
treatment of SCLC. Their strategy to manipulate specific adult lung cell populations in a 
controlled manner by cell type-restricted somatic gene transfer vectors could help to answer 
the question of whether distinct lung pathologies have a unique cell of origin, and whether 
this cell of origin is a determining factor in the drug resistance profile of the various tumor 
subtypes. 
The work of Calbo et al. showed a specific type of tumor heterogeneity, in which the 
interaction between clonally derived but diversified subclones alters the behavior of the 
tumor as a whole. One outcome was substantially increased metastasis, a feature with 
important clinical ramifications. Thus, tumor cell behavior not only depends on the 
interactions with stromal cells, but also interactions with tumor cell variants that fulfill a 
distinct role in the tumor tissue. Enhanced metastatic capacity serves as an illustrative 
example of crosstalk between specialized tumor cell clones. Disrupting the paracrine 
signaling involved in this interaction is worth further exploring as a strategy to mitigate 
tumor progression in SCLC. 
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1. Introduction 
The centrosome, which functions as a major microtubule-organizing center (MTOC), is 
composed of a pair of centrioles and surrounding protein aggregates called pericentriolar 
material (PCM); at any given time during the cell cycle, each cell contains one or two 
centrosomes (Fukasawa, 2007). Centrosomes play a crucial role in the formation of bipolar 
mitotic spindles, which are essential for accurate chromosome segregation (Zyss & Gergely, 
2009). Numerical and functional abnormalities of centrosomes result in an increase in 
aberrant mitotic spindle formation, merotelic kinetochore-microtubule attachment errors, 
lagging chromosome formation, and chromosome segregation errors, all of which are 
thought to be possible causes of chromosome instability (Ganem et al., 2009; Nigg & Raff, 
2009). Centrosome abnormalities and chromosome instability are characteristics of human 
lung cancer (Masuda and Takahashi, 2002; Koutsami et al., 2006; Jung et al., 2007; Shinmura 
et al., 2008), and abnormalities in genes responsible for centrosome regulation have been 
reported in lung cancer (Fukasawa, 2007; Lee et al., 2010). In this Review, the status of 
centrosome abnormalities in lung cancer, the mechanisms responsible for inducing 
centrosome abnormalities, and the relationship between centrosome abnormalities and 
chromosome instability are summarized. 
2. Centrosome abnormalities in human lung cancer: Mechanisms causing 
centrosome abnormalities and chromosome instability 
The presence of two centrosomes at mitosis is an important factor in the formation of bipolar 
mitotic spindles. Therefore, the numerical integrity of centrosomes is carefully controlled in 
human cells, and abrogation of this control results in centrosome amplification. First, we 
describe the normal centrosome duplication cycle, followed by three reports on centrosome 
abnormalities in lung cancer. Next, we describe investigations of the mechanism responsible 
for inducing centrosome amplification. Finally, we summarize the possible reasons why 
centrosome abnormalities cause chromosome instability. 
2.1 Centrosome duplication cycle in human cells 
Centrioles are cylindrical structures (-0.2 m in diameter and 0.2-0.5 m in length) and are 
composed of nine triplet microtubule arrays organized around a central cartwheel. 
Centrioles contain several tubulin isoforms and non-tubulin proteins such as CETN2, CP110, 
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SAS-6, and SAS-4 (Bettencourt-Dias & Glover, 2009). In animal cells, a pair of centrioles is 
embedded in a cloud of electron dense material known as PCM, and both structures 
constitute a larger structure named the centrosome, which serves as the main MTOC during 
both interphase and mitotic phase (Vorobjev & Nadezhdina, 1987). Centrosome duplication 
occurs once per cell cycle and is subject to strict control within cells. To organize a bipolar 
mitotic spindle, a centrosome is duplicated in S phase, additional PCM proteins are 
recruited during centrosome maturation in G2, and the two centrosomes separate at mitotic 
entry (Figure 1). The primary function of PCM is microtubule nucleation. The assembly of 
microtubules is initiated on a -tubulin ring complex (TuRC), composed by -tubulin and 















Fig. 1. Centrosome duplication cycle. 
The centrioles duplicate once per cell cycle. The formation of the daughter centriole on each 
mother centriole occurs during the late G1 and S phases of the cell cycle. The daughter and 
mother centrioles are tightly associated in an orthogonal manner until the end of mitosis, 
and centriole disengagement occurs during mitotic exit. The initiation of centriole 
duplication requires the activity of several proteins, such as Cdk2-cyclin E and PLK4 
kinases. The procentriole starts to assemble, and elongation depends on several proteins 
including centrin, CEP135, and -tubulin. During G2 phase, additional PCM proteins are 
recruited, and centrosome maturation requires the activity of Aurora A and PLK1 kinases. 
During late G2, the daughter centriole of the parental pair acquires subdistal appendages. 
Then, the two duplicated centrosomes separate and move to opposite end of the cell 
(centrosome separation). Finally, the two centrosomes form the poles of the bipolar mitotic 
spindle. 
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2.2 Centrosome abnormalities in lung cancer 
Centrosome amplification has been reported in a variety of human primary cancers (e.g., 
breast cancer, lung cancer, bladder cancer, pancreatic cancer, and prostatic cancer) (Pihan et 
al., 1998; Sato et al., 1999; Pihan et al., 2001; Kawamura et al., 2004; Zyss & Gergely, 2009). 
With regard to primary lung cancer, Koutsami et al. (2006) examined 68 primary non-small 
cell lung carcinomas (NSCLCs) for the presence or absence of centrosome amplification 
using an immunofluorescence analysis with a monoclonal antibody for -tubulin, a 
centrosome marker; they showed that 36 (53%) of the 68 NSCLCs exhibited centrosome 
amplification. Centrosome amplification was not associated with clinicopathological 
markers such as stage, tumor grade, and histological subtype, but was associated with 
aneuploidy. Jung et al. (2007) examined 175 NSCLCs for centrosome abnormalities using an 
immunofluorescence analysis with an anti--tubulin antibody; they showed that 50 (29%) of 
the 175 NSCLCs exhibited a centrosome abnormality. Aneuploidy, p16 expression, and the 
loss of pRB expression were significantly associated with centrosome abnormalities. 
Shinmura et al. (2008) examined 182 primary lung carcinomas for the presence or absence of 
centrosome amplification using an immunohistochemical analysis with an anti--tubulin 
antibody and showed that 67 (37%) of the 182 cancers exhibited centrosome amplification. 
Thus, centrosome amplification is a common abnormality seen in human primary lung 
cancers. 
2.3 Mechanisms inducing centrosome abnormalities 
An immunofluorescence analysis using an antibody for centrosome or centriole markers in 
cultured cell lines can be used to determine the status of the centrosome number in the cells. 
The involvement of many kinds of agents and genes in centrosome regulation has been 
examined using such analyses. Here, these analyses are divided into those using lung cells 
and those using cells derived from other organs. 
2.3.1 Mechanisms identified by using the lung cells 
Holmes et al. (2006) showed that chronic exposure to lead chromate causes centrosome 
abnormalities and aneuploidy using WTHBF-6 cells, a cell line derived from normal human 
bronchial fibroblasts. Hexavalent chromium compounds [Cr(VI)] are human lung 
carcinogens (Le´onard & Lauwerys, 1980), and “particulate” Cr(VI) compounds are one of 
the most potent forms. They reported centrosome amplification in interphase and mitotic 
cells in response to treatment with lead chromate as a model particulate Cr(VI) compound. 
They suggested that one possible mechanism for lead chromate–induced carcinogenesis is 
through centrosome dysfunction, leading to the induction of aneuploidy. The same group 
(Holmes et al., 2010) also showed that chronic exposure to zinc chromate, another 
particulate Cr(VI) compound, induces centrosome amplification and spindle checkpoint 
bypass using human lung fibroblasts. 
Arsenic is another environmental toxicant, and the biological effects of arsenic have been 
studied. Liao et al. (2007) showed that arsenic promotes centrosome abnormalities and cell 
colony formation in p53 compromised human lung cells. They used H1355 (a lung 
adenocarcinoma cell line with a p53 mutation), BEAS-2B (immortalized lung epithelial cells 
with functional p53) and pifithrin--treated BEAS-2B (p53-inhibited cells) and reported an 
increase in centrosome abnormalities in both arsenite-treated p53 compromised cell lines, 
compared with that in arsenite-treated BEAS-2B cells. Their findings provided evidence of 
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the carcinogenic promotional role of arsenic, especially in the presence of p53 abnormalities. 
The group also showed that arsenite promoted centrosome abnormalities in the presence of 
a p53-compromised status induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(nicotine-derived nitrosamine ketone, NNK) using BEAS-2B cells (Liao et al., 2010). Their 
findings provided evidence of an interaction between arsenite and cigarette smoking. 
Benzo[a]pyrene diol epoxide (B[a]PDE), the ultimate carcinogenic metabolite of 
benzo[a]pyrene, has been implicated in the mutagenesis of the p53 gene, which is involved 
in smoking-associated lung cancer. Shinmura et al. (2008) showed that the exposure of p53-
deficient H1299 lung cancer cells to B[a]PDE resulted in S-phase arrest, leading to abnormal 
centrosome amplification. They also revealed that the centrosome amplification could be 
primarily attributed to excessive centrosome duplication, rather than to centriole splitting, 
and the forced expression of POLK DNA polymerase, which has the ability to bypass 
B[a]PDE–guanine lesions in an error-free manner, suppressing B[a]PDE-induced centrosome 
amplification. The B[a]PDE exposure also led to chromosome instability, which was likely to 
have resulted from centrosome amplification. Thus, they concluded that B[a]PDE 
contributes to neoplasia by inducing centrosome amplification and consequent chromosome 






Fig. 2. Induction of centrosome amplification in p53-deficient H1299 lung cancer cells by 
exposure to benzo[a]pyrene diol epoxide (B[a]PDE). 
H1299 cells were exposed to 0.6 M B[a]PDE for 72 hr and then immunostained with mouse 
anti--tubulin monoclonal antibody (GTU-88; Sigma-Aldrich, St. Louis, MO, USA). Alexa 
Fluor 546 (red)-conjugated anti-IgG antibody (Molecular Probes, Eugene, OR, USA) was 
used to detect the antibody–antigen complexes. The nuclei were stained with 4',6-
diamidino-2-phenylindol (DAPI, blue). An increase in the number of centrosomes, i.e., 
centrosome amplification, was observed in both interphase cells and mitotic phase cells. The 
arrows indicate the positions of centrosomes. 
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The lung is easily subjected to many kinds of environmental agents, some of which may be 
derived from cigarette smoking or occupational exposure. As described in the above three 
paragraphs, some environmental carcinogens induce centrosome amplification. Other 
environmental carcinogens attacking DNA may also induce centrosome amplification, since 
cell cycle arrest has been shown to occur during centrosome amplification. Further precise 
analyses of environmental agent-related centrosome amplification are needed to understand 
the relationship between environmental carcinogens and lung cancer more clearly. 
The S-phase kinase-interacting protein-2 (SKP2) plays a key role in the progression of cells 
from a quiescent to proliferative state, and the SKP2 protein is overexpressed in lung cancer. 
Jiang et al. (2005) showed that the RNA silencing of SKP2 inhibits proliferation and 
centrosome amplification using the lung cancer cell lines A549 and H1792. Their results 
suggest that SKP2 plays an oncogenic role in lung cancer and has a centrosome regulating 
function. 
NORE1 (RASSF5) is a member of the RASSF gene family, and NORE1A is the longest and 
major splice isoform of the NORE1 gene (Nakamura et al., 2005). Its product, NORE1A, is a 
nucleocytoplasmic shuttling protein and has a growth-suppressive function (Moshnikova et 
al., 2006). Shinmura et al. (2011) showed that NORE1A suppresses the centrosome 
amplification induced by hydroxyurea using a p53-deficient H1299 lung cancer cell line, and 
NORE1A expression was down-regulated in NSCLC. Both of these findings imply that 
NORE1A has a key preventative role against the carcinogenesis of NSCLC. 
2.3.2 Mechanisms identified using cells derived from other organs 
CDK2–cyclin E, a known inducer of S-phase entry (Heichman, 1994), has an important role 
in the regulation of centrosome duplication (Hinchcliffe et al., 1999; Matsumoto et al., 1999). 
The activation of CDK2–cyclin E during late-G1 phase coordinates the initiation of 
centrosome and DNA duplication. Several CDK2–cyclin E targets, including nucleophosmin 
(NPM) (Okuda et al., 2000), have been identified. NPM binds and modulates the activities of 
multiple proteins including tumor suppressor proteins (e.g., p53) and some oncogenic 
proteins (e.g., ROCK2) (Colombo et al., 2002; Ma et al., 2006b). The reduced as well as 
increased expression of NPM can lead to the oncogenic transformation of cells. Actually, 
NPM is frequently mutated, lost or overexpressed in cancers (Grisendi et al., 2006), and both 
the overexpression and the depletion of NPM in cultured cells can lead to neoplastic 
transformation (Kondo et al., 1997; Grisendi et al., 2005). NPM localizes between the paired 
centrioles of the unduplicated centrosome, probably functioning in centriole pairing 
(Shinmura et al., 2005). When NPM is phosphorylated by CDK2–cyclin E, most of the NPM 
dissociates from the centrosomes, leading to the centrosome duplication. In this context, 
NPM negatively controls centrosome duplication; indeed, the depletion of NPM leads to 
centrosome amplification (Grisendi et al., 2005; Wang et al., 2005). NPM was reported to 
have the ability to control centrosome duplication in association with ROCK2 (Ma et al., 
2006b), a member of the Rho-associated, coiled-coil containing protein kinase family that is 
frequently overexpressed in cancer (Nishimura et al., 2003). After NPM phosphorylation by 
CDK2–cyclin E, the binding between NPM and ROCK2 increases and ROCK2 is activated at 
centrosomes, leading to centrosome duplication (Ma et al., 2006b). In ROCK2 activation, the 
binding of Rho small GTPase to the auto-inhibitory region is also required (Kanai et al., 
2010). Among three isoforms of Rho, both RhoA and RhoC, but not RhoB, promoted 
centrosome duplication and centrosome amplification. 
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Another target of CDK2–cyclin E in centrosome regulation is MPS1, a spindle checkpoint 
kinase that is localized at the centrosome (Fisk et al., 2003). MPS1 is stabilized and activated 
by CDK2–cyclin E phosphorylation and involved in centrosome duplication. Mortalin, a 
member of the heat-shock protein 70 molecular chaperone family, is localized at the 
centrosome and physically interacts with and is phosphorylated by MPS1. The 
phosphorylation of mortalin activates MPS1 in a positive-feedback manner, and this 
phenomenon is important for MPS1-related centrosome duplication (Kanai et al., 2007). 
Mortalin is frequently upregulated in cancers (Wadhwa et al., 2006). 
CDK2 forms a complex with cyclin A in addition to cyclin E, and CDK2–cyclin A has been 
implicated in the regulation of centrosome duplication (Meraldi et al., 1999). CDK2–cyclin A 
and CDK2–cyclin E share some substrates (Tokuyama et al., 2001). The CDK2–cyclin A 
complex is active in S and G2 phases during the cell cycle, and CDK2–cyclin A may have a 
crucial role in centrosome over-duplication and/or amplification (Hanashiro et al., 2008). As 
another type of CDK-cyclin complex, the overactivation of CDK4/6–cyclin D has been 
shown to induce centrosome amplification (Nelsen et al., 2005). The major target of 
CDK4/6–cyclin D is the RB tumor-suppressor protein (Duensing et al., 2000). The 
conditional loss of Rb in mice results in centrosome amplification (Balsitis et al., 2003; Iovino 
et al., 2006). 
CDK2 activity is also negatively controlled by the CDK inhibitor p21, one of the major 
transactivation targets of the p53 tumor-suppressor protein (Bálint & Vousden, 2001). p53 is 
involved in the regulation of centrosome duplication, which was first demonstrated in cells 
and tissues from p53-deficient mice (Fukasawa et al., 1996; Fukasawa et al., 1997). When 
cells are exposed to DNA-synthesis inhibitors such as hydroxyurea, centrosomes undergo 
reduplication without DNA synthesis, resulting in centrosome amplification (Balczon et al., 
1995). Centrosome reduplication occurs efficiently when p53 is mutated or lost (Tarapore et 
al., 2001a). In normal cells, p53 is stabilized under cellular stresses by the inhibition of 
MDM2, leading to the upregulation of p21, which blocks the initiation of centrosome 
reduplication through the inhibition of cyclin–CDK2 complexes (Bálint & Vousden, 2001). 
On the other hand, p21 is not upregulated in cells lacking p53, allowing the activation of 
CDK2, which in turn triggers centrosome reduplication. 
Besides the p53–p21 pathway, p53 has the ability to control centrosome duplication. p53 is 
localized at centrosomes (Blair Zajdel & Blair, 1988; Brown et al., 1994; Tarapore et al., 2001b; 
Tritarelli et al., 2004; Ma et al., 2006a; Shinmura et al., 2007) and appears to control 
centrosome duplication independently of its transactivation function. Even if p53 is a 
mutant without transactivation function, p53 retains the ability to localize to centrosomes 
and partially suppresses centrosome duplication (Shinmura et al., 2007). However, the 
mechanism underlying this role of p53 is currently unknown. 
The proteins that control p53 stability are also involved in the regulation of centrosome 
duplication. The ectopic expression of human papilloma virus (HPV) E6 protein, which 
promotes the degradation of p53, induces centrosome amplification (Duensing et al., 2000). 
MDM2 is an E3 ubiquitin ligase that promotes the degradation of p53 and is often 
overexpressed in cancers (Manfredi, 2010). The forced expression of MDM2 in cells 
containing wild-type p53 efficiently leads to centrosome amplification (Carroll et al., 1999). 
Aurora A kinase (AURKA) phosphorylates p53 at Ser315, resulting in MDM2-mediated p53 
destabilization (Katayama et al., 2004), and the forced expression of Aurora A induces 
centrosome amplification (Zhou et al., 1998). 
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Polo-like kinase 1 (PLK1) is a key regulator of centrosome maturation (Barr et al., 2004; 
Bettencourt-Dias and Glover, 2007). Its deregulation is linked to centrosome abnormalities 
and oncogenesis (Zyss and Gergely, 2009). PLK1 belongs to the mammalian PLK family, 
which is comprised of five members (PLK1 - PLK4 and PLK5P) (Lens et al., 2010). PLK1 is 
involved in a variety of mitotic events, including centrosome maturation and separation, 
G2/M transition, mitotic spindle formation, chromosome segregation, and cytokinesis, and 
several kinds of PLK1 substrates are known (Barr et al., 2004; Petronczki et al., 2008). PLK1 
targets multiple centrosomal proteins (e.g., -tubulin) to fulfill the mitotic function of 
centrosomes. Ninein-like protein (NLP) interacts with TuRC during interphase, and 
participates in the establishment of the cytoplasmic microtubule network (Casenghi et al., 
2003; Rapley et al., 2005). At the onset of mitosis, the cooperation of PLK1 and NLP 
promotes the centrosomal localization of -tubulin and other mitosis specific PCM 
components, resulting in a higher microtubule nucleation capacity of the mitotic centrosome 
(Casenghi et al., 2003; Rapley et al., 2005). The phosphorylation of NEDD1 by PLK1 is 
required for the targeting of TuRC to the centrosome (Zhang et al., 2009). In mitosis, 
centrosomes must withstand the pulling forces exerted by chromosome-attached 
microtubules. To withstand such forces, PLK1 also plays a role in maintaining the structural 
integrity of the centrosome during mitosis (Oshimori et al., 2006). Kizuna is localized at the 
centrosomes and is phosphorylated by PLK1 during mitosis. The reduced expression of 
kizuna results in centrosome fragmentation and the dispersion of PCM, leading to the 
formation of aberrant mitotic spindles and chromosome segregation errors. 
Another PLK, PLK4, is involved in recruiting the structural components required for the 
formation of procentrioles at the proximal side of the older centriole, in cooperation with 
CDK2-cyclin E (Habedanck et al., 2004). The upregulation of PLK4 expression is a strong 
stimulus for centriole multiplication (Kleylein-Sohn et al., 2007). The timely degradation of 
PLK4 by the SCF slimb ubiquitin ligase is important for the restriction of procentriole 
formation (Cunha-Ferreira et al., 2009). The SCF component CUL1 also functions as a 
centrosomal suppressor of centriole multiplication by regulating the PLK4 protein level 
(Korzeniewski et al., 2009). PLK4 kinase activity also regulates its own stability (Holland et 
al., 2010; Guderian et al., 2010). CEP152 interacts with PLK4 and CPAP and controls 
centrosome duplication in human cells (Dzhindzhev et al., 2010). PLK4 is transcriptionally 
regulated by p53 (Li et al., 2005). Clinically, the expression of PLK4 is upregulated in colon 
cancer (Macmillan et al., 2001), while the expression of PLK4 is downregulated in 
hepatocellular carcinoma because of promoter hypermethylation and the loss of 
heterozygosity (LOH) (Pellegrino et al., 2010; Rosario et al., 2010). 
The role of the morgana/chp-1 in centrosome regulation has been reported by Ferretti et al. 
(2010). Mutations in morgana result in centrosome amplification. Morgana forms a complex 
with Hsp90, ROCK1 and ROCK2, and directly binds to ROCK2. Morgana downregulation 
promotes the interaction between ROCK2 and NPM, leading to an increase in ROCK2 
activity, which in turn results in centrosome amplification. Morgana is downregulated in a 
large fraction of lung and breast cancers. They suggested that morgana plays a role in 
preventing centrosome amplification and tumorigenesis. 
NLP, a previously described substrate of PLK1 (Casenghi et al., 2003), is a BRCA1-associated 
centrosomal protein that is involved in microtubule nucleation and spindle formation (Jin et 
al., 2009). NLP is overexpressed as a result of NLP gene amplification in lung cancer, and 
NLP overexpression causes centrosome amplification (Shao et al., 2010). 
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The BRCA1 gene is responsible for susceptibility to familial breast/ovarian cancer and 
participates in diverse cellular functions (Venkitaraman, 2002). The BRCA1 is localized at 
the centrosomes (Hsu & White, 1998; Okada & Ouchi, 2003) and is involved in the 
regulation of centrosome duplication (Xu et al., 1999). BRCA1 is associated with BARD1, 
and this association mediates the ubiquitylation of -tubulin, which is important for 
maintaining the numeral integrity of centrosomes. The BRCA2 gene is another causative 
gene of familial breast/ovarian cancer and its protein product functions in homologous 
recombination (HR) repair (Venkitaraman, 2002). The loss of BRCA2 results in centrosome 
amplification (Tutt et al., 1999), implying a relationship between a defect in DNA repair and 
the abnormal amplification of the centrosomes. HR repair is mediated by several proteins 
including RAD51, and the downregulation of RAD51 leads to centrosome amplification 
(Bertrand et al., 2003). The reduced expression or loss of XRCC2, XRCC3, and RAD51B-D, 
which are other HR components, induces centrosome amplification and chromosome 
instability (Griffin et al., 2000; Smiraldo et al., 2005; Date et al., 2006; Renglin Lindh et al., 
2007; Cappelli et al., 2011). 
Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase 
(Dodson et al., 2004). A centrosome-autonomous signal that involves centriole disengagement 
causes centrosome amplification in G2 phase after DNA damage (Inanç et al., 2010), 
suggesting that genotoxic stress can decouple the centrosome cycle and chromosome cycle. 
The active nucleocytoplasmic transport of proteins is mediated by the nuclear localization 
signal (NLS) and nuclear export signal (NES) (Turner & Sullivan, 2008). NLS-containing 
proteins are transported from the cytoplasm to the nucleus, whereas NES-containing 
proteins are exported from the nucleus to the cytoplasm by XPO1, the human homolog of 
yeast Crm1. The inhibition of XPO1 causes centrosome amplification via the disruption of 
the nucleocytoplasmic transport of NPM (Forgues et al., 2003; Shinmura et al., 2005; Wang et 
al., 2005). XPO1 is involved in the centrosomal localization of various proteins (Han et al., 
2008). Importin  and RANBP1 are other proteins involved in nucleocytoplasmic transport, 
and these proteins also have the ability to regulate centrosomes (Di Fiore et al., 2003; 
Ciciarello et al., 2004). 
SGOL1 interacts with protein phosphatase 2A, is localized in the centromere, and prevents 
the cohesin complex from precocious cleavage at the centromere via the dephosphorylation 
of SA2, one of the cohesin subunits (Kitajima et al., 2006; Riedel et al., 2006). Clinically, 
SGOL1 expression is downregulated in colorectal cancer, and SGOL1-knockdown leads to 
centrosome amplification and chromosome instability in a colon cancer cell line (Iwaizumi 
et al., 2009; Dai et al., 2009). A SGOL1-P1 transcript containing an exon-skip of exon 3, 
resulting in the formation of a premature stop codon, is expressed in colorectal cancer, and 
the overexpression of SGOL1-P1 in a colon cancer cell line resulted in an increased number 
of cells with aberrant chromosome alignment, precociously separated chromatids, delayed 
mitotic progression, and centrosome amplification (Kahyo et al., 2011). Furthermore, the 
overexpression of SGOL1-P1 inhibited the localization of endogenous SGOL1 and cohesin 
subunit RAD21/SCC1 to the centromere, suggesting that SGOL1-P1 may function as a 
negative factor to native SGOL1 (Kahyo et al., 2011). 
2.4 Relationship between centrosome abnormalities and chromosome instability 
Chromosome instability is defined as a persistently high rate of the gain and loss of whole 
chromosomes (Thompson et al., 2010). Chromosome instability is a major source of 
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aneuploidy (Lengauer et al., 1997; Rajagopalan and Lengauer, 2004), and chromosome 
instability is thought to be involved not only in cancer initiation, where aneuploidy may 
have a causal role, but also in cancer development, where increased rates of chromosome 
missegregation may enable the clonal expansion of cells with a greater malignant potential 
(Rajagopalan & Lengauer, 2004; Weaver et al., 2007; Gao et al., 2007; Ganem et al., 2009). 
Defects in chromosome cohesion, weakened spindle assembly checkpoint (SAC) signalling, 
impaired microtubule-kinetochore attachment, defects in cell cycle regulation, and 
centrosome abnormalities can cause chromosome instability (Lingle et al., 1998; Draviam et 
al., 2004; Thompson & Compton, 2008; Weaver & Cleveland, 2008; Thompson et al., 2010). 
Regarding centrosome abnormalities, two mechanisms underlying chromosome instability 
have been proposed. The first mechanism is that centrosome amplification generates 
chromosome instability by promoting multipolar anaphase, which is an abnormal division 
that produces more than three aneuploid daughter cells (Nigg, 2002). The other mechanism 
is that centrosome amplification generates chromosome instability by promoting merotelic 
kinetochore–microtubule attachments (Ganem et al., 2009; Silkworth et al., 2009). Merotely is 
a type of error in which single kinetochores attach to microtubules emanating from different 
poles (Salmon et al., 2005; Cimini, 2008) and is common in cells showing chromosome 
instability (Thompson & Compton, 2008). Cells with centrosome amplification often coalesce 
the extra centrosomes during mitosis to ensure that anaphase occurs with a bipolar spindle 
(Quintyne et al., 2005). The extra centrosomes induce transient multipolar spindle 
intermediates prior to the coalescence of the centrosomes into bipolar spindles; this event 
increases the incidence of merotelic kinetochore–microtubule attachments and elevates the 
chromosome missegregation rates (Ganem et al., 2009; Silkworth et al., 2009). Ganem et al. 
(2009) showed that the presence of extra centrosomes is correlated with an increase in 
lagging chromosomes (Figure 3), promoting chromosome missegregation through excessive 
merotely induced by transient multipolar spindle intermediates. Since merotelic 
attachments are poorly sensed by the SAC (Salmon et al., 2005; Cimini, 2008), the merotelic 
attachments arising from centrosome amplification are not fully repaired and give rise to 





Fig. 3. Lagging chromosomes in human cancer cells. 
(A, B) Lagging chromosome formation detected in a B[a]PDE-treated H1299 lung cancer cell 
line. (A) Normal segregation; (B) an anaphase cell showing lagging chromosome formation. 
The nuclei were stained with DAPI (blue). (C) Lagging chromosomes are shown in a 
hematoxylin-and-eosin-stained section of a squamous cell carcinoma of the lung. In (B) and 
(C), the arrows indicate lagging chromosomes. 
 




The progress in our understanding of the relationship between centrosome abnormalities 
and cancer during the past 15 years has been enormous. We have learned that centrosome 
abnormalities are common among diverse human cancers including lung cancer. Many 
molecules are involved in the control of the numeral and/or functional integrity of 
centrosomes, and the abrogation of these mechanisms results in centrosome abnormalities, 
which promote chromosome instability. From a therapeutic standpoint, anti-cancer drugs 
targeting the centrosome have now been developed (Mazzorana et al., 2011). Future studies 
using a genome-wide approach and new scientific technologies will further increase our 
knowledge of the role of the centrosome in human cells, and such knowledge will likely 
help to establish effective cancer therapies. 
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1. Introduction 
Lung cancer is one of the most commonly diagnosed malignant tumors, and has the highest 
death rate of all cancer types. Both the incidence rate and death rate of lung cancer have 
increased rapidly worldwide during the last 50 years. Lung cancer has now become the 
leading cause of cancer death in males, and the second most common cause of cancer death 
in females, after breast cancer. According to data provided by the International Agency for 
Research on Cancer, about 1.6 million new lung cancer patients were confirmed in 2008, 
accounting for 13% of the total cancer cases, while about 1.4 million patients died, 
amounting to 18% of the total deaths caused by cancer worldwide (Jemal et al., 2011). 
Lung cancer can be divided according to histological subtype into non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC), with the latter accounting for about 14% of new 
lung cancer cases in the USA and Europe in 2004 (Jemal et al., 2004). The clinical and 
histological features of SCLC were first recognized by Barnard in 1926 as being distinct from 
those of other types of lung cancer (Barnard, 1926). SCLC cells develop from lung 
Kulchitsky cells, and SCLC can be further subdivided into three different types: oat-cell 
type, intermediate-cell type and mixed-cell type (Travis, 1999). Smoking is the key risk 
factor for SCLC, and more than 95% of patients develop SCLC as a result of tobacco 
smoking. Smoking more cigarettes and prolonging the duration of smoking can both 
increase the risk of developing SCLC (Brownson et al., 1992), while stopping smoking 
reduces its risk, compared to persistent smokers (Khuder and Mutgi, 2001; Jackman and 
Johnson, 2005). SCLC is very aggressive and the median survival time without treatment is 
less than 4 months. Chemotherapy and radiotherapy represent the two major treatments for 
SCLC. According to the standards developed by the Veterans Administration Lung Cancer 
Study Group, SCLC can be divided into two stages: a limited stage and an extensive stage 
(Simon, 2003). Cancer cells in limited-stage SCLC are restricted to the ipsilateral hemithorax 
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and can be treated by both chemotherapy and radiation therapy. About 20% of patients are 
cured after treatment, and the median survival time is about 18 months. Patients with 
extensive-stage SCLC have a high response rate to chemotherapy, which is the primary 
treatment for this disease, but the median survival time is only about 9 months because 
most patients relapse and the results of salvage therapy are poor (Janne et al., 2002; Demedts 
et al., 2010). 
Transforming growth factor-beta (TGF-β) belongs to a large superfamily of cell cytokines, 
and is an important component of several cellular metabolic pathways. TGF-β signaling 
pathways regulate many aspects of cellular function, such as cellular proliferation, 
differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance and 
survival (Jakowlew, 2006). TGF-β plays a very complex dual role in cancer development, 
progress and metastasis (Akhurst & Derynck, 2001; Elliott & Blobe, 2005). TGF-β inhibits 
primary tumor development and growth by inducing cell cycle arrest and apoptosis as a 
tumor suppressor during the early phase of tumorigenesis (Arteaga, et al. 1993), but also 
promotes tumor invasion and metastasis by inducing the epithelial-mesenchymal transition 
in some epithelial cells, indicating that TGF-β can also act as a tumor promoter in the late 
stage of cancer (Miyazono, 2009).  
There are two types of TGF-β signaling pathways; Smad-dependent and Smad-independent 
pathways. In Smad-dependent TGF-β signaling pathways, autocrine or exogenous TGF-β 
binds to the TGFBR2 and TGFBR1 membrane receptors. TGFBR2 then phosphorylates 
TGFBR1, which activates receptor-regulated Smads (also known as R-Smads). The R-Smads 
usually comprise Smad2 and Smad3. Activated Smad2 and Smad3 form complexes with 
Smad4, the common-partner Smad (co-Smad) in mammals. The subsequent R-Smad-co-
Smad complexes shuttle between the nucleus and cytoplasm, and interact with various 
transcription factors and transcriptional co-activators such as AP-1, Sp1, p300, and SMIF to 
regulate the transcription of target genes (Derynck & Zhang, 2003). The phosphorylation of 
R-Smads can be blocked by inhibitory Smad, which starts the ubiquitination and 
degradation of the R-Smad-co-Smad complexes, thus inhibiting signal transduction (Itoh & 
ten Dijke, 2007). This TGF-β signal transduction pathway mainly regulates cell metabolism 
through this network involving cell cycle capture and apoptosis. In addition to Smad-
mediated signaling pathways, TGF-β also activates other pathways, including Erk, JNK and 
p38 MAPK kinase pathways, via Smad-independent mechanisms (Moustakas & Heldin, 
2007). 
Both Smad-dependent and -independent TGF-β signaling pathways start by binding TGF-β 
to its transmembrane receptor TGFBR2, which then activates the downstream signal 
transduction. However, TGFBR2 expression is often reduced or even blocked in tumor cells 
(Levy & Hill, 2006). In bladder cancer, deficient TGFBR2 expression leads to loss of the 
growth inhibition function of TGF-β, and loss of expression of TGFBR2 has been shown to 
correlate with tumor grade (Tokunaga, et al., 1999). Other studies also found that 
inactivation of TGFBR2 played a central role in the development and progression of human 
gastric cancer, and TGFBR2 expression has shown a strong association with the degree of 
malignancy in gastric cancer (Chang, et al., 1997). The expression of TGFBR2 was also 
reduced in breast cancer (Gobbi, et al. 2000). Although the reasons for defective TGFBR2 
expression are still unknown, loss of or reduced expression of TGFBR2 may be caused by 
histone deacetylation in lung cancer cell lines (Osada et al., 2001). 
TGFBR2 mutations have also been observed in tumor cells. A DNA variant with a frameshift 
mutation in the poly(A)10 repeat, resulting in microsatellite instability (MSI), has been 
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detected in the coding region of the TGFBR2 gene in several types of tumors, including 
colon cancer, gastric cancer, and gliomas (Markowitz et al. 1995; Pinto et al., 1997; Izumoto 
et al. 1997). This frameshift could affect gene function and be related to cancer development. 
This MSI also been detected in both NSCLC and SCLC (Kim et al., 2000; Tani et al., 1997), 
though the mutation rate seems to be much lower than that of deficient TGFBR2 expression 
rate in lung cancer. A previous study identified a novel microdeletion (c.492_507del) in giant 
cell carcinoma (GCC) and large cell carcinoma (LCC) patients, compared to other NSCLC 
subtypes. This 16-bp microdeletion introduced a premature stop codon at positions 590–592 
of the cDNA, resulting in a truncated TGFBR2 protein with a mutated transmembrane 
domain and loss of a kinase domain. Although the mutated TGFBR2 played an important 
role in the abrogation of TGF-β signal transduction in LCC cells (Wang et al., 2007), it was 
not correlated with the reduced TGFBR2 expression seen in NSCLC (Xu et al., 2007).  
However, TGFBR2 has rarely been studied in Chinese SCLC samples and its role in TGF-β 
insensitivity in this population thus remains unknown. The present study therefore 
examined the levels of TGFBR2 expression in 27 pairs of formalin-fixed, paraffin-embedded 
SCLC tumors and compared them with NSCLC samples. The entire cDNA region and 
promoter of the gene was then sequenced to identify the causal variants in the TGFBR2 gene 
that accounted for its defective expression. 
2. Materials and methods 
2.1 Specimens 
Twenty-seven formalin-fixed, paraffin-embedded SCLC samples and their corresponding 
normal tissues were collected by the Laboratory of the Department of Thoracic Surgery, 
Changhai Hospital between 2000 and 2007. All the patients had undergone pulmonary 
resection for primary SCLC at Changhai Hospital and had provided informed consent, and 
none had received preoperative radiotherapy or chemotherapy. The demographic and 
clinical features of these SCLC cases are summarized in Table 1. This research was 
conducted with the official approval of the academic advisory board of the Institute of 
Genetics, Fudan University, Shanghai, P. R. China. 
An additional 65 formalin-fixed, paraffin-embedded NSCLC samples and their 
corresponding normal tissues were collected between 2005 and 2007, as a control group to 
compare with SCLC (Table 2). These tissues were also provided by the Laboratory of the 
Department of Thoracic Surgery, Changhai Hospital after obtaining the patients’ consent. 
None of these patients had received radiotherapy or chemotherapy prior to surgery. 
2.2 Immunohistochemistry 
Expression of TGFBR2 was detected by immunohistochemistry assay using a monoclonal 
antibody against the extracellular domain of TGFBR2 (R & D Systems, Minneapolis, MN) 
via two-step immunohistochemical staining using the EnVision system (DAKO Cytomation, 
Denmark), as described in our previous report (26). In brief, after the paraffin sections were 
deparaffinized and hydrated, serial 4-μm thick sections were placed into 3% hydrogen 
peroxide solution for 10 min to block endogenous peroxidase activity. For antigen retrieval, 
the sections were treated with boiling 0.01 mol/L citrate buffer (pH 6.0) for 25 min and then 
incubated with 10% fetal calf serum for 20 min at room temperature. After the blocking 
serum was removed, the sections were incubated with the primary antibody (1:50) at room 
temperature for 1 h, followed by rinsing three times with phosphate-buffered saline (PBS).  
 




Re: reduced TGFBR2 expression in tumor tissues, Loss: loss of TGFBR2 expression, Pr: preserved 
TGFBR2 expression. 
The staining score of each tissue is the product of the proportion of positive staining cells and intensity 
scores. 
Table 1. Clinical features and TGFBR2 expression of the 27 SCLC patients 
 






AdC 33 21 12 
SqC 27 18 9 
Ad-SqC 3 2 1 
Atypical Carcinoid 1 1 
Low Differentiation Sarcoma 1 1 
Grand Total 65 42 23 
Re: reduced TGFBR2 expression in tumor tissues, Pr: preserved TGFBR2 expression. 
Table 2. Clinical features and TGFBR2 expression in NSCLC samples  
The sections were then incubated with a working solution of horseradish peroxidase-labeled 
goat anti-mouse immunoglobulin, as provided in the EnVision kit, for 30 min. Finally, the 
peroxidase activity was developed with 3,3-diaminobenzidine tetrahydrochloride and 
hydrogen peroxide. Because NSCLC develops from bronchial epithelium precursors, human 
normal bronchial epithelium was used as a positive control. A negative control for each 
specimen was provided by treating the sections with PBS instead of the primary antibody. 
2.3 Interpretation of the staining and data evaluation 
All sections were examined by standard light microscopy and scored semi-quantitatively on 
the basis of the percentage of immunoreactive cells and on the intensity of the staining 
reaction. The samples were initially classified into one of four grades, according to staining 
intensity: 0 (negative staining, equivalent to the negative control), 1 (weak staining), 2 
(medium staining) and 3 (strong staining). The percentages of positively-stained cells were 
assigned as 0 for 0–25%, 1 for 26–50%, 2 for 51–75% and 3 for 76–100%, respectively. The 
final score was determined as the product of the proportion and intensity scores, and ranged 
from 0–9. Samples were considered to be negatively stained if the final score was 0, and 
positively stained if the final score was 1–9. Moreover, cancer samples were classified as 
preserved- or reduced-type in terms of TGFBR2 expression, depending on whether the final 
score was the same as or less than that of its corresponding normal lung tissue. 
2.4 DNA Extraction and mutation analysis 
Target cells from formalin-fixed, paraffin-embedded tissue sections were microdissected 
and scraped into microtubes. After deparaffinization with xylene and washing in ethanol, 
DNA was extracted by standard proteinase K digestion and phenol-chloroform extraction 
(Sambrook & Maniatis, 1989).  
The presence of the 16-bp microdeletion in exon 4, which was previously detected in LCC 
and GCC, was examined in all SCLC tissues using the following forward and reverse 
primers to amplify the fragments of 117/101 bp, representing the wild/mutant alleles: 5'-
caccagcaatcctgacttgttg-3' and 5'-cggttaacgcggtagcagtag-3'. The MSI in exon 3 was detected 
by the STR  method using an ABI 3100 Sequencer and the following forward and reverse 
primers were used to amplify the exon 3 fragment (normally 242 bp) of the TGFBR2 gene: 
5’-tccaatgaatctcttcactc-3’ and 5’-cccacacccttaagagaaga-3’. c.1167 C>T in exon 4 of TGFBR2 
was detected by direct sequencing using an ABI 3100 Sequencer and the following forward 
and reverse primers to amplify the exon 4 fragment (242 bp) of the TGFBR2 gene: 5’-
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cccaagatgcccatcgtg-3’ and 5’-tcccaggctcaaggtaaagg-3’. The other primers used for promoter 
and exon sequencing are listed in Table 3. 
 
Fragments Region Direction Sequence (5' - 3') 
TGFBR2 promoter Promoter part1 Forward aactacaaaacatgtacaccagg 
TGFBR2 promoter   Reverse ttctttaggtcgaagtctagagg 
TGFBR2 promoter Promoter part2 Forward atgcagaatctctgcctgcctc 
TGFBR2 promoter   Reverse cgagagctttggccgacttt 
TGFBR2 promoter Promoter part3 Forward gtaaatacttggagcgaggaactc 
TGFBR2 promoter   Reverse ttctgaacgtgcggtgggat 
TGFBR2 exon exon 1 Forward tcggtctatgacgagcag 
TGFBR2 exon   Reverse gggaccccaggaagaccc 
TGFBR2 exon exon 2 Forward gggctggtatcaagttcatttg 
TGFBR2 exon   Reverse ggagacagagatacactgactgtg 
TGFBR2 exon exon 3 Forward tccaatgaatctcttcactc 
TGFBR2 exon   Reverse cccacacccttaagagaaga 
TGFBR2 exon exon 4-1 Forward ccaactccttctctccttgttttg 
TGFBR2 exon   Reverse tccaagaggcatactcctcatagg 
TGFBR2 exon exon 4-2 Forward gtcgctttgctgaggtctataagg 
TGFBR2 exon   Reverse ccaggctcaaggtaaaggggatctagca 
TGFBR2 exon exon 5 Forward ggcagctggaattaaatgatgggc 
TGFBR2 exon   Reverse tgctcgaagcaacacatg 
TGFBR2 exon exon 6 Forward tttcctttgggctgcacatg 
TGFBR2 exon   Reverse cctaagaggcaacttggttgaatc 
TGFBR2 exon exon 7 Forward ccaactcatggtgtccctttg 
TGFBR2 exon   Reverse tctttggacatgcccagcctg 
TGFBR2 MSI Exon 3 Forward Fam-tccaatgaatctcttcactc 
TGFBR2 MSI   Reverse cccacacccttaagagaaga 
TGFBR2 LOH Exon 4 Forward cccaagatgcccatcgtg 
TGFBR2 LOH   Reverse tcccaggctcaaggtaaagg 
Table 3. Primers used in the study 
2.5 Statistical analysis 
Data were analyzed using χ2 tests, corrected χ2 tests, or Fisher’s exact tests. A P value of less 
than 0.05 was considered statistically significant. 
3. Results 
3.1 TGFBR2 expression was more often reduced in SCLC than in NSCLC 
TGFBR2 expression was assessed using immunohistochemistry. Normal human lung tissues 
and normal human bronchial epithelium were used as positive controls. Over 75% of cells in 
these tissues exhibited consistently strong staining, both showing staining scores of 3 × 3 = 
9, indicating normal TGFBR2 expression (Figure 1). Immunostaining of TGFBR2 was 
performed in 27 SCLC tumor tissue samples and their corresponding normal tissues. All the 
normal tissues showed strong staining in over 75% cells with staining scores of 9. One SCLC 
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sample showed negative TGFBR2 expression (score of 0), while the remaining 26 were 
TGFBR2-positive. Furthermore, 16 of the total 27 SCLC tumor samples showed reduced 
TGFBR2 expression (score of 1–6) and 10 showed preserved expression (Table 1).  
None of the 65 NSCLC samples showed negative TGFBR2 expression (staining score of 0). In 
addition, only 35.4% (23/65) of all NSCLC tumor tissues showed reduced (score of 1–6) 
TGFBR2 expression and 64.6% (42/65) of tumors had preserved expression (score of 9) 
(Table 2). When adenocarcinoma and squamous cell carcinoma tissues were analyzed 
separately, the frequencies of preserved type were also higher (63.6% (21/33) and 66.7% 
(18/27) respectively) than those of reduced type (36.4% (12/33) and 33.4% (9/27) 
respectively). In contrast, the frequency of preserved type in SCLCs (47%, 10/27) was much 
lower than that of reduced type (63%, 17/27), indicating that reduced TGFBR2 expression 
was more frequent in SCLC cells (Table 1 & 2). 
 
 
Fig. 1. Expression of TGFBR2 in lung cancer by immunohistochemical analysis (×400).  
A. The expression of normal lung epithelium; 
B. The expression of normal bronchus epithelium; 
C. Reduced expression of SCLC; 
D. Preserved expression of SCLC; 
E. Reduced expression of AdC; 
F. Preserved expression of AdC; 
G. Reduced expression of SCC; 
H. Preserved expression of SCC. 
3.2 No significant relationship was found between TGFBR2 expression and clinical 
features in SCLC patients 
The associations between TGFBR2 expression and other clinical features were analyzed. No 
significant associations were found between TGFBR2 expression and gender (P = 1.00), age 
(P = 0.14), tumor size (P = 1.00), nodal involvement (P = 1.00), metastasis (P = 1.00) or stage 
(P = 0.12) (Table 4). 
 




Gender TGFBR2 expression 
Age P-value M F Re Pr 
Age        
≤60 16（59.26%） 11 5 10 6 32-57 P=1.0000 
＞60 11（40.74%） 10 1 7 4 61-77  
Gender        
Male 21（77.78%） 21 0 15 6  P=0.1358 
Female 6（22.22%） 0 6 2 4   
Tumor Size        
T1 4 3 1 3 1  P=1.0000 
T2 16 11 5 14 9 T≥2  
T3 3 3 0     
T4 4 4 0     
Nodal 
involvement        
N0 5 5 0 3 2  P=1.0000 
N1 10 8 2 14 8 N≥1  
N2 10 8 2     
N3 2 2 0     
Metastasis        
M0 26 20 6 16 10  P=1.0000 
M1 1 1 0 1 0   
Stage        
Ⅰ 2 2 0 1 1  P=0.1164 
Ⅱ 11 8 3 5 6   
Ⅲ 13 10 3 11 2   
Ⅳ 1 1 0 0 1   
Table 4. Association between TGFBR2 expression and clinical features of 27 SCLC patients 
3.3 TGFBR2 expression is related to tumor types 
The relationship between TGFBR2 expression and histological type was analyzed. Samples 
were categorized as SCLC or NSCLC subtypes because they developed from different lung 
cells. As shown in Table 5, a significant association between TGFBR2 expression and 
histological type was identified (P = 0.0151), indicating the existence of a significant 
difference in TGFBR2 expression levels between SCLC and NSCLC subtypes (Table 5).  
For further statistical analysis, NSCLC cases were divided into AdC, SqC, Ad-SqC and other 
subtypes. Because of the sample sizes, comparisons were only made between SCLC and 
AdC, and between SCLC and SqC. The results demonstrated significant differences in 
TGFBR2 expression between SCLC and AdC, and between SCLC and SqC (P = 0.0402 and 
0.0293, respectively) (Table 5). 
3.4 Mutations in exon 4 of TGFBR2 
In a previous study, we identified a microdeletion (c.492_507del) in patients with GCC and 
LCC. We therefore investigated the occurrence of this microdeletion in SCLC in the present 
study. Genomic DNA was extracted from 21 pairs of formalin-fixed, paraffin-embedded 
SCLC tissues and their corresponding normal tissues. The coding and promoter regions of  
 
Defective Expression and DNA Variants of TGFBR2 in Chinese Small Cell Lung Carcinoma 
 
197 
Item n Reduced Preserved P-value 
(1)     
SCLC 27 17 (63.0%) 10 (37.0%) 0.0151 
NSCLC 65 23 (35.4%) 42 (64.6%)  
(2)     
SCLC 27 17 (63.0%) 10 (37.0%) 0.0402 
AdC 33 12 (36.4%) 21 (63.6%)  
(3)     
SCLC 27 17 (63.0%) 10 (37.0%) 0.0293 
SqC 27 9 (33.3%) 18 (66.7%)  
Table 5. TGFBR2 expression in different subtypes of tumor 
TGFBR2 were sequenced. The DNA from the other six pairs of tissues was degraded and 
was unsuitable for amplification. No microdeletion was observed in any of the tested SCLC 
samples.  
However, another novel variant in exon 4 of TGFBR2 was identified in 11 of 21 SCLC tumor 
samples. This variant at c.1167 in the TGFBR2 coding region was T/T homozygous in eight 
out of 11 cases, and C/T heterozygous in the other three cases, compared with C/C 
homozygous in normal individuals. The corresponding normal samples for these were C/T 
heterozygous. In the other 10 pairs of samples, however, the site was C/C homozygous. 
These results suggest that loss of heterozygosity (LOH) occurred in the eight tumors whose 
alleles became T/T homozygous from C/T heterozygous (Figure 2 and Table 6).  
Interestingly, this change was a synonymous mutation that did not alter the amino acid 
sequence. We investigated its effect on the expression of TGFBR2, and found that TGFBR2 
expression was reduced in nearly all T carriers (81.8%), compared with that in normal 
tissues, while only 60% of CC carriers had reduced TGFBR2 expression (Table 6). 
 
 
Fig. 2.  LOH in SCLC. 
A. CC sequence in normal lung tissue from SCLC patients; 
B. TC sequence in normal lung tissue from SCLC patients; 
C. TT sequence in tumor tissue from SCLC patients. 
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Patient No. Tissue LOH TGFBR2 expression 
S1 + TT Pr - CT 
S3 + CC Re - CC 
S5 + CC Re - CC 
S6 + TT Re - CT 
S7 + CC Re - CC 
S8 + TT Re - CT 
S9 + CC Pr - CC 
S11 + CC Pr - CC 
S12 + TT Re - CT 
S13 + TT Re - CT 
S15 + CT Re - CT 
S16 + CC Re - CC 
S18 + CC Pr - CC 
S19 + TT Pr - CT 
S20 + CT Re - CT 
S21 + CC Pr - CC 
S22 + CT Re - CT 
S23 + TT Re - CT 
S25 + CC Re - CC 
S26 + TT Re - CT 
S27 + CC Re - CC 
+: tumor tissues; -: normal lung tissue of patients; 
Re: reduced TGFBR2 expression in tumor tissues, Pr: preserved TGFBR2 expression. 
Table 6. Relationship between LOH in exon 4 and TGFBR2 expression 
3.5 MSI in TGFBR2 in SCLC 
Poly(A)10/(A)9 heterozygosity in exon 3 of TGFBR2, representing MSI, was detected in 60% 
of SCLC samples (9 out of 15), as shown in Table 7. However, no association between MSI 
and TGFBR2 expression was found (P = 0.264). 
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Patient No. Tissue MSI TGF-BRII expression 
S1 + poly (A)10 Preserved - poly (A)10 
S2 + poly (A)10 Preserved - poly (A)10 
S3 + poly (A)10/(A)9 Reduced - poly (A)10/(A)9 
S5 + poly (A)10/(A)9 Reduced - poly (A)10/(A)9 
S6 + poly (A)10/(A)9 Reduced - poly (A)10/(A)9 
S9 + poly (A)10/(A)9 Preserved - poly (A)10 
S13 + poly (A)10/(A)9 Reduced - poly (A)10 
S16 + poly (A)10/(A)9 Reduced - poly (A)10/(A)9 
S19 + poly (A)10/(A)9 Preserved - poly (A)10 
S21 + poly (A)10 Preserved - poly (A)10 
S22 + poly (A)10 Reduced - poly (A)10 
S23 + poly (A)10/(A)9 Reduced - poly (A)10/(A)9 
S25 + poly (A)10 Reduced - poly (A)10 
S26 + poly (A)10/(A)9 Reduced - poly (A)10/(A)9 
S28 + poly (A)10 Reduced - poly (A)10 
S29 + poly (A)10 Reduced - poly (A)10 
S30 + poly (A)10 Reduced - poly (A)10 
+: tumor tissues;  -: normal lung tissue of patients; 
Re: reduced TGFBR2 expression in tumor tissues, Pr: preserved TGFBR2 expression. 
Table 7. MSI detection and relation with TGFBR2 expression 
4. Discussion 
Tumor cells are often able to escape from TGF-β-signaling-induced cell cycle capture and 
apoptosis. TGF-β has a dual function in tumor development (Akhurst & Derynck, 2001;  
Elliott & Blobe, 2005); it acts as a tumor suppressor during the initial stages of tumor 
development (Arteaga, et al. 1993), but promotes tumor progression during the later stages 
(Miyazono, 2009). High levels of TGF-β expression in tumor cells can induce tumor 
evolution by stimulating angiogenesis and through other potential immunosuppressive 
effects, as well as by directly affecting tumor cell invasion and metastasis (Pardali & 
Moustakas, 2007). These direct effects can be achieved via Smad-dependent pathways, or 
may be mediated by interference with these pathways (Derynck & Zhang, 2003). Changes in 
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the TGF-β signaling pathway may lead to abnormal signal transduction and cause 
dysregulated cell growth and differentiation. The first step in any mechanism involves 
binding of autocrine or paracrine TGF-β to the TGFBR2 receptor on the cell membrane, 
before activation of various downstream receptors can occur. TGFBR2 thus plays a key role 
in TGF-β signaling pathways, and its expression is reduced or blocked in many tumors 
(Chang et al., 1997; Tokunaga et al., 1999; Gobbi et al. 2000;Levy & Hill, 2006), resulting in 
partial or complete disruption of the TGF-β pathway. 
Previous studies demonstrated that TGFBR2 expression in NSCLC differed between LCC 
and AdC, SqC or non-LCC cases, but the role of defective TGFBR2 expression in the 
initiation and/or development of SCLC (Xu et al., 2007), and its expression status in SCLC 
remain largely unknown. Furthermore, SCLC is phenotypically distinct from and much 
more malignant than NSCLC. We therefore compared TGFBR2 expression between SCLC 
and NSCLC. Immunohistochemical staining with TGFBR2 antibody revealed significant 
differences in the incidence of reduced expression in SCLC (63.0% of cases) versus AdC 
(36.4% of cases, P = 0.0402) and SqC (33.3% of cases, P = 0.0293), or SCLC versus NSCLC 
(35% of cases, P = 0.0151). These differences in expression levels between SCLC and NSCLC 
were consistent with the histopathologic classification of these tumors, suggesting that 
defective TGFBR2 expression might contribute to the initiation and/or development of 
SCLC.  
To determine the reason for the reduced expression of TGFBR2, we examined the mutation 
status of c.492 507del in exon 4, but found no changes in this sequence in SCLC tumor 
samples. We subsequently determined the MSI status in exon 3, and identified a DNA 
variant with a frameshift mutation in the TGFBR2 poly(A)10 repeat (which causes MSI) in 
the coding region of the TGFBR2 gene. A total of 60.0% of SCLC were poly(A)10/(A)9 
heterozygous, but no association was found between the MSI and TGFBR2 expression. 
However, no MSI was identified in our previous study of NSCLC, suggesting that the MSI 
in SCLC is at least partly associated with its carcinogenesis. We also sequenced all seven 
exons and the promoter region of the TGFBR2 gene and identified a novel LOH at c.1167 in 
38.1% (8/21) of SCLC tissues. Further analysis showed that most of the mutant T-allele 
carriers (81.8%) had reduced TGFBR2 expression in tumor tissues, compared with only 60% 
of C-allele carriers. These results suggest that the change from wild type to mutant type 
might contribute, at least in part, to the defective expression of TGFBR2 in SCLC patients, 
though further studies are needed to clarify the mechanisms responsible. 
5. Conclusion 
The present study identified reduced TGFBR2 gene expression levels in formalin-fixed, 
paraffin-embedded sections from most SCLC tumors examined, suggesting that this might 
contribute to the initiation and/or development of SCLC. Sequencing analysis also indicated 
that change of the wild-type C-allele to the mutant T-allele at c.1167 might contribute to the 
defective expression of TGFBR2 in SCLC patients. Another DNA variant with a frameshift 
mutation in the TGFBR2 poly(A)10 repeat, leading to MSI, was found in the coding region of 
the TGFBR2 gene, but this was not associated with TGFBR2 expression.  
These results suggest that defective expression of TGFBR2 might inactivate TGF-β signal 
transduction, leading to the loss of growth inhibition and acceleration of tumor formation, 
and that a C>T substitution at c.1167 might be partially responsible for this reduced 
expression of TGFBR2 in SCLC. 
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1. Introduction 
Lung cancer arises from neoplastic changes of the epithelial cells in the lung. However, it is 
not known whether all or only a subset of these lung epithelial cells is susceptible to 
malignant transformation. Specifically, a major question is whether the changes need to take 
place in lung epithelial cells involving stem-cell–like properties. Lung cancer is a clinically, 
biologically, histologically, molecularly, and genetically heterogeneous disease. The 
underlying causes of this heterogeneity are unknown and could reflect changes occurring in 
cells with various potential for differentiation or represent different molecular changes 
occurring in the same lung epithelial target cells. Transformation from a normal to 
malignant lung cancer phenotype is thought to arise in a multistep fashion, through a series 
of genetic versus epigenetic alterations, ultimately evolving into an invasive cancer by clonal 
expansion. These progressive pathological changes in the bronchial epithelium occur 
primarily as one of three distinct morphological forms: squamous dysplasia, atypical 
adenomatous hyperplasia, and diffuse idiopathic pulmonary neuroendocrine cell 
hyperplasia. Bronchial squamous dysplasia and carcinoma in situ (CIS) are the recognised 
preneoplastic lesions for squamous cell carcinoma (SCC); atypical adenomatous hyperplasia 
(AAH), a putative preneoplastic lesion, for a subset of adenocarcinomas (ADC); and diffuse 
idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) for neuroendocrine lung 
carcinomas. Pulmonary neuroendocrine tumours comprise approximately 2% of all lung 
malignancies. According to the most recent World Health Organization classification, 
pulmonary neuroendocrine tumours are histologically divided into a three-tier, four-
category system including low-grade (typical carcinoid), intermediate-grade (atypical 
carcinoid), and high-grade (small cell carcinoma and large cell neuroendocrine carcinoma) 
tumours. Nearly all lung cancers exhibit the morphological and molecular features of 
epithelial cells and are accordingly classified as carcinomas. The cells of origin of virtually 
all lung cancers reside in the epithelial lining of the airways. As more is learned about the 
origin of neuroendocrine lung tumours, it is also increasingly clear that the biology of 
neuroendocrine lung tumours arising in the central airways (i.e., SCLC) is distinct from that 
of peripheral airway lesions. The purpose of this chapter is not so much to recapitulate the 
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details of the neuroendocrine lung tumour classification but rather to provide an 
understanding of the main categories of lung carcinoma, to highlight potential pitfalls in the 
histopathological diagnosis of lung cancer, to summarise current information on molecular 
properties and cellular origins of individual neuroendocrine lung tumour subtypes, and to 
relate pathologies to biological behaviours. 
2. Neuroendocrine system of the lung 
The endocrine cells within the gut epithelium (foregut, midgut, and hindgut) constitute the 
largest population of hormone producing cells in the body. So far, approximately 10 
different neuroendocrine lineages have been identified, and most of them show a specific 
rostro-caudal distribution. Pulmonary neuroendocrine cells (PNECs) are part of the diffuse 
neuroendocrine system (DNES) distributed throughout the body. The PNEC system 
(solitary PNECs and neuroepithelial bodies, or NEBs) consists of a distinct population of 
airway epithelial cells displaying endocrine and paracrine secretory mechanisms. 
Pulmonary neuroendocrine cells were readily demonstrated and uniformly distributed in 
normal adult human lungs. Overall, as identified by neurone specific enolase 
immunoreactivity, there were 10.5 neuroendocrine cells per 10 cm of epithelial length and 4 
per 10,000 epithelial cells; they extended from the trachea to the alveolar ducts but none was 
seen in the alveoli (72% were in bronchi, 24% in bronchioles, and 4% in alveolar ducts). Of 
the cells identified by gastrin-releasing peptide immunoreactivity, there were 6.9 
neuroendocrine cells per 10 cm of epithelial length and 2.4 per 10,000 epithelial cells. Of the 
cells identified by calcitonin immunoreactivity, there were 3.5 neuroendocrine cells per 10 
cm of epithelial length and 1.3 per 10,000 epithelial cells. Minor cells contained serotonin (all 
in the terminal bronchioles), and in a small minority no peptide or amine was detected. It is 
currently thought that PNECs, like their counterparts in the gastrointestinal tract, are 
derived from multipotent epithelial progenitors, and that all epithelial cells arise from a 
single stem cell. All pulmonary epithelial cells including PNECs and non-NE airway 
epithelial cells are likely to be derived from a single stem cell. Epithelial lung stem cells, as 
in many organs, are often confined to discretely localised niches that are protected from 
environmental insults. In the lung, PNECs are associated with the stem cell niches in both 
the proximal and distal airways. One of the lung stem-cell niches is located in the trachea 
that reveals two stem-cell niches: gland ducts in the proximal compartment and select foci 
near the cartilage-intercartilage junction in the distal trachea. Other intrapulmonary stem 
cell niches include NEBs located at the airway bifurcation. Another stem cell niche is at the 
bronchoalveolar junctions, although PNECs may play a diminished role at this location. 
Among many functions assigned to them, there is a possible dual role: the regulation of lung 
maturation/growth and chemoreception. First, during the early stages of lung 
organogenesis, PNECs acting via their amine and peptide products may function as local 
modulators of lung growth and differentiation. Second, later in foetal life and in postnatal 
stages, PNECs and in particular innervated NEBs could play a role as airway 
chemoreceptors. The diffuse neuroendocrine system (DNES) of the lung involves 
neuroendocrine cells that have been shown to express a functional oxygen sensing 
mechanism. Aggregates of neuroendocrine cells, called neuroepithelial bodies (NEBs), are 
diffusely spread in the epithelium at all levels of the intrapulmonary airways, preferentially 
located at the airway bifurcation of the lungs. Neuroendocrine cells are selectively contacted 
by different nerve fibres. NEBs are contacted by at least three different nerve-fibre 
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populations: vagal sensory calbidin D28k, calcitonin gene related peptide (CGRP)/substance P 
(SP) innervation, and intrinsic pulmonary nitrergic neurons. 
2.1 Neuroendocrine epithelial cells  
Neuroendocrine epithelial cells (NEC) of the respiratory system tend to occur either as 
single cells that are sparsely distributed throughout the epithelium of the tracheobronchial 
tract or in small, well-defined clusters that are supported by nonciliated bronchiolar (Clara) 
cells. The latter are referred to as neuroepithelial bodies (NEBs) and are located only in the 
epithelium of the intrapulmonary airways, often at or near a bronchiolar bifurcation. The 
solitary pulmonary NEC cells of most of the investigated species are fusiform or flask-
shaped, resting on the basement membrane with an apical process pointing toward the 
airway lumen. Adult human NEC cells generally lack luminal contact. Although there are 
some differences between solitary NEC cells and NEBs, a large body of evidence points to 
their being a member of the amine precursor uptake and decarboxylation (APUD) cell series 
or of the paraneuron family. The endocrine system of the lung consists of at least two 
different cell categories. These categories exhibit similar main characteristics. They contain a 
biogenic amine and neuropeptide mediators, and their cytoplasm harbours neurosecretory-
like granules. Regarding morphological features and location, these cells presumably have a 
receptor secretory function. Consequently, these classes of endocrine cells can be designated 
as paraneurons. Solitary NEC cells were found to be distributed over almost the entire 
respiratory system, while NEBs seemed to be restricted to the epithelium of the 
intrapulmonary airways. Neuroepithelial bodies generally consist of nonciliated, cylindrical 
cells with a palisade-like arrangement between the airway surface and the underlying 
connective tissue, although they may also appear as stratified cells. Most of the luminal side 
of the NEBs is covered by the supporting Clara cells. The NEBs are strategically located on 
the surface of the airway bifurcations. They, in fact, contain the serotonin-bioactive amine 
and neuropeptides, leading to the speculation of these cells as a homogeneous or 
heterogeneous class. They also exert control on pulmonary vessels and airway tone. The 
NEC cell may function as the transducer of the stimulus or the sensory nerve ending, the 
activity of the latter being modulated by the release of bioactive substances from NEC cells. 
Investigations have indicated the influence of NEC cells on epithelial cell differentiation, 
mucous secretion, and proliferation of local endoderm in developing airways. 
2.2 Pulmonary neuroendocrine cells 
Pulmonary neuroendocrine cells (PNECs) are commonly organised into innervated clusters, 
called NEBs, which have been proposed to serve various functions, including the regulation 
of embryonic lung growth and maturation through the elaboration of a variety of potent 
neuropeptides. Several studies have suggested that PNECs are quiescent cells with limited 
self-renewal capacity. However, it was recently demonstrated that PNECs have a self-
renewal capacity and can be activated to undergo multiple rounds of proliferation after TA 
(Clara) cell depletion. It has been suggested that PNEC-derived paracrine factors might play 
a role in the regulation of epithelial cell differentiation and proliferation during foetal lung 
development and possibly in the normal or injured adult lung. Cell proliferation has also 
been shown to contribute to the maintenance of PNE cells in the normal lung as well as in 
hyperplasia of this population in various disease states. PNE cells are known to act as a 
progenitor cell for the establishment of NEB hyperplasia and represent one of two 
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proliferative populations within hyperplastic NEBs of the naphthalene-injured lung. 
Participation of non-PNE progenitor cells in this process has also been demonstrated and 
may contribute to the intermediate phase of NEB hyperplasia. These data suggest that 
multiple cell types contribute to the maintenance and expansion of the NEB-associated PNE 
population and that progenitor selection may be a dynamic feature of NEB hyperplasia. 
Findings from various studies have established PNE cells as a progenitor population that is 
sufficient for the development of both NEB hypertrophy and hyperplasia. Although NEB 
dysplasia is correlated with preneoplastic conditions and PNE cells are thought to serve as a 
precursor for the development of small cell lung carcinoma, mechanisms regulating the 
expansion of the PNE cell population are not well understood. Based on studies performed 
in animal models, it has been suggested that NEB-associated progenitor cells that are 
phenotypically distinct from PNE cells contribute to PNE cell hyperplasia. However, when 
considering mechanisms that may account for PNE cell hyperplasia, the finding that 
multiple cell types proliferate in the NEB microenvironment raises the possibility that a non-
PNE cell progenitor may yield progeny cells with the capacity to undergo PNE cell 
differentiation. 
2.3 Neuroepithelial bodies 
Neuroendocrine bodies were illustrated in 1949 in the description of neuroendocrine cells in 
the bronchiolar mucosa. Neuroendocrine bodies consist of a cluster of 4 to 10 
neuroendocrine cells. On well-oriented sections, they can extend from the subepithelial 
basement membrane to the airway lumens. They are found not only in the epithelium of 
bronchi and bronchioles, but also in alveoli. The neuroepithelial body (NEB) is a highly 
dynamic structure that responds to chronic airway injury through hyperplasia of the 
associated PNEC. NEB-associated epithelial cells share many morphological and 
biochemical characteristics with cells that are distributed throughout the airway. Pulmonary 
NEBs are prime candidates to serve as sensory end organs in the lung. NEBs consist of 
highly organised clusters of specialised cells with neuroendocrine characteristics, arranged 
into organoids that are dispersed throughout the epithelium at all levels of the 
intrapulmonary airways. Structurally, NEB cells harbour cytoplasmic neurosecretory 
granules that are known to contain monoamine, peptide, and purine transmitters. 
Neuroendocrine cells are able to synthesise and release ATP, monoamine, and peptide 
transmitters, resulting in autocrine, paracrine, or endocrine effects. Morphologically, NEBs 
resemble other known chemoreceptors, such as taste buds and carotid bodies, and are 
thought to represent “chemosensors” among other possible functions. Hypoxic conditions 
appear to depolarise NEB cells via a potassium channel-mediated mechanism. In particular, 
the extensively innervated aggregates of the neuroendocrine cells, called neuroepithelial 
bodies (NEBs), are diffusely spread in the epithelium at all levels of the intrapulmonary 
airways but are preferentially located at the airway bifurcation points in the lungs. 
Proportionally, most NEBs are found in the bronchioles and in the terminal respiratory 
bronchioles. The NEB microenvironment may represent an analogous structure within the 
conducting airway epithelium for maintenance of an airway stem-cell pool. It may 
influence the phenotype of the CE cells, blocking the differentiation from Clara to ciliated 
cells and preserving a population of regenerative cells that can contribute to epithelial 
renewal after exposure to Clara cell toxicants. Regeneration of the chronically injured 
airway epithelium is associated with alterations in the number and cellularity of the NEBs 
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as well as the enrichment of nascent epithelial cell populations of epithelial cells that are 
candidate stem cells. The NEB microenvironment is multifunctional, serving to maintain 
slow-cycling epithelial cells in the steady state epithelium and to stimulate the 
proliferation of TA cells either after airway injury or during airway development. Many 
studies have presented extensive evidence that NEBs in the lungs may be selectively 
contacted by at least 5 distinct nerve-fibre populations that are both sensory and motor in 
nature. In addition, they have different origins, indicating that NEBs should be regarded 
as very complex airway receptors that may be capable of accommodating various chemo- 
and mechano-sensory modalities.  
2.3.1 Functions 
It has been estimated that NEBs represent <1% of the epithelial cells in human lungs. 
Some of the supposed functions of NEB in mammalian lungs include the following: 1) the 
ability of NEB to function as transducers (hypoxia); 2) modulation of bronchomotor tone via 
targeting bronchial smooth muscle and the associated nerves located directly beneath NEB; 
3) promotion and regulation of the growth of developing airways by stimulating the 
proliferation of local endoderm; 4) release of amine and peptide modulators; and 5) neonatal 
respiratory adaptation. The lung bud epithelium grows into the adjacent mesenchyme and 
stars branching to form the future bronchial tree. The various stages are divided into the 
embryonic, pseudoglandular, canalicular, saccullar and alveolar/microvascular periods. 
Pulmonary neuroendocrine cells are the first specialised epithelial cell type to appear in 
lung development. In humans, ultrastructurally distinct primitive PNECs (pre-NE cells), 
which contain serotonin and neuro-specific enolase (NSE), can be detected in the beginning 
of the pseudoglandular period. Solitary and clustered PNECs contain bombesin, the major 
neuropeptide in human lungs, which appears in the early weeks of gestation. As the distal 
segments of the developing airways elongate, a process referred to as the canalicular period, 
PNECs differentiate first, followed by ciliated and secretory (Clara) cells. Parallel with the 
increasing number of peripheral airways, the number of PNECs also increases. In the 
developing bronchioles, small NEBs composed of 3-5 bombesin and serotonin-
immunoreactive cells appear at the airway branching points, and rare nerve endings have 
been demonstrated to be in contact with NEBs already in the human foetal lung. Proposed 
roles for PNECs in foetal and newborn lung development include the regulation of 
branching morphogenesis as well as cellular growth and maturation.  
2.3.2 Airway oxygen sensors 
Since 1930, evidence has accumulated to suggest that NEBs may function as hypoxia-
sensitive airway sensors. NEB cells express membrane-bound O2 sensors and are the 
transducers of the hypoxic stimulus. NEB cells respond to acute hypoxia, but apparently not 
to hypercapnia with the degranulation of dense core vesicles and release of 5-
hydroxytryptamine (5-HT). Morphologic and experimental studies to support NEB 
functions as hypoxia-sensitive airway chemoreceptors modulated by the central nervous 
system include the following: a) preferential location of NEB at airway branching points; b) 
apical microvilli in contact with the airway lumen; c) cytoplasmic neurosecretory granules 
containing monoamine and neuropeptides; d) afferent sensory innervation derived from the 
vagus nerve; and e) proximity to blood capillaries. NEBs are predominantly innervated by 
sensory nerve fibres derived from cell bodies in the nodose ganglion of the vagus nerve. 
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Morphological data support the role of NEBs as hypoxia-sensitive airway sensor systems. 
Studies on the effects of chronic hypoxia have shown induced cellular hyperplasia and 
hypertrophy in the peripheral chemoreceptors; chronic normobaric hypoxia showed a 
significant increase in the number of solitary pulmonary neuroendocrine cells (PNECs) as 
well as the enlargement of NEBs. NEB cells possess an oxygen-binding protein, cytochrome 
b, an NADPH oxidase located in the cellular membranes that acts as the O2 receptor both 
during normoxia and hypoxia.  
3. Pathology of neuroendocrine tumours of the lung 
The neuroendocrine cell system is divided into cell types that form glands and diffusely 
distributed cells. This second group is collectively known as the diffuse neuroendocrine 
system (DNES), and its representatives are found in the lung, gastrointestinal tract, or 
urogenital tract. Neuroendocrine tumours of the lung arise from bronchial mucosal cells 
known as Kulchitsky cells, which are part of the DNES. The classification of lung 
neuroendocrine malignancies has been an evolving process (Table 1). 
 
WHO/IASLC histological classification 
Preinvasive Lesions 
   Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) 
Large Cells carcinoma (Variants) 
   Large cell neuroendocrine carcinoma (LCNEC) 
   Combined large cell neuroendocrine carcinoma (C-LCNEC) 
Carcinoid tumour 
   Typical carcinoid (TC) 
   Atypical carcinoid (AC) 
Small cell carcinoma 
   Combined small cell carcinoma 
Non-small Cell Lung Carcinoma with Neuroendocrine Differentiation (NSCLC-NED) 
WHO: World Health Organization; IASLC: International Association for the Study of Lung Cancer 
*From Travis WD, Colby TV, Corrin B, et al in collaboration with pathologists from 14 countries.  
Histological typing of lung and pleural tumors. 3rd ed. Berlin: Springer Verlag, 1999, with permission. 
Table 1. Lung tumours with neuroendocrine morphology include the low-grade typical 
carcinoid (TC), intermediate-grade atypical carcinoid (AC), and the high-grade LCNEC and 
SCLC. 
These classifications date back to 1972, when atypical carcinoids were initially defined 
according to histological criteria, including the number of mitoses per high-power field 
(hpf), the presence of necrosis, increased cellularity with disorganisation, nuclear 
pleomorphism, hyperchromatism, and an abnormal nuclear to cytoplasmic ratio (Table 2). 
In 1991, a new classification proposed 4 categories of neuroendocrine lung tumours that 
included the following: typical carcinoid (TC), which is a low-grade malignancy; atypical 
carcinoid (AC), which is a medium-grade malignancy; large-cell neuroendocrine carcinoma 
(LCNEC), which is a high-grade malignancy; and small-cell lung cancer (SCLC), which is 
also a high-grade malignancy. The 2004 WHO categorisation of tumours with 
neuroendocrine features included the classic carcinoid low-grade TC and intermediate-
grade AC, as well as the high-grade malignancies LCNEC and SCLC. 
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Moderate Common +(focal) Round,oval 
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N/C: nuclear/cytoplasmic; HPF: high power fields; LCNEC: large cell neuroendocrine carcinoma; 
SCLC: small cell lung carcinoma 
Table 2. Histopathological Classification of Neuroendocrine Tumours of Lung 
3.1 Tumourlets 
Carcinoid tumours that grow in the peripheral lung and are smaller than 5 mm are referred 
to as tumourlets. By definition, tumourlets are comprised of increased numbers of 
individual cells, small group cells, or nodular aggregates of cells that are confined to the 
bronchial/bronchiolar epithelium (with larger lesions bulging into the lumen but not 
breaking the subepithelial basement membrane). 
3.2 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia 
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare 
condition in which neuroendocrine cells proliferate throughout the peripheral airways in 
the form of neuroendocrine cell hyperplasia, tumourlets, and sometimes carcinoid tumours. 
In DIPNECH, neuroendocrine cell hyperplasia and tumourlets are thought to be a primary 
proliferation in contrast to the much more common situation where these lesions are seen as 
a reactive secondary lesion in the setting of airway inflammation and/or fibrosis. This 
condition is regarded as a precursor to carcinoid tumours because a subset of these patients 
experience one or more carcinoid tumours. More aggressive forms of lung carcinoma, 
including SCLC, have not been associated with DIPNECH. 
3.3 Carcinoid tumours 
Pulmonary or bronchial carcinoid tumours account for over 25% of all carcinoid tumours 
and for 1%-2% of all pulmonary neoplasms. Approximately 10%-20% of pulmonary 
carcinoids are typical carcinoids; the remaining 80%-90% are atypical carcinoids. Most of 
these tumours occur centrally and involve the main, lobar, or segmental airways. Sometimes 
they are located distal to the segmental bronchi; such tumours are the so-called peripheral 
carcinoids. Atypical carcinoids have been reported to be larger than typical carcinoids, with 
mean diameters of 3.6 cm and 2.3 cm, respectively. Moreover, atypical carcinoids are more 
likely to occur in the periphery of the lung than are typical carcinoids. It was generally 
accepted that a carcinoid tumour was a very slow-growing and benign neoplasm with no 
potential for invasiveness and no tendency to give rise to metastases. Carcinoid tumours 
have subsequently been reported in a wide range of organs, but they most commonly 
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involve the lungs and the gastrointestinal tract. The histopathologic features that distinguish 
atypical carcinoids from typical carcinoids are as follows: increased mitotic activity; greater 
cytological pleomorphism and higher nuclear to cytoplasmic ratios; increased cellularity 
and architectural irregularities, and more areas of tumour necrosis. In terms of histological 
features, typical carcinoids show no evidence of necrosis and fewer than 2 mitoses per 10 
high-power fields (or 2 mm2) of viable tumour, whereas atypical carcinoids do have areas of 
necrosis and 2-10 mitoses per 10 high-power fields. 
3.4 Large-Cell Neuroendocrine Carcinoma  
Large-cell neuroendocrine carcinoma (LCNEC) was proposed as the fourth category of 
pulmonary neuroendocrine tumours due to its distinct clinical and pathologic findings 
versus the typical carcinoid, atypical carcinoid, and SCLC. LCNEC is defined as a poorly 
differentiated and high-grade neuroendocrine tumour that morphologically is between an 
atypical carcinoid and SCLC. According to the WHO suggestions, the morphologic features 
of LCNEC represent a spectrum between those of atypical carcinoid and those of SCLC. In 
70%-80% of cases, LCNEC appears as a peripheral mass or nodule, whereas 25% manifests 
as a central mass. Histopathologic diagnosis criteria for LCNEC are as follows: 
neuroendocrine morphologic features; a high mitotic rate (>10 per 10 high-power fields); 
necrosis (often large zones); cytologic features different from those of SCLC; and positive 
immunohistochemical staining for one or more neuroendocrine markers including 
chromogranin A, synaptophysin , and neural cell adhesion molecular (NCAM/CD56). 
3.5 Small-cell lung carcinoma  
SCLC accounts for approximately 20% of all bronchogenic carcinomas. Approximately 90%-
95% of SCLCs occur centrally, apparently arising in a lobar or main bronchus. In 5%-10% of 
cases, SCLC manifests as a peripheral nodule. These tumour cells are usually small with a 
round or fusiform shape and have high cellularity with a very high mitotic rate. SCLCs are 
highly proliferative and rarely are the mitotic rates less than 10 mitoses per 10 high-power 
fields. As such, virtually every high-power field contains one or more mitoses. The 
architecture of the tumour clusters is poorly preserved, with large areas of necrosis 
separating small islands of viable tumour. A distinguishing feature of SCLC is its expression 
of neuroendocrine markers including neuron specific enolase (NSE), synaptophysin, neural 
cell adhesion molecule (NCAM/CD56), and Leu-7 (CD57). 
4. The neuroendocrine differentiation in lung tumours 
4.1 Non-small cell lung cancer (NSCLC) 
The hypothesis that tumours with neuroendocrine properties should be grouped into a 
single category is not universally accepted for several reasons. First, a large proportion of 
lung carcinomas have mixed non-neuroendocrine and neuroendocrine properties. This is 
particularly evident in molecular profiling studies where otherwise unremarkable 
adenocarcinomas have been shown to express clusters of genes that are thought to reflect 
neuroendocrine differentiation. Second, many of the markers that are regarded as 
neuroendocrine markers are expressed in a variety of cells in addition to neuroendocrine 
cells. Third, neuroendocrine markers are expressed during the embryonic development of 
the lung. 
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4.1.1 Adenocarcinoma (ACA) 
Pathology reports frequently mention the presence of NE immunophenotype or NE 
differentiation in NSCLC. Travis et al. have provided a new classification of the pulmonary 
NE proliferations and neoplasms of the lung, as part of the WHO classification of lung 
cancers. In this classification, NSCLC with NE differentiation (NSCLC-ND) detected only by 
immunostaining via electron microscopy is presented as a distinct entity in which no 
histological features of NE differentiation are appreciated on routine hematoxylin and eosin 
(HE). NSCLC represents a histologically heterogeneous group of tumours with variable 
clinical behaviours. Evidence for NE differentiation in non-small cell lung carcinomas 
(NSCLCs) is, at present, based on histochemical, ultrastructural, and immunohistochemical 
data. The existence of nonsmall cell lung carcinoma with neuroendocrine differentiation as a 
distinct entity, as well as its relevance for prognostic and treatment purpose, is 
controversial. A minority of NSCLCs (10-30%) show NE differentiation, and in contrast to 
large cell NE carcinoma, they show no evidence of this differentiation on routine light 
microscopic examination. Previous studies have identified NE differentiation in NSCLC in 
10 to 70% of cases. Positivity for all 3 NE (Ch, SNP, and CD56) markers was not seen. The 
co-expression of SNP and Ch, the two most commonly used NE markers, accounted for only 
0.2% (ACA) of the NSCLC. SNP staining was observed in a significant minority of NSCLC 
(7.5%), whereas Ch, the most specific NE marker, was very uncommon (0.4%) (Table3).  
 
NSCLC Cell Type Chromogranin (Ch) Synaptophysin (SNP) N-CAM (CD56) 
Adenocarcinoma 0.4% 11.2% 5.1% 
Squamous cell 
carcinoma 0.4% 4.3% 12.4% 
Non-small cell 
carcinoma 0% 12% 7.4% 
Large cell carcinoma 0% 9.3% 6.2% 
Others 0% 0% 0% 
Table 3. Immunoreactivity for Neuroendocrine Markers in Different Subtypes of NSCLC 
As has been suggested, the derivation of all lung tumours from a common endodermal stem 
cell, along with the adoption of amine precursor uptake and decarboxylation properties by 
this endodermal stem cell, explains divergent differentiation in NE lung tumours and the 
occurrence of NE subsets in NSCLC. 
4.1.2 Large cell carcinoma (LCC) 
Large cell carcinomas of the lung are classified into four types based on light microscopic 
evidence of neuroendocrine morphology. Immunohistochemical or electron microscopic 
assessments of neuroendocrine differentiation are categorised as follows: (1) large cell 
neuroendocrine carcinoma exhibits both neuroendocrine morphology and evidence of 
neuroendocrine differentiation; (2) large cell carcinoma with neuroendocrine differentiation 
exhibits neuroendocrine markers but lacks neuroendocrine morphology; (3) large cell 
carcinoma with neuroendocrine morphology exhibits neuroendocrine markers; and (4) 
classic large cell carcinoma exhibits neither neuroendocrine morphology nor differentiation. 
Neuroendocrine markers in NSCLC are expressed not only in large cell carcinoma but also 
in adenocarcinomas. 
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4.2 NETs of the lung with NE differentiation 
Lung tumours with neuroendocrine morphology include the low-grade typical carcinoid 
(TC), intermediate-grade atypical carcinoid (AC), and the high-grade LCNEC and SCLC. 
Neuroendocrine differentiation may be detected by immunohistochemical or ultrastructural 
studies in 10% to 20% of histologically ordinary NSCLCs such as squamous cell carcinomas, 
adenocarcinomas, or large cell carcinomas.  
4.2.1 Small cell lung carcinoma (SCLC)  
SCLC tumors are considered poorly differentiated NE cancers in contrast to typical and 
atypical bronchial carcinoid tumors. In addition to SCLC, approximately 20-30% of NSCLC 
tumors express some degree of NE differentiation, predominatly in adenocarcinomas and 
large cell cancers. SCLC exhibits characteristic molecular abnormalities which partially 
overlap with those of NSCLC including frequent inactivation of the Rb-p16INK4A-related 
G1 checkpoint pathway, loss of p53, and frequent abnormalities in chromosome  
 
 
Fig. 1. Hypothetical carcinogenetic pathway in lung cancer: The specification of distinct cell 
fates is often achieved through the activation of specific intercellular signaling pathways by 
growth factors whose expression must be spatially and temporally controlled to ensure 
accurate response. Typically, a target cell expresses an excess of receptors such that the 
availability of its ligands is rate-limiting for pathway activation. Overall, for a signal to elicit 
the desired response, the intensity and duration of ligand expression must be sufficient to 
meet its threshold concentration, and yet the signal response must be restricted to prevent 
excessive signaling. Excessive activation of a signaling pathway can have broad deleterious 
effects, thus prompting a requirement for antagonistic regulation. Abbreviations: AAA 
(Atypical Adenomatous Hyperplasia), ADC (Adenocarcinoma), BAC (Bronchioalveolar 
Carcinoma), BSD (Basal Squamous Dysplasia), DIPNECH (Diffuse Idiopathic Pulmonary 
Neuroendocrine Cell Hyperplasia), LCC (Large Cell Carcinoma), LCNEC (Large Cell 
Neuroendocrine Carcinoma), NEBs (Neuroepithelial Bodies), PNCs (Pulmonary 
Neuroendocrine Cells), SCC (Squamous Cell Carcinoma), SCLC (Small Cell Lung 
Carcinoma). 
 
Neuroendocrine Tumours of the Lung 
 
213 
3p-assocaited tumor suppressor activity. In addition to these changes, SCLCs frequently 
overexpress myc genes, especially c-Myc, often via gene amplification events. Of all the 
genetic changes in SCLC, Rb gene mutations are utterly characteristic. Functioning RB 
protein is lacking in greater than 90% of SCLC and NSCLC with NE features. 
4.2.2 Large cell neuroendocrine carcinoma (LCNEC) 
The term combined LCNEC is used for those tumours associated with other histologic types 
of NSCLC. Most often this represents a component of adenocarcinoma. LCNEC must be 
distinguished from adenocarcinoma, SCLC, large cell carcinoma, and large cell carcinoma 
with neuroendocrine differentiation (LCC-ND). 
5. Embryological pathways in lung tumours 
5.1 Notch  
The three main functions of Notch signalling in self-renewing tissues include stem-cell 
maintenance, binary cell-fate decisions, and induction of differentiation. A critical aspect of 
Notch function in both development and post-natal life is the maintenance of stem cell 
viability and asymmetric cell division. Intrinsic to this process is an unequal distribution of 
Notch signals in the daughter cells, with the Notch-active cell maintaining its stem cell  
 
 
Fig. 2. Heat map for Notch1-4 expression in a serie of 64 carcinoids studied by tissue array 
technology in our lab gave the next information: The mean of expression for Notch1 is 2.33 
and the mode 0. 76.6% of the samples showed no expression for this marker, 4.7% showed 
weak expression, 1.6% moderate expression; 4.7% of the samples showed strong reactivity 
for Notch1 in more than 75 % of tumour cells in the core biopsy arrayed, 12.5% of the 
samples did not show enough tissue for testing. The average expression for Notch2 is 8.56 
and the mode 12. 7. 8% of the samples showed no expression for this marker, 4.7% showed 
weak expression, 17.2% moderate expression, 54.7% of the samples showed intense staining 
for Notch2 in almost all tumour cells present in the sample, 15.6% of the samples did not 
show enough tissue for testing. The average Notch3 expression is 6.3, and mode of 8. 10.9% 
of the samples showed no expression for this marker, and 25% showed weak expression, 
14% moderate expression, 31.3% of the samples showed intense staining for Notch3 in 
almost all tumour cells present in the sample 18.8% of the samples did not show enough 
tissue for testing. Finally, for Notch4 we did not find reactivity in any of the 87, 5% samples 
with enough tissue for its evaluation.  
 




Fig. 3. Immunohistochemical findings for Notch1-4 in carcinoids tumors. 
character and with transit-amplifying cells typically losing Notch activity. Interestingly, 
Notch function in lung cancer exhibits properties suggesting both tumour promotion and 
inhibition, depending on the tumour cell type. A prominent function of Notch signalling is 
to inhibit the transcriptional activities of the widely expressed E2A proteins. Notch 
signalling rapidly induces degradation and inactivation of E proteins and tissue-specific 
bHLH proteins such as hASH1. This inhibition may occur as a consequence of forming 
inhibitory complexes of E2A proteins with the Hes/HERP/HEY proteins, as well as the 
promotion of E2A protein ubiquitinylation and degradation by Notch. Notch1 and Notch2 
proteins are frequently expressed in non-small-cell lung cancer (NSCLC), while Notch3 
mRNA expression was detected in one-third of all NSCLC cell lines. NSCLC, which includes 
adenocarcinoma, squamous cell carcinoma, large cell undifferentiated carcinoma, and 
bronchoalveolar cell carcinoma, was initially shown to express significant levels of the Hes1 
protein. In addition, there is an inverse correlation in these cell lines between the 
expressions of hASH1/ASCL1 and of the Hes1 protein. In contrast to NSCLC, where Notch 
is suspected to have a growth promoting function, SCLC appears to be growth inhibited, at 
least by the high level over-expression of activated Notch1 and Notch2. Notch1 is rarely 
detectable or inactive in SCLC, whereas a subset of SCLC exhibit Notch2. Notch3 mRNA 
expression was not detected in the SCLC cell lines. Expression of Notch3 has been reported 
to be common in NSCLC but not in SCLC. Significantly, Notch signaling has recently been 
shown to be induced by the ras pathway, which is active in a large fraction of NSCLC, but 
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only rarely in SCLC. Notch in the SCLC cells lead to a significant increase in Hes1 and a 
marked down-regulation of the neurally related transcription factors hASH1 and Hes6. The 
loss of hASH1 may be critical in mediating the growth inhibitory effect of Notch1 in SCLC, 
although a role for other as yet unidentified targets cannot be excluded Activated Notch1 
and Notch2, but not Hes1, caused a potent G1 arrest in the SCLC cells, accompanied by the 
marked up-regulation of p21wasl/cip1, overall abundance of p53, and a Rb mutant typifying 
the majority of SCLC 
5.2 Hedgehog signalling in lung cancer 
The hedgehog (Hh) signalling network functions in cell-cell communication and regulates 
pattern formation, proliferation, cell fate, and the stem/progenitor cell maintenance and self-
renewal in many organs. A greatly simplified version of “canonical” hedgehog signalling in 
mammals typically involves two types of cells, a signalling cell expressing a member of the 
Hedgehog family of secreted ligands (Sonic Hedgehog (Shh), Indian Hedgehog (Ihh), or Desert 
Hedgehog (Dhh)) and a responding cell expressing one or more Patched family hedgehog 
receptors (Patched-1 (PTCH2)). In the Hh pathway, increased signalling results in activation of 
the GLI oncogenes (GLI1, GLI2, and GLI3) that can regulate gene transcription. The Hh 
signalling pathway was originally shown to have persistent activation in SCLC with high 
expression of Shh, PTCK, and GLI1, but an important role in NSCLC, was also demonstrated. 
5.3 BMPs and BMPRs 
The BMPs comprise a branch of the TGF- superfamily that also plays a key role in 
development. Several BMP ligands and BMPRs including BMP3, 4 and 7 as well as type I 
BMPR are expressed during embryonic lung development. BMP4 mRNA is localized at high 
levels in the epithelium of distal tips of terminal buds, with lower levels in the adjacent 
mesenchyme. These loci of BMP expression overlap with the expression domains of some 
other important morphogenetic signaling molecules including HNF-3, Wnt-2, Shh and 
FGF-10. Also, since BMPs and Shh are co-expressed in the same domains, and since 
Decapentaplegic, the Drosophila BMP homologue, is regulated by the Hedgehog signaling 
pathway, it seems possible that BMP-Shh interactions may prove to play key roles in lung 
morphogenesis. Recently published data on fibroblast growth factor interactions suggest 
that Shh, TGF-1 and BMP4 all counteract the bud-promoting effects of FGF-10. 
5.4 Wnt pathway in lung cancer 
Wnt signaling has many functions in animal development including its development role in 
empbryogenesis and in the adult lung. More specifically, studies of knockout mice 
demonstrated the importance of Wnt-2, Wnt-5a, and Wnt-7b in lung maturation. In addition 
to its role in stem cell self-renewal, tissue regeneration, and lung development, Wnt 
signaling is also intimately involved in tumorigenesis and cancer progression. For example, 
the organs where Wnt signaling influences stem cell self-renewal are the same organs where 
those Wnt-pathway-dependent cancers originate. Numerous reportes have demonstrated 
aberrant Wnt activation in lung cancer. Overexpression of Wnt-1 has been demonstrated in 
NSCLC cell lines and primary cancer tissues. This activation can be caused by mutations 
and/or deregulation of many different Wnt signaling components. Mutations in Wnt 
pathway components are rarely found in lung cancer. Also overexpression of Wnt-2 in 
NSCLC has been demonstrated. The human Wnt-2 gene, located on chromosome 7q31.3, is 
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highly expressed in fetal lung. The link between Wnt-2 and tumorigenesis was first 
proposed after data indicated that Wnt-2 was amplified in human cancers. Indeed, in 
patients with NSCLC found that Wnt-5a expression is squamous cell carcinoma was 
significantly higher than that in adenocarcinoma. Recently there has been a suggested role 
for Wnt-7 in lung cancer. It has been reported that expression of Wnt-7a is downregulated in 
most lung cancer cell lines and tumor samples. 
5.5 bHLH 
Helix-loop-helix proteins are a diverse family of transcriptional regulators involved in fetal 
development and cancer. The 125 recognized human HLH proteins can be subdivided into 45 
families, almost all of which have Drosophila representatives as well. These families include 
achaete-scute homologs, E proteins, Atonal, NeuroD, neurogenin, ID proteins, HES, and Hes-
related proteins, and others. bHLH genes control cell differentiation in various tissues and are 
categorised into two distinct groups, activator genes and repressor genes. In mammals, bHLH 
genes such as mammalian achaete-scute complex homolog-1 (MASH1) and mammalian atonal 
homolog (MATH)-1 are expressed in neural precursor cells, and they up-regulate late-
expressing bHLH genes such as NeuroD to direct terminal differentiation. On the other hand, 
HES1, one of the hairy and enhancer of split (HES) homologues, represses neuronal 
differentiation by the suppression of proneural bHLH factors. Repressive bHLH factors such 
as HES1 are regulated by the Notch pathway. The Notch ligands activate the Notch receptors, 
and the activated intracellular domain of the Notch receptors interacts with the DNA-binding 
protein RBP-Jk to activate the expression of repressive bHLHs such as HES1 and HES5, which, 
in turn, suppress the expression of activator bHLHs such as MASH1 and NeuroD. 
Immunohistochemical studies have revealed that Notch1, Notch3, Jagged1, and Jagged2 were 
expressed in neuroendocrine cells of the airway epithelium, while Dll1 was detected in the 
pulmonary neuroendocrine cells. Thus, the differentiation of the lung epithelial cells depends 
on a bHLH factor network, and the Notch pathway may be involved in determining the cell 
differentiation fate in the airway epithelium. 
5.5.1 Achaete-scute homolog (ASH-1) 
Mash1 (termed Hash1 in humans) plays a critical role in development of the central and 
autonomic nervous systems and in tissues of the so-called diffuse NE system including the 
adrenal medullary chromaffin cells, thyroid parafollicular C-cells, and pulmonary NE cells. 
MASH1 is important in the development of the diffuse neuroendocrine system, including 
pulmonary neuroendocrine cells. During neurogenesis, MASH1 expression is confined to 
mitotically active precursors where it is involved in the early stages of lineage commitment; 
in more mature neurons the expression is extinguished. MASH1 and mammalian atonal 
homolog-1 (Math1) up-regulate NeuroD in neural precursor cells to direct terminal 
differentiation, whereas HES1 represses neuronal differentiation by the suppression of pro-
neural factors such as MASH1. In the developing mouse lung, Mash1 first becomes 
detectable at approximately E13.5 in neuroepitelial bodies (NEB´S), clusters of NE cells 
frequently located at branchpoints of large and medium-sized airways. Mash 1 expression in 
mouse lung peaks near birth and the declines in adulthood, following the peak and decline 
of lung NE cells. One target of achaete-scute proteins is the cell surface ligand delta, which 
leads to activation of the Notch pathway in adjoining cells and repression of the neuronal 
fate. In human lung tumours, the expression of hASH1 mRNA was significantly higher in 
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SCLC (75%) than in LCNEC (50%); conversely, HES1 mRNA was lower in SCLC (59%) than 
in LCNEC (87%). These findings reveal that SCLC more strongly expresses the 
neuroendocrine phenotype, while LCNEC shows characteristics that are more similar to the 
epithelium phenotype, suggesting that the biological characteristics of these two tumours 
are different.  On the contrary, non-neuroendocrine carcinoma cells do not express hASH1 
but show high HES1 expression. In NSCLC (squamous cell carcinoma vs. adenocarcinoma), 
the expression of hASH1 mRNA was lower, (0% vs. 15%, respectively), whereas HES1 
mRNA was higher (10% vs. 100%, respectively). Neuroendocrine pulmonary carcinomas 
express MASH1 but not HES1, whereas adenocarcinoma and squamous cell carcinoma 
express HES1. Surprisingly, Merkel cell carcinoma, the cutaneous counterpart of small cell 
carcinoma MASH1, was completely negative in 100% of the cases. 
5.5.2 Hairy and Enhancer-of-split (HES) 
Hes1, a key effector of the Notch signalling pathway, is expressed broadly in non-
neuroendocrine cells in the airway epithelium. In the developing lung, Notch1 and HES1 
are strongly expressed in the non-neuroendocrine airway epithelial cells, whereas MASH1 is 
restricted to the clustered pulmonary neuroendocrine cells. HES1 directly represses hASH1 
expression by binding to a class C site in the ASH1 promoter. Today, the published results 
suggest that the differentiation of neuroendocrine cells in normal lungs is affected by the 
absence of the MASH1 gene. Elements of the Notch signalling pathway, especially that of 
HES1, appear to be critical negative regulators of achaete-scute homolog 1 expression in 
normal lungs and in lung cancer. For example, HES1 transgenic knockout mice exhibit 
substantial hyperplasia and premature differentiation of lung NE cells associated with an 
increase in MASH1-expressing pulmonary epithelium. It has been shown that the over-
expression of HES1 in SCLC cells leads to the repression of hASH1 expression via a 
transcriptional mechanism. 
5.5.3 Retinoblastoma (Rb) 
The RB gene is a prototypical tumour suppressor gene, and the loss of RB function is 
believed to be a key event in the initiation or progression of several human malignancies. 
Most RB gene alterations result in the loss of RB protein expression or in a truncated RB 
protein, which does not enter the nucleus. Thus, heterogeneous positive nuclear RB 
immunostaining is, in general, indicative of normal RB function, whereas negative 
intranuclear RB immunostaining in all tumour cells reflects aberrant RB protein expression. 
Typical and atypical carcinoids manifest a heterogeneous RB-positive staining pattern. 
Atypical carcinoids in general show an increase in the number of tumour cells with nuclear 
staining compared to typical carcinoids. In contrast, small-cell and large-cell neuroendocrine 
carcinomas fail to show RB staining in any tumour nuclei, indicating the loss of RB function. 
From these results, it can be concluded that a progressively higher degree of malignancy 
from typical carcinoids to atypical carcinoids to small-cell carcinomas is paralleled by the 
loss of neuroendocrine markers, increased proliferative markers, increased frequency of p53 
immunostaining, and decreased frequency of RB immunostaining. 
5.5.4 p53 
Although p53 alterations have been previously studied in pulmonary neuroendocrine 
tumours, either these studies have used immunochemistry alone rather than genotypic 
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analysis or they have examined a limited spectrum of pulmonary neuroendocrine 
neoplasias. The distribution of p53 immunohistochemical staining has 4 patterns: negative 
in typical carcinoids (TCs), 50% of ACs, 20% LCNECs, and 12% SCLCs; less than 10% but 
more than 5-10 HPF (focal) in a subset (30%) of aggressive adenocarcinomas; and 50-100% of 
tumour cells (diffuse), exclusively seen in LCNECs and SCLCs. Three patterns of 
immunohistochemical staining intensities of the p53 protein were seen: negative; weak or 
mild; and moderate to marked staining. Similar to other cancers, multiple genetic events 
contribute to the development of neuroendocrine lung tumours. This has already been 
demonstrated in SCLCs, which are known to exhibit alterations in their oncogenes such as c-
myc and in tumour suppressor genes such as p53 and Rb. In addition, it has been shown that 
alterations in oncogenes such as H-ras, c-myc, and c-raf-1 can modulate the expression of 
neuroendocrine antigens in lung cancer cell lines. Thus, evidence is accumulating that the 
expression of neuroendocrine differentiation in pulmonary neuroendocrine tumours is 
fundamentally controlled by multiple genetic determinants. 
6. Conclusions 
Although incidence of newly diagnosed patients with carcinoid tumors of the lung is low, 
the long survival for those with low and intermediate differentiation grade, and the deeper 
knowledge we now have on molecular processes that governs tumors growth make these 
tumors a challenging field in Oncology. Systemic treatment for metastatic carcinoid tumors 
of the lung has not change significantly in the last two decades, and this fact leads to a poor 
improvement in overall survival, contrary to what has happened in other solid tumors. 
Nowadays, most of researchers in neuroendocrine field consider that every single 
neuroendocrine tumors has its own features depending on the organ where it seats, the 
capacity to produce and secrete active hormones to blood stream, and the proliferation rate. 
Novel agents like antiangiogenic tyroisine kinase inhibitors, mTOR inhibitors or oral 
chemotherapeutic agents like temozolomide and capecitabine have been used to treat 
metastatic neuroendocrine tumors of the lung without a clear activity. Unfortunately, these 
clinical trials with new agents were not driven to lung tumors but to other neuroendocrine 
tumors of the gastrointestinal tract. Therefore, other pathways are needed to be investigated. 
A non insignificant number of recent publications are correlating embryological pathways 
with carcinoid tumors of the lung development. In this sense, some elements of the Notch 
signalling pathway, especially HES1, appear to be critical negative regulators of hASH-1 
expression in normal lungs and in lung cancer. This fact may influence in carcinoid tumor 
development at this place. New compounds under clinical development targeting 
embryological pathways like Notch, Hedgehog or Wnt pathways may have a future impact 
in the treatment of disseminated carcinoids of the lung. The more we are able to select 
patients molecularly the greater the chance of success in future clinical trials conducted in 
this setting. However, none of this would be meaningless if the histological diagnosis is not 
accurate. There is a need to leverage the knowledge in the scientific community of the 
variety of neuroendocrine-derived tumors that may arise in the lung. The teamwork 
between pulmonologists, thoracic surgeons, pathologists, molecular biologists, oncologists, 
and radiotherapists is mandatory to offer to our patients the best treatment approach at the 
right time for their diseases. 
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1. Introduction 
Lung cancer is leading cause of cancer death in many advanced countries and one of the 
challenging malignancies because of poor prognosis. Lung cancer is traditionally divided 
into two major categories, so called small cell lung carcinoma (SCLC) and non-small cell 
lung carcinoma (NSCLC) because of distinctive prognostic and treatment strategies between 
them. On the other hand, there is a spectrum of tumors called pulmonary neuroendocrine 
(NE) tumors that are thought to originate from neuroendocrine cells in the pulmonary and 
bronchial epithelium. Until recently, pulmonary NE tumors were classified into three 
categories, i.e., typical carcinoid (TC), atypical carcinoid (AC), and SCLC. Large cell 
neuroendocrine carcinoma (LCNEC) of the lung was officially identified by Travis et al. in 
1991 as a fourth category, a unique higher grade NSCLC existing between TC and SCLC 
(Travis et al., 1991). It is often difficult to diagnose LCNEC with small biopsy specimens 
because accurate diagnosis needs morphological and immunohistochemical information. 
Although earlier reports mainly focused on prognosis after surgical procedures, several 
recent studies reported on the efficacy of chemotherapy for advanced LCNEC. Because of 
the limited numbers of cases (in surgical series, LCNEC represents ~3% of lung cancers), 
large scale prospective studies have not been reported. Standard treatment for LCNEC, 
especially if advanced, is not established although LCNEC is included in NSCLC in the 
treatment algorithm in many guidelines. However, accumulating data including recent 
retrospective studies have suggested that there is similarity in the prognosis and treatment 
response between LCNEC and SCLC.  
In this review, we will focus on the treatment of advanced LCNEC for the better selection of 
chemotherapeutic regimens for the patients with this relatively rare lung cancer.  
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2. Large cell neuroendocrine carcinoma of the lung 
LCNEC is classified as a variant of large cell carcinoma in NSCLC whilst LCNEC has 
neuroendocrine characteristics similar to SCLC such as morphology and the 
immunohistochemical staining pattern. This discrepancy raises the question as to what the 
best therapeutic modality is, that is, should we treat LCNEC as NSCLC or SCLC? 
 
Typical Carc inoid Atypical Carc inoid LCNEC Small ce ll carc inoma
Morphology carcinoid carcinoid neuroendocrine neuroendocrine
Mitosis  <2 / 2mm2 (10HPF)  <2-10 / 2mm2 (10HPF) high: >11 / 2mm2 (10HPF) high: >11 / 2mm2 (10HPF)
Necrosis abscent present (focal punctate) present (extensive) present (extensive)
Cytologic features NSCLC (large cell, low N/C) small cell, scant cytoplasm
Immunohistochemistry positive for NE markers positive for NE markers  
Abbreviations: LCNEC, large cell neuroendocrine carcinoma;  
HPF, high power field;  
NSCLC, non-small cell lung carcinoma;  
N/C, nuclear-cytoplasmic ratio;  
NE, neuroendocrine 
Table 1. Tumors with neuroendocrine morphology (Travis 2010, Gollard et al., 2010) 
Recently, Varlotto et al. reported survival analysis of resected cases with LCNEC and SCLC 
(Varlotto et al., 2011). They compared overall survival (OS) and lung cancer-specific survival 
(LCSS) of patients with LCNEC and SCLC or other large cell lung carcinomas (OLCs) using 
the US National Cancer Institute database (SEER program). Although, the survival rates 
tended to be better in LCNEC and OLCs compared to SCLC, multivariate analysis showed 
no statistical differences (4-year OS rates are 41 % in LCNEC, 42% in OLC, and 32% in 
SCLC; 4-year LCSS rates are 57 % in LCNEC, 54% in OLC, and 42% in SCLC). The SEER 
database does not include chemotherapy information, so that we do not know the impact of 
chemotherapy on survival. Other reports also noted that survival in the early stage LCNEC 
is similar to SCLC (Asamura et al., 2006, Sun et al., 2009) and not better than NSCLC (Iyoda 
et al., 2007).  
3. Chemotherapy for advanced LCNEC 
LCNEC is classified in the category of NSCLC pathologically (Brambilla et al., 2001), so that 
the guideline recommended treatment of advanced LCNEC as NSCLC (NCCN guidelineTM 
2011), and many trials have included this disease as a NSCLC. However, recent 
accumulating data have brought new insights regarding possibly better results with SCLC 
regimens.  
From the published literature, we found four major studies showing the treatment results 
with chemotherapy for advanced LCNEC (Igawa et al., 2010, Fujiwara et al., 2007, Yamazaki 
et al., 2005, Rossi et al., 2005) (Table 2). All studies were retrospective and a total of 83 
patients were treated with first line systemic chemotherapy. Chemotherapy regimens can be 
classified into two groups: SCLC-based regimens (total n=44; platinum and etoposide n=27, 
platinum and irinotecan (CPT-11) n=16, CPT-11 only n=1) and NSCLC-based regimens 
(total n=39; platinum and paclitaxel (PTX) n=11, platinum and gemcitabine n=10, cisplatin 
with vindesine and mitomycin n=6, cisplatin and vindesine n=4, other platinum doublet 
n=2, other single agent n=6).  
Chemotherapy for Large Cell Neuroendocrine Carcinoma of the Lung:  
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Abbreviations: OS, overall survival;  
Pt, patient number;  
RR response rate;  
PTX, paclitaxel;  
VNR, vinorelbine;  
DTX, docetaxel;  
MVP, mitomycin + vindesine + cisplatin;  
VDS, vindesine;  
GEM, gemcitabine.   
 
Table 2. Previous report regarding 1st line chemotherapy for advanced large cell 
neuroendocrine cell carcinoma (LCNEC) 
The response rate (RR) was 47.7% (21/44) for SCLC-based regimens and 35.9% (14/39) for 
NSCLC-based regimens (Table 3). In particular, a platinum doublet yielded a RR of 56.3% 
(9/16) with platinum and CPT-11, 44.4% (12/27) with platinum and etoposide, 54.5% (6/11) 
with platinum and PTX, 16.7% (2/12) with platinum and other third generation agents. 
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Rossi et al. (2005) showed a significant survival benefit with a SCLC-based regimen 
compared with a NSCLC regimen (OS of 51 months (M) vs 21M). This result is far better 
than other reports (OS 7.9M-10.3M, 1-year survival rate 35-47.6%), suggesting that the result 
was from combined effects of surgery and chemotherapy. 
 
Chemotherapy Pt RR


















(Abbreviations are the same as in Table 1) 
Table 3. Summary of previous reports regarding 1st line chemotherapy for advanced large 
cell neuroendocrine cell carcinoma (LCNEC) 
As for second line treatment, there is no report other than a recent publication with 
amrubicin treatment (Yoshida et al., 2011). Amrubicin has efficacy for both SCLC and 
NSCLC, and has been used commonly in Japan in a second line setting with SCLC. 
Promising results for SCLC have also been recently reported from the USA (Ettinger et al., 
2010, Jotte et al., 2011).  
Currently there are a few prospective clinical trials for LCNEC in the 1st line settings 
(ClinicalTrials.gov and UMIN-CTR Clinical Trial, accessed 2nd Aug, 2011). One is not yet 
open but is an interesting phase II study with RAD001 + carboplatin/paclitaxel for 
advanced LCNEC. The other is an ongoing phase II study with cisplatin + irinotecan for 
advanced LCNEC.  
The former study with RAD001 is an interesting study utilizing an mTOR inhibitor which 
inhibits one of the signaling pathways, i.e. the PI3K-mTOR pathway, that lies downstream 
of receptor tyrosine kinases (RTKs) such as EGFR and c-MET. EGFR is one of the most   
Chemotherapy for Large Cell Neuroendocrine Carcinoma of the Lung:  






Disease Report Study Pt RR PFS OS
LCNEC Yoshida, 2011 retrospective n=18 27.7% 3.1M 5.1M
SCLC (sensitive) Jotte, 2011 prospective n=50 44% 4.5M 9.2M
SCLC (refractory) Ettinger, 2010 prospective n=75 21.3% 3.2M 6.0M
SCLC (sensitive) Inoue, 2008 prospective n=9 53% 3.9M 9.9M
SCLC (refractory) n=2 17% 2.6M 5.3M
SCLC (sensitive) Onoda, 2006 prospective n=44 52% 10.3M 11.6M
SCLC (refractory) n=16 50% 2.6M 4.4M  
 
Table 4. Efficacy of Amrubicin in the 2nd line treatment for LCNEC and SCLC 
important RTKs in NSCLC (Paez et al., 2004), and moreover c-MET is reported to be an  
important RTK in SCLC as well as NSCLC (Nakachi et al., 2010, Rossi et al., 2005, Schmid et 
al., 2010). RAD001 has limited but apparent antitumor activity against pretreated SCLC as a 
single agent (Tarhini et al., 2010). According to these results, targeting signaling pathways 
with cytotoxic agent might be the next challenge for SCLC and LCNEC. Because many of 
the current effort in NSCLC is searching for driver mutations (Paez et al., 2004, Naoki et al., 
2002), such an effort is also important in SCLC and LCNEC.  
4. Conclusion 
Although there is an issue regarding accurate diagnosis with small biopsy specimens, 
accumulating retrospective data suggest that patients with advanced LCNEC will benefit 
from systemic chemotherapy.  
The current recommendation for the treatment of advanced LCNEC is similar to that of 
SCLC, i.e. platinum based combination chemotherapy, mainly with etoposide or CPT-11 
and possibly with PTX. Further prospective data is needed to elucidate the best combination 
therapy.  
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1. Introduction 
Worldwide, lung carcinoma (LC) is the commonest and deadliest form of cancer in men and 
women, exceeding the mortality of prostate, breast, and colorectal cancers combined (Jemal 
et al., 2009). Irrespective of histologic subtype, more than 90% of all LC is strongly 
associated with cigarette smoking (Alavanja et al., 2002), and the risk significantly increases 
with the number of cigarettes smoked per day, degree of inhalation, age at initiation, and 
life-long cumulative exposure (Tyczynski et al., 2003). Although survival at 5-year is less 
than 15%, yet,  there exists no single proven chemopreventive measure reducing the risk of 
LC development, except for cessation of cigarette smoking. 
Histologically, non-small cell LC (NSCLC) and small-cell LC (SCLC) are the two commonest 
types of LC, constituting 85-90% and 10-15% of all cases, respectively (Rosenzweig et al., 
2010). SCLC (previously called oat cell carcinoma) is relatively less common than NSCLC; 
however, because of a more aggressive growth pattern and clinical course, its treatment is 
more challenging. Although there is no significant difference in outcome by histologic 
subtype, the World Health Organization classification subdivides SCLC into three cell types; 
pure or classic, variant cell, and mixed (Brambilla et al., 2001). SCLC displays a high 
propensity to metastasize, and usually a remarkable but temporary responsiveness to 
chemotherapy and radiotherapy (RT). Although some may be cured, most patients succumb 
to disease because of rapid development of drug resistance and resultant disease 
progression. Median survival for metastatic SCLC is only 10 months, which is interestingly 
very similar to patients with relatively much more drug resistant NSCLC of similar stage 
(Chute et al., 1997). Despite great improvements in imaging, pathology, genetics, 
chemotherapy, and RT techniques, this did not translate into the clinical outcomes, thus, the 
current overall survival rate for SCLC patients is not different than that was 20 years before 
(Chute et al., 1997). 
This chapter has been designated to focus specifically on treatment of SCLC patients, with 
specific emphasises on the technical basis and outcomes of current RT and concurrent 
chemoradiotherapy (C-CRT). Therefore, readers interested in more comprehensive 
information about the epidemiology, etiology, preventive measures, pathologic and  
genetic basis and surgical treatment of SCLC are referred to excellent reviews available in 
this book. 
 




Management of SCLC begins with the accurate staging of the disease. Historically, using the 
Veteran’s Administration Lung Study Group (VALG) criteria (Zelen, 1973), staging of SCLC 
was simplified to include two stages: limited stage SCLC (LS-SCLC), and extensive stage 
SCLC (ES-SCLC). LS-SCLC is defined as the disease confined to the ipsilateral hemithorax 
which can be safely encompassed within a tolerable single radiation port. Involvement of 
ipsilateral supraclavicular lymph node region is also included in limited-stage disease. In 
contrast; patients with ES-SCLC have disease that is beyond the ipsilateral hemithorax. 
Besides the hematogenous spread, involvement of contralateral supraclavicular lymph node 
region and/or presence of malignant pleural- and/or pericardial effusion are included in 
extensive-stage disease. Only less than one third of SCLC patients present with limited-stage 
disease, while remaining two thirds have extensive-stage disease, and are treated with 
palliative chemotherapy. 
The revised American Joint Committee on Cancer (AJCC) staging system implemented the 
TNM staging for NSCLC, but its use for SCLC was also recommended in sixth and seventh 
editions (Edge, 2010; Greene, 2002). Recent study by Vallieres et al., constituting of 349 
patients with resected SCLC confirmed the utility of TNM-based pathologic staging in terms 
of survival outcomes. But, because of being restricted to only 5% SCLC patients presenting 
with an operable disease at presentation, TNM-based staging has not been routinely 
adopted two tired VALG staging system (LS-SCLC and ES-SCLC) in this group of patients 
(Vallieres et al., 2009). 
3. Prognostic factors 
Despite paramount improvements in imaging and treatment modalities,  prognosis of 
patients with SCLC is still unacceptably poor with median survival ranges of only 15-20 
months for LS-SCLC and 8-13 months for ES-SCLC (Lally et al, 2007). Furthermore, 5-year 
survivors are reported to be only in the respective ranges of 10-13% and 1-2%, emphasizing 
the futility of the condition (Lassen, 1995; Tai, 2003). A number of factors have been assigned 
to carry prognostic importance for patients with SCLC but the most important tumor related 
factor is the VALG stage (LS-SCLC versus ES-SCLC). In LS-SCLC, early stage disease that 
corresponds to TNM stage 1 carries the best prognosis specifically in the absence of elevated 
serum lactate dehydrogenase levels (Byhardt, 1986; Lassen, 1995). Similar to other tumor 
sites, weight loss and poor performance status are significant predictors of unfavorable 
outcome (Paesmans et al., 2000). Likewise, men fare poorer than women (Lally et al, 2007). 
In ES-SCLC, the number of organ sites and site of involvement are also strongly associated 
with prognosis (Albain et al, 1991). Compared to other sites, involvement of bone marrow, 
liver, or central nervous system signify unfavorable disease course. 
Compared to NSCLC, SCLC is more frequently associated with paraneoplastic syndromes 
either via antibody-mediated tissue destruction or via ectopic hormone production (Lally et 
al, 2007). Although, some debate exists, unlike antibody-mediated paraneoplastic 
syndromes, ectopic hormone production is generally accepted as a predictor of poor 
outcome. Favorable prognosis linked to antibody-mediated paraneoplastic syndromes may 
be related with presence of a fully competent immune system, indicating the need for 
exploration of immunotherapy adjunct to standard treatment approaches in this patients 
group.          
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4. Treatment for limited-stage small cell lung carcinoma 
4.1 Chemotherapy 
In LS-NSCLC, chemotherapy trials conducted in the 1970s improved survival from weeks to 
months. Over the following three decades, several studies have shown that combination 
chemotherapy regimens were clearly more efficacious than single agent regimens. Response 
rates of 70%-85%, with complete response of 20%-30%, are encouraging but virtually almost 
every patient relapses (Lally et al, 2007). Results of randomized investigations and meta-
analysis for the most active regimen indicated the superiority of etoposide plus cisplatin 
(EP) combination over the other tested combinations (Fukuoka, 1991; Pujol, 2000; Roth, 1992; 
Sundstrom, 2002). Therefore, the EP combination has become the standard care 
chemotherapy combination in United States and Europe since 1980s. Although cisplatin is 
the backbone of chemotherapy, carboplatin may be substituted for cisplatin in older patients 
or in those with renal insufficiency without an apparent efficacy loss (Okamoto et al., 2005). 
Chemotherapy combinations constituting a variety of newer agents, like irinotecan, have 
been tested in an effort to improve current outcomes in LS-SCLC. However, these agents do 
not appear to be more active than older counterparts. Irinotecan, which was the most 
promising of them, has been tested in three randomized phase 3 trials (Hanna, 2006; Lara, 
2009; Noda, 2002). The first trial by Noda et al. demonstrated the superiority of cisplatin 
plus irinotecan (IP) over the standard EP combination in a Japanese Clinical Oncology 
Group (JCOG) trial (Noda et al., 2002). However, two subsequent trials launched in United 
States could not validate these results (Hanna, 2006; Lara, 2009). In both trials response and 
survival rates in patients treated with investigational IP were found to be equivalent to 
standard EP. The potential benefit of adding a third agent to standard EP has also been 
extensively investigated. Higher response rates at a cost of significantly increased toxicity 
were achieved, with no notable improvement in median survival duration over EP alone 
(Loehrer, 1995; Mavroudis, 2001; Niell, 2005; Pujol, 2001).  
Based on these results, the current standard for the first line chemotherapy in this group of 
patients is 4 to 6 cycles of EP combination, and further treatment with either maintenance 
therapy or four cycles of topotecan following standard EP regimen has not been proved to 
improve outcomes (Schiller, 2001; Sculier, 1998).  
4.2 Thoracic radiotherapy 
Before the introduction of chemotherapy in the 1970s, thoracic radiotherapy (TRT) was the 
mainstay of treatment for LS-SCLC. However, management of LS-SCLC with chemotherapy 
alone results in unacceptable rates of intrathoracic failures, ranging from 75 to90% (Faivre-
Finn et al. 2005). In this setting, integration of TRT to chemotherapy reduces these failures 
up to 30 to 60%. Impact of such a decrease in intrathoracic failures has been extensively 
investigated by two meta-analyses (Pignon, 1992; Warde & Payne, 1992). In the first one, 
Warde and Payne (Warde & Payne, 1992) analyzed 11 randomized studies including 1911 
patients, and reported a significantly longer overall survival with the combination of TRT 
and chemotherapy than with chemotherapy alone, with an absolute benefit of 5.4% at 2-year 
(p<0.001). In the other meta-analysis, Pignon et al. (Pignon et al., 1992) included 13 trials 
consisting of 2103 LS-SCLC patients. Combination of TRT and chemotherapy again resulted 
in an absolute survival advantage of 5.4% at 3-year compared to chemotherapy alone 
(p=0.001). Based on the results of these two meta-analyses combination of TRT and 
chemotherapy became the established standard of care in LS-SCLC. 
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TRT delivered both sequentially and concurrently with chemotherapy has been intensively 
assessed. Although sequential treatment approach has the theoretical benefits by chance of 
irradiating smaller target volumes with resultant reduced toxicity rates, the associated longer 
overall treatment time potentially increases the risk of accelerated tumor repopulation and 
development of treatment-resistant clones. In this context, concurrent use of chemotherapy 
and TRT does not only reduce the risk for accelerated repopulation but also offers a chance for 
better locoregional control by utilizing the radiosensitizing efficacy of chemotherapeutic 
agents. Nevertheless, despite such potential benefits, because of increased risk for higher rates 
of acute toxicity with concurrent chemoradiotherapy, sequential use of chemotherapy and TRT 
may be more feasible in elderly patients or those with larger tumors.  
Data on the optimum radiotherapy dose and fractionation come mostly from retrospective 
and phase 2 prospective studies. The results from non-randomized studies indicate a 
notable increase in local control when the dose of TRT is increased from 35 to 40 Gy, and a 
slightly further gain with 50 Gy. Laboratory studies have suggested that typical SCLC cell 
lines have radiation survival curves with little shoulders indicating that accelerated 
fractionation schemes would, therefore, be advantageous (van Meerbeeck et al., 2011). In 
1999, two different cooperative groups randomized patients to once-a-day versus twice-a-
day TRT with concurrent chemotherapy, as depicted in Table 1 (Bonner, 1999; Turrisi, 1999). 
In the study by Bonner et al., authors reported the North Central Cancer Treatment Group 
(NCCTG) experience, and concluded that there was no difference in survival with twice-
daily TRT versus once daily counterpart (Bonner et al., 1999). However, this study has been 
criticized because of using split-course RT schedule which is currently an established factor 
to increase the chance for accelerated repopulation, and therefore, affect treatment outcomes 
in an unfavorable fashion. In the landmark study by Turissi et al. (Int-0096), authors 
reported the long-term outcomes of 358 patients enrolled onto the cooperative group study 
of Eastern Cooperative Oncology Group/ Radiation Therapy Oncology Group 
(ECOG/RTOG) with the diagnosis of LS-SCLC. Results of this study demonstrated that 
twice-daily 45 Gy (1.5 Gy BID) and concurrent CRT was significantly superior over 
conventionally fractionated TRT scheme (Turrisi et al., 1999). Based on the results of this 
latter study, the current standard of care for medically fit LS-SCLC became the 45 Gy (1.5 Gy 
BID) TRT and concurrent EP. Nonetheless, because of the higher frequency of dose limiting 
≥ Grade 3 esophagitis in twice-daily TRT scheme, 54 Gy (1.8 Gy per fraction) in 30 days and 
concurrent EP is also a common and acceptable treatment scheme. 
Carcinoma and Leukemia Group B (CALGB) conducted two phase 2 trials to investigate the 
potential benefit of a higher dose of 70 Gy given in 35 fractions within 7 weeks (Bogart, 2004; 
Miller, 2007). In the first study, median survival, 2-year survival rate, and ≥ Grade 3 
esophagitis rate were 22 months, 48%, and 21%, respectively (Bogart et al., 2004). In the 
second study respective rates were 20 months, 35%, and 30% (Miller et al., 2007). Based on 
the promising results of these two trials, two ongoing randomized Phase 3 trials were 
conducted to compare standard Turissi protocol with escalated doses of conventionally 
fractionated TRT. Results of these two landmark trials summarized in Table 2, will address 
the question whether the higher doses delivered by once daily scheme in 7-week, could 
compensate for the longer interval between the initiation of treatment  and the end of TRT, 
in the expense of increased risk for accelerated tumor cell repopulation. 
In treatment of LS-SCLC, another issue of interest is whether TRT should be administered 
early or late during the chemotherapy course. This question has been addressed by a 
number of trials with no firm conclusions (Gregor, 1997; Jeremic, 1997; Murray, 1993; Perry,  
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 ECOG/RTOG P NCCTG P 
Study Arms Chemo + 
TRT 
Chemo + twice 
daily TRT  
Chemo + 
TRT 
Chemo + twice 
daily TRT  
Number 176 182 - 133 130 - 
Total cycles of CTX  4 4 - 6 6 - 
Cycles of 
concurrent CTX  2 2 - 2 2 - 
Median survival 
(mo) 18.6 20.3 
0.04 
21 21 
0.49 2-year survival (%) 42 44 47 45 
3-year survival (%) - - 34 29 
5-year survival (%) 16 26 - - 
≥Grad 3 
Esophagitis 33 (16%) 67 (32%) <0.001 7 (5.3%) 16 (12.3%) 0.05 
≥Grad 3 Pulmonary 
toxicity 8 (4%) 14 (5%) 0.97 6 (4.5%) 8 (6.2%) >0.05 
Table 1. Limited-stage small cell lung cancer with daily versus twice-daily TRT 
 
Study CTX Standard arm Experimental arm Primary endpoint 
Expected 
enrollment 
CONVERT 4xEP 45 Gy/30 fx, 3 
week, BID, 
starting at second 
course 
66 Gy/33 fx, 6.6 
week, once-daily, 







4xEP 45 Gy/30 fx, 3 
week, BID, 
starting at first or 
second course 
A: 70 Gy/35 fx, 7 
week, once-daily 
B: 61.2 Gy/34 fx, 5 
week, BID, 
starting at first 




Table 2. Benchmark ongoing trials of chemoradiotherapy for limited-stage small-cell lung 
carcinoma 
1987; Skarlos, 2001; Takada, 2002; Work, 1997). In the landmark phase 3 ECOG/RTOG trial 
reported by Turissi et al., the shortening of total irradiation period from 5 weeks to 3 weeks 
was associated with an absolute 10% (16% versus 26%) increase in 5-year survival (Turrisi et 
al., 1999). Results of three other trials revealed a significantly superior survival advantage 
for early TRT over late TRT, confirming the findings of intergroup trial (Jeremic, 1997; 
Murray, 1993; Takada, 2002). The impact of timing of TRT relative to chemotherapy has also 
been addressed by various meta-analyses. De Ruysscher and colleagues conducted a meta-
analysis of phase III trials combining TRT and platinum-based chemotherapy, and 
concluded that the most important predictor of 5-year survival was the interim between the 
start of any treatment until the end of RT (SER), with shorter SERs (<30 days) being associated 
with the highest 5-year survival rates (>20%) (De Ruysscher et al., 2006). With a subsequent 
meta-analysis, Pijls-Johannesma and colleagues evaluated the impact of timing of TRT by 
comparing early versus late TRT, by defining early TRT as within 30 days of beginning 
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chemotherapy. In presence of platinum-based chemotherapy, the 2- and 5-year survival rates 
were favoring early TRT, and this difference was significant only if the TRT was administered 
in a treatment period of less than 30 days. In this study, patient compliance was found to be of 
paramount importance, indicating the importance of patient selection in clinical trials (Pijls-
Johannesma et al., 2007). In a relatively older meta-analysis by Fried et al., late TRT was 
defined as beginning 9 weeks after the initiation of chemotherapy or after the completion of 
third cycle of chemotherapy. Similar to other subsequent meta-analyses, this meta-analysis 
also demonstrated a statistically significant benefit of early TRT over late TRT in terms of 2-
year overall survival. On subset analysis of studies that used hyperfractionated TRT, treatment 
with early versus late TRT revealed a survival benefit, but not when once-daily TRT was 
employed. Likewise, the survival benefit for early versus late TRT was observed uniquely in 
studies using platinum-based chemotherapy, which was not notable in studies using non-
platinum-based chemotherapy (Fried et al., 2004). Results of the available studies and meta-
analyses suggested an interaction between TRT and chemotherapy and, accelerated tumor cell 
repopulation was postulated to be triggered by the first dose of any effective cytotoxic agent 
(De Ruysscher et al., 2006). Therefore, to obtain the highest chance for local/regional control, 
the last clonogenic tumor cell should be killed by the end of TRT (van Meerbeeck et al., 2011). 
Hence, long-term survival decreases with increasing time between the initiations of any 
treatment and the completion of TRT.  
In summary, current evidence recommends the early administration of 45 Gy (1.5 Gy, BID) 
with concurrent EP at systemic doses in medically fit LS-SCLC patients.          
4.4 Radiotherapy techniques and treatment fields 
Treatment for lung tumors, including SCLC, is complex. In order to ensure safe and effective 
RT, several issues must be considered: (a) accurate target volume delineation; (b) proximity 
of dose limiting normal structures (lung, spinal cord, esophagus, heart, brachial plexus, and 
liver); (c) anatomic slope of the chest surface; (d) inhomogenities resulting from the  
presence of nonuniform tissues on the way of RT; (e) frequent need for irregular field dose 
calculations; (f) respiratory motion of the targeted tumor and normal tissues such as lung, 
heart and liver, depending on the location of the primary tumor and involved lymphatic 
region(s). 
The ultimate goal of any RT application is to deliver the prescribed dose homogenously (not 
cooler than 95% and not hotter than 107%) to the planned target volume and keep the dose to 
non-tumorous normal tissues as minimum as possible respecting their tissue architecture 
(serial versus parallel) and their radiation tolerance limits. In this setting, with the aid of 
imaging with anatomic computerized tomography (CT), functional 18-F-fluorodeoxyglucose 
positron emission tomography (PET), preferably fusion of both) and the use of 3–dimensional 
conformal RT, and novel 4-dimensional image-guided RT (IGRT), it is easier than before to 
achieve these goals. Additionally, the dose-volume histograms (DVH) created for each patient 
makes it possible to anticipate the potential early and late toxicity risks based on the organ of 
interest measures and, therefore, modify the treatment plans as necessitated. 
There is considerable debate on the size of the RT portals of SCLC. Historically, RT portals 
were large, encompassing the primary tumor as well as both hilar, entire mediastinal and 
both supraclavicular lymph node regions with generous margins. This was believed to be 
necessary to ensure adequate coverage of gross disease prior to the routine use of CT- based 
RT planning. Although such large field plans may guarantee the irradiation of target 
volumes, they are also associated with increased acute and late toxicity rates and unplanned 
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treatment delays, which may negatively impact both quality of life measures and 
local/regional control rates and related survival outcomes. This issue is specifically argued 
when TRT is delayed after the completion of induction chemotherapy. Although some 
authors advocate generous portals encompassing the pre-chemotherapy volumes as stated 
above, others argue that only limited portals encompassing the pre-chemotherapy primary 
tumor and high-risk nodal areas with a 1-cm margin are adequate, since effective 
chemotherapy has the theoretical chance to cope with subclinical or microscopic disease 
eliminating the need for generous portals. This latter approach has the additional potential 
for decreased treatment related toxicity specifically when TRT is administered concurrently 
with chemotherapy. Treatment directed at pre- versus post-chemotherapy volumes is also 
an ongoing issue of conflict. The unique randomized trial that addressed this issue is the one 
conducted by the South West Oncology Group (SWOG). In this study, patients achieving a 
partial response after chemotherapy were randomized to pre- versus post-chemotherapy 
volume irradiation arms. Outcomes of this benchmark study did not indicate any 
superiority for pre-chemotherapy volume irradiation arm over post-chemotherapy 
irradiation counterpart, in terms of neither local/regional nor survival rates (Kies et al., 
1987). This issue has latter been investigated by Liengswangwong et al. in a retrospective 
analysis. The authors were unable to find a benefit favoring pre-chemotherapy large-field 
TRT over post-chemotherapy limited-field TRT (Liengswangwong et al., 1994).  
In NSCLC, elective irradiation of hilar and/or mediastinal lymphatic regions has gradually 
been replaced by treatment limited to nodes identified by CT or FDG –PET as being 
involved. For SCLC, evidence is scarce to support this approach. In a prospective study by 
De Ruysscher et al., authors limited the RT fields to only CT-positive mediastinal lymph 
nodes in a cohort of 27 patients with LS-SCLC. The authors reported an isolated regional 
recurrence rate of 11%, which was higher than similar studies using elective mediastinal 
irradiation. However, because of small sample size, no definitive conclusions can be drawn 
from this study (De Ruysscher et al., 2006). In a larger phase 2 study including 60 LS-SCLC 
patients, van Loon et al., irradiated only the lymph nodes that appeared to be involved on 
FDG-PET, and reported an isolated nodal failure rate of 3%, which awaits to be confirmed 
by further studies with larger cohorts (van Loon et al., 2010). A typical 3-D conformal RT 
plan used in our institution and associated DVH is shown in Figure 1. 
4.5 Prophylactic cranial irradiation 
Approximately 10-14% of SCLC patients have detectable brain metastases (BM) at the time 
of initial diagnosis (Hardy et al., 1990). During the course of disease, the incidence of BM 
increases up to more than 50%, which is far beyond in postmortem examinations (Hirsch, 
1983; Nicholson, 2002). The incidence of BM is directly proportional with the survival time, 
indicating a potential for further increase with implementation of more effective treatment 
protocols (Komaki, 1981; van Oosterhout, 1996). Compared to patients with LS-SCLC, the 
risk for BM occurrence is higher for patients with ES-SCLC reaching 69% at 2- years of 
diagnosis (van Oosterhout, 1996; Yang GY & Matthews, 2000).   
Impact of BM on socioeconomic issues and quality of life is significantly worse than the 
impact of failure at other metastatic sites. Patients with BM are often obliged to spend 
significant time hospitalized, and suffer loss of independence (Felletti et al., 1985). Despite 
cranial irradiation and/or chemotherapy, the treatment of clinically established BM is 
partially satisfactory with intracranial disease control rates of about 50% and overall 
survival of 4 to 6 months (Carmichael, 1988; Lucas, 1986; Postmus, 1989). 
 




Fig. 1. An example of typical 3-D conformal RT plan and associated DVH. 
Several randomized trials have been conducted to investigate the utility of prophylactic 
cranial irradiation (PCI) in prevention of BM development in patients with LS-SCLC. 
Logically, in patients with extracranial disease under control, PCI may eliminate the 
intracranial microscopic tumor cell deposits with relatively low radiation doses and, 
therefore, may increase the long-term survival. Results of two randomized controlled trials 
from France (PCI85) and United Kingdom (UK02) demonstrated a trend for better survival 
with PCI but neither could reach statistical significance (Arriagada, 1995; Gregor, 1997). Up 
till now, no individual randomized trial has conclusively demonstrated a survival benefit 
for PCI, which may be related with their deficiency in provision of sufficient power to detect 
moderate differences in survival. 
To conduct a meta-analysis of trials using PCI and to make recommendations for clinical 
practice, the PCI Overview Collaborative Group was established. The meta-analysis reported 
by Auperin et al. in 1999 included individual data from patients enrolled on seven prospective 
randomized PCI trials. Trials eligible in the meta-analysis were limited to those, in which 
patients had been treated with systemic chemotherapy with/without TRT to a complete 
clinical response, and no known BM. PCI treatments were generally between 24 to 40 Gy, 
administered in 2-3 Gy per day. Results of this meta-analysis, for the first time, demonstrated a 
statistically significant survival advantage favoring PCI over non-PCI arm. The relative risk for 
death in the treatment group, as compared to control group, was 0.84 (95 CI, 0.73-0.97; P= 
0.01), which corresponds to a 5.4% higher rate of survival at 3 years (20.7% versus 15.3%), and 
the survival advantage persisted over time. As a percent gain over control, this represents a 
35% increase in the proportion of surviving patients. There was also significant difference in 
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disease-free survival at 3 years from 13.3% in the non-PCI group to 22.1% in the PCI group 
(p<0.0001). PCI was additionally associated with a 25.3% absolute decrease in the cumulative 
incidence of BM at 3 years, from 58.6% to 33.3% (p<0.0001) (Auperin et al., 1999). Results of 
this comprehensive meta-analysis have recently been confirmed by the review of data from 
Surveillance Epidemiology and End Results (SEER) reported by Patel et al. Of 7995 LS-SCLC 
patients included, 670 received PCI. Better overall and cause-specific survival were observed 
in patients treated with PCI, and corresponding 2- and 5-year survival rates were 23% and 11% 
without PCI and 425% and 19% with PCI (Patel et al., 2009).  
Based on the results of meta-analysis by Auperin et al., PCI became the standard of care in 
patients with LS-SCLC demonstrating complete response following systemic and/or 
local/regional treatment (Auperin et al., 1999). However, an important concern about the use 
of PCI is the need for determination of an established non-toxic but effective fractionation 
scheme and total dose. Available data have shown that lower doses of PCI may be less 
effective in preventing CNS failures (Auperin, 1999; Gregor, 1997). Recently, Le Pechoux et al. 
published the results of benchmark international PCI trial evaluating radiation dose for PCI in 
LS-SCLC. The study randomized 720 LS-SCLC patients from 157 centers to one of two PCI 
arms: Arm-1 included patients receiving standard-dose PCI to 25 Gy in 2.5 Gy per fraction, 
and Arm 2 included patients receiving higher dose PCI to 36 Gy delivered in 2 Gy once daily 
or 1.5 Gy twice daily. No significant difference of BM incidence was reported between two 
study arms, but there was a significantly higher rate of cancer-related mortality in the higher 
dose arm as a result of unexplained finding of more deaths from extracranial disease 
progression (Le Pechoux et al., 2009). Based on the results of this study, 25 Gy delivered at 2.5 
Gy per fraction per day remains the standard of care for PCI in LS-SCLC patients.     
5. Treatment for extensive-stage small cell lung carcinoma 
5.1 Radiotherapy 
Combination chemotherapy is the mainstay in the management of ES-SCLC, but as 
intrathoracic disease control may be a significant challenge to overcome in a significant 
proportion of patients, role of consolidative TRT has been addressed in several trials. 
Jeremic et al. randomized patients with ES-SCLC, who responded completely at 
extrathoracic sites and at least partially at thorax, to consolidation TRT versus observation 
arms after 3 cycles of systemic chemotherapy. In experimental arm, TRT was administered 
in an accelerated hyperfractionated scheme of 54 Gy given in 1.5 Gy twice daily fractions 
concurrently with EP chemotherapy. The median and a 5-year overall survival in the TRT 
arm and no TRT arm were 17 versus 11 month and 9.1% versus 3.7%, respectively (Jeremic 
et al, 1999). However, the results of ongoing studies addressing the question of TRT both in 
Netherlands and in Canada should be awaited before its routine recommendation for 
patients with ES-SCLC.  
5.2 Prophylactic cranial irradiation 
Although the beneficial effects of PCI on prevention of BM occurrence and on augmentation 
of overall and disease-free survival have been well established in LS-SCLC patients, this 
issue had remained to be answered in ES-SCLC until the publication of the results of recent 
EORTC trial. In this benchmark study, patients with ES-SCLC who had a response to 
chemotherapy were randomized to PCI versus observation arms. The cumulative risk of 
symptomatic BM at 1-year and the 1-year survival rate were 14.6% versus 40.4% (p<0.001), 
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and 27.1% versus 13.3% (p=0.003), both favoring the PCI arm (Slotman et al., 2007). 
Following this study, similar to LS-SCLC, PCI became the standard of care in ES-SCLC 
patients except for those experience disease progression during chemotherapy.    
6. Treatment related toxicity 
Acute side effects of CRT often begin during the second or third weeks of treatment. 
Cessation of the tobacco abuse should be the first step in the management of SCLC patients 
to increase the efficacy of intended CRT as well as to decrease the incidence and severity of 
the treatment related side effects. Dermatitis may be seen but severe cases are rare. 
Prevention of trauma is the key for prevention of severe and difficult to treat dermatitis 
development. Aloe vera gel and perfume-free ointments can be safely used in mild to 
moderate dermatitis. Acute esophagitis is usually the dose limiting toxicity of mediastinal 
irradiation, which rarely progress to severe late esophagitis. In patients with mild to 
moderate swallowing difficulty, semisolid nutrition and liquid form analgesics may be 
beneficial. Although confirmation with randomized controlled Phase 3 trials are needed, 
based on the results of two recent retrospective series by Algara et al. and Topkan et al., 
prophylactic use of glutamine may be beneficial in preventing and reducing the severity of 
acute esophagitis (Algara, 2007; Topkan, 2009). Nonproductive dry cough may be seen if 
trachea and/or major bronchi is/are involved in the high dose radiation portals. 
After the completion of TRT, radiation pneumonitis (RP) may be seen at 2 to 4 weeks. RP is a 
form of radiation-induced lung disease, mimicking bacterial pneumonia. Symptoms usually 
include non-productive dry cough, dyspnea, chest pain, palpitations, malaise, and occasionally 
fever. Rales can be noted on auscultation. Plain X-rays and CT are beneficial in demonstrating 
the extent of perivascular haziness and alveolar filling densities primarily within the radiation 
portal. Treatment of RP includes use of 60 mg/day prednisone for two weeks followed by 
gradual tapering at following 3 to 12 weeks. There is no evidence supporting the use of 
prophylactic use of glucocorticoids or antibiotics in preventing or reducing the severity of RP.  
Late toxicities involve chronic esophagitis, pericarditis, myocarditis, pancarditis, spinal cord 
injury, radiation induced lung fibrosis, and secondary cancers. Incidence and severity of all 
these late toxicities depend on the total dose and dose per fraction, fractionation scheme, 
interim between subsequent fractions, volume of non-target organ exposed to specified 
doses of RT, and concurrent use of chemotherapy. Currently, excluding the symptomatic 
management measures, the best treatment method is prevention of toxicity in the presence 
of agents with at best limited healing efficacy. To achieve this, tolerance doses must be 
strictly respected. Specific for radiation-induced lung fibrosis, which may potentially be 
fatal, a recent study demonstrated promising efficacy of pentoxyfilline and alpha-tocopherol 
combination in reduction of fibrotic lung area up to 50% at median 24 months of drug use. 
At long-term, potential neurocognitive toxicity of PCI is of great concern, since sequalae like 
severe memory loss, intellectual impairment or even dementia, ataxia, or seizures have been 
reported in retrospective studies with small size and questionable methodology. For 
example, neurocognitive assessments prior to chemotherapy and/or PCI are lacking despite 
the fact that almost 50% of SCLC patients have neurologic and neurocognitive impairments 
prior to onset of PCI (Arriagada, 1995; Gregor, 1997; Grosshans, 2008; Komaki, 1995). 
Neurocognitive impairment risk has been reported to strongly associate with daily fraction 
sizes of >3 Gy (Paumier & A Le Péchoux, 2010). In one study, Shaw et al. found that the risk 
for neurocognitive impairment following PCI was 2% and 10% at 2- and 5-year follow-ups, 
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respectively. Furthermore, the authors reported that all toxicities were seen with regimens 
using daily fraction sizes of >3 Gy (Shaw et al., 1994). Notably, two randomized studies with 
neurocognitive assessments in patients randomized to PCI versus non-PCI did not 
demonstrate any deterioration in neurologic functions at 30 months, and quality of life 
measures at baseline, at 6 and 12 months (Arriagada, 1995; Gregor, 1997). However, these 
findings do not mean that PCI has no potential toxicity and should be administered to every 
patient with the diagnosis SCLC, rather they impact the importance of patient selection 
based on neurocognitive tests for safer PCI applications.  
7. Treatment algorithm for LS-SCLC and ES-SCLC 
Our current instutitional treatment algorithm for LS-SCLC and ES-SCLC patients is as 
depicted in Figure 2. 
 
 
Fig. 2. Management Algorithm for LS-SCLC and ES-SCLC 
 




Significant progress has been made in diagnosis and treatment of SCLC in the last 25 years, 
but, with an overall median survival time of 18 to 20 months, even in patients with limited-
stage disease, it is still not possible to consider SCLC in the category of curable cancers. 
Despite this disappointing figure, mandating further research on this highly fatal disease, all 
improvements in LS-SCLC have been achieved by concurrent use chemotherapy and TRT 
(as early as possible), chemotherapy and PCI. For medically fit patients with ES-SCLC, 
combination chemotherapy followed by PCI (in non-progressive cases) is the standard of 
care, and further consolidation with TRT is currently under investigation. It is of paramount 
importance that patients with ES-SCLC be given the chance to participate in future trials for 
identification of a new and effective treatment combination, which may potentially offer a 
longer survival.    
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1. Introduction 
It is well-known that the incidence of lung malignancies increases. The increase of primary 
lung cancer is especially alarming. But the lung is also a target organ for other secondary 
malignancies, such as metastases of different origins. For the primary lung cancer, the 
therapy of choice is its radical resection (together with systematic lymphadenectomy). For 
pulmonary metastases, less radical resections are necessary. Both could be challenging for 
thoracic surgeons in case of limited lung function and in the case of multiple bilateral lung 
nodules – metastases. Furthermore, the newly detected lung tumor is in most cases 
diagnosed in elderly, active smokers with a limited lung function and significant 
comorbidity. Therefore, the above-mentioned planned radical resection in these “limited” 
patients is not possible. Thoracic surgeons face apparently a dead-lock situation having to 
operate radically and sparing enough functional lung parenchyma at the same time.  
This paper is dedicated to the topic of lung parenchyma sparing resection. It’s first part 
describes a laser resection of multiple lung lesions – metastases. The laser segmental lung 
resection and the sleeve bronchoplastic (angioplastic) resection are introduced in it’s second 
and third part, respectively. 
2. Laser resection for lung metastases 
2.1 History 
Already in 1786, John Hunter reported the first case report in history of pulmonary 
metastases. The primary cancer was a malignant tumor of the femur and the patient died of 
widespread pulmonary metastazing only 7 weeks after the leg was amputated (Allen et al., 
1993; Van Schil et al. 2008). In 1927, the first surgeon who performed a lung resection of 
pulmonary metastasis was Jan Divis from Prague (Divis, 1927). Barney and Churchill could 
note the real success after the surgery, removing a lung metastasis by a lobectomy. The 
renal-cell carcinoma was removed by nephrectomy, subsequently. The patient survived for 
over 20 years without any signs of recurrence (Barney & Churchill, 1939). 
Finally, a retrospective analysis of 205 patients after resection of pulmonary metastases 
should be mentioned. This report was published by Thomford in 1965 with a 5 Years-
Survival-Rate (Y-S) of 30.3% (Thomford 1965). 
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2.2 Introducing the laser in thoracic surgery 
In 1985, after establishing a 1064 nm Nd:YAG laser for standard endobronchial interventions 
(Häusinger et al, 1984), LoCicero reopened the debate on the use of lasers in open thoracic 
surgery as well (LoCicero, 1985, 1989). However, since his CO2 laser was a pure absorption 
or cutting laser, it proved inadequate for lung surgery and thus could not establish itself in 
this medical discipline. As a result, a number of medical centers in the United States, Japan 
and Europe began experimenting with 1064 nm Nd:YAG lasers, using bare fibers and 
sapphire tips to perform superficial resections (Branscheid, 1992; Kodama 1991, 1992; Lo 
Cicero 1985, 1989; Mineo, 1998; Moghissi, 1988; Rolle, 1988). As it follows, all of these teams 
achieved only low patient-loads and published no further results, mainly because the 
technical difficulties posed by the available 1064 nm lasers could not be overcome without 
further basic research. Table 1. 
The new era began by introducing the 1318 nm wavelength Nd:YAG laser system of  40 W 
power output. This high performance Nd: YAG laser system consisted of the thin flexible 
quartz fibres (400 μm) with low water content and of a four lens focusing handpiece. This 
new laser system was exclusively used in all patients undergoing a lung parenchyma 
sparing resection in our study. The next Section presents the description of this laser system. 
 
Author Article Laser Wave Length (nm) Laser Application 
LoCicero   1985 
Ann Thorac Surg  
CO2    Hemostasis,  
Sealing of Air Leaks 
Rolle 1988 
Laser in Med and Surg  
Nd:YAG 1064/1318 Experimental/clinical 
n=47 Wedge and 
Segmental Resections 
Moghissi 1988 
J Thoracic Cardiovasc Surg  
Nd:YAG 1064 Local Excision,  
“Coin Lesions” 
LoCicero 1989 
J Thoracic Cardiovasc Surg  
Nd:YAG 1064 Laser assisted pulmonary 
resections 
Kodama       1991 
J Thoracic Cardiovasc Surg  
Nd:YAG   1064  Resection of Lung 
Metastases n=25 
Branscheid  1992 
Eur J Cardiothorac Surg  
Nd:YAG   1064                Resection of Lung 
Metastases  
n=14 Laser only 
n=51 comb. with with 
Lobectomy 
Kodama       1992 
Kyobu Geka  






Nd:YAG   1064   Resection of Lung 
Metastases n=23 
Rolle 2006  
J Thorac Cardiovasc Surg  
Nd:YAG 1318 Lobe-Sparing Resection 
of Multiple Pulmonary 
Metastases n=328 
Table 1. Literature Survey: Nd:YAG/CO2 Laser resection in thoracic surgery. 
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2.2.1 Scientific background, description of 1318 Nd:YAG Laser 
Due to its parenchymal tissue having a typical water content of 80% but a very low tissue 
density (just a fifth of the liver parenchyma), a very low heat capacity and a variable air 
content, the lung is an ideal organ for phototermal laser applications. Therefore, resecting 
lung parenchyma requires a laser with a powerful coagulation capability in addition to 
excellent cutting properties, given the high vessel density. After all, the surgeon must 
always expect fistulae and increasing bronchopulmonary leaks, particularly when dissecting 
lung parenchyma, the more so the deeper one works down in central direction. The 
absorption behavior of different lasers in water differs a lot (Bayly, 1963; Bramson, 1968; 
Dinstl, 1981).  
The 1318 nm wavelength Nd:YAG laser significantly differs from the standard (1064 nm) 
wavelength by its ten times higher absorption in water but still offers sufficient laser light 
scatter, due its proximity to the beginning infrared spectrum, to satisfy the vital coagulation 
requirement as well. In fact the 1318 nm wavelength provided the intended combination 
effect - cutting capability plus coagulation capability - so perfectly as it could not be 
achieved with the 1064 nm wavelength (Rolle, 1988, 1989). As a welcome side-effect, we also 
found strong lung tissue shrinkage, which provides two additional advantages: mechanical 
reinforcement of the coagulation effect, and fistula sealing far into the central lobe region. In 
fact, the surfaces coagulated and sealed off through defocused irradiation with the 1318 nm 
laser withstand artificial ventilation pressures of up to 25 cm H20.  
As for the founding and developing of the above mentioned laser system, the name of 
Professor Axel Rolle has to be mentioned in this place (Rolle, 1988, 1989, 1999). 
The following design features were incorporated to develop a 1318 nm commercial design 
Trumph (formerly Hüttinger Medizintechnik, Umkirch, Germany) and Martin companies. 
The second wavelength is first generated by adapted reflection of the laser mirrors. High 
beam quality allows coupling into thin (less than 0.6 mm) optical quartz fibers with 
minimum losses. For flexible transmission to the area of application, special water-free 
quartz fibers are required as laser light absorption in water is 10 times higher at the 1318-nm 
wavelength (Bayly, et al., 1963; Stokes et al., 1981).  
A four-lens focusing handpiece was developed to concentrate the laser light and allow man-
ual manipulation of the beam onto lung tissue to keep the working-point focus in the tissue 
at 4 mm while avoiding heat generation in the focusing handpiece. The extremely high laser 
power density of 24kW/cm2 allows fast and precise cutting with simultaneous coagulation 
and sealing of lung tissue. A high performance smoke evacuation system eliminates the 
vaporization fumes, which are unavoidable during parenchyma dissection with this laser 
(Fig.1). 
2.3 Surgical technique 
Laser metastasectomy is performed via an anterolateral thoracotomy (staged 3 to 4 weeks, if 
bilateral) after fulfilling the standard indication criteria for pulmonary metastasectomy 
(histologically confirmed primary tumor after its radical resection or its fully controlled 
stage). Preoperative evaluations are the same as a for routine thoracic intervention; 
including a history and physical examination, chest computed tomography (CT), pulmonary 
function tests, and a bone scan. If the signs or symptoms are suggestive, a head CT is also 
obtained. Patients with identified extrapulmonary metastases are excluded from surgery.  
The technique, indication and possibility to save lobes are demonstrated on a case report. A 
59-years-old female patient with a history of radically resected colorectal carcinoma  
 




Fig. 1. Components of modern Laser equipment for the application on lung tissue (1318 nm 
wavelength, 40 W power output, beam quality, energy efficiency, high performance smoke 
evacuation system, 0.4 mm diameter of fibre, focusing handpiece, flexible quartz fibres /low 
water content/). 
(Adenocarcinoma of rectosigmoid pT4 pN1 pM1 (Liver), G3, Status post hemihepatectomy, 
chemotherapy and radiation) was referred to our Institute. A significant progress of 
(isolated) lung metastases was reported. The chest CT demonstrates the situation after the 
successful laser resection of pulmonary metastases on the right side and just before the 
procedure on left (Fig. 2).  
 
 
Fig. 2. Case Report 1: The Chest CT demonstrates the situation after the successful laser 
resection of pulmonary metastases on the right side and just before the procedure on left. 
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The new 1318 nm Nd:YAG laser system offers a unique opportunity to perform the 
procedure in a  parenchyma-saving and lobe-sparing way. Therefore, the bilateral laser 
procedure was performed. The intraoperative situation can be seen on the series of 
photographs: the pulmonary artery is mobilized on a vessel loop; the upper vein lies next to 
the central, 30 mm great metastasis (Fig. 3). The laser resection of this metastasis was than 
performed. The next figure (Fig. 4) shows the situation immediately after the laser resection. 
The intraoperative situation – its close relation to segmental pulmonary vein - can be easily 
recognized. Exposed bronchial branches and segmental vessels at the segmental level were 
over-sewn and ligated with absorbable suture (4-0/ 3-0). The lung architecture and 
orientation was reconstructed following each nodular resection by reapproximating the 
visceral pleura with a running absorbable suture (4-0 Vicryl) (Fig. 5). This technique avoided 
a distortion of the lung tissue to allow consistent orientation and palpation of the initially 
noted lung nodules. At the end of the procedure, the resected lung was re-insuflated by a 
standard way in accordance with the routine thoracic surgical practice. 
By performing the metastasectomy the above-described way, it was possible to save the 
patient’s lobes and to operate on both lungs by a laser parenchyma sparing manner. The 
patient, now one year after the procedure, is in good condition with a full physical activity, 





Fig. 3. Intraoperative view: Laser resection of 30 mm central metastasis localized in left 
upper lobe centrally to pulmonary artery. Intraoperative situation: pulmonary artery and 
the upper vein are mobilized on vessel loop (blue). 
 







Fig. 4. The intraoperative situation – its close relation to segmental pulmonary vein - can be 
easily recognized. Exposed bronchial branches and segmental vessels at the segmental level 




Fig. 5. Intraoperative view: Reconfiguration of the left upper lobe with continuous suture of 
the pleura visceralis. 
 




From January 1996 to May 2004, lung laser resections were performed in 328 patients. There 
were 164 males and 164 females and the main indications for laser lung resections included 
lung metastases of the following primaries: renal carcinoma in 112 cases, colorectal in 91 and 
breast cancer in 35 cases. In the remaining 90 cases laser resection was performed for 
metastases of lung cancer (n=12), malignant melanoma (n=1), sarcomas (n=15), head and 
neck carcinoma (n=12) and for metastases of other less frequent ones (n=27). These results 
were already reported and published elsewhere (Rolle et al., 2006). 
This retrospective study analyzes the second largest indication group of colorectal 
carcinoma lung metastases (Pereszlenyi et al., 2006a, 2006b). 46 females and 45 males with 
median age of 64 yrs, ranged from 43 to 80 years were included. The number of complete 
removed metastases was 629, ranged 1-56; median 7 per patient. All laser resections were 
performed by the Nd:YAG laser system of 1318 nm wavelength with its lung parenchyma 
saving effect. The complete resection (R0) was achieved in 78 patients, incomplete (R1/2) in 
13 patients. 
There was no perioperative mortality. Follow-up was completed for all patients and ranged 
from 1-30 Mo with a median of 20 months. 1 Year-Survival (Y-S) for complete (R0) resection 
was 82%, 2 Y-S was 68%, 3 Y-S 42% and 5 Y-S was 22% (Fig. 6).  For incomplete (R1/2) 
resection (n=13):  1 Year-Survival was 85%, 2 Y-S was 54%, 3 Y-S 46%, 4 Y-S 9% and 5 Y-S 
was 0 (Fig. 6).  
Despite of that the 7 Metastases pro patient was removed and 19% of lymphatic-nodes 
involvement, the radical resection (R0) could be achieved. In 13 patients was the resection 
incomplete (R1/R2). For the R0 versus R1/2 see the Figure 6. The survival with and without 
lymphatic-node-involvement (N1-hilum, N2-mediastinum) after the radical resection (R0N0 
versus R0N1/2) is demonstrated in Figure 7. 
 
 
Fig. 6. Kaplan-Meier curve showing survival according to resection (Bullets = complete R0, 
squares = incomplete R1/R2 resections).  
 




Fig. 7. Kaplan-Meier curve showing survival according to lymphnode-involvement (Bullets 
= complete without LN-involvement R0N0, squares = complete with LN1/N2-involvement 
R0 N1/N2).  
3. Laser segmental lung resection 
The technique of conventional lung segment resection, so called segmentectomy, is well 
known from the pioneer age of the thoracic surgery (pneumoftiseology) when the apical 
sublobar lung resections were performed for lung tuberculosis. Nowadays, those resections 
are not so widely spread due to their “not enough radicalism” for lung cancer cases.  
However, as it is already stated in the Introduction, these resections will gain more and 
more importance due to their lung parenchyma-sparing effect and the improving results on 
early postoperative morbidity and mortality (Keenan et al., 2004; Harada et al., 2005). 
In this place, it should be emphasized that the segmental resection is also an anatomical 
lung resection as the lobectomy. It respects the anatomical structure of the lung with its 
bronchial and vascular composites together with its lymphatic flows.  
A significant role in the technique of the segmental resection belongs to the laser system. Its 
cutting effect enables the thoracic surgeon to perform this kind of resection exactly within 
the anatomical boarders of the pulmonary segment. Therefore it is feasible also for segments 
where the “classical” segment resections can only hardly be obtained, e.g. segment III, IX, X etc.  
3.1 Surgical technique 
Laser segmentectomy is performed via an anterolateral muscle-sparing thoracotomy after 
fulfilling the standard indication criteria for a lung cancer resection (histologically 
confirmed lung tumor in its functional and oncologic operable stage). Preoperative 
evaluations are the same as for a routine thoracic intervention; including a history and 
physical examination, chest computed tomography (CT), pulmonary function tests, and a 
PET scan. If there are positive mediastinal lymphatic nodes proved by the test, a video-
mediastinoscopy in order to clarify the N2/N3 status is added prior to the resection.  
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Next, a case report presents the technique of laser segmental lung resection. A 66-years-old 
male patient with histological confirmed Adenocarcinoma of the right upper lobe was 
evaluated for a lung resection. Because of the patient’s significant comorbidity (ischemic 
heart disease, arterial hypertension, diabetes mellitus) and poor lung function (COPD, active 
smoker with history of 30 Pack/Years, FEV1 55%), the limited lung resection – Laser 
resection of the Segment 1 - was performed. 
For the patient’s preoperative images see Figure 8.  
 
 
Fig. 8. Chest CT and X-ray pictures of Case 2. The perioperative images are on the left and 
the postoperative images are on the right side.  
After the mobilization of the lung hilus, the segmental vessels and bronchus were mobilized 
on vessel loops. Fig.9. After this step, the lung parenchyma resection was performed by the 
laser system within the anatomical boarders of the Segment 1. Fig.10. The visceralisation 
(reapproximating the visceral pleura with a running absorbable suture /4-0 Vicryl/) in 
order to restore the architecture of the upper lobe followed. As it was already described 
above, this technique avoided a distortion of the lung tissue to allow consistent orientation 
and palpation of the lung parenchyma. At the end of the procedure, the resected lung was 
re-insuflated by a standard way in accordance with the routine thoracic surgical practice. 
Radical lymphadenectomy is routinely added to this procedure (Pereszlenyi et al., 2006).  
The patient is now 3 years after the procedure, without any signs of tumor recurrence. The 
histological examination of the resected specimen has proved an Adenocarcinoma of the 
lung 3 cm of diameter, radically (R0) removed via the laser resection of the Segment 1. For 
postoperative CT scans see Figure 8. 
 




Fig. 9. Right lung hilus is mobilized; truncus anterior on the blue vessel loop with its 
segmental artery branches A1, A3. 
 
Fig. 10. Laser segmental resection within the anatomical boarders of the Segment 1. 
3.2 Results 
From January 1996 to December 2001, laser segmental lung resections were performed in 53 
patients (Pereszlenyi et al., 2006). The results after these resections were compared to 
standard lobectomies /n=154/ for non-small cell lung cancer (NSCLC). The data of this 
comparison are presented in the Table 2.  
As it follows, the 1, 3, 5 Year-Survival (Y-S) is comparable in both groups, there is no 
statistical significance /p=0.696/ in terms of tumor recurrence rate (26.4% versus 29.2%). 
The postoperative mortality rate (11.3%) after laser lung segmental resection is explained by 
the significant comorbidity, limited lung function in elderly patients in whom this kind of 
lung parenchyma sparing resection was performed. Tab.2. 
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To conclude, we are convinced that radical surgical resection is still the therapy of choice in 
NSCLC treatment. However, laser segmental lung resection represents an optimal treatment 
eventuality especially for those high risk patients in whom the standard resection – 
lobectomy is not feasible or performable.  
Our study demonstrates the possibility and justification of this treatment modality with 
comparable results after the standard ones (Harada et al., 2005).  
 
























Table 2. Laser segmental lung resection versus standard lobectomy for primary lung cancer 
(n=207). Selection criteria for laser segmental resection: high risk patients (elderly patient, 
poor performance status, FEV1<65%, significant comorbidity) and peripheral tumors of ≤ 
4cm diameter. 
4. Sleeve bronchoplastic lung resection 
Last but not least, the sleeve lobectomy should be mentioned. Centrally localized lung 
tumors can be resected by a lobectomy extended into a resection of central part of the 
invaded bronchus. The shape of such resected bronchus has a form of a sleeve. That’s where 
the term “sleeve” lobectomy originates.  There are numerous published studies showing the 
clear benefit for this type of lung resections. The most important advantage includes the 
avoidance of a major lung resection, e.g. pneumonectomy by performing a sleeve 
lobectomy. Its technique is well known, but in case of constructing so called “Neo-carina” 
followed by its re-implantation to the main stem bronchus can be very challenging also for 
experienced surgeons. Fig.11.  
 
Fig. 11. Sleeve middle and lower (bi-)lobectomy: Re-implantation the upper lobe bronchus 
into main-stem bronchus right (or into distal trachea with construction of the “neo-carina”) 
after resection the tumor within the bilobectomy. Scheme. 
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In case of multiple lung lesions, the laser system plays a significant role. The centrally 
located endobronchial tumor is removed by a sleeve lobectomy, and any smaller peripheral 
lesions (satellites) are resected by laser. Fig.12. The technique of the laser resection is 
presented in detail in the first part of this chapter. Fig. 13.  
 
 
Fig. 12. Case Report 3: Chest CT shows the central lung tumor in the right lower lobe and 
two small satellites in the periphery of the lung.  
 
Fig. 13. Scheme of laser resection of small peripheral nodule located in the middle lobe after 
sleeve lower lobe resection for a large central located endobronchial tumor. 
4.1 Surgical technique, patients and methods 
Between January 2005 and January 2011, 58 patients (42 males, 16 females, mean age 61 yrs 
range 24 – 83) underwent sleeve lobectomy (SL) in our Institute. The indications for SL were: 
non-small cell lung carcinoma (NSCLC) in 47 /Fig.14/, and pulmonary metastases in 11 
patients. Fig.15. As the metastatic pulmonary lesions were multiple, the Laser Resection (LR) 
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of these satellites was added to the SL procedure. The main indication for laser resection 
were metastases of renal-cell (n=4) and colorectal-carcinoma (n=3).  Fig.15. The most 
detected histologic type of NSCLC was squamous-cell carcinoma (n=22), followed by 
adenocarcinoma (n=14). The laser resection (combined by SL) was performed after fulfilling 
the standard criteria for metastasectomy: primary tumors were radically removed and there 
were no evidence of any distant extrathoracic metastases. In four NSCLC patients the 
arterial sleeve was added to the left upper bronchial SL. Lymphadenectomy was routinely 
added to the both parenchyma-saving procedures. 
The Tumor Stage is shown in the Figure 16 according to the newest, revised TNM 
Classification from 2009 (Goldstraw et al., 2007).  
 
 
Fig. 14. Tumor histology distribution (NSCLC; n=47). 
 
 
Fig. 15. Tumor histology distribution (Lung Metastases; n=11). 
 






Fig. 16. Tumor Stage according to TNM Classification 2009 (n=47). yT0N0 - As the result of 
the successful neoadjuvant treatment, the tumor is not detectable in the resected lung 
specimen.   
The location of the tumors and types of sleeve resections are shown in Table 3. Almost 40% 
of the patients underwent right sleeve upper lobe resection. 
 
 
Side and Type of Procedure Number of Patients (%) 
Right Lung   
   Upper Lobe 23 (39) 
   Middle Lobe 1 (2) 
   Middle and Lower Lobe 1 (2) 
   Lower Lobe 14 (24) 
   
Left Lung  
   Upper Lobe 12 (21) 
   Lower Lobe 7 (12) 
Table 3. The location of tumors and types of sleeve resections (n=58). 
Following the double-lumen tube intubation and the standard anterolateral, muscle-sparing 
thoracotomy, we proceed with the resection. A bronchial anastomosis is performed by 
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interrupted monofilament absorbable suture of PDS 3-0 or 4-0. The vascular anastomosis 
was performed by running suture of the non-absorbable material of Prolene 5-0 (or 4-0) in 
four NSCLC patients after the left upper sleeve lobectomy was finished. 
Mediastinal (hilar) lymphadenectomy is routinely performed as well as an intraoperative 
frozen section analysis of the resected bronchus (and vessel). After the reconstruction of the 
bronchus, a routine fiber bronchoscopy is always performed by the first surgeon. In our 
series, we didn’t cover the bronchial anastomosis by any autologeous flap or any other 
materials.  
4.2 Results 
A negative bronchial (vascular) margin was achieved in all. No 30-days postoperative 
mortality occurred. Follow-up (completed for all patients with median of 12 Mo) showed no 
anastomotic complications, no local recurrence on the bronchial (arterial) anastomosis. 
Survival was analyzed according to Kaplan-Meier method with the estimated 1, 2, 4 years 





Fig. 17. Kaplan-Meier curve showing Survival at 20, 40, 60 Months. 
In accordance with the reported results from the literature we can also conclude, the 
bronchial and vascular sleeve lobectomy can be performed safely, and is a good alternative 
solution to avoid pneumonectomy (Konstantinou et al., 2009; Ludwig et al., 2005).  
As shown in our study, selected patients with central lung metastases can be also included 
for this procedure after fulfilling the standard criteria for pulmonary metastasectomy. The 
central role for these kinds of procedures belongs to the laser lung-parenchyma-saving 
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resection. In our study all laser resections were performed by a 1318-nm Nd:YAG laser 
system of 40 W power output.  
Laser resection may expand the scope of surgical treatment for pulmonary metastases, 
allowing a more complete resection. The indications for laser resection may expand to 
include patients who are not considered ideal candidates for lung metastasectomy because 
of poor residual lung function or multifocal pulmonary disease. The 1318-nm Nd:YAG laser 
for the resection of pulmonary metastases demonstrates a significant influence on the con-
servation of tissue during metastasectomy and appears to minimize complications. 
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1. Introduction  
Small-Cell Lung Carcinoma (SCLC) represents about 15% of all lung cancers diagnosed 
worldwide. Although its incidence is diminished in the last decades, SCLC continues to 
represent an almost fatal disease due to its propensity to local relapse and distant 
metastasis, despite initial responsiveness to therapies. Biological behaviour of SCLC has 
therefore lead to consider it as a systemic disease per se not amenable of surgical resection: 
the Veterans Administration Lung Study Group (VALSG) two-stage classification was in 
fact based on field irradiation criteria and has been applied to SCLC for long-time. 
The introduction of TNM staging system, the common recurrences of local disease despite 
initial complete response after chemo-radiation therapy, the lack of a valid maintenance 
therapy after remission or a second-line therapy after relapse renewed interest in surgery in 
a multimodal treatment setting. However, the second prospective randomized trial in 1994, 
did not confirm any significant advantage of surgery compared to chemo-radiation therapy 
and several retrospective studies published in the same years failed to provide strong 
evidences of surgery's benefits. Lack of homogeneity in design of clinical trials, which are 
mostly dated, patients selection and other confounding factors made results of meta-
analysis too much inconsistent to be added to guidelines; for these reasons, nowadays, 
surgery is recommended only in small peripheral nodules without nodal involvement 
(proven by invasive preoperative staging). 
Advances in comprehension of biological pathways underlying carcinogenesis in SCLC are 
the next steps that could deeply modify the approach to disease (patients selection and 
prognostic stratification, chemosensitivity and treatment modality) beyond the mere 
histology. Molecular profile should lead to identify subsets of tumours with more 
favourable prognosis, especially in terms of systemic control of disease, which is actually a 
major issue in SCLC; these subsets could be overlapped to NSCLC regarding to natural 
history of disease, making their treatment similar, including indication to surgery. 
The aim of this review is to analyze literature to deduce which has been, is actually and 
could be the role of surgery on overall survival and pattern of recurrence of patients affected 
by SCLC. 
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2. Clinical background 
2.1 Epidemiology 
Small-cell Lung Carcinoma (SCLC) accounts for approximately for 13-15%% of all newly 
diagnosed cases of lung cancer worldwide (in United States, more than 220.000 new cases 
lung carcinoma were diagnosed in 2010, with about 160.000 cancer-related deaths 
[American Cancer Society, 2010]. 
More than 90% of patients with SCLC are elderly, current or past heavy smokers, and risk 
rises with increasing duration and intensity of smoking [Devesa et al., 2005]; rare cases have 
been reported in people who never smoked [Antony et al., 2010].  
Incidence of SCLC is decreasing compared to that of adenocarcinoma [Govindan, 2006]; this 
reflects the decreased prevalence of smoking in industrialised countries. However, the 
burden of disease is shifting to developing countries (Asia and Eastern Europe), where, on 
the contrary, an increase of incidence is expected in next years. Further investment in 
research against SCLC is therefore warranted.  
A revision in the WHO classification of lung cancers might also have contributed to 
incidence falling of SCLC, as some borderline cases previously described as mixed subtypes 
are now classified as NSCLC [Travis et al., 2004]. 
Median survival of untreated patients ranges from 2 to 4 months from diagnosis: historical 
data of untreated patients come from an old study of VALSG (Veterans Association of Lung 
Study Group) comparing cyclophosphamide to placebo. In IASLC (International Association 
for Study of Lung Cancer) database for staging project (the largest series of SCLCs reported), 
5-year survival rates were 38/21% for clinical stages IA/IB and 38/18% for clinical stages 
IIA/IIB, respectively. Considering only resected, fully staged patients, 5-years survival rates 
were 53/44% for p-stages IA/IB and 43/35% in p-stages IIA/IIB, respectively.  
2.2 Clinical presentation 
Two thirds of SCLCs present as peribronchial lesions with infiltration of bronchial 
submucosa. Extensive mediastinal lymph node metastases are a common finding at 
diagnosis; sometimes mediastinal involvement presents as “bulky” disease, causing 
superior vena cava syndrome. Only in 4-12% of cases SCLC presents as a peripheral “coin 
lesion” [Quoix et al., 1990]. 
Clinical presentation of SCLC is strictly related to stage and presence of paraneoplastic 
syndrome. Common symptoms are cough, wheeze, dyspnoea, haemoptysis for hilar 
localization. Symptoms may reflect direct involvement of chest wall, superior vena cava, 
oesophagus, recurrent nerve (pain, mediastinal syndrome, dysphagia, dysphonia) or the site 
of metastasis (brain, liver, adrenal glands, bone and bone marrow). SCLC is more frequently 
associated to paraneoplastic syndromes than NSCLC [Gandhi et al., 2006]. The most 
common are syndrome of inappropriate antidiuresis (15-40% of SCLC patients) and 
Cushing's syndrome (2-5% of SCLC patients), that can be responsible of infective 
complications during chemotherapy. Sometimes SCLC presents with dermatological 
abnormalities as acquired tylosis, trip palms, erythema gyratum repens [Master et al., 2010]. 
Occasionally SCLC is associated to dermatomyositis, hyperglycemia or hypoglicemia, 
hypercalcemia and gynecomastia. Neurological syndromes, that may precede diagnosis of 
SCLC by several months, are caused by cross-reaction of auto-antibodies and T-lymphocytes 
specific for common tumour epitopes and nervous components  [Darnell et al., 2003]. 
Antibodies directed against the P/Q- type voltage-gated calcium channel in the presynaptic 
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nerve terminal (expressed by 3% of SCLC) are responsible of Lambert-Eaton syndrome 
[Payne et al., 2010], that should be differentiated from miastenia gravis, rarely associated to 
SCLC. Similarly, paraneoplastic encephalomyelitis and paraneoplastic sensory neuropathy 
have been associated with antibodies directed against Hu proteins, a family of DNA-
binding proteins (<1% of SCLC patients) [Gultekin et al., 2000]; neurological symptoms are 
not always reversible with therapy. 
2.3 Diagnosis 
Although diagnosis of SCLC could be suspected on the basis of clinical and radiological 
findings, histo-patological diagnosis is required prior to establish the proper treatment.  
SCLC represents the extreme of spectrum of neuro-endocrine lung carcinomas and is 
defined as pure SCLC or combined SCLC if the non small-cell component accounts for at 
least 10%of burden disease. 
While pre-invasive and in situ lesions are frequently found in NSCLC, they are uncommon 
in SCLC [Kumar et al., 2005]. 
Samples can be obtained by bronchoscopy biopsy or fine-needle aspiration from primary 
tumour, lymph nodes or other metastatic sites. Since tumour shows propensity to spread 
through tunica submucosa, superficial bronchoscopic biopsy or brush may be falsely 
negatives. Colliquative necrosis can sometimes hamper diagnosis, especially for cytological 
samples; however there is a good interobserver agreement among pathologists for 
differential diagnosis with NSCLC. Immunohistochemistry is used in difficult cases:  less 
than 10% of SCLC tumours are negative for all neuroendocrine markers (chromogranin, 
synaptophysin, and CD56. Positivity for TTF-1 and cytokeratins helps to distinguish them 
from lymphomas and other small-cell tumours [van Meerbeeck et al., 2011] 
2.4 Staging 
Historically, SCLC had been classified according to the Veterans Administration Lung Study 
Group (VALSG). In 1957 the VALSG created a dichotomous staging system that took into 
account the aggressive behaviour of SCLC and the standard of care at that time. This 
classification underlined the highest importance of radiation therapy and allowed a better 
selection of patients for this kind of treatment.  
The Limited Disease (LD) was characterized by a tumour volume encompassed in one 
radiation portal (30% of cases): all that was not comprised in one radiation portal was 
classified as extensive stage (ED), including malignant pleural effusion and haematogenous 
metastases. [Zelen et al., 1973]. In 1989 the International Association for the Study of Lung Cancer 
modified the VALSG staging including all non-metastatic patients in the limited stage 
[Stahel et al., 1991] (Tab.1).  
More recently, in 2007, the IASLC based on a retrospective analysis of survival of 8088 
patients with SCLC recommended the TNM classification system also for SCLC [Shepherd 
et al., 2007]. This suggestion comes from the evidence of significantly worse survival of 
patients with limited-stage disease and N2-N3 lymph node involvement, than for those with 
N0-N1 lymph node involvement. Patients with pleural effusion without extrathoracic 
metastasis showed a survival intermediate between stage III and stage IV. In the TNM 
classification patients with cytology-negative pleural effusion are classified as having stage 
III disease. This classification is used less frequently in clinical practice because it relies on 
surgical confirmation for its accuracy and patients with SCLC seldom present at a stage for 
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which surgery is appropriate (in IASLC database only 349 patients out of 12.620 affected by 
SCLC were resected, representing only 2,8%). 
 
VALSG staging TNM staging 
Limited Disease: disease encompassed 
within a tolerable radiation therapy portal 
 Tumour confined to one hemithorax 
 Involvement of ipsilateral and 
contralateral mediastinal nodes 
 Involvement of ipsilateral 
supraclavicular nodes 
 Ipsilateral pleural effusion 
From IA to IIIB 
Extensive Disease: any other IV 
Table 1. Comparison between VALSG and TNM staging 
Considering the therapeutic options (chemotherapy and radiotherapy) representing, to date, 
the standard of care, it could be argued that the more precise staging of SCLC using the 
TNM system does not provide extra benefits to select the treatment modality. However 
TNM has been shown to be prognostic of outcome [Micke et al., 2002], and a more precise 
definition of nodal involvement may be relevant for radiation treatment. Moreover, surgery 
for limited disease (T1-2, N0, M0) is nowadays considered a valid therapeutic option 
[Varlotto et al., 2011]. For these reasons clinicians and cancer registrars recommend to 
classify SCLC with the TNM staging system [Shepherd et al., 2007]. This recommendation is 
particularly strong for those trials in LD addressing thoracic and prophylactic cranial 
irradiation questions and those that include a surgical treatment arm [Vallieres et al., 2009]. 
In the future a better definition of N stage is needed and prognostic difference in patients 
with or without cytology-positive pleural and/or pericardial effusions must be addressed. 
To assess the extent of disease, which remains the main prognostic factor, several staging 
tests are available; their execution sequence should be guided by the patient’s signs and 
symptoms at presentation and the availability of the diagnostic tests. Staging should be 
accurate and fast, considering the rapid growth of SCLC. Staging work-up should include 
full medical history, physical examination, chest X-ray, hematology and chemistry panels 
including differential blood count, liver and renal function tests, lactate dehydrogenase 
(LDH) and sodium levels (hyponatremia, due to ectopic production of antidiuretic hormone 
or atrial natriuretic peptide, is observed in up to 15% of patients), pulmonary function tests, 
and contrast-enhanced CT of the chest and upper abdomen. SCLC displays the propensity 
for early distant metastases to liver, bones, adrenal glands, and above all brain. Therefore, in 
patients with suspect for distant metastases, additional tests may include bone scintigraphy, 
CT scan with intravenous contrast or MRI of the brain, and bone marrow aspiration and 
biopsy. Bone marrow is involved in 15 to 30 percent of patients at presentation, but it 
represents rarely a solitary site of metastatic disease (2 to 6%). Bone-marrow infiltration 
should be suspected in presence of an isolated rise in lactate dehydrogenase (LDH) 
concentration or blood counts indicating otherwise unexplained anemia or a 
leucoerythroblastic response or if bone scan is positive [Campling et al., 1986]. CT or MRI of 
the brain are recommended if chemo-radiation with curative intent is under consideration. 
In one report, the prevalence of brain metastases was 10% with CT and 24% with MRI. In 
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this series all CT-detected brain metastases were symptomatic, whereas 11% of those 
detected by MRI were asymptomatic [Seute et al., 2008]. Chest CT scan, abdominal CT scan, 
brain MRI and bone scintigraphy are mandatory in the evaluation of patients amenable to 
surgery [Koletsis et al., 2009]. Fluorodeoxyglucose (FDG) uptake is usually high in SCLC, 
leading to a sensitivity of nearly 100% but its routine use in SCLC remains controversial 
[Thomson et al., 2011]. PET is, anyway, useful to plan radiotherapy in some countries [Van 
Loon et al., 2010]. Pathological confirmation is still required for PET-detected lesions that 
could result in upstaging, in particular if radical resection could be offered. The role of 
combined fluorodeoxyglucose PET (FDG-PET) and CT scanning is yet to be completely 
defined but, if available, it may be useful to improve the accuracy of staging by the detection 
of mediastinal nodal and occult distant metastatic spread. In patients who present with 
pleural effusion, in the absence of extrathoracic disease, cytopathologic confirmation of 
tumour involvement is needed. 
With improvements in staging through the use of PET/CT and magnetic resonance imaging 
(MRI), more patients are found to have ES-SCLC: the ratio of LS-SCLC to ES-SCLC was 
formerly 1:1 and is now 1:3 as more subtle lesions, such as silent adrenal and brain 
metastases, are identified. 
If extensive disease is detected by one test, further staging can be omitted, although bone 
scintigraphy may be used to identify symptomatic lesions amenable of palliation 
radiotherapy and brain CT/MRI could be performed or repeated in patients who respond to 
treatment in order to plan a brain irradiation of symptomatic lesions or to plan PCI in 
absence of metastasis (since PCI has been extended to ED-SCLC responsive to primary 
treatments) 
2.5 Prognosis 
Stage is the major prognostic factor of survival but some other prognostic factors have been 
identified: performance status, weight loss, sex and some laboratory tests (CEA, LDH, NSE, 
hypoalbuminemia, elevated alkaline phosphatase). No histological or molecular features 
have been validated yet. Several algorithms have been elaborated for predicting survival but 
the reliability for individual patients remains poor. Paraneoplastic syndromes are more 
frequently found in patients with limited-stage SCLC and they are considered positive 
prognostic factors. 
3. Historical background of SCLC 
SCLC was firstly recognized by Barnard in 1926, who noted that “oat-cell sarcomas of the 
mediastinum” were metastatic carcinomas of the lung instead.  
In the 85 years of SCLC life, some milestones should be reminded: 
1959: Pathogists recognized SCLC as a separate entity among carcinomas of the lung and 
Azzopardi defined six features of cells at light microscopic examination [Azzopardi, 1959] 
1963: VALSG introduced the 2-stage system for SCLC 
1969: British Medical Research Council reported better survival of radiotherapy arm versus 
surgical arm in the first clinical randomized trial on SCLC [Miller et al., 1969]. 
Cyclophosphamide showed to be effective against lung cancer [Green et al., 1969] 
1979: Medical Research Council showed advantage in survival with combination of 
chemotherapy (cyclophosphamide) and radiation therapy compared with radiation alone in 
LD-SCLC [Medical Research Council Lung Cancer Working Party, 1979] 
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1982: Shields re-evaluated surgery as initial treatment in SCLC after introduction of TNM 
staging system [Shields, 1982] 
1987: Adding RT to chemotherapy improved survival in LD-SCLC [Perry et al., 1987] 
1989: The International Association for Study of Lung Cancer (IASLC) was revised for the 
first time by its introduction the Veterans Administration Lung Study Group staging system 
[Stahel, 1989] 
1994: Lung Cancer Study Group published results of the first (and unique, so far) 
perspective randomized trial in LD-SCLC comparing surgery to RT after induction 
chemotherapy: Authors concluded that surgery offered no advantage in terms of either 
survival or local control of disease. 
1995-1999: Prophylactic Cranial Irradiation (PCI) showed to improve overall and disease-
free survival in selected patients (responders to first-line treatments) [Aupérin et al., 1999] 
1999: studies of dose fractionation of RT demonstrated that twice-daily administration was 
superior compared to once-daily in terms of local control and overall survival [Turrisi et al., 
1999] 
Combining this dates we can schematically recognize three periods.  
3.1 The “Surgical Era” (early 1900-1960s) 
The dramatic increase of tobacco consumption in early 900’s produced a sharp increase of 
incidence of SCLC; on the other hand, prevalence of pulmonary tuberculosis and chest 
wounds during World Wars promoted advances in thoracic surgery and lung resections. 
Surgery was considered the standard of care for Small-Cell as well as Non small-cell lung 
cancer. However high rates of recurrence (both local and distant), even after apparently 
complete resection, were observed. Results published by British Medical Council Group in 
first clinical prospective trial randomizing patients affected by SCLC to either surgery or 
thoracic radiation therapy reported the slight advantage in survival of RT arm. This was 
enough to abandon surgery at least for primary therapy for SCLC. Dichotomous staging by 
Veterans Administration Lung Cancer Study Group (1968) reflected and anticipated the 
centrality of RT as primary treatment for local control of disease 
3.2 The “advent of Chemotherapy” (1960s-1980s) 
Few years later report of British Medical Council, the pathology study conducted by 
Matthews in autopsies of patients deceased within 30 days of attempted curative resection 
showed that SCLC had, in almost all patients, microscopic but widely metastatic disease 
[Matthews et al., 1973]. This enforced the importance of accurate staging of disease and 
promoted the need of systemic control of disease. The chemosensitivity of SCLC was first 
recognized in 1940s when nitrogen mustard (methyl-bis-B-Chloro-ethyl amine 
hydrochloride) demonstrated capability of inducing tumour regression in more than 50% of 
patients. Despite a large amount of active drugs towards SCLC, it was perceived quite early 
that single-agent regimens were associated to frail remissions and high rates of precocious 
recurrences. In 1970s combination chemotherapy, mainly based on cyclophosphamide 
showed dramatic responses, even in very incapacitated patients, although long term 
disease-free survival remained disappointing and natural history of disease did not seem to 
change. Chemotherapy became the standard of care also in limited disease when Medical 
Research Council demonstrated the advantage of a combination of cyclophosphamide and 
radiation compared with radiation alone. During the 1970s thoracic radiation was relegated 
to an adjuvant, “consolidative” role in LD-SCLC.  
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3.3 Evolution of combined modality treatment (1980s-today) 
The last period could be considered as “quiescent”: no tools against disease proved to be 
revolutionary and efforts were made towards integration of multimodal approach. 
Paradigms and flow charts of treatment did not reflect the chronological sequence of most 
important studies but rather controlled studies and consensus expressed by expertise panels 
of Authors. Etoposide and platinum became from 1980s the first-line treatment. An 
important study from National Cancer Institute (NCI) in 1976 firstly tested a very aggressive 
protocol involving simultaneous irradiation of brain, primary tumour and mediastinum and 
concomitant CAV chemotherapy (cyclophosphamide/doxorubicine/vincristine). Despite 
unacceptable toxicity (radiation pneumonitis in 38%, mielodepression with fatal sepsis in 
24%), this regimen showed the best results, never reached before (nearly 100% complete 
remissions, 80% of long term survival) [Greco et al., 1979]. This work firstly recognized the 
importance of tumour repopulation by clones of cells whose resistance was allowed by 
sequentiality of treatments. Efforts were made in order to minimize tissue interaction 
without compromising delivery of both radiation and chemo-therapy: timing of radiation 
therapy [Perry et al., 1987] and dose fractioning [Turrisi et al. 1999] were largely studied by 
various Authors.  
In this period surgery revived with first report from Shields and coll. who concluded that 
primary surgery and adjuvant chemotherapy could be offered to patients with SCLC in 
early stages (i.e. T1N0). A large number of subsequent studies (discussed in the chapter) 
reported favourable long-term survival after surgery with improved local control of disease: 
one of the most remarkable experience was that of Toronto Group [Shepherd, 1983]. 
Undoubtedly, advances in both imaging and invasive staging tools (spiral CT, PET/CT, 
FNA-EBUS) lead to a more precise stratification of disease, allowing selection of patients in 
really “limited” disease amenable for radical resection. Application of TNM staging as used 
for NSCLC eliminated one of the barriers that divided SCLC and NSCLC and contributed to 
better define prognosis of patients previously classified as having Limited Disease (an 
heterogeneous stage ranging from isolated coin lesion to extensive hilar mass with 
supraclavicular node metastasis). 
Times were mature for another clinical perspective randomized trial involving surgery: it 
was started by Lung Cancer Study Group in 1983 and ended in 1994. Results again excluded 
a benefit of surgery even on a multimodal approach, but did not prevent further Authors to 
report their retrospective experiences on surgically resected SCLC, criticizing at the same 
time this study. 
Main changes of treatment modalities in SCLC are summarized in Fig. 1 
 
 























Fig. 1. Evolution of treatment modalities through decades 
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4. Current guidelines for treatment (NCCN/ACCP)  
It should be noted that guidelines for the treatment of SCLC are based on review of a 
literature that lacks of big randomized prospective trials and is heterogeneous regarding to 
kind of treatment, timing, endpoints and selection of patients. 
The National Comprehensive Cancer Network (NCCN) has recently developed a review of 
its guidelines, declaring that every recommendation for SCLC has to be considered category 
2A, because they are “based upon lower-level evidence” but “uniform NCCN consensus 




Table 2. NCCN category of recommendation. 
The American College of Chest Physicians (ACCP) in 2007 produced a systematic literature 
review resulting in evidence–based guidelines, graded upon the “ACCP grading system for 
guideline recommendations” 
Both documents debate on diagnostic and therapeutic options for SCLC and are quite 
similar in recommendations, except for the use of PET (not yet standardized in 2007 ACCP 
guidelines) and for the choice of staging system (NCCN recommending the use of the new 
TNM instead of Veterans Administration Lung Study Group classification). 
Guidelines for treatment have a key point in the use of platinum-based chemotherapy plus 
radiotherapy for all fit patients (Performance Status 0-2) with limited stage disease, followed 
by Prophylactic Cranial Irradiation (PCI); topics of discussion are timing of radiotherapy 
(concurrent versus sequential, early versus late), volume, dose and fractionation of radiations, 
treatment of unfit-elderly patients, maintenance and second line chemotherapy and surgery. 
Cisplatin has to be preferred to Carboplatin in combination with Etoposide in first line 
treatment; in phase III randomized trials, Irinotecan was substituted for Etoposide in 
combination with Carboplatin in advanced disease with mild improve in survival and thus 
being added to guidelines as an option for patients with extensive-stage disease. In these 
patients, where the treatment of choice is chemotherapy alone with initial response of about 
60-70% but median survival of 9-11 months due to early relapse, maintenance or 
consolidation chemotherapy beyond 4 to 6 cycles is currently not recommended outside 
clinical trials (grade of recommendation IB); likewise, the introduction of a third agent 
(alkylating agent with or without anthracycline) showed minor advantage in duration of 
response without improving survival and carried greater cumulative toxicity. The use of 
cytochine or anti-angiogenetic agents (i.e. Bevacizumab) is not currently recommended in 
first line treatment, even though randomized phase III trials are currently running. 
Second line treatment is generally a single agent therapy, administered with an interval of at 
least 3 month since initial therapy (otherwise disease has to be considered refractory or 
resistant) and should be given until 2 cycles beyond best response, progression of disease, 
development of major toxicity.  
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The addition of thoracic radiotherapy has improved survival in patients with limited stage 
disease (grade of recommendation 1A); staging of SCLC actually involves relationship 
between extension of disease and radiation port field. As far as timing is concerned, early 
(within 30 days to 9 weeks since the beginning of chemotherapy) concurrent chemo-
radiotherapy is recommended for patients with limited-stage disease (grade of 
recommendation 1A). Hyper-fractionation of radiation dose has not yet being correctly 
compared to once-daily administration in available trials, according to NCCN review of 
literature. 
PCI given after completion of chemotherapy in a low dose per fraction causes less 
neurological toxicity and prevent the emergence of brain metastasis, both in limited and 
extensive stage disease; it is recommended for fit patients who achieve a complete or partial 
response to initial treatment (Grade of recommendation 1B). 
Radiotherapy is also recommended in relapse for palliation of symptoms. 
The European Society of Medical Oncology (ESMO) in the 1st consensus conference in lung 
cancer stated guidelines for diagnosis, treatment and follow up of SCLC, underlying the 
absence of randomized trials comparing surgery with concurrent chemo-radiotherapy. 
Nevertheless, with grade of recommendation III D, surgical resection may be considered for 
very limited disease (T1-2, N0), only after histological confirmation of N parameters by 
mediastinoscopy, followed by PCI. 
ACCP guidelines stress the importance of invasive mediastinal staging, with grade of 
recommendation 1A. NCCN guidelines specify that lobectomy has to be preferred if 
resection is performed and that adjuvant chemotherapy alone is recommended for patients 
without nodal metastasis, while mediastinal RT has to be added in case of nodal 
involvement (Fig. 2) 
5. Studies regarding surgery in SCLC 
Except from those by British Medical Council and Lung Cancer Study Group, all studies 
focused on surgery in SCLC are retrospective or prospective non-randomized, so 
conclusions should be interpreted cautiously.  
However, also those phase III trials have been criticised on several points.  
The British Medical Council study, dated 1963, did not include patients with peripheral lung 
lesions, since  preoperative evaluation and diagnosis were made using rigid bronchoscopy 
available at that time; secondly, rate of complete (R0) resection was low (approximately 
50%) compared to resections for NSCLC; finally, staging was performed without modern 
tools, like contrast CT-scan or PET, nor histological confirmation by mediastinoscopy was 
obtained. So it is likely that a remarkable number of patients with occult intrathoracic and 
extrathoracic disease was included in the study and randomized to surgery, compromising 
the long term survival results. 
Twenty years later, after advent of chemotherapy as standard primary treatment, times 
were mature for another randomized trials, set up by Lung Cancer Study Group in 1983. 
Eligibility criteria include LD stage, according to VALSG staging: this means that also 
patients with clinical evident mediastinal adenopaties were included in the study. 
Conversely, patients with peripheral nodules and normal bronchoscopy were specifically 
excluded from the study. Induction therapy was quite heterogeneous (anthracycline based 
regimen) and only 144 of 340 patients (42%) accrued in the trial were randomized (68 to 
surgery arm and 76 to radiotherapy arm). Six patients randomized to surgery refused  
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Fig. 2. NCCN clinical practice guidelines 
thoracotomy and, on the contrary, eight patients requested surgical intervention and 
received off-randomization surgery, representing a significant cross-over (10%) between the 
two arms. Moreover, few other data should be pointed out: only 65% of patients responded 
to induction chemotherapy, in 17% of patients assigned to surgery only exploratory 
thoracotomy was performed and, above all, the high proportion of patients included with 
bulky N2 or N3 nodal metastasis (who unlikely achieved a complete mediastinal 
downstaging). Interestingly N status and post-treatment clinical stage did not influence 
resectability (a result correlated with clinical understaging).  
The conclusion of the study was that surgery did not add any benefit neither in terms of 
survival nor of pattern of recurrence. 
The same results were anticipated in a retrospective study of 1985 based on 33 operated 
patients compared to 46 patients who fulfilled criteria of operability and resectability but 
were treated with non-surgical management. However microscopic or macroscopic residual 
disease was left in half of patients, suggesting that clinical staging was not so accurate in 
predicting resectability of disease [Østerlind, 1985] 
Considering these weak points, rejection of surgery did not discourage several Authors, 
which continued to report good results with surgery combined to either induction or 
adjuvant chemotherapy and radiotherapy in some cases. 
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Rostad et al. analyzed 2442 patients with SCLC in a national survey in Norway, 38 of which 
were surgically resected (25 received adjuvant therapies). For stage I addition of surgery to 
conventional treatments (chemo-radiation) improved 5-year survival rate from 11.3% to 
44.9%, so Authors concluded that patients with resectable disease in stage I should be 
referred to surgery [Rostad, 2004]. 
The same conclusion is reported by Leo and Pastorino in their review [Leo & Pastorino, 
2003] for T1-2N0M0 patients which can be treated by surgery and adjuvant chemotherapy, 
while patients in stage II-III should undergo surgery only in the context of clinical trials. 
Rea et al. reported a 32% overall survival in 104 patients with SCLC surgically resected, 
despite a remarkable percentage of stage III (43.3%), which resulted as a major negative 
prognostic factors [Rea, 1998] 
Brock et al reviewed their institutional experience of 1415 SCLC among whom 82 (6%) 
underwent surgery with curative intent from 1976 to 2002 [Brock, 2005]. Surgery was 
accompanied by induction or adjuvant chemotherapy in 77% of patients. Authors found a 5-
year survival of 85.7% for stage I SCLC (similar to that historically expected for completely 
resected stage I NSCLC without adjuvant chemotherapy). Favourable prognostic factors 
were early stage, lobectomy as surgical procedure, female gender and date of intervention 
after 1987 (a surrogate marker for availability of platinum based chemotherapy). Pattern of 
recurrence was not reported in this study, however Authors concluded that lobectomy plus 
platinum based chemotherapy is a feasible option yielding excellent results in T1-T2N0-M0 
SCLC. 
High 5 years survival rate was reported also by Tsuchiya in a retrospective series of patients 
treated with a similar protocol [Tsuchiya, 2005]. Interestingly, Authors reported only 10% of 
local failure after surgery, which is lower than commonly reported after chemo-radiation 
therapies alone. 
Badzio and coll. in a retrospective series of patients treated with surgery or non-surgical 
management reported a significative improvement in survival in surgical resected patients 
(22 months Vs 11, P<0.001) [Badzio, 2004]. The control group of patients treated with chemo-
radiotherapy was built using pair-matched case-control according to main prognostic 
factors, stage and resectability; moreover diagnosis of surgical treated patients was 
established only postoperatively, thus minimizing some bias related to selection of patients. 
In 2006 the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of 
Pneumology and Thoracic Surgery (GCCB-S) presented a multicenter study on 47 patients 
with SCLC out a total of 2994 lung cancers resected [Gomez de Antonio, 2006]. Thirty-three 
% of patients had incomplete resection suggesting that the criteria for surgery were not 
predictable enough for resectability. The routine use of mediastinoscopy (performed only in 
19% of cases) might have identified some of the patients whose clinical staging was 
underestimated and which added to low rate of respectability. Moreover a low proportion 
of patients received adjuvant treatments. These factors accounts for an overall survival 
which does not exceed that reported in literature for patients with possibly more advanced 
stage managed with chemo-radiotherapy. 
Recently, Schreiber and coll. analyzed patients included in the Surveillance, Epidemiology 
and End Results registry (SEER), which is the cancer registry representative of United States 
[Schreiber, 2010]. Among 14.179 patients affected by SCLC coded as localized (T1-2Nx-0) or 
regional disease (T3-4Nx-0), 863 (6%) had undergone surgical resection, making them one of 
the larger population based cohort ever reported in literature. Overall 5-year survival rates 
were 26.3 Vs 9.3% (P=0.01) in favour of surgery with median survival of 22 Vs 12 months, 
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respectively. Advantage of surgery to survival was much more substantial in N0 patients 
(median survival 40 Vs 15 months), which on the other hand did show benefit from addition 
of PORT (Post-Operative Radiation Therapy). These data seem to suggest that radical 
surgery alone could be adequate for local control of disease and, conversely PORT may be 
detrimental for survival. Another retrospective analysis of SEER database conducted in 2010 
and focused only on stage I confirmed reasonable outcome in patients who underwent 
lobectomy without PORT [Yu et al., 2010]. Unfortunately both studies, although based on 
large population, lack of data concerning chemotherapy, margins of resection, pathologic 
confirmation of diagnosis and performance status (not recorded in SEER database). 
 
Study Number of 
patients  
Treatment Modality Local 
recurrence 
5-year survival 
Fujimori, 1997 22 PE x 2/4  S 5% Cumulative: 66.7% (3-year) 
Stage I-II: 73.3% (3-year) 
Stage IIIA: 42.9% 
Lucchi, 1997 127 S (15) 
S  CT (RT) (92) 





Cumulative:  22.6% 
47% in stage I 
0% in N2 patients 
0% with surgery alone 
Eberhardt, 
2003 
46 Stage I-IIA: PE x 4  S 
Stage IIB-IIIA: PE x 3 
 CTRx (HfRTx)  S 
0% Cumulative: 39% 
 




Cumulative: 27% (4% 
CTRx) 
Stage IA: 59% 
Rostad, 2004 38 S 
S  adjuvant 
n/a Stage I: 44.9% 
Brock, 2005 82 (CT)  S  (CT)  Stage I: 58% 
Stage II: 18% 
Stage III: 23% 
Stage IV: 0% 
Tsuchiya, 2005 62 S  PE x 4 10% Stage IA/IB: 73/67% 
Stage II: 38% 
Stage III: 39% 
Granetzny, 
2006 
95 S  CTRx (Stage I) 
CT  S  CTRx 
(Stage III) 
n/a Median survival (months) 
31.3 (Stage I) 
31.7 (Stage III – 
downstaged) 




47 CT  S (3) 
S  CT (30) 
S (14) 
n/a Cumulative: 26% 
R0 resection: 31% 




S  RT 
CT data n/a 
 Cumulative: 34.6% 
Stage I: 44.8% 
Stage II-III: 26.3% 
S: surgery, CT: chemotherapy, CTRx: chemoradiation therapy, PE: Platinum-Etoposide, HfRTx: 
Hyperfractioned Radiation therapy 
Table 3. Some of the recent trials supporting the role of surgery 
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A current year report on a small series of patients (28) underlines the low rate of local failure 
(3/28) after surgery compared to distant (especially brain) metastasis, which confirms the 
role of PCI [Ogawa et al. 2011] 
5.1 Rationale of surgery in SCLC 
As pointed out by Anraku and Waddell [Anraku, 2006] in their review, rationale of surgery 
can be can summarized in the following clinical presentations. 
 Small peripheral coin lesions: typical or atypical carcinoids may be misdiagnosed as 
SCLC since their diagnosis is often made on cytological samples obtained by either 
trans-thoracic fine needle biopsy or trans-bronchial biopsy by bronchoscopy 
 Combined histology tumours: definitive histology of tumours initially diagnosed as 
pure SCLC reveals a Non Small-Cell component in 11-25% [Asamura, 2006]. 
Percentages are higher in surgical reports possibly due to the fact that combined SCLC 
tends to arise peripherally and resection is feasible more frequently and because a 
larger amount of tissue for individuation of both components is available with surgical 
specimen [Mangum, 1989]. Although prognosis is mainly determined by the 
aggressiveness of Small-Cell component, the Non Small-Cell one may fail to 
chemoradiation protocols commonly used against SCLC being responsible of weak 
responses or early relapses. 
 Early stages (T1-2N0M0) benefit of surgical resection in terms of improved local control 
of disease: first site of recurrence (which occurs in approximately 50% of cases after 
concurrent chemo-radiation protocols [Turrisi, 1999]) is the tumour bed site followed by 
hilar/mediastinal lymph nodes, even in patients who achieve complete pathological 
remission [Elliott, 1987]. Adjuvant radical resection (i.e. with R0 margins) after 
induction chemoradiotherapy has shown local control of disease in almost all cases and 
this is reflected in a slight advantage in long-term survival [Eberhardt, 2003]. Table with 
local recurrences and survival 
 If general criteria for operability and resectability are met, adjuvant “salvage” surgery 
is preferable in cases of a chemotherapy resistant tumour or early local relapse (usually: 
3 months) after an initial response, compared to second-line therapies which are often 
uneffective against SCLC. In their report, the Toronto Group identified a small subset of 
patients without node metastasis that benefit from salvage surgery). A second biopsy, if 
feasible, is worthy to be considered before surgery [Shepherd, 1991] to demonstrate a 
NSCLC component. 
 New metachronous tumours appearing two years after a SCLC successfully treated 
patients could be second primary NSCLC and after a complete re-staging should be 
surgically resected even if histology can not be obtained preoperatively [Anraku, 2006] 
5.2 Patient selection criteria and choice of surgical procedure 
If a diagnosis is obtained preoperatively, pathologists should exclude any possible 
coexisting NSCLC component. Even more than in NSCLC, accurate staging is crucial before 
planning surgery in fit patients, as discussed before. Toronto Group demonstrated better 5-
year survival (18% vs 6%) in patients without mediastinal nodes involvement 
preoperatively [Shepherd, 1991]; in a recent phase II trial on surgery after induction 
chemotherapy only patients who achieved complete nodal downstaging had a fair survival. 
Mediastinoscopy and eventually re-mediastinoscopy after primary treatment is therefore 
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recommended to detect nodal involvement which is microscopic and subclinical in a 
considerable percentage of patients. This matter accounts for discordance between clinical 
and pathological staging in SCLC. 
If a SCLC is diagnosed in operative theatre at frozen section of specimens, radical resection 
(preferably lobectomy) is recommended if intraoperative histological examination of 
mediastinal lymph nodes does not reveal metastasis; however, surgery can be proposed to 
patients with mediastinal nodes micrometastasis  if they can easily tolerate the procedure. 
Sublobar resections are recommended in less fit patients or in presence of nodal 
involvement. 
6. Targeting the complex biology of SCLC 
First cytogenetic studies, dated 1982, found that a deletion on chromosome 3p was present 
in 95% of SCLC [Whang, 1982]. This chromosomal region contains tumour-suppressor genes 
relevant to the pathogenesis of the tumour e.g. RARβ [Naylor 1987, Kok 1987] and FITH 
[Franklin, 2010]. The 3p loss alone is not specific of SCLC, since it is frequent encountered 
also in other tumours. Thanks to the high-throughput technology as comparative genomic 
hybridization (CGH) and gene expression arrays, researchers discovered that in 90% of 
SCLC samples, the most frequent sites of chromosome loss are 3p, 5q and 13q, the last 
determining the loss of  retinoblastoma gene (RB1) [Ried, 1994]. Mutation studies on biology 
of SCLC showed that this type of tumour has frequent mutation in the gene encoding for 
p53 protein (TP53) [Hanahan, 200] but rarely presents mutation in the tyrosine-kinase 
signalling gene including KRAS and EGFR [Franklin, 2010], which are actually the most 
known pathways with larger number of active drugs (mainly tested in lung 
adenocarcinomas). 
Targeted cancer therapies are drugs or antibodies that block the growth and the spread of 
cancer by interfering with specific molecules involved in tumour growth and progression. 
These therapies are being studied for use alone, in combination with other targeted 
therapies, and in combination with other cancer treatments, such as chemotherapy. By 
blocking signals that make cancer cell grow and replicate, targeted cancer therapies can help 
to stop cancer progression and may induce cancer cell death through apoptosis. 
To give an example the PI3K/AKT/mTOR intracellular pathway is chronically activated in 
SCLC through inactivating mutations in PTEN gene and this activation pathway correlates 
with sensitivity to Everolimus in vitro [Marinov, 2009]. Furthermore, the amplification of 
BCL-2 genes seems to be correlate with the sensitivity to the highly potent small-molecule 
called ABT-737 suggesting that patients with bcl-2 protein over expression, may have some 
benefits from bcl-2 inhibitors [Olejniczak, 2007]. In SCLC cell lines, microRNA and gene-
expression signatures of chemo-resistance have been described [Guo, 2010] and several 
inhibitors of growth factor pathways implicated in SCLC are in clinical development 
(NCT00896752); the compound PD173074 induces apoptosis in vitro and in vivo in SCLC by 
inhibition of  FGF2 signalling [Pardo, 2009].  
The targeting of specific molecules has been already studied in several trials, even though 
with limited success. One of the emerging need in clinical research dealing with SCLC is 
inadequacy of preclinical models of disease used to date. Cancer-cell-line-based xenograft 
models employed as standard testing ground especially for drugs have revealed as a 
surrogate of disease. In vitro activity level is then weakly predictable of clinical efficacy thus 
explaining the high rates of failure of new drugs tested in clinical studies. Human cancers 
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cells, compared to cancer-cell cultures, grow up in hypoxic and nutrient-poor complex 
environments which promotes continue selection of  more aggressive cell-clones. This 
explains the reason why cell-line-based SCLC xenografts tend to grow as relatively indolent 
tumours, while corresponding human disease is characterized by aggressive clinical and 
biological behaviour. 
Moreover, as for standard chemotherapy, the use of a single molecular target drug in such 
complex malignancy as SCLC, is wrong. The inhibition of multiple targets or the 
combination with standard chemotherapic agents are likely to have greater potential. The 
customizing of therapy with novel agent to individual patient's characteristics is becoming 
the most beneficial approach to treatment of SCLC. In addition to new agents, biomarkers of 
chemosensitivity need be identified to efficaciously assess single agents for relapse after 
first-line therapy or as a maintenance therapy in placebo-controlled, randomised designs. 
Several studies have identified genes or proteins in lung cancer whose expression levels are 
associated with response to antitumor drugs. The breast cancer resistant protein (BCRP), is 
one of  the ABC transporters reported to be associated with resistance to anticancer drugs 
like doxorubicin, irinotecan, mitoxantrone, and its expression  was found to be associated 
with a poor clinical outcome in SCLC patients undergoing chemotherapy [Kim, 2009]. 
Chiappori et al. reported that RRM1 and Topo2 alpha proteins expression are biomarkers of 
chemotherapeutic efficacy in SCLC [Chiappori, 2010] and, recently, Usuda et al. 
demonstrated that the expression levels of Klotho protein was correlated with the prognosis 
following resection in SCLC patients [Usuda, 2011]. These results are encouraging; however, 
this findings need to be incorporated into common signatures for individual therapies and 
further tested in prospective clinical trials. Of course, biostatistical concerns still exist for 
predicting response to drugs as for predicting patient prognosis. 
7. Conclusions 
Although the incidence of SCLC has been steadily decreasing over time, it continues to 
represent a relevant problem of public health due to its aggressive clinical behaviour and 
the lack of effective therapies; it is considered one of the most elusive cancers. Twenty-five 
years ago it was considered to be the next malignancy added to the list of curable cancers, 
because of the effectiveness of several chemotherapeutic agents and radiation therapy, and 
the discover of central nervous system sanctuary, which would require distinct treatment.  
Conversely, despite active and ongoing research involving novel approaches to treat SCLC, 
few discovers had a successful translation in clinical practice over the past 25 years, with 
cumulative improvement of only 15% in survival which remains dismal and moreover 
seems to have now reached a plateau. 
7.1 Current evidences 
Over the last 25 years, few landmarks in therapy have been provided by clinical trials 
focused on LS-SCLC. Minimal progress was noted in ES-SCLC. 
Main strategies that demonstrated able to add small but significant improvements in 
survival can be summarized in the followings: 
 Advantage of addition of radiotherapy to chemotherapy:  The defining report, Cancer 
and Leukemia Group B (CALGB) 8083 [14], published in the New England Journal of 
Medicine, showed, for patients with LS-SCLC, a local control, failure-free survival, and 
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overall survival benefit with the addition of thoracic radiation to chemotherapy using a 
cyclophosphamide and doxorubicin–based regimen. At 2 years, only 13% of patients 
who received chemotherapy alone maintained local control, compared with 54% of 
patients receiving chest radiotherapy. Although the likelihood of relapse in the chest 
may be reduced by up to 50% when thoracic irradiation is administered after 
chemotherapy, 20–36% of patients will have local recurrence even after combined 
modality treatment [12,13]. An analysis of the site of first relapse demonstrated that, 
even for patients who have achieved clinical complete response, the primary tumour 
bed and hilar or mediastinal lymph node areas are the most frequent single sites of 
failure [Elliott, 1987]. Failure to achieve control at the primary site remains the most 
important obstacle to cure in patients with limited SCLC [Shepherd, 1991]. 
 superiority of twice-daily radiation therapy over daily fractionation: hyperfractioning 
radiation therapy was defined and experimented in order to respond to the need of 
improve local control of disease, which remains a serious issue in non-surgical 
managed patients 
 advantage of prophylactic central nervous system radiation (PCI) in all responding 
patients (also with ES-SCLC)  
7.2 Take home messages 
There are other recommendations without strong evidence, but for which there is general 
agreement: 
 Resection is a reasonable option as initial treatments for early stages T1-2N0-M0 
patients: if preoperative diagnosis of SCLC has been obtained, nodal or distant 
metastasis must be excluded using by either non invasive or invasive staging, avoiding 
futile thoracotomies. Induction chemo-radiotherapy did not demonstrated superior to 
adjuvant setting. In any other stage of presentation, surgery is contemplated only in 
clinical trials. 
 Clinical understaging is frequent in SCLC (concordance with pathological stage is 
only 58% in IASLC database) and common criteria of resectability often fails to predict 
complete resections in SCLC, due to propensity to spread through peribronchial 
lymphatic vessels to regional lymph-nodes. Introduction and more liberal use of EUS in 
flexible bronchoscopy or mediastinoscopy may help to rule out patients with 
micrometastasis not amenable of surgical resection 
 Surgery improves local control of disease if radical resection is achieved. Local failure 
rates vary in literature from 0 to 15%, which is considerably lesser than 35-50% reported 
for chemo-therapy with twice-daily radiation therapy (the standard of care, to date) 
[Pijls-Johannesma et al., 2007; Turrisi et al., 1999]. In resected specimens after concurrent 
CT with HfRTx, Eberhardt found persistence of vital disease at the primary site 
[Eberhardt & Korfee, 2003]. However, there is no evidence, to date, that this translates 
in an improvement of overall and disease-free survival, which could eventually derive 
from progresses in systemic treatments. 
7.3 Challenge to systemic disease 
Since the overwhelming majority of patients with LD-SCLC have subclinical metastatic foci 
at the time of diagnosis, chemotherapy is an essential part of multimodal treatment to 
control systemic disease. 
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Cytotoxic drugs active in SCLC discovered in the early 1980s remains a standard of care at 
present. Advances in supportive care and technical advances in radiation therapy have 
allowed the application of therapies with less toxicity and well tolerated by most patients. 
Fall in treatment-related deaths implies an improvement on survival (compared to history of 
20-yrs ago) which is actually difficult to be discriminated by the true prolongation of 
survival due to change in natural history of disease. 
At now, most of ongoing clinical trials deal with various combination of active cytotoxic 
agents, but it has become evident that only small improvements in survival should be 
expected by such protocols. The issue is not spectrum of active drugs, as is the case in 
melanoma, for example but rather the rapid development of drug resistance and the failure 
of second-line therapy, especially in case of no response to primary treatment or early 
relapse of disease (< 3 months). Therefore clinical research on SCLC is shifting towards 
target-therapy, although most efforts have been and are still spent on lung adenocarcinoma, 
because its arise in incidence makes it more attractive in terms of cost/effectiveness of 
research.  
Another issue in SCLC-related researches is paradoxically the introduction of fine-needle 
aspiration techniques rather than biopsy for histologic diagnosis: this has dramatically 
diminished the material available for studying compared with other lung cancers and other 
epithelial tumors. 
7.4 Current perspectives: “Time to fish or cut bait” 
“Immortalization” of old randomized trials which refused surgery in multimodal treatment of 
SCLC in others era is no more acceptable today. A different staging system, lack or routine 
diagnostic tools and some evident weak points make these milestones anachronistic at now. 
However, due to small number of cases and bias in selection of patients, retrospective series 
starts to carry a small usefulness in adding greater evidence in any type of treatment not 
contemplated in current guidelines. Meta-analyses too seem not to be reliable on studies 
that encompass sometimes two or three decades: lack of homogeneity between cohorts 
characteristics, staging system, diagnostic tools and type of treatments administered are a 
major issue to significance of results reported. 
As brilliantly stated from Shepherd in comment to another retrospective trial on SEER 
database [Yu, 2010] “it is time to fish or cut bait”: thoracic oncologists have to seriously face 
the question of role of surgery in multimodal approach to SCLC,: if they decide to fish, a 
large multi-center, international prospective randomized trial seem the only feasible option 
to achieve powerful statistical results [Shepherd, 2010]. Trial should accrue a large number 
of patients in a limited period of time with strict eligibility criteria in order to ensure as more 
homogeneity as possible among centres regarding patients selection, staging criteria and 
treatment modalities. In the forthcoming seventh edition of the TNM staging system, the 
IASLC has recommended to apply TNM stratification to SCLC in future clinical trials on 
LD-SCLC. At least one of the arm should be treated with chemo-radiation therapy followed 
by PCI, which represents actually the standard of care. 
The small number of patients eligible for surgical trials makes accrual extremely slow, so 
that 3 trials started before 2003 have not been published yet (Essen Thoracic Oncology 
Group, West Japan Thoracic Oncology group, German Multicenter Randomised Trial). 
Meanwhile advances in comprehension of molecular biology of SCLC will perhaps improve 
systemic control of disease, supporting and not excluding the role of surgery as the most 
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powerful tool of cytoreduction local strategy even in more locally advanced disease in order 
to eliminate potential residual clones of resistant cells. It seems in fact still REMOTE the 
possibility discover of definitive systemic therapy capable of achieve complete local and 
distant, permanent remission of disease 
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1. Introduction 
In all mammals, including humans, the immune system is responsible for the protection 
against potentially hazardous pathogens, such as bacteria, viruses, parasites and fungi. In 
this remarkably effective defense system leukocytes, which mediate both innate and 
adaptive immune responses, play a central role. 
The innate immune system comprises granulocytes (neutrophils, eosinophils and basophils), 
natural killer (NK) cells, mast cells and macrophages. These cells are the first line of defense 
and provide the immediate response against pathogens. Neutrophils and macrophages can 
eliminate a pathogen directly by phagocytosis. Moreover, their pattern-recognition 
receptors, recognizing structurally conserved molecules derived from microbes such as 
bacterial lipopolysaccharides, unmethylated CpG, or viral double-stranded RNA, allow 
them to respond to a wide variety of microbial invaders, e.g. by producing cytokines that 
activate T lymphocytes of the adaptive immune system.  
Acquired or adaptive immunity is characterized by a slower but highly specific immune 
response. Three major cell types are involved in adaptive immunity: antigen presenting cells 
(APCs), T lymphocytes and B lymphocytes. Dendritic cells (DCs) are the most potent APCs. 
They act as messengers between the innate and the adaptive immune system by taking up, 
processing and presenting antigens to T lymphocytes. In response to presented antigens, T 
lymphocytes may react in different ways: CD4+ T helper cells produce various cytokines 
that direct the immune response, whereas CD8+ cytotoxic T cells produce toxic granules that 
induce death of infected cells. B cells are able to respond to pathogens by terminal 
differentiation into plasma cells after which they produce large quantities of antibodies. 
Modulation of B cell function and antibody production by CD4+ T cells is an important step 
in coordinating immune responses. Upon activation, B cells can migrate to germinal centers, 
which are specialized structures in secondary lymphoid organs, where they interact with T 
cells and DCs. Costimulatory signals from T cells then facilitate selection of B cells with high 
affinity for immunoglobulins and control class switching of the immunoglobulin (Ig) to IgG, 
IgA and IgE. 
Following pathogen elimination, lymphocytes leave a lasting legacy of the antigens they 
have come across represented by memory cells. As a result, lymphocytes are able to mount a 
faster and stronger immune response in future encounters with the same antigen. Defective 
T cell function can increase susceptibility to infections, allergies and autoimmune diseases. T 
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lymphocytes can however also be manipulated to either eradicate tumor or control graft 
rejection after organ transplantation. Therefore, in addition to basic biological interest, 
knowledge on T cell biology is important to the understanding of the etiology of a wide 
variety of diseases and may improve current therapies.  
During activation in a particular cytokine milieu, naïve CD4+ T cells can differentiate into 
one of the several subsets of T helper (Th) cells. Already in 1986, Mosmann and Coffman 
introduced the concept of distinct types of T helper cells, which was based on the distinct 
cytokines profiles that T cells produce when they are stimulated to differentiate (Mosmann 
and Coffman 1989).  They described two types of Th lymphocytes, type 1 helper T cells (Th1 
cells) and type 2 helper T cells (Th2 cells). Th1 cells produce large quantities of interferon 
(IFN)γ, induce delayed hypersensitivity reactions, activate macrophages, and are essential 
for the defense against intracellular pathogens. Th2 cells produce mainly interleukin (IL)-4 
and are important in inducing IgE production, recruiting eosinophils to sites of 
inflammation, and helping to clear parasitic infections. Cytokines produced by cells of the 
innate immune system govern the differentiation of these T helper cells. IFNγ and IL-12 
drive naive T cells into the Th1 pathway, whereas IL-4 initiates the differentiation of naive T 
cells into Th2 cells. At a molecular level, the differentiation of Th1 and Th2 cells requires 
specific transcription factors: T-bet for Th1 cells (Szabo et al. 2000) and GATA3 for Th2 cells 
(Zheng and Flavell 1997) (Figure 1). An additional T helper subset was recently identified 
which restrains excessive effector T cell responses and therefore accounts for the 
maintenance of immune homeostasis and prevention of immunopathology. These cells are 
called regulatory T (Treg) cells and are naturally present in the immune system as a 
functionally distinct CD4+ T cell expressing the forkhead transcription factor FoxP3 and 
producing the cytokines IL-10 and transforming growth factor (TGF)-β. The differentiation 
of naïve T cells towards this lineage is driven by IL-2 and TGF-β (Weaver and Hatton 2009) 
(Figure 1). T follicular helper (Tfh) cells are yet another CD4+ T cell population (Nurieva et 
al. 2008; Vogelzang et al. 2008). They are important for the formation of germinal centers. 
Once these germinal centers are formed, Tfh cells are needed to maintain and regulate B cell 
differentiation into plasma cells and memory B cells. The signals that specifically instruct the 
differentiation of human Tfh cells remain unclear, but IL-12 and IL-21 seem to be required. 
Tfh cells express Bcl6 as their master transcription factor and may produce IL-21 and IL-4 
(Yusuf et al. 2010; Ma et al. 2009; Crotty 2011) (Figure 1).  
Interestingly, in recent years T cells were shown to produce proinflammatory cytokines that 
could not be classified according to this Th1-Th2 scheme. IL-17 is the most prominent 
amongst these cytokines, and T cells that preferentially produce IL-17 but not IFNγ or IL-4 
were named Th17 cells. The discovery of this new subset of helper T cells that selectively 
produces IL-17 has provided better and exciting insights into immunoregulation, host 
defense and the pathogenesis of autoimmune diseases. In particular, it now appears that 
Th17 cells do not only play a key role in chronic inflammatory lung disorders, but also 
mediate protective immunity against various pathogens at respiratory mucosal sites.  
2. Interleukin 17 and T helper 17 cells 
IL-17 (also denoted IL-17A) was cloned in 1993 and initially called CTLA-8 (Rouvier et al. 
1993). In 1995, it was renamed as IL-17, its receptor was cloned and it was identified as a 
cytokine expressed by T cells, exerting effects on epithelial, endothelial, and fibroblast cells 
(Yao et al. 1995). IL-17 has diverse biological functions, but the best characterized functions  
 






Fig. 1. Overview of human CD4+ effector T cell differentiation. 
Upon activation in a particular cytokine milieu, naïve CD4+ T cells may differentiate into one 
of several lineages of T helper (Th) cells, including Th1, Th2, Th17, and Treg cells. These 
separate lineages are characterized by their distinct cytokine production pattern. The 
differentiation pathways are mainly based on the induction of transcription factors that 
serve as master regulators of specific lineages. However, cytokine production by Th cells 
seems to be more flexible than previously believed and recently new cells, such as Th22 and 
Tfh cells have been described. Whether these new subsets represent distinct lineages 
remains to be elucidated. 
relate to its proinflammatory effects. Specifically, IL-17 recruits neutrophils via effects on 
granulopoiesis (Schwarzenberger et al. 1998; Fossiez et al. 1996) and CXC chemokine 
induction, including CXCL8/IL-8 (Laan et al. 1999). Furthermore, it acts on macrophages to 
promote their recruitment and survival and stimulates the production of proinflammatory 
cytokines and anti-microbial peptides, particularly β-defensins, from a variety of immune 
and non-immune cells (Kolls and Linden 2004; Weaver et al. 2007; Ouyang, Kolls, and 
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Zheng 2008; Crome, Wang, and Levings 2010). By now we know that the IL-17 family 
includes 6 family members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17A and 
IL-17F are the most closely related isoforms, sharing 55% homology with each other. 
Because of their structural and functional similarities and the fact that they are both 
produced by Th17 cells, IL-17A and IL-17F have been most thoroughly studied and 
characterized. Although it was known for more than 15 years that IL-17 is a product of 
activated CD4+ T cells, it was not until 2005 that the Th17 cell was described as a distinct 
CD4+ T-cell subset, critically responsible for the production of IL-17 in the context of 
autoimmunity (Harrington et al. 2005). 
2.1 Phenotype and differentiation of Th17 cells 
IL-17A is the hallmark cytokine for Th17 cells. Nevertheless, these cells also produce other 
cytokines, such as IL-21, IL-22, tumor necrosis factor (TNF)-α, other members of the IL-17 
family and, specifically in humans, IL-26 (Dong 2008). As with Th1 and Th2 cells, no single 
surface marker is specific for Th17 cells. However, human Th17 cells are thought to 
preferentially express CD161 on the cell surface (Cosmi et al. 2008). Additionally, the 
selective expression of chemokine receptors in subsets of human memory T cells has been 
useful in defining lineages with different effector functions and migratory capacity (Sallusto, 
Mackay, and Lanzavecchia 2000). It has been shown that human Th17 cells express the 
chemokine receptor CCR6 and its ligand CCL20 (Dong 2008; Wilson et al. 2007). 
Coexpression of CCR4 and CCR6 further defines human T cells that produce IL-17 but not 
IFNγ (Acosta-Rodriguez, Rivino et al. 2007). In contrast, expression of CCR6 and CXCR3 
identifies a more heterogeneous effector T cell population that produces both IFNγ and IL-
17 (Acosta-Rodriguez, Rivino et al. 2007). These patterns of chemokine receptors appear to 
be biologically significant, as memory Th17 cells specific for Candida albicans are mainly 
CCR6+CCR4+ positive, whereas those that recognize Mycobacterium tuberculosis antigens are 
present in the CCR6+CXCR3+ subgroup producing both IFNγ and IL-17 (Acosta-Rodriguez, 
Rivino et al. 2007; Annunziato et al. 2007).  
The combination of cytokines that stimulate differentiation of Th17 cells has been subject of 
much debate. Initial studies on human T cell differentiation indicated that T cell activation 
in the presence of IL-1β, IL-6 and/or IL-23 was sufficient to induce Th17 cells, and that TGF-
β inhibited this process (Acosta-Rodriguez, Napolitani et al. 2007; Chen et al. 2007; Crome, 
Wang, and Levings 2010; Wilson et al. 2007). In subsequent studies, however, TGF-β was 
reported to be important for the development of human IL-17 producing cells (Manel, 
Unutmaz, and Littman 2008; Volpe et al. 2008; Yang, Anderson et al. 2008). This discrepancy 
could be explained by more recent reports showing that the requirement for TGF-β in the 
differentiation process is indirect and relates to suppression of Th1 differentiation (Crome, 
Wang, and Levings 2010; Santarlasci et al. 2009). In the current view, the combination of IL-
1β and IL-6 is essential for proper human Th17 cell differentiation whereas IL-23 is 
important for both expansion and survival of lineage-committed Th17 cells (Wilson et al. 
2007). In addition to cytokine-driven Th17 lineage commitment, it has also been shown that 
prostaglandin E2 (PGE2), which is a mediator of tissue inflammation, directly promotes 
differentiation, expansion and proinflammatory function of human and mouse Th17 cells 
(Yao et al. 2009). In humans, PGE2 induces up-regulation of the IL-23 and IL-1 receptors (IL-
23R and IL-1R, respectively) and by synergism with IL-1β, IL-6 and IL-23 (Boniface et al. 
2009).  
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The observation that Th17 cells are a distinct lineage of cells with a unique cytokine and 
chemokine/chemokine receptor profile, led to the discovery of RORγt in mice (Ivanov et al. 
2006). RORγt encodes the retinoid orphan nuclear receptor, and this transcription factor is 
required for the differentiation of Th17 cells. In the human system it has also been shown 
that forced over-expression of RORC2 (the human equivalent of RORγt) in human naïve T 
cells induces a Th17-like phenotype, by inducing IL-17A, IL-17F, IL-26 and CCR6 expression 
and down-regulating IFNγ secretion (Manel, Unutmaz, and Littman 2008; Crome et al. 2009) 
(Figure 1). Activation of RORγt also causes expression of the IL23R, indicating that IL-23 
acts on T cells that are already committed to the Th17 lineage. Exposure of developing Th17 
cells to IL-23 not only enhances the expression of IL-17 but also induces IL-22 and 
suppresses IL-10 and IFNγ (McGeachy et al. 2007). Yet, RORC2 alone can induce IL-17 
production in only 20% of the T cell population (Chen and O'Shea 2008) indicating that it 
acts in cooperation with other transcription factors for full commitment of precursors to the 
Th17 lineage. In addition to RORC2, the most specific and master transcription factor, at 
least four other transcription factors are linked to the human Th17 cell fate. These include 
signal transducer and activator of transcription-3 (STAT3), interferon regulatory factor-4 
(IRF4), runt box transcription factor-1 (Runx1), and the aryl hydrocarbon receptor (AhR) 
(Chen and O'Shea 2008). Together they form a sophisticated network with positive and 
negative feedback loops. In addition, Th17 cells are inhibited by IL-2 (produced by Treg 
cells), IFNγ (produced by Th1 cells), and IL-4 (produced by Th2 cells) but also by other 
negative regulators such as retinoic acid (Elias et al. 2008).  
Although this scheme of T helper cell differentiation might seem complex (Figure 1), it is in 
fact an oversimplification. Recent studies on T helper cell differentiation have revealed more 
plasticity in cytokine production than predicted by conventional models of T helper cell 
lineage commitment. Activated memory T cells preserve plasticity to alter their cytokine 
program according to the stimuli they receive. A cytokine restricted to one T helper subset 
can therefore be secreted by another subset under changing stimulation conditions. This 
feature is also observed in human Th17 cells (Chen and O'Shea 2008). Acquisition of IFNγ-
producing potential by Th17 cells, particularly the simultaneous production of IFNγ and IL-
17, is common (Chen et al. 2007; Wilson et al. 2007) (see Figure 2). Additionally, Th17 cells 
can even stop producing IL-17 and become selective IFNγ producers resulting in a complete 
subset switch (O'Shea and Paul 2010). Although Th1 cells do not become IL-17 producers, 
under particular circumstances they can make IL-13 (Hayashi et al. 2007). Th17 cells produce 
IL-22, but cells that make IL-22 and not IL-17 (“Th22 cells”) have recently been identified as 
well (Duhen et al. 2009; Trifari et al. 2009). Simultaneous production of IL-22 and IFNγ has 
also been described (O'Shea and Paul 2010). This plasticity even concerns master regulators: 
FoxP3 expression within Treg cells is heterogeneous and transient and former.  
Treg cells have the capacity to produce proinflammatory cytokines such as IL-17 (Bluestone 
et al. 2009). 
Moreover, also multiple master regulators can be expressed, such as Gata3 and FoxP3 in Tregs 
(Mantel et al. 2007), or a combination of RORC2 and FoxP3 (mixed Th17-Treg) (O'Shea and 
Paul 2010). Therefore, expression of master regulators should not be simplified as mutually 
exclusive but rather as a gradient of transcription factors (O'Shea and Paul 2010). It remains to 
be shown whether there are preferential directions for plasticity or whether effector T cells can 
change in any direction from every starting point (Bluestone et al. 2009). Plasticity could be an 
answer to the evolution of pathogens, allowing a proper response to new threats. 
 




Fig. 2. Flow cytometric analysis of cytokine production by CD4+ T helper cells. 
With the use of a technique called flow cytometry, it is possible to depict the cytokine 
producing potential of individual cells. In this experiment peripheral blood mononuclear 
cell (PBMC) suspensions were stained with monoclonal antibodies specific for CD3, CD4, 
CD8, and the indicated cytokines. Live CD4+ CD3+ T cells were gated and analyzed for the 
presence of the indicated cytokines in combination with the CD45R0 marker for memory T 
cells. Results are shown as dot plots and illustrate that CD4+ T helper cells are capable of 
producing all of the tested cytokines (top row, right upper quadrants). Moreover, CD4+ T 
helper cells have the potential to be simultaneously positive for IL-17 and IFNγ, and IL-17A 
and IL-22 respectively (bottom row, right upper quadrants). 
2.2 IL-17 producing cells other than Th17 cells 
Th17 cells are not the exclusive producers of IL-17 nor is this production their only function. 
Other cell populations capable of producing IL-17 include both adaptive and innate immune 
cells.  
Within the adaptive arm of the immune system, a subset of CD8+ cytotoxic T cells is also 
capable of producing IL-17. Studies have shown that these cells develop under conditions 
that are similar to those required by Th17 cells, but different from those required by IFNγ 
producing CD8+ T cells (Kondo et al. 2009). However, adaptive immune responses cannot 
explain the early IL-17-mediated immune responses that have crucial roles during stress 
responses and host defense. Early responses are induced within hours following tissue 
injury or exposure to pathogens (Ferretti et al. 2003; Happel et al. 2003; Zheng et al. 2008), 
which is not enough time to allow for  Th17 differentiation, indicating that innate immune 
cells play a crucial role in these early responses. The key feature of this innate IL-17 response 
is the early neutrophil recruitment. This results in a more efficient resolution of infection, in 
the maintenance of mucosal barrier integrity, but also in the potential induction of 
autoimmunity (2). Recent studies have shown that γδ T cells are important innate-like IL-17-
producing cells during infectious diseases and autoimmune inflammation (Aujla, Dubin, 
and Kolls 2007; Sutton et al. 2009; Ito et al. 2009). Additionally, innate(-like) IL-17-producing 
cells described in literature include CD3+ invariant natural killer T (iNKT) cells, lymphoid 
tissue inducer (LTi)-like cells, natural killer (NK) cells and myeloid cells (Cella et al. 2009; 
Cua and Tato 2010; Michel et al. 2007).  
The γδ T cell subset is an innate-like immune cell population that has an important role at 
the mucosal barrier. These cells do not express the classical αβ T cell receptor (TCR) but a γδ 
TCR instead. They bind to epitopes in much the same way as antibodies do and provide a 
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rapidly available source of IL-17 (Sutton et al. 2009). Like γδ T cells, iNKT cells play a 
pivotal role in immunity as they provide a rapid response, with the capacity to critically 
amplify and regulate adaptive immune responses (Godfrey et al. 2004). Initially, they have 
been divided into subsets that produce either IL-4 or IFNγ, but recently a new IL-17-
producing subset that develops in the thymus has been described. This subset seems already 
committed to making IL-17 (Michel et al. 2008). The LTi cell represents a primitive precursor 
of NK, NKT, and CD4+ T cells. Specifically immature (CD127+) NK cells are closely related 
to LTi cells (Eberl et al. 2004). LTi cells promote the formation of lymphoid organs and 
sustain primed CD4+ T cell memory responses (Eberl et al. 2004). Thus, like IL-17 producing 
γδ T cells and NKT cells, LTi cells provide a rapidly available source of IL-17. Interestingly, 
it was recently recognized that innate lymphoid cells (ILCs) can be considered a family of 
non-T/non-B lymphocytes that includes not only NK and LTi cells, but also cells that 
produce IL-5, IL-13, IL-17 or IL-22. These ILC subsets are developmentally related and 
require cytokine signals through the common γ-chain of the IL-2 receptor. The distinct ILC 
subsets, which seem to have important roles in protective immunity analogous to helper T 
cell subsets, were recently reviewed by Spits and DiSanto (Spits and Di Santo 2011). Next to 
LTi and NK cells, other innate IL-17 producers have been postulated, including 
macrophages and neutrophils (reviewed by (Cua and Tato 2010; Song et al. 2008), however 
data is limited and further studies are needed to understand more of their role in mucosal 
tissue.  
2.3 Interactions between Th17 and other cells of the immune system  
Cells of the immune system modulate each other’s function. Many cells may interact with 
Th17 cells including APCs, other T helper subsets, B cells and neutrophils (Figure 3). APCs 
play a central role in directing immune responses by secreting cytokines that polarize CD4+ 
T cells into distinct lineages. Several studies support the hypothesis that changes in APC 
function probably precede inappropriate development and expansion of Th17 cells. For 
example, monocytes from inflamed joints of rheumatoid arthritis patients promote the 
development to Th17 cells but not Th1 or Th2 cells via a cell-contact-dependent mechanism 
(Evans et al. 2009). Furthermore, it was found that monocyte-derived DCs from patients 
with multiple sclerosis secrete elevated levels of IL-23 when compared to healthy controls 
(Vaknin-Dembinsky, Balashov, and Weiner 2006). Additionally, in psoriasis DCs secrete IL-
1β, IL-23 and CCL20, promoting both the development of Th17 cells and their migration to 
the skin (Kryczek et al. 2008). However, the initial stimuli that polarize APCs to produce 
cytokines that promote Th17 cells are still unclear. 
It has long been known that Th1 and Th2 cells antagonize each other’s differentiation and 
function. Not surprisingly, IFNγ produced by Th1 cells and IL-4 produced by Th2 cells 
inhibit Th17 development (Bettelli, Oukka, and Kuchroo 2007). For Treg cells and Th17 cells 
there appears to be an even closer developmental relationship because the differentiation of 
both of these cell types require transforming growth factor (TGF)β (Veldhoen et al. 2006). 
Additionally, Th17 differentiation is inhibited by Treg cells, via the production of IL-2. Th17 
cells can also modulate B cell function as has been shown by their ability to promote 
antibody production (IgM, IgG and IgA but not IgE) (Acosta-Rodriguez, Napolitani et al. 
2007). 
There is growing evidence that T cells are involved in orchestrating sustained mobilization 
of neutrophils. In the lungs for instance, in a subpopulation of COPD patients there is an 
accumulation of CD4+ and CD8+ T cells, which is associated with the presence of neutrophils  
 




Fig. 3. Th17 cells act on other immune cells and on cells of non-hematopoietic origin. 
Cytokines produced by Th17 cells have the ability to act on other cells. This allows for a 
crosstalk between immune and non-immune cells to provide protection and promote 
inflammation. 
(Turato et al. 2002). IL-17 seems to be an important mediator of linking activated T cells to 
accumulation of neutrophils, although solid data on T helper cells and neutrophils are lacking. 
In vitro work confirmed that IL-17 orchestrated neutrophilic influx by the production of 
CXCL8 (IL-8), CXCL1 (GRO-a), and granulocyte-macrophage colony stimulating factor (GM-
CSF) in airway epithelial cells, smooth muscle cells, endothelial cells, and fibroblasts (Murphy 
et al. 2008). So, the importance of Th17 cells in neutrophilic inflammation lies in the ability of 
IL-17 to induce granulopoiesis, neutrophil chemotaxis, and the anti-apoptotic properties of G-
CSF (Kolls and Linden 2004; Ouyang, Kolls, and Zheng 2008). Accordingly, administration of 
IL-17A to the lung induces robust neutrophil recruitment (Laan et al. 1999), although – by 
contrast - chronic IL-17A/F overexpression resulted in enhanced lymphocyte and macrophage 
but not neutrophil numbers (Park et al. 2005; Yang, Chang et al. 2008).  
3. IL-17 in lung diseases 
Although Th17 cells have only recently been recognized as a distinct lineage of CD4+ T cells, 
associations between IL-17 and human disease have been known for many years. 
Particularly disorders previously classified as typical Th1 disease, such as rheumatoid 
arthritis (Kotake et al. 1999), inflammatory bowel disease (Fujino et al. 2003), and psoriasis 
(Arican et al. 2005), are now considered to be primarily Th17-driven. For that reason 
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(chronic) lung conditions previously believed to be Th1 cell disorders deserve special 
attention as Th17 cells might contribute to their pathogenesis. Moreover, immunity 
mediated by Th17 cells seems particularly important at epithelial and mucosal surfaces, as 
indicated by the distinct pattern of expression of Th17 subset-associated chemokine and 
cytokine receptors (Aujla et al. 2008; Ouyang, Kolls, and Zheng 2008).  
Because Th17 cells and IL-17 play a role in regulating neutrophilic and macrophage 
inflammation in the lung, a potential role in many different lung diseases including asthma 
and chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pulmonary infectious 
diseases, sarcoidosis and other interstitial lung diseases and rejection after lung 
transplantation, seems legitimate. Asthmatics were shown to have elevated levels of IL-17A 
mRNA and protein levels in induced sputum and these levels were positively correlated with 
disease severity (Bullens et al. 2006; Molet et al. 2001; Al-Ramli et al. 2009). In COPD, recent 
studies showed increased expression of Th17 cytokines in bronchial mucosa and sputum (Di 
Stefano et al. 2009; Doe et al. 2010). Airway neutrophilia is a major feature of CF exacerbations 
and it is shown that sputum IL-17 is upregulated and correlates with Pseudomonas aeruginosa 
colonization (Dubin and Kolls 2007). In infection models in mice, there is considerable 
evidence that IL-17 and/or IL-23 are important in host responses against Klebsiella pneumoniae 
(Tesmer et al. 2008). Furthermore, several studies have now linked IL-17 to fibrosis in the lung 
in mouse models of pulmonary fibrosis and idiopathic pulmonary fibrosis in humans (Braun 
et al. 2010; Kurasawa et al. 2000; Wilson et al. 2010). Similarly, Th17 cells and IL-17 may be 
important regulators of the airway fibrotic response driving the development of bronchiolitis 
obliterans syndrome (BOS) upon lung transplantation.  
For functional analysis of IL-17 producing cells in relation to other immune cells or 
epithelial cells, it is important to consider their anatomical localization. Obviously, 
bronchoscopy-guided or surgically guided biopsies allow histopathologically examination 
in situ, but are not frequently performed because they are invasive techniques. 
Bronchoalveolar lavage (BAL) is again not commonly performed except in lung 
transplantation and interstitial lung disease. For this reason sputum and nasopharyngeal 
washes are often studied. Blood and serum might be ideal to study because they are easily 
accessible. However, it is not always clear to what extend these compartments reflect what is 
happening in the lung. The methodology to study IL-17+ T cells in biopsies or in serum and 
BAL represents only indirect evidence of Th17 cells. Flow cytometry does provide direct 
evidence as it can combine several parameters (Figure 2). In this way, identification of 
distinct IL17+ T cells and even separate subpopulations is relatively simple. 
3.1 COPD and asthma 
COPD and asthma represent two classes of chronic obstructive lung disorders that may 
share some similar immunological disease mechanisms. COPD is marked by a progressive 
and irreversible airway obstruction and emphysematic changes in the lung. In asthma the 
airway obstruction is reversible and there is a marked airway hyperresponsiveness and 
airway inflammation. Recent studies on the immunological mechanisms of COPD and 
asthma pathogenesis point towards a role for IL-17 and Th17 cells in both diseases. 
3.1.1 COPD 
In COPD, chronic inhalation of toxic particles and gases causes destruction of lung 
parenchyma, activates epithelial cells, increases mucus production and stimulates migration 
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of many inflammatory cells (Hogg 2004; Hogg et al. 2004). This results in an abnormal 
inflammatory response in the small airways and alveoli. It is believed that both the innate 
and the adaptive immune system are involved in this inflammatory process (Barnes 2008; 
Hogg et al. 2004). Progression of the disease is associated with the presence of lymphoid 
follicles, a histological hallmark of an adaptive immune response and termed bronchus-
associated lymphoid tissue (BALT) collections. The presence of neutrophils, BALT 
collections, autoantibodies in the lungs, and also autoreactive T cells in the periphery, 
indicate CD4+ T cell involvement in the pathogenesis of COPD (Curtis, Freeman, and Hogg 
2007; Feghali-Bostwick et al. 2008; Hogg et al. 2004; Vanaudenaerde et al. 2011). A potential 
role for adaptive immune responses in COPD has also been suggested in studies that show 
expansion of lung T and B cells with oligoclonality in patients with COPD and in murine 
emphysema models (Motz et al. 2010; Sullivan et al. 2005). To date, there are only few 
studies examining the expression of IL-17A and IL-17F in COPD. However, since 
neutrophilic inflammation (including elevated CXCL8 levels) is a common feature of COPD 
(Barnes 2000), and infiltrating CD4+ T cells in COPD were previously considered to be Th1 
cells, it is expected that Th17 cells play an important role in this disease. 
Although direct evidence for the role of IL-17 and Th17 cells in COPD remains largely 
absent, the importance of IL-17 in stimulating chemokine production and the role of 
neutrophils and macrophages in promoting COPD pathogenesis have led to interest in a 
potential connection (Curtis, Freeman, and Hogg 2007). Another possible link derives from 
the ability of IL-17 to drive matrix metalloproteinases (MMP)9 production, a protein which 
is involved in the breakdown of extracellular matrix, as is observed in emphysema (Prause 
et al. 2004). It is also known that IL-17-mediated signalling induces target cells to produce 
various inflammatory mediators such as TNF-α, IL-6 and IL-1β. Interestingly, increased 
levels of IL-6 and TNFα are found in sputum and BAL fluid and have been associated with 
disease severity in patients with COPD (Hacievliyagil et al. 2006). TNFα promotes CXCL8 
expression from airway epithelial cells. Elevated levels of serum TNFα have also been 
linked to exacerbations in COPD patients (Calikoglu et al. 2004). In addition TNFα 
production by mast cells is increased due to IL-17A, leading to neutrophil infiltration in the 
airways (Feldmann et al. 2001). Furthermore, IL-17 is capable of increasing mucin 
production from airway epithelial cells (Prause et al. 2004) and excessive mucus production 
is one of the characteristic of COPD. Recently it was shown that patients with stable COPD 
exhibited elevated numbers of IL-22- and IL-23-positive cells in the bronchial epithelium 
and IL-17-positive cells in the submucosa when compared to healthy controls (Di Stefano et 
al. 2009; Doe et al. 2010; Chang et al. 2011). Additionally, airway smooth muscle cells from 
COPD patients express IL-17RA and respond to IL-17 by inducing CXCL8 production 
(Rahman et al. 2005). In contrast to these findings, the levels of IL-17 in sputum from 
patients with COPD do not differ from control subjects (Barczyk, Pierzchala, and Sozanska 
2003). In addition to human studies, mice exposed to cigarette smoke exhibit enhanced IL-17 
production (Melgert et al. 2007; Harrison et al. 2008). Experiments on murine lung epithelial 
cells have also shown that overexpression of IL-17A induces a COPD-like lung 
inflammation (Park et al. 2005). Taken together, these findings indicate a role for Th17 cells 
in COPD, but it is still unclear whether and how these cells contribute to disease 
pathogenesis or progression. Moreover, to what extend Th1 and Th17-mediated immune 
responses affect airway obstruction, emphysematic changes, inflammation or COPD 
exacerbations are questions that need to be addressed.   
 




Asthma is usually characterized by concurrent airway inflammation, cytokine production, 
and airway hyperresponsiveness to relevant antigens and a specific trigger. The central role 
of the Th2 subset in the disease, inducing airway eosinophilia and bronchial 
hyperresponsiveness, is well accepted. Individually, the Th2 cytokines can explain many of 
the salient features of asthma, including IgE induction in B cells (IL-4), airway eosinophilia 
(IL-5) goblet cell hyperplasia (IL-4, IL-13) and bronchial hyperreactivity (IL-13 acting on 
bronchial smooth muscle cells) (Wills-Karp et al. 1998). However, some individuals with 
asthma display airway neutrophilia rather than eosinophilia (Anderson 2008). It appears 
that in those patients with asthma in which inflammation is nonatopic, non-IgE-dependent, 
and noneosinophilic, airway neutrophilia is correlated with asthma severity. This suggests a 
major role for neutrophils, at least in this subset of patients with asthma (Louis et al. 2000). 
Neutrophilic inflammation has also been described in sudden-onset fatal asthma and 
neutrophil numbers are highly elevated in status asthmaticus (Lamblin et al. 1998). These 
observations suggest a role for these cells in severe and fatal asthma (Cosmi et al. 2011). 
With the involvement of neutrophils, several studies tried to find an association between 
Th17 lymphocytes and asthma. 
Asthmatics have elevated levels of IL-17A mRNA and protein in breath condensate, 
sputum, BAL, and airway biopsies (Bullens et al. 2006; Pene et al. 2008; Molet et al. 2001).  
Furthermore, increased IL-17A and IL-17F levels are positively correlated to disease 
severity, suggesting an important role for IL-17A and IL-17F in severe asthma (Al-Ramli et 
al. 2009). Indeed, elevated IL-17A levels also correlate to increased neutrophilic 
inflammation, a characteristic of severe and steroid-resistant asthma (Bullens et al. 2006). 
One could also hypothesize that IL-17 may have opposite pathophysiological roles in 
different disease stages, as would be supported by findings in an asthma mouse model, 
indicating that IL-17A is required for induction of disease but negatively regulates 
established asthma (Schnyder-Candrian et al. 2006). IL-17F may also play an important role 
in the development of asthma, as a polymorphism in IL-17F which results in a loss-of-
function mutation, is inversely related to asthma risk (Hizawa et al. 2006). In these studies 
however, the cellular source of IL-17 remained unknown, but recent studies attributed the 
production of IL-17 primarily to CD4+ T cells (Pene et al. 2008; Tesmer et al. 2008). A novel 
subset of Th2 memory cells that co-express the key Th2 and Th17 transcription factors, 
GATA3 and RORCT, respectively, and coproduce Th2 and Th17 cytokines was recently 
described (Wang et al. 2010).  Interestingly, the number of IL-17+ Th2 cells was significantly 
increased in peripheral blood of atopic asthma patients. Compared with classical Th17 or 
Th2 cells, these IL-17+ Th2 cells had an increased capacity to induce influx of inflammatory 
leukocytes, and therefore are thought to represent key pathogenic cells promoting 
exacerbation of allergic asthma. 
3.2 Pulmonary infections 
There is considerable evidence that IL-17 and other Th17 cytokines are important in 
pulmonary host responses to infection by a variety of different bacteria, fungi and protozoa, 
and viruses. Also in infection, the major function of IL-17 appears to be to promote 
chemokine and pro-inflammatory cytokine production and consequent recruitment and 
activation of neutrophils and macrophages. Additionally, Th17 cytokines can control the 
infection by induction of anti-microbial peptides during the early immune responses at 
mucosal sites. Upon stimulation with various microbial agents, activated DCs secrete 
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cytokines which determine the type of adaptive immunity that develops, i.e., whether the 
immune response is skewed toward Th1 or Th17 cells. Nevertheless, Th17 responses do not 
always seem to have a protective effect in mucosal infections. Current studies suggest that 
limited and correctly timed Th17 responses are protective, when appropriately balanced 
with concurrent Th1 immunity, but that uncontrolled Th17 cell activity could lead to a 
counterproductive level of organ inflammation (Tesmer et al. 2008). 
Human studies on the role of IL-17 and Th17 cells in pulmonary infections are limited. The 
best human “model’’ demonstrating the role of IL-17 and Th17 cells in clearing pulmonary 
infections is Job's syndrome or the hyper-IgE syndrome. This syndrome is caused by loss-of-
function mutations in STAT3, resulting in the inability of naïve T cells to differentiate into 
Th17 cells. These patients manifest chronic, recurrent and severe bacterial and fungal 
infections (Milner et al. 2008). Although other factors such as disturbed neutrophil 
chemotaxis are also involved in hyper-IgE syndrome (Hill et al. 1974), the Th17 cell 
deficiency is prominent. This therefore suggests an essential role for Th17 cells in the host 
immune system.   
3.2.1 Bacteria 
The host response to bacteria is largely triggered by Toll like receptor (TLR) ligands 
stimulating the production of inflammatory mediators, such as the pro-inflammatory 
cytokines IL-1β, IL-6 and TNFα, and the recruitment of phagocytic cells to the lung (Akira, 
Uematsu, and Takeuchi 2006). Several components of the innate immune system have been 
identified as key mediators of bacterial clearance such as neutrophils and macrophages. The 
role of Th17 cells in bacterial pneumonia is less clear. However, HIV patients with depleted 
CD4+ T cells are more susceptible to bacterial infections in the lung (Wolff and O'Donnell 
2003), indicating a role for T cells in bacterial pneumonia.  
One of the best studied bacterial pathogens in pulmonary host defense is Klebsiella 
pneumoniae. Klebsiella pneumoniae is a virulent Gram-negative pathogen that can cause 
pneumonia. In mice infected with this organism, TLR4 activation in the lung leads to 
production of IL-23 by DCs, which then stimulates CD4+, CD8+ and even γδ T cells to 
release IL-17 (Happel et al. 2003). Interestingly, both IL17A and IL17F are induced in a dose-
dependent fashion (Aujla et al. 2008; Happel et al. 2005). Accordingly, the protective effects 
of IL-17 in host defense against bacterial pathogens were shown in studies that compared 
the susceptibility of IL-17R-deficient and control mice to K. pneumoniae infection (Ye et al. 
2001). After intranasal infection, IL-17R-deficient mice were more susceptible to lung 
infection with K.  pneumoniae (Happel et al. 2005; Ye et al. 2001). The increased bacteraemia 
and mortality observed in these mice were associated with delayed neutrophil recruitment 
and reduced expression levels of CXCL1, CXCL2, and G-CSF in the lung 12–24 hrs after 
infection. Related experiments demonstrated the essential role of IL-23 in triggering IL-17 
production during this infection. Also IL-23-deficient mice are highly susceptible to K. 
pneumoniae and do not upregulate IL-17 in response to infection, whereas IL-17 production 
readily occurs after infection in control mice (Happel et al. 2005). Furthermore, 
administration of recombinant IL-17 restores the early chemokine response, enhances local 
production of TNFα and IL-1β, and reduces the bacterial burden in IL-23-deficient mice 
after K. pneumoniae infection (Happel et al. 2005; Ye et al. 2001). Together, these findings 
demonstrate that IL-17 produced in an IL-23-dependent fashion is essential for early 
recruitment of neutrophils and other inflammatory cells to provide immunity to K. 
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pneumoniae infection. In these studies it was also shown that in addition to IL-17 also IL-22 is 
measurable during infection. In contrast to gene deletion of IL-17, which results in a 
substantial reduction of CXCL1 and G-CSF in response to bacterial challenge, antibody 
neutralization of IL-22 causes an even more profound defect in mucosal immunity that leads 
to rapid dissemination of bacteria from the lung to the spleen (Aujla et al. 2008). The loss of 
mucosal immunity was not associated with defects in G-CSF or CXCL1 but with loss of 
barrier function and anti-microbial protein expressed in lung epithelium. Thus while IL-17 
production by Th17 cells is critically important in host defense against K. pneumoniae 
infection in the airway because of its role in neutrophil recruitment and activation, IL-22 acts 
by augmenting the barrier defense against pathogens by triggering the production of anti-
microbial peptides and enhancing healing of the epithelium should it be breached (Aujla et 
al. 2008). Importantly, not only Th17 responses are necessary for optimal protective 
immunity to K. pneumonia. Also IL-12-driven Th1 responses, resulting in efficient IFNγ 
production, contribute to the optimal bacterial clearance in a mouse model of K. pneumonia 
(Happel et al. 2005).  
Following these initial studies with K. pneumoniae, the importance of IL-23 and IL-17 in host 
defense has been further established for a growing list of pathogens. Similar to K. 
pneumoniae, in mice infected with Mycoplasma pneumoniae, infiltration of the lungs by 
neutrophils is dependent on IL-23–induced upregulation of IL-17 (Wu et al. 2007). 
Additionally, accumulating evidence suggests that another Gram-negative extracellular 
respiratory pathogen, Bordetella pertussis which causes the whooping cough, may bias the 
host response towards the production of Th17 cytokines by preferentially inhibiting IL-12 
and inducing IL-23 (Fedele et al. 2008). The above-referenced studies clearly demonstrate a 
protective role for Th17 effector cytokines in host defense against primary challenges with 
specific extracellular Gram-negative pathogens. Th17 response may also play a role in 
controlling primary infection with intracellular pathogens such as Mycobacterium 
tuberculosis, although a much more limited one when compared with extracellular bacterial 
pathogens. It was shown that although Th17 cells are not critical to the primary response to 
M. tuberculosis, Th17 activation is clearly involved in response to vaccination against 
tuberculosis (Khader et al. 2007). In addition to this Th17-mediated vaccine-induced 
immunity to M. tuberculosis, Th17 cytokine responses have also been implicated in vaccine-
induced immunity against B. pertussis (Higgins et al. 2006) and Streptococcus pneumoniae 
(Malley et al. 2006). This indicates that the host Th17 effector cytokines have evolved as 
protective immune mechanisms against extracellular bacteria but are dispensable for 
primary protection against most intracellular pathogens that require a Th1 pathway for 
protection, such as in tuberculosis infection. 
Pseudomonas aeruginosa is another Gram-negative pathogen. Although not as virulent as K. 
pneumoniae, P. aeruginosa is a highly adaptable pathogen that causes both acute and chronic 
pulmonary infections. Chronic colonization and infection in the lung is associated with pre-
existing airway disease such as CF. CF is a disease characterized by the excessive production 
of aberrantly hydrated mucus in the airways, resulting from mutations in the ion channel 
cystic fibrosis transmembrane conductance regulator (CFTR). This increased mucus 
production, blocks normal ciliary function and thereby enhances recurrent pulmonary 
infections. During pulmonary exacerbation, CF patients exhibit airway neutrophilia and 
elevated levels of IL-23 and both IL-17A and IL-17F in bronchoalveolar lavage fluid and 
sputum (McAllister et al. 2005). Recently it was shown that CD4+ Th17 cells are prominently 
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featured in the airway walls of CF patients but that NKT cells and γδ T cells are also sources 
of IL-17 in patients with CF (Tan et al. 2011). In the latter study, IL-17+ cells were correlated 
with CF and non-CF bronchiectasis, but not with the presence of P. aeruginosa. It has been 
shown that clearance of P. aeruginosa is dependent on Th17 responses (Dubin and Kolls 
2007).  
3.2.2 Fungi, viruses and other opportunistic pathogens 
Several reports from mouse and human studies have shown that Th17 cells are important 
for clearing opportunistic infections such as Cryptococcus neoformans, Pneumocystis jirovecii 
and Candida albicans. E.g. patients with Job’s syndrome are extremely susceptible to 
mucocutaneous fungal infections caused by Candida species. It has been suggested that 
Th17 cytokines, particularly IL-17, contribute to tissue pathology in invasive Aspergillus 
infection in the lung particularly in the setting of NADPH oxidase deficiency (Romani et al. 
2008). In respiratory tract models of fungal infections using P. jirovecci, induction of IL-23 
and IL-17 following pathogen challenge is protective, since IL-23KO mice or neutralization 
of the IL-23/IL-17 axis resulted in impaired clearance of the pathogen (Rudner et al. 2007). 
Human viruses can induce IL-17 responses, as shown for herpes simplex virus (Maertzdorf, 
Osterhaus, and Verjans 2002) and respiratory syncytial virus (Hashimoto et al. 2005). 
Human rhinovirus infections are associated with exacerbations of asthma and COPD and 
IL-17 was shown to function synergistically with human rhinovirus to induce IL-8 from 
epithelial cells. This may contribute to the recruitment of neutrophils, immature DCs and 
memory T cells to the lung contributing to severe inflammatory profiles seen during viral 
exacerbations of airway disease (Wiehler and Proud 2007).  
Taken together, there is accumulating evidence for the involvement of IL-17 in bacterial, 
fungal and viral infection in the respiratory system in the mouse, whereas in human the role 
of IL-17 or Th17 cells is largely unexplored. 
3.3 Sarcoidosis, pulmonary fibrosis and other interstitial lung diseases  
Interstitial lung diseases (ILD) refer to a very heterogeneous group of lung diseases affecting 
the lung parenchyma. The exact nature of the initiating event and the subsequent cascade of 
mechanistic proceedings are most likely different in every single ILD. Multiple factors are 
likely to be involved but it is now clear that the immune system plays a major part in the 
pathogenesis of ILD. A similarity in every ILD is the interaction of growth factors, cytokines, 
and other mediators with cells that reside in the lung which seem to form part of the cascade 
of events that have been identified in the pathogenesis.  
Recent data point to a potential role of IL-17 and Th17 cells in a number of ILD. E.g. 
Wegener granulomatosis (Abdulahad et al. 2008), Langerhans histiocytosis (Coury et al. 
2008), and hypersensitivity pneumonitis (Joshi et al. 2009; Simonian et al. 2009) have been 
reported to be linked to IL-17. Pulmonary IL-17 producing γδ T cells have also been detected 
in response to bleomycin-induced tissue damage, a model for induced pulmonary fibrosis 
(Braun et al. 2010). Conversely, a particular subset of γδ T cells secreting IL-17 has been 
shown to contribute to hyperinflammatory granulomatous disease and fatal lung tissue 
damage during pulmonary aspergillosis (Romani et al. 2008). Recently, also sarcoidosis was 
suggested as a Th1/Th17 multisystem disorder (Facco et al. 2011), based on the presence of 
IL-17 positive CD4+ T cells in sarcoid lung tissue and their ability to respond to the 
chemotactic stimulus CCL20. Moreover IL-17A was expressed by macrophages infiltrating 
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sarcoid tissue. Sarcoidosis is a systemic inflammatory disease characterized by non-
caseating granulomas in various organs with pulmonary involvement in over 90% of 
patients (ATS 1999). These granulomas are compact, organized collections of macrophages 
and epithelioid cells, surrounded by and infiltrated with T lymphocytes, but the 
pathological processes that result in granulomatous inflammation are largely unknown. The 
accumulation in the lung of apparently oligoclonal IFN-producing T helper cells in 
sarcoidosis indicated an antigen-driven Th1 response (Rosen 2007; Zaba et al. 2010). Also 
because IL-17A has been implicated in the formation of a mycobacterial infection-induced 
granuloma in the lung (Curtis and Way 2009), we investigated Th17 cells by intracellular 
flow cytometry and immunohistochemistry in blood, BAL and bronchial mucosal biopsies 
from a cohort of newly diagnosed sarcoidosis patients and healthy controls. These studies 
provided evidence for the involvement of the Th17 lineage in sarcoidosis: IL-17A-expressing 
T cells were present in and around the granuloma and IL-22-expressing T cells were found 
in the subepithelial lamina propria in mucosal biopsies of sarcoidosis patients (Figure 4). 
This was accompanied by the presence of IL-17A+, IL-17A+IFN+ and IL-17A+IL-4+ memory 
T helper cells in BAL and by a significant increase in the proportions of these cells in the 
circulation (ten Berge et al. 2011).  
 
  
Fig. 4. IL-17A+ and IL-22+ cells in sarcoidosis lung biopsies containing granulomas. 
Hematoxylin nucleus staining and IL-17A (left) and IL-22 (right) staining of lung mucosal 
frozen sections from a granuloma-containing sarcoidosis biopsy (40 x magnifications). 
Arrows indicate IL-17A+ cells as well as diffuse IL-17A staining in red (left) and IL-22+ cells 
as well as diffuse IL-22 staining in the epithelium in red (right). 
3.4 IL-17 in transplantation 
Organ transplantation is currently a valid treatment option for selected patients with end-
stage disease. Graft rejection is still the most severe complication following organ 
transplantation. In lung transplantation, episodes of acute rejection (AR) tend to lead to 
chronic rejection, which is the main cause of late graft loss and poor long-term survival (Lee, 
Christie, and Keshavjee 2010; Burton et al. 2007). The diagnosis of AR is based on clinical 
findings and/or histological confirmation in transbronchial biopsies (Vanaudenaerde et al. 
2006). It has been shown that in addition to the frequency and severity of AR, also other risk 
factors such as ischemia-reperfusion injury (Lee, Christie, and Keshavjee 2010), gastro-
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oesophageal reflux (King et al. 2009), CMV pneumonitis and other infections (Valentine et 
al. 2009) are associated with an increased risk of chronic rejection. Chronic graft rejection, 
clinically known as BOS is defined as a progressive decline in lung function with other 
underlying conditions being absent (Estenne et al. 2002). More than 50% of the patients 
surviving five years after lung transplantation suffer from BOS (Christie et al. 2010). 
Classically, graft rejection has been shown to be mediated by CD4+ and CD8+ T cells (Heeger 
2003). Th1 cells were associated with graft rejection, whereas Th2 cells were considered to 
protect against rejection (Piccotti et al. 1997). Evidence is accumulating for an important role 
of IL-17 in allograft rejection, both in rodent models and humans. Prior to the first 
description of Th17 cells, IL-17 was implicated in the process of allograft rejection. Blocking 
IL-17 function in a rat cardiac allograft transplantation model increased graft survival 
significantly (Antonysamy et al. 1999). Around that same period, a number of reports 
highlighted the importance of IL-17 in the context of renal transplantation. Already in 1998 
it was shown that IL-17 was detectable by immunofluorescent staining of acutely rejecting 
human renal transplant biopsies, but not in healthy kidneys or pre-transplant biopsies (Van 
Kooten et al. 1998). Moreover, elevated IL-17 mRNA and protein levels could be detected in 
renal biopsy specimens and urinary sediment from patients found to have subclinical 
rejection when compared with control samples without any evidence of rejections (Loong et 
al. 2002). Additionally, elevated IL-17 mRNA and protein levels were detectable as early as 
the second post-operative day in a rat renal allograft model and its appearance is followed 
by the local production of pro-inflammatory molecules known to be induced by IL-17 
(Hsieh et al. 2001).  
It is important to keep in mind that transplantation procedures themselves may have a 
direct effect on the cytokine profile within the graft. Following an organ harvest the 
ischemia-reperfusion injury results in the release of a number of inflammatory mediators. 
These mediators include some of the cytokines that are important in T cell differentiation 
such as TGFβ (Basile et al. 2001). A recent study demonstrated that factors released by 
human endothelial cells as a consequence of ischemia-reperfusion injury could enhance the 
production of both IL-17 and IFNγ by CD4+ T cells (Rao, Tracey, and Pober 2007). These 
findings indicate that perioperative factors might result in increased Th17 activity within the 
graft. 
3.4.1 IL-17 in lung transplantation 
In lung transplantation, IL-17 has been implicated in ischemia reperfusion injury, acute 
rejection, infection and BOS (Bobadilla et al. 2008; Vanaudenaerde, De Vleeschauwer et al. 
2008; Yoshida et al. 2006). At day 28 after lung transplantation, IL-17 mRNA levels were 
found to be elevated in the bronchoalveolar lavage (BAL) fluid from patients with acute 
rejection when compared with those without rejection. This difference disappeared at longer 
follow up (Vanaudenaerde et al. 2006). These increased IL-17 levels were associated with 
increased numbers of both BAL lymphocytes and neutrophils and correlated with the 
severity of rejection (Vanaudenaerde et al. 2006). However, such a correlation with severity 
of rejection could not be confirmed in another study even though this study did show 
increased numbers of IL-17 positive cells in endobronchial biopsies early after lung 
transplantation (Snell et al. 2007). These apparently conflicting results may be explained by 
differences in the time of sampling, suggesting that early events after transplantation may 
be critical for inducing IL-17 production or that patient selection is crucial (Shilling and 
 
Interleukin-17 and T Helper 17 Cells in Mucosal Immunity of the Lung 
 
315 
Wilkes 2011). Additionally, patient heterogeneity may also cause conflicting results, e.g. by 
including both unilateral and bilateral transplant patients or by not discriminating between 
primary lung diseases.  
Protein levels of IL-6 and IL-1β and mRNA levels for TGF-β, IL-17, IL-23 and IL-8 in BAL 
fluid were increased in lung transplant recipients with BOS when compared to controls 
(Vanaudenaerde, Wuyts et al. 2008). CXCL8, a potent chemoattractant for neutrophils, has 
previously been associated with BOS, but it was unclear whether the presence of neutrophils 
was just a marker of general inflammation or a key mediator of obliterative bronchiolitis 
(McDyer 2007). Since IL-17 promotes neutrophil chemotaxis, the presence of neutrophils has 
been suggested to be secondary to a Th17-mediated alloimmune or autoimmune response 
(Shilling and Wilkes 2011). In a mouse model increased levels of IL-6 and IL-17 also 
correlated with tracheal obliteration, and blockade of IL-6 decreased both allograft fibrosis 
and IL-17 transcripts (Nakagiri et al. 2010). Increased neutrophilic inflammation of the 
airways with upregulation of IL-8 is common in the BAL of BOS patients. However, there 
are also many of these patients without considerable BAL neutrophilia despite the fact that 
they seem to be in an identical clinical condition with progressive decline in lung function, 
compatible with BOS. This may indicate the existence of different phenotypes within BOS 
with possible different treatment strategies. BAL neutrophilia might therefore be an 
important tool to select patients who might benefit from azithromycin treatment, since it has 
been demonstrated that azithromycin significantly reduces airway neutrophilia and CXCL8 
in patients with BOS (Gottlieb et al. 2008).  
Th17 cell responses may also trigger BOS by facilitating autoimmune responses, because 
autoantibodies against collagen type V have been described to be involved in lung allograft 
rejection (Burlingham et al. 2007). Immunohistochemical analysis indicated that collagen V 
becomes exposed in the lung matrix after ischemia-reperfusion injury in rat lung isografts 
and allografts (Yoshida et al. 2006), and that collagen V peptides are released in the BAL 
(Haque et al. 2002). Additionally, in humans it has been shown that pre-transplant patients 
who exhibit collagen V reactivity have an increased incidence of early graft dysfunction 
following lung transplantation (Bobadilla et al. 2008). 
Recent observations in our own group indicate that not only in BOS but also in stable lung 
transplantation patients IL-17 and other Th17 cytokines might play a role. We found 
enhanced Th17 differentiation of peripheral blood mononuclear cells (PBMC) in a group of 
stable lung transplantation patients, compared with both healthy individuals and patients 
on the waiting list for a lung transplantation. The increase in the proportions of circulating 
Th17 cells was not linked to donor-specific haploreactivity. Interestingly, increased 
proportions of circulating IL-17A+ CD4+ T cells co-expressing IFNγ were found, indicating 
that specific Th17 subpopulations may have a functional role in stable lung transplantation 
patients (Paats et al., unpublished data). 
4. Therapeutic potential 
Accumulating evidence suggests that IL-17 and other cytokines involved in the Th17 
pathway play an important role in the pathogenesis of various lung diseases. Interference 
with the activity of Th17 cells or the inflammatory mediators that either induce them (IL-1β, 
IL-6, and IL-23), act in concert with IL-17 (TNFα and IL-1β), or work downstream of IL-17 
could be an effective treatment modality. One of these novel treatment modalities is cell 
blockade by monoclonal antibodies. Most antibody therapies have not yet been tested in 
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lung pathology, which is remarkable because of the lung’s continuous exposure to external 
triggers and pathogens. The risks of monoclonal antibody therapies must also be kept in 
mind. Adverse effects including infections, cancer and autoimmune disease are all issues 
that need consideration before antibody treatment can be introduced (Hansel et al. 2010). 
The most direct way to control the biologic effects of Th17 cells would be to target 
production of their effector cytokines. Monoclonal antibodies against IL-17 or the IL-17R 
and a soluble IL-17R have been developed for clinical application. Administration of 
LY2439821, an anti-IL-17 monoclonal antibody, has been described in RA and improved 
signs and symptoms of the disease, without significant adverse events (Genovese et al. 
2010). Additionally, it is promising that clinical trials with the fully human antibody, 
AIN457, in RA, psoriasis and noninfectious uveitis, show that targeting IL-17A interrupts 
inflammation and reduces disease activity (Hueber et al. 2010). Inhibitors of other products 
of Th17 cells such as IL-21 and IL-22 have not reached the clinical setting (Ma et al. 2008; 
Young et al. 2007). Another option might be to down-regulate IL-1β, IL-6 and IL-23, the 
cytokines that induce Th17 differentiation. Targeting the IL-6R with a monoclonal antibody 
(e.g., tocilizumab, a humanized monoclonal antibody against the receptor) and neutralizing 
the IL-1R with an antagonist (e.g., anakinra, a recombinant human IL-1R antagonist) are two 
effective approaches to the treatment of rheumatoid arthritis and other autoimmune 
inflammatory diseases (Dinarello 2005; Yokota et al. 2005). A monoclonal antibody 
(ustekinumab) targeting the shared IL-12/IL-23 p40 subunit, blocks both Th1 and Th17 cells 
and was shown to be efficient in the treatment of psoriasis and Crohn’s disease (Griffiths et 
al. 2010). IL-17 induces the production of IL-1β and TNFα. Antibodies, antagonists or 
receptor antagonists to IL-1 and TNFα are already in use for a range of autoimmune and 
chronic inflammatory conditions (Sutton et al. 2009). Unfortunately, recurrence of 
immunoinflammatory disease when treatment with TNFα inhibitors is discontinued is 
common. A combination of IL-17 and TNFα inhibitors, administered either simultaneously 
or sequentially, might be a good alternative to better control inflammation (Nadkarni, 
Mauri, and Ehrenstein 2007; Miossec, Korn, and Kuchroo 2009). Targeting intracellular 
signaling molecules or transcriptional factors involved in the activation of IL-17 production 
e. g. by small molecule inhibitors is an alternative approach for the development of new 
drugs. However, it is complicated by the fact that many of the signaling pathways are not 
unique to the IL-23-IL-17 axis and may also inhibit responses of other cell types involved in 
protective immunity (Mills 2008).  
Non-selective blockade of the adaptive immune system by the use of steroids or 
cyclosporine seem ineffective in patients with severe asthma, COPD and CF (Barnes 2008; 
Vanaudenaerde et al. 2011). This is probably due to the reported steroid resistance of the 
Th17 cell–neutrophil axis (McKinley et al. 2008). Other medication capable of dampening the 
innate immune system might be an alternative way to interfere with the Th17 pathway. The 
best documented therapy for reducing IL-17-T cell-mediated neutrophilia is macrolide 
therapy, which is being used effectively in clinical practice in patients with CF, asthma, 
COPD and BOS (Jaffe and Bush 2001; Seemungal et al. 2008). In addition, in vitro studies 
have shown that vitamin D inhibits Th17 cells (Mora, Iwata, and von Andrian 2008; Colin et 
al. 2010), hence vitamin D therapy might have potential in controlling Th17-mediated lung 
diseases. Clinical trials that could prove the importance of vitamin D in chronic lung 
diseases are currently in progress. Furthermore, other medication capable of interfering with 
the innate immune system, such as vitamin A or statins, merits attention (Vanaudenaerde et 
al. 2011). 
 




We still have much to learn about the phenotype, function and regulation of human Th17 
cells. It is however clear that IL-17 and other Th17 associated cytokines play a central role in 
regulating diverse immune responses. With their potential to induce a pronounced 
neutrophilic inflammation, which is a common feature of many pulmonary inflammatory 
conditions, Th17 cells are subject of great research interest. Important to realize is that 
besides Th17 cells there are also other sources of IL-17, including CD8+ T cells, γδ T cells, NK 
T cells, and LTi cells.  Depending on the timing, the tissue, and the local microenvironment, 
IL-17 secreting cells appear to be able to play both beneficial and detrimental roles in lung 
immunity and disease. The exact balance of these roles during the processes of many 
autoimmune and infectious diseases is however not fully understood yet. Therefore, the 
challenge lies in uncovering strategies to maximize the protective effect of IL-17 producing 
cells while simultaneously preventing these cells from causing immune-mediated host 
damage. At present, therapies that modulate the Th17 cell pathway are being tested in the 
clinic with promising results.  
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1. Introduction 
The microorganisms referred as mycoplasmas ("mushroom form") are eubacteria included 
within the Class Mollicutes (from latin mollis ="soft”, cutis= “skin"), which comprises the 
smallest self-replicating bacteria, showing distinctive features such as: a) lack of a rigid cell 
wall envelope, b) sterol incorporation into their own plasma membrane, and c) Reduced 
cellular (0.3 - 0.8 m diameter) and genome sizes (0.58-2.20 Mb). Some genera use the UGA  
stop codon to encode tryptophan [Bove, 1993; Razin et al., 1998].  
The term “mycoplasmas” will be used herein when referring to any species within the Class 
Mollicutes. Due to their reduced genome sizes, the mycoplasmas exhibit restricted metabolic 
and physiological pathways for replication and survival [Razin et al., 1998]. This makes 
evident why these bacteria display strict dependence to their hosts for acquisition of 
aminoacids, nucleotides, lipids and sterols as biosynthetic precursors. [Baseman & Tully, 
1997; Razin et al., 1998].  
Recognized human pathogenic mycoplasma species mostly belongs to the Mycoplasma and 
Ureaplasma genera (Table 1). Acute or fulminant diseases are rarely caused by these bacteria, 
instead they produce subclinical or covert infections that become chronic and/or persistent 
[Baseman & Tully, 1997; Razin et al., 1998]. Cell surface colonization and in some cases 
subsequent invasion and intracellular residence have been well documented for several 
Mycoplasma species which infect humans [Andreev et al., 1995; Baseman et al., 1995; Díaz-
García et al., 2006; Giron et al., 1996; Jensen et al., 1994; Lo et al., 1993; Taylor-Robinson et al., 
1991]. 
The primary habitats of the mycoplasmas infecting humans are the mucosal surfaces of the 
respiratory and genitourinary tracts [Cassell et al., 1994a; Taylor-Robinson, 1996]. Moreover, 
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the mycoplasmas display host- and tissue-specific tropism, reflecting their nutritional 
demands and parasitic lifestyle [Razin et al., 1998].  Thus, M. pneumoniae is found principally 
in the respiratory tract, whereas M. genitalium, Ureaplasma spp., M. hominis, M. fermentans 
and M. penetrans are primarily urogenital residents, but exceptionally they can be isolated 
from other unusual tissues and organs, especially in immunocompromised patients or in 
patients undergoing solid organ transplantation [Waites & Talkington, 2004; Waites et al., 
2005; Waites,  2008].  
Mycoplasmal respiratory infections in humans can be ascribed mainly to M. pneumoniae and, 
in fetuses or newborns, to Ureaplasma species. M. pneumoniae is a well-known pathogen in 
atypical and community-acquired pneumonia, whereas U. urealyticum and U. parvum have 
been associated with vertically-transmitted intrauterine and neonatal pneumonia [Taylor-
Robinson, 1996; Waites et al., 2005].  
 
Species 




tract Glucose Arginine Urea 
Mycoplasma 
fermentans      
M. genitalium      
M. hominis      
M. penetrans      
M. pneumoniae      
Ureaplasma parvum      
U. urealyticum      
 Present;  Absent 
Modified from Taylor-Robinson, 1996. 
Table 1. Mycoplasma species pathogenic for humans. 
A worldwide rise in the frequency of M. pneumoniae-associated lower respiratory tract 
disease has been observed, from 6 - >30% in the 1990s, to 0 - 66.7% in 2010 [Reviewed by 
Loens et al., 2003, 2010]. Therefore the pathogenic role of M. pneumoniae in respiratory 
disease has been proved in persons of all ages, sometimes causing severe respiratory 
disease, and it may induce clinically significant manifestations in extrapulmonary sites by 
direct invasion and/or immunologic effects. Only in the USA, M. pneumoniae is responsible 
for more than 100,000 hospitalizations of adults each year [Waites & Talkington, 2004; 
Waites, 2008]. This close interplay between M. pneumoniae and the host's respiratory 
epithelium induces local damage and in turn elicits release of inflammatory mediators by 
the host. The magnitude of the later response appears to be related to the severity of disease 
[Waites, 2008].  
Respiratory tract colonization with Ureaplasma spp., and rarely with M. hominis, in preterm 
infants has been associated with higher incidence of pneumonia, severe respiratory failure, 
bronchopulmonary dysplasia, and ultimately with death [Viscardi et al., 2002]. These 
bacteria can be transmitted from infected females to their fetus or newborn by three main 
different routes: a) Ascending intrauterine infection from vaginal colonization; b) 
Hematogenous spreading from placental infection,  and c) Acquisition of the microorganism 
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by the neonate during passage through an infected maternal birth canal. [Viscardi et al., 
2002; Waites et al., 2005]. An inverse correlation between ureaplasmal vertical transmission 
rate and gestational age has been established, and this increases with duration of premature 
rupture of membranes. Improved molecular detection of colonizing Ureaplasma in 
respiratory tract specimens suggests a higher frequency of colonization in very low birth 
weight infants than that previously reported with culture-based studies (25–48% vs. 20%) 
[Viscardi & Hasday, 2009]. 
Infrequently, M. fermentans has been detected in adults who developed respiratory distress 
syndrome and/or from bronchoalveolar lavage in AIDS patients with pneumonia, 
highlighting the potential of this species to cause lower respiratory tract disease in 
susceptible hosts [Waites &Talkington, 2004]. 
2. Taxonomic characterization of Mollicutes 
Modern mycoplasmal taxonomy relies on combined data from phenotypic traits and 
phylogeny based on the 16S rRNA gene sequences [Brown et al., 2007; International 
Committee on Systematics of Prokaryotes- Subcommittee on the taxonomy of Mollicutes 
(ICSP-STM), 2010]. Among the phenotypic characteristics, there are few useful metabolic 
markers including the ability to ferment glucose, the ability to hydrolyze urea and arginine, 
and dependence on cholesterol for growth and anaerobiosis. Despite the high rate of surface 
antigenic variation, serologic relatedness at the species level is still used in routine 
identification of mycoplasmas [Brown et al., 2007; ICSP-STM, 2010; Razin et al., 1998]. There 
are currently more than 200 species allocated into four orders, five families and eight genera 
within the class Mollicutes (Figure1), including the undefined candidatus Phytoplasma [Brown 
et al., 2007; ICSP-STM, 2010]. 
2.1 Phylogeny, genome content and molecular analysis 
The Mollicutes 16S rRNA-based phylogenetic tree is monophyletic arising from a single 
branch of the Clostridium ramosum branch. The Mollicutes split into two major branches: the 
AAP branch, containing the Acholeplasma, Anaeroplasma and Asteroleplasma genera, and the 
Candidatus Phytoplasma phyla; the other is the SEM branch that includes the Spiroplasma, 
Entomoplasma, Mesoplasma, Ureaplasma and Mycoplasma genera [Johansson et al., 1998; 
Maniloff  1992; Razin et al., 1998). Interestingly, the genus Mycoplasma is polyphyletic, with 
species clustering within the Spiroplasma, Pneumoniae and Hominis phylogenetic groups 
[Behbahani et al., 1993; Johansson et al., 1998; Maniloff 1992]. Nevertheless, additional 
phylogenetic markers such as the elongation factor EF-Tu (tuf) gene, ribosomal protein 
genes, the 16S/23S rRNA intergenic sequences, etc, have been already used as 
complementary comparative data, thus there is no unique phylogenetic tree for Mollicutes 
[Razin et al., 1998].  
The mycoplasmas may have evolved through regressive evolution from closely related 
Gram positive bacteria with low content of guanine plus cytosine (G+C), probably the 
Clostridia or Erysipelothrix [Bove, 1993; Brown et al., 2007; Razin et al., 1998]. The massive 
gene losses (i.e. genes involved in cell wall and aminoacid biosynthesis) had left 
mycoplasmas with a coding repertoire of 500 to 2000 genes [Sirand-Pugnet et al., 2007]. The 
G+C content in DNA of mycoplasmas varies from 23 to 40 mol%, while genome size range 
is 580–2200 Kbp, much smaller than those of most walled bacteria [Razin et al., 1998].  
 




* Includes more than one hundred species. At present five species are recognized human pathogens. 
** Includes seven species, two of them are pathogenic for humans. 
Adapted from: Razin et al, 1998. 
Fig. 1. Taxonomy of Class Mollicutes.  
From a comparative analysis of the complete genome sequences from 17 mycoplasma species, 
Sirand-Pugnet et al., 2007, identified 729 clusters of orthologous groups of proteins (COGs) that 
represent 21 categories of diverse cellular functions. This analysis revealed that mycoplasmas 
shared a limited core genome (i.e. the essential translation machinery), while there is a wide 
diversity of COGs that are only found in one or a few species. Moreover, frequent chromosomal 
rearrangements occurring at specific loci involved in expression of surface proteins were also 
identified [Momynaliev & Govorun, 2001; Sirand-Pugnet et al., 2007]. 
3. Immune response  
Host defense in respiratory mycoplasmosis is dependent on both innate and humoral 
immunity. In general terms, mycoplasmas reaching the lower respiratory tract may be 
opsonized by antibody and complement, and then activated macrophages begin 
phagocytosis and migration to the site of infection by chemotaxis. Finally, complement-
mediated cytolysis may then play a role in limiting the growth of the mycoplasmas. 
However, immunity against mycoplasmal infection is typically short-lived, hence infection 
recurrence is common (Waites et al., 2007, 2008). 
3.1 Innate and adaptive immune response 
M. pneumoniae infection is able to activate the host innate immune system, so the 
inflammatory event elicited by accounts for the early signs and symptoms of the infection.  
After become opsonized, M. pneumoniae is susceptible to complement-mediated cytolysis, 
probably through both the alternative and classical pathways [Waites et al., 2007].  It has 
been suggested that innate immune recognition of M. pneumoniae has also a pivotal role for 
mucin expression in the airway, at both mRNA and protein levels, since blockage of the toll-
like receptor (TLR)-2 signaling pathway results in marked reduction of mucin expression 
[Chu et al., 2005]. Moreover, M. pneumoniae is capable of interact with mast cells and 
surfactant protein (SP)-A, resulting in cytokine production and bacterial growth inhibition, 
respectively [Waites et al, 2007].  
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After primary encounter with M. pneumoniae, the immune system of an immunocompetent 
host responds by rapidly producing antibodies (mainly directed against the P1 adhesin and 
glycolipid antigens) that peak after 3 to 6 weeks, followed by a gradual decline over months to 
years [Waites & Talkington, 2004]. The onset of symptoms may coincide with demonstrable 
antibody titers due to prolonged incubation period. Acute infection can often be difficult 
observed by evidence of rising M. pneumoniae-specific IgM antibodies, especially in pediatric 
populations. [Waites, 2007, 2008]. IgA antibodies are produced early in the course of disease, 
rise quickly to peak levels, and decrease earlier than IgM or IgG [Waites & Talkington, 2004]. 
Adaptive immunity, characterized by both B and T lymphocyte responses, has a major 
impact on the progression of M. pneumoniae respiratory disease. Mycoplasmas activate the 
immune system by inducing non-specific proliferation of B- and T-lymphocyte populations 
(mitogenic stimulation), thereby inducing autoimmune responses with concurrent 
production of cytokines (Table 2). Immune responses that develop after infection often fail  
 
Organism Cells / Experimental system Cytokine(s) released 
M. 
pneumoniae 
 Lung Alveolar type II pneumocytes 
 
 






 Peripheral blood mononuclear cells 
 
 
 Lung ephitelial carcinoma A549 
cells 
 M. pneumoniae-infected patients 
Interleukin (IL)-1β, tumour 
necrosis factor (TNF)-α, IL-8.  
 
IL-2, IL-6, RANTES, 
intercellular adhesion 
molecule (ICAM)-1, 
transforming growth factor 
(TGF)-β1 and TNF-α 
 
IL-1β, IL-2/IL-2R, IL-6, 
Interferon (IF)-γ, and TNF-α. 
 
IL-1β, IL-8, and TNF-α. 
 
IL-2/IL-2R, IL-4, IL-5, IL-6, 




 Neonatal fibroblasts 
 
 Peripheral blood/Cord blood 
monocytes 
 
 THP-1-derived macrophages / 
Human lung fibroblasts 
 
 
 THP-1 monocytes 
IL-6 and IL-8. 
 
TNF-α, IL-8, IL-6, and IL-10. 
 
 
TNF-α, IL-6, ICAM-1, and 
vascular endothelial growth 
factor (VEGF).  
 
IL-1α, TNF-α, and IL-8. 
Data from Dakhama et al., 2003; Kazachkov et al., 2002;  Li et al., 2000a; Manimtim et al., 2001; Peltier et 
al., 2008 ; Stancombe et al., 1993; Yang et al, 2004. 
Table 2. Mycoplasma-induced cytokine secretion.  
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to eliminate the mycoplasma, indicating that adaptive immunity apparently has a limited 
effect on clearance of an established infection, thus leading to asymptomatic carriage for 
variable periods of time. Cytokine production and lymphocyte activation may either 
minimize disease through the enhancement of host defense mechanisms and subsequent 
elimination of the infecting organisms, or exacerbate disease through the development of 
immunologic hypersensitivity [Waites et al, 2007, 2008]. It has been suggested that there is 
no correlation between severity of pneumonia caused by M. pneumoniae and T-cell 
deficiencies, thus cell-mediated defense against respiratory mycoplasmosis appears to be 
rather limited [Cartner et al, 1998]. 
Molecular mimicry, survival within cells and phenotypic plasticity (antigenic variation) are 
the major mechanisms by which mycoplasmas evade the immune response [Chambaud et 
al, 1999; Razin et al., 1998; Rottem & Naot, 1998]. Furthermore, a transient impairment of T-
lymphocyte function, or depletion of CD4+ T cells, can be induced by M. pneumoniae [Waites 
et al., 2007].  
In the context of perinatal pneumonia, very low birth weight infants have relative 
deficiencies in mucosal barrier function and in both the innate and adaptive immune 
responses. These immature hosts may generate poor immune responses, including secretory 
IgA, serum complement components, defensins, fibronectin, and altered cytokine 
production. Impaired chemotaxis, phagocytosis, and microbial killing by neonatal immune 
cells highlight the vulnerability of preterm neonates to systemic infections, and partially 
explain the eventual systemic spread of bacteria [Waites et al., 2005]. 
3.2 Cell culture models 
Mycoplasmas possess an impressive capability of maintaining a dynamic surface 
architecture that is antigenically and functionally versatile, contributing to their capability to 
adapt to a large range of habitats and cause diseases that are often chronic in nature 
[Rottem, 2003]. The probable role of mycoplasmas in chronic respiratory diseases has been 
studied in vitro using diverse cell culture models. Several of these models are focusing in the 
study of adherence, invasion and fusion as the strategies to induce damage to the host cells 
[Baseman et al., 1995; Razin, 1999; Rottem, 2003].  
M. pneumoniae is the most extensively studied system with respect to adhesions and 
receptors [Rottem, 2003] because of its significance as pathogen for humans. Models in 
human lung cells analyzed by inmunofluorescence and confocal microscopy reveal that M. 
pneumoniae parasitize cells surface, enter the intracellular spaces and locate throughout the 
cytoplasmic and perinuclear regions within 2 hr postinfection [Baseman et al., 1995]. The 
microorganism can survive within the host cells for prolonged periods of time, well 
protected from the immune system and from de action of many antibiotics and may explain 
its pathogenic potential [Yavlovich et al., 2004]. Another in vitro studies show that this 
microorganism has a polar, tapered cell extension at one of the poles containing an electron-
dense core in the cytoplasma. This structure, termed the tip organelle, functions both as an 
attachment organelle and as the leading end in gliding motility [Baseman et al., 1995; Razin, 
1999; Rottem, 2003; Svenstrup et al., 2002]. Host-pathogen studies in an air-liquid culture of 
differentiated human airway epithelial cells revealed that the microorganism bounds 
initially to ciliated epithelial cells, but colonization become more evently distributed over 
the entire surface with time [Krunkosky et al., 2007]. We recently studied the adherence of 
U. urealyticum to a respiratory epithelial cell line, as a virulence factor for lung disease. We 
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describe that U. urealyticum induce changes in cell morphology mediated probably by the 
loss of microvilli, and that the microorganism invades the cell forming vacuoles [Torres-
Morquecho et al., 2010]. 
Since chronic lung disease is characterized by an early increased number of activated 
neutrophils and alveolar macrophages, with later architectural epithelial and endothelial cell 
damage [Li et al., 2002], all of these cells represent excellent targets for the study of 
mycoplasmal infections. As the key processes occurring in all respiratory diseases are the 
exacerbation of lung inflammation and injury, most of the in vitro models have been 
developed to study the inflammatory response mediated primarily by cytokines.  
Different studies have demonstrated that the release of Interleukin (IL)-2, IL-6 RANTES, 
ICAM-1, TGF-β1 and TNF- by human nasal epithelial cells and peripheral monocytes 
infected with M. pneumoniae could be implicated in the asthma exacerbation in children and 
may play a role in the pathogenesis of chronic asthma [Dakhama et al., 2003; Kazachkov et 
al., 2002; Krunkosky et al., 2007]. Additionally, it has been recently demonstrated that M. 
pneumoniae infection induces reactive oxygen species and DNA damage in human lung cells 
[Sun et al., 2008]. 
A number of studies show that Ureaplasma urealyticum induce the production of TNF-α, IL-8, 
IL-6 [Li et al., 2000a; Manimtim et al., 2001; Peltier et al., 2008], NF-B and nitric oxide [Li et 
al., 2000b] by human macrophages and monocytes. Infection assays in macrophages 
performed in combination with LPS showed that U. urealyticum enhances the 
proinflammatory response to a second infection by blocking expression of 
counterregulatory cytokines (IL-6 and IL-10), predisposing the preterm infant to prolonged 
and dysregulated inflammation, lung injury, and impaired clearance of secondary infections 
[Manimtim et al., 2001]. Furthermore, U. urealyticum stimulates macrophages to produce 
vascular endothelial grow factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) in 
vitro, which are potentially associated with both early and later pathological changes in the 
lung during the development of chronic lung disease [Li et al., 2002a]. The same raise in 
proinflammatory cytokine release is observed when U. urealyticum interacts with neonatal 
pulmonary fibroblast [Stancombe et al., 1993], suggesting a role in the development of 
bronchopulmonary dysplasia. Finally, it has been demonstrated that U. urealyticum induces 
apoptosis in human lung epithelial cells and macrophages [Li et al., 2002b], involving in 
impairing lung structure observed in chronic lung disease.  
4. Lung disease in humans 
4.1 Mycoplasma pneumoniae  
Respiratory infections due to M. pneumoniae can affect either the upper or the lower tract, or 
both simultaneously. This pathogen is responsible for up to 40% of cases of community-
acquired pneumonia [Atkinson, et al., 2008]. Nearly 50% of the M. pneumoniae-infected 
patients show non-specific signs and symptoms, often similar to those produced by other 
respiratory pathogens such as Chlamydophila pneumoniae, Streptococcus pneumoniae and some 
viruses, and although these infections are usually mild or  asymptomatic, they are not 
always self-limiting [Waites & Talkington, 2004; Waites et al.,  2008]. 
Symptomatic disease emerges gradually within few days post-infection and persists for 
several weeks or months. Upper respiratory tract symptoms include sore throat, fever, 
cough, headache, coryza, myalgias, chills, earache and malaise. Clinical manifestations of 
lower respiratory tract infections generally include: non-productive cough which later turns 
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productive with non-hemorrhagic sputum, dyspnoea, adenopathy, wheezing and, rarely, 
respiratory failure [Waites & Talkington, 2004; Waites et al., 2008]. 
4.1.1 Pathogenesis 
Occurrence of airway disease initiates from the close interplay between the microorganism 
and the mucosal epithelium as a result of cytadherence, the main virulence factor of the 
bacterium, which is mediated through a polarized tip attachment organelle. This tip 
structure comprise the main protein adhesin, named P1, along with several other adhesins 
and accessory proteins (High Molecular Weight  [HMW]-1, HMW-2,  HMW-3, Protein [P]-
90, P-40 and P-30) [Waites et al., 2008].  
Unlike other bacterial lung pathogens (S. pneumoniae, Pseudomonas aeruginosa and 
Haemophilus influenzae) which bind specifically to glycolipids containing unsubstituted  
GalNAcβ1-4Gal residues, M pneumoniae attaches to host cells either through a sialic acid-free 
glycoprotein or sulfated glycolipids containing terminal Gal(3SO4)_1 residues. It is worthy 
to note that the apical microvillar border and cilia of the epithelium express the 
sialoglycoconjugate-type receptors, thus allowing the selective attachment of M. pneumoniae 
to the ciliated cells [Krivan et al., 1988, 1989; Roberts, D.D. et al, 1989; Olson & Gilbert, 1993; 
Rottem & Naot, 1998]. 
Cytadhered M. pneumoniae is able to cause damage through generation of reactive oxygen 
species (ROS), which act in concert with host’s endogenous ROS to induce oxidative stress. 
Bacteria-derived superoxide anions act to inhibit catalase in host cells, thereby reducing the 
enzymatic breakdown of peroxides, rendering the host cell more susceptible to oxidative 
damage [Rottem & Naot, 1998; Waites et al., 2004]. Mycoplasmal species exert primarily 
deleterious effects on the host respiratory epithelium, such as ciliostasis and apoptosis, 
resulting in localized damage and an immune response which, although often robust, is 
poorly efficacious in terms of clearing the organism or preventing subsequent reinfections 
[Waites et al., 2004]. 
Recently, a M. pneumoniae protein homolog to the pertussis toxin S1 subunit was identified 
and it showed specific binding to surfactant protein A [Kannan et al., 2005] This protein also 
showed protein:ADPribosyltransferase activity, inducing vacuolation and ciliostasis in 
cultured host cells. This immunodominant protein has been named as community-acquired 
respiratory distress syndrome toxin (CARDS TX). Host-cell targets for CARDS TX remain 
unidentified at present, as does how the toxin's function might relate to its specific binding 
to surfactant protein A [Kannann & Baseman, 2006; Waites et al., 2004, 2008].  
Cytopathic effects observed in M. pneumoniae-infected host cells include loss of ciliated 
epithelia, cell vacuolation, reduced oxygen consumption, reduced glucose utilization, 
diminished amino acid uptake and macromolecular synthesis, ultimately leading to 
exfoliation. Clinically, the above mentioned events in the lung tissues are noticeable by the 
persistent hacking cough [Waites et al., 2004, 2008].  
Some clinical characteristics of M. pneumoniae infections are consistent with an intracellular 
location of the pathogen, mainly the establishment of latent or chronic infections, limited 
efficacy of some antimicrobials, necessity for prolonged treatment to eradicate infection in 
some instances and circumvention of the host immune response [Waites & Talkington, 2004] 
4.1.2 Role in COPD and asthma 
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lungs 
that leads to blockage of the airways which eventually interferes with the exchange of 
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oxygen and carbon dioxide, making breathing progressively more difficult. It is mainly 
associated with long-term smoking, but presence of persistent bacterial infections has been 
related to the etiology, pathogenesis and clinical course of COPD [Blasi, 2004; Sethi, 2000].  
Well-known bacterial pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, 
and Moraxella catarrhalis have been associated with acute exacerbations in COPD and 
asthma. [Guilbert & Denlinger, 2010; Sethi, 2000; Waites & Talkington, 2004]. Since late 
1970’s, several authors suggested a relationship between COPD and M. pneumoniae infection 
[Buscho et al., 1978; Gump et al., 1976; Smith et al., 1980], but it was until late 1990’s and early 
2000’s that several studies based on serology brought attention once more on this issue. 
[Lieberman et al., 2001, 2002; Mogulkoc et al., 1999]. It is well known that mycoplasmas 
species pathogenic for humans have the ability to induce chronic disease states in which 
clearance of the bacteria is extremely difficult. [Rottem & Naot, 1998].  
A growing body of evidence indicates that there is a link between M pneumoniae infection 
and COPD. In a Yemeni study, M. pneumoniae infection was demonstrated by culture and 
serologic methods in 20.4% (11/54) of COPD patients [Al-Moyed & Al-Shamahy, 2003]. In a 
group of 144 Dutch patients with CAP, 12.5 % were infected with M. pneumoniae and less 
than 40% of these M. pneumoniae-infected patients had COPD, even though specific 
serologic tests were mainly negative [Dorigo-Zetsma et al., 2001]. In contrast. M. pneumoniae 
was the most frequent pathogen (22.7%, alone or in association with other microorganisms) 
among CAP patients that required hospitalization related to COPD, asthma and/or 
pulmonary fibrosis. [Caberlotto et al., 2003].  
A rather weak association between M. pneumoniae infection and acute asthma has been 
suggested on the basis of contradictory data about mycoplasma infection frequencies from 
several trials. Conversely, strong associations of this pathogen with chronic asthma have 
been established [Guilbert & Denlinger, 2010; Sutherland & Martin, 2007]. Evidence for this 
association includes the following: a) Higher prevalence of M. pneumoniae in asthmatics than 
in healthy subjects; b) Improved pulmonary function in mycoplasma-infected asthmatic 
patients after treatment with macrolide antibiotics; c) Demonstration of long-term airway 
dysfunction consistent with a persistent infection; and d) M. pneumoniae-induced production 
of inflammatory mediators (IgE, substance P and neurokinin 1, and IL-5) implicated in the 
pathogenesis of asthma [Waites & Talkington, 2004]. 
By means of murine models of chronic respiratory infection, it has been demonstrated M. 
pneumoniae can produce pneumonia, with consistent immunologic responses in term of 
specific IgM antibodies [Wubbel et al., 1998]. Other findings revealed post-infection time-
dependent differential cytokine production, with increased expression of TNF-α, IL-1, IL-6, 
and IFN-γ in the acute phase, whereas IL-2 and IL-2 receptor gene expression was seen only 
during reinfection. [Pietsch et al., 1994].  
Relationship between the timing of Mycoplasma infection, allergic sensitization, and 
subsequent pulmonary physiologic and immune response was assessed by Chu et al., 2003. 
Before ovalbumin sensitization, experimental M. pneumoniae infection resulted in reduced 
airway hyperresponsiveness (AHR), reduced lung inflammatory cell recruitment, and a 
predominantly Th1 response. In contrast, M. pneumoniae infection post-sensitization initially 
caused a transient reduction in AHR, followed by augmented AHR, and a Th2-dominant 
airway inflammatory process that potentiates organism survival in the lungs. Further 
characterization of the M. pneumoniae effects on ovoalbumin sensitized mice, long-term 
infection provoked collagen deposition in airway wall accompanied by augmented 
expression of TGF-β1 in the lungs [Chu et al., 2005]. 
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4.2 Mycoplasmas in immunocompromised hosts 
Association between immunodeficiency and mycoplasmal infections has been reported 
since the mid 1970s to the date. Mycoplasmas can disseminate from localized infections and 
cause invasive diseases, especially in hypogammaglobulinemic subjects.  Significance of 
mycoplasma species other than M. pneumoniae or Ureaplasma spp. in respiratory diseases is a 
matter of controversy [Cassell et al., 1994a].  
4.2.1 Mycoplasma fermentans associated to lung diseases 
It has been well documented that M. pneumoniae produces respiratory disease in adults; it is 
also worthy of consideration as a cause of respiratory infections in persons of all age groups, 
though very few attempts have been made to determine whether it occurs in neonates and 
young infants [Waites et al., 2005]. However, due to their fastidious growth requirements 
and presumably less frequent occurrence than Ureaplasma spp. or M. hominis, much less is 
known about the epidemiology and disease associations of organisms such as M. fermentans, 
M. genitalium, and M. penetrans in humans. Waites and Talkington, 2005, recently reviewed 
the importance of M. fermentans in human diseases and provided more detail on the 
conditions described above as well as others [Waites et al., 2005]. 
The role of M. fermentans as a pathogen is unclear, it has been associated with the 
pathogenesis of rheumatoid arthritis [Williams et al., 1970]. However, the potential 
importance of M. fermentans in human diseases has recently been further demonstrated. 
Isolation of about 30 strains of M. fermentans from previously healthy non-AIDS patients 
who had a sudden onset of a severe and often fatal form of respiratory distress syndrome 
was recorded by R. Dular in Ottawa, Canada [unpublished, as cited by Hu et al., 1998]. Also 
they have reported the detection by PCR of Mycoplasma fermentans in the respiratory tract of 
children with pneumonia [Cassell et al., 1994b]. It has been demonstrated that a wild strain 
of M. fermentans isolated from the respiratory tract of an asthma patient was able to produce 
severe experimental respiratory disease in hamsters [Yáñez, 1997]. Román-Méndez et al., 
2007, have showed that Mycoplasma fermentans persisted in the respiratory tract of hamsters 
during 120 days and all hamsters developed histological evidence of pulmonary 
inflammation. Lo et al., 1993, have reported the presence of infections due to Mycoplasma 
fermentans in patients with adult respiratory distress syndrome with or without systemic 
disease. M. fermentans can be detected in the upper and lower urogenital and respiratory 
tracts and bone marrow, and has been associated with a variety of systemic conditions in 
adults including inflammatory arthritis and pneumonia [Ainsworth et al., 2000a, 2001; 
Gilroy et al., 2001;  Lo et al., 1989; Schaeverbeke et al.,1996; Taylor-Robinson, 1996; Tully, 
1993; Waites & Talkington, 2005]  
It has been recovered from the throats of 16% of children with community-acquired 
pneumonia, some of whom had no other etiologic agent identified, but the frequency of its 
occurrence in healthy children is not known. [Taylor-Robinson, 1996].  
M. fermentans has also been detected in adults with an acute influenza-like illness who 
developed respiratory distress syndrome, and from bronchoalveolar lavage in AIDS patients 
with pneumonia, sometimes as the sole microbe, so it clearly has the potential to cause 
respiratory tract disease in susceptible hosts [Lo et al., 1993; Ainsworth et al., 2001]. This 
mycoplasma is also known to colonize mucosal surfaces in healthy persons, complicating 
efforts to understand its role in disease [Ainsworth et al., 2000b].  
Mycoplasma fermentans, isolated decades ago from the urogenital tract, has been implicated 
in several disease conditions. Interest in this organism has recently increased because of its 
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possible role in the pathogenesis of rheumatoid arthritis. Over the last decade, intensive 
studies have been carried out in order to understand the strategy employed by M. fermentans 
to interact with host cells and to avoid or subvert host protective measures [Rechnitzer et al., 
2011]. 
Attention was focused on M. fermentans in the late 1980’s because of reports that it may be 
important as a mediator or cofactor in the development of AIDS [Lo et al., 1989; Saillard et 
al., 1990]. The identification of mycoplasmal membrane components that participate in the 
adhesion of the parasite and the finding that some mycoplasmas can reside intracellularly 
[Rottem, 2003] open up new horizons in the study of the role of mycoplasma and host 
surface molecules in mycoplasma–host cell interactions [Rechnitzer et al., 2011]. 
Unlike M. pneumoniae, M. fermentans lacks a well-defined terminal attachment tip to mediate 
attachment and cell invasion. Since intracellular organisms are resistant to host defense 
mechanisms and to antibiotic treatment, this feature may account for the difficulty in 
eradicating mycoplasmas from cell cultures. A study by Yavlovich et al., 2001, demonstrated 
that M. fermentans binds plasminogen and converts it to plasmin, where upon mycoplasmal 
cell surface proteins are altered to promote its internalization. The role of plasminogen 
activation as a virulence factor and other aspects of M. fermentans pathogenesis, including 
the importance of membrane surface proteins that mediate cell fusion, cytadherence, and 
antigenic variation, are discussed by Rottem, 2003. The fusion of M. fermentans with 
eukaryotic host cells raises exciting questions on how microinjection of mycoplasmal 
components into eukaryotic cells affects host cells [Rottem, 2003]. 
The fusion process as well as the invasion of host cells by M. fermentans brings up an 
emerging theme in mycoplasma research, the subversion by M. fermentans of host cell 
functions mainly in signal-transduction pathways and cytoskeletal organization [As cited by 
Rechnitzer et al., 2011].  
4.2.2 Mycoplasma penetrans, Mycoplasma pirium and Human Immunodeficiency 
Virus (HIV) disease 
M. penetrans was first isolated from urine of homosexual men infected with (HIV), but not 
from healthy age-matched subjects. Subsequent studies suggested an association of this 
mycoplasma with Kaposi's sarcoma, but later findings did not confirm such association. 
This organism has been detected in HIV-negative persons, and despite its ability to invade 
epithelial cell, there is no conclusive evidence of any significant role in human disease 
[Yañez et al., 1999; Waites et al, 2005; Baseman & Tully, 1997]. 
Initial isolation of M. pirum from human peripheral blood lymphoid cells of HIV-positive 
patients, along with M. penetrans and M. fermentans, lead scientists to suggest a role as 
cofactor in acquire immunodeficiency syndrome (AIDS) progression. However, despite M. 
pirum was detected in rectal specimens of homosexual men and in urine of patients with 
AIDS, no conclusive evidence of its pathogenic role in human disease has been found. 
[Waites et al, 2005; Baseman & Tully, 1997]. Taking into account that M. penetrans and M. 
pirum have been associated with immune compromise, extragenital dissemination in 
infected patients, including respiratory disease, should be considered. 
4.3 Ureaplasma urealyticum and Ureaplasma parvum in urogenital and respiratory 
tract infections 
Although U. urealyticum and U. parvum are common commensals of the urogenital tract of 
humans, they are considered as important pathogens associated with infertility and non-
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gonococcal urethritis in men, multiple obstetrical complications in women, and neonatal 
lung disease [Viscardi, 2010; Volgmann et al., 2005; Waites et al., 2005).  
Genital ureaplasmas are natural residents of male urethra contaminating the semen during 
ejaculation. However, these microorganisms, particularly U. urealyticum, play and etiologic 
role in both genital infections and male infertility (Gdoura et al., 2008). Recent studies reveal 
that U. urealyticum strains are isolated more often in men with non-gonococcal urethritis 
than in healthy men (Deguchi et al., 2004; Maeda et al., 2004; Povlsen et al., 2002). 
Ureaplasmas are widespread among the male partners of infertile couples (Gdoura et al., 
2007, 2008), and their presence is correlated with the alteration of some characteristics of 
semen, such as density, sperm motility, concentration, and probably morphology (Naessens 
et al., 1986; Reichart et al., 2000; Wang et al., 2006). The attachment to sperm and the 
induction of germ cell apoptosis have been proposed as mechanisms by which U. 
urealyticum affects sperm quality (Shang et al., 1999; Waites et al., 2005). 
The infection of the female urinary tract with U. urealyticum is frequently overlooked. 
However, since a high isolation rate of this microorganism has been observed in urine and 
urethral samples from women with unexplained chronic urinary symptoms, treatment of 
the infection is now indicated (Baka et al., 2009; Potts et al., 2000).  
Genital ureaplasmas can be found in vaginal flora in 40% of sexually inactive and 67% 
sexually active women (Viscardi, 2010). The infection is generally asymptomatic in nature, 
and is sexually transmitted between partners. Ureaplasmas can survive in the reproductive 
tract for many years, undetected, until the patient is specifically tested for the infection.  
U. urealyticum is recovered from the lower genital tract of 70-80% of pregnant women (Carey 
et al., 1991; Volgmann, 2005), but vaginal carriage is not reliably predictive of preterm birth 
(Kafetzis et al., 2004; Povlsen et al., 2001). However, there is a consistent association when 
the infection is present in the amniotic fluid, chorioamnion or placenta (Eschenbach, 1993; 
Kundsin et al., 1996; Yoon et al., 2000, 2003). The secretion of phospholipases A and C has 
been suggested to be the means by which ureaplasmas may initiate preterm labor by 
liberating arachidonic acid and altering prostaglandin synthesis (De Silva & Quinn, 1986). In 
addition, recently we reported that the interaction between U. urealyticum, intrauterine 
leukocytes and fetal membranes results in the secretion of high amounts of IL-1b and 
prostaglandin E2, which could induce uterine contraction leading to preterm labor (Estrada 
et al., 2010). Isolation of U. urealyticum from chorioamnion has been consistently associated 
with histological chorioamnionitis and is inversely related to birth weight, even when 
adjusting for duration of labor, rupture of the fetal membranes, and the presence of other 
bacteria [Cassel et al., 1993; Waites et al., 2005]. 
There is accumulating epidemiologic and experimental evidence that intrauterine or 
postnatal infection with genital ureaplasmas is a significant risk factor for complications of 
extreme preterm birth such as bronchopulmonary dysplasia (BDP) and intraventricular 
hemorrhage [Kafetzis, et al., 2004; Viscardi, 2010].  Ureaplasma spp can be transmitted from 
an infected mother to the fetus or neonate by ascending intrauterine infection, 
hematogenous route involving umbilical vessels, or through passage of an infected maternal 
birth canal with resultant colonization of the skin, mucosal membranes or respiratory tract 
[Waites, 2005]. 
Among premature infants, respiratory tract colonization with genital ureaplasmas has been 
associated with pneumonia, chronic lung disease, infant wheezing, respiratory distress 
syndrome, acute respiratory insufficiency, and increased mortality [Cultrera et al., 2006; 
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Kafetzis et al., 2004]. For some infants, ureaplasmal infection triggers a vigorous response in 
the lungs involving the elevation of adhesion molecules, collagenases, proinflammatory 
cytokines and neutrophil activation and migration, which increase the risk of developing 
bronchopulmonary dysplasia characterized by delayed alveolarization, chronic 
inflammation, and fibrosis [Manimtim et al., 2001; Schelonka & Waites, 2007]. Additionally, 
free radical generation and oxidative injury induced by recruited neutrophils could 
contribute to lung damage [Buss et al., 2003]. Apoptosis of pneumocytes and pulmonary 
mesenchymal cells has been shown to occur as part of the pathogenesis of U. urealyticum [Li 
et al., 2002], while U. parvum lipoproteins activate NF-kB and induce TNF- in 
macrophages, favoring the inflammatory response (Shimizu et al., 2008). Apparently, there 
is no trend in the prevalence of either species between infants with or without 
bronchopulmonary dysplasia [Katz et al., 2005]. 
5. Diagnostic procedures  
Much of the mycoplasmal respiratory diseases, especially those caused by M. pneumoniae, 
are underdiagnosed because the laboratory diagnostic strategies are quite different than 
those for fast-growing bacteria. It is noteworthy that mycoplasmal etiology of respiratory 
diseases is considered only after failure of diagnosis of other common bacterial etiologies. In 
addition, there are few specialized or reference laboratories and skilled personnel [Cassell et 
al., 1994a; Waites et al., 2000]. 
5.1 Types of specimens, transport and collection 
Detection or isolation of mycoplasmas in clinical specimens requires careful consideration of 
the type of specimen available and the organism (species) sought [Cassell et al., 1994a]. 
Specimens appropriate for laboratory diagnosis of respiratory mycoplasmal infections 
include: Bronchoalveolar lavage (BAL), sputum, pleural fluid, nasopharyngeal and throat 
swabs, endotracheal aspirates (ETA) and lung biopsies. Liquid specimens or tissues do not 
require special transport media if culture can be performed within 1 hour, otherwise 
specimens should be placed in transport media, such as SP-4 broth, 10B broth or 2SP broth. 
When swabbing is required, aluminum- or plastic-shafted calcium alginate or dacron swabs 
should be used, taking care to obtain as many cells as possible [Atkinson et al., 2008; Cassell 
et al., 1994a; Waites et al., 2002]. 
Other specimens such as blood, cerebrospinal fluid, pericardial fluid and synovial fluid 
must be considered when extrapulmonary disease is suspected, thus specimen collection 
should reflect the site of infection and/or the disease process. [Atkinson et al., 2008; Waites 
& Talkington, 2004]. 
5.2 Culture 
Routine culture methods for isolation/detection of most mycoplasma species are time-
consuming, thus emission of results may delay up to 5-6 weeks. Furthermore, there is no 
ideal formulation of culture media for all pathogenic species, mainly due to their different 
substrate and pH requirements [Waites et al., 2000]. Modified SP-4 media (broth and agar) 
[Lo et al., 1993], containing both glucose and arginine, can support the growth of all human 
pathogenic Mycoplasma species, including the fastidious M. pneumoniae and M. genitalium.  A 
set of Shepard´s 10B broth and A8 agar can be used for cultivation of Ureaplasma species and 
M. hominis.   
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For cultivation, specimens in transport media should be thoroughly mixed, and then should 
be 10-fold serially diluted in broth (usually up to 10-6) in order to overcome potential 
inhibitory substances, and to allow semiquantitative estimation of mycoplasmal load. 
Subcultures in agar media should be also performed. [Cassell et al., 1994a]. All inoculated 
media are incubated under microaerophilic atmosphere at 37°C.   
Detection of M. pneumoniae in broth culture is based on its ability to ferment glucose, causing 
an acidic shift after 4 or more days, readily visualized by the presence of the phenol red pH 
indicator.  Broths with any color change, and subsequent blind broth passages, should be 
subcultured to SP4 agar, incubated, and examined under the low-power objective of the light 
microscope in order to look for development of typical “fried egg”-like colonies of up to 100 
µm in diameter (Figure 2). Examination of agar plates must be done on a daily basis during the 
first week, and thereafter every 3 to 4 days until completing 5 weeks or until growth is 
observed [Waites et al., 2000, 2004].  M. genitalium, M. fermentans and M. penetrans are also 
glucose-fermenting and formed colonies morphologically indistinguishable from those of M. 
pneumoniae, thus serologic-based definitive identification can be done by growth inhibition, 
metabolic inhibition, and mycoplamacidal tests [Cassel et al., 1993].  
 
 
A) Typical ”Fried-egg”  appearance of Mycoplasma spp. colonies on SP-4 agar. B) Dienes-stained 
mycoplasma colonies. C)  Tiny brown-colored ureaplasmal colonies on modified SP-4 agar. D) 
Macroscopic view of Dienes-stained mycoplasma colonies growth on SP-4 agar in 30 mm-diameter Petri 
dishes. E) Closer view of  an ureaplasma colony. 
Fig. 2. Morphology of mycoplasma colonies in culture. 
Hidrolysis of urea by Ureaplasma and hidrolysis of arginine by M. hominis cause an alkaline 
shift, turning the colour of 10B broth from yellow to pink. Tiny brown or black irregular 
colonies of Ureaplasma species develop between 1 -5 days on A8 agar plates, due to urease 
production in the presence of manganese sulfate (Figure 2). Typical fried egg colonies are 
produced by M. hominis in this medium [Cassell et al., 1994a, Waites et al., 2000]. 
5.3 Immunodiagnosis by serological tests 
As culture of M. pneumoniae is slow and insensitive, the laboratory diagnosis of M. 
pneumoniae infection has largely relied on serological testing. Seroconversion or rising 
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specific antibody titers are observed among M. pneumoniae-infected patients. This 
immunologic response can be measured by several tests, including: metabolic inhibition 
assay, complement fixation or enzyme-linked immunoassays (EIA). Serum samples are easy 
to collect and handle, but it is required paired acute- and convalescent-phase specimens. 
Commercial assay formats include indirect immunofluorescence, particle agglutination 
assay, and EIA [Atkinson et al., 2008, Cassell et al., 1994a; Waites & Talkington, 2004]. 
Prior to the widespread availability of commercialized antibody assays, presence of cold 
agglutinins ( IgM antibodies that are produced 1 to 2 weeks after initial infection in about 
half of M. pneumoniae-infected subjects) was used to confirm primary atypical pneumonia 
(Waites & Talkington, 2004). Although there have been recent improvements, the sensitivity 
and specificity of antibody detection is still suboptimal. Nevertheless, the complex and time-
consuming nature of many of the serological assays that have been used in the past have 
limited acceptance of serology for routine diagnostic testing. [Cassell et al., 1994a; Waites et 
al., 2000]. 
At present, besides research laboratories, no serologic tests assays for mycoplasmas other 
than M. pneumoniae have been standardized for diagnostic purposes in routine clinical 
microbiology laboratories nor made commercially available elsewhere. [Cassell et al., 1994a, 
Waites et al., 2005]. 
5.4 PCR and other molecular tests 
Nucleic acid amplification techniques (NAATs) are more sensitive, and considerably more 
rapid than culture, showing a fair to good correlation with serology.  PCR testing for 
species-specific mycoplasmal infection are suitable for both upper and lower respiratory 
samples. Interestingly, sample processing prior amplification must be optimized depending 
of the type of specimen to overcome the presence of PCR inhibitors (i.e., nasopharyngeal 
samples have higher rate of PCR inhibition than throat swabs). Differential sample 
preparation from the same specimen has been done when testing separate single-species 
PCRs on BAL [De Barbeyrac et al., 1993]. A culture-enhanced PCR approach has also been 
suggested to overcome the effect of inhibitors in the amplification process [Abele-Horne et 
al., 1998]. 
In early 2000s, Loens et al.(2003) stated that the development and application of new nucleic 
acid amplification techniques (NAATs) in diagnostic mycoplasmology required proper 
validation and standardization, and performance of different NAATs must be compared 
with each other in order to define the most sensitive and specific tests. The NAATs have 
demonstrated their potential to produce rapid, sensitive and specific results, and are now 
considered the methods of choice for direct detection of M. pneumoniae, M. genitalium, and 
M. fermentans [Cassell et al., 1994a]. There is a great variation in methods used from study to 
study, including variability of target gene sequences (P1, 16S RNA, ATPase, tuf), assay 
format (single, multiplex) or technologies (Real-time PCR, NASBA) [Loens et al., 2003a, 
2010]. Also, different specimens have been used, such as sputum, nasopharyngeal or 
pharyngeal swabs, brochoalveolar lavages or pleural fluid, and then it is difficult to compare 
these data. A comprehensive review about the use of NAATs for the detection of M. 
pneumoniae in clinical samples was done by Loens et al., 2003b, 2010, and by Ieven, 2010. 
Table 3, shows a selection of primers sets developed in the 1990s for testing diverse clinical 
samples.  
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ACT CCT ACG GGA GGC AGC AGT A  













GGT TAT TCG ATT TCT AAA TCG CCT 
GGA CTA TTG TCT AAA CAA TTT CCC 
GCT GTG GCC ATT CTC TTC TAC GTT 
IS-like 
element 206 








GAA GCC TTT CTT CGC TGG AG 
ACA AAA TCA TTT CCT ATT CTG TC 













GAG CCT TTC TAA CCG CTG C 
GTG GGG TTG AAG GAT GAT TG 











GAG CCT TTC TAA CCG CTG C 
GTT GTT ATC ATA CCT TCT GAT 












ATA CAT GCA TGT CGA GCG AG 
CAT CTT TTA GTG GCG CCT TAC 
CGC ATG GAA CCG CAT GGT TCC GTT G 
rDNA 







TGA AAG GCG CTG TAA GGC GC 
GTC TGC AAT CAT TTC CTA TTG CAA A 













CAT GCA AGT CGG ACG AAG CA 
AGC ATT TCC TCT TCT TAC AA 
CAT GAG AAA ATG TTT AAA GTC TGT TTG 
rDNA 









GAA GCT TAT GGT ACA GGT TGG 
ATT ACC ATC CTT GTT GTA AGG 
CGT AAG CTA TCA GCT ACA TGG AGG 
Unknow
n gene 144 








TGC CAT CAA CCC GCG CTT AAC 
CCT TTG CAA CTG CTC  ATA GTA 













CAA TCT GCT CGT GAA GTA TTA C 
ACG ACG TCC ATA AGC AAC T 
GAG ATA ATG ATT ATA TGT CAG GAT CA 
Urease 
genes 429 








TAA ATG TCG GCT CGA ACG AG 
GCA GTA TCG CTA GAA AAG CAA C 












GTA TTT GCA ATC TTT ATA TGT TTT CG 






Kong et al., 1999 
bp, Base pairs; FW, Forward; RV, Reverse; IP, Internal probe. 
Table 3. Selected primer sets used for detection of mycoplasmas in clinical specimens 
6. Treatment and prevention 
Due to absence of the cell wall envelope, mycoplasmas are insensitive to β-lactam 
antibiotics. However, antibiotics targeting protein synthesis or DNA modification molecules 
are highly effective against these bacteria. Macrolides, tetracyclines and fluoroquinolones 
eliminate mycoplasmas efficiently both in vivo and in vitro [Cassell et al., 1994a; Waites et al., 
2000, 2008].  
Mycoplasmal infections in the upper respiratory tract are usually self-limiting, so antibiotic 
treatment is not generally recommended, even though some clinicians recommend it to 
prevent the risk of recurrence of respiratory illness [Waites & Talkington, 2004]  
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The antimicrobial of choice for treating lower respiratory tract M. pneumoniae infections are 
the macrolides in both adults and children. Patients receiving macrolides of recent 
generation showed improved tolerance, require fewer doses and have shorter treatment 
duration than older compounds. However, empirical antimicrobial treatment for M. 
pneumoniae-infected ambulatory patients is more practical; hence if hospitalization is 
required and/or patient has underlying risk factor, antimicrobial susceptibility testing is 
recommended. Use of tetracycline and fluoroquinolones is restricted to treat adult patients 
and should not be used in children aged <8 years [Cassell et al., 1994a; Waites et al., 2000]. A 
potential problem in the antimicrobial management of M. pneumoniae infections is the 
emergence of macrolide resistance [Atkinson et al., 2008; Waites et al., 2008]. 
The recovery of Ureaplasma spp and/or M. hominis in pure or mixed cultures from clinical 
specimens of symptomatic patients, in absence of associated biota, should be considered 
sufficient to initiate antimicrobial therapy. These microorganisms are resistant to 
sulfonamides and trimethoprim, and often exhibit resistance to aminoglycosides and 
chloramphenicol. Ureaplasma spp is resistant to clindamycin and susceptible to 
erythromycin, whereas M. hominis shows the opposite susceptibility profile. While 
tetracyclines are the antibiotics of choice for treating ureaplasmal infections in adults, 
erythromycin therapy is recommended for neonates. In contrast, M. hominis infections other 
than central nervous system in children under 8 years of age can be treated with 
clindamycin [Cassell et al., 1994a; Waites et al., 2000, 2005].  
Since strains from several mycoplasma species rapidly acquire resistance to antimicrobials, 
prevention of mycoplasmal infections via chemoprophylaxis is not recommended [Razin et 
al, 1998].  
6.1 Mycoplasmal susceptibility testing 
As antibiotic-resistant strains of mycoplasmas have appeared and become more common, 
antibiotic susceptibility testing for these microorganisms has become important. [Roberts, 
M.C., 1992]. However there are no official guidelines for performance, interpretation, or 
quality control of in vitro susceptibility tests for human mycoplasmas [Waites & Talkington, 
2004].  
The broth dilution method is the most widely used. Prior to test, pure cultures should be 
passage in appropriate broth and the color-changing units (CCU) or colony-forming units 
(CFU) quantitative method.  For the assay, bacterial cultures should be adjusted to 1000 – 
10000 CCU in 0.2 mL, followed by a 2-hour incubation at 37ºC, to begin active growth. The 
broth microdilution assay involves the addition of 100-μL aliquots of adjusted cultures to 
wells 2 – 12, then 100 μL of broth containing the highest concentration of the antibiotics is 
added to wells 1 and 2, followed by 2-fold serial dilutions up to well 12 (concentration range 
256-0.008 μg/mL). Positive and negative controls should be included.  The initial minimal 
inhibitory concentration (MIC) is defined as the lowest dilution of antibiotic in which 
metabolism of the organism is inhibited, as evidenced by lack of color change in the media 
at the time the control organism well first shows color change. Presumptive MICs for 
ureaplasmas will be available at 16 to 24 h and those for M. hominis will be at 36 to 48 h but 
M. pneumoniae may require 5 days or more until evidence of grow in the control wells is 
evident [Cassell et al., 1994a; Waites et al., 2000]. 
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There are commercial kits for mycoplasma susceptibility testing such as: Mycoplasma IST, 
Mycoplasma SIR, Mycofast “All In”, and MYCOKIT ATB, although they are available only 
in Europe.  
Reports of macrolide resistance in M. pneumoniae strains have been published since the past 
decade. These resistant strains were shown to possess gene mutations in the 23S rRNA.  The 
impact of macrolide resistance on the clinical course of infections is still unclear, but PCR 
assays have been developed to detect some of these mutations in order to identify these 
resistant strains [Atkinson et al., 2008]. 
Tetracycline resistance among Ureaplasma spp and M. hominis  isolates can be distinguished 
by broth- or agar-based methods since the resistant strains consistently have MICs of ≥ 8 
μg/mL whereas susceptible strains have MICs of ≤ 2 μg/mL, with no overlapping between 
the two populations [Waites et al., 2000; Cassell et al., 1994a]. Tetracycline resistance among 
M. hominis and Ureaplasma spp. isolates has been associated with the presence of Tet M 
determinant which codes for production of a ribosome-binding protein that prevents 
tetracycline binding to ribosomes [Roberts, M.C., 2002].  
6.2 Vaccines  
The initial vaccine candidate for M. pneumoniae was formalin-inactivated bacteria, but their 
protective efficacy results were generally disappointing, since some immunized volunteers 
developed more severe illness after experimental challenge with live mycoplasmas. 
Development of live attenuated vaccines never made it to human use due to concern over 
residual virulence of the vaccine strain of M. pneumoniae [Waites et al., 2008]. Other vaccine 
candidates have included acellular protein and polysaccharide components and 
recombinant DNA. While the importance of the P1 adhesin in mediating M. pneumoniae 
cytadherence and initiation of disease cannot be denied, animal studies using P1 as a 
vaccine antigen have not demonstrated protective efficacy [Razin et al., 1998; Waites & 
Talkington, 2004].  
As higher rates of surface antigenic variation among several human mycoplasmas have been 
described, whenever promising antigens are selected as vaccine candidates they are rapidly 
discarded. The three types of antigenic variation are: 1) Phase variation, a feature involving 
selective turning on/off of gene transcription; 2) Size variation as a result of variation in the 
number of tandem repeats near the 5’ end; and 3) Differential masking of surface antigens 
by the lipid moiety of lipoproteins [Chambaud et al., 1999; Momynaliev & Govorun, 2001].  
The availability of the full genome sequences of several human mycoplasmas, will allow 
better understanding of the structure and functionality of these bacteria, including virulence 
factors and immunogenic molecules.  
7. Concluding remarks 
It is undeniable the ability of Mycoplasma pneumoniae and Ureaplasma spp. to cause 
pneumonia. Other mycoplasma species are potential respiratory pathogens, especially in 
conjunction with immune compromise. There is strong evidence that mycoplasmal 
respiratory infections elicit inflammatory responses that can result chronic lung injury both 
in adults and neonates. Improvement of laboratory methods for research and diagnostic 
purposes in mycoplasmology has allowed establishing associations with pulmonary 
diseases such as COPD, asthma, and BPD. However additional work must be done for 
prevention, treatment strategies and vaccine development. 
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1. Introduction    
The systemic endemic mycoses are a group of microbial pathologies affecting primarily the 
lower respiratory tract, often overlooked in the evaluation of community-acquired 
pneumonia. They form a heterogeneous group caused by dimorphic fungi that share similar 
characteristics. All of them have the respiratory tract as the portal of entry and from the 
lungs they may disseminate to the mucous membranes, the skin, and many other organs. 
Nonetheless, each fungal disease has specific characteristics concerning its clinical course, 
diagnosis, and management. Interestingly, specific geographical areas of the world have 
been associated with acquisition of these mycoses. The diagnosis may be difficult and 
delayed owing to the varied manifestations and the multitude of differential diagnoses 
(Bonifaz et al., 2011; Hsu et al., 2010).  
The major endemic systemic mycoses include histoplasmosis, coccidioidomycosis, 
blastomycosis, paracoccidioidomycosis (PCM), and penicilliosis. All of them can cause 
disease in both immunocompetent and immunocompromised hosts, in particular, AIDS and 
organ transplantation patients, and more recently recipients of biological therapies, such as 
TNF inhibitors or antagonists. These mycoses have similar clinical and radiologic 
presentations but require different treatments. Furthermore, when they have spread to the 
lymph nodes or skin, they may mimic other pathologies such as leishmaniasis, lymphoma, 
and syphilis, among others (Bonifaz et al., 2011).  
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In addition, some of them have been reported outside of the endemic areas (Europe, Japan, 
USA), all cases occurring in immigrants, tourists, or workers returning from endemic 
countries (Buitrago et al., 2011; Poisson et al., 2007).  
For these reasons, it is essential that physicians around the world be informed of the clinical 
characteristics of these fungal diseases in order to include them in their differential 
diagnosis of patients coming from or visiting the recognized endemic areas. 
2. Defining paracoccidioidomycosis (PCM) 
Paracoccidioidomycosis (PCM) is an endemic systemic mycosis caused by the thermally 
dimorphic fungus, Paracoccidioides brasiliensis. The infection is acquired after inhalation of 
the infectious particles (conidia) produced by the fungus’s mycelia form present in its as yet 
unknown natural habitat (Restrepo & Tobón, 2009; Restrepo et al., 2011). This fungal 
pathogen has two morphotypes, a mold at temperatures under 28°C that frequently reveals 
chlamydoconidia and more rarely conidia  (size <5 µm): the latter can transform into yeast 
cells under the influence of body temperature. In tissues and cultures at 35°C–37°C, this 
fungus grows as a yeast resembling a pilot's wheel due to its multiple buds (Figure 1). Yeast 
cells are round to oval but quite variable in size (4–40 µm).  
 
 
Fig. 1. P. brasiliensis budding yeast cells. (A) Pilot’s wheel-like appearance of yeasts observed 
in a lactophenol cotton blue preparation from a colony grown at 36ºC.  (B) Multiple budding 
yeast cells observed in lung tissue with small spheric buds (arrow), attached to or released 
(arrow) from a large mother cell. Confocal indirect immunofluuorescence for fibronectin-
covered P.brasiliensis yeast cells. 
P.brasiliensis is only known in its asexual (anamorph) stage, but through molecular 
techniques it has been classified in the phylum Ascomycota, order Onygenales, family 
Onygenacea, close to Histoplasma capsulatum, Blastomyces dermatitidis, and Emmonsia parva 
phylogenetic tree, all of which have a teleomorphic, sexual stage in the genus Ajellomyces 
(Bialek et al., 2000b; Brummer et al., 1993).  
More recently, the presence and expression of the mating type locus in several isolates of 
this fungus have been reported (Torres et al., 2010). Other studies have revealed that there 
are at least three distinct phylogenetic species, or clades, which are recognized within the 
genus (PS2, PS3, and S1) (Matute et al., 2006). In addition and based on high polygenetic 
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diversity and exclusive morphogenetic characteristics, a different species, designated as 
P.lutzi, has been proposed (Teixeira et al., 2009).  
2.1 General concepts on ecology 
Geography sets PCM apart from other endemic mycoses of the Americas, such as 
histoplasmosis and coccidioidomycosis, as it is strictly confined to Latin America from 
Mexico at 23° North to Argentina at 34° South (Colombo et al., 2011; Nucci et al., 2009; 
Restrepo et al., 2011). The endemic areas are thus contained within the Tropics of Cancer 
and Capricorn (Bonifaz, 2010). PCM, however, is much more frequently reported in South- 
than in Central-American countries respecting Chile, Surinam, the Guyana, Nicaragua and 
Belize and with rare exceptions (one case each in Trinidad, Grenada and Guadeloupe), also 
the Caribbean Islands (Lacaz et al., 2002; Restrepo et al., 2011). Brazil accounts for over 80% 
of all reported cases with Venezuela, Colombia, Ecuador, Bolivia and Argentina informing 
lesser proportion of cases (Colombo et al., 2011; Restrepo et al., 2011). 
Additionally, this mycosis is not distributed homogeneously within a particular endemic 
territory but is concentrated in tropical and subtropical regions with abundant forests and 
waterways, high annual rainfall indices (1400–2999 mm), and mild temperatures (17°C–
24°C) predominating throughout the year (Borelli, 1972; Calle et al., 2001; Restrepo et al., 
2001). Soil texture and moisture availability are also important (Conti-Díaz, 2007; Restrepo et 
al., 2001), as found in Brazil by spatial and ecologic correlate analyses (Simões et al., 2004). 
Studies on this aspect discovered a cluster of juvenile patients with the acute or subacute 
form who were potentially connected to the 1982–83 El Niño Southern Oscillation (ENSO) 
climatic anomalies (Barrozo et al., 2010).  
P. brasiliensis’s microniche has not been pinpointed precisely because the few isolations from 
natural sources have been sporadic, with soil being the substrate most frequently mentioned 
(Franco et al., 2000). Presently, there are indications that the habitat is to be found near 
waterways or in humid areas also propitious to agricultural crops such as coffee, tobacco 
and sugar cane (Calle et al., 2001; Restrepo et al., 2001). One hypothesis postulated that fish 
and aquatic birds would be required around the microniche to allow survival and 
dispersion of the fungus in nature (Conti-Díaz, 2007). Of ecological importance is the regular 
isolation of the fungus from armadillos (Dassypus novemcinctus, Cabassous centralis) captured 
in the endemic areas, some of which revealed internal lesions (Bagaggli et al., 2003). Dogs 
and other domesticated and feral animals have also been implicated (Ricci et al., 2004; 
Richini-Pereira et al., 2008). Nonetheless, P. brasiliensis's microniche remains unknown 
despite many attempts to isolate it from suspected sites such as the permanent areas of 
residence of patients, in and around armadillos' burrows and their foraging areas (Restrepo 
et al., 2001).  
Another circumstance that has hindered tracing the habitat has been the lack of information 
on outbreaks, which could have facilitated detection of the common source of infection 
(Lacaz et al., 2002; Restrepo et al., 2001). An increased number of childhood cases in areas 
where this disorder had previously been considered rare was noted by Coimbra et al. (1994) 
and Gonçalves et al. (1998), who suggested that colonization, gradual felling of the original 
native forests or changes in agricultural practices had probably exposed children to 
aerosolized fungal propagules, leading to increased disease rates. By the same token, in their 
study of 1,000 patients, Bellissimo-Rodrigues et al. (2011) pinpointed an area with the 
highest number of juvenile PCM cases, all of whom had resided close to coffee plantations, 
thereby raising the possibility of aerosol infection through agriculture-related work. None of 
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the above reports, however, mentioned attempts at isolating the fungus from the 
environment.  
Another important blocking factor in the search for the fungus's habitat is its capacity to 
enter prolonged quiescent stages, which has been demonstrated by the approximately 90 
imported cases reported from nonendemic countries, as exemplified by the patients recently 
diagnosed in Europe (Buitrago et al., 2011; Mayayo et al., 2007; Poisson et al., 2007). All 
patients corresponded to emigrants living in Japan, the USA, Canada or several of the 
European countries where they had lived for a mean of 14 years after abandoning their 
native PCM-endemic homelands (Lacaz et al., 2002; Nucci et al., 2009; Shankar et al., 2011). 
These data clearly reveal P. brasiliensis's ability to enter prolonged latency, to revive without 
notice and cause clinically manifested disease. This latency period prompted Borelli to 
create the term reservarea to indicate the site where the primary infection is thought to have 
occurred and distinguishing it from the site, the endemic area, where the infection was 
diagnosed (Borelli 1972).  
2.2 General concepts on epidemiology 
2.2.1 Distribution by age 
The disease is relatively uncommon in children and adolescents with approximately 2% of 
all patients less than 10 years of age and 8% less than 20 years old. (Bellissimo-Rodrigues et 
al., 2011; Paniago et al., 2003; Shankar et al., 2011). Clinically manifested PCM occurs, 
consequently, more often (>80%) in adult patients 30–60 years old with the fourth decade of 
life presenting the largest number of cases (Colombo et al., 2011; Nucci et al., 2009; Paniago 
et al., 2003). The predominance of adult patients is reflected in higher mortality rates for 
those within this age group (Bittencourt et al., 2005; Coutinho et al., 2002; Prado et al., 2009; 
Santo, 2008). Although co-existence of the mycosis with HIV infection is relatively 
uncommon, 4%–5% according to data in the two largest series of cases published in Brazil 
(Belissimo-Rodrigues et al., 2011; Morejon et al., 2009), this dual infection has introduced a 
significant change in age distribution as these patients are younger (mean, 34 years of age) 
than the PCM non-AIDS cases (mean, 45 years of age).  
2.2.2 Distribution by gender 
Gender differences are also important markers of this fungal disorder, with adult males 
exhibiting overt disease much more often than females (Bellisimo-Rodrigues et al., 2011; 
Lacaz et al., 2002; Restrepo et al., 2011). Data taken from different series encompassing 5,500 
patients revealed that 5,045 were males and 455 females for a male-to-female ratio of 11.1 to 
1 (Shankar et al., 2011). In the largest Brazilian series totaling 1,000 patients, the male-to-
female ratio was lower: 6 to 1. It should be noted that important variations have become 
apparent when comparing the series with the lowest ratio of 5.3 to 1 reported in Brazil by 
Blotta et al. (1999) and the highest 70.6 to 1 reported by Shankar et al. (2011) for Colombia. 
These findings indicate that present knowledge is insufficient to explain the male-to-female 
differences according to country of residence and indicate that inter-country variability 
needs further study.  
The difference in the incidence of overt PCM between adult men and women has also been 
explained on hormonal grounds. In 27 women with the mycosis, 70% had menopausal signs 
and in 11% hysterectomy had been performed (Severo et al., 1998). Interestingly, in a series 
of 95 children with PCM collected from various Brazilian reports, there were 51 boys and 44 
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girls for a 1.16 to 1 ratio (Shankar et al., 2011). Such results contrast sharply with the 11.1 to 1 
ratio recorded for overt PCM in adults. Since in children hormonal expression has not yet 
been fully developed, the finding of an almost equal gender distribution in prepubertal 
patients strengthens the protective role of hormones in this fungal disorder. 
Additionally, in the experimental mouse model of PCM infection, differences in male and 
female animals have been noted. The fungus secretes a 17 beta estradiol-binding protein that 
attaches to the female hormone, regulating protein expression and hindering the mycelia to 
yeast transition so that in females fungal development is halted and the infection is 
controlled. On the other hand, in males conidia transform promptly into yeast cells and 
these multiply actively, resulting in progressive infection (Shankar et al., 2011). Additionally 
and as will be explained below, females exhibit a more active cellular immune response 
capable of halting the progress of the infection.  
2.2.3 Distribution by occupation 
Approximately 60% of the patients with active PCM work or have worked in agriculture-
related jobs, notably in tobacco, coffee and sugarcane fields (Calle et al., 2001; Colombo et 
al., 2011; Nucci et al., 2009; Paniago et al., 2003). Other occupations mentioned in large series 
are masonry, bricklaying and mining, as well as lumberjacking in indigenous forests. These 
occupations are, ultimately, associated with inhalation of dust (Conti-Diaz & Calegari, 1979; 
Lacaz et al., 2002; Paniago et al., 2003; Restrepo et al., 2011). Even though residence in rural 
areas is a common trait among PCM patients, migration to urban settlements would be 
accompanied by a change in jobs so that when the diagnosis is established in these 
secondary localities, the medical history may record a different, non-PCM-related 
occupation. Additionally, recent land exploitation methods rely on insecticide application 
and soil burning, as done in sugarcane plantations, which should kill the fungus if present 
in the soil (Nucci et al., 2009; Restrepo et al., 2011). As a consequence, human exposure 
would no longer be as common; however, further observations are required to fully 
understand this point. 
2.2.4 Incidence and prevalence 
Despite the measures being implemented in Brazil, PCM is not yet a reportable disease, with 
the exception of the States of Mato Grosso do Sul, Minas Gerais and São Paulo (Bellissimo-
Rodrigues et al., 2011). Consequently, prevalence and incidence rates are not fully 
dependable. Coutinho et al. (2002) reported an annual incidence rate of 1–3 per 100,000 
inhabitants, and, based on 3,181 deaths known to have occurred as a result of PCM, a mean 
annual mortality rate of 1.45 per million inhabitants was estimated with a nonhomogenous 
spatial distribution among Brazil’s regions and states. The authors concluded that PCM was 
important because it was the eighth cause of death from predominantly chronic or recurrent 
types of infections and parasitic diseases. It also had the highest mortality rate among the 
systemic mycoses but had low visibility. The great majority of deaths occurred in males 
(84.75%) and in the older age groups.  
Bittencourt et al. (2005) analyzed 551 deaths of the mycosis in Parana State, Brazil, with an 
average annual mortality rate of 3.48 per million inhabitants, accounting not only for the 
fifth cause of death among the predominantly chronic infectious diseases, but also the 
highest mortality rate among the systemic mycoses. Santo (2008) reviewed 1,950 PCM death 
certificates finding that the largest number of deaths had occurred in men in the older age 
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groups and among rural workers. The largest series of cases ever published (Bellissimo-
Rodrigues et al., 2011) analyzed 1,000 Brazilian PCM patients and indicated that in the 1980–
1999 period, the incidence rates for the Riberão Preto district in São Paulo State were 
equivalent to a mean of 2.70 cases per 100,000 inhabitants. Colombian estimates show a 
much lower incidence rate, with the highest being 0.24 per 100,000 inhabitants. Since these 
were annual mean mortality rates calculated on the basis of 7,482 deaths reported to be 
caused by PCM, the figures varied from 1.45 to 3.48 per one million inhabitants (Bellissimo-
Rodrigues et al., 2011).  
The importance of this mycosis can be inferred by the high burden of deaths occurring 
among the working population in individuals aged 30–60 years, mostly men engaged in 
agriculture (Bellissimo-Rodrigues et al., 2011). 
2.3 Clinical presentations 
PCM presents a gamut of clinical manifestations grouped according to the organs involved 
and the duration of the disease (Franco et al., 1987; Restrepo et al., 2008). Depending on the 
age and immune status of the host and on the size of the inhaled fungal inoculum, infection 
could be asymptomatic or may give rise to several different forms of disease. In 
immunocompetent individuals, they usually overcome fungal invasion; nonetheless, the 
fungus could remain quiescent, and a latent infection may be established. Four different 
clinical presentations are recognized, as follows. 
2.3.1 Subclinical infection 
After inhalation of the fungal particles, individuals may develop minor pulmonary 
symptoms that cannot be differentiated from those produced by other agents of pneumonia. 
The clinical manifestations often resolve spontaneously without medical intervention; 
however, the fungus could persist in a latent form and may later give rise to disease through 
endogenous reactivation, an event that may coincide with an alteration of the host's immune 
response (Benard et al., 2005). In some cases, the initial infection may leave a residual lung 
lesion. The latter situation presents the so-called regressive form of PCM. The latency 
process is known to exist and is frequently prolonged (mean, 14 years), as revealed by the 
cases reported outside the endemic areas (Buitrago et al., 2011; Walker et al., 2008; Shankar 
et al., 2011). 
2.3.2 Acute/subacute or juvenile-type disease 
This form of the mycosis is the result of the progression of a unresolved initial infection. The 
acute/subacute progressive form is seen mainly in undernourished children and adults less 
than 30 years of age and is the form observed in immunosuppressed individuals, such as 
those with HIV infection. The juvenile form is characterized by predominant involvement of 
the reticuloendothelial system. The mean duration of symptoms at consultation is 60 days 
and the most frequently involved organs are lymph nodes, skin, liver and spleen; less 
frequently bone marrow, stomach, small bowel, bones and joints are also invaded (Benard et 
al., 1994; Londero et al., 1996; Mendes, 1994; Morejon et al., 2009; Pereira et al., 2004). 
2.3.3 Chronic or adult-type disease 
This is the most frequently reported form of PCM, it has a prolonged course (months to 
years) and is diagnosed mainly in patients ranging from 30 to 50 years of age. This clinical 
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form is characterized by significant lung damage as well as extrapulmonary manifestations. 
The respiratory symptoms become apparent only after several years with productive cough 
seen in 50% of the patients. Physical examination reveals few abnormalities even if extensive 
radiographic alterations are noted. The scarcity of respiratory symptoms explains why 
patients seek medical consultation based mainly on extrapulmonary manifestations, such as 
the presence of mucosal and skin lesions (Gomes et al., 2008; Marchiori et al., 2011; Mendes, 
1994; Tuder et al., 1985). Besides the lungs, the most frequently compromised organs are the 
oral mucosa (involving oropharynx and larynx), skin and adrenal glands. Less frequently, 
the nasal and anal mucosa, genital organs and central nervous system may also be attacked. 
Mucosal lesions may be single or multiple, are progressive and destructive, giving rise to 
bleeding and pain, and are accompanied by dysphonia, dysphagia and sialorrhea. 
2.3.4 Residual form 
This form manifests the sequelae of prior disease at a moment when fungal growth has been 
arrested and the patient has overexpressed his immune responses to the point of developing 
fibrosis. This is exemplified by the chronic form of the mycosis where the lungs support the 
most prominent fibrotic changes, a complication recorded in approximately 60% of the 
patients (Funari et al., 1999; Naranjo et al., 1990; Tobón et al., 1995, 2003; Tuder et al., 1985).  
The chronic progressive adult form often precedes the establishment of the residual form. In 
most cases, when the patient is finally diagnosed, this sequela is already present, reflecting 
the corresponding structural and functional alterations (Benard et al., 2005; Bethlem et al., 
1999; Lacaz et al., 2002; Restrepo et al., 2008). It is noteworthy that residual lesions do not 
respond to antifungal treatment. Pulmonary fibrosis is an incapacitating disorder that may 
lead to core pulmonale and, finally, to death (Tobón et al., 2003; Tuder et al., 1985). 
In the differential diagnosis of PCM, various diseases including tuberculosis, 
histoplasmosis, leishmaniasis, malignancies, lymphomatous disorders and certain 
abdominal syndromes should be considered (Campos et al., 2008; Nogueira et al., 2006; 
Ramos & Saraiva, 2008). It is important to note that PCM may coexist with tuberculosis in 
approximately 10% of the cases (Gomes et al., 2008; Quagliato et al., 2007). 
2.4 Establishing the diagnosis 
Diagnosis of PCM is based on the identification and isolation of the fungus. The microscopic 
visualization in representative clinical samples (including respiratory specimens or biopsies) 
of multiple budding yeast cells with a pilot’s wheel-like appearance by direct KOH 
preparations or special stains, establishes the diagnosis (Lacaz et al., 2002; Nucci et al., 2009; 
Restrepo et al., 2009, 2011). Isolation of the fungus in culture is considered the gold standard 
and is successful in 60–85% of the cases. Additionally, serologic and immune-based tests 
[including agar gel immunodiffusion, complement fixation, enzyme-linked immunosorbent 
assays (ELISA) and antigen detection] are also frequently employed. These laboratory tests 
have great value and can also be employed in follow-up studies (Gómez et al., 1997, 1998; 
Lacaz et al., 2002; Nucci et al., 2009; Restrepo et al., 2009, 2011). In addition, in the last 
decade, molecular tests to diagnose PCM have been implemented; these tests require further 
research (Buitrago et al., 2011; Gomes et al., 2000; Bialek et al., 2000a; Koishi et al., 2010). 
2.5 Therapeutic options 
Treatment of PCM should be implemented according to the disease form; in addition, 
adequate nutrition, control of associated diseases, and measures to stop smoking must be 
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implemented. Treatment of this mycosis includes sulfonamides, amphotericin B and azoles 
(Quagliato et al., 2007). Thus, in the case of minor and moderate forms of PCM, the 
combination of trimethoprim-sulfamethoxazole can be used (Shikanai-Yasuda et al., 2008). 
In cases of severe illness, treatment must be implemented using amphotericin B and 
continued with an oral antifungal, preferably itraconazole (Quagliato et al., 2007). Among 
the azoles, the latter is the drug of choice as it is effective in 98% of cases, irrespective of the 
clinical form, and has a low relapse rate (3%) (Naranjo et al., 1990; Shikanai-Yasuda et al., 
2002). Nonetheless, it may not be possible to eradicate the etiologic agent completely, and 
the risk of endogenous reactivation may persist. Treatment of PCM is prolonged, usually 
taking 6 months to 1 or maximum 2 years, but in general it should continue until clinical 
manifestations are resolved, except for those due to residual fibrotic sequelae (Hahn et al., 
2000; Shikanai-Yasuda et al., 2002). 
3. Pathogenesis of experimental PCM in mice 
Animal models are excellent tools to study the pathogenesis of the different infectious 
diseases. In order to understand the pathogenesis of PCM, different animal models of this 
mycosis have been established, using different hosts such as mice (Calich et al., 1985; Cano 
et al., 2000; Defaveri et al., 1982; McEwen et al., 1987; Moscardi & Franco, 1980), hamsters 
(Essayag et al., 2002; Iabuki & Montenegro, 1979; Peraçoli et al., 1982), guinea pigs (Fava-
Netto et al., 1961) and rats (Iovannitti et al., 1999). All of these are powerful tools to explore 
the molecular and cellular aspects of PCM pathogenesis. The ability to control multiple 
variables in the establishment of the experimental models allows simulation of the human 
disease states and monitoring their course quantitatively. Therefore, animal models are a 
useful alternative to study the kinetics of the mechanisms involved in the pathogenesis of 
PCM.   
3.1 Establishment of a pulmonary PCM model induced by Pb-conidia 
Problems determining the initial stages of the host–P. brasiliensis interaction in humans 
when the fungal habitat is unknown indicate that an animal model of pulmonary PCM that 
would mimic, as closely as possible, human disease is needed. Such a model was established 
by the intranasal administration of Pb-conidia to male BALB/c mice to be studied 
sequentially during the course of infection (McEwen et al., 1987; Restrepo et al., 1992). In this 
model, we have determined certain immune, histological and radiological aspects of 
pulmonary lesions by histopathology (early and chronic periods) (González et al., 2008a, b, 
c; Lopera et al., 2010, 2011) as well as by high-resolution computed tomography-HRCT 
(chronic periods) (Lopera et al., 2010). The local immune response has been measured by 
determining different cytokines in supernatants of pulmonary homogenates (González et 
al., 2003, 2005b, 2008d; Naranjo et al., 2010).  
3.2 Early immunological and histopathological findings in the model 
It has been hypothesized that once P. brasiliensis conidia reach the lung, they interact initially 
with the extracellular matrix (ECM) proteins (expressed predominantly in lung tissue), lung 
epithelial cells (which also express these ECM proteins on their own surface), alveolar 
macrophages (Ms) and pulmonary dendritic cells. In addition, it has been reported that the 
different fungal morphotypes of P. brasiliensis (conidia, yeast cells and mycelia) exhibit on 
their surface adhesin-type molecules that allow both binding to several ECM proteins – 
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mainly fibronectin, fibrinogen and laminin – and adherence to epithelial cells (Caro et al., 
2008; González et al., 2005a, 2008a, b; Hernández et al., 2010). Activation of pulmonary cells, 
mainly Ms, took place after fungal interaction, thus initiating the inflammatory process 
through production of pro-inflammatory cytokines and chemokines, which in turn induced 
the expression of adhesion molecules on the leukocytes' surface (González et al., 2003, 
2005b).   
3.2.1 Early pulmonary inflammatory process    
During the first 4 days post-infection, an acute inflammatory process, composed mainly of 
polymorphonuclear neutrophils (PMNs) and Ms, was observed in the lungs (Cock et al., 
2000; González et al., 2003, 2005b; Restrepo et al., 1992). At the histopathological level, this 
inflammatory event concurred with a bronchopneumonic process in which PMNs and Ms 
accumulated and fused with each other to constitute extensive, ill-defined masses, located 
inside the alveolar and the surrounding peribronchiolar spaces, resulting in involvement of 
approximately 40% of the lung’s area (Cock et al., 2000; González et al., 2005b; Restrepo et 
al., 1992). It should be noted that during the first 3 days post-challenge, eosinophils and 
lymphocytes were also observed at the perivascular level (González et al., 2005b). After the 
4th day post-challenge, the cellular infiltrate was replaced by mononuclear cells, mainly Ms. 
The results of additional studies conducted in bronchoalveolar lavage fluids (BALs) 
coincided with the in situ description, with predominance of PMNs and Ms during the 
period indicated (González et al., 2003). Interestingly, at the end of the 2nd week post-
infection, the inflammatory process decreased, indicating transient control of fungal 
invasion (González et al., 2005b).  
Similarly, high levels of pro-inflammatory cytokines [interleukin (IL)-1, IL-6, tumor 
necrosis factor-alpha (TNF-) and chemokine, macrophage inflammatory protein (MIP)-2)] 
were recorded, especially in the pulmonary compartments and during the first 4 days post-
challenge, (González et al., 2003). The production of these molecules by both inflammatory 
and endothelial cells accounted for the recruitment of certain inflammatory cells indirectly 
through induction of adhesion molecule expression, which in turn mediated migration of 
the inflammatory cells into the injured tissue (Tracey & Cerami, 1994). In accordance with 
the above results, a significant decrease in the mouse pulmonary fungal burden occurred 
after the first 2 days post-challenge (Cock et al., 2000; González et al, 2005b).  
3.2.2 Expression of adhesion molecules and extracellular matrix proteins in the lungs 
Adhesion molecules expressed on the cell’s surface of both leukocytes and endothelial cells 
are important mediators in the recruitment of leukocytes to sites of inflammation including 
the lungs (Albeda et al., 1994; Pilewski & Albelda, 1993). Expression of these adhesion 
molecules is induced by the production of pro-inflammatory cytokines such as TNF- and 
IL-1 (Osborn et al., 1989; Masinovsky et al., 1990), which have been reported as important 
inflammatory components in a variety of lung diseases including those caused by fungi 
(Hamacher & Schaberg, 1994; Izzo et al., 1998; Yokomura et al., 2001; Yu & Limper, 1997). In 
our PCM mouse model, we have observed that lungs of mice infected intranasally with 
P.brasiliensis conidia show a higher expression of adhesion molecules during the first 4 days 
post-challenge. Thus, the intercellular adhesion molecule-1 (ICAM-1) was overexpressed 
mainly on bronchiolar epithelium, vascular endothelium, pneumocytes and Ms; the 
vascular cell adhesion molecule-1 (VCAM-1) was also overexpressed but only in the 
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vascular endothelial cells, while CD18 and Mac-1, two molecules belonging to the 2 
integrin family, were strongly expressed on PMNs and Ms (González et al., 2005b). 
In lungs of mice infected with P. brasiliensis conidia, an initial deposition of fibrin-like 
material was detected after 2 days post-infection. In addition, an increased deposition and 
rearrangement of the following ECM proteins – laminin, fibronectin, fibrinogen, collagen 
and proteoglycans – were observed not only at the beginning of infection, but also during 
the late periods of fungal infection (González et al., 2008c). Interestingly, this increased 
deposition of ECM proteins in the lungs of infected mice was accompanied by a marked 
afflux of pro-inflammatory cells (González et al., 2008c).  
In addition, P. brasiliensis is known to express adhesin-like molecules on its surface that 
recognize and bind to ECM proteins (Barbosa et al., 2006; González et al., 2005a). More 
recently, in elegant experiments using antisense technology, the role of a P. brasiliensis-
adhesin molecule was confirmed when a 32-kDa protein, a putative adhesion member of the 
haloacid dehalogenase (HAD) superfamily of hydrolases, conferred both adherence capacity 
to pulmonary human epithelial cells and virulence in a mouse model of infection 
(Hernández et al., 2010) 
The observations described above may suggest that ECM proteins modulate the 
pathogenesis of PCM by means of two mechanisms: 1) participation in the migration of pro-
inflammatory cells into the lungs and 2) serving as a binding protein for P. brasiliensis 
expressing on its surface adhesin-like molecules (receptors). These interactions may serve 
the fungus both for attachment to host tissue (evading the physical barriers) and 
dissemination to other organs, contributing in this manner to the establishment of the 
disease process. 
3.2.3 Expression by pulmonary phagocytes of microbicidal molecules 
During any infectious process, phagocytic cells are the main effector cells, which upon their 
activation (e.g., by cytokines), produce microbicidal substances [i.e., degradative enzymes, 
defensins, lysozymes, reactive oxygen intermediates (ROS) and reactive nitrogen 
intermediates (RNI)] capable of inhibiting and destroying several pathogens (Nathan & 
Shiloh, 2000; Newman et al., 2000).  
Taking into account that both PMN and Ms are the principal components of the pulmonary 
inflammatory infiltrate of mice infected with P. brasiliensis conidia, the expression of 
microbicidal molecules produced by these phagocytic cells in the PCM model was 
determined. In vivo studies failed to detect nitric oxide (NO) production or inducible nitric 
oxide synthase (iNOS, the enzyme responsible for NO production) during the early days 
post-challenge in the lungs of mice infected with P. brasiliensis. Interestingly, as will be 
described below, a higher expression of iNOS was observed in the late periods of infection 
(González et al., 2008d). In additional studies, we observed an increase of in situ lysozyme 
expression (PMN and Ms) in the lungs of mice infected with P. brasiliensis conidia during 
the first 4 days post-challenge. This expression was accompanied by a decrease in the 
number of fungal propagules (González et al., 2008), observations suggesting that 
lysozymes may exert an antifungal effect against P. brasiliensis. 
Altogether, the above observations led us to propose a description of the initial mechanism 
triggered by the infection with P. brasiliensis conidia:  
1. Once the conidia reach the lungs, they adhere to both ECM proteins and epithelial cells 
through the interaction with adhesins present on their own surface; in addition, the 
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fungal cells may interact with alveolar Ms or dendritic cells present on the alveolar 
space.  
2. Once the adhesion process or the cellular interaction takes place, induction of the 
production of pro-inflammatory cytokines takes place, which in turn stimulates the 
expression of adhesion molecules with such expression modulating the migration of 
circulating inflammatory cells into the lung tissue. This event triggers a strong 
inflammatory process, enhancing cytokine and chemokine production as well as 
increasing the deposition and rearrangement of ECM proteins.  
3. P. brasiliensis conidia will experience a transitional process to yeast cells if no inhibitory 
mechanism intervenes in such process.  
4. Once the phagocytes are activated, they will express, or produce, microbicidal 
molecules capable of destroying the fungus.  
5. If the fungus is able to overcome the fungicidal mechanisms exerted by the host's 
defenses, dissemination to other organs will occur, perhaps using their adhesins to bind 
to ECM proteins or by producing degradative enzymes able to cleave such ECM 
proteins. Finally, the disease process will become established. 
3.3 Chronic immune responses in the model 
The intranasal inoculation of P. brasiliensis conidia into BALB/c male mice resulted in a 
progressive disease characterized by an increase of CFUs in the lungs, with maximal values 
at the 12th and 16th week’s post-infection (Franco et al., 1998). In addition, extrapulmonary 
dissemination to the spleen (week 4) and liver (week 12) will take place, as indicated by the 
isolation in culture of the fungus from these organs (McEwen et al., 1987). 
Then, during the infectious process corresponding to the chronic stages, different 
immunological mechanisms such as inflammatory responses, cytokine production, 
metalloproteinase expression, nitric oxide participation, granuloma formation and, finally, 
the chronic pulmonary sequelae characterized by fibrosis enter into play, as described 
below.  
3.3.1 Production of cytokines 
Additionally, several studies on the cytokines implicated in the chronic stages of 
experimental PCM have demonstrated, through ELISA assays and the Multiplex system, 
that from the 4th to the 8th week post-challenge, infected mice exhibited a significant increase 
in IL-1, TNF-, IL-12p40, RANTES, MIG, PDGF-b, IL-13 and TGF-. Even though these 
cytokines have been implicated in the formation and maintenance of granuloma, some of 
them (IL-1, TNF-, IL-13 and TGF-) are also directly involved in fibrosis generation 
(Franco et al., 1998; Lopera et al., 2011; Naranjo et al., 2011; Wynn, 2007).  
Other authors, using both male and female mice in a PCM experimental model, have shown 
different immune responses that are gender-dependent with high production of Th1 cytokines 
and T-beta expression by the paracoccin-stimulated cultures of spleen cells from infected 
female mice; in contrast, cells from infected males produced higher levels of the Th2 cytokines 
and expressed GATA-3 (Pinzan et al., 2010). These results were confirmed using mice that had 
been submitted to gonadectomy followed by inverse hormonal reconstitution, where spleen 
cells derived from castrated males reconstituted with estradiol had produced higher levels of 
IFN-γ and lower levels of IL-10 than normal males in response to paracoccin stimulus. In 
contrast, spleen cells from castrated female mice that had been treated with testosterone 
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produced more IL-10 and less IFN-γ than cells from normal females (Pinzan et al., 2010). In 
conclusion, these results reveal that the sexual hormones had a profound effect on the biology 
of immune cells, with estradiol favoring protective responses against P.brasiliensis infection. 
3.3.2 iNOS expression and nitric oxide (NO) production in the lungs 
In this PCM pulmonary model, the role of the NO system was determined during the 
chronic immune response by means of lung biopsies from infected mice. We developed an 
immunohistochemical stain for iNOS (NOS2) and observed that this enzyme was expressed 
mainly in vivo by the epithelioid histiocytes, with its maximal expression occurring 12 weeks 
after infection (González et al., 2008d). The expression of iNOS correlated significantly 
(r=0.77891) with the number of granulomas present in the pulmonary parenchyma 
(González et al., 2008d), suggesting that at this stage iNOS induction may depend on factors 
or mechanisms related to the environment in the granuloma (Goldman et al., 1996).  
In addition, the in vivo administration of aminoguanidine (a highly specific inhibitor of 
iNOS) to P. brasiliensis-infected and noninfected mice induced in the former a significant 
reduction of their survival in comparison with negative control mice. These results suggest 
that during the chronic stages (12–17 weeks post-infection), the NO system played an 
important protective role against fungal infection (González et al., 2008d). This effect has 
also been observed in a model of latent tuberculosis (Flynn et al., 1998). However, 
Nascimento et al. (2002) proposed a dual role for nitric oxide in another experimental PCM 
model, where NOS2-derived NO would be essential for resistance to the fungus, but its 
overproduction would be associated with susceptibility. 
Using NOS2-deficient mice, Livonesi et al. (2009) demonstrated that this enzyme is to be 
considered as a resistance factor during experimental PCM because it controls fungal 
proliferation, cytokine production, development of a high inflammatory response and 
consequently formation of necrosis. Other authors demonstrated that NO has an important 
role in granuloma modulation, by controlling osteopontin and MMP production, as well as 
by inducing loose granuloma formation and fungal dissemination, resulting, at later phases, 
in progression of experimental PCM (Nishikaku et al., 2009). However, iNOS-derived NO 
seems not to be the sole factor responsible for the immunosuppression observed during the 
infections caused by P. brasiliensis. 
3.3.3 Granulomatous inflammation in the lungs during experimental PCM 
The granuloma is the histologic hallmark of a variety of infectious and noninfectious 
processes, including PCM, all of which elicit chronic granulomatous inflammation. The 
word “granuloma” is derived from the Latin word granulum, which means a small particle 
of grain and, traditionally, is microscopically described as a compact, rounded aggregate of 
Ms usually surrounded by a rim of lymphocytes that results in a response to chronic 
antigenic stimulation. Aggregation of Ms is the minimum requirement of a granuloma, 
regardless of whether the lesion also contains necrosis, lymphocytes, plasma cells, or 
multinucleated giant cells (Mukhopadhyay & Gal, 2010). The granuloma functions both as a 
niche in which some microorganisms can grow or persist and as an immunologic 
microenvironment in which cells interact to control and prevent dissemination of the 
eliciting pathogen (Flynn et al., 2011). 
Pulmonary granulomatous inflammation in experimental PCM is a dynamic process that 
goes from dispersal parenchymal inflammation, to well-defined nodules, from periarterial 
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sheath inflammation to pseudotumoral masses (Figure 2) (Lopera et al., 2011). The lung’s 
area occupied by the inflammatory reaction increases gradually from 8 to 12 weeks after 
P.brasiliensis infection, involving up to 40% of the lung’s area. In the following subsections, 
we will describe the structure and cellular composition of granuloma during the 
experimental infection; review the formation and maintenance of the granuloma reported in 
the literature and compare the main features of human and experimental pulmonary 
histopathology during the course of P. brasiliensis infection.  
 
 
Fig. 2. Pulmonary lesions observed in BALB/c mice infected with P. brasiliensis conidia. (A) 
Well-defined nodules. (B) Confluent granulomas. (C) Periarterial sheath inflammation. (D) 
Dispersed parenchymal inflammation. H&E stained slides, 10X.   
Structure and cellularity of pulmonary lesions: The well-defined granuloma or the nodular 
pattern corresponds to multiple sphere-like or oval parenchymal granulomas adjacent to 
terminal bronchioles, about 400 µm in diameter, sometimes isolated but becoming confluent 
as infection progresses. This is the predominant pattern throughout the infectious process in 
the lungs of BALB/c mice infected with P. brasiliensis conidia. In humans and experimental 
PCM, the general structure of granuloma consists in two distinct zones: one noncollagenic 
central zone composed of P. brasiliensis yeasts and Ms, and one peripheral zone composed 
by lymphocytes and fibroblastoid-like cells (Kerr et al., 1988). However, the cellularity and 
pattern of lesions change as infection progresses. A summary of the main structural and 
cellular changes in the granulomas sequentially observed in the experimental model of PCM 
is presented below (Lopera et al., 2011).  
During the early stages of granuloma development, 4 weeks post-infection in our 
experimental model, granulomas were composed of a central core or zone of Ms and fungi 
with a frequent and intense infiltration by PMNs, sometimes presenting an apoptotic aspect. 
Some Ms formed multinucleated giant cells. The central zones of the granulomas were 
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surrounded by a fibroblast-like layer expressing concentric layers of reticular fibers with a 
lesser amount of interstitial collagen. The peripheral zone consisted of a noncontinuous halo 
of small lymphocytes, at times forming pseudofollicular lymphocyte aggregates. At this 
time, an intense and diffuse parenchymal inflammation, disposed near or around the 
granulomas, accompanied the pulmonary response to P. brasiliensis. 
During the most chronic stages of the infection (8, 12 and 16 weeks), Ms acquired a 
xanthomatous aspect, cholesterol crystals appeared in the central zone of the granuloma and 
a large number of mature plasma cells located at the periphery and mixed with the 
fibroblastic-like cells were observed. Besides well-defined granulomas, the peak of 
inflammation (8–12 weeks p.i.) was characterized by periarterial inflammation accompanied 
by lymphatic dilatation and edema. The cellular infiltrate defined the periarterial 
inflammatory sheaths with dispersed fungi (Figure 3) and more mature plasmocytes and 
eosinophils in comparison with the granuloma.  
 
 
Fig. 3. Fungal aspects as seen in the lesions of a mouse with experimental pulmonary PCM. (A) 
Nodule full of fungi in the central area (10X), that present multiple-budding yeast cells with 
varying sizes (insert 100X). (B) Numerous fungi spread all over the periarterial space (10X), 
several of them presenting a special perifungal space (insert 100X).  Grocott’s stained slides. 
Multiple granulomas fused and formed pseudotumoral masses or “paracoccidioidomas” 
five to six times larger than nodules (2,000 ± 194 µm in length) were observed in the final 
period of evaluation (16 weeks p.i.) in this experimental model. 
Formation and maintenance of P. brasiliensis-induced granuloma: The mechanisms that drive the 
migration of cells that will form and maintain the granuloma around P. brasiliensis have 
begun to be explored. However, important differences in the experimental models as 
concerns the infective propagules (conidia, yeast cells) and the fungal isolates used, as well 
as the route of inoculation and the experimental host’s genetic background, makes 
conclusions difficult. Table 1 presents the main results of research that has analyzed the 
cells and mediators involved in P. brasiliensis-induced granulomatous inflammatory 
response centered on pulmonary findings.  
The major biological significance of granuloma is the limitation of the infection to a local 
area . However, diffuse and loose granulomatous inflammation does not limit infection  and 
is associated with incapacity to control the disease, as shown by the large number of fungal 
cells and the diminished survival time of infected animals (Livonesi et al., 2008, 2009).  
An inflammatory response is necessary for disease control but it is also responsible for the 
typical immunopathology caused by diseases such as PCM that include tissue necrosis and 
cavitations in the center of granulomas.  
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Experimental model Main results Reference 
Male BALB/c mice infected i.n. 
with 26×106 viable or heat-
killed P.brasiliensis yeasts; or 
inoculated with 6.5×106 
nonviable fragmented yeast 
cells 
Granuloma formation required viable yeast cells or 
conidia. Heat-killed Pb yeasts or yeast fragments did 
not induce granuloma formation. 
(Bedoya et al., 
1986; Cock et 
al., 2000) 
Rats infected i.p. with 
P.brasiliensis  yeasts 
Although most lesions developed in peritoneal cavity, 
granulomas also appeared in lung.  
Pulmonary granulomas were less collagenic than 
those observed in omentum, diaphragm and liver. 
(Kerr, et al., 
1988) 
Male C57Bl/6 mice and IFN-γ 
and TNF receptor p55-deficient 
mice infected i.v. with 1×106 
P.brasiliensis yeast cells 
IFN- and TNF receptor p55-deficient mice were not 
able to build organized granulomas, presented greater 
number of fungi and high rates of mortality. 
(Souto et al., 
2000) 
Male C57BL/6 and ICAM-1KO 
mice infected i.t. with 1×106 Pb 
18 yeast cells 
ICAM-1 was required for the early formation of 
granulomas. In the absence of ICAM-1, granuloma 
development delayed 60 days vs. 30 days in control 
mice. 
(Moreira et al., 
2006) 
In vitro granuloma model 
induced by gp43-coated beads 
In vitro granuloma formation required B1-cells and 
Ms interaction. Ms alone were not able to migrate 
to the beads and form granulomas. Soluble gp43 
antigen-enhanced granuloma-like structure 
formation.  
(Vigna et al., 
2006) 
BALB/c and BALB/Xid mice 
infected i.t. with 1×106 Pb18 
yeast cells 
Mice deficient in B1-cells (BALB/Xid mice) exhibited 
smaller pulmonary granulomas with less fungi and 
longer survival. Therefore, B1-cells participated in the 
exacerbation of granulomatous lesions and increased 
host susceptibility to infection. 
(Popi et al., 
2008) 
C57BL/6 IL-12p40−/− and WT 
mice infected i.v. with 1×106 
Pb18 yeast. 
In the absence of the IL-12p40 subunit, involved in 
both IL-12 and IL-23 formation, mice developed high 
number of pulmonary granulomas without defined 
delimitations associated with high number of yeast 
cells.  
(Livonesi et al., 
2008) 
C57BL/6 iNOS−/− and WT mice 
infected i.v. with 1×106 Pb18 
yeast 
iNOS−/− mice showed granulomas with high 
inflammatory response, central necrotic areas, diffuse 
distribution of cells, incipient reticulin fiber pattern 
and high number of yeast cells.  
(Livonesi et al., 
2009) 
BALB/c male mice infected i.n. 
with 4×106 P.brasiliensis conidia 
Extracellular matrix proteins overexpressed and 
suffered rearrangement process during the course of 




Abbreviations:  i.n.: intranasally, i.p.: intraperitoneally, i.t.: intratracheally i.v.: intravenously, Pb: P. 
brasiliensis, WT: wild-type 
Table 1. Contribution of cell subsets and molecules in pulmonary granuloma formation 
following infection with P. brasiliensis.  
3.3.4 Fibrosis as sequelae of PCM disease 
Pulmonary fibrosis is detected in several disorders with known or unknown etiologies 
(Datta et al., 2011). In this sense, this progressive and prominent complication is also 
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observed in approximately 60% of patients suffering from the chronic form of PCM 
(Restrepo et al., 2008). Given that the P. brasiliensis microniche remains uncharacterized and 
taking into consideration the prolonged latency observed in PCM, the characteristics of the 
primary infection have not been defined, and great difficulties have arisen when 
sequentially evaluating the development of fibrosis attributed to this infection in humans. 
However, results from the experimental pulmonary PCM model have given convincing 
evidence as to the progress of this disease (González et al., 2008b).  
In contrast with idiopathic pulmonary fibrosis (IPF) for which current research indicates that 
inflammation is of lesser importance with fibrosis appearing primarily as a disorder of 
fibroblast proliferation and activation in response to an as yet unknown trigger (Meltzer & 
Noble, 2008), the development of fibrosis in PCM is a progressive event, resulting from a 
persistent antigenic stimulus leading to chronic inflammation and establishment of fibrosis 
mainly located in the perihilar region, the main bronchi and their branches, and the large 
pulmonary vessels (Restrepo et al., 2011). The functional limitation caused by the 
development of fibrosis may advance toward cor pulmonale, progressive lung incapacity 
and finally death (Restrepo et al., 2008; Tobón et al., 2003; Tuder et al., 1985). 
The fibrosis process begins with acute injury caused by the interaction of P. brasiliensis 
conidia with ECM proteins and lung epithelial cells; this interaction is followed by chronic 
granulomatous inflammation with fibroblast proliferation and activation, an increase in 
ECM proteins predominantly composed of fibronectin, fibrinogen, collagen type I and III, as 
observed in the surroundings of the granulomas. 
These EM proteins contribute to the establishment of fibronodular lesions that continue to 
advance even after appropriate antifungal therapy with itraconazole, a medication that 
effectively controls the active stage of this mycosis but does not hinder lung fibrosis 
(González et al., 2008a, c; Naranjo et al., 2010; Tobón et al., 2003).  
Even though patients with chronic PCM show well-established pulmonary lesions at 
diagnosis, all of them are not in the same stage of infection development, explaining why, 
although not sequentially, several studies have been able to describe certain histological 
patterns present during the development of fibrosis in humans. Tuder et al. (1985) described 
the lungs of 12 patients with chronic PCM in histopathological terms and concluded that 
chronic pulmonary PCM is a disease that affects both lungs equally and that fibrosis is 
mainly related to the progressive course of the granulomatous reaction to cicatrization and, 
to a lesser degree, is probably due to direct induction by the fungi. This study described 
extensive areas of dense fibrosis close to the hilar region and involved structures such as the 
bronchi and lymph nodes with fibrosis extending as fibrous septa of variable thickness 
throughout the lung parenchyma (Tuder et al., 1985).  
With the development of HRCT, several studies have been published demonstrating the 
correlation between histopathological and radiological findings, thus providing a more 
precise characterization of the pattern and magnitude of the lung abnormalities, as well as 
better follow-up of patients with chronic pulmonary PCM. In regards to fibrotic findings on 
chest tomography, this process has been described as thickening of interlobular and alveolar 
septa, primarily those interconnecting the granulomas (Marchiori et al., 2011). This has been 
correlated histopathologically with prominent collagen deposition, especially near the hilar 
regions, comprising lymph nodes, bronchi and the main pulmonary artery branches; 
additionally, pulmonary architectural alterations were also observed (Funari et al., 1999; 
Marchiori et al., 2011; Souza et al., 2006).  
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Notwithstanding, in some patients, fibrosis development has been recorded in the absence 
of a clearly established granulomatous reaction, thus allowing speculation that the fungus 
itself might induce an active and higher collagen deposition (Marchiori et al., 2011; Tuder et 
al., 1985). 
In reference to PCM animal models, several have been developed with the purpose of 
understanding the complete course of the disease; despite differences on the inoculum used 
(infective forms and concentration), fungal isolates, route of inoculation and host genetic 
background, the results have made it possible to define certain common phases during the 
granulomatous inflammation process (Burger et al., 1996; Calich et al., 1985; Da Silva et al., 
2009; Xidieh et al., 1999). However, only the murine model of chronic pulmonary PCM in 
male BALB/c mice induced by the intranasal inoculation of naturally infective conidia has 
provided a reproducible model to observe in detail not only the characteristics of the 
inflammatory response induced by P. brasiliensis conidia, but also the important components 
of the PCM residual form (Cock et al., 2000; González et al., 2008a; Restrepo et al., 1992).  
In the murine model described above, it was determined that at 4 weeks post-infection, 
when the granuloma are well shaped, thin fibers of collagen and reticulin became evident, 
suggesting the beginning of a fibrotic process, which progressed simultaneously with the 
presence of leukocyte infiltrates surrounding the granuloma (Lopera et al., 2010). After the 
8th week post-infection, thick fibers of collagen and reticulin became evident as an indicator 
of established fibrosis; fibers of both proteins gradually increasing up to 12 weeks post-
infection indicated the collagenesis process reaching its highest intensity, with particular 
involvement of the periarterial space and the surrounding area of the granuloma (Figure 4), 
whether or not it was confluent. Observations made in the 16th week post-infection revealed 
a well-established pulmonary fibrosis process (González et al., 2008b, c; Lopera et al., 2010; 
Naranjo et al., 2010). 
 
 
Fig. 4. Characteristics of lung fibrosis in P. brasiliensis infected mice.  (A) Increased collagen 
(red fibers) noticed in the periarterial inflammatory reaction (thin arrow), in the periphery of 
granulomas (thick arrow) and in the bronchial wall (arrow's head). (B) Panoramic view of 
the entire lung. (C) Detail of collagen fibers deposition in the periphery of a granuloma and 
around a bronchus. Picrosirius and fast green (PIFG) stained lung sections. (Scale bars: A = 
100µm, B = 2mm and C = 30µm).  
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One of the pathogenic mechanisms involved in the progressive accumulation of collagen 
and later development of fibrosis could be the disproportion between synthesis and 
degradation of ECM components such as reticulin and collagen, primarily due to an 
imbalance among the mediators of matrix degradation, metalloproteinases (MMPs) and 
their inhibitors (Garcia-de-Alba et al., 2010; Pardo & Selman, 2006). The presence of MMPs, 
specifically collagenase MMP-1 and gelatinase-A MMP-2, and the tissue inhibitors of MMPs 
(TIMP-1) was evaluated using immune stain in the murine model of pulmonary PCM. The 
results indicated that 4 weeks after P. brasiliensis intranasal inoculation, 85% of infected mice 
expressed MMP-1 as MMP-2 and 71% of them expressed TIMP-1, both with moderate 
intensity; at 16 weeks post-infection, almost all them showed equally positive immune stains 
to the TIMP-1 and MMPs evaluated, with the difference that close to 37% of them exhibited 
high stain intensity (Bárcenas et al., 2004). The immune stain was observed on epithelial 
alveolar cells and alveolar Ms located in peribronchial tissue, although by immune 
staining, it was not possible to observe an imbalance between MMPs and TIMP-1. This 
study suggested that as more collagen becomes deposited, more activity of MMPs and their 
inhibitors will be present. 
Although much remains to be done, the results offered by animal models have contributed 
greatly to understanding the genesis of the fibrotic process in PCM. 
3.3.5 Experimental attempts to control fibrosis 
Although currently several antifungal drugs are available for the treatment of PCM, as 
mentioned above in the diagnosis and treatment sections, the majority of them require 
prolonged therapies oscillating between 1 and 2 years (Borges-Walmsley et al., 2002). 
Additionally and even though these antifungal drugs can arrest the progression of the 
infection by restricting fungal proliferation, the principal sequelae of PCM, pulmonary 
fibrosis, persists, and it has been observed in both humans and murine models (Naranjo et 
al., 2010; Tobón et al., 2003). The fibrosis process generates progressive lung incapacity and 
it is probably a source of P. brasiliensis in future relapses of the disease (Borges-Walmsley et 
al., 2002). For these reasons, the need to search for new drugs or for the implementation of 
combined therapies has been indicated (Pappas, 2004), including experiments aiming to 
prevent or at least reduce the appearance of this serious sequela. 
According to the recommendations given by the American Thoracic Society, the basic 
therapy for the treatment of patients suffering from pulmonary fibrosis includes certain 
immunosuppressive drugs based on the theory that the development of fibrosis is 
attributable to persistent inflammatory stimulus. However, the effect of using this kind of 
medication in humans with the chronic form of PCM remains unknown. 
Recently, we evaluated the effect of two combined therapies (itraconazole + prednisolone) 
and (itraconazole + pentoxifylline) on the development of fibrosis using our murine model 
of pulmonary PCM, which reproduces the human infection from its inception until reaching 
the chronic form (Naranjo et al., 2011). In this study, the azolic derivative (itraconazole) was 
used because it is the antifungal treatment of choice for PCM (Restrepo et al., 2011; Shikanai-
Yasuda et al., 2006). In reference to the combined itraconazole + prednisolone therapy, the 
authors reported that although a significant reduction in both granulomatous inflammation 
and development of fibrosis was observed when this combined therapy was used, once it 
was ended, the fibrotic process reappeared and progressed over the levels observed when 
treatment with itraconazole alone was given. On the contrary, the use of itraconazole 
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combined with pentoxifylline, a methylxanthine compound with recognized immune 
modulatory properties (Inoue et al., 2004; Tong et al., 2004) and antifibrotic effects when 
acting on fibroblast cells (Fang et al., 2003; Romanelli et al., 1997; Valente et al., 2003), 
generated good results. 
The combined itraconazole + pentoxifylline therapy promptly reduced the granulomatous 
inflammation and caused a significant and rapid decrease of both thin reticulin and collagen 
fibers. The most important result was that thick fiber deposition of these proteins, which are 
considered fibrosis indicators, was reduced to normal levels, as seen in the uninfected mice, 
and remained low even after the end of the treatment. Considering fungal loads, it was 
demonstrated that the addition of pentoxifylline to itraconazole treatment did not produce 
additional deleterious effects on itraconazole antifungal activity; on the contrary, a tendency 
towards a faster reduction of fungal burdens was observed when the combined therapy was 
used (Naranjo et al., 2011). These beneficial effects were noted even when such combined 
therapy was started belatedly at 8 weeks post-infection, a time at which the fibrosis process 
was already established in the murine model. 
The fact that in mice the combined itraconazole + pentoxifylline therapy promptly reduced 
the development of pulmonary fibrosis to levels lower than those seen with antifungal 
therapy alone, and that this effect was maintained even after treatment termination, presents 
a promising advance in the development and establishment of adjunctive immunotherapies 
for the treatment not only of pulmonary chronic PCM but also of several disorders or 
chronic infections that lead to the development of fibrosis.   
These findings could imply not only a reduction of treatment costs but, more importantly, 
improvement in the chronic pulmonary PCM patients' quality of life. 
4. Pulmonary histopathology in patients with PCM: The counterpart of the 
experimental infection 
Reports on the pathologic features of pulmonary lesions in patients with the chronic adult 
form of PCM are scarce in the literature. The classical report was published by Tuder et al. 
(1985), who described five main pathologic aspects in the lungs of 12 patients with PCM as 
follows:  
1. Pneumonic reaction characterized by acute alveolitis with histiocytes, few PMNs, 
lymphocytes and plasma cells;  
2. Early granulomatous formation described as circumscribed epithelioid granulomas 
with reticulin fibers but with no dense collagen layer surrounding them;  
3. Mature and healed granuloma with collagen in their periphery;  
4. Mixed pattern (early and mature granuloma in the same pulmonary area);  
5. Pulmonary fibrosis.  
In addition, the pulmonary lesions could be either diffuse or circumscribed (Machado, 
1965).  
Most recently, a study that included 23 patients with lung samples obtained by surgical 
biopsy or at necropsy showed similar pathological features that included alveolar wall and 
interlobular septal thickening, as determined by the accumulation of inflammatory cells or, 
less frequently, by fibrosis; filling of the alveolar spaces with inflammatory exudate; 
granulomas with or without fibrosis; and other evidence of fibrosis, such as architectural 
distortion and honeycombing. Cavitation secondary to necrosis was also a common finding 
(Marchiori et al., 2011).  
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As mentioned before, the PCM experimental animal models revealed a chronic, progressive 
infection that closely resembled human lesions but that did not reproduce certain 
histopathological aspects such as cavitated nodules, emphysema and the honeycombing 
pattern. 
5. Radiological aspects of PCM in humans and experimental mice 
Conventional HRCT has been applied as a noninvasive tool to evaluate and quantify 
pulmonary damage occurring in our experimental model of PCM (Lopera et al., 2010). This 
work has revealed that noninvasive conventional medical x-ray tomography is adequate to 
follow the sequential lung lesions in experimental PCM in mice. This procedure allowed 
detection of the main pathological patterns, the differential topographic distribution of the 
pulmonary lesions in both lungs, and their intensity.  
The intensity of the inflammatory reaction, evaluated by histomorphometry, increased until the 
12th week of infection, with a subsequent decrease due to the tendency to form predominantly 
compact and more isolated pseudotumoral masses. This histopathological behavior was also 
detected by HRCT, as expressed by lung density measures (Hounsfield units, HU) that showed 
a significant correlation, mainly in the upper or hilar lung region (Figure 5).  
When the mice were followed up sequentially, HRCT showed that 80% of them had 
peribronchial consolidations that persisted throughout the evaluation periods. Pulmonary 
consolidations were associated with a significant increase in upper lung density as 
compared with controls, −263±29 vs. −426±8 HU at week 4 (p<0.001), −191±25 vs. −403±17 
HU at week 8 (p<0.001), and −269±43 vs. −445±12 at week 12 (p<0.001). At week 16, upper 
consolidations tended to decrease as well as the corresponding density, −356±33 vs. −466±9 
(p<0.01).  
Histopathological analysis revealed that consolidation, as assessed by HRCT, was 
equivalent histologically to a confluent granulomatous reaction, while nodules 
corresponded to individual compact granulomas. During the same period of infection, 
confluent granulomas formed pseudotumoral masses that obstructed large bronchi. Discrete 
focal fibrosis was visible gradually around granulomas, but this finding was only evident 
with histopathology. 
Comparing the above results with radiological findings in patients is difficult because the 
size of lungs, the resolution of the topographer and the protocols used.  
In humans, assessment of disease progression and treatment outcome normally includes 
chest x-rays and then CT studies. At the time of diagnosis and in patients with active 
disease, chest x-ray revealed interstitial and alveolar-interstitial infiltrates, often bilateral 
and symmetrical, occasionally confluent, located preferentially in the central and basal areas 
of the lung (pattern in butterfly wings) (do Valle et al., 1992; Trad et al., 2006). A study of 
radiological monitoring carried out in 173 patients with chronic PCM reported presence of 
reticular interstitial infiltrates in 89.3% of the cases and nodular in 54.5%, bilateral alveolar 
in 45.4%, and mixed (in butterfly wings) in 44.7%. Emphysema was reported in 34.1%, septal 
lines by 25.7%, pleural thickening by 7.5%. Nine cases (6.8%) presented cavitations and three 
cases (2.2%) giant nodules or masses (Trad et al., 2006).  
CT proved superior to conventional radiographs in demonstrating early interstitial reticular 
and nodular infiltrates and showed abnormal findings in the majority of patients with 
chronic pulmonary PCM (more than 93%).  
 




Fig. 5. Patterns of the main lung lesion as detected by conventional medical HRCT and 
histopathological methods in the experimental mouse PCM model.  A, C, E correspond to 
HRCT images and B, D, F show the corresponding histopathological lesions taken in a 
coronal plane. The upper right symbol in (A) indicates posterior or dorsal (P), anterior or 
ventral (A), left (L) and right (R) regions.  Dotted lines in B, D and F show an approximated 
position of the tomographic section. (A) Large nodular lesion represented by a peri-
bronquial consolidation (arrow) is located at right hilar region and other left small nodules 
are indicated by arrowhead. (B) Several nodules with varied sizes. (C) Confluent lesion 
expressed by left central peri-bronchial consolidation (arrow) extended from the hilum to 
large area of the parenchyma. (D) Consolidated areas of perivascular and justabronchial 
granulomatous lesions. (E) Pseudotumoral lesion defining a left central pulmonary mass 
(arrow). (F) Left central pseudotumoral mass obstructing the bronchus. Scale bar for HRCT 
images = 1 cm. Scale bar for histopathological images = 2 mm. Adapted from PLoS Negl 
Trop Dis 4(6): e726. doi:10.1371/journal.pntd.0000726.g005. 
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The most frequent HRCT findings in patients with pulmonary PCM were ground-glass 
attenuation areas; small centrilobular, cavitated and large nodules; parenchymal bands; 
airspace consolidations; interlobular septal thickening; architectural distortion; traction 
bronchiectasis; paracicatricial emphysema and fibrosis. Most of those HRCT findings 
concentrated in the periphery and posterior regions involving all lung zones, with slight 
increased intensity in the middle zones (Funari et al., 1999; Marchiori et al., 2008, 2009; 
Muniz et al., 2002; Souza et al., 2006). The radiologic patterns described above in patients 
with pulmonary PCM were dependent on the stage of the disease and on the exclusion or 
inclusion of patients who had received previous treatment were excluded. 
 
 
Fig. 6. Radiological findings in a patient with chronic pulmonary PMC at diagnosis.  
(A, B) Postero-anterior chest and lateral radiographs showing bilateral reticulonodular and 
ground-glass opacities with cavitations. (C) HRCT shows consolidations, ground glass 
attenuations and cavitated masses.  
6. Final remarks 
Infection by P. brasiliensis is, no doubt, acquired only in the endemic areas of Central and 
South America, especially in Brazil. However, as the fungus exhibits the capacity to remain 
dormant in the tissues of the infected human host for extended periods and is, likewise, able 
to regain its vitality giving rise to overt disease, one may encounter the mycosis in 
individuals living in non-autochthonous areas, distant from those where the primary 
infection was acquired. 
This is why it is imperative to keep informed physicians and other health-related 
professionals on this endemic mycosis and be prepared to include it among the differential 
diagnoses of disorders compatible with PCM. A detailed interrogation on the patient’s 
former places of residence or visit should be obtained in order to focus the diagnosis. On the 
same token, P. brasiliensis should be taken into considerations whenever clinical samples and 
biopsies are being analyzed. It is only through knowledge that the specific diagnosis will be 
made in these difficult to diagnose non-autochthonous cases.  
One of the main aims of this chapter was educational, namely, informing pneumologists 
and related professionals of the existence of this “tropical” disorder. It should be 
remembered that P. brasiliensis travels along with its host to any part of the world and that 
this host, now ill, may well be your own patient. 
 
Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
381 
7. References  
Albeda, S.M., Smith, C.W. & Ward, P.A. (1994). Adhesion molecules and inflammatory 
injury. FASEB J, Vol.8: 504–512, ISSN 0892-6638. 
Bagaggli, E., Franco, M., Bosco, S. de M., Hebeler-Barbosa, F., Trinca, L.A. & Montenegro, 
M.R. (2003). High frequency of Paracoccidioides brasiliensis infection in armadillos 
(Dasypus novemcinctus): an ecological study. Med Mycol,Vol. 41, No. 3, pp. 217-223, 
ISSN 1369-3786. 
Barbosa, M. S., Bao, S. N., Andreotti, P. F., de Faria, F. P., Felipe, M. S., dos Santos-Feitosa, 
L., Mendes-Giannini, M. J. & Soares, C. M. (2006). Glyceraldehyde-3-phosphate 
dehydrogenase of Paracoccidioides brasiliensis is a cell surface protein involved in 
fungal adhesion to extracellular matrix proteins and interaction with cells. Infect 
Immun, Vol. 74, No. 1, pp. 382–389, ISSN0019-9567. 
Bárcenas, C., Cano, L. E., Cock A. M., Martínez, A. R. & Restrepo, A. (2004). Expresión de 
metaloproteinas y sus inhibidores de tejido en un modelo murino de fibrosis 
pulmonar. Med-UNAB, Vol. 7, No.19, pp. 9-14, ISSN 0123-7047. 
Barrozo, L.V., Benard, G., Silva, M.E., Bagagli, E., Marques, S.A. & Mendes, R.P. (2010). First 
description of a cluster of acute/subacute paracoccidioidomycosis cases and its 
association with a climatic anomaly. PLoS Negl Trop Dis.Vol. 4: e643. ISSN 1935-
2735. 
Bedoya, V., McEwen, J.G., Tabares, A.M., Jaramillo, F.U. & Restrepo, A. (1986). Pathogenesis 
of paracoccidioidomycosis: a histopathological study of the experimental murine 
infection. Mycopathologia, Vol. 94, No.3, pp. 133-144, ISSN 0301-486X. 
Bellissimo-Rodrigues, F., Machado, A. & Martinez, R. (2011). Paracoccidioidomycosis: 
epidemiological features of a 1,000 cases series from a hyperendemic area on the 
Southeast of Brazil. Am J Trop Med Hyg, Vol. 85, No.3, pp.546-50. ISSN 0002-9637. 
Benard, G., Orii, N. M., Marques, H. H., Mendonça, M., Aquino, M. Z., Campeas, A. E., del 
Negro, G. B., Durandy, A. & Duarte, A. J. (1994). Severe acute 
paracoccidioidomycosis in children. Pediatr Infect Dis J, Vol. 13, No. 6, pp. 510-515, 
ISSN 0891-3668. 
Benard, G., Kavakama, J., Mendes-Giannini, M. J., Kono, A., Duarte, A. J. & Shikanai-
Yasuda, M. A. (2005). Contribution to the natural history of 
paracoccidioidomycosis: identification of the primary pulmonary infection in the 
severe acute form of the disease--a case report. Clin Infect Dis, Vol. 40, No. 1, pp. e1-
4. ISSN1537-6591. 
Bethlem, E. P., Capone, D., Maranhao, B., Carvalho, C. R. & Wanke, B. (1999). 
Paracoccidioidomycosis. Curr Opin Pulm Med, Vol.5, No. 5, pp. 319-325, ISSN 1070-
5287. 
Bialek, R., Ibricevic, A., Aepinus, C., Najvar, L. K., Fothergill, A. W., Knobloch, J. & Graybill, 
J. R. (2000a). Detection of Paracoccidioides brasiliensis in tissue samples by a nested 
PCR assay. J Clin Microbiol, Vol. 38, No. 8, pp. 2940-2942, ISSN0095-1137. 
Bialek, R., Ibrecevic, A., Fothergill, A. & Begerow, D. (2000b). Small subunit ribosomal DNA 
sequences shows Paracoccidioides brasiliensis closely related to Blastomyces 
dermatitidis. J Clin Microbiol, Vol.38, No. 9, pp. 3190-3193, ISSN0095-1137. 
Bittencourt, J.I., de Oliveira R.M. & Coutinho Z.F. (2005). Paracoccidioidomycosis mortality 
in the State of Parana, Brazil, 1980/1998. Cad Saude Publica, Vol. 21, No. 6, pp. 1856 -
1864, ISSN 0102-311X. 
 
Lung Diseases – Selected State of the Art Reviews 
 
382 
Blotta, M. H., Mamoni, R. L., Oliveira, S. J., Nouer, S. A., Papaiordanou, P. M., Goveia,A. & 
Camargo, Z.P. (1999). Endemic regions of paracoccidioidomycosis in Brazil: a 
clinical and epidemiologic study of 584 cases in the southeast region. Am J Trop Med 
Hyg, Vol. 61, No. 3, pp. 390-394, ISSN0002-9637. 
Bonifaz, A. (2010). Chapter 219: Paracoccidioidomicosis,  in Bonifaz, A. (ed.), Micología 
Médica Básica, 3rd Ed. McGrow Hill, Mexico, pp. 259-270. 
Bonifaz, A., Vázquez-González, D. & Perusquía-Ortiz, A.M. (2011). Endemic systemic 
mycoses: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and 
blastomycosis. J Dtsch Dermatol Ges. Vol. 9, No. 9, pp.705-14. ISSN 1610-0387. 
Borelli, D. (1972). Some ecological aspects of paracoccidioidomycosis. Proceedings 
Panamerican Symposium on Paracoccidioidomycosis, Washington: Pan American 
Health Organization, Washington, D:C., PAHO Scientific Publication Nº 254, pp. 
59-64. 
Borges-Walmsley, M. I., Chen, D., Shu, X. & Walmsley, A. R. (2002). The pathobiology of 
Paracoccidioides brasiliensis.Trends Microbiol, Vol. 10, No.2, pp. 80-87, ISSN 0966-
842X. 
Brummer, E., Restrepo, A., Stevens, D.A., Azzi, R., Gómez, A.G., Hoyos, G., McEwen, J.G., 
Cano, L.E. & de Bedout, C. (1984). Murine model of paracoccidioidomycosis 
production of fatal acute pulmonary or chronic pulmonary and disseminated 
disease. Immunological and pathological observations. J Exp Pathol, Vol.1, No. 3, 
pp. 241–255, ISSN0730-8485. 
Brummer, E., Castañeda, E. & Restrepo, A. (1993). Paracoccidioidomycosis: an update. Clin 
Microbiol Rev, Vol. 6, No. 2, pp. 89-117, ISSN 0893-8512. 
Buitrago, M.J., Bernal-Martinez, L., Castelli, M.V., Rodríguez-Tudela, J.L. & Cuenca-Estrella, 
M. (2011). Histoplasmosis and paracoccidioidomycosis in a non-endemic area: a 
review of cases and diagnosis. J Travel Med, Vol.18, No. 1, pp. 26-33, ISSN 1708-
8305. 
Burger, E., Miyaji, M., Sano, A., Calich, V. L., Nishimura, K. & Lenzi, H. L. (1996). 
Histopathology of paracoccidioidomycotic infection in athymic and euthymic mice: 
a sequential study. Am J Trop Med Hyg, Vol. 55, No.2, pp. 235-242, ISSN 0002-9637. 
Calich, V. L., Singer-Vermes, L. M., Siqueira, A. M. & Burger, E. (1985). Susceptibility and 
resistance of inbred mice to Paracoccidioides brasiliensis. Br J Exp Pathol, Vol. 66, No.5, 
pp. 585-594, ISSN 0007-1021. 
Calle, D., Rosero, S., Orozco, L.C., Camargo, D., Castañeda, E. & Restrepo, A. (2001). 
Paracoccidioidomycosis in Colombia: an ecological study. Epidemiology Infection, 
Vol. 126, No. 2, pp. 309-315, ISSN 0950-2688. 
Calvi, S. A., Soares, A. M., Peraçoli, M. T.,Franco, M., Ruiz, R. L. Jr., Marcondes-Machado, J., 
Fecchio, D., Mattos, M. C. & Mendes, R. P. (2003). Study of bronchoalveolar lavage 
fluid in paracoccidioidomycosis: cytopathology and alveolar macrophage function 
in response to gamma interferon; comparison with blood monocytes. Microbes 
Infect, Vol. 5, No. 15, pp. 1373-1379, ISSN 1286-4579. 
Campos, M. V., Penna, G. O., Castro, C. N., Morales, M. A., Ferreira, M. S. & Santos, J. B. 
(2008). Paracoccidioidomycosis at Brasilia’s university hospital. Rev Soc Bras Med 
Trop,Vol. 41, No. 2, pp. 169-172, ISSN 0037-8682. 
Cano, L.E., Singer-Vermes, L.M., Costa, T.A., Mengel, J.O., Xidieh, C.F., Arruda, C., André, 
D.C., Vaz, C.A., Burger, E. & Calich, V.L. (2000). Depletion of CD8 (+) T cells in vivo 
 
Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
383 
impairs host defense of mice resistant and susceptible to pulmonary 
paracoccidioidomycosis. Infect Immun, Vol.68, No. 1, pp. 352-359, ISSN 0019-9567. 
Carlos, T. M. & Harlan, J. M. (1990). Membrane proteins involved in phagocyte adherence to 
endothelium. Immunol Rev,Vol. 114, No. 1, pp. 5–27, ISSN 0105-2896. 
Caro, E., González, A., Muñoz, C., Urán, M. E., Restrepo, A., Hamilton, A. J. & Cano, L.E. 
(2008). Recognition of laminin by Paracoccidioides brasiliensis conidia: a possible 
mechanism of adherence to human type II alveolar cells. Med Mycol, Vol. 46, No. 8, 
pp. 795-804, ISSN 1369-3786. 
Cock, A. M., Cano, L. E., Vélez, D., Aristizábal, B. H., Trujillo, J. & Restrepo, A. (2000). 
Fibrotic sequelae in pulmonary paracoccidioidomycosis: histopathological aspects 
in BALB/c mice infected with viable and non-viable Paracoccidioides brasiliensis 
propagules. Rev Inst Med Trop Sao Paulo, Vol. 42, No. 2, pp. 59-66, ISSN 0036-4665. 
Coimbra, Jr. C.E., Wanke, B., Santos, R.V., do Valle, A.C., Costa, R.L. & Zancope-Oliveira, 
R.M. (1994). Paracoccidioidin and histoplasmin sensitivity in Tupi-Monde 
Amerindian populations from Brazilian Amazonia. Ann Trop Med Parasitol, Vol. 88, 
No. 2, pp. 197-207, ISSN 0003-4983. 
Colombo, A. L., Tobón, A., Restrepo, A., Queiroz-Telles, F. & Nucci, M. (2011). 
Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol, 
Vol. 49, No. 8, pp.785-98. ISSN1460-2709. 
Conti-Díaz, I.A. & Calegari L.F. (1979). Paracoccidioidomycosis in Uruguay: its status and 
current problems. Bol Oficina Sanit. Panam, Vol. 86, No. 3, pp. 219–229, ISSN0030-
0632. 
Conti-Díaz, I. (2007). Point of view on the unknown ecological niche of Paracoccidioides 
brasiliensis. Our hypothesis of 1989: Present status and perspectives. Rev. Inst. Med. 
Trop. S. Paulo, Vol. 49, No. 2, pp. 131-134, ISSN0036-4665. 
Coutinho, Z.F., Silva, D., Lazera, M., Petri, V., Oliveira, R.M., Sabroza, P. C. & Wanke, B. 
(2002). Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad Saude Publica, 
Vol. 18, No. 5, pp. 1441-1454, ISSN 0102-311X. 
Da Silva, F. C., Svidzinski, T. I., Patussi, E. V., Cardoso, C. P., De Oliveira Dalalio, M. M. & 
Hernandes, L. (2009). Morphologic organization of pulmonary granulomas in mice 
infected with Paracoccidioides brasiliensis. Am J Trop Med Hyg, Vol. 80, No.5, pp. 798-
804, ISSN 1476-1645. 
Da Silva, M. B., Marques, A. F., Nosanchuk, J. D., Casadevall, A.,Travassos, L. R. & Taborda, 
C. P. (2006). Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: 
effects on phagocytosis, intracellular resistance and drug susceptibility. Microbes  
Infect, Vol. 8, No. 1, pp. 197–205, ISSN1286-4579. 
Datta, A., Scotton, C. J. & Chambers, R. C. (2011). Novel therapeutic approaches for 
pulmonary fibrosis. Br J Pharmacol, Vol. 163, No.1, pp. 141-72, ISSN 1476-5381. 
Defaveri, J., Rexkallah-Iwasso, M.T. & Franco, M.F. (1982). Experimental pulmonary 
paracoccidioidomycosis in mice: morphology and correlation of lesions with 
humoral and cellular immune response. Mycophatologia, Vol. 77, No. 1, pp. 3–11, 
ISSN 0301-486X. 
Essayag, S.M., Landaeta, M.E., Hartung, C., Magaldi, S., Spencer, L., Suárez, R., García, F. & 
Pérez, E. (2002). Histopathologic and histochemical characterization of calcified 
structures in hamsters inoculated with Paracoccidioides brasiliensis. Mycoses, Vol.45, 
No.(9-10), pp. 351-357, ISSN0933-7407. 
 
Lung Diseases – Selected State of the Art Reviews 
 
384 
Fang, C. C., Lai, M. N., Chien, C. T., Hung, K. Y., Tsai, C. C., Tsai, T. J. & Hsieh, B. S. (2003). 
Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal 
fibrosis. Perit Dial Int, Vol. 23, No.3, pp. 228-36, ISSN 0896-8608. 
Fava-Netto, C., De Brito, T. & Lacaz, C.S. (1961). Experimental South American 
blastomycosis of the guinea pig. Pathol Microbiol, Vol. 24, No. 2, pp. 192–206, 
ISSN0031-2959.  
Flynn, J.L., Scanga, C.A., Tanaka, K.E. &  Chan, J. (1998). Effects of aminoguanidine on latent 
murine tuberculosis. J Immunol,  Vol. 160, No.4   pp. 1796–1803, ISSN 0022-1767. 
Flynn, J.L., Chan, J. & Lin, P.L. (2011). Macrophages and control of granulomatous 
inflammation in tuberculosis. Mucosal Immunol, Vol.4, No.3, pp. 271-278, ISSN 1935-
3456. 
Fornazim, M. C., Balthazar, A., Quagliato, R., Mamoni, R. L., Garcia, C. & Blotta, M. H. S. L. 
(2003). Evaluation of bronchoalveolar cells in pulmonary paracoccidioidomycosis. 
Eur Respir J, Vol. 22, No. 6, pp. 895–899, ISSN 0903-1936. 
Franco, L., Najvar, L., Gómez, B. L., Restrepo, S., Graybill, J. R. & Restrepo, A. (1998). 
Experimental pulmonary fibrosis induced by Paracoccidioides brasiliensis conidia: 
measurement of local host responses. Am J Trop Med Hyg, Vol. 58, No.4, pp. 424-30, 
ISSN 0002-9637.  
Franco,  M., Montenegro, M. R., Mendes, R. P., Marques, S. A., Dillon, N. L. & Mota, N. G. 
(1987). Paracoccidioidomycosis: a recently proposed classification of its clinical 
forms. Rev Soc Bras Med Trop, Vol. 20, No. 2, pp.129-132, ISSN 0037-8682. 
Franco, M., Bagagli, E., Scapolio, S. & da Silva Lacaz, C. (2000). A critical analysis of isolation 
of Paracoccidioides brasiliensis from soil. Med Mycol, Vol. 38, No. 3, pp. 185-191, ISSN 
1369-3786. 
Funari, M., Kavakama, J., Shikanai-Yasuda, M. A., Castro, L. G., Bernard, G., Rocha, M. S., 
Cerri, G. G. & Muller, N. L. (1999). Chronic pulmonary paracoccidioidomycosis 
(South American blastomycosis): high-resolution CT findings in 41 patients. AJR 
Am J Roentgenol, Vol. 173, No.1, pp. 59-64, ISSN 0361-803X.  
Garcia-de-Alba, C., Becerril, C., Ruiz, V., Gonzalez, Y., Reyes, S., Garcia-Alvarez, J., Selman, 
M. & Pardo, A. (2010). Expression of matrix metalloproteases by fibrocytes: 
possible role in migration and homing. Am J Respir Crit Care Med,Vol. 182, No.9, pp. 
1144-52, ISSN 1535-4970. 
Gaur, N. K., Klotz, S. A. & Henderson, R. L. (1999). Overexpression of the Candida albicans 
ALA1 gene in Saccharomyces cerevisiae results in aggregation following attachment 
of yeast cells to extracellular matrix proteins, adherence properties similar to those 
of Candida albicans. Infect Immun, Vol. 67, No. 11, pp. 6040–6047, ISSN 0019-9567. 
Goldman, D., Cho, Y., Zhao, M.L., Casadevall, A. & Lee, S.C. (1996). Expression of inducible 
nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am J 
Pathol, Vol. 148,  No. 4,  pp. 1275–1282, ISSN 0002-9440. 
Gomes, E., Wingeter, M. A., & Svidzinski, T. I. (2008) Clinical-radiological dissociation in 
lung manifestations of paracoccidioidomycosis. Rev Soc Bras Med Trop, Vol. 41, No. 
5, pp. 454-458, ISSN 1678-9849. 
Gomes, G. M., Cisalpino, P. S., Taborda, C. P. & de Camargo, Z. P. (2000). PCR for diagnosis 
of paracoccidioidomycosis. J Clin Microbiol, Vol. 38, No. 9, pp. 3478-3480, ISSN 
0095-1137. 
 
Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
385 
Gómez, B. L., Figueroa, J. I., Hamilton, A. J., Diez, S., Rojas, M., Tobón, A. M., Hay, R. J. & 
Restrepo, A. (1998). Antigenemia in patients with paracoccidioidomycosis: 
detection of the 87-kilodalton determinant during and after antifungal therapy. J 
Clin Microbiol, Vol. 36, No. 11, pp. 3309-3316, ISSN0095-1137. 
Gómez, B.L., Figueroa, J.I., Hamilton, A.J., Ortiz, B., Robledo, M.A., Hay, R.J. & Restrepo, A. 
(1997). Use of monoclonal antibodies in diagnosis of paracoccidioidomycosis: new 
strategies for the detection of circulating antigens. J ClinMicrobiol, Vol. 35, No. 12, 
pp. 3278-3283, ISSN 0095-1137. 
Gonçalves, A. J., Londero, A. T., Terra, G. M., Rozenbaum, R., Abreu, T. F. & Nogueira, S. A. 
(1998). Paracoccidioidomycosis in children in the state of Rio de Janeiro (Brazil). 
Geographic distribution and the study of a "reservarea". Rev Inst Med Trop São 
Paulo, Vol. 40, No. 1, pp. 11-13, ISSN 0036-4665. 
González, A., Sahaza, J. H., Ortiz, B. L., Restrepo, A. & Cano, L. E. (2003). Production of pro-
inflammatory cytokines during the early stages of experimental Paracoccidioides 
brasiliensis infection. Med Mycol, Vol. 41, No. 5, pp. 391-399, ISSN1369-3786. 
González, A., Gómez, B. L., Díez, S., Hernández, O., Restrepo, A., Hamilton, A. J. & Cano, L. 
E. (2005a). Purification and partial characterization of a Paracoccidioides brasiliensis 
protein with capacity to bind to extracellular matrix proteins. Infect Immun, Vol. 73, 
No. 5, pp. 2486-2495, ISSN 0019-9567. 
González, A., Lenzi, H. L., Motta, E. M., Caputo, L., Sahaza, J. H., Cock, A. M., Ruiz, A. C., 
Restrepo, A. & Cano, L. E. (2005b).Expression of adhesion molecules in lungs of 
mice infected with Paracoccidioides brasiliensis conidia. Microbes Infect, Vol. 7, No. 4, 
pp. 666-673, ISSN 1286-4579. 
González, A., Caro, E., Muñoz, C., Restrepo, A., Hamilton, A. J. & Cano, L .E. (2008a). 
Paracoccidioides brasiliensis conidia recognize fibronectin and fibrinogen which 
subsequently participate in adherence to human type II alveolar cells: involvement 
of a specific adhesin. Microb Pathog, Vol. 44, No. 5, pp. 389-401, ISSN 0882-4010. 
González, A., Gómez, B. L., Muñoz, C., Aristizábal, B. H., Restrepo, A., Hamilton, A. J. & 
Cano, L. E. (2008b). Involvement of extracellular matrix proteins in the course of 
experimental paracoccidioidomycosis. FEMS Immunol Med Microbiol, Vol. 53, No. 1, 
pp. 114-125, ISSN 0928-8244.  
González, A., Lenzi, H. L., Motta, E. M., Caputo, L., Restrepo, A., & Cano, L. E. (2008c). 
Expression and arrangement of extracellular matrix proteins in the lungs of mice 
infected with Paracoccidioides brasiliensis conidia. Int J Exp Pathol, Vol. 89, No. 2, pp. 
106-116, ISSN 1365-2613. 
González, A., Restrepo, A.  & Cano, L. E. (2008d). Pulmonary immune responses induced in 
BALB/c mice by Paracoccidioides brasiliensis conidia. Mycopathologia, Vol. 165, No. 4-
5, pp. 313-330, ISSN 0301-486X.  
Hahn, R. C., & Hamdan, J. S. (2000). Effects of amphotericin B and three azole derivatives on 
the lipids of yeast cells of Paracoccidioides brasiliensis. Antimicrob Agents Chemother, 
Vol. 44, No. 7, pp. 1997-2000, ISSN 0066-4804. 
Hamacher, J. & Schaberg, T. (1994). Adhesion molecules in lung diseases. Lung, Vol. 172, No. 
4, pp. 189–213, ISSN 0341-2040. 
Hernández, O., Almeida, A. J., González, A., García, A. M., Tamayo, D., Cano, L. E., 
Restrepo, A. & McEwen, J. G. (2010). A 32-kilodalton hydrolase plays an important 
 
Lung Diseases – Selected State of the Art Reviews 
 
386 
role in Paracoccidioides brasiliensis adherence to host cells and influences 
pathogenicity. Infect Immun, Vol. 78, No. 12, pp. 5280-5286, ISSN 1098-5522. 
Hsu, L.Y., Ng, E.S. & Koh, L.P. (2010). Common and emerging fungal pulmonary infections. 
Infect Dis Clin North Am, Vol. 24, No. 3, pp. 557-577, ISSN 1557-9824. 
Iabuki, K. & Montenegro, M.R. (1979). Experimental paracoccidioidomycosis in the Syrian 
hamster: morphology, ultrastructure and correlation of lesions with presence of 
specific antigens and serum levels of antibodies. Mycopathologia,  Vol. 67, No. 3, pp. 
131–141, ISSN0301-486X. 
Inoue, K., Takano, H., Yanagisawa, R. & Sakurai, M. (2004). Anti-inflammatory Effect of 
Pentoxifylline. Chest, Vol. 126, No.1, pp. 321, ISSN 0012-3692. 
Iovannitti, C.A., Finquelievich, J.L., Negroni, R. & Elías-Costa, M.R. (1999). 
Histopathological evolution of experimental paracoccidioidomycosis in Wistar rats. 
Zentralbl Bakteriol, Vol.289, No. 2, pp. 211-216, ISSN0934-8840. 
Izzo, A. A., Lovchik, J. A. & Lipscomb, M. F. (1998). T and B cell independence of endothelial 
cell adhesion molecule expression in pulmonary granulomatous inflammation. Am 
J Respir Cell MolBiol, Vol. 19, No. 4, pp. 588–597, ISSN 1044-1549. 
Kerr, I.B., de Oliveira, P.C. & Lenzi, H.L. (1988). Connective matrix organization in chronic 
granulomas of experimental paracoccidioidomycosis. Mycopathologia, Vol. 103, 
No.1, pp. 11-20, ISSN 0301-486X. 
Koishi, A. C., Vituri, D. F., DionízioFilho, P. S., Sasaki, A. A., Felipe, M. S. & Venancio, E. J. 
(2010). A semi-nested PCR assay for molecular detection of Paracoccidioides 
brasiliensis in tissue samples. Rev Soc Bras Med Trop, Vol. 43, No. 6, pp. 728-730, 
ISSN 1678-9849. 
Lacaz, C. S., Porto, E., Martins, J.E.C., Heins-Vaccari, E.M. & Melo, N.T. (2002). 
Paracoccidioidomicose, in Lacaz C, Porto E, Martins JEC., Heins-Vaccari, E.M., 
Melo, N.T. (eds.), Tratado de Micología Médica Lacaz. 9th ed. Servier. São Paulo, Brazil, 
pp. 639-729.  
Livonesi, M.C., Souto, J.T., Campanelli, A.P., Maffei, C.M., Martinez, R., Rossi, M.A. & Da 
Silva, J.S. (2008). Deficiency of IL-12p40 subunit determines severe 
paracoccidioidomycosis in mice. Med Mycol, Vol. 46, No.7, pp. 637-646, ISSN 1369-
3786. 
Livonesi, M.C., Rossi, M.A., de Souto, J.T., Campanelli, A.P., de Sousa, R.L., Maffei, C.M., 
Ferreira, B.R., Martinez, R. & da Silva, J.S. (2009). Inducible nitric oxide synthase-
deficient mice show exacerbated inflammatory process and high production of 
both Th1 and Th2 cytokines during paracoccidioidomycosis. Microbes Infect, Vol. 
11, No.1, pp. 123-132, ISSN 1286-4579. 
Londero, A. T. (1986). Paracoccidioidomicose: Patogenia, formas clinicas, manifestacões 
pulmonares e diagnostico. J Pneumol (Brazil), Vol. 12, No. 1, pp. 41–57, ISSN0102-
3586. 
Londero, A. T., Rios-Gonçalves, A. J., Terra, G. M. & Nogueira, S. A. (1996). 
Paracoccidioidomycosis in Brazilian children. A critical review (1911–1994). Arq 
Bras Med, Vol. 70, No. 4, pp. 197–203, ISSN.0365-0723 . 
Lopera, D., Naranjo, T., Hidalgo, J. M., de Oliveira Pascarelli, B. M., Patiño, J. H., Lenzi, H. 
L., Restrepo, A. & Cano, L. E. (2010). Pulmonary abnormalities in mice with 
paracoccidioidomycosis: a sequential study comparing high resolution computed 
 
Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
387 
tomography and pathologic findings. PLoS Negl Trop Dis, Vol. 4, No.6, pp. e726, 
ISSN 1935-2735. 
Lopera, D., Naranjo, T. W., Cruz, O. G., Restrepo, A., Cano, L. E. & Lenzi, H. L. (2011). 
Structural and topographic dynamics of pulmonary histopatology and local 
cytokine profiles in mice infected with Paracoccidioides brasiliensis conidia. PLoS 
Neglected Tropical Diseases, Vol.5, No.7, pp. e1232, ISSN 1935-2735.  
Machado, J.M.J. & Teixeira G.A. (1965). Das sequelas da blastomicose Sul-Americana. 
Hospital, Vol. 68, No. X, pp.141–147. 
Marchiori, E., Escuissato, D.L., Souza, A.S.Jr., Barillo, J.L., Warszawiak, D. & de Souza, A.S. 
(2008). Computed tomography findings in patients with tracheal 
paracoccidioidomycosis. J Comput Assist Tomogr, Vol. 32, No.5, pp. 788-791, ISSN 
1532-3145. 
Marchiori, E., Valiante, P.M., Mano, C. M., Zanetti, G., Escuissato, D. L., Souza, A. S. Jr., & 
Capone, D. (2011). Paracoccidioidomycosis: High-resolution computed 
tomography-pathologic correlation. Eur J Radiol, Vol. 77, No. 1, pp. 80-84, ISSN 
1872-7727. 
Masinovsky, B., Urdal, D. & Gallatin, W. M. (1990). IL-4 acts synergistically with IL-1 beta to 
promote lymphocyte adhesión to microvascular endothelium by induction of 
vascular cell adhesion molecule-1. J Immunol, Vol. 145, No. 9, pp. 2886–2895, 
ISSN0022-1767. 
Matute, D. R., Sepulveda,V. E., Quesada, L. M., Goldman, G. H., Taylor, J. W., Restrepo, A. 
& McEwen, J. G. (2006). Microsatellite analysis of three phylogenetic species of 
Paracoccidioides brasiliensis. J Clin Microbiol, Vol.44, No. 6, pp. 2153-2157, ISSN. 
Mayayo, E., Lopez-Aracil, V., Fernandez-Torres, B., Mayayo, R. & Dominguez, M. (2007). 
Report of an imported cutaneous disseminated case of paracoccidioidomycosis. Rev 
Iberoam Micol, Vol.24, No.1, pp. 44-46, ISSN 1130-1406.  
McEwen, J.G., Bedoya, V., Patiño, M.M., Salazar, M.E. & Restrepo, A. (1987). Experimental 
murine paracoccidioidomycosis induced by the inhalation of conidia. J Med Vet 
Mycol, Vol. 25, No. 3, pp. 165–175, ISSN0268-1218. 
McMahon, J. P., Wheat, J., Sobel, M. E., Pasula, R., Downing, J. F. & Martin, W. J. (1995). 
Murine laminin binds to Histoplasma capsulatum. A possible mechanism of 
dissemination. J Clin Invest, Vol. 96, No. 2, pp. 1010-1017, ISSN0021-9738. 
Meltzer, E. B. & Noble, P. W. (2008). Idiopathic pulmonary fibrosis. Orphanet J Rare Dis, Vol. 
3, No. 1, pp. 8, ISSN 1750-1172. 
Mendes, R. P. (1994). The gamut of clinical manifestations, in Franco, M., Lacaz, C., 
Restrepo, A., & del Negro, G (eds). Paracoccidioidomycosis, CRC Press, Boca Raton, 
FL, pp. 233–258. 
Moreira, A. P., Campanelli, A. P., Cavassani, K. A., Souto, J. T., Ferreira, B. R., Martinez, R., 
Rossi, M. A. & Silva, J. S. (2006). Intercellular adhesion molecule-1 is required for 
the early formation of granulomas and participates in the resistance of mice to the 
infection with the fungus Paracoccidioides brasiliensis. Am J Pathol, Vol. 169, No. 4, 
pp. 1270-1281, ISSN0002-9440. 
Morejon, K.M., Machado, A.A. &  Martinez, R. (2009). Paracoccidioidomycosis in patients 
infected with and not infected with human immunodeficiency virus: a case-control 
study. Am J Trop Med Hyg, Vol.  80, No. 3, pp. 359-366, ISSN1476-1645. 
 
Lung Diseases – Selected State of the Art Reviews 
 
388 
Moscardi, M.& Franco, M.F. (1980). Experimental paracoccidioidomycosis in mice. I. 
Immunopathological aspects of intraperitoneal infection. Rev Inst Med Trop Sao 
Paulo, Vol.22, No.6, pp. 286-293, ISSN 0036-4665  
Mukhopadhyay, S. & Gal, A.A. (2010). Granulomatous lung disease: an approach to the 
differential diagnosis. Arch Pathol Lab Med, Vol.134, No.5, pp. 667-690, ISSN 1543-
2165. 
Muniz, M.A., E, M., Magnago, M., Moreira, L.B. & de Almeida Junior, J. (2002). 
Paracoccidioidomicose pulmonar – aspectos na tomografia computadorizada de 
alta resolução. Radiol Bras, Vol. 35, No.3, pp. 147-154, ISSN 0100-3984 
Naranjo, M. S., Trujillo, M., Múnera, M. I., Restrepo, P., Gómez, I., & Restrepo, A. (1990). 
Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol, Vol. 28, 
No. 1, pp. 67-76, ISSN 0268-1218. 
Naranjo, T. W., Lopera, D. E., Diaz-Granados, L. R., Duque, J. J., Restrepo, A. & Cano, L. E. 
(2010). Histopathologic and immunologic effects of the itraconazole treatment in a 
murine model of chronic pulmonary paracoccidioidomycosis. Microbes Infect, Vol. 
12, No.14-15, pp. 1153-62, ISSN 1769-714X. 
Naranjo, T. W., Lopera, D. E., Diaz-Granados, L. R., Duque, J. J., Restrepo, A. & Cano, L. E. 
(2011). Combined itraconazole-pentoxifylline treatment promptly reduces lung 
fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice. Pulm 
Pharmacol Ther, Vol. 24, No.1, pp. 81-91, ISSN 1522-9629. 
Nascimento, F.R.F., Calich, V.L.G., Rodrigues, D. & Russo, M. (2002). Dual role of nitric 
oxide in paracoccidioidomycosis: essential for resistance but overproduction 
associated with susceptibility. J Immunol, Vol. 168, No.9  , pp. 4593–4600, ISSN  
0022-1767. 
Nathan, C., & Shiloh, M. U. (2000). Reactive oxygen and nitrogen intermediates in the 
relationship between mammalian host and microbial pathogens. Proc Natl Acad Sci 
USA, Vol.97, No. 16, pp. 8841-8848, ISSN 0027-8424. 
Newman, S. L., Goote, L., Gabay, J. E. & Selsted, M. E. (2000).Identification of constituents of 
human neutrophil azurophil granules that mediated fungistasis against Histoplasma 
capsulatum. Infect Immun, Vol. 68, No. 10, pp. 5668–5672, ISSN0019-9567. 
Niño-Vega, G. A., Calcagno, A. M., San-Blas, G., San-Blas, F., Gooday, G. W. & Gow, N. A. 
(2000). RFLP analysis reveals marked geographical isolation between strains of 
Paracoccidioides brasiliensis. Med Mycol, Vol. 38, No. 6, pp. 437-441, ISSN1369-3786. 
Nishikaku, A. S.,  Sanchez-Molina, R. F.,  Ribeiro, L. C., Scavone, R.,  Albe, B. P.,  Silva-
Cunha, C. & Burger, E. (2009). Nitric oxide participation in granulomatous 
response induced by Paracoccidioides brasiliensis infection in mice. Med Microbiol 
Immunol, Vol. 198, No. 2,  pp.123–135, ISSN 1432-1831.  
Nogueira, M. G., Andrade, G. M., & Tonelli, E. (2006). Clinical evolution of 
paracoccidioidomycosis in 38 children and teenagers. Mycopathologia, Vol. 161, No. 
2, pp. 73-81, ISSN 0301-486X. 
Nucci, M., Colombo, A.L. & Queiroz-Telles,  F. (2009). Paracoccidioidomycosis. Curr Fungal 
Infect Rep., Vol. 3, No. 1, pp.  15-20, ISSN 1936-3761. 
Osborn, L., Hession, C., Tizard, R., Vasallo, C., Luhowsky, S., Chi-Rosso, G. & Lobb, R. 
(1989).Direct expression of vascular cell adhesion molecule-1, a cytokine-induced 
endotelial protein that binds to lymphocytes. Cell, Vol. 59, No. 6, pp. 1203–1211, 
ISSN0092-8674. 
 
Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
389 
Pappas, P. G. (2004). Immunotherapy for invasive fungal infections: from bench to bedside. 
Drug Resist Updat, Vol. 7, No.1, pp. 3-10, ISSN 1368-7646. 
Pardo, A. & Selman, M. (2006). Matrix metalloproteases in aberrant fibrotic tissue 
remodeling. Proc Am Thorac Soc, Vol. 3, No.4, pp. 383-388, ISSN 1546-3222. 
Peraçoli, M.T.S., Mota, N.G.S. & Montenegro, M.R. (1982). Experimental 
paracoccidioidomycosis in the Syrian hamster. Morphology and correlation of 
lesions with humoral and cell mediated immunity. Mycopathologia, Vol. 79, No. 1, 
pp. 7–17, ISSN0301-486X. 
Pereira, R. M., Bucaretchi, F., Barison-Ede, M., Hessel, G. & Tresoldi, A. T. (2004). 
Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. 
Rev Inst Med Trop São Paulo, Vol. 46, No. 3, pp. 127-131, ISSN 0036-4665. 
Pilewski, J. M. & Albelda, S. M. (1993). Adhesion molecules in the lung. An overview. Am 
Rev Respir Dis, Vol. 148, No. 6, pp. S31–37, ISSN0003-0805.  
Pinzan, C.F., Ruas, L.P., Casabona-Fortunato, A.S., Carvalho, F.C. & Roque-Barreira, M. C. 
(2010). Immunological basis for the gender differences in murine Paracoccidioides 
brasiliensis infection. PLoS ONE, Vol. 5, No. 5,  pe10757. ISSN 1932-6203. 
Poisson, D., Heitzmann, A., Mille, C., Muckensturm, B., Dromer, F., Dupont, B. & 
Hocqueloux, L. (2007). Paracoccidioides brasiliensis in a brain abscess: First French 
case. J Mycol Med, Vol. 17, pp. 114-118, ISSN1156-5233. 
Popi, A.F., Godoy, L.C., Xander, P., Lopes, J.D. & Mariano, M. (2008). B-1 cells facilitate 
Paracoccidioides brasiliensis infection in mice via IL-10 secretion. Microbes Infect, 
Vol.10, No.7, pp. 817-824, ISSN 1286-4579. 
Prado, M., da Silva, M. B., Laurenti, R., Travassos, L. R. & Taborda, C. P. (2009). Mortality 
due to systemic mycoses as a primary cause of death or in association with AIDS in 
Brazil: a review from 1996 to 2006. Mem Inst Oswaldo Cruz, Vol.104, No. 3, pp. 513–
521, ISSN 1678-8060. 
QuagliatoJr, R., Grangeia, A. T., de Massucio, R. A., De Capitani, E. M., RezendeSde, M. & 
Balthazar, A. B. (2007). Association between paracoccidioidomycosis and 
tuberculosis: reality and misdiagnosis. J Bras Pneumol, Vol.33, No. 3, pp. 295-300, 
ISSN 1806-3756. 
Ramos, E. S, & Saraiva, L. E. (2008). Paracoccidioidomycosis. Dermatol Clin, Vol. 26, No. 2, 
pp. 257-269, ISSN 0733-8635. 
Restrepo, A., McEwen, J.G. & Castañeda, E. (2001). The habitat of Paracoccidioides brasiliensis: 
how far from solving the riddle? Med Mycol, Vol. 39, No. 3, pp. 233-241, ISSN 1369-
3786. 
Restrepo, A., Benard, G., de Castro, C. C., Agudelo, C. A. & Tobón, A. M. (2008). Pulmonary 
paracoccidioidomycosis. Semin Respir Crit Care Med, Vol. 29, No.2, pp. 182-97, ISSN 
1069-3424. 
Restrepo, A., & Tobón, A.M. (2009). Paracoccidioides brasiliensis, in Mandell, G. L., Bennett, J. 
E., & Dolin, R., (eds), Mandell, Douglas and Bennett's Principles and Practice of 
Infectious Diseases, 7th ed. Elsevier, Philadelphia, pp. 3357-3363. 
Restrepo, A., González, A. & Agudelo, C.A. (2011). Chapter 21: Paracoccidioidomycosis, 
inW. Dismukes, C. Kauffman, P. Pappas, J. Sobel (eds): Essentials of Medical 
Mycology, 2nd Ed.: Springer, N.Y, N.Y., pp 367-385. 
 
Lung Diseases – Selected State of the Art Reviews 
 
390 
Restrepo, S., Tobón, A., Trujillo, J. & Restrepo, A. (1992). Development of pulmonary fibrosis 
in mice during infection with Paracoccidioides brasiliensis conidia. J Med Vet Mycol, 
Vol.30, No. 3, pp. 173–184, ISSN0268-1218. 
Ricci, G., Mota, F. T., Wakamatsu, A., Serafim, R. C., Borra, R. C. & Franco, M. (2004). Canine 
paracoccidioidomycosis. Med Mycol, Vol.42, No. 4, pp. 379-383, ISSN1369-3786. 
Richini-Pereira, V.B., Bosco, S.M.G., Griese, J., Theodoro, R.C., Macoris, S.A.G., Silva, R.J., 
Barrozo, L., Tavares, P.M.S. & Zancopé-Oliveira, R.M. (2008). Molecular detection 
of Paracoccidioides brasiliensis in road-killed wild animals. Med Mycol, Vol.46, No. 1, 
pp. 35-40, ISSN1369-3786. 
Rodrigues, M. L., Dos Reis, G., Puccia, R., Travassos, L. R. & Alviano, C. S. (2003). Cleavage 
of human fibronectin and other basement membrane-associated proteins by a 
Cryptococcus neoformans serine proteinase. Microb Pathog, Vol. 34, No. 2, pp. 65–71, 
ISSN0882-4010. 
Romanelli, R. G., Caligiuri, A., Carloni, V., De Franco, R., Montalto, P., Ceni, E., Casini, A., 
Gentilini, P. & Pinzani, M. (1997). Effect of pentoxifylline on the degradation of 
procollagen type I produced by human hepatic stellate cells in response to 
transforming growth factor-beta 1. Br J Pharmacol, Vol. 122, No.6, pp. 1047-54, ISSN 
0007-1188. 
San-Blas, G., Niño-Vega, G. & Iturriaga, T. (2002). Paracoccidioides brasiliensis and 
paracoccidioidomycosis: Molecular approaches to morphogenesis, diagnosis, 
epidemiology, taxonomy and genetics. Med Mycol, Vol.40, No. 3, pp. 225-242, 
ISSN1369-3786. 
Santo, A.H. (2008). Paracoccidioidomycosis-related mortality trend, state of São Paulo, 
Brazil: a study using multiple causes of death. Rev Panam Salud Publica, Vol.23, 
No.5, pp. 313-324, ISSN 1020-4989. 
Severo, L. C., Roesch, E. W., Oliveira, E. A., Rocha, M. M. & Londero, A. T. (1998). 
Paracoccidioidomycosis in women. Rev. Iberoam. Micol., Vol. 15, No. 2, pp. 88–89, 
ISSN1130-1406. 
Shankar, J., Restrepo, A., Clemons, K.V. & Stevens, D.A. (2011). Paracoccidioidomycosis: 
hormones and the resistance of women. Clinical Microbiology Reviews, Vol. 24, No. 2, 
pp. 296-313, ISSN1098-6618. 
Shikanai-Yasuda, M. A., Benard, G., Higaki, Y., Del Negro, G. M., Hoo, S., Vaccari, E. H., 
Gryschek, R. C., Segurado, A. A., Barone, A. A. & Andrade, D. R. (2002). 
Randomized trial with itraconazole, ketoconazole and sulfadiazine in 
paracoccidioidomycosis. Med Mycol, Vol. 40, No. 4, pp. 411-417, ISSN1369-3786. 
Shikanai-Yasuda, M., Queiroz-Telles, F., Poncio, R., Lopes, A. & Moretti, M. (2006). 
Guideliness in paracoccidioidomycosis. Rev. Soc. Bras. Med. Trop, Vol. 39, No.3, pp. 
297-310, ISSN 0037-8682. 
Shikanai-Yasuda, M. A., Conceição, Y. M., Kono, A., Rivitti, E., Campos, A. F. & Campos, S. 
V. (2008). Neoplasia and paracoccidioidomycosis. Mycopathologia, Vol. 165, No. 4-5, 
pp. 303-312, ISSN 0301-486X. 
Simões, L.B., Marques, S.A. & Bagagli, E. (2004). Distribution of paracoccidioidomycosis: 
determination of ecologic correlates through spatial analyses. Med Mycol, Vol. 42, 
No. 6, pp. 517-523, ISSN1369-3786. 
Soares, A.M., Rezkallah-Iwasso, M.T., Oliveira, S.L., Peraçoli, M.T., Montenegro, M.R. & 
Musatti, C.C. (2000). Experimental paracoccidioidomycosis in high and low 
 
Pulmonary Paracoccidioidomycosis: Clinical, Immunological and Histopathological Aspects 
 
391 
antibody responder mice of Selection IV-A. Med Mycol. Vol. 38, No.4, pp. 309-315, 
ISSN1369-3786. 
Souto, J.T., Figueiredo, F., Furlanetto, A., Pfeffer, K., Rossi, M.A. & Silva, J.S. (2000). 
Interferon-gamma and tumor necrosis factor-alpha determine resistance to 
Paracoccidioides brasiliensis infection in mice. Am J Pathol, Vol.156, No.5, pp. 1811-
1820, ISSN 0002-9440. 
Souza, A.S., Jr., Gasparetto, E.L., Davaus, T., Escuissato, D.L. & Marchiori, E. (2006). High-
resolution CT findings of 77 patients with untreated pulmonary 
paracoccidioidomycosis. AJR Am J Roentgenol, Vol. 187, No.5, pp. 1248-1252, ISSN 
1546-3141. 
Teixeira, M. M., Theodoro, R. C., de Carvalho, M. J., Fernandes, L., Paes, H. C., Hahn, R. C., 
Mendoza, L., Bagagli, E., San-Blas, G.  & Felipe, M. S. (2009). Phylogenetic analysis 
reveals a high level of speciation in the Paracoccidioides genus. Mol Phylogenet Evol, 
Vol. 52, No. 2, pp. 273-283, ISSN1095-9513. 
Tobón, A. M., Gómez, I., Franco, L. & Restrepo, A. (1995). Seguimiento post-terapia en 
pacientes con paracoccidioidomicosis tratados con itraconazol. Rev Colomb Neumol, 
Vol. 7, No. X, pp. 74–78, ISSN0121-5426. 
Tobón, A. M., Agudelo, C. A., Osorio, M. L., Alvarez, D. L., Arango, M., Cano, L. E. & 
Restrepo, A. (2003). Residual pulmonary abnormalities in adult patients with 
chronic paracoccidioidomycosis: prolonged follow-up after itraconazole therapy. 
Clin Infect Dis, Vol. 37, No. 7, pp. 898-904, ISSN1537-6591. 
Tong, Z., Chen, B., Dai, H., Bauer, P. C., Guzman, J. & Costabel, U. (2004). Extrinsic allergic 
alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar 
macrophages. Ann Allergy Asthma Immunol, Vol. 92, No.2, pp. 234-239, ISSN 1081-
1206. 
Torrado, E., Castañeda, E., de la Hoz, F. & Restrepo A. (2000). Paracoccidioidomicosis: 
definición de las áreas endémicas de Colombia. Biomédica, Vol.20, No. 4, pp. 327-
334, ISSN.0120-4157. 
Torres, I., García, A. M., Hernández, O., González, A., McEwen, J. G., Restrepo, A. & 
Arango, M. (2010). Presence and expression of the mating type locus in 
Paracoccidioides brasiliensis isolates. Fung Genet Biol. Vol. 47, No. 4, pp. 373-380, 
ISSN1096-0937. 
Tracey, K. J. & Cerami, A. (1994). Tumor necrosis factor: a pleiotropic cytokine and 
therapeutic target. Ann Rev Med, Vol. 45, No. 1, pp. 491–503, ISSN0066-4219. 
Trad, H.S., Trad, C.S., Junior, J.E. & Muglia, V.F. (2006). Revisão radiológica de 173 casos 
consecutivos de paracoccidioidomicose. Radiol Bras, Vol.39, No.3, pp. 175-179, ISSN 
0100-3984. 
Tuder, R. M., el Ibrahim, R., Godoy, C. E. & De Brito, T. (1985). Pathology of the human 
pulmonary paracoccidioidomycosis. Mycopathologia, Vol. 92, No. 3, pp. 179-188, 
ISSN0301-486X. 
Valente, E. G., Vernet, D., Ferrini, M. G., Qian, A., Rajfer, J. & Gonzalez-Cadavid, N. F. 
(2003). L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the 
Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide, Vol. 9, No.4, 
pp. 229-44, ISSN 1089-8603. 
 
Lung Diseases – Selected State of the Art Reviews 
 
392 
Vigna, A.F., Almeida, S.R., Xander, P., Freymuller, E., Mariano, M. & Lopes, J.D. (2006). 
Granuloma formation in vitro requires B-1 cells and is modulated by Paracoccidioides 
brasiliensis gp43 antigen. Microbes Infect, Vol.8, No.3, pp. 589-597, ISSN 1286-4579. 
Walker, S. L., Pembroke, A. C., Lucas, S. B. & Vega-Lopez, F. (2008). Paracoccidioidomycosis 
presenting in the UK. Br J Dermatol, Vol. 158, No. 3, pp. 624-626, ISSN0007-0963. 
Wasylnka, J. A. & Moore, M. M. (2000). Adhesion of Aspergillus species to extracellular 
matrix proteins: evidence for involvement of negatively charged carbohydrates on 
the conidial surface. Infect Immun, Vol. 68, No. 6, pp. 3377–3384, ISSN0019-9567. 
 Wynn, T. A. (2007). Common and unique mechanisms regulate fibrosis in various 
fibroproliferative diseases. J Clin Invest, Vol. 117, No.3, pp. 524-529, ISSN 0021-9738. 
 Xidieh, C. F., Lenzi, H. L., Calich, V. L. & Burger, E. (1999). Influence of the genetic 
background on the pattern of lesions developed by resistant and susceptible mice 
infected with Paracoccidioides brasiliensis. Med Microbiol Immunol, Vol. 188, No.1, pp. 
41-9, ISSN 0300-8584. 
Yokomura, I., Iwasaki, Y., Nagata, K., Nakanishi, M., Natsuhara, A., Harada, H., Kubota, Y., 
Ueda, M., Inaba, T. & Nakagawa, M. (2001). Role of intercellular adhesion molecule 
1 in acute lung injury induced by candidemia. Exp Lung Res, Vol. 27, No. 5, pp. 417–
431, ISSN0190-2148. 
Yu, M. L. & Limper, A. H. (1997). Pneumocystis carinii induces ICAM-1 expression in lung 
epithelial cells through a TNF-alpha-mediated mechanism. Am J Physiol, Vol. 273, 
No. 6, pp. L1103–1111, ISSN0002-9513. 
17 
Nocardia Infection in Lung Transplantation 
Pilar Morales1, Ana Gil-Brusola2 and María Santos2 
1LungTrasplant Unit, 2Microbiology Department, 
Hospital Universitario La Fe, Valencia 
Spain 
1. Introduction 
Organ transplant recipients (OTR) in general and, in particular, lung transplant recipients 
(LTx) – due to their underlying disease, extensive surgery, and the continual and profound 
immunosuppression to which they are subjected – become perfect targets for the 
development of infections. These are more frequent and severe than in the non-transplanted 
population, and may be caused by either common or less frequent opportunistic pathogens 
such as the Nocardia species. 
Nocardia are ubiquitous bacteria found mainly in soil, organic matter and water (Lerner, 
1996). Based on the available literature and on our own experience, we know that they can 
cause infections in both immunocompetent (40%) and immunocompromised patients (B.L. 
Beaman & L. Beaman, 1994), with a low frequency in transplantations in general , which is 
somewhat higher in LTx. Onset of disease is generally insidious and it is difficult to 
diagnose and treat. It produces mainly respiratory symptoms, but complications can occur, 
spreading to other organs and causing high mortality. In this chapter, we intend to review 
various epidemiological, clinical, diagnostic, therapeutic and prophylactic aspects of 
Nocardia infections in adult LTx. 
2. Epidemiology and pathogenesis 
2.1 General aspects 
The genus Nocardia includes aerobic, gram-positive, weakly acid-fast bacteria of the order 
Actinomycetales. Other microorganisms that belong to this order are Corynebacterium, 
Rhodococcus, Gordonia, Tsukamurella, Actinomadura and Mycobacterium, particularly rapidly 
growing nontuberculous mycobacteria (Sorrell et al., 2005), which can also cause infections 
in humans. More than 50 species of Nocardia have been defined either phenotypically or by 
molecular methods (Brown-Elliott et al., 2006). Originally, only 10-12 species were known to 
cause disease in humans, the most frequently described being N. asteroides, N. nova, N. 
farcinica, N. transvalesis, N. brasiliensis, N. pseudobrasiliensis, N. otitidiscaviarum and N. 
brevicatena complex, with variations according to different environments and authors. 
Nowadays, taxonomy of this genus has undergone considerable changes due to modern 
molecular techniques, such as identification by 16S ribosomal RNA gene sequencing. New 
species have been described, such as N. cryacigeorgica (Schlaberg et al., 2008), N. veterana 
(Pottumarthy et al., 2003), N. abscessus (Yassin et al., 2000), N. paucivorans (Eisenblatter et al., 
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2002) and N. kruczakiae (Conville et al., 2004), which should be taken into account in case of 
isolation in LTx samples. 
Immune response to Nocardia is T-cell mediated (Deem, 1983). Therefore, the reduced 
cellular immune response of solid OTR is one of the major factors predisposing a patient to 
infection; in fact, 60% of cases occurs in immunocompromised patients. 
2.2 Frequency  
Estimated frequency of Nocardia infection among solid OTR globally ranges from 0.1 to 3.5 
(Peleg et al., 2007a). In the past, these cases were more frequent in kidney, heart and liver 
transplantations, and less in LTx (Husain et al., 2002), but recently infections in the latter have 
been described as the most frequent (3.5%, Peleg et al., 2007a; 1.8%, Santos et al., 2011; 1.9%, 
Ponyagariyagorn et al., 2008). This increased risk of Nocardia infection in LTx may be due to 
several factors: a) the graft may have anatomical deficiencies, including lung denervation, 
reduced cough reflex and poor mucociliary clearance (Kramer et al., 1993; Husain et al., 2002); 
b) the organ has been continuously exposed to the atmosphere, with constant stimulation of 
the lung by environmental antigens and an increased risk of rejection; and, therefore, c) a need 
for more intense immunosuppression than in other solid OTR. Moreover, high average levels 
of calcineurin inhibitors 30 days prior to infection have been independently associated with 
subsequent infection by Nocardia (Hewagama et al., 2011). 
The most frequently reported species of Nocardia in LTx, with variations in percentage in 
different studies, are N. nova, N. farcinica, N. asteroides and N. brasiliensis. 
2.3 Risk factors 
There are two multivariate studies (Peleg et al., 2007a; Martinez-Tomás et al., 2007) which 
investigate the influence of several variables as risk factors for Nocardia infection in solid 
OTR. Among them, three have been described as independent: a) the doses of 
immunosuppressive therapy, as already mentioned; b) chronic use of corticosteroids; and c) 
cytomegalovirus disease in the previous 6 months (Paya, 1999). 
The relationship between opportunistic infections, including nocardiosis, and alemtuzumab, 
a monoclonal antibody that targets the antigen D52 and is used to prevent graft rejection 
(Basu et al., 2005; Peleg et al., 2007 b) by causing profound lymphopaenia, has been also 
reported. Moreover, the use of rituximab (Kundranda et al., 2007), another 
immunomodulator that targets the CD20 protein found on B cells and used in solid OTR to 
prevent or treat antibody-mediated rejection, has also been described. 
Finally, hypogammaglobulinaemia, combined with immunosuppression, may favour the 
development of Nocardia infections (Corales et al., 2000), as has been observed in heart 
transplantation. 
Renal failure, prolonged respiratory support and early graft rejection may also be risk 
factors but have not yet been demonstrated in multivariate analysis. 
2.4 Transmission 
The main route for Nocardia infection is inhalation of aerosolised microorganisms. From the 
respiratory tract, bacteria can then move to other organs, the most commonly and seriously 
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affected being the central nervous system (CNS). Involvement of skin and subcutaneous 
tissue, bones and joints, retina and, less frequently, other organs or structures (heart, kidney, 
peritoneum, endocardium, testicles, etc.) is also possible. Primary cutaneous infection can 
occur by direct inoculation in both immunocompetent and immunocompromised patients 
(Brown-Elliot et al., 2006). There is no evidence for human-to-human transmission and 
disease presents mainly as isolated cases, although an outbreak related to contamination by 
dust pollution (Sahathevan et al., 1991) in a liver transplantation unit and some spread by 
contamination of hands in a cardiovascular surgery unit (Wenger et al., 1998) have been 
documented based on molecular data. 
3. Symptoms and radiology 
Time of onset of infection after transplantation is variable, but tends to be late. It rarely 
occurs in the first month and may range from 1 to 28 years (Santos et al., 2011). The greatest 
risk is within the first year (Peleg et al., 2007a, Clark, 2009), but later cases have also been 
described (Peraira et al., 2003, Oszoyoglu et al., 2007). Pulmonary presentation is the most 
common, with subacute and insidious pneumonia. Less frequent is the cutaneous form, 
following a minor injury or by direct inoculation (Ambrosioni et al., 2010). Symptoms are 
usually non-specific and include fever, fatigue, dyspnoea, cough and pleuritic pain (Patel & 
Payá, 1997; Minero et al., 2009). Common radiographic abnormalities include irregular 
nodular lesions which may cavitate, diffuse interstitial infiltrates and lung consolidation 
with parapneumonic pleural effusion (Balikian et al., 1978; Morales et al., 2011) (Figure 1). 
Both lungs are usually affected, without significant anatomical or zonal distribution 
(Oszoyoglu et al., 2007). In the case of single-lung transplantation, Nocardia can infect both 
the native and the transplanted organ (Husain et al., 2002). 
 
Fig. 1. Radiographic changes associated with Nocardia infection. 
 
Lung Diseases – Selected State of the Art Reviews 396 
Haematogenous spread has been reported in up to 50% of cases (Clark, 2009), so it is 
important to exclude Nocardia clinically and/or radiologically in other organs, especially in 
the CNS (Singh & Husain, 2000). Moreover, and especially when the patient has a central 
venous catheter, blood should be cultured to rule out Nocardia. Cerebral involvement may 
be asymptomatic, therefore requiring neuroimaging with magnetic resonance or high 
resolution computed tomography (Ambrosini et al., 2010), or symptomatic, with headache, 
vomiting, altered level of consciousness, focal signs and seizures. Multiple radiographic 
cerebral lesions are observed in 40% (Singh & Husain, 2000). Meningitis is uncommon. 
Other forms of presentation of dissemination are cutaneous, ocular, intestinal, testicular and 
bone and joint disorders. Primary as well as disseminated cutaneous forms may present as 
subcutaneous nodules, cellulitis, abscess, mycetoma and sporotrichoid skin changes 
(Merigou et al., 1998). In this location, N. brasiliensis is the most common. The presence of the 
cutaneous form in organ transplant recipients should be followed by the exclusion of other 
forms of presentation of nocardiosis. 
We must take into account the possible and frequent co-infections that occur with common 
and opportunistic bacteria, viruses, especially CMV, and fungi, mainly Aspergillus (Cabada 
et al., 2010) that make the patient's clinical and therapeutic management difficult (Santos et 
al., 2011). Differential diagnosis of pulmonary infection and brain nodule must include 
Nocardia, Aspergillus spp., Cryptococcus neoformans, Mycobacteria, Rhodococcus equi, post-
transplant lymphoproliferative disease and primary lung cancer with metastasis. 
4. Microbiological diagnosis 
Definitive diagnosis of nocardiosis requires microscopic observation, isolation or nucleic 
acid detection of Nocardia in one or more samples from a suspected site. Specimen collection 
can be spontaneous, such as in the case of sputum (which is useful in up to 53% of cases), 
superficial such as in the case of a skin smear, or may require deeper samples such as 
bronchoaspirate, bronchoalveolar lavage or tissue biopsies. Smear staining with Gram stain, 
Ziehl-Neelsen (ZN) and modified ZN is the most useful and fastest diagnostic method. It 
can provide a diagnosis within the first few hours, showing abundant gram-positive or 
partially acid-fast branched bacilli (Figure 2), which are very characteristic of Nocardia, with 
moderate or abundant leukocytes resulting from the inflammatory response. 
Differential diagnosis with Rhodococcus, Gordonia and rapidly growing mycobacteria must be 
considered, as discussed above. This information provides a reliable presumptive diagnosis 
and may guide empiric antibiotic therapy. Although Nocardia may grow in non-selective 
culture media, samples that can be contaminated with normal flora, such as those from the 
respiratory tract, should also be cultured in selective media such as Thayer-Martin agar with 
antibiotics (Shawar et al., 1990). Typical colonies appear chalky white (Figure 3) with aerial 
hyphae. Its growth is aerobic and may take from 2 to 5 days, sometimes even a week.  
Species identification may by phenotypic, at least for the most common Nocardia, but 
genotypic methods such as polymerase chain reaction (PCR), restriction endonuclease 
analysis and sequencing of a portion of the 16S rRNA gene provide a safer and more 
accurate diagnosis. These techniques, however, are carried out by a limited number of 
laboratories (Brown-Elliot et al., 2006). 
Identification of the species can be useful to guide treatment, since some have intrinsic 
resistance to several antibiotics, or to predict prognosis, since some species, such as N. 
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farcinica, are more virulent. In cases in which disseminated nocardiosis is suspected, 
Nocardia can also be isolated from a blood culture, although this is rare. 
 
Fig. 2. Nocardia ZN stain. 
 
Fig. 3. Colonies of Nocardia. 
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Antimicrobial susceptibility testing of the Nocardia isolate is strongly recommended by the 
Clinical Laboratory Standard Institute (CLSI), which published the first approved methods 
in 2003 (Wayne, 2003). Primary susceptibility testing must include amikacin, 
amoxicillin/clavulanic acid, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, linezolid, 
minocycline, trimethoprim-sulfamethoxazole (TMP/SMX) and tobramycin. Secondary 
recommendations include cefepime, cefotaxime, doxycycline, gentamicin and moxifloxacin. 
Some species of Nocardia have more predictable susceptibility patterns or, in other words, 
there are patterns of known resistance, such as N. otitidiscaviarum to imipenem, or the multi-
resistance of N. farcinica, so it is sometimes necessary to perform in vitro synergy studies. 
The susceptibility patterns of the most common Nocardia can be seen in table 1.  
 
 N. asteroides N. nova N. farcinica N. brasiliensis 
TMP/SM
X S (91-100) S (89-100) S (89-100) S (100) 
AMC R (0-70) R (3-50) S (40-100) S (65-100) 
CEF S (75-100) S (70-100) S (70-100) V (50-100) 
IMP S (70-100) S (100) S (100) V (0-100) 
AMK S (85-100) S (100) S (100) S (100) 
LZD S (100) S (100) S (100) S (100) 
MIN V (25-100) V (29-100) V (12-96) S (0-100) 
CIP R(0-98) R (0) S (50-100) R (0-30) 
MXF (50) - (88) - 
Table 1. Expected and reported antimicrobial susceptibility of selected Nocardia species (% of 
isolates susceptible in various series). Composite data from references (Clark, 2009; 
Hewagama et al., 2011; Brown-Elliott et al., 2001). TMP/SMX, trimethoprim-
sulfamethoxazole; AMC, amoxicillin/clavulanic acid; CEF, ceftriaxone; IMP, imipenem; 
AMK, amikacin; LZD, linezolid; MIN, minocycline; CIP, ciprofloxacin; MXF, moxifloxacin; 
S, sensitive; R, resistant; V, variable. 
5. Treatment and evolution 
5.1 General aspects 
Treatment of Nocardia infections in LTx is based primarily on antibiotics. In some cases, such 
as brain or cutaneous abscesses that do not respond to initial antibacterial therapy, surgical 
drainage is also required and, whenever possible, especially in more severe cases, a 
reduction of immunosuppressive therapy should be applied. The best treatment has not yet 
been determined. In the past, the antimicrobial of choice was TMP/SMX, but since the 
development of new antibiotics, in vitro synergy studies, the insidious nature of the disease 
and its high mortality, the recommendation is a combination of two or three drugs (Clark, 
2009). 
There are few studies correlating susceptibility data with clinical outcome (Sorrell et al., 
2005), so the best combination is uncertain. Nevertheless, it is often chosen on the basis of: a) 
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the species of Nocardia isolated; b) its sensitivity to antibiotics and possible interactions with 
the complex medication of transplanted patients; c) the location, extent and severity of the 
infection; and d) the experts' opinion and documented experience in the literature. 
5.2 Empiric therapy 
According to clinical experience, TMP/SMX remains the antimicrobial agent of choice for 
many Nocardia infections (Hewagama et al., 2011), supported by the in vitro synergy of its two 
components, the fact that it reaches high levels in lung, brain, skin and bone (Smego et al., 
1983) and that it can be used as intravenous or oral maintenance therapy (Table 2). The main 
side effects include rash, nausea, vomiting, erythema multiforme, bone marrow suppression, 
hyperkalaemia and crystalluria, which may limit its use. Some species – N. farcinica, N. 
otitidiscaviarum and N. nova – may be resistant to sulphonamides, so it is important to 
determine the species and its in vitro susceptibility. These resistances and possible allergies to 
sulphonamides promoted the search for alternative antibiotics. Amikacin is universally active 
against most Nocardia species, except for N. transvaliensis and N. brasiliensis. The main 
limitations for its use are optical and renal toxicity. The combination of imipenem and 
amikacin is accepted as initial therapy in patients with severe nocardiosis (Minero et al., 2009) 
while the antibiogram is pending. This antibiotic combination is additive and synergic in vitro 
(Kanemitsu et al., 2003), maintains synergy when associated with sulphonamides (Gombert et 
al., 1986) and is effective in humans, so this triple combination has also been recommended as 
first-line treatment in patients with severe disease including dissemination to the CNS, where 
it is always better to use at least two drugs with good intracranial diffusion and, when severe, 
a triple combination (Ambrosioni et al., 2010). During the administration of amikacin and 
imipenem, doses should be adjusted according to renal function and auditory function should 
be monitored. In addition, in LTx, co-administration of cyclosporine or tacrolimus with 
amikacin may enhance the nephrotoxicity of aminoglycosides. 
 
INFECTION PRIMARY THERAPY ALTERNATIVE THERAPY 
Primary cutaneous TMP/SMX* TMP/SMX+ Fluoroquinolone 
Pulmonary stable TMP/SMX iv or po Imipenem+amikacin or minocycline or linezolid 
Pulmonary critical Imipenem+amikacin or TMP/SMX Linezolid 
Cerebral Imipenem+amikacin or TMP/SMX 
Linezolid or ceftriaxone or 
cefotaxime or minocycline 
Disseminated Imipenem+amikacin or TMP/SMX 
Ceftriaxone, cefotaxime, linezolid 
or minocycline 
Table 2. Antibiotics suggested for Nocardia infections in organ recipients (Clark, 2009, 
Ambrosioni et al., 2010, modified). TMP/SMX, trimethoprim-sulfamethoxazole. 
As regards the carbapenems, imipenem and meropenem have a similar spectrum of activity 
and effectiveness and, although the latter is somewhat less effective against N. asteroides 
complex (NAC) and more effective against N. brasiliensis and N. otitidiscaviarum, it is 
preferred in cases with CNS involvement, since imipenem has been associated with 
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seizures. Ertapenem has slightly less activity against several species of Nocardia and 
doripenem, with a similar spectrum of antibiotic activity to meropenem (Lai et al., 2009) but 
without CNS penetration, has not been tested.  
Other beta-lactam antibiotics such as the third-generation cephalosporins ceftriaxone or 
cefotaxime, due to their good CNS penetration, may be combined with other antimicrobials for 
treatment of intracranial infections with good results, depending on the species of Nocardia, 
since some may be intrinsically resistant (Garlando et al., 1992; Durmaz et al., 2001). 
5.3 Other alternatives 
The literature includes experiences of varying degrees of success with other antibiotic 
treatments, including minocycline and tigecycline, macrolides, ampicillin, piperacillin/ 
tazobactam, fluoroquinolones (ciprofloxacin, moxifloxacin and gatifloxacin), but experiences 
are limited and there is not enough scientific basis to include them in general 
recommendations. With moxifloxacin, which is active against N. farcinica (Hanse et al., 
2008), good results have been obtained in some cases; however, in others there has been 
recurrence in the CNS, despite its activity and having achieved high levels of drug in the 
abscess material (Dahan et al., 2006). 
In recent years, the oxazolidinone linezolid has been gathering attention due to its excellent 
activity against all species of Nocardia, including N. farcinica (Brown-Elliot et al., 2001). It has 
been used successfully, even in monotherapy, in six patients with disseminated nocardiosis 
(Moylett et al., 2003) and also in combination with other antimicrobials (Lewis et al., 2003; 
Rivero et al., 2008). It has extensive intravenous and oral bioavailability, crosses the blood-
brain barrier, does not require renal or liver dose adjustments and has few interactions with 
immunosuppressive agents (Jodlowski et al., 2007), which makes it a very reasonable 
alternative as first- or second-line treatment of Nocardia infections in LTx (especially in cases 
of kidney involvement). Limitations on long-term use are conditioned by its high cost and 
possible toxicity, since, in addition to its minor adverse effects such as rash, nausea and 
vomiting, it may also induce, less frequently, thrombocytopaenia, aplastic anaemia, 
peripheral neuropathy, lactic acidosis and serotonin syndrome (Beekmann et al., 2008). 
5.4 Duration of treatment 
The optimal duration of treatment has not been standardised, but should be several months 
due to the difficulty of eradicating Nocardia and frequency of relapse (Sorrell et al., 2005). 
Most patients begin to improve in 1-2 weeks, but more severe cases must follow an 
additional 3 to 4 weeks of intravenous therapy before switching to oral treatment. Cerebral 
nocardiosis requires at least 9-12 months of treatment, whereas soft tissue and lung 
presentations require 6-12 months, depending on the clinical course and response to 
treatment (Clark, 2009). If the infection is associated with a central venous catheter, this 
must be removed and followed by administration of antibiotic treatment for several months.  
5.5 Consolidation therapy 
When the patient improves and intravenous treatment can be withdrawn, oral alternatives 
may include amoxicillin-clavulanate, TMP/SMX, linezolid, clarithromycin, ciprofloxacin 
and moxifloxacin as consolidation therapy. There are no trials comparing the effects of these 
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antibiotics. Some studies recommend a dual oral combination after severe infections, such as 
those involving the CNS (Sullivan & Chapman, 2010). 
After discontinuation of treatment, the patient should be monitored for a minimum of one 
year to detect possible relapses. In some hospitals, prophylaxis is maintained for as long as 
the patient remains immunosuppressed (King et al., 1993; Poonyagariyagorn et al., 2008). 
5.6 Evolution 
Despite combined treatment, the prognosis is variable and depends heavily on: the extent of 
infection, the underlying conditions of the organ recipients and co-infections that precede or 
coincide with Nocardia infection (Peleg et al., 2007b). Overall mortality is around 40% 
(Husain et al., 2002). In CNS infections it is 30-55% (Mamelak et al., 1994) and in the lung 
about 14-18% (Poonyagariyagorn et al., 2008; Morales et al., 2011). The prognosis is better in 
isolated skin lesions, in which some studies report up to 90% healing. 
Delayed diagnosis and discontinuation of treatment has also been associated with poor 
prognosis. There is little information on the crude mortality rate, because in many cases the 
patient died due to multiple causes and it is difficult to determine the impact of Nocardia 
infection on the final outcome. 
6. Prevention/Prophylaxis 
Given the low incidence of Nocardia infection in LTx and that its onset tends to be late, 
primary chemoprophylaxis is not indicated. However, in patients with solid organ 
transplant in general, TMP/SMX is administered daily for at least six months post-
transplant and then on alternate days indefinitely to prevent infection by Pneumocystis 
jiroveci (Hewayama et al., 2011). Some works suggest that this prophylaxis reduces infection 
by Nocardia and this benefit extends to other microorganisms. Nevertheless, there is an 
increasing number of reports of TMP/SMX susceptible Nocardia isolations in transplant 
recipients taking this antibiotic as prophylaxis (Roberts et al., 2000; Husain et al., 2002; 
Poonyagariyagorn et al., 2008; Khan et al., 2008; Minero et al., 2009). This fact raises doubts 
concerning the prophylactic role of TMP/SMX to prevent nocardiosis. The lack of efficacy 
may be due to different protocols in SOT recipients. Relapse has also been documented in 
LTx (Poonyagariyagorn, 2008; Roberts et al., 2000) after one cycle of antibiotic treatment, 
possibly due to short-term duration or interruption, but the data are controversial with 
regard to recommending secondary prophylaxis. Long-term prophylaxis to prevent these 
relapses is only suggested in a few hospitals. 
Moreover, considering that Nocardia is a ubiquitous microorganism, it is important to teach 
LTx to alter their lifestyle and adopt a careful and alert attitude in order to reduce their high 
epidemiological risk of exposure, especially in the community. Recently, Avery and 
Michaels have published an excellent guide to strategies for avoiding infection following 
solid organ transplantation (Avery & Michaels, 2009). 
7. Peri-Transplant considerations 
7.1 Pre-Transplant 
The future LTx may have had an infection that has already been treated or that is still active 
during the pre-transplant evaluation period. In fact, this happens with some frequency in 
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patients with cystic fibrosis (CF). Neither situation, according to most experts and to our 
own experience, is an absolute contraindication for transplantation. Nevertheless, the 
patient must be monitored closely, being aware of possible relapses, complications or 
dissemination of infection, and ensuring full compliance with treatment. 
7.2 Post-Transplant 
Considerations are similar when nocardiosis occurs after transplantation, as we have 
previously discussed in the text, paying special attention to possible relapses. 
7.3 Donor 
Even though there is no documented case of Nocardia infection in the organ donor, 
nocardiosis would hypothetically be a relative contraindication for transplantation. In any 
case, treatment would be obligatory. 
8. Final considerations 
The practice of organ transplantation in general and lung transplantation in particular is a 
growing technique in the clinical setting and transplant recipients inevitably need 
immunosuppressive treatment. Therefore, the appearance of opportunistic infections, 
specifically nocardiosis, is expected. Given the nonspecific clinical and radiological signs, 
diagnosis of these infections is based on high clinical suspicion, proper sample collection 
and rapid microbiological diagnostic methods to confirm it and properly orient the 
antibiotic treatment as early as possible. The future challenge seems to be the application of 
molecular methods directly on the sample (Couble et al., 2005) and perhaps fewer but more 
effective and less toxic antibiotics, less aggressive immunosuppressive therapy and, overall, 
to try to avoid infection with a healthy lifestyle. 
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Development of new therapeutics for lung diseases requires good modeling systems in 
which to test hypotheses. Often, how lung diseases are modeled in vivo, are not at all 
initiated by the same events that cause the disease in humans. The models for interstitial 
pulmonary fibrosis or chronic obstructive lung disease for example, require the use of toxic 
reagents and models for asthma do not use the same antigenic stimuli. What this means is 
what is used to initiate disease in vivo using animal models is not necessarily totally 
responsible for the same disease in humans. Even in situations of generating genetic models 
focusing on identified genes associated with specific disease entities modeled in vivo, the 
disease in the animal model is still not the same as the disease in humans even if the gene is 
most certainly involved. The focus of this chapter is to describe a variety of the animal 
models that have been developed to study specific lung disease entities including 
understanding the strength and the weaknesses of the in vivo modeling systems. The main 
goal of animal modeling is to provide an in vivo complex scenario which allows for the 
pursuit of defining the underlying mechanisms of diseases or importantly to provide a 
format for studying new interventional therapeutics. The focus of the chapter will start with 
basic anatomy, physiological differences and immunological responses which either 
enhance the selection of the model or are used to study specific components of the disease 
process.  
Anatomy and Lung Models: For an in vivo model to provide the appropriate conditions, 
modeling the anatomy and the physiology of the lung model must first be considered. 
Whether dealing with small rodents such as mice, rats, and ferrets or larger animal such as 
pigs, sheep or monkeys, a detailed understanding of the model’s anatomy and physiology 
must be considered for the correlation to human diseases (1,2). The issues to consider 
include the anatomical patterns of the alveolar spaces, the bronchial tree, milieu differences 
including the changes in the surfactant proteins, phospholipids, and physiological 
differences including the respiratory rate and airway clearance mechanisms (3,4). Some of 
the issues of correlating with human disease have to do with how the lung structure is 
different with the human lung and how this relates to differences in lung structure and 
function. This also relates to size, oxygenation and gaseous exchange. Another important 
issue is how the lung structure relates to the physiology and whether the mechanisms for 
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homeostasis maintenance the same? This complicates things further since in most instances 
a direct cross-over between animal models and human disease is not complete. The relevant 
comparative anatomy of the lung would include all of the variables outlined in Figure 1. 
 
Fig. 1. Contributions to In vivo Lung Models. Here we show the lung and the variables 
associated with model selection regardless of the lung disease to be studied. 
Function and Lung Model: The selection of an in vivo model must take into consideration 
not just the similarities and differences between the model and the human disease but also 
the question being asked in the disease application. The more common comparisons are 
listed in Table 1, when evaluating murine and rat models. Certainly, some animal models 
provide good in vivo correlates to the clinical situation; other are not so realistic. Choosing 
the model has to do with the question being answered and the reasoning behind selecting 
the model. For examples, cats and horses have been shown to develop spontaneous airway 
hyper-responsiveness, which would be consistent with human asthma (5,6). However, given 
the size of the animals, the inability to generate congenic species makes these models 
economically unrealistic. The opposite perspective is the ability to use mice for diseases such 
as asthma and cystic fibrosis (CF). Although the specific disease can be mimicked, the 
spectrum of the pathophysiology is different. For example, the mouse model for CF does not 
develop spontaneous lung disease (4,7). The model does provide an invaluable tool to study 
infection induced inflammation and in some case cell specific contribution of disease (8). In 
the murine asthma model, a variety of antigens can be used to induce disease, but it has 
been shown that many of the pathways associated with disease in humans are not played 
out in the murine model of the disease (9,10). It is a balance between the clinical or 
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mechanistic question and the goal of the study for the selection of the appropriate model. 
Animal models afford the opportunity for investigators to experimentally manipulate a 
number of controlled variables such as strain of animal, and environment to investigate the 
molecular interactions involved in the pathogenesis of many lung diseases. The selection is 
based upon the basic pathophysiology, anatomy and the ability to induce the disease in a 







Offers the ability to study 
specific genes associated with 
repair and remodeling. 
Depends on species 
susceptibility to either the Th1 
or Th2 process. 
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develop Th2 driven cellular 
immune responses. Larger 
airways, easier to measure 
breathing dynamics. 
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often different proteins. Careful 
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the differences. 
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Injury response is relative to the 
total surface area at the air-
liquid interface. Mouse models 
use chemicals, which are not the 
initiators in human disease. 
Injury associated with chemicals 
of mechanical contributions can 
be used due to the size 
difference from the murine 
counterparts. Chemicals used 
are always associated with real 
human disease. 
Table 1. In Vivo Models and Studies of Lung Disease Pathophysiology 
Acute Lung Injury: Acute lung injury (ALI) and acute respiratory distress syndrome 
(ARDS) results from severe injury to the lung parenchyma (11). Animal modeling 
experiments of ALI and ARDS have been very useful in providing some directions into the 
mechanisms related to disease pathogenesis and providing opportunities to explore new 
and innovative therapeutic targets. As with most lung disease modeling systems, the design 
of the model and its manipulation is predominately dictated by the hypothesis and the focal 
point of pathology. The pathology associated with ALI and ARDS includes inflammatory 
cell recruitment, exudation with edema in the small airways potentially resulting in alveolar 
collapse (12). The recruitment of inflammatory cells, the changes in tonicity at the tissue 
interface are all pathologies which contribute to the injurious process. This occurs through 
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enhancing the production of inflammatory proteins, proteases and reactive oxygen radicals 
at the tissue interface. This gets to the mechanisms associated with the development of ALI 
and ARDS including the processes involving the injury and down-stream response to the 
injury which also contributes to tissue damage (13,14). There are three different models that 
are used for inducing different aspects of ALI and ARDS. These include the surfactant 
washout (LAV) model, oleic acid intravenous injection (OAI) model and the 
lipopolysaccharide (LPS) model (15). The LAV model utilizes a series of broncholaveolar 
lavages which requires larger animals like rats and ferrets. In the surfactant washout 
models, the focus is removing the protective anti-inflammatory molecules such as surfactant 
protein A (SP-A) potentially altering the air-liquid interface surface tension, resulting in 
changes in oxygenation efficiency. The change in surface milieu signals the production of 
pro-inflammatory cytokines with results in recruitment of inflammatory cells which 
ultimately ctonritbutes to interstitial tissue damage (15). The OAI model uses an infusion of 
oleic acid into the central vein or the right atrium (16,17), necessitating the requirement of 
larger animals. There is considerable diversity in terms of the dosing and the timing of the 
administration of OAI, making the model highly variable and not well accepted. The precise 
mechanisms by which the oleic acid induces lung edema, and the mechanisms associated 
with the recruitment of inflammatory cells and injury are not completely understood. The 
response of the animal to the oleic acid, results in a series of inflammatory events that create 
ALI/ARDS which has been theroretically associated with anhanced pro-inflammatory 
cytokine production.  
The production of the pro-inflammatory cytokines in the LPS model is the common process 
involved with ALI development, as discussed in reference to the OAI and LAV models. The 
LPS model uses the product of gram negative bacteria (LPS) to induce cytokines and the 
down-stream events which result in inefficiency in the ability to resolve infection (15,18). In 
a sense it is a process that confuses the immune system so that it is unable to perform 
efficiently. The LPS is usually extracted from Escherichia coli, but could be from other gram 
negatives such as Pseudomonas aeruginosa, a common pathogen associated with community 
acquired pneumonia and ventilator associated pneumonia (19,20). The development of 
stable lung injury is dependent on dosage, time, route of administration and size of the 
model selected. In the murine models of the ALI/ARDS the LPS is administered intra-
tracheally. The process of infection induced ALI and/or ARDS may include sepsis in the 
animal model but also in human disease. In fact, about 50% of sepsis cases ultimately 
account for ALI and ARDS ventilator support (21). The development of sepsis, results from 
a sustained and uncontrolled inflammatory response to the infectious insult contributing to 
dysfunction of at least one organ system. The sequences of events which lead to sepsis are 
unknown as well as the events that result in pulmonary failure (22,23). In the models of 
sepsis induced ALI/ARDS, LPS is administered intra-tracheally or induced by surgically 
clipping the gastrointestinal tract (11,15).  
In Vivo Models, Clinical Relevance and Limitations. Histologically, human ALI/ARDS 
can be sub-divided into an exudative and fibroproliferative phase (24). The exudative phase 
is characterized by the accumulation of inflammatory proteins containing neutrophils (25), 
followed by the accumulation of macrophages initiating the fibroproliferative phase of the 
disease (26,27). In some patients the process and side-effects of the acute inflammatory 
response completely resolves whereas others progress with chronic inflammation, fibrosis 
and neovascularization (28). Each of the different models used to develop ALI/ARDS have 
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both valid and controversial contributions to studying these diseases in vivo. How these 
models compare and provide insight into ALI/ARDS is outlined in Figure 2. In the 
surfactant washout model, it is a useful tool in studying the importance of surfactant 
maintenance in airway-interface surface tension and pathophysiology of ALI. The issue is 
that most clinical conditions do not result in clinically significant surfactant abnormalities in 
the adult population (29). In the OAI model, the ability to induce the pathophysiology of 
ALI/ARDS is dependent on using injectable oleic acid, which is obviously not similar to the 
in vivo clinical development of the disease. However, it is still a useful model for studying 
the pathology of ARDS especially with a focus on membrane injury (16,17). Since infection 
has been closely associated with the development of ALI/ARDS, the LPS model seems to be 
the most translatable. However the other two models probably represent up-stream events 
in the exposure, specificity and sensitivity of the development of infection based ALI/ARDS 
(30-32). As with most in vivo animal models it does not appear that the model is consistent 
with all of the components of the human disease. The LPS model does not appear to develop 
the fibroproliferative phase of ALI/ARDS; which limits the use of these models for studying 
the secondary issues associated with ALI/ARDS chronic inflammation and fibrosis (15,30).  
 
Fig. 2. In Vivo Models of Acute Lung Injury. Three principal models exist for studying 
ALI/ARDS. In each case the model has important contribution to the pathophysiology 
shown in blue, and potential therapies shown in green. The important caveats and 
limitations are shown in red. 
Chronic Obstructive Pulmonary Disease (COPD) and Emphysema: COPD is the fifth 
leading cause of death worldwide and is associated with pollution and smoking history (33). 
COPD is a very complex disease with four described traits: emphysema, small airway 
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remodeling, chronic bronchitis and pulmonary hypertension (34). The underlying 
pathophysiology of COPD is dependent on the structure and function of the lung along with 
the immunological processes that occur post-insult. Although patients present with 
variations and combinations of these pathologies, all patients progress into severe 
pulmonary failure. The kinetics of disease progression is dependent on the patient, patient 
compliance to therapeutic intervention and the ability to respond to current therapeutics. In 
this case the animal model of choice should require a close attention to lung anatomy and 
physiology since these play very important roles in the overall development of COPD and 
emphysema (35), especially as it relates to the overall development of new therapeutics. 
Besides the basics of understanding the similarities and differences between lung anatomy 
of the animal model and that of the human disease some consideration must also be given to 
the overall lung mechanics.  
The in vivo model most commonly used to study COPD includes cigarette smoke (36). The 
issue lies with the ability to deliver a homogenous dosing of cigarette smoke over a defined 
time range, and that these models do not completely recapitulate the human disease. 
Further, since there are genomic differences which increase susceptibility to COPD, the 
translatable ability is always in the background. Additionally, the pulmonary pathology 
produced in the context of the cigarette model produces subtle pathologies which may also 
introduce subjective interpretation in quantifying the histopathology (37). Better 
computerized-microscopic programs need to be developed that can better quantify and 
minimize subjective interpretation of the studies (26,38).  
Non-specific inflammation is another indicator of COPD, with a predominance of 
neutrophils and the inflammation approach to studying COPD focuses on apoptosis and 
elastase (39,40). The apoptosis model focuses on the failure of the COPD lung to repair itself 
post-injury focusing on dysregulated normal lung tissue turnover. The mechanism 
associated with apoptosis induced COPD has been linked to the production of vascular 
endothelial growth factor (VEGF) and/or the VEGF receptor (40). It is not clear whether this 
VEGF/VEGF receptor dysfunction is by itself critical for inducing endothelial cell apoptosis 
and the processes that result in decreased vascularization in the lung or whether it is in the 
context of a variety of other factors which ultimately contribute to COPD.  
The elastase model uses a product of the inflammatory response to initiate and perpetuate 
the inflammatory response seen in COPD. The original hypothesis for the importance of 
elastase came patients α1-anti-trypsin deficiency (41,42). Individuals with this disease 
develop emphysema and COPD. These patients are treated with exogenous α1-anti-
trypsin, the endogenous inhibitor of elastase. In COPD/emphysema, the recruitment of 
inflammatory cells and the disproportionate production of proteases without the 
appropriate anti-protease counter-part ultimately results in extracellular matrix 
degradation, inflammatory cell recruitment, matrix metalloprotease activity, cellular 
activation which all contribute to the lung damage similar to the mechanisms in α1-anti-
trypsin deficiency (43,44). The disadvantage of the elastase model, is that the function of 
elastase and cigarette smoke in COPD emphysema are potentially mediated through very 
different pathophysiological mechanisms which again brings up the issue of clinical 
translation. It is efficient to have a very specific inducer of emphysema for investigating 
specific mechanisms and therapeutic development. However, results obtained from 
specific products need to be taken into consideration as compared to the complex in vivo 
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environment post complex insult (45,46). Some investigators have used LPS to induce 
airway and parenchymal changes, although the pathophysiology is more reminiscent of 
ALI/ARDS than COPD (33,47). Table 2 lists the pros and cons of each of the COPD 
models.  
 
Model Pathology Positives of 
Model 
Negatives of Model 
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Induced COPD 
Dilated alveolar ducts, 
abnormal parenchyma 
and increased 
numbers of goblet 
cells. Pulmonary 
function tests show 
decrease in 
effectiveness. 
The most similar 
to the human 




It is not debilitating in 
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certain point to mimic 
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Table 2. Models of COPD 
Bronchopulmonary Dysplasia: Bronchopulmonary dysplasia (BPD) remains the leading 
cause of respiratory morbidity and mortality in severely pre-term infants (48,49). The 
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treatment of prematurity itself induces BPD, which complicates matters including ventilator 
induced surfactant deficiency and inflammation (44,50). Intrinsic BPD is characterized by 
immaturity, decreased growth, and immature vascularization (51). The main model for BPD 
is hyperoxic exposure in animal models such as rats and mice (49). Hyperoxia inhibits the 
normal budding and branching of the bronchi (52) leading to arrest in lung development 
resembling pre-term infant BPD (53). In these studies, it appears that both the airways and 
capillary vessels are affected requiring ventilation which can also contribute to 
inflammation and dysplasia (48,49,51). To understand the mechanisms and outcomes in 
BPD, animal models must contain elements of the normal fetal lung and the mechanisms 
associated with development and function. For the pulmonary mechanics studies, the in vivo 
models consist of larger animal models including lamb, rabbits and guinea pigs (49). The 
change in lung mechanics and the accumulation of fluid, changes the airway surface tension 
contributing to robust inflammatory cytokine production contributing further to the 
histopathology. Using these models, studies have provided avenues for understanding the 
role of surfactant therapy, decreased tidal volumes, improved control of oxygenation on 
BPD development and translation clinically (49,54).  
Alveolar Proteinosis: The lung faces physical and environmental challenges, due to 
changing in lung volumes as well as exposure to foreign pathogens. The pulmonary 
surfactant system is integral in protecting the lung from these challenges via two different 
and distinct groups of surfactant proteins (55). Surfactant protein (SP)-B and SP-C are small 
molecular weight hydrophobic surfactant proteins that regulate air liquid interface surface 
tension. SP-A and SP-D are the larger hydrophilic surfactant proteins which aide in surface 
tension but which also have microbicidal function. Additionally, there are other non-
surfactant proteins called defensins which also aid in inflammation and host defense (56). 
Pulmonary alveolar proteinosis (PAP) is a process by which there is a surfactant 
accumulation in the lungs potentially due to the inability to catabolize surfactant (57). There 
are three forms of the disease: genetic, exposure induced and idiopathic (58). The genetic 
disease specifically impacts children, and is associated with mutations in some of the 
surfactant protein genes (59-61). Exposure induced PAP is found in scenarios of particulate 
inhalation including silica and titanium (62-65). The idiopathic form is associated with 
circulating auto-antibodies against the macrophage growth and differentiation factor 
granulocyte-macrophage colony stimulating factor (GM-CSF) (66,67). Clinical studies have 
correlated the presence of the neutralizing antibody to PAP (66,68,69). Clinical trials of GM-
CSF, plasmapheresis and whole lung lavage have shown limited successes with some 
sustainable relief, but none of the treatments are curative (70). In terms of animal models, 
most have been done with mice since the defects are most often associated with the absence 
of surfactant or GM-CSF proteins and murine GM-CSF knockout development of alveolar 
proteinosis (71-73). The surfactant protein knockouts develop diseases very reminiscent of 
pediatric interstitial proteinosis (50). The GM-CSF knockout mouse has many 
pathophysiological outcomes which are reminiscent of the human PAP adult disease (74). 
The nice part of these models is that they do not have to be induced, so there is relatively 
little variability between animal to animal. There have been some attempts to develop an 
autoimmune model of idiopathic PAP using monkeys and mice (75,76). These efforts have 
provided important insight into the potential mechanisms of development in early and late 
stages of PAP due to autoimmunity against GM-CSF. 
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Agent utilized  Pathology Advantages Disadvantages 
Bleomycin Induced lung 















silica is not resolved 
by macrophages. 
Not a natural 
inducer of fibrosis. 
The mechanisms 
may not be 
translatable. 
FITC Inflammatory 






Visualize areas of 
repair and fibrosis. 
Some characteristics 
of the lung disease 
are absent. There is 
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depending on the 
FITC batch. 
Irradiation Induces direct cell 
death via DNA 
damage with a 
subsequent influx 
of inflammatory 
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Viruses used to up-
regulate mediators 
of fibrosis. 
Specific in vivo 
molecules 
associated with IPF 
formation such as 
TNF or TGFB.  
Deal with potential 
mechanisms but is 
not realistic to 
defining disease 
process. 
Table 2. In vivo Models for Interstitial Pulmonary Fibrosis 
Interstitial Pulmonary Fibrosis: Fibrosis is an important cause of morbidity and mortality 
in a variety of lung diseases, but it has a very prominent role in idiopathic pulmonary 
fibrosis (IPF) (77). IPF presents with a homogenous phenotype with both definable 
physiologic and radiographic presentation but without identifiable etiology (78) although, 
the literature suggests that alveolar type II cell injury is an important early feature in the 
pathogenesis of pulmonary fibrosis (79). The source of injury is unknown. Different 
approaches to modeling pulmonary fibrosis have been used by investigating exposure to 
bleomycin, silica, fluorescein isothiocyannate (FITC) and irradiation (77). At the genetic 
level, some models of IPF have included over-expression of ‘hypothesized” genes in the 
pathogenesis of IPF or utilization of transgenics for cell specific contribution to IPF. 
Bleomycin is the most frequently used agent in modeling IPF (80,81). The advantage of 
bleomycin is the ease with which it can be administered and the consistency of the IPF 
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pathophysiology. Bleomycin is a chemotherapeutic agent which induces lung damage 
through direct DNA strand breakage and the generation of free radicals. The response to the 
injury is healing and fibrosis. Silica aerosolized into the lung induces pulmonary fibrosis 
through inducing chronic inflammation and frustrated phagocytosis by macrophages 
(77,82). Post-ingestion, the macrophages constitutively produce pro-fibrotic cytokines (83). 
The greatest advantage of the silica based system is that the silica particles are not easily 
cleared from the lungs creating a persistent stimulus and a non-reversible fibrotic process. 
Regardless of the model fibrosis is dependent on the strain of animals, suggesting immune 
dependent contribution to the overall susceptibility of IPF development. FITC is another 
chemical used to induce pulmonary fibrosis (77,84). Fluorescein, delivered directly into the 
airway acts as a hapten attaching to lung proteins providing a depot for continuous lung 
exposure to antigen. The advantage of the FITC model is the ability to actually image the 
processes as they occur in the lung.  
Asthma: Asthma is a very complex and heterogeneous disease affecting 300 million people 
worldwide especially in Westernized countries (85). Why developing countries seem to be 
somewhat protective has been the foundation for the hygiene hypothesis (86). Asthma is a 
complex trait caused by multiple environmental factors with the main characteristics being 
airway inflammation and airway hyper-reactivity (AHR) (87). The pathogenesis of asthma is 
associated with many environmental factors, many cell types and several molecular and 
cellular pathways. Some specific presentations of asthma are outlined in Figure 3 (88,89). 
The majority of the induced asthmas are due to exposure to an irritant such as air pollution, 
allergen or viral exposure. Even aspirin and drug induced asthma can be associated with 
changes in the pulmonary milieu upon dosing. Interestingly, some asthma phenotypes are 
not associated with identifiable exposures, such as exercise induced and metabolic 
syndrome associated asthma.  
 
Fig. 3. Asthma Phenotypes. Asthma is a heterogeneous disease with multiple factors 
associated with the development and response to therapy. Given these issues, designing 
experiments and translating into clinical significance become a challenge. 
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These different pathways and phenotypes probably suggest mechanisms that are co-existent 
but also synergistic depending on the patient, environment, compliance and documentation.  
Animal models of asthma have helped to clarify some of the underlying pathophysiological 
mechanisms contributing to the development of asthma (5,9,10). Much of the focus of these 
models is on T cell driven allergic responses contributing to understanding of the 
heterogeneity of asthma (90). The murine model of asthma using Balb/C mice has defined 
the important role of allergen-specific Th2 cells in recruiting eosinophils into the airway, 
their activation and the release of histamine associated with atopic airway reactive disease. 
The major caveat in the murine asthma studies is that the allergen sensitization process does 
not completely recapitulate the allergic response in humans complicating the ability to 
utilize these models for therapeutic development (91). This has been quite frustrating in 
asthma therapy development, even though certain biomarkers have been identified in the in 
vivo models they have ultimately not translated into efficient therapeutic care for patients 
with asthma (10). The inability to translate the observations from the animal models to 
patient care were very disappointing and increased the lack of the appreciation of the 
animal models toward mechanisms and pathogenesis of asthma. The fortunate component 
of the murine asthma model is the ability to sensitize the animals to a variety of foreign 
proteins and to use transgenic animals for studying mechanisms and response to different 
exposures. In most scenarios, the challenge results in a Th2 polarization and enhanced 
allergen-specific IgE production (92). Pathologically the lungs have eosinophilia, mucus 
secretion and goblet cell hyperplasia, airway hyper-responsiveness and remodeling with 
fibrosis (5,88). These asthmatic phenomena have suggested that cytokines and cells other 
than T-cells, such as IFN, IL-17 and/or neutrophils, may also play a significant role in the 
lung pathology (93,94). Further, Th2 targeted therapies have not been as effective as hoped 
in many clinical trials of asthma, suggesting alternative pathways to the lung inflammation 
and remodeling. These have resulted in several distinct alternatives to the traditional 
allergen challenge model. Table 3 outlines the different animal models currently available to 
study various aspects of the pathophysiology associated with asthma. 
Lung Cancer: Several in vivo models exist which provide the opportunity to study cancer 
(95). The complications in these models are their inability to completely correlate with 
histologic patterns of the malignancies, natural strain susceptibility and time frames for 
cancer induction in humans. One important difference between the animal models and the 
human disease is that these animals have higher basal metabolic rates changing metastatic 
potential (33). Failure to develop specific tumor types is probably due to the variability of 
the transgene expression early in lung development. The most common compound utilized 
for the development of tumors in animal models is urethane (96). Mouse models have been 
used to study the roll of mutant oncogenes in the genesis of lung adenocarcinomas (97-99). 
These models have also proven useful for studying potential therapeutics. The development 
of a tyrosine kinase inhibitor which blocks epidermal growth factor receptor (EGFR) was 
found to benefit some patients after testing in mouse models. The deletion of other genes 
associated with human small-cell lung cancers could also be mimicked in a murine lung 
model aiding in therapeutic development of inhibitors (33,95).  
Malignant mesothelioma is a cancer associated with environmental exposure to asbestos 
(95). The disease has a poor prognosis, with little to offer patients in terms of therapy. 
Mouse models of pleural mesothelioma have been produced by exposing mice to asbestos  
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Table 3. In Vivo Models for the Versatility of the Asthma Phenotypes 
fibers. A wide range of natural and synthetic fibers, chemicals and metals have also been 
shown to induce pleural and peritoneal mesotheliomas (100,101). Recently the technology of 
xenographic transplantation of human malignant mesotheliomas into rats or mice has been 
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used to study new chemotherapeutic agents including immunotherapy, gene therapy and 
multimodality therapy (95). Asbestos-induced malignant mesotheliomas produced in 
rodents resemble the human disease with respect to latency and growth of the tumor cells. 
Even with these similarities, mice are not perfect models for humans.  
Cystic Fibrosis: Cystic fibrosis (CF) is the result of defects in the gene encoding the cystic 
fibrosis transmembrane regulator (CFTR) and is the most common genetic disease among 
Caucasians (102).. Even though new therapeutics including correctors and activators like 
VX-770 has shown great promise in new phases of CF therapy, the cure has been elusive 
(103). The development of the in vivo models has focused on four major points of 
pathophysiology: anatomy, physiology, airway clearance and intrinsic and/or induced 
inflammation. The mouse model been the main model in CF research for several years, 
however, the model does not develop spontaneous lung disease requiring the introduction 
of bacteria to initiate the pathophysiological events associated with CF infection and 
inflammation (104). There are several different models of CFTR deficiency ranging from the 
complete absence of CFTR (null) to the partial expression and/or function (4). There have 
also been murine models developed in which the lung mutation remains but the 
gastrointestinal phenotype is corrected or it is cell specific (105). The reason for these later 
series of animals is that the murine CFTR null mutant consistently has gastrointestinal 
blockage once the mice have been weaned, increasing mortality and expense of the animals. 
To prevent obstruction, the animals are put on a laxative. Investigators have a choice 
whether to use laxative treated animals or gut corrected animals. In either case, it is likely 
that gastrointestinal obstruction is important in the overall immunity and host response to 
infection in CF. Therefore, observations in the gut corrected mouse may ultimately have to 
be verified in the null mouse depending on the focus of the studies. Even with the 
differences in the gastrointestinal constitution, the severity of the different murine models is 
defined by CFTR protein function  related to the mRNA expressed, protein synthesis or 
folding of the complete CFTR protein (4). In addition to the gastrointestinal obstruction, 
most of the models display inflammation (106), failure to thrive (107), decreased survival 
(108,109) and hyper-responsiveness to stimulation (110). To improve the ability to look at CF 
globally, larger models of CFTR deficiency have been developed to better investigate the 
airway pathogenesis and progression of lung disease. Further, unique models have been 
developed using transgenic technology to induce CFTR deficiency in specific cell types, 
allowing for the sequential investigation of all of the contributing cellular abnormalities and 
how they contribute to the CF pathophysiology (105,107,111).  
The pig has become an exciting new direction for CF model development. The pig lungs and 
human lungs have similar comparative anatomy (112,113) and have been used to study a 
variety of aspects of lung pathophysiology including surfactant homeostasis, airway hyper-
responsiveness and lung injury (114). The first studies have shown that there were no 
differences in the newborn pig birth weight or appearance (4). Deficient CFTR in the pigs 
did not appear to alter normal birth weight, appearance and/or lung anatomy or function. 
The absence of CFTR however, did result in defective nasal transepithelial cell potential and 
all piglets developed severe gastrointestinal obstruction. Further, with piglet aging there 
appears to changes in lung physiology and function resembling that of infant with CF. 
However, the development of lung disease is still being investigated as to whether it is an 
intrinsic phenomena due to the absence of CFTR, or the result of environmental exposure 
(112). The pig is a great model for studies in CF lung pathophysiology, however husbandry 
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and cost and reproductive cycle play a major part in being able to conduct several studies 
with reasonable numbers of animals.  
The ferret has been shown to also be a good animal model for studying CFTR lung biology 
(7,115). The ferret lung shows CFTR expression in the airway epithelium and submucosal 
glands, identical to that in humans (4,7). Like the pig model, the majority of the CFTR deficient 
ferrets also developed gastrointestinal obstruction with “failure to thrive” (115,116).  
To study CF, the availability of three established in vivo model systems provides ample 
ability to study various components of CF pathophysiology. Besides CFTR deficient mice, 
pigs and ferrets, other models have also been developed or observed (117) including the 
sheep (118) and monkey models (119). These have been less studied for a variety of reasons. 
Although these models have provided invaluable insight into the development of new CF 
therapeutics, new model systems should be considered to get even closer to the overall 
mechanisms associated with CF.  
Summary: Human lung disease is a major cause of morbidity and mortality in the world. 
The pulmonary dysfunction may be primary or secondary to a variety of events. The 
pathophysiological mechanisms associated with the disease processes are different 
depending upon whether the insult is external as in the case of infection or injury or internal 
as in the case of genetic anomalies associated with important pulmonary or secretion 
functions. Studying lung disease requires models that attempt to recapitulate the human 
phenomena. There are no perfect models, and the selection for studies must be based upon 
the criteria of study and the ability of the model to meet the needs of the study. In this 
chapter we have highlighted a variety of pulmonary diseases and syndromes with a focus 
on the models used to study the various pathophysiological mechanisms associated with 
that specific disease entity. In the end, model development and usage will continue as a 
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1. Introduction 
Cystic Fibrosis is a lethal autosomal recessive lung disorder resulting from a mutation in the 
transmembrane conductance regulator (CFTR) protein. The CFTR is a chloride channel 
encoded by a single gene on chromosome 7.  More than 1200 mutations have been identified 
that result in defective or absent CFTR protein [1]. The most common mutation is ΔF508 
(deletion of phenylalanine 508).  This deletion leads to a non-functional, misfolded protein 
that is subsequently degraded [2]. While multiple organ systems are affected, CF is most 
often characterized by thickened mucus secretions and an inability to clear the lungs [1, 3-4].   
In recent decades, improvements in life expectancy were achieved by new methods of 
antibiotic delivery as well as addition of new treatments to thin lung fluids.  An example is 
the use of DNase to clear the buildup of extracellular DNA that occurs in the CF lung.  This 
also relieves some of the exaggerated inflammatory response that is a characteristic of the 
CF lung [5].   
Over their life time, CF patients experience multiple infections by various pneumonia-
causing bacteria [6].  With more patients surviving to adulthood, chronic infections with 
Pseudomonas aeruginosa are coming to the forefront as a leading cause of death [7].  Problems 
presented by infected CF lung are multi-dimensional; the electrolyte balance and pH of the 
fluids are abnormal. The mucus is thick and of an alternative composition compared to 
normal lung and may contribute to colonization with Pseudomonas aeruginosa [2, 3, 5]. As 
such, research is multi-pronged and includes gene therapy to correct the defective protein, 
amelioration of inflammatory response and thinning of alveolar surface fluids [8, 9]. 
Significantly, Pseudomonas bacteria colonize the CF lung far easier than normal lung.  
Normal lung tissue has several naturally occurring defenses that work in concert with 
commonly prescribed antibiotics for recovery from lung infections [4, 10]. The CF patient 
appears to lack these natural defenses [1, 7].  
Pseudomonas aeruginosa biofilms are difficult to treat due to multi-drug resistance. Many 
aspects of biofilms from physical structure to genetics and protein expression are under heavy 
investigation to elucidate the mechanisms by which biofilms develop antibiotic resistance. 
Within the biofilm matrix, bacteria are well protected from hostile environmental elements 
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and host defenses. Cells in different areas of the biofilm take on various patterns of gene 
expression, as such; biofilms are described as a community or as functioning similar to a multi-
cellular organism [3].  Biofilms develop slowly, destroy surrounding tissue and evade even 
healthy immune systems. Standard dose antibiotic therapy can reduce biofilm as well as 
planktonic cells shed from the biofilm, but rarely eradicate the entire biofilm.  This allows a 
cycle of subsequent regrowth and new shedding of planktonic cells which possess altered 
antibiotic resistance [11].  Some theories describe the heavy matrix, flow channels and oxygen 
gradients within the biofilm structure as contributing to problems with penetration of 
antibiotics into the biofilm.  Others describe a counteraction of host defenses or alterations in 
gene and protein expression not only within the biofilm, but also in the CF host [11-13].   In 
this proposal we will discuss a novel experimental approach to study the pharmacodynamics 
of antibiotics used to treat Pseudomonas aeruginosa biofilms in CF lung versus normal lung.  
Pseudomonas aeruginosa is an important human pathogen that can cause a wide range of 
infectious diseases that are associated with high morbidity and mortality rates [14]. Exposed 
tissue surfaces lined with epithelia are the most common targets of that pathogen e.g. 
epithelial surface of the eye and airways. 
Adhesion of Pseudomonas aeruginosa to the airway cellular receptors is the initial event to 
establish respiratory colonization and infection [12, 15-16]. Interestingly, the affinity of 
Pseudomonas aeruginosa to bind to the inflamed or injured epithelial cells (CF or mechanically 
ventilated patients) is significantly higher than that to bind normal cell surfaces; thus 
preventing bacterial adherence may minimize lung pathology for high-risk patients [16].   
The exploit of natural compounds, especially carbohydrates, to prevent infection has been 
considered in lung infectivity studies; since bacteria associated with pneumonia is known to 
bind the carbohydrate receptors on the pulmonary epithelium [12]. Dextran, a polymer of α 
(11,16) linked D- glucose (branched at the 3 position), is a widely available polysaccharide 
that has been used in the in vitro and in vivo infection models to block the adherence of 
Pseudomonas aeruginosa, Hemophilus influenza and Staphylococcus aureus [12, 15]. Berries of 
Vaccinium family (include cranberry) and their extracts that contain a saccharide effective in 
preventing the attachment of Escherichia coli to the uroepithelial receptors are well-known 
examples as well [12]. 
Recent studies suggested that many pathogenic organisms have the ability to invade and 
reside in the host cells during the early stage of infection. The discovery of antibiotic-
resistant intracellular Heamophilus influenzae in the lung of individuals with Chronic 
Obstructive Pulmonary Disease (COPD) implicates intracellular bacteria as an important 
reservoir for the persistent infection [17]. Pseudomonas aeruginosa can also survive for up to 
24 hours inside the lung epithelium without inducing cytotoxicity and is known to develop 
resistance to the treatments afterwards [17]. Accordingly, it is equally substantial to combat 
bacterial adhesion and invasion as a preventive step of the infection as well as the 
development of bacterial resistance. 
It has been reported that some inexpensive natural extracts (e.g. Berries of Vaccinium family 
and dextran) have shown promising anti-adhesion properties with some micro-organisms 
(e.g. Escherichia coli) in the urinary tract infections, therefore, they might worth testing as 
topical therapeutics for prevention of Pseudomonas aeruginosa adhesion and invasion to lung 
epithelial cells [18-19].   
In this study, the efficacy of some natural extracts with potential anti-adhesion properties 
and their combinations with ciprofloxacin was evaluated as blocking agents for the adhesion 
and the invasion of Pseudomonas aeruginosa PAO1 to A549 lung epithelial cells.  
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2. Building CF infection model 
Ciprofloxacin and gentamicin sulfate were purchased from Sigma/Aldrich (St. Louis, MO, 
USA) and their stock solutions were prepared in 0.1N HCl (32 mg/ml) and water (32 
mg/ml), respectively, and stored at -80oC. Before use; the antibiotic dilutions were made in 
F12-K cell culture medium (Cellgro, Mediatech, Inc, Manassas, VA, USA).  Other Cell 
culture reagents were also obtained from Cellgro, Mediatech Inc. (Manassas, VA, USA).  
Dextran of molecular weight (MW) 40,000 was provided by Dr. John Brekke (University of 
Minnesota Duluth, MN, USA). Bacterial culture reagents were obtained from Difco 
Laboratories (Detroit, MI, USA). 
The commercially available Vaccinium macrocarpon (cranberries) and Glycine max (soybean) 
were blended and extracted with distilled water (1:1 and 1:3.5, respectively) at room 
temperature.  
Both crude mixtures were left to decant overnight at 4oC. Their supernatants were then 
subjected to two steps centrifugation at 4750 rpm for 20 min followed by 12,000 rpm for 10 
min. The resultant supernatants were membrane filtered (0.22 µm, Millipore Corp. Billerica, 
MA). The sterile extracts were then stored at -80oC in 1ml aliquots till they were used in the 
adhesion or invasion assays.  
The concentrations of the solid contents of such extracts were determined by evaporating 
the water content at 40oC and weighing the solid residues until constant weights were 
achieved. 
Pseudomonas aeruginosa strain PAO1 was purchased from American Type Culture Collection 
(ATCC, Rockville, MD). P. aeruginosa PAO1 was grown until achieving the exponential 
growth phase over 16 hours at 37oC in Cation Adjusted Muller Hinton Broth (CAMHB) 
(Sigma-Aldrich, St. Louis. MO) from which 0.5 McFarland (1.5 × 108 CFU/ml) was prepared 
in F12-K tissue culture medium to initiate adhesion or invasion assays.  
A549 lung epithelial cell line was obtained from American Type Culture Collection (ATCC, 
Rockville, MD). The cells were passed in 75 cm2 flasks (BD Falcon, San Jose, CA), and then 
1.5 x 105 cells were counted using the Hemocytometer and seeded into 12 well tissue culture 
plates (Becton Dickinson, NJ, USA). The cells were incubated in F12-K medium 
supplemented with 10% (vol/vol) Fetal Bovine Serum (FBS) at 37oC in the presence of 5% 
CO2 to achieve confluence over 48 hours.  
Minimum Inhibitory Concentration (MIC) and Minimum Cytotoxic Concentration (MCC) 
were two factors controlled the choice of the extract or ciprofloxacin concentrations selected 
in the adhesion and invasion assays.  In order to prevent adhesion or invasion, the bacterial 
cells need to be alive but incapable of clinging to or intruding into the lung epithelial cells; 
therefore, sub-MIC had to be determined prior to the assays.  On the other hand, the lung 
cells integrity was kept intact via using sub-MCC of the different tested agents. MICs were 
determined according to the Clinical and Laboratory Standards Institute (CLSI, M7-A7 and 
M100-S16, Criteria for Pseudomonas aeruginosa). Cytotoxicity of the tested agents against the 
A549 lung epithelial cell line was determined using crystal violet nuclei staining method as 
described by Gillies, et al. (1986) [10] with minor modifications. Briefly, confluent monolayer 
of A549 lung epithelial cell was incubated for 2 hrs with 200 µl of two-fold serial dilutions of 
different tested agents prepared in F12-K Medium, and then the cells were washed twice 
with phosphate-buffered saline (PBS). After rinsing, the cells were fixed with 1% (vol/vol) 
gluteraldehyde (Sigma/Aldrich, St. Louis, MO) and stained with 0.1% crystal violet (Fisher 
Scientific, Pittsburgh, PA) for 15 min. The dye was removed through multiples sterile water 
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rinsing and the absorbed crystal violet was then dissolved with 0.5% (vol/vol) Triton X-100 
(Sigma/Aldrich, St. Louis, MO).  
Absorbance was measured at λ590 nm using SynergyTM2 Microplate Reader (BioTech 
Instruments, Inc. Vermont, USA). Absorbance data were analyzed using Excel spread sheet 
and sub-MCCs were determined for different agents.     
For SEM analysis, A549 lung epithelial cells were challenged with PAO1 cells for 1 hour, 
washed 3 times with F12-K medium and subsequently fixed with 5% (vol/vol) 
gluteraldehyde over 24 hours. The cells were then flushed with sterile deionized water to 
remove salts and dried before scanning with JSM-6490LV SEM (Peabody, Massachusetts) 
equipped with a tungsten filament, an accelerating voltages of 15-20 kV and a chamber 
pressure of 60-70 Pa according to the method described by Carterson et al with minor 
modifications [11]. All infectivity studies were carried out in a sterile class II biological 
safety cabinet (Sterilgard III Advance, Baker Company, Sanford, Maine, USA) according to 
the method described Plotkowski, et al [12] with some modifications. Initially, the confluent 
monolayer of A549 lung epithelial cells  was incubated with 500µl fresh F12-K cell culture 
medium (control wells), 500µl of the natural extract or combination solutions (natural 
extract and ciprofloxacin) in F12-K medium at 37oC for 15 min followed by mixing with 
500µl of 0.5  McFarland (1.5 × 108 CFU/ml) suspension of P. aeruginosa PAO1 prepared in 
F12-K medium for one minute to achieve homogenous bacterial distribution in MultiwellTM 
12-well tissue culture plate (Becton Dickinson, NJ, USA). Ciprofloxacin (0.0625 µg/ml), 
dextran (50.0 mg/ml), and the aqueous extracts of soybean (42.8 mg/ml), and cranberry 
(25.4 mg/ml) as well as the combinations of the three later agents with ciprofloxacin were 
applied as potential anti-adhesion agents in the aforementioned assay. The mixture was 
incubated at 37oC for 1 hour to establish bacterial adhesion. Each plate had a control well 
and all experiments were carried out in triplicates. 
At the end of the incubation time, cells were gently washed thrice with FBS free F12-K 
medium to eliminate the non-adhered bacterial cells of P. aeruginosa PAO1 and then lysis of 
the mammalian cells was carried out with 1ml of 1% (vol/vol) tween-20 (Astoria-Pacific, 
Clackamas, Oregon, USA) at 37oC for 30 min.  
After lysis, ten-fold serial dilutions for the P. aeruginosa PAO1 suspension in each well 
followed by plating onto Cation Adjusted Muller Hinton II (CAMHII) agar were carried out. 
All CAMHII agar plates were incubated at 37oC for 18 hours for determining CFU/ml 
through viable cell counting for different treatments as well as for the untreated control. 
Percentage adhesion for each treatment relative to the untreated control was calculated and 
the averages of triplicate experiments were expressed graphically + standard deviations 
(S.D). Data analysis was carried out using Graphpad prism 5 (GraphPad Software Inc. La 
Jolla, CA ) that utilized One Way Analysis of Variance (ANOVA) followed by Dunnett 
Multiple Comparison test to determine the significant treatment differences as compared to 
the untreated control.           
Parallel experiments were carried out as described under adhesion assay except for an extra 
step performed to assess P. aeruginosa PAO1 invasion into A549 lung epithelial cells. After 
15 min incubation with 500 µL of the drug or the combination solutions in F12-K medium at 
37oC, bacterial suspension (500 µL of 0.5 McFarland) was added and mixed with the 
aforementioned solutions for 1min in MultiwellTM 12-well tissue culture plates. The plates 
were incubated at 37oC for 2 hours to allow for invasion. Gentamicin exclusion method as 
described by Fleiszig et al [13] was then used to kill the adherent bacterial cells. This step 
involved washing of the adherent cells with FBS free F12-K medium followed by incubation 
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of the infected cells with fresh F12-K medium containing 300µg/ml gentamicin for 1 hour at 
37oC. After incubation, the dead bacteria were washed thrice with FBS free F12-K medium 
and the lung epithelial cells A549 were lysed with 1% (vol/vol) Tween-20 solution to 
determine the count of internalized P. aeruginosa PAO1 cells. The resultant cell suspensions 
were tenfold serially diluted, plated onto CAMHII agar plates, and incubated as previously 
described under adhesion assay. 
Percentage invasion for each treatment relative to the control was calculated and the 
averages of triplicate experiments were expressed graphically + standard deviations (S.D). 
Data analyses were carried out using Graphpad Prism 5 (GraphPad Software Inc. La Jolla, 
CA) that utilized the one way ANOVA followed by Dunnett Multiple Comparison 
adjustment to determine the significance of treatment differences on the invasion of P. 
aeruginosa PAO1 as compared to the control.   
Adhesion of P. aeruginosa PAO1 to lung epithelial cells A549 was visualized using Scanning 
Electron Microscopy (SEM). Imaging revealed that P. aeruginosa PAO1 could adhere to the 
lung epithelial cells without disrupting the lung cells morphology (Figure 1).  
 
 
Fig. 1. Scanning Electron Micrograph illustrating the adherence of  Pseudomonas aeruginosa 
PAO1 to A549 lung epithelial cells. 
The soluble solid ingredients for the applied extracts were determined as described under 
Materials and Methods and their concentrations were 50.9 mg/ml and 85.7 mg/ml for the 
aqueous extracts of cranberry, and soybean respectively. Dextran was applied at a 
concentration level of 50.0 mg/ml. 
MIC of ciprofloxacin and natural extracts against P. aeruginosa PAO1 and MCC of the same 
agents on A549 lung epithelial cells were determined according to CLSI criteria and the 
method described by Gillies et al. [10], respectively. The results showed that all the tested 
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natural extracts had relatively high concentrations of MICs against P. aeruginosa PAO1 and 
of MCC on A549 lung epithelial cells (Table 1). These results may indicate that these agents 
are relatively non-toxic to the A549 lung epithelial cells as well as they cannot inhibit the 
growth of P. aeruginosa PAO1 at the tested concentrations.  
 
Treatment MICa (µg/ml) MCCb (µg/ml) 
Ciprofloxacin 0.125 > 64 
Dextran >10000 >10000 
Cranberry Extract >5090 >5090 
Soybean Extract >8570 >8570 
aMinimum Inhibitory Concentration 
bMinimum Cytotoxic Concentration 
Table 1. MIC and MCC (µg/ml) values for ciprofloxacin and different natural extracts 
against P. aeruginosa PAO1 and A549 lung epithelial cells, respectively. 
Based on the data shown in table (1), sub-MIC and sub-MCC concentrations of both 
ciprofloxacin and the natural extracts were selected in the adhesion and invasion assays to 
evaluate their effects, as single agents or in combination with ciprofloxacin, on P. aeruginosa 
PAO1 adhesion and invasion without interfering with the viability of the bacterial or 
mammalian cells. Accordingly, ciprofloxacin (0.0625 µg/ml), dextran (50.0 mg/ml), 
cranberry extract (25.5 mg/ml), and soybean extract (42.8 mg/ml) were selected at their 
subMIC/subMCC for testing the effects of the single treatments on P. aeruginosa PAO1 
adhesion and invasion to the lung epithelial cells. In combination treatments, the effect of 
ciprofloxacin (0.0625 µg/ml) on the adhesion and invasion of P. aeruginosa PAO1 was 
assessed with halves of the aforementioned concentrations of the tested single agents. 
2.1 Effect of natural extracts and their combinations with ciprofloxacin on the 
adhesion of P. aeruginosa PAO1 to A549 lung epithelial cells  
Adhesion of the P. aeruginosa PAO1 to the lung epithelial cells was assessed through viable 
cell counting of the bound bacteria to the cell surface from each independent triplicate 
experiment and the untreated controls. Adhesion of P. aeruginosa PAO1 to A549 lung 
epithelial cells in the presence of different natural extracts, as single agents and in 
combination with ciprofloxacin, was expressed as the percentage of adhered bacterial cells 
to the epithelial cell surface and normalized to that of the untreated controls. In that regard, 
ciprofloxacin (0.0625 µg/ml), dextran (50.0 mg/ml), cranberry extract (25.5 mg/ml), 
soybean extract (42.8 mg/ml) could reduce P. aeruginosa PAO1 adhesion by 26.3%, 16.4%, 
54.5%, and 45%, respectively compared to the untreated control. On the other hand, 
ciprofloxacin combination with dextran (25.0 mg/ml), cranberry extract (12.7 mg/ml), 
soybean extract (21.4 mg/ml) could reduce P. aeruginosa PAO1 adhesion by 87.5%, 100%, 
and 72%, respectively as compared to that of the control (Figure 2). Interestingly, 
combination of ciprofloxacin (0.0625 µg/ml) with cranberry extract (12.7 mg/ml) could 
completely inhibit the adhesion (0.0%) of P. aeruginosa PAO1 to A549 lung epithelial cells. 
Although dextran was relatively the least effective single anti-adhesion treatment 
(83.6%±12.1%), it achieved a significant higher effect upon combination with ciprofloxacin 
(12.5%±4.2%). 
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Soybean extract was an effective anti-adhesion agent (55.0%±6.4%) compared to 
ciprofloxacin (73.7%±2.08%) and their combination could synergistically (28.03%±0.65%) 
and significantly (P<0.0001) reduce the ability of P. aeruginosa PAO1 to adhere to the A549 






































































Fig. 2. The effect of different natural extracts alone and in combination with ciprofloxacin on 
the adhesion of P. aeruginosa PAO1 to A549 lung epithelial cells as compared to the 
untreated control.  
2.2 Effect of natural extracts and their combinations with ciprofloxacin on the 
invasion of P. aeruginosa PAO1 to A549 lung epithelial cells 
The ability of the adhered bacterial cells to internalize into the lung epithelial cells in the 
presence of different natural extracts, as single agents or in combination with ciprofloxacin, 
was assessed through calculation of percentage invasion of P. aeruginosa PAO1 from three 
independent experiments relative to the untreated controls. The results of gentamicin 
exclusion assay are believed to reflect the count of bacteria that has invaded cells [4, 13] with 
different treatments. Expectedly, both single cranberry and combination with ciprofloxacin 
were able to completely abrogate the invasion of P. aeruginosa PAO1 to the lung cells (0.0%). 
Although 45.5%±6.7% of the initial bacterial inoculum was able to bind to the epithelial cells 
after treatment in the presence of cranberry extract, none of this adhered population was 
able to penetrate the lung epithelial cells. Following  the synergistic effect of cranberry 
extract, the combination of ciprofloxacin with both of soybean (17.6%±7.12%) and dextran 
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(11.8%±2.1%) achieved comparable and significant (P<0.0001) anti-invasion effects 
compared to the control. Similar to the results for the adhesion assay, dextran and soybean 
were more effective in combination with ciprofloxacin in preventing invasion rather than 



































































Fig. 3. The effect of different natural extracts alone and in combination with ciprofloxacin on 
the invasion of P. aeruginosa PAO1 to A549 lung epithelial cells as compared to the untreated 
control. 
3. Discussion 
Pseudomonas aeruginosa is a major cause for mortality seen in CF patients [6]. Adhesion and 
subsequent invasion of that organism to the lung epithelial cells are considered as the initial 
and substantial steps in the lung infection [5, 14-16].  Once the colonization of the organism 
is established, it is rarely eradicated. Several strategies have been developed to prevent P. 
aeruginosa infection in CF patients through different antibiotics and immunizations, but 
were not successful [8, 17-19]; therefore, development of other prophylactic measures as 
anti-adhesion and anti-invasion approaches is required.  Ciprofloxacin, a fluoroquinolone, is 
considered as an antibiotic of choice for the treatment of the lung infections with 
Pseudomonas aeruginosa [7]. The current study aimed at introducing a new strategy to 
prevent Pseudomonas aeruginosa adhesion and invasion to the lung epithelial cells using 
different combinations of ciprofloxacin and aqueous extracts from widely available natural 
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products such as cranberry, and soybean. Dextran, which has been tested before in many 
occasions and found to be an effective anti-adhesion agent [2, 8, 11], was tested on that 
epithelial cell infection model as well to assess its anti-adhesion and anti-invasion activities 
compared to the other natural products, alone and in combination with ciprofloxacin. 
The virulence factors of different Pseudomonas aeruginosa strains were attributed either to 
their direct host cell cytotoxicity or ability to adhere, invade, and survive within the 
epithelial cells. P. aeruginosa PAO1 virulence is categorized under the second types of 
isolates and invasion of that strain was suggested to contribute to biofilm formation and 
establishment of chronic lung infections [7]. Interestingly, the binding of Pseudomonas 
aeruginosa to the uninjured epithelial surfaces was found to be minimal. However, the 
binding ability of the organism increases dramatically in presence of epithelial surface 
inflammation or injury (such as in CF patients) [6, 20].  Scanning electron microscopy 
imaging revealed establishment of P. aeruginosa PAO1 binding to lung epithelial cells as the 
first step of Pseudomonas aeruginosa infection. Such binding did not affect the cells integrity 
or morphology (Figure1). Similarly, Fleiszig et al. [13] noted that integrity of the infected 
cells remains unaffected since the strain P. aeruginosa PAO1 does not use cytotoxicity as a 
virulence mechanism against the lung epithelial cells.   
In order to exclude the inhibitory effect of ciprofloxacin and the applied natural extracts on 
P. aeruginosa PAO1 and A549 lung epithelial cells, the MICs of ciprofloxacin and the natural 
extracts against P. aeruginosa PAO1 and the MCCs of the same agents were determined to 
aid selection of the concentrations of different agents that will be tested on the adhesion and 
invasion models. 
Unsurprisingly, the MICs and MCCs values could not be reached within the tested 
concentration levels for the different natural extracts, which were relatively high compared 
to ciprofloxacin, indicating that they are relatively non-toxic to the A549 lung epithelial cells 
as well as to P. aeruginosa PAO1.  It has been reported that extracts of the natural sources are 
considered as endless reservoirs of safe and relatively inexpensive bioactive agents [9]. 
Dextran is a widely available polysaccharide that has been used in clinical settings as 
plasma expander [2]. It was previously tested as a carbohydrate treatment that blocks the 
epithelial glycoconjugates and impedes the bacterial legends from binding to pulmonary 
epithelial cell receptors [2].  Aerosolized dextran has been examined in a mouse infection 
model to prevent pneumonia caused by Pseudomonas aeruginosa and it could significantly 
reduce the development of pneumonia in the treated group relative to the untreated control 
animals,   being an immuno-stimulant and a sputum rheology enhancer [2]. 
The combination treatment of dextran with ciprofloxacin disabled the internalization 
abilities of 85% of the bacterial population that adhered in the control experiments. 
Application of dextran resulted in an average of 14% reduction in both adhesion and 
invasion of P. aeruginosa PAO1 to the lung epithelia. This reduction is slightly less than that 
was found by Bryan et al. [2] who reported 35% reduction on P. aeruginosa PAO1 adhesion to 
nasal polyp primary culture cells when pretreated with dextran. Factors such as difference 
in the cell culture type or the experimental conditions may provide an explanation for the 
disparity in the activities. The same authors proposed that the likely mechanism through 
which dextran blocks bacterial adhesion was through the non-specific interaction with the 
epithelial cells; since pre-incubation of P. aeruginosa PAO1 with dextran before performing 
the infection abolished its anti-adhesion properties [2]. Consequently, the inhibitory action 
of dextran might not only involve P. aeruginosa PAO1 adhesion, but also other potential 
pathogens especially those targeting respiratory epithelia.  
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To our knowledge, there were no previous studies that reported the utilization of soybean 
extract as a potential anti-adhesion or anti-invasion treatment. The present study, however, 
proposes that the aqueous extract of soybean (Glycine max) is an additional promising 
treatment against adhesion and invasion of P. aeruginosa PAO1 to the lung epithelial cells. 
Compared to the control treatment, 28% and 17% of the applied bacterial inoculum were 
able to adhere and invade the lung epithelial cells, respectively, upon application of soybean 
extract combination with ciprofloxacin. These results suggest that on average half of the 
bacterial population that were able to adhere after treatment with soybean extract were  not 
capable to invade the lung epithelial cells  
Aqueous extract of cranberry (Vaccinium macrocarpon) was by far the most effective anti-
adhesion and anti-invasion treatment when used in combination with ciprofloxacin. 
Cranberry belongs to Vaccinum family that has a wide spectrum of in vitro antimicrobial 
activity [21]. Many reports have demonstrated that proanthocyanidines and saccharides of 
cranberry were able to inhibit adhesion and invasion of some pathogenic microbes in vitro, 
and that cranberry juice clinically prevents urinary tract infection in women by inhibiting 
Escherichia coli adhesion to uroepithelial glycolipid receptors [3, 9]. The activity of the 
cranberry extract extended to provide protection against resistant strains of Escherichia coli 
by a mechanism that is unlikely to increase the selective pressure associated with antibiotics 
resistance [3]. Therefore, combining cranberry extract with ciprofloxacin sub-MIC may block 
the initial steps of infection, adhesion and invasion, as well as minimizing the development 
of bacterial resistance. 
The results of this study may indicate that cranberry extract could turn the adhered bacteria 
unable to invade the lung epithelial cells since 45% of P. aeruginosa PAO1 population that 
were able to adhere to the lung cells under treatment with cranberry were, simultaneously, 
incapable of  invading those cells and further molecular studies are required to elucidate 
this interesting point.  
In published randomized clinical trial, cranberry juice was found to only affect harmful 
bacteria leaving normal bacterial flora unaffected; an observation that could suggest the 
therapeutic benefits of cranberry without having major unexpected side effects [21]. 
Cranberry juice, capsules and powder were also found to reduce urinary tract infection 
recurrences as well as the salival counts of the bacteria causing dental carries [21-24].  
The significance of proposing the anti-adhesion treatments emanates from the fact that the 
earlier the establishment of airway infection is prevented the better the expected therapeutic 
outcome; since the persistence of intracellular bacteria causes sloughing of epithelial cells 
containing these bacteria and may contribute to spreading of the infection,  establishment of 
the biofilm, rendering the bacterial eradication by the antibiotics difficult and favoring  the 
bacterial  endurance in the host airway [7]. 
In light of these in vitro anti-adhesion and anti-invasion effects of the promising   natural 
extracts, further in vivo studies are required to explore their putative applications as an 
alternative strategy to combat the respiratory infections and the potential reduction of the 
antibiotic resistance rates.  
4. Abbreviations 
CF: Cystic Fibrosis 
COPD: Chronic Obstructive Pulmonary Disease 
CAMHB: Cation Adjusted Muller Hinton Broth  
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MIC: Minimum Inhibitory Concentration  
MCC: Minimum Cytotoxic Concentration  
CLSI: Clinical and Laboratory Standards Institute  
SEM: Scanning Electron Microscopy  
ANOVA: Analysis of Variance  
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1. Introduction 
For a paediatrician, children with bronchitis are part of the daily work. Infections of the 
respiratory system are the most common reason for children presenting at the doctor´s 
practice. Almost all infants and younger school children become sick several times a year 
with a bronchitis. In most cases with the beginning of day nursery or nursery school there is 
an abrupt accumulation and many parents have the feeling that their child is permanently 
ill. That bronchitis occurs much more frequently in winter than in summer, as everyone 
knows from personal experience. The cold air outside and the dry heated air indoors, 
increases the vulnerability of the mucosa for pathogens. Whether the clinical course of a 
bronchitis is uncomplicated or associated with a bronchial obstruction, is partly caused by 
the genetic predisposition of the child. Depending on family history of bronchial asthma 
and allergies, the risk may be increased many times over. The health damage due to 
exposure to tobacco smoke is a major point which should not be underestimated. 
The following pages describe in the form of a brief overview symptoms and signs of 
bronchitis in children. The different types and stages of bronchitis are shown. The most 
common viruses that cause bronchitis are described, in particular the respiratory syncytial 
virus. One chapter deals with bronchopulmonary dysplasia, an important risk factor for 
bronchitis in children. Furthermore, some important differential diagnoses are presented, 
which can become manifest with the typical symptoms of a bronchitis. The laboratory 
diagnosis with the aim of differentiating between viral and bacterial bronchitis is discussed. 
Finally, therapeutic options are mentioned. 
2. Signs and symptoms of bronchitis in children 
2.1 Cough 
The main symptom of bronchitis is a cough. At the beginning of the disease it tends to be 
dry and unproductive. With increasing production of secretion the mucus becomes less 
viscous, which makes coughing more effective. Some children have such severe coughing 
attacks that vomiting can be induced. An adequate supply of volume and inhalation therapy 
with 0.9% NaCl can help to make the mucus more fluid, enabling it to be brought up more 
easily by coughing. There are medications, usually in the form of so-called cough syrups, 
which will also assist mucolytic activity. After regression of an acute bronchitis, an 
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unpleasant dry cough can still remain for several days or weeks. This is caused by a 
transient hyperreactivity of the bronchial system due to the infection-induced inflammation. 
2.2 Tachypnoea and dyspnoea 
If secreted mucus, an oedema of the bronchial mucosa or a spasm of the bronchial 
musculature induce bronchial obstruction, tachypnoea and dyspnoea may belong to the 
acute disorders. Typical clinical signs for dyspnoea are movement of the nostrils, inter- or 
subcostal retractions, use of accessory respiratory muscles, an upright upper body position, 
and in the auscultation wheezing and sometimes also rales. In this situation inhalation 
therapy with bronchodilatatory agents and the systemic administration of steroids may be 
helpful. Because the expiration is more difficult that the inspiration, an emphysema may be 
formed due to air trapping. Children with respiratory distress may become anxious and 
excited, which makes the situation worse. The excitement and anxiety of the parents may 
also be transferred to the child. In the case of severe respiratory distress, the oxygen 
saturation in the blood may decrease critically, making oxygen substitution necessary. 
Measurement of vital parameters and blood gas analyses are standard procedures. The 
suctioning of secretions and mucus, or the application of respiratory supportive procedures, 
such as CPAP or intubation and ventilation, should be made immediately possible. 
2.3 Pain 
Pain in the context of bronchitis can be caused by an inflammatory involvement of the 
trachea or pleura. In the case of retrosternal pain during coughing, a tracheitis is most 
probable. Respiratory-dependent, especially in deep inspiration increasing pain, which is 
localized more laterally in one or both sides of the chest, makes a pleuritis more probable. 
Especially the dry chafing of inflamed visceral pleura and parietal pleura against each other 
is very painful. If the child develops shallow breathing to avoid the pain, an insufficient 
ventilation of the lung may result with the increased risk of a secondary bacterial infection. 
For this reason, an appropriate analgesia is strongly recommended. 
2.4 Fever 
Fever is a general clinical sign, which may occur in any infection, including one of the 
respiratory system. The increase of body temperature is a non-specific symptom and can 
range from low-grade fever up to hyperpyrexia with acute physical stress for the child. In 
the case of an infection of the upper respiratory tract, additionally clinical signs (in addition 
to the cough, tachydyspnea, pain and fever) are sniffing (rhinitis), a sore throat (pharyngitis) 
and earache (otitis media). Furthermore, swollen and aching cervical lymph nodes are a 
common local response to the inflammation process. 
3. Different types of bronchitis in children 
3.1 Acute, complicated, chronic, recurrent 
The average duration of an acute bronchitis is about 1 week with the range from ½ week up 
to 2 weeks. Afterwards a nervous cough may remain for several days or a few weeks. The 
acute bronchitis has a very high rate of complete recovery; the prognosis is very good. An 
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exception is an acute bronchitis caused by adenovirus; in this case complications in the 
clinical course or a chronification of the bronchitis are described. 
If the symptoms and signs of an acute bronchitis persist for 4 – 6 weeks, we call it compli-
cated bronchitis. If an acute bronchitis is followed by another one, they can be taken for a 
complicated bronchitis by mistake. Approximately 20% of acute bronchitis has a complica-
ted course. One possible complication is the secondary bacterial superinfection of a primary 
viral infection. In this case the child needs to be treated with antibiotics. Another possible 
complication is the transition from bronchitis into bronchopneumonia. In many cases this is 
detectable by pulmonary auscultation, but to confirm the diagnosis, a chest X-ray is 
necessary. A primary bacterial bronchitis usually presents clinically as a complicated 
bronchitis. 
Signs and symptoms of a bronchitis persisting for more than 3 months are called chronic 
bronchitis. 
If children repeat lots of acute bronchitis over months, it is called recurrent bronchitis. 
Mainly children in day nursery or nursery school are affected quite often, because the risk of 
infection is particularly high there. In the cold seasons bronchitis occurs more frequently 
compared to the warm seasons. 
3.2 Non-obstructive or obstructive 
Bronchitis can be associated more or less with bronchial obstruction. The risk of an 
obstruction depends on the lumen of the inflamed bronchus; the smaller the lumen, the 
more likely is a clinically relevant obstruction. For this reason, the terms “obstructive 
bronchitis” and “bronchiolitis” were sometimes used as synonyms. Bronchial obstruction 
can be caused by the following pathophysiological alterations:  
1. The smooth muscles of the bronchus get contracted, which can lead to an acute 
shortness of breath.  
2. The mucosa of the respiratory epithelium is swollen due to the inflammation, which 
narrows the bronchial lumen. 
3. The increased production of mucus clogs the lumen as well. Furthermore, due to the 
inflammation in the respiratory epithelium, the function of the cilia is reduced, and 
mucus cannot be transported adequately. 
Auscultation of the lung shows wheezing. A so-called silent lung is typical for a severe 
bronchial obstruction with air trapping and emphysema. In this case the resting expiratory 
position is shifted to the inspiration, what may create a circulus vitiosus. 
3.3 Non-allergic or allergic 
Bronchitis is an inflammatory disease of the bronchial mucosa. In most cases the 
inflammation is caused by an infection. Also allergens may cause an acute or chronic 
bronchitis, they act mostly as a trigger. The presence of one or more allergies increases the 
statistical risk for the development of bronchial asthma. Relevant inhalation allergens are 
dust mites, animal dander, mould fungus and pollen. 
As their zoological name "Dermatophagoides" indicates, dust mites feed on epithelia from 
the skin, of which one person loses about 1.5 grams per day. They are, depending on the 
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type, 0.1 - 0.5 mm in size and they live in normal house dust. They are found in carpets, 
curtains, upholstered furniture, mattresses, duvets and pillows, stuffed animals etc. The 
allergen comes from the faeces of the mites. In order to avoid exposure, the following 
protections should be carried out: the use of an encasing such as a mattress cover, monthly 
washing of duvets and pillows, occasional freezing of soft toys at -20 °C, followed by 
rinsing, no long carpets, regular vacuuming and avoidance of dust turbulence. 
With regard to animal dander, those species which are most relevant and which human 
beings have close contact with are especially dogs, cats, guinea pigs, hamsters, horses and 
birds. The allergen concentration varies within a species, depending on the breed. For this 
reason it could happen that someone tolerates contact with one cat very well, whereas 
contact with another cat induces an acute bronchial obstruction. In the case of a clinically 
relevant allergy against an animal, the contact should be avoided. 
The spores of mould fungus can also cause an allergic reaction, like bronchial 
hyperreactivity or bronchial obstruction. If at home the walls are infested with mould 
fungus, the house has to be renovated. 
Among the pollen, early flowering plants (birch, alder, hazel, willow) and grasses are most 
relevant. The occurrence of pollen-induced disorders, namely rhinoconjunctivitis and 
bronchial asthma, are strongly season-dependent and time-limited. On the basis of cross-
reactions, for example between birch pollen and apple, in the case of an allergy against birch 
pollen, an allergic reaction against apple in the form of an oral allergy syndrome may occur. 
In the case of pollen, allergen avoidance is almost impossible. In order to reduce the 
intensity of pollen-induced allergy symptoms, desensitization  is recommended. 
3.4 Special forms: Bronchitis fibroplastica, bronchioloitis obliterans 
A special form of bronchitis in childhood is the bronchitis fibroplastica. Older synonyms are 
fibrinous bronchitis, pseudomembranous bronchitis or Hoffmann’s bronchitis. It is 
characterized by obstruction of the bronchi, usually a lobe or segment, consisting of mucin, 
which forms large endobronchial casts of rubber-like consistency. Pre-existing pathological 
conditions, such as bronchial asthma or cystic fibrosis, which are attended by hypersecretion 
of viscous mucus, may act as triggers. Childhood tuberculosis or primary immunodeficiency 
seem to be associated with a higher incidence of bronchitis fibroplastica as well. However, 
exact epidemiological data are still missing. Main symptoms are a cough and dyspnoea, and 
sometimes pleuritic pain and fever occur. In pulmonary auscultation over the affected area 
of the lung the breath is quiet or absent; sometimes wheezing or rales can be heard. X-rays 
of the chest typically show an atelectatic area next to an emphysematic one. The therapy 
consists in the prompt removal of the sticky casts consisting of mucin via rigid 
bronchoscopy. If they are not removable, administration of N-acetylcysteine or DNase may 
be helpful. If a child without known pre-existing diseases falls ill with bronchitis fibro-
plastica, additional diagnostic investigations should be carried out: sweat tests, tuberculin 
tests, allergy tests. 
Another special form of bronchitis in children is the bronchiolitis obliterans. An inflammation 
of the small airways induces a pathologic tissue remodelling with granulations, which obstruct 
the lumen of the bronchioles. This process may be triggered by infections, inhalation of toxic 
agents, autoimmune diseases or a chronic rejection after lung transplantation. In the group of 
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long-term survivors after lung transplantation, bronchioltis obliterans is the most frequent 
cause of death. The clinical signs and symptoms are quite unspecific: a cough and reduced 
general condition. In pulmonary auscultation the breath is quiet and rales can be heard. The X-
ray of the chest eventually shows some infiltration or it looks normal. The disease may begin 
rapidly or slowly and the clinical course may be progressive or stable. Therapeutic options are 
a high-dose glucocorticoid administration, and in the case of lung transplantation, an increase 
in the dosage of the immunosuppressive medication. 
4. Different stages of bronchitis in children 
4.1 Bronchial hyperreactivity 
Bronchial hyperreactivity is a chronic inflammation of the bronchial mucosa with recurrent 
bronchial obstruction, which may be triggered by infections, allergens or nonspecific 
stimuli, such as cold air, physical or even emotional stress. The inflammatory activity causes 
a swelling of the bronchial mucosa with a reduction of the bronchial lumen consecutively. 
The smaller the lumens are physiologically, such as in infants, the more relevant is its 
reduction regarding clinical symptoms. Furthermore, inflammation of the bronchial mucosa 
increases the vulnerability to viruses or bacteria. 
To make the diagnosis “bronchial hyperreactivity”, an accurate and detailed medical history 
is the most important step. Additionally, measurement of the lung function may confirm the 
diagnosis, in particular in the case of a reduced flow in the smaller airways; after 
administration of a beta-sympathomimetic via inhalation the bronchial obstruction should 
be reversible, at least partly. The lung function test can be carried out with children who are 
old enough to participate actively. Furthermore, measurement of the NO-exhalation may be 
useful to monitor the amount of bronchial inflammation. In some cases it may be helpful to 
carry out a bronchial provocation test via inhalation of methacholine, histamine or 
carbachol. Of course, all emergency tools have to be available. 
4.2 Bronchitis 
Bronchitis is a clinically apparent inflammation of the bronchi, triggered by a bronchial 
hyprerreactivity, by viruses or bacteria or by allergens. The symptoms (cough, tachypnoea 
and dyspnoea, pain, fever), the different courses (acute, complicated, chronic, recurrent) and 
different forms (non-obstructive, obstructive) have been described. 
4.3 Bronchiolitis 
Bronchiolitis is an inflammation of the smallest bronchi and bronchioles. Due to the small 
lumens of these airways, swelling of bronchial mucosa may induce severe obstruction quite 
rapidly, in most cases associated with pulmonary hyperinflation. This can lead to the 
phenomenon of the so-called silent obstruction, that means barely wheezing, humming or 
whistling, but fine bubble rales at the end of inspiration. Bronchiolitis is a typical disease of 
infancy, the age peak is between 4 and 6 months. 
4.4 Bronchopneumonia 
Bronchopneumonia is a possible course of a complicated bronchitis. Whereas a primary 
pneumonia normally is localized to one segment or lobe of the lung, in the case of a 
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bronchopneumonia there is a disseminated inflammation from the bronchi down to the 
alveoli. 
4.5 Bronchial asthma 
Bronchial asthma is a disease with chronic inflammation of the respiratory system with 
bronchial hyperreactivity and variable airway obstructions. In many children and 
adolescents we find a positive family history for asthma and/or allergies. The restriction of 
the air flow, mainly during the expiration, is caused by spastic contraction of the smooth 
muscle in the bronchial wall, oedematous swelling of the bronchial mucosa and 
hypersecretion of viscous mucus. In addition to these pathological mechanisms, a tissue 
remodelling may take place after bronchial asthma over several years, which makes the 
airways less elastic. In most cases patients have an allergic bronchial asthma; case of non-
allergic asthma and mixed forms are possible as well. 
Criteria for the diagnosis of bronchial asthma in children and adolescents are a relative 
forced ventilation capacity (FEV1/VK) < 75% of age- and gender-related norm and a 15 % 
increase with prolonged expiratory time, or after inhalation of a short-acting beta-
sympathomimetic. A further criterion is a decrease in respiratory resistance (R) > 50% of 
baseline after inhalation of a short-acting beta-sympathomimetic. If the lung function 
measurement shows a normal result, but the clinical history is typically for bronchial 
asthma, then a circadian variability of the measured peak expiratory flow (PEF) > 20% 
confirms the diagnosis. If the doctor is still in doubt with the diagnosis, a provocation test 
(for example physical stress or inhalation of metacholine) may be helpful to make the right 
diagnosis. 
The therapy of bronchial asthma is successful if clinical signs and symptoms of the disease 
are under control, so that the affected children or adolescents feel free from disorders if they 
are able to partake in sport without any restriction, if there are no side effects of the 
medications and if no long-term injury will occur. Taken together, if the children or 
adolescents just have a normal life with this chronic disease. Parts of the therapy are 
prevention (for example not smoking, either actively or passively, avoidance of allergens, if 
possible), general procedures (for example participation on training courses of instruction, 
doing sports, doing physiotherapy), pharmacotherapy and rehabilitation, if it is required. 
The prescription of drugs should be carried out in accordance with an algorithm, which has 
various steps depending on the severity of the bronchial asthma and gives the opportunity 
to step up or step down. Standard drugs in pharmacotherapy of bronchial asthma are low-
dose inhaled glucocorticoids and orally administered leukotriene antagonists (additionally 
or alternatively) for long-term therapy, as well as inhaled short-acting beta-sympatho-
mimetics for acute therapy. Because of this treatment, severe asthma attacks have become 
very rare incidents. 
5. Common viruses causing bronchitis in children 
Acute bronchitis is almost (in approximately 90%) induced by viruses. The most common 
ones are respiratory syncytial, parainfluenza-, influenza-, adeno-, rhino-, metapneumo- and 
human bocavirus. Acute bronchitis, which is induced by bacteria primary, is rare (approxi-
mately 10%).  In 15% of viral bronchitis a secondary bacterial  infection will happen. 
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5.1 Respiratory syncytial virus (RSV) 
It is a member of the family of paramyxoviridae, has a single-stranded RNA and is 
enveloped. We distinguish two serological groups A and B from each other. The 
pathogenicity of the virus depends crucially on two glycoproteins on the viral surface: 
glycoprotein G enables the docking with the host cell, such as pneumocytes, glycoprotein F 
is responsible for the endocytosis into the cell. The fact that the affected cell undergoes a 
fusion with neighbouring cells and form syncytia has given the virus its name. Further 
details of incubation time, infection and clinical signs and symptoms are in the section 
"Characteristics of RSV infection." 
5.2 Parainfluenzavirus 
It belongs to the family of paramyxoviridae, has a single-stranded RNA and an envelope. It 
is (in contrast to the influenza viruses) genetically stable. There are 4 different types. The 
transmission of the virus proceeds via droplet or smear infection. The incubation period is 
3 - 6 days. At the age of 2 years, almost all children have been sick at least once with a 
parainfluenza infection. In infancy and early childhood parainfluenza virus causes an acute 
laryngotracheobronchitis with typical croup symptoms. 
5.3 Influenzavirus 
It is assigned to the family of orthomyxoviridae. It is divided into the 3 types A, B and C, of 
which A and B are most relevant for infections of humans. The genome of influenza viruses 
type A and B consists of eight single-stranded RNA segments. This creates a high genetic 
variability of antigenic drift and antigenic shift, in the case of a dual infection.  The eight 
RNA segments contain the genetic information for 11 proteins, of which one is the 
neuraminidase. Transmission paths of the virus are aerosols and saliva, as well as contact 
with contaminated surfaces. The incubation period is 1 - 4 days. Typically we see a high 
incidence of influenza during the winter months. The epidemic often has its origin in the 
nursery, kindergarten or school. Because of the high contagiosity, pandemics with high 
lethality may occur, recently caused by the H1N1 subtype, the so-called "swine flu". In 
contrast to the common cold, the clinical course of the influenza infection is characterized by 
significantly reduced general condition, high fever and a much higher complication rate. 
Children with a disease of the respiratory tract, a heart failure or a deficiency of the immune 
system have an especially high risk for severe complications. The diagnosis of influenza can 
be made with a rapid test (usually an Elisa) or by RT-PCR, which is more sensitive and 
specific, from a nasal or throat swab or corresponding rinse water. 
In the case of a severe or complicated clinical course, treatment with an antiviral compound 
is indicated. In childhood, the neuraminidase inhibitors oseltamivir (oral administration, 
approved from the first year of life) and zanamivir (inhalation, approved from the fifth year 
of life) are used. Safety studies were carried out in order to extend the approval of 
oseltamivir on the first year of life. The vaccination against influenza provides the best 
protection. Because of the high genetic variability of the virus, the vaccination has to be 
repeated each year with a current antigen mixture. In addition to the self-protection, the 
collective protection is of great importance. 
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5.4 Adenovirus 
It is a member of the family of adenoviridae. It is a double-stranded DNA virus with a 
strong environmental resistance. More than 50 serotypes with various clinical manifesta-
tions have been identified so far. The transmission proceeds via droplet or smear infection. 
The incubation time is between 2 and 10 days. Most adenovirus-induced diseases occur in 
the age between 6 months and 5 years, usually in the form of a common cold. However, it 
can lead to complicated clinical courses with severe obstruction, pneumonia or persistent 
bronchial hyperreactivity for months. 
5.5 Rhinovirus 
It belongs to the family of picornaviridae, the RNA is single stranded. We know about 
100 subtypes; the genetic variability is large. Rhinovirus is transmitted primarily via aerosol. 
The incubation period is 2 - 5 days. In the first years of life, the incidence of infection with 
the virus is around 1 - 2 times per year. Whereas in adults rhinovirus infections usually 
cause a common cold, in infants and small children obstructive bronchitis appear quite 
often. 
5.6 Metapneumovirus 
It is a member of the paramyxoviridae, a RNA virus and enveloped. We know 2 subtypes 
A and B, each with two sub-groups A1 and A2, as well as B1 and B2. Droplet and smear 
infections are the transmission paths. Incubation time is 4 – 6 days. During the first year of 
life about one quarter of infants become infected with the metapneumovirus; by the time 
children start school, almost everyone has had an infection with this ubiquitous virus. Most 
prevalent symptoms are rhinitis and bronchitis. 
5.7 Human bocavirus 
The human bocavirus was discovered only in 2005. It belongs to the Parvoviridae family 
and has a single-stranded DNA. The transmission of the virus proceeds via droplet or smear 
infection. Accurate epidemiological data are yet to be collected. Clinically, acute respiratory 
symptoms are most relevant. 
6. Characteristics of RSV infection in children 
6.1 Risk factors 
An RSV infection, which occurs in infancy, may have a severe clinical course. Not only in 
infancy, but until the age of 5 years, RSV infection may cause disorders of clinical relevance. 
The majority of children undergo one or more RSV infections during the first 2 years of life, 
usually without a severe or complicated course. Risk factors for a severe or complicated 
clinical course are small, narrow airways (this is the reason why infants suffer worse than 
older children). Boys are affected slightly more often than girls. Another risk factor, which 
should not be underestimated, is the exposure to tobacco smoke. Furthermore, the family 
history to allergies has an adverse influence. Pre-term birth or chronic diseases of the lung 
increase the risk for a complicated course of a RSV infection considerably. We see a seasonal 
accumulation with endemic-like clusters of RSV infections during the cold autumn and 
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winter months. The transmission occurs by droplet and smear infection. The incubation time 
is at 3 - 6 days. 
6.2 Severity of the clinical course 
If the RS virus affects the respiratory epithelium of the smallest bronchi and bronchioles 
with desquamation of the epithelial cells and oedema of the mucosa, the main symptom is 
bronchial obstruction. Distal to an obstructed airway, atelectatic areas may be formed, next 
to emphysematic areas. If this causes a mismatch between ventilation and perfusion, the 
main symptom is tachydyspnoea with partial or even global respiratory insufficiency. In 
this case, the infant needs to get hospitalized for oxygen substitution and, if necessary, with 
respiratory support or even mechanical ventilation. An additional reason for hospitalization 
is the risk, especially in very young infants, of apnoea and death due to apnoea. 
6.3 Diagnosis 
The diagnosis can be carried out using a rapid test, which is based on the 
immunofluorescence method. The inflammation parameters in the blood are only slightly 
increased. The X-ray of the chest often shows diffuse infiltrations of the lung and a partial 
reduction of the transmission due to emphysema. 
6.4 Limitation of therapeutic options 
The therapeutic options are very limited. Because the replication of the RS virus takes place 
inside the epithelial cells of the lung, bronchodilatatory agents show no positive effect. 
Treatment with steroids has no effect as well, what is confirmed by meta-analysis. An 
antiviral therapy with the nucleoside analogue ribavirin is not recommended for the 
following reasons: firstly, there seems to be no relevant effect; secondly, it is teratogenic and 
has to be administered via aerosol, which could lead to an exposure of pregnant women 
who are in contact to the child. There is only one agent with a small, but significant benefit 
in the case of an RSV bronchitis or bronchiolitis; it is the leukotriene receptor antagonist 
montelukast. Additionally, supportive therapy, such as inhalation with 0.9% NaCl or 
decongestant nose drops may be helpful. 
6.5 Indications for palivizumab 
Palivizumab is a monoclonal antibody against the RS virus. It can be used for passive 
immunization. It binds to the glycoprotein F, the fusion protein, and thereby prevents the 
virus entering the cell. During the months with high incidence of RSV infections, 
palivizumab has to be injected every 4 weeks. Palivizumab is indicated for significant 
prematurity, bronchopulmonary dysplasia and hemodynamic relevant congenital heart 
failures. The prophylactic immunization with palivizumab reduces severity and duration of 
the disease significantly; the hospitalization frequency is halved. 
6.6 Recent research on an active immunization 
Previous research on an active vaccine, already carried out in the 1960s, was not successful. 
Currently there are new research activities in this area. A life vaccine against RSV and PIV3 
(parainfluenza virus type 3) is in phase 1 / 2 study. 
 
Lung Diseases – Selected State of the Art Reviews 452 
7. Bronchopulmonary dysplasia as a risk factor for bronchitis in children 
7.1 Definition and pathophysiology 
Today bronchopulmonary dysplasia (BPD) is more relevant than ever. Because of the major 
advances in neonatology with high survival rates of extremely immature preterm infants, 
there is an increase of diseases and complications, which are typically associated with 
prematurity, like BPD. If very preterm infants are born, their lungs are not completely 
developed, neither structurally nor functionally, especially with respect to the synthesis of 
surfactant. Because of the respiration prior to maturity, the lung tissue undergoes a fibrotic 
remodelling process of the alveoli. Prenatal and postnatal factors, such as inflammation, 
infection, hyperoxia and mechanical ventilation, have an additional adverse effect. 
Because the morphological alterations are not visible and the radiological ones do not 
correlate well with the clinical severity, the BPD is defined by the duration of oxygen 
supplementation for longer than 28 days. Depending on the amount of oxygen supplemen-
tation and the requirement of breathing support, we distinguish mild, moderate and severe 
BPD. 
7.2 Prophylaxis and therapy 
The following prophylactic procedures may reduce the severity of BPD: the prenatal anti-
inflammatory treatment via administration of beta-dexamethasone to the mother, the so-
called “lung maturation”, is standard. The application of surfactant as soon as possible is 
very important. A patent ductus arteriosus with hemodynamic relevance should be treated 
early, if possible pharmacologically, if necessary via ligature. A protective effect of vitamin 
A has been demonstrated, although the effect is only minor. 
Therapeutic procedures are avoidance of hyperoxia, moderate infusion or even forced 
diuresis. high-caloric nutrition, gentle ventilation mode, physiotherapy, and in very rare 
cases, the postnatal application of corticosteroids. 
7.3 Prognosis 
The BPD also affects the future life of the children: they suffer more frequently with 
bronchial hyperreactivity and asthma, they have an increased risk for the incidence of 
respiratory infections, and in the first year of life they are more often hospitalized for acute 
respiratory problems. Even if they have no symptoms, the measurement of lung function 
will show worse values. 
8. Differential diagnoses of bronchitis in children 
8.1 Croup 
In distinction from the original diphtheritic croup (which has become very rare thanks to the 
vaccination), the common croup is a subglottic laryngitis with an inflammatory oedema of 
the mucosa in the context of a viral infection of the respiratory system. The main prevalence 
is at the age between 6 months and 6 years. Typically in the late evening or during the night 
in the cold winter, the affected infants and children get an acute attack with a barking 
cough, hoarseness, inspiratory stridor and dyspnoea. We divide the croup into 4 different 
 
Bronchitis in Children 453 
degrees of severity, from just cough and hoarseness without dyspnoea to dramatic 
dyspnoea with the feeling of combustion. 
What are the urgent measures in the case of a croup attack? The first step is to reassure the 
anxious and excited child. It should be kept in an upright position, in order to allow the use 
of the thoracal muscles for breathing. The child should be brought into the fresh and cold 
air, which may reduce the swelling of the respiratory mucosa. If available, a glucocorticoid 
suppository can be administered by the parents. Prophylactically, a moistening of the air 
indoors is recommended. In many cases of a moderate croup episode, these easy measures 
may stabilize the situation, that the parents are able to manage it at home without any 
professional help. However, in severe cases or in any cases of doubt, the ambulance should 
be called immediately. The emergency doctor can initiate an inhalation with adrenaline, an 
oxygen supplementation and an intravenous application of a glucocorticoid. If necessary, 
the child can be hospitalized and monitored via pulse oximetry. In very rare cases, the 
sedation of a child (for example with chloral hydrate) is unavoidable. In extreme severe and 
complicated clinical courses, the treatment of the child at an intensive care unit is 
recommended.  
In the extremely rare case of a diphtheritic croup, the treatment with diphtheria antitoxin 
has to start immediately. Also extremely rare (thanks to the haemophilus vaccination), a 
bacterial epiglottitis occurs. But because of its rarity, the risk of misinterpretation as a 
normal croup is quite high. In contrast to the croup, the epiglottitis usually is associated 
with high fever, a very poor general condition, a septic clinical course, an increased 
salivation and dysphagia. An epiglottis is always a peracute emergency.  Inspection of the 
pharynx using a spatula is strictly contraindicated, because the slightest mechanical 
provocation can induce a complete occlusion of the epiglottis without any possibility for an 
intubation. Then only cricothyrotomy or tracheostomy can be carried out, to save the life of 
the child. 
8.2 Aspiration 
Aspiration of gastric juice or of a foreign body causes coughing. Common foreign bodies are 
small pieces of an apple or a carrot, half or whole peanuts and all sorts of small parts made 
of plastic or metal, quite often from the toys, the child has played with. We distinguish 
between the acute and the chronic foreign body aspiration. 
In the case of an acute aspiration the child has an abrupt coughing attack and dyspnoea. 
Because the beginning of the right main bronchus from the trachea is angulated to a lesser 
extent compared with the left one, it is preferentially affected. Over the affected side the 
breath is quiet and wheezing can be heard. Radiologically, a mediastinal shift to the healthy 
side can be seen. 
In contrast to an acute aspiration, which is associated with an abrupt coughing attack and 
dyspnoea, in the case of a chronic aspiration the clinical symptoms are milder and less 
severe. In most cases the foreign body is smaller compared to those of an acute aspiration, so 
that it can slide into a segmental bronchus, settle there and maintain an inflammatory 
response, which occurs as a chronic cough. This is the reason why chronic aspirations quite 
often get misinterpreted as a chronic bronchitis of infectious or allergic origin. 
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For treatment the bronchoscopical removal of the foreign body is necessary, almost always 
in the form of a rigid bronchoscopy. 
8.3 Tuberculosis 
In the case of a chronic cough it is important to take the possibility of a pulmonary 
tuberculosis as a differential diagnosis into account, especially in children who come from 
high-incidence countries, or if they have had or still have close contact with people coming 
from such areas. The mycobacterium tuberculosis is transmitted via the aerosols, which 
comes from coughing people with an open pulmonary tuberculosis. Children are generally 
less contagious, even if they have an open pulmonary tuberculosis, because there are only a 
few bacteria in the sputum. This phenomenon is called paucibacillary tuberculosis. 
At the slightest suspicion of a tuberculosis infection, an appropriate diagnostic investigation 
has to be made: next to an accurate medical history and physical examination, 
immunological tests have to be carried out. These are an intracutanously applied tuberculin 
test and an IGRA (interferon-gamma release assay) from the blood. The combination of both 
tests results in an optimal specifity. Additionally, an X-ray from the chest at two levels 
belongs to the standard diagnostic. The microscopical and microbiological analysis is made 
from induced sputum or from gastric juice, because children younger than 10 years usually 
are not able to give sputum spontaneously. 
If, in the case of an exposure to tuberculosis, all diagnostic investigations have a negative 
result, a chemoprophylaxis with isoniazid for 3 months is recommended. If the 
immunological tests are positive, but the clinical course, the X-ray and the analysis of 
induced sputum or gastric juice show normal results, then a preventive chemotherapy with 
either isoniazid as monotherapy for 9 months or alternatively with isoniazid and rifampicin 
as dual therapy for 4 months should be carried out. If a child has signs or symptoms of a 
tuberculosis, if pulmonary or extra-pulmonary, a combination therapy with at least 3 tuber-
culostatic drugs has to be initiated, for example with isoniazid, rifampicin and 
pyrazinamide. In most cases, after 2 months of treatment the medication can be reduced to 
an isoniazid/rifampicin - dual therapy. The total duration of the treatment depends on the 
clinical course and the severity of complication and is at least 6 months. Of course the choice 
of the tuberculostatic drugs has to be adjusted to possible resistances. 
8.4 Cystic fibrosis (CF) 
If infants have recurrent obstructive bronchitis with a chronic cough and problems to 
dissolve the mucus, one differential diagnosis, which has to be taken into account, is CF. 
Even though it is a rare disease, it is still one of the most common hereditary diseases. The 
mode of inheritance is autosomal recessive and caused by a mutation in the CFTR (cystic 
fibrosis transmembrane conductance regulator) - gene, which encodes a chloride ion 
channel. More than 1500 mutations have been known. The mutation deltaF508 describes the 
deletion of 3 base pairs, what causes the lack of phenylalanine at position 508 of the protein 
chain, and is with 70% by far the most frequent one. Depending on the amount of the CFTR 
defect, there are milder and more severe clinical courses of the disease. Due to the 
dysfunction of the chloride ion channel, the epithelial fluid film becomes hyperosmolar and 
the produced mucus gets dyscrinic. 
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The clinical course is characterized by this problem. Shortly after birth, due to the viscous 
intestinal secretion, a meconium ileus can be the first complication of a CF. The same 
problem may occur in later life as distal intestinal obstruction syndrome (DIOS). The most 
important focus in the progress of the CF is the respiratory system. The viscous sputum 
cannot be mobilized and brought out adequately, what gives bacteria a good medium for 
colonization, unfortunately quite often with mucoid pseudomonas aeruginosa and other 
multi-resistant bacteria. Also pulmonary mycoses (for example an aspergillosis) may occur. 
These permanent inflammatory processes lead to an irreversible tissue remodelling of the 
respiratory tract. At the end, atelectatic areaes and emphysematic bullae, insufficient for 
ventilation or diffusion, replace the normal tissue. Haemoptysis and pneumothoraces are 
dreaded complications. About 90% of all patients with CF develop an exocrine pancreatic 
insufficiency with the consequence of an inadequate intestinal absorption of proteins, fats 
and fat-soluble vitamins, which leads to dystrophy of the affected patients. With further 
progress of the disease, an endocrine pancreatic insufficiency may occur, which is why 
about 15% of all patients with CF develop an insulin-dependent diabetes mellitus. 
Therapeutical tools are the removal of bronchial secretions by autogenic drainage, 
physiotherapy, inhalations, mucolysis and ample fluid intake, the antibacterial treatment by 
intravenous antibiotics, the stimulation of the digestion by dietary fibre enriched food and 
physical activity, the improvement of the intestinal absorption by replacement of enzymes 
(porcine pancreas powder) and substitution of vitamins, and the counteraction of dystrophy 
by high-caloric nutrition. 
In the most patients with CF, the life limiting factor is the global respiratory insufficiency. 
Often, lung transplantation is the only life-prolonging option. Because of the enormous 
medical progress, especially in the development of new antibiotics, the life expectancy of 
people with CF increases steadily and rapidly. CF as a disease which occurs exclusively in 
childhood is part of medical history. 
8.5 Primary ciliary dyskinesis 
A primary ciliary dyskinesis often causes recurrent bronchitis. It is a genetically determined 
(usually autosomal recessive) disorder of the respiratory ciliated epithelium and other 
ciliated cells, resulting in a reduction in mucociliary clearance. Typical clinical symptoms are 
chronic rhinitis and sinusitis with much secretion, chronic bronchitis with a productive 
cough and recurrent pneumonia. Additional possible abnormalities are the formation of a 
hydrocephalus (due to the lack of ciliary motility of the ependymal cells), infertility in male 
(due to the lack of motility of the sperms) and in female patients (due to the lack of motility 
of the cilia of the fallopian tube) or a situs inversus (due to the absence of a directed cilia 
beat during the embryogenesis). A situs inversus occurs in 50% of the patients who are 
affected by the primary ciliary dyskinesis and it is called Kartagener's syndrome. In the 
diagnostic investigation of the primary ciliary dyskinesis the measurement of exhaled NO 
and the analysis of the ciliary function using a light microscope are purposeful tools. For 
confirmation of the diagnosis, an analysis via an electron microscope is needed. Therapeutic 
options are physiotherapy, inhalation and antibiotic treatment in the case of bacterial 
infections. 
 
Lung Diseases – Selected State of the Art Reviews 456 
8.6 Vocal cord dysfunction 
The vocal cord dysfunction (VCD) is a functional disorder with an acute spasm of the vocal 
cords. In most cases school children are affected. A VCD attack can range from a mild 
dyspnoea to the feeling of suffocation. Fortunately, such episodes are not life threatening, 
because despite the vocal cord spasm a small air gap still remains. Possible triggers for a 
VCD attack are coughing, physical exertion, inhalation of cigarette smoke or reflux of gastric 
juice, postnasal drip syndrome and general stress. 
8.7 Gastroesophageal reflux 
In the case of a recurrent or chronic cough, of course at first everybody thinks of a disease of 
the respiratory system. However, a gastroesophageal reflux may also cause such symptoms. 
Especially in the first months of life, chyme and gastric juice can flow back into the 
oesophagus and induce an inflammation of the mucosa there. Clinical symptoms may be 
heartburn, regurgitation, vomiting, feeding problems and finally dystrophia. Further 
symptoms may be a cough, hoarseness, bronchial obstruction, episodes with apnoea and 
cyanosis, as well as pneumonia due to aspiration. In order to avoid the gastroesophageal 
reflux in infants, the nutrition can be thickened and the feeding portions can be reduced by 
increasing the feeding frequency. In addition, the upper body should be slightly elevated. 
Potential drugs are antacids or proton pump blockers. 
9. Inflammation parameters in the case of bronchitis in children 
9.1 C-reactive protein (CRP) 
CRP is an annular pentamer with sub-units composed of 206 amino acids each. It is 
synthesized in the liver and then secreted into the blood. Its concentration in the blood 
increases within 6 to 48 h in the case of any systemic inflammation. That can be an infectious 
disease, an immune reaction of non-infectious etiology or large tissue damage. Thus, CRP is 
an unspecific marker for inflammation and its increase starts with delay. Depending on the 
laboratory, a plasma concentration up to 0.1 - 1 mg/dl is in the normal range. 
Concentrations between 1 – 10 mg/dl are typical for mild to moderate concentrations,  
> 10 mg/dl for severe inflammation. Because of the reasonably long half-life of 
approximately 24 h, CRP is ideal for the follow-up monitoring of an inflammatory process 
which can help to evaluate the effectiveness of a treatment. 
9.2 Interleukin-6 (IL-6) 
IL-6 is a proinflammatory cytokine consisting of 184 amino acids. It is released primarily by 
monocytes, but also by T-lymphocytes, as well as endothelial and epithelial cells. Infections, 
non-infectious immunological reactions, tissue hypoxia and trauma induce the release of 
IL-6 within 6 h. Thus, IL-6 is an unspecific marker for various forms of inflammation as well, 
but its increase starts much faster. Depending on the laboratory, a plasma concentration up 
to 10 – 50 ng/l is in the normal range. The half-life in the blood is just a few minutes. 
Because of this very short half-life, the kinetics shows a narrow peak with the risk of false 
negative results in the case of measurements outside this peak. 
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9.3 Complete blood count (CBC) 
The CBC may also be helpful in the diagnosis of an inflammation. High increases in the 
amount of the leucocytes occur in bacterial infections, but also in other inflammatory 
processes. Like CRP and IL-6, CBC is a non-specific marker of general inflammation. The 
increase of the leucocytes needs several hours and starts a little bit earlier than the increase 
of the CRP level. The standard value of the amount of leucocytes depends on the age of life: 
for adults 4 - 10 / nl, for school children 5 - 15 / nl, for small children 6 - 17,5 / nl and for 
newborns even 9 - 30 / nl are physiological. The differential blood count shows a reactive 
shift to the immature leucocytes, because their reinforced presence in the peripheral blood 
induces an enhanced release of still premature leucocytes from the bone marrow. 
9.4 Erythrocyte sedimentation rate (ESR) 
The ESR is a very non-specific marker for any kind of inflammation. The pathophysiological 
mechanisms, which lead to a higher ESR, are as follows: in the case of an inflammatory 
condition, erythrocytes form aggregates, which have a lower flow resistance compared to 
the sum of each separate erythrocyte. Furthermore, higher concentrations of acute phase 
proteins (like CRP), of fibrinogen or of immunoglobulins in the plasma, increase the ESR. It 
takes several weeks, after an inflammation has taken place, until an increased ESR gets 
normalized again. Standard value for boys or male adolescents is a sedimentation of 15 mm 
during 1 h, for girls or female adolescents 20 mm during 1 h. 
9.5 Procalcitonin (PCT) 
PCT is a protein which is constructed from 116 amino acids. It is produced mainly in the 
parafollicular C cells of the thyroid gland and in various neuroendocrine cells. Under 
physiological conditions, it acts as a prohormone of calcitonin. It is known that the release of 
PCT increases in the case of an infection, which is caused by bacterials, fungi or parasites. In 
this special condition, PCT is secreted predominantly in cells other the thyroid gland, 
including leukocytes, adipocytes, myocytes and hepatocytes. Stimuli for the synthesis of 
PCT in these cells are bacterial endotoxins (lipopolysaccharides = LPS) and cytokines 
(Interleukin - 1 beta, tumour necrosis factor - alpha). The pathophysiological significance of 
PCT increase has not yet been clarified. Anyway, there is no effect on the thyroid gland. 
The PCT level in the blood increases within 3 h after stimulation by endotoxins or cytokines. 
The maximum of the PCT level is reached after 8 – 24 h and will be stable for another 24 h. 
Then the PCT amount will decrease again with a quite long half-life of 20 – 24 h. In healthy 
individuals, the physiological PCT level is < 0.5 µg/l. Values from 0.5 to 2.0 µg/l are 
associated with a mild respective moderate systemic infection, values from 2.0 to 10.0 µg/l 
with a severe systemic infection and values > 10.0 µg/l are in the majority of cases a sign of 
a sepsis. The amount of PCT correlates with the severity of the infectious disease and the 
mortality rate. In other very severe diseases, such as multiple trauma, large-scale burning, 
cardiogenic shock or multiple organ failure, the PCT level increases as well. 
PCT remains nearly unaffected in the case of a localized, a viral, an autoimmunological or 
an allergic inflammation. For this reason it is an excellent marker for the rapid 
differentiation between viral and bacterial systemic (= antibiotic-requiring) infections. 
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Furthermore, PCT is well suited for the monitoring of the course of a systemic bacterial 
infection. 
A big advantage of PCT, compared to CRP, CBC and ESR, is its much faster increase, which 
allows a very early detection of a systemic bacterial infection. Moreover, its predictive value 
for prediction of sepsis with 0.93 is much better than that of CRP, which is only 0.68. 
Furthermore, the interference by a therapy with steroids is much lower. One advantage 
compared to IL-6 is the better biological stability with a much longer half-life, what reduces 
the risk of false negative results. Additionally, in contrast to IL-6, autoimmunological 
inflammations do not interfere with PCT. 
The measurement of the PCT level in patients with a febrile infection may be helpful to 
decide whether or not a patient needs an antibiotic treatment. In a clinical study it has been 
shown that by using a simple algorithm, the knowledge of the PCT level could reduce the 
administration of antibiotics from 80% previously to 44%. 
On the one hand one wants to avoid the “treatment” of a viral infection with antibiotics, on 
the other hand one wants to assure the start of a required antibiotic therapy in time. 
Especially newborns and young infants may undergo fulminant clinical courses in the form 
of severe sepsis, for which reason this age group is very critical, and it is not acceptable to 
delay the start of an antibiotic treatment. Generally, it seems to be useful to give the 
measurement of PCT a higher priority than is currently given. 
10. Therapeutic concepts for bronchitis in children - pro and contra 
In general, a bronchitis may be treated symptomatically, because in most cases it is caused 
by an viral infection, and there exists no specific treatment. But the importance of the so-
called household remedies should not be underestimated: an adequate fluid intake and 
inhalation of 0.9% NaCl may help to keep the bronchial mucosa moist and to liquefy the 
mucus. Sage drops may reduce the tussive irritation. The inhalation of essential oils, which 
are suitable for children, may also help to reduce discomfort, but it should be noted that 
there is a small risk of sensitization. In addition, there are a number of drugs (some are 
available in the pharmacy without prescription, some have to be prescribed), which have a 
reasonably proficient efficacy. 
10.1 Sympathomimetic 
For the treatment of an acute bronchial obstruction beta 2 - agonists are used, which have a 
selective effect on the respiratory system, in order to minimize beta 1 – receptor - mediated 
adverse effects on the heart. The binding of the drug to its receptor activates the adenylyl 
cyclase whereby ATP is converted to cAMP. That leads to a relaxation of the smooth 
musculature via a reduction in calcium ion concentration in the cells, and it leads to an 
inhibition of the release of mediators from mast cells. Generally, short-acting beta 2 - 
agonists, such as salbutamol, are used. In most cases salbutamol is applied in the form of 
inhalation, the common dosage is about ½ drop per kg body weight in about 2 ml 0.9% 
NaCl, administered with an ultrasonic nebulizer. Alternatively, especially en route,  
1 – 2 puffs of a spray via a spacer can be used. The frequency of inhalation depends on the 
severity of bronchial obstruction. 3 - 6 applications in 24 hours are an average frequency 
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during an acute obstructive bronchitis, but it can be increased, if necessary. The oral 
administration of salbutamol is possible, but because of a lower efficacy and an increase of 
adverse effects due to a higher intake into the blood this is not recommended as a first 
choice. Common adverse effects are restlessness, heart palpitations and shakiness. These 
symptoms are induced by an increased sympathetic activity and can be reduced by 
reduction of the single dosage or the frequency of administration. In pregnant female 
adolescents, salbutamol can induces tocolysis via the beta 2 - receptor. 
10.2 Anticholinergic 
Anticholinergics inhibit acetylcholine due to competition on the muscarinic acetylcholine 
receptors and antagonize its bronchoconstrictive effect. They were applicated via inhalation. 
In comparison to the sympathomimetics, their effect is weaker and occurs with a delay. 
Ipratropium bromide is used most frequently, usually in addition to a beta 2 - agonist, if the 
sympathomimetic effect is not sufficient. Possible side effects include dry mouth, a bitter 
taste, tachycardia and arterial hypertension. 
10.3 Methylxanthine 
The exact mechanism of action of methylxanthines, such as theophylline, is not fully known. 
Several different mokecularbiological pathways seem to be involved: methylxanthines 
inhibit the phosphodiesterase, increase intracellular cAMP and antagonize effects on the 
adenosine receptors. Due to these mechanisms, methylxanthines have bronchodilatatory 
and anti-inflammatory effects and they stimulate the respiratory centre in the brain stem. 
They are rarely used, mainly as reserve medication for severe asthma - attacks. Theophylline 
is then usually given as a continuous infusion. The side effects can be serious: tachycardia, 
extrasystoles, arterial hypertension, restlessness, insomnia, gastrointestinal disorders or 
increased diuresis. 
10.4 Glucocorticoid 
Glucocorticoids induce the secretion of lipocortin, a glycoprotein which inhibits the 
phospholipase A2 and thereby reduces the release of arachidonic acid. Due to this 
mechanism, the cyclooxygenase pathway produces less prostaglandins and the 
lipoxygenase pathway less leukotrienes. Several cytokines, particularly interleukin-1, 
interleukin-2 and tumour necrosis factor – alpha, are produced in a reduced amount as well. 
In the peripheral blood the number of monocytes is decreased and also their bactericidal 
and chemotactic effects, as well as their migration are reduced. All these changes have a 
non-specific anti-inflammatory effect. Depending on the half-life, glucocorticoids are 
divided into short-acting (for example cortisone and cortisol), medium-acting (for example 
prednisone, prednisolone and methyl prednisolone) and long-acting (for example 
dexamethasone) substances. The systematic administration of glucocorticoids over a short 
time period may be necessary in the case of an acute severe bronchial obstruction. In infants 
and young children the application can be carried out in the form of a suppository, which 
can be done at home by the parents. If a child with an acute severe bronchial obstruction is 
brought into the emergency room, the intravenous application is part of the standard 
therapy. The long-term treatment with a glucocoticoid should be done topically, that is via 
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inhalation. Commonly used corticosteroids for an inhalation therapy are budesonide, 
beclomethasone and fluticasone. The dosages are here in the microgram range; that means, 
they are by a factor of 100 – 1000 lower than the systemically given dosages. Thereby any 
side effects are reduced to a minimum. Parents who are afraid of the possible adverse effects 
of corticoids from long-term treatment should have an informative consultation. If they have 
the relevant knowledge, then their worries should be placated. If there are local side effects , 
for example the development of an oral thrush these can arise after inhalation if the mouth 
is not rinsed with water. 
10.5 Leukotriene antagonist 
Leukotrienes, products of the arachidonic acid metabolism, are synthesized in mast cells, 
macrophages, eosinophils and basophils. They have a very strong bronchoconstrictive effect 
(1000-fold more potent than histamine), induce an oedema of the bronchial mucus via 
increasing the capillary permeability and increase the production of mucus. Additionally, 
leukotrienes have a chemotactic influence on inflammatory cells, especially the eosinophils, 
which sensitizes the nerve fibres occurring in the respiratory tract, resulting in a bronchial 
hyperreactivity. The most common leukotriene antagonist is montelukast. Because its 
structure is similar to the leukotriene D4, it acts as a selective competitor at the receptor 
without the effects mentioned above. Montelukast is used as a long-term anti-inflammatory 
therapy, often in combination with a topical corticosteroid. Montelukast is administered 
orally in the evening. The adverse effects that may occur include headache and abdominal 
pain. 
10.6 Mucolytic 
Mucolytic respective secretolytic drugs are expectorants. In contrast to secretomotoric 
drugs, which increase the activity of the ciliated epithelium, expectorants should cause a 
liquefaction of the bronchial mucus to make it easier to cough it up. Among the mucolytics 
are acetylcysteine, bromhexin and ambroxol. Acetylcysteine cleaves the disulfide bonds of 
the mucopolysaccharides. Furthermore, it has an anti-inflammatory effect due to catching 
free radicals with its reactive SH group. Bromhexin activates enzymes, which cleave the 
molecules of the mucus and stimulate the glandular cells to increase the mucus production, 
reduce the viscosity. Ambroxol is a metabolite of bromhexin. In addition to the effects of 
bromhexin, it stimulates the synthesis of surfacant. Some herbal substances, such as ivy, also 
belong to mucolytic drugs. Generally, the therapeutic significance of all these so-called 
cough syrups should not be overestimated. It is much more important that the children 
drink enough and make inhalations. 
10.7 Antitussive 
Antitussives reduce the cough by acting on the brain stem. Opiates, like codeine, 
dihydrocodeine, hydrocodone or noscapine, are the most common drugs against tussive 
irritation. There are newer substances, such as pentoxiverin, which have the advantage of 
lacking a sedative effect or an addiction potential. Pentoxiverin is an agonist at the sigma 
receptor and also acts antagonistically at the muscarinic M1 receptor. Potential side effects 
are nausea, vomiting and diarrhoea. It is contraindicated in children younger than 2 years 
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because a depressant effect on the respiration cannot be excluded, and in pregnant women 
because there are no sufficient safety data. However, in childhood antitussives, these should 
be prescribed only in rare cases with a non-productive cough. Otherwise, if a productive 
cough is inhibited, the mucus remains in the airways, increasing the risk of secondary 
bacterial infections with bronchopneumonia. 
10.8 Antibiotic 
In the case of a bacterial infection treatment with antibiotics is recommended. The choice of 
the appropriate antibiotic depends on the age of the child, because in different age groups 
there are different spectra of bacteria. After receiving the antibiogram, the antibiotic therapy 
can be specified in accordance to sensitivities and resistances of the bacterium. Between 
community-acquired and nosocomial infections, bacterial spectra differ as well. Sometimes 
it is not possible to distinguish between a viral and a bacterial infection, since the clinical 
course and the blood parameters can be quite similar. In this situation it may be that a child 
will be treated with an antibiotic, although it is just a viral infection with high fever. 
10.9 Oxygen supplementation 
In the case of severe bronchial obstruction with spasms of the bronchial musculature, with 
oedema of the bronchial mucosa and production of viscous secretions, ventilation in the 
airways and diffusion in the alveoli may be disturbed. This can cause a partial (hypoxia, 
normocapnia) or global (hypoxia, hypercapnia) respiratory insufficiency. If the 
transcutanously measured oxygen saturation in the blood is too low, the supplementation of 
oxygen is necessary. Usually the oxygen is supplied via nasal prongs. If small children do 
not tolerate nasal prongs, a mask can be placed in front of the face, especially during sleep. 
In the treatment of premature infants with a respiratory distress syndrome, we have 
different procedures, because there the toxic effect of oxygen on the immature organs has to 
be taken into account. Complications caused by oxygen can be BPD, the retinopathy of 
prematurity and an apoptosis-mediated neurodegeneration. The monitoring of the 
premature infants should contain a capnometric analysis next to the measurement of the 
oxygen saturation. 
10.10 Physiotherapy 
Physiotherapy is required in the case of chronic diseases of the respiratory system (for 
example cystic fibrosis or primary ciliary dyskinesis), but also in the case of acute 
pneumological problems (for example the formation of an atelectasis as a complication of 
pneumonia). The aims of physiotherapy are to attain effective ventilation of all lung sections 
and an effective drainage of secretion. 
10.11 Nasal drops 
0.9% NaCl - nose drops are used to moisten and clean the nasal mucosa. Decongestant nose 
drops (dependent on age 0.25%, 0.5% or 1% xylometazoline) should be given, if the 
eustachian tube is swollen in response to an infection of the upper airways, in order to 
guarantee the ventilation of the middle ear. These nose drops should not be given for longer 
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than 7 days, otherwise they could lead to an irreversible damage of the mucosa. A stuffy 
nose is not a good reason for the application of decongestant nose drops. Depending on the 
age of the child, a nose spray may be used instead of nose drops. 
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Bronchopulmonary dysplasia (BPD) continues to be the most common and most important 
complication in preterm infants with RDS. The incidence varies from 20 to 60 % in preterm 
infants whose weight are < 1500 gram. The presence of BPD is often associated with 
significant mortality and short term and long term morbidity, including growth failure and 
neurodevelopment delay. 
The exact mechanism and pathogenesis of BPD is not completely understood. However, 
epidemiology study suggests a changing prevalence and clinical features in recent years. 
The traditional descriptions of BPD (so call classic or old BPD) are essentially related to lung 
injuries following mechanical ventilation while the recent description of BPD (new BPD) is 
probably related more to prematurity of the lungs. The relation between these two types of 
BPD is not clear. Recent studies indicated that inflammation may play an important role for 
both the classic and new BPD. Once lung injuries have established, managements are 
essentially supportive, therefore every effort should be focus on prevention. Proper 
respiratory care is the most essential in preventing lung injury. Other medications, either to 
improve the pulmonary function or to reduce the lung inflammation, have been tried with 
various successes. There is no magic bullet to cure the disease.  
2. Definition  
The original definition of bronchopulmonary dysplasia by Northway was base on 
radiological and pathological characteristics in prematurely born infants with respiratory 
distress syndrome (RDS) who were treated with mechanical ventilation and oxygen 
supplementation. Subsequently, the definition of BPD was changed to respiratory sequelae 
in infants requiring oxygen supplementation more than 28 days after birth since BPD may 
occur in tiny premature infants who have not previously had RDS. This definition was not 
                                                 
* Corresponding Author 
 
Lung Diseases – Selected State of the Art Reviews 
 
464 
without debate, because it includes a wide range of infants, i.e. from those ultimately appear 
to have no residual problems to those with severe BPD. A more practical definition was 
used: respiratory sequelae in infants who reach term age but are oxygen or mechanical 
ventilation dependent. The introduction of antenatal steroid prophylaxis, postnatal 
surfactant treatment caused revolutionary care of premature infants. Nowadays, more 
extreme low birth weight infants with birth weight < 1000gm and gestation age 23-28 weeks 
survived, they experienced a mild initial respiratory course, but required a low 
concentration of oxygen for a long time. In 2001, the United States National Institute of 
Child Health and Human Development (NICHD) conducted a workshop. A new definition, 
which categorizes the severity of BPD, was proposed. 
2.1 Classic bronchopulmonary dysplasia ( Classic BPD ) 
As described above, the classic BPD was defined as a chronic lung disease occurs in 
premature infants who had respiratory distress after birth, require oxygen supplementation 
or mechanical ventilator support at 28 postnatal days or 36 weeks postmenstrual age (PMA). 
Four stages I, II, III and IV are classified base on radiological findings and associated 
pathologic changes. Stage I and II describe acute and subacute course of respiratory distress 
syndrome. Stage III and IV often represent changes associated with chronic lung disease. 
Stage I  (2-3 days) is a period of acute RDS. The radiologic picture is similar to RDS. 
Stage II (4-10 days) is a period of regeneration. The chest radiograph shows complete  
 opacity of the lung obscuring the heart and lung borders. 
Stage III (10-20 days) is a period of transition to chronic disease. The early radiographic changes  
 are replaced by areas of coarse, irregular shaped densities and areas of cyst lesions.  
 Areas of density are caused by interstitial edema or atelectasis due to obstruction of  
 small bronchioles with luminal debris. The cysts represent foci of emphysema. 
Stage IV (beyond 1 month) is a period of chronic disease. Chest radiograph shows large cysts  
 and marked fibrosis and edema with areas of consolidation and areas of 
 overinflation. 
This definition becomes less relevant in current practice, since the improvement care of RDS, 
and survival of very tiny babies, classic BPD is uncommonly seen now, instead a new form 
of BPD (new BPD) is much increased. 
2.2 New bronchopulmonary dysplasia ( New BPD ) 
BPD is now defined clinically as a chronic lung disease occurring in premature infants who 
need for supplemental O2 for at least 28 days after birth, and its severity is graded according 
to the oxygen concentration and positive pressure of respiratory support at near term. For 
gestation age 32 weeks or more, the time of determination varies between 28 days to 56 days 
before discharge. For gestation age less than 32 week, the time of determination is 36 weeks 
postmenstrual age 36 weeks. A physiologic test such as pulse oximetry saturation is 
recommended to confirm the requirement of oxygen supplementation at the time of 
assessment (Table 1). Again, this definition is made clinically and the incidence of BPD can 
be various from hospital to hospital. 
3. Epidemiology 
The incidence of BPD varies among different institutions. This is due to differences in 
neonatal risk factors among different populations, patient care management and the 





Gestation age < 32 weeks > 32 weeks 
Time point of 
assessment 
36 wk PMA or discharge to home, 
whichever comes first 
28 d to 56 d postnatal age or 
discharge to home, whichever 
comes first 
  Treatment with oxygen > 21% for at least 28 d plus 
Mild BPD Breathing room air at 36 wk PMA 
or discharge, whichever comes first  
Breathing room air by 56 d 
postnatal age or discharge, 
whichever comes first 
Moderate BPD Need for <30% oxygen at 36 PMA 
or discharge, whichever comes first 
Need for < 30% oxygen at 56 d 
postnatal age or discharge, 
whichever comes first 
Severe BPD Need for > 30% oxygen and/or 
positive pressure (PPV or NCPAP) 
at 36 wk PMA or discharge,  
whichever comes first   
Need for > 30% oxygen and/or 
positive pressure (PPV or NCPAP) 
at 56 d   postnatal age or discharge,  
whichever comes first 
Adapt from Jobe A. Bancalarie E. Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2001; 163: 
1723-1729. 
Table 1. Definition of New Bronchopulmonary Dysplasia: Diagnostic Criteria 
For example, better prenatal and postnatal care increase survival of the very tiny infants, 
more infants who previously would have died now survive and remain oxygen/ventilator 
dependent at 28 days of age, the overall rate of BPD may increase, but the severity is much 
less. The denominator may also be different, some reports used all live births of premature 
infants as denominator; while others used only survived infants. 
Parker et al reported the incidence of BPD increased from 10.6% in 1976 through 1980, to 
21.7% (981 through 1985), and to 32.9% (1986 through 1990) in very low birth weight 
neonates (1500 g or less) admitted to a regional newborn care center in USA, while there was 
concurrent decline of neonatal death during the same periods (26.4%, 18.3%, and 15.9%, 
respectively). The diagnosis of BPD was given if neonates were treated supplemental 
oxygen for at least 28 days as a surrogate for oxygen treatment on postnatal day 28. 
In 2007, a report from NICHD Neonatal Research Network database of USA shows the 
survival rate and the incidence of BPD (defined by supplemental O2 at 36 weeks PMA) in 
infants with birth weight of 501-1500g almost unchanged between1997and 2002. The 
survival increases slightly (from 84 to 85%) and the incidence of BPD decreases by 1% (from 
23 to 22%). Tiny infants have highest rate and severity of BPD: 6% in 1250-1500g; 14%in 
1001-1240g; 33% in750-1000g and 46% in 501 to 750g. 
Since the release of a consensus statement by the American Academy of Pediatrics and the 
Canadian Pediatric Society in 2002, the use of postnatal corticosteroid has decreased. There 
was concern that the decreased use of postnatal steroid might increase the risk of BPD. A 
recent report from America which includes 77520 premature infants born at <32 weeks 
gestation in California, the overall rate of BPD increased over the decade: 20% in 1997-1999, 
24% in 2000-2003 and 25.4% in 2004-2006. The rate of severe BPD also increased 
significantly: 3.6% 1997-1999, 5.1% in 2000-2003, and 9.5% in 2004-2006.  
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4. Pathology of bronchopumonary dysplasia 
The characteristic changes of classic BPD are airway injury and inflammation, airway 
epithelial cell metaplasia, and parenchymal fibrosis. In contrast, the characteristic 
morphology of “new” BPD is disruption of lung development (Figure 1).  
4.1 Classic bronchopumonary dysplasia 
Four stages are classified according to the severity and anatomic component involved.  
Stage I alveolar and interstitial edema with hyaline membranes, atelectasis, and necrosis of  
bronchial mucosa are present.  
Stage II atelectasis becomes more evident, alternating with areas of emphysema. There is 
 widespread necrosis and repair of bronchial mucosa. Cellular debris fills the 
 airways. 
Stage III extensive bronchial and bronchiolar metaplasia and hyperplasia evolve. Areas of  
 emphysema are surrounded by areas of atelectasis, accompanied by massive 
 interstitial edema with thickening of the basement membranes. 
Stage IV massive fibrosis of the lung with destruction of alveoli and airways are present. In 
 addition, there is hypertrophy of bronchial smooth muscle and metaplasia of 
 airway mucosa. Finally, there is actual loss of pulmonary arterioles and capillaries 




Fig. 1. Airway and Parenchymal Damage in Old and New BPD. „Old“ and „new“ BPD are 
two different morphologic outcomes of variable combinations of factors capable of injuring 
lungs of differing maturity. In old BPD, intense inflammation and disruption of normal 
pulmonary structures lead to a nonhomogeneous airway and parenchymal disease. In 
contrast, the main feature of new BDP is diffusely reduced alveolar development, which is 
associated with a clinically significant loss of surface area for gas excange, with airway 
injury, inflammation, and fibrosis that are usually milder than in old BPD.  






4.2 New bronchopulmonary dysplasia 
Hislop et al. reported that mechanical ventilation of low birth weight infants leads to fewer 
alveoli. Husain et al. reported that extremely premature infants (gestation age ranged 24 to 
32 weeks) dying of BPD had partial to complete arrest in acinar development whether 
infants received surfactant treatment or not. The alveolar structures are larger, simplified, 
and fewer in numbers. The amount of alveolar septal fibrosis is substantially less and tends 
to be more diffuse in surfactant-treated infants than in infants who did not have surfactant 
treatment. Coalson studied the autopsy lung specimens from infants who had received both 
prenatal steroids and surfactant treatment and have found the following findings: enlarged 
air spaces with minimal alveolization, dysmorphic capillary configuration and variable 
alveolar wall cellularity and fibrosis. Airway and vascular lesions, when present, tend to be 
present in infants, who over time develop more severe disease. 
5. Pathogenesis 
The pathogenesis of BPD is multifactorial. The original concepts of risk factors include: (1) 
prematurity; (2) respiratory distress; (3) mechanical ventilation; (4) oxygen supplementation. 
These factors still play an important role in the development of new BPD. However, 
infection and inflammation, pulmonary edema as result of and patent ductus arteriosus 
(PDA) or fluid overloading, nutritional deficiencies and genetic factors may also contribute 
to lung injury. Classic BPD is heavily influenced by injury inflammation and fibrosis; while 
new primarily is an arrest of development, disorder or delayed modeling and remodeling. ( 
Figure 2 ) 
5.1 Prematurity 
Bronchopulmonary dysplasia occurs most commonly in premature infants. Extreme low 
birth weight infants have a deficiency of surfactant and immature lung parenchyma, 
compliant chest wall , inadequate respiratory drive and immature antioxidant enzyme 
system. Most of these infants need supplemental oxygen and assisted ventilation after birth 
to achieve adequate gas exchange. The functional and structural immaturity increases the 
risk of lung injury and disruption of normal alveolar development from antenatal and 
postnatal insults.  
Infants born at 23-28 weeks gestation are just beginning to alveolarize the distal saccule of 
the lung in parallel with the development of the alveolar capillary bed. Alveolar 
development can be delayed with hypoxia, hyperoxia, inflammations, glucocorticoids, and 
poor nutrition. 
Patent ductus arteriosus (PDA) is present in most ELBW infants. PDA shunt increases 
pulmonary blood flow, and may result in pulmonary edema. Lung compliance is reduced 
and lung resistance is increased, creating a need for more vigorous and protracted ventilator 
support. 
5.2 Oxygen toxicity  
Inspiration of high oxygen concentration is a major factor in the pathogenesis of BPD, 
though the precise concentration and duration of oxygen that is toxic to the immature lung 
has not been established. Any concentration in excess of room air might increase the risk of 
lung damage when administered over a period of time. Early pulmonary change caused by 
oxygen toxicity consists of atelectasis, edema, alveolar hemorrhage, inflammation, fibrin 
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deposition, and thickening of alveolar membrane. Continuous high oxygen exposure causes 
influx of polymorphonuclear leukocytes containing proteolytic enzymes which causes 
inflammatory reaction and cytotoxic damage. 
  




















LTB4, IL1,  IL-6, IL-8, IL 16  C5a, PAF, PG 
Genetic 
susceptibility 
New BPD Old BPD  
Fig. 2. Pathogenesis of Bronchopulmonary Dysplasia 
The fetal lung is exposed to relatively low oxygen tension around 20 to 30 mmHg. 
Immediately after birth, the arterial oxygen tension climbs to 100 mmHg. The sudden 
increase of oxygen tension cause substantial oxidative stress. The principle mechanism 
involves the univalent reduction of molecular oxygen and formation of free oxygen radicals 
such as superoxide free radical (O2-), hydrogen peroxide (H2O2), hydroxyl free radical (OH) 
and singlet oxygen (1O2). These oxygen free radicals are highly reactive molecules that can 
cause oxidative damage to lung tissue and trigger the inflammatory reaction. Premature 
infants have inadequate antioxidant defense system because their antioxidant enzymes such 
as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GP) are not mature 
and nutrients deficiencies (vitamin E, vitamin C, beta-carotene, uric acid) are common, thus 
they are vulnerable to develop lung injury from oxygen toxicity.  
5.3 Mechanical ventilation-barotrauma and volutrauma 
Barotrauma is the lung injury caused by the pressure used to inflate the lung. The 
inspiratory pressures needed to inflate the surfactant-deficiency premature lungs often 





homogenous inflated; some units remain collapsed and require higher pressure to reopen, 
whereas others become over distended. The resistance of collapsed alveoli to inflate leads to 
over distension of distal bronchioles during peak inflation and damage of bronchiolar 
epithelium. These over distension of airways and irregular aeration of alveoli lead to 
inflammation and release of cytokine.  
Barotrauma produces alveolar shear stress, disruption of alveolarization, pulmonary air 
leak, and release of damaging cytokine and other biologically substances. High ventilator 
pressure has long been considered as a major cause of BPD, but tissue damage is now more 
attributed to over-distension of the lung from high tidal volume ventilation (volutrauma). In 
an animal experiment, Dreyfuss et al. demonstrated the most severe lung injury was seen 
with high tidal volume with high or low pressure. There were no abnormalities with low 
volume at high pressure. In clinical settings, however, high pressure usually delivers high 
volume, which in turn stretches alveolar wall and capillaries. 
5.4 Inflammation  
Inflammation plays the central role in the development of BPD. Inflammatory reaction may 
be triggered by factors including infection before or after birth, oxygen free radicals, 
barotraumas or volutrauma from mechanical ventilation, and pulmonary edema. 
Neutrophils and macrophages are recruited in the airway and pulmonary tissues. The 
activated neutrophils adhere to the endothelium of the pulmonary vascular system and thus 
initiate a sequence of pathogenetic events. Infants who subsequently develop BPD are found 
to have high concentration of proinflammatory and chemotactic factors in the 
tracheobronchial aspirate such as leukotrine B4, interleuleukin-1β, interleukin-8, soluble 
ICAM-1, anaphylatoxin C5a, platelet aggregation factor and prostaglandin. Pulmonary 
inflammation affects normal alveolization and angiogenesis, these may further lead to 
remodeling of developing lung resulting in BPD. Leukotrienes may remain elevated in BPD 
infants even at 6 months of age and cause bronchoconstrictoin, vasoconstriction, edema, 
neutrophils chemotaxis and mucus production. 
5.5 Prenatal and postnatal infection 
5.5.1 Chorioamnionitis 
Premature infants who were exposed to maternal chorioamnionitis and required mechanical 
ventilation after birth have higher incidence of BPD. Proinflammatory mediators IL-1, IL-6 
and IL-8 were detected in the early tracheal aspirates from these infants, suggesting lung 
inflammation occurred before birth. Ureaplasma urealyticum is the most common organism 
associated with chorioamnionitis. Several studies have suggested an association between 
Ureaplasma urealyticum tracheal colonization and the development of severe respiratory 
failure and BPD in very low birth weight infants, but results have not been consistent.  
5.5.2 Postnatal infection  
Very low birth weight infants with early onset systemic infection or local pneumonia 
usually present with respiratory signs including cyanosis and apnea which required oxygen 
therapy or ventilator support. Intubated infants are prone to develop nosocomial infection 
with deteriorating gas exchange, and are at great risk for development of BPD. The presence 
of a systemic infection in premature infants was noted to increase the risk of late ductal 
reopening and failure to respond to medical treatment with indomethacin. Infants with 
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infection and those with PDA had higher levels of 6-ketoprostaglandin F1-α than did control 
subjects. Levels of tumor necrosis factor-α were also elevated in infants with infection and in 
those with late PDA. The risk of BPD is enhanced if there is active PDA present at the time 
of infection.  
5.6 Pulmonary edema, patent ductus arteriosus and fluid overloading 
Increases pulmonary blood flow from left-to-right shunt blood flow crossing patent ductus 
arteriosus may result increasing interstitial fluid and pulmonary edema. Pulmonary 
compliance is reduced and resistance is increased, creating a need for prolonged ventilator 
support with higher oxygen concentration and ventilation pressure. Clinical evidence 
suggests that infants with RDS who receive great fluid intake or who do not show a diuretic 
phase during the first few days of life have a high incidence of BPD. This may be because 
high fluid intake increases the incidence of PDA. Elevated concentration of myeloperoxidase 
was noted in the tracheal fluid of infants with PDA, suggesting the increased pulmonary 
blood flow may result in damage of the pulmonary endothelium and adhesion and 
migration of polymorphonuclear cells into the lung tissue.  
5.7 Nutrition, Vitamin A 
Premature infants are undernutrition for days and weeks after birth due to critically ill state, 
intolerance of  enteral feeding and fluid restriction. Sick infants have high caloric demand 
for growth, increased work of breathing and metabolism. Inadequate nutrition may amplify 
the lung injury of mechanical ventilation, oxygen toxicity and hinder the repair and 
recovery course. Vitamin C scavenges free oxygen radicals, as well as it interacts with 
vitamine E. Vitamin A is important in regulating early lung development and alveolar 
formation.  Vitamin A deficiency may promote chronic lung disease by impairing lung 
healing, increasing the loss of cilia and squamous-cell metaplasia, increasing susceptibility 
to infection, and decreasing the number of alveoli.  
5.8 Genetics 
Studies in VLBW twins demonstrated that BPD status in one twin was a highly significant 
predictor of BPD in the other twin, irrespective of birth order, Apgar scores and other 
factors. Monozygotic twins had more BPD and a long duration of hospitalization. Lung 
development is regulated by a variety of genes that balance between pro- and anti-
inflammation, oxygen toxicity, cell injury and death, tissue repair, and infection. Specific 
genes that are known to be involved in these biologic pathways have been evaluated for 
their potential contribution to BPD. Approximately half of the initial genetic-association 
studies have not been replicated.  
6. Clinical course 
Most infants who develop BPD usually have various degree of respiratory insufficiency 
resulting from RDS, pneumonia or poor respiratory effort after birth. Oxygen therapy or 
mechanical support is needed to maintain adequate gas exchange. Their pulmonary 
condition may show improvement in the first few days but deteriorate later. The pulmonary 
resistance increases gradually and blood gas shows carbon dioxide retention. Infants require 





by (1)systemic or local infection; (2) the presence of pulmonary edema associated with PDA, 
fluid overload or congestive heart failure; (3) severe airway obstruction caused by 
bronchospasm or tracheobronchomalasia. BPD is often anticipated when mechanical 
ventilation and oxygen supplementation extend beyond10 to 14 days.  
Some infants who have mild or moderate BPD show a slow but steady improvement and 
wean from support after 28 days old. On the other hand, some deteriorate and ultimately 
require months of oxygen supply and ventilator support. Respiratory acidosis with high 
PCO2 greater than 55 mmHg associated with compensated metabolic alkalosis is common. 
Hypoxemia and hypercarbia result from ventilation-perfusion mismatch and alveolar 
hypoventilation.  
The oxygen requirement decrease gradually as the disease process improves, but it can 
increase during feeding, physical activity or episode of infection. Intubated infants are easily 
agitated either because of discomfort or airway obstruction; they are also prone to get 
nosocomial infection. Growth failure with poor weight gain is common due to insufficient 
enteral intake and increase work of breathing. Some infants with severe BPD develop 
pulmonary hypertension, right ventricular hypertrophy and eventually die of right-side 
heart failure (cor pulmonale).  
Radiologic manifestation of mild BPD usually appears normal or mild haziness lung field. 
Moderate to severe BPD may show hyperinflation, lobar or segmental atelectasis, gas 
trapping with pulmonary interstitial emphysema (PIE) and increased lung streaking. 
Fibrosis band and enlarged cyst usually occurs in severe BPD. 
 
Supplemental oxygen and /or ventilator dependent 






Wheezing and bronchospasm 
Signs of inappropriate ADH 
Signs of pulmonary hypertension and cor-pulmonale 
Poor postnatal growth 
Increase incidence of sudden infant death 
Increase fetal hemoglobin 
                  Neurodevelopmental  delay 
Table 2. Clinical features associated with BPD 
7. Prevention of bronchopulmonary dysplasia 
As stated above, the pathogensis of BPD has been linked to immature lung tissue, 
barotraumas and volutrauma resulting from mechanical ventilation, oxygen injury, and 
proinflammatory factors. Reduction of the incidence and severity of BPD may be possible 
through reduction of the causes of BPD. Among many strategies studied in the past, 
antenatal corticosteroids treatment, postnatal surfactant therapy, and gentle ventilation have 
been proved to be the most effective methods to target the development of BPD and 
decrease its severity.  
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7.1 Pharmacologic agents 
7.1.1 Antenatal corticosteroid 
Antenatal corticosteroid (ANC) was noted to be the most successful agent in reducing 
respiratory syndrome and increasing survival in premature infants by Liggins and Howie in 
1972. It was not widely used until 1994 when the Consensus Development Conference 
Statement of National Institute of Health was published. Now women are at risk of preterm 
birth between 24 and 34 weeks’gestation are routinely given a course of corticosteroid before 
delivery. A single course of antenatal corticosteroids treatment is associated with an overall 
reduction of neonatal death, RDS, intraventricular hemorrhage, necrotizing enteritis, 
respiratory support, intensive care admissions and systemic infections in the first 48hoursof 
life. Long term follow up study demonstrates improvement of neurodevelopmental 
outcomes. Steroids accelerate structural maturation and surfactant synthesis of the lung, 
thus decrease the severity of RDS and BPD. The overall incidence of BPD in the population 
is not decreased due to increased survival of tiny babies. 
Antenatal corticosteroid is most effective if given more than 24 hours after and up to 7 days 
after administration of the second dose of antenatal corticosteroids. Treatment for less than 
24 hours is still associated with better outcome, ANC should be given unless immediately 
delivery is anticipated or there is evidence corticosteroid will have an adverse effect on the 
mother. Caution should be exercised when giving corticosteroid therapy to women with 
systemic infection including tuberculosis and infection. 
Betamethasone is the steroid of choice, when available, to be given in a course of two doses 
of 12mg administered intramuscularly 24 hours apart. An alternative regimen would be four 
doses of 6mg dexamethasone intramuscularly every 12 hours. Betamethasone is associated 
with a greater reduction in the risk of death than dexamethasone; it also decreases risk of 
periventricular leukomalacia which was not found with dexamethasone treatment. Weekly 
repeat course of ANC reduce the occurrence and severity of RDS, but the short benefits are 
upset with a reduction in weight and head circumference. Weekly repeat course of ANC are 
not recommended. Prenatal steroid may decrease airway septation and aveolarization in 
animal, it is not clear if prenatal steroid itself or the associated increased survival of tiny 
infant would contribute to the recently high incidence of new BPD. 
7.1.2 Postnatal surfactant therapy 
The surfactant deficiency lung of premature infants is highly susceptible to lung injury and 
significant inflammatory reaction. The function of surfactant is to recruit alveoli and prevent 
atelectasis. Surfactant replacement reduces initial inspired oxygen and ventilation 
requirements as well as the incidence of respiratory distress syndrome, death, 
pneumothorax, pulmonary interstitial emphysema and the combined outcome of death or 
BPD. Combined use of prenatal steroid and postnatal surfactant therapy has proved to have 
an additive effect in improving lung function. As results of these treatments, the severe 
classic BPD is rarely seen today. 
7.1.3 Methylxanthines 
Apnea of prematurity occurs in at least 85 percent of infants who are less than 34 weeks 
gestation. Widely used treatments include application of continuous positive airway pressure 
and the prescription of methylxanthines. In fact, methylxanthines – caffeine, theophylline and 





sleepiness-inducing adenosine and improve respiratory drive, reduce the frequency of apnea 
and the need for mechanical ventilation. Methylxanthines also inhibit TNF-α and leukotriene 
synthesis, thereby reducing inflammation and innate immunity.  
Toxicity with theophylline is more common than with caffeine. Side effects are usually 
associated with plasma level over 20ug/ml. Serum levels less than 10ug/ml is not beneficial 
as an aid to wean the ventilator. Because of the narrow range of therapeutic levels of 
theophylline, caffeine is the drug of choice in the treatment of apnea of prematurity. Davis at 
el demonstrated an improvement in minute ventilation, an increase in tidal volume, a 
decrease in lung resistance and improved lung compliance 1 hour following 10 mg/kg of 
caffeine. In a randomized study by Schmidt et al, infant who received caffeine were less 
likely to use oxygen at 36 weeks postmenstrual age, and more likely to have ventilator 
discontinued earlier. 
7.1.4 Postnatal corticosteroid 
Because inflammation plays a central role in the pathogeneses of BPD, systemic corticosteroids 
especial dexamethasone have long been used for prevention and treatment of BPD. Lung 
inflammation is down-regulated by dexamethasone therapy. Dexamethasone is a potent, long 
acting steroid with almost exclusive glucocorticoid effect. Compared to hydrocortisone, 
dexamethasone is 25-50 times more potent. The half-life is 36-54 hours. Dexamethasone has 
been extensively studied in neonatal medicine and has shown to improve pulmonary function, 
facilitate extubation and decrease the incidence of BPD. However; many associated adverse 
side effects prevent the routine use of dexamethasone. The short term side effects include 
hyperglycemia, hypertension, hypertrophic cardiomyopathy, growth failure, GI bleeding and 
perforation. The risk of GI perforation increases with concomitant indomethacin treatment. 
There is also a concern of the chronic suppression of the hypothalamic-pituitary-adrenal axis, 
and long term neurodevelopmental delay. 
Striking evidence from multiple studies of the adverse effects of dexamethasone and its 
long-term neurological effects on preterm infants prompted the American Academy of 
Pediatrics and the Canadian Pediatric Society to strongly discourage the use of 
corticosteroids to prevent or treat BPD in 2002. Since the release of this consensus statement, 
the use of corticosteroids has decreased significant, the incidence and severity of BPD 
increased significantly during this decade. To each gestation age, the time-related increase in 
BPD is inversely related to the decrease of dexamethasone use. The decline in use of 
dexamethasone associated with a concomitant increase in the use hydrocortisone. However, 
the use of hydrocortisone did not have any impact on the rate and severity of BPD. 
7.2 Gentle ventilation 
Mechanical ventilation both causes and treats BPD. When used, lowest ventilator setting to 
obtain adequate ventilation must be applied to minimize the barotrauma-volutrama and 
oxygen toxicity.  
7.2.1 Tidal volume, inspiratory pressure and target range of oxygen saturation 
In premature infants with lung disease, functional residual volume is reduced and some 
parts of alveoli are collapsed. The ideal tidal volume would be that open these collapsed 
area without over-distend the other areas. In general, initial PIP is set 16-20 cmH2O in order 
to achieve a tidal volume of 4-6 ml/Kg in ELBW with respiratory failure. Peak inspiratory 
 
Lung Diseases – Selected State of the Art Reviews 
 
474 
pressure >20 mmHg is rarely needed. Peak end expiratory pressure is usually set at 4 
cmH2O, and short inspiratory time 0.3-0.4 seconds are used.  
Oxygen saturation monitored by pulse oximetry offers the most reliable estimate of arterial 
oxygenation and easy to use. The ranges of oxygen saturation should be targeted between 
91 to 95%. Oxygen therapy is very toxic for preterm babies, and maintaining even slightly 
high oxygen saturation contributes to retinopathy of prematurity and increases the duration 
of oxygen treatment. The STOP-ROP (Supplemental Therapeutic Oxygen for prethreshold 
Retinopathy of Prematurity) research group showed that newborn babies who had received 
oxygen supplementation to maintain saturation at 96-99% presented more pneumonia and a 
greater incidence of chronic lung disease than did those whose saturation was maintained at 
89-94%. The results of the Surfactant, Positive Pressure, and Oxygenation Randomized Trial 
(SUPPORT) demonstrated that lower target range of oxygenation at 85to 89% did not 
significantly decrease the combined risk of death or BPD, but it resulted in an increase in 
mortality. 
7.2.2 Permissive hypercarbia 
Higher levels of PCO2 45-65 mmHg with pH above 7.20 now are accepted, thus allowing 
gentle ventilation to minimize lung injury. Early studies suggest that BPD occur more often 
among newborn infants with PaCO2 below 40mmHg. A randomized, controlled study of 
NICH Neonatal network demonstrated that mechanical ventilated extremely low birth 
weight infants who were assigned to minimal ventilation (PCO2 target >52 mm Hg) 
required less ventilator support at 36 weeks compared with infants with routine ventilation 
(PCO2 target <48 mm Hg) (1% vs. 16% respectively, p<0.01). Unfortunately, after enrollment 
of 220 patients, the trial was halted because of unanticipated non-respiratory adverse events 
related to dexamethasone therapy. The relative risk for death or BPD at 36 weeks in both 
groups is no difference. 
7.2.3 Nasal continuous positive pressure (nCPAP) 
Nasal continuous positive pressure supports the breathing through a number of 
mechanisms: (1). splinting the airway thereby preventing airway obstruction, (2). dilating 
the airways and reducing resistance to airflow and so diminishing work of breathing, (3) 
aiding lung expansion and so reducing ventilation perfusion mismatch and improving 
oxygenation. Nasal CPAP used after extubation can prevent the instability associated with 
possible respiratory failure and reintubation.  
Nasal CPAP, rather than intubation and ventilation, might be started shortly after birth for 
infants born at 25 to 28weeks’ gestation. In the randomized, controlled Continuous Positive 
Airway Pressure or Intubtion at Birth (COIN) trial, there were fewer days of ventilation in 
the CPAP group, and a few CPAP infants received oxygen therapy at 28 days, but not at 36 
PMA weeks. The early CPAP group did not significantly reduce the rate of death or BPD. 
Pneumothorax occurs in 6% of the CPAP infants and 3 % in the intubated group. Report 
from SUPPORT study, infants born 24-28 weeks of gestation, were randomly assigned to 
intubation and surfactant treatment, or to CPAP treatment initiated in the delivery room. 
There is no significant difference of death or BPD at 36 weeks. Infants who received CPAP 
treatment, as compared with infants who received intubation and surfactant treatment, less 
frequently required intubation or postnatal corticosteroids for BPD, and required fewer days 





The value of early CPAP as a replacement of intubation and ventilation apparently to be 
established. Surfactant treatment is most effective if given shortly after birth. Tiny infants 
with respiratory distress receive nCPAP alone after bith may miss the benefit of 
prophylactic surfactant therapy. In our practice, we intubate these infants soon after birth, 
give a dose of surfactant treatment, then extubated and change to CPAP support if infants 
can tolerate, to avoid mechanical ventilation. 
8. Management of BPD 
Despite of the recent advances of neonatal medicine, little progress has been made in 
treatment of BPD. Cornerstones of treatment are pulmonary support to maintain optimal 
oxygen saturation and prevent complications and nutritional support to promote growth. 
Most patients with mild to moderate BPD gradually improve as healing occurs and lung 
growth continues. Infants with severe BPD especial who are ventilator dependent are more 
likely to have acute episodes of pulmonary decompensation secondary due to nosocomial 
infection, severe airway constriction, pulmonary air leak, increased pulmonary edema and 
the development of tracheobronchmalacia or cor pulmonale. Physical examination, 
radiographic survey, laboratory tests and echocardiogram are important in differential 
diagnosis and guide for specific treatment.  
Respiratory support 
Infants with established BPD who are ventilator dependent, gentle ventilation are preferred to 
avoid further lung injury. Oxygen saturation should be kept within 90-95%. Inappropriate low 
oxygen tension may induce pulmonary vasoconstriction and /or bronchospasm with resultant 
increase frequency of apnea and hypoxia. Higher PCO2 (55 to 65 mmHg) is accepted if pH is 
in normal range. Weaning these from mechanical ventilation is difficult and must be 
accomplished gradually. Caffeine or theophylline are usually used during the weaning phase 
to stimulate respiratory drive. Nasal CPAP may be applied to infants after extubation. 
Infants with BPD who are not on oxygen therapy may experience oxygen desaturation with 
feeding or physical activity, additional oxygen supply might be need. 
Phamacologic agents 
Most medications used for treatment of BPD are targeted on one of the following 
pathophysiologic mechanisms of BPD: (1) bronchopulmonary constriction and airway 
hyperreactivity, (2) pulmonary edema, (3) airway inflammation, and (4) chronic lung injury 
and repair. 
Bronchodilators 
Infants with BPD have increased airway resistance due to peribronchial smooth muscle 
hypertrophy and airway hyperactivity. Acute bronchospasm in response to  hypoxia event 
could lead to sudden deteriorating pulmonary status. Bronchodilators have been shown to 
reduce airway resistance, improve lung compliance and increase tidal volume in infants 
with BPD during acute episodes of bronchospasm. However, their effects are usually short-
lived, and many drugs have significant cardiovascular side effects. Inhaled β-2 agonists such 
as albuterol or levalbuterol have shown to reverse acute episodes of bronchoconstriction 
and cause few cardiovascular side effects. An initial trial dose can be administered through 
a meter-dose inhaler with a spacer device or as a nebulized solution. If patients show 
improvement of gas exchange, the β-2 agonists can be given up to 48hours duration. 
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Chronic use of β-2 agonists is not recommended since there is no long term benefit in 
treatment or prevention of BPD in preterm infants. Ipratropium bromide is another 
anticholinergic preparation that dilates airway. 
Methylxanthines are competitive nonselective phosphodiesterase inhibitors, prevent 
breakdown of cyclic AMP and cyclic GMP. This leads to raise intracellular c-AMP and c-
GMP. They also inhibit TNF-α and leukotriene synthesis, thereby reducing inflammation 
and innate immunity. Methylxanthines are nonselective adenosine receptor antagonists. 
Adenosine can cause broncho-constriction and potentiate immunologically induced 
mediator release from lung mast cells. Inhibition of this action will cause bronchodilatation. 
Theobromine, a metabolic product of caffeine and theophylline, causes vasodilatation and 
increases urine volume. But methylxanthines are weak bronchodilators with mild diuretic 
effect, and are infrequently used in the treatment for acute bronchospasm.  
Corticosteroid 
As discussed above, systemic corticosteroids improve lung function and reduce the need of 
mechanical ventilation, but because the concern of long term adverse neurological outcome, 
now this treatment is reserved for infants with severe BPD who cannot be weaned from 
ventilator support. Dexamethsone with lower dose and shorter duration are usually used to 
facilitate extubation. A recent pilot study by Yeh et al , has shown that intratracheal 
instillation of budesonide by using surfactant as vehicle can effectively deliver budesonide 
to the lung and suppress the lung inflammation and improves pulmonary outcome without 
significant short term and long term side effects. More studies are needed before it can be 
recommended.  
Nutrition and fluid supply 
Adequate nutrition is difficult to achieve in infants with BPD because of high caloric 
demand, poor tolerance of enteral feeding and restriction of fluid intake. Impaired growth is 
common in these infants. Malnutrion can delay somatic growth and the development of 
new alveoli, making successful weaning from ventilator less likely. Infants with poor 
nutrition are also susceptible to infection. Also, there are special nutrients and vitamins that 
are frequently deficient in these infants and their lack may increase the risk of lung injury. 
Many infants with BPD experience increased energy needs. The reasons for this are not 
entirely clear; increased work of breathing, catecholamine release due to stress, increased 
energy requirements for feeding, and the effects of medications probably all play a role. It is 
not unusual for infants with BPD to require 130 or even 160 Kcal/kg/day to support adequate 
growth. It may be difficult to provide adequate calories for these infants. They may have 
ongoing fluid restrictions due to concerns about pulmonary edema. They may experience 
fatigue with feeding or delayed gastric emptying. Increasing the caloric density of formula or 
breast milk with a balanced proportion of carbohydrate and fat may be helpful. A high 
carbohydrate load increases production of CO2 which may be a concern in infants with 
respiratory compromise. Excess carbohydrate may also lead to osmotic diarrhea. Excess 
dietary fat may delay gastric emptying and exacerbate gastroesopageal reflux. 
Diuretics 
Infants  with  chronic  lung  disease  tend  to retain  interstitial  fluid  which  results  in  
increased  respiratory  distress,  increase  in oxygen  requirement,  increase  in  ventilator 
settings, hypoxemia and hypercarbia. Diuretics mobilize fluid, improve lung compliance 






Furosemide is the most commonly used diuretic. It is a potent and rapid acting loop 
diuretic. It can be used orally and intravenously. The main benefit of the intravenous route 
is a quick response. 
Mechanism of Action: At the ascending loop of Henle, furosemide inhibits active 
reabsorption of chloride resulting in lower sodium and water reabsorption. It also acts 
against antidiuretic hormones, and increases urine aldosterone excretion. Furosemide 
decreases left ventricular filling pressure by increasing venous capacitance. Furosemide 
helps in chronic lung disease by both diuretic and vasculature effects. 
Adverse effects: Main adverse effects of chronic furosemide therapy are hypercalciuria, 
nephrocalcinosis and hypochloremia. Electrolytes should be monitored carefully. 
Ototoxicity is related to plasma concentration and is usually reversible after cessation of 
therapy. Other side effects include: osteopenia, cholelithiasis, displacement of bilirubin and 
hyperparathyroidism. 
According to Cochrane review in preterm infants < 3 weeks of age with BPD, intravenous 
furosemide administration has either inconsistent effects or no detectable effect. In infants 
less than 3 weeks of age with BPD, a single intravenous dose of 1 mg/kg of furosemide 
transiently improves pulmonary mechanics. Chronic enteral or intravenous furosemide 
administration improves both oxygenation and pulmonary mechanics. The Cochrane 
review concluded that there is little evidence to support any benefit of fu- rosemide 
administration with respect to ven- tilatory support, length of hospital stay, survival or 
long-term outcome. Accordingly, routine or sustained uses of systemic loop diuretics in 
infants with BPD cannot be recommended. 
Inhaled furosemide has been shown to transiently improve pulmonary function. No long-
term outcomes have been studied. More trials are needed before this delivery method can be 
recommended for routine use. 
Thiazide Diuretics 
Thiazides work by inhibiting sodium reabsorption in the distal tubule. In contrast to 
furosemide, thiazides decrease calcium excretion. 
Potassium Sparing Diuretic 
Spironolactone is a competitive antagonist of aldosterone. It is a weak diuretic and is usually 
given in combination with thiazides. There are very few randomized control trials. By 
Cochrane reviewer’s opinion, in infants less than 3 weeks of age with BPD, chronic 
administration of thiazide and spironolactone improves lung compliance at four weeks of 
treatment and reduces need for furosemide. Only one study showed long-term benefits such 
as decreased rates of death and artificial ventilation. 
 
Diuretics 
Drug Site of Action Route Onset Dose 




Hydrochlorothiazide Distal tubule PO 1-2 hrs 2-4 mg/kg/day 
Spironolactone Aldosterone 
antagonist 
PO 3-5 days 1.5-3 mg/kg/day 
Table 3. 
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Inhaled Nitric Oxide (INO) 
INO decreases pulmonary vascular resistance and improves oxygenation. It is pro- posed 
that INO will improve oxygenation, improve ventilation and will decrease respiratory 
support. Side effects include methemoglobinemia and direct pulmonary injury if excessive 
INO is used 
Studies on INO were done with different doses, started at different ages, different durations 
of treatment, and in infants whose characteristics were different among the studies. INO 
was approved by FDA to term and near-term infants. AAP Committee on Fetus and 
Newborn recommended that centers that provide INO therapy should provide 
comprehensive long-term medical and neurodevelopment follow-up and should establish 
prospective data collection for treatment time, course, toxic effects, treatment failure, use of 
alternative therapies, and outcomes. 
A systematic review which included 11 studies failed to show a significant benefit of INO on 
BPD. Cochrane database for systematic review by Keith J Barrington in 2006 concluded: INO 
as rescue therapy for the very ill ventilated preterm infant does not appear to be effective, 
and may increase the risk of severe IVH. Later use of INO to prevent BPD also does not 
appear to be effective. Early routine use of INO in mildly sick preterm infants may decrease 
serious brain injury, and may improve survival without BPD. Further studies are needed. 
Antioxidants 
Free radical and oxidant stress cause dam- age to DNA, cell membrane, protein and lipids. 
Free radicals are produced by many mechanisms such as mitochondrial electron transport 
chain, prostaglandin metabolism, ischemia-reperfusion, hypoxia, neutrophil and 
macrophage activations, and endothelial cell hypoxanthine-xanthine oxidation. There is a 
balance between free radical production and clearing by the antioxidant system. The 
antioxidant defense system includes enzymatic components such as Co-Zn superoxide 
dismutase (SOD) glutathione peroxidase, and a non-enzymatic components such as 
glutathione, selenium, zinc, vitamin E and vitamin C. Preterm infants have an immature 
antioxidant defense system, and are highly exposed to oxidant stress, therefore prone to get 
tissue damage. Many antioxidant agents have been tried to treat or prevent BPD in new- 
born. These include: 
Vitamin E: Tocopherol is a fat-soluble, anti- oxidant and it decreases reactive oxygen species 
The American Academy of Pediatrics Committee on Nutrition has recommended daily 
supplementation of 5-25 IU of vitamin E in preterm infants. Supplementing very low birth 
weight infants with vitamin E as an anti- oxidant agent has been proposed for pre- venting 
or limiting retinopathy of prematurity, intracranial hemorrhage, and chronic lung disease. 
In clinical trials, vitamin E supplementation did not affect the incidence of BPD. Vitamin E 
supplementation significantly increased the risk for necrotizing enterocolitis and sepsis. 
Superoxide dismutase: Intra-tracheal ad- ministration of CuZn SOD in preterm infants did 
not reduce BPD. It decreased the need for asthma medications, emergency department visits 
and hospitalizations during the one year follow-up.Rosenfeld et al showed that radiologic 
evidence, clinical signs of BPD and days of CPAP were less in patients treated with SOD, 
and no side effects were observed. Cochrane database concluded that there is insufficient 
evidence that super- oxide dismutase is efficient in preventing chronic lung disease of 





N acetyl cysteine (NAC): NAC is a precursor of cysteine, which is essential in Glutathione 
synthesis. Glutathione is a non- enzymatic antioxidant. NAC treatment in preterm infants 
did not prevent BPD or death, and did not improve lung function at discharge from the 
hospital . 
Allopurinol: Allopurinol is inhibitor of xanthine oxidase, an enzyme which generates 
superoxide radicals. It did not decrease BPD in preterm infants of 24-32 weeks' gestation. 
Metaltonin: Metaltonin is a hormone that is found in all biological organisms, and is a 
potent free radical scavenger. Melatonin treatment reduced the proinflammatory cytokines 
(IL-6, IL-8 and tumor necrosis factor (TNF)-alpha), and improved the clinical out- come in 
mechanically ventilated newborns with respiratory distress. 
Vitamin A: Vitamin A is very important for the health of epithelial tissues. It reduces ciliary 
loss, and is associated with increased alveoli. In animals studies, vitamin A deficiency has 
been associated with necrotizing tracheobronchiolitis and squamous metaplasia the changes 
akin to BPD. Very low birth weight infants are known to have low vitamin levels. 
There have been several studies looking at vitamin A in the prevention of BPD. The largest 
study by Tyson et al showed significant decrease (from 62% to 55%) in combined outcome of 
death or chronic lung disease. 
Meta-analysis also revealed similar results. 
A follow-up study did not show any untoward outcome at 18 to 22 months of age. Many 
units routinely use vitamin A for prevention of BPD. Five thousand IU of Vitamin A has to 
be given by tri-weekly intramuscular injections for four weeks. In one study it was given by 
oral route but was not effective in preventing BPD. Intravenous emulsion preparation needs 
to be studied by randomized control trials. 
Cimetidine: In animal studies, lung injury as result of induction of cytochrome P450 by 
oxygen exposure may result in the release of free radical oxidants and arachidonic acid 
metabolites, that can be reduced by cimetidine. In study by Cotton et al of infants weighing 
less than 1250 grams who were mechanically ventilated and required oxygen, Cimetidine 
had no significant effect on the severity of respira tory insufficiency at 10 day postnatal age, 
and did not affect the tracheal aspirate levels of inflammatory markers or arachidonic acid 
metabolites. 
Azithromycin: A macrolid antibiotic, azithromycin, acts act as a free radical scavenger, 
inhibits cytokines, and inhibits neutrophil chemotaxis. In a study by Bal- lard HO et al on 
extremely premature infants requiring mechanical ventilation, azithromycin did not affect 
mortality, incidence of BPD and days on ventilator. 
Alpha-1 protease inhibitor (A1PI): Matrix Metalloproteinase is a member of a family of 
extracellular enzymes that are essential in proteolysis activity against extra cellular matrix 
proteins such as collagen, elastic lamina and fibronectin. These enzymes are produced by 
variety of cells such as fibro- blasts, osteoblasts, macrophages, monocytes and neutrophils. 
These enzymes are essential in growth, tissue remodeling, angiogenesis and wound healing. 
If the balance between activation and inhibition of this enzymes is disturbed, many 
pathological conditions can occur such as bronchopulmonary dysplasia. In a study by 
Stiskal JA et al, the incidence of CLD in survivors was lower in infants treated with 
intravenous A1PI as compared with a placebo group, but the difference was not statistically 
significant. The incidence of pulmonary hemorrhage was lower in the treated group. 
Thyroxine, did not reduce the incidence of BPD. Estradiol and progesterone hormonal 
replacements were studied in 83 infants, but did not show decrease in incidence of BPD. 
 




BPD is disease of multi-etiology. A large number of extremely preterm infants who survive 
are developing BPD, but the severity of the lung damage is considerably less than that 
observed in the classic form of BPD. Because most of these infants have only mild initial 
respiratory distress and, therefore, do not receive aggressive ventilation, other factors must 
be involved in the pathogenesis of this new, milder type of BPD. Clinical and 
epidemiological data strongly suggest that infections, either prenatal or postnatal, and the 
presence of PDA are major factors in the development of BPD. For this reason, efforts to 
prevent BPD in extremely low-birth weight infants should include an aggressive approach 
in the prevention and effective treatment of  infections and PDA. BPD has long term adverse 
pulmonary and neurodevelopment outcome. Steroids usage for treatment of BPD also has 
been shown to have adverse neurodevelopment. Available data are sometime conflicting 
and inconclusive; clinicians must use their own clinical judgment to balance the adverse 
effects of BP D with the potential adverse effects of steroids for each individual patient.. 
Very low birth weight  infants who remain on mechanical ventilation after 1 to 2 weeks of 
age are at very high risk of developing BPD . When considering corticosteroid therapy for 
such an infant, clinicians might conclude that the risks of a short course of glucocorticoid 
therapy  is warranted . This individualized decision should be made in conjunction with the 
infant's parents. Other treatment and management are largely been supportive and most of 
them have no long term benefits. A recent pilot study from Yeh et al indicated that  
intratracheal  instillation of budesonide using surfactant as vehicle  can effectively deliver 
budesonide into the lungs and can significantly suppress lung inflammation, improve 
pulmonary outcome and without immediate and long term adverse effect.. More studies are 
needed to prove this. Until that time, proper respiratory care and avoidance of NICU 
infection are the most important steps leading to lower incidence of BPD. 
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1. Introduction 
One of the critical and chronic complications of preterm birth is bronchopulmonary 
dysplasia (BPD). The incidence of BPD is high, ranging from 40% to 70% of infants born 
before 28 completed weeks’ gestation (Stoll et al., 2010). The disease is characterized by 
impaired alveolar and vascular maturation, with long-term consequences on a number of 
systems including neurodevelopment. Risk factors for BPD include gestational age at birth, 
sex, inflammation and/or infection, oxygen supplementation, mechanical ventilation, and 
parenteral nutrition. Although the etiology of BPD is not well understood, risk factors are all 
associated with oxidative stress. A modulation of the redox environment is believed to play 
a major role in the pathogenesis of BPD.  
This chapter will start by describing BPD, and then focus on the molecules involved in 
oxidative stress, the aim being that a better understanding favours more effective clinical 
intervention. Each of the risk factors in turn will be discussed according to the implied redox 
modifications occurring during BPD development.  
2. Description of BPD 
2.1 Historical perspective  
Prior to the era of mechanical ventilation, few infants of very low birth weight (less than 
1500 g) survived, and neonatal mortality for extremely low birth weight infants (less than 
1000 g) exceeded 90% (Behrman et al., 1971). Most survivors required little or no oxygen 
supplementation initially but later deteriorated to requirements of up to 40% in order to 
prevent cyanosis. On radiography, findings included microcystic changes as well as varying 
degrees of hyperinflation and flattening of the diaphragm. Some infants recovered 
spontaneously over weeks to months but others died, with postmortem examination 
revealing hyperaeration and reduced alveolar septa. Wilson and Mikity in 1960 were the 
first to describe this chronic pulmonary syndrome, in a case report of five very small 
preterm survivors (Wilson & Mikity, 1960). At that time, assisted ventilation was not used in 
preterm infants. An additional 29 babies with Wilson–Mikity syndrome (WMS) were 
identified at the same medical institution in 1969 (Hodgman et al., 1969), and many other 
cases worldwide. 
After the introduction of mechanical ventilation to manage respiratory distress syndrome in 
the mid-1960s, reports began to appear of radiographic and pathological abnormalities that 
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seemed to result from exposure to high concentrations of oxygen and mechanical 
ventilation. In 1967, Northway et al. coined the term “bronchopulmonary dysplasia” to 
describe findings of pulmonary complications following respiratory therapy for hyaline 
membrane disease (Northway et al., 1967). Northway et al. believed the critical factor to be 
exposure to an inspired oxygen concentration > 80% for longer than 150 hours. 
The 1990s saw major changes in both obstetric and neonatal care for preterm labour, with 
surfactant administration and assisted ventilation. The outcome of most preterm infants 
improved in the first half of the decade, particularly for infants with very low birth weight, 
who benefitted from decreased mortality and morbidity (Horbar et al., 2002). Following 
these changes, classical BPD, which occurred as a result of injury to the immature lung, 
became less common. Chronic lung disease in preterm infants became increasingly 
attributable to the response of the immature lung to early air breathing rather than to 
damage from barotrauma or oxygen toxicity. In 1999, Jobe described the “new” BPD as 
occurring in immature infants who did not have extensive lung disease soon after birth 
(Jobe, 1999). Jobe attributed the “new” BPD to pulmonary anomalies resulting from an 
inhibition of alveolar and vascular development (Jobe, 1999). 
2.2 Clinical definitions 
With the change in clinical presentation over time, a variety of definitions of BPD have been 
used in the literature. 
i. Original criteria for BPD: A U.S. National Institutes of Health (NIH) workshop held in 
1979 proposed to define BPD as a “continued oxygen dependency during the first 28 
days plus compatible clinical and radiographic changes” (Natl Inst Health Consens Dev 
Conf Summ, 1979). 
ii. Traditional definition: Instead of the original definition, Shennan et al. (1988) 
suggested a more accurate predictor of BPD to be, “the requirement for additional 
oxygen at a corrected postnatal gestational age of 36 weeks in infants born with a birth 
weight of less than 1,500 g”.  This definition appears to also predict pulmonary outcome 
among infants with the “new” BPD (Davis et al., 2002).  
iii. Severity definition: Participants at a joint U.S. National Institute of Child Health & 
Human Development (NICHD)-National Heart, Lung, and Blood Institute (NHLBI) 
workshop defined mild, moderate and severe BPD according to both 28 days’ and 36 
weeks’ criteria (Jobe & Bancalari, 2001). Mild BPD was defined as the need for 
supplemental oxygen at 28 days after birth but not at 36 weeks’ postmenstrual age 
(PMA); moderate BPD, the need for supplemental oxygen at 28 days and at a fraction of 
inspired oxygen (FiO2) < 0.30 at 36 weeks’ PMA; and severe BPD, the need for 
supplemental oxygen at 28 days and, at 36 weeks’ PMA, the need for mechanical 
ventilation and/or FiO2 > 0.30. In a validation study, the NICHD–NHLBI workshop 
definitions accurately predicted pulmonary outcomes including percent of patients 
needing treatment with pulmonary medications and rehospitalization for pulmonary 
causes (Ehrenkranz et al., 2005). 
iv. Physiological definition: An inherent limitation of all previous definitions is that the 
need for oxygen is determined by individual physicians rather than on the basis of a 
physiologic assessment. The assumption that the criteria on which the decision to 
administer oxygen is uniform and applied similarly across institutions is erroneous 
because there is no consensus in the literature, neonatologists have widely divergent 
 
Bronchopulmonary Dysplasia:  The Role of Oxidative Stress 
 
487 
practices regarding oxygen-saturation targets. Indeed, published literature cites 
acceptable saturation ranges from 84% to 98% (Garg et al., 1988; Moyer-Mileur et al., 
1996; Sekar & Duke, 1991; Walsh, 2003; Zanardo et al., 1995). Accordingly, the 
physiological definition determined BPD at 36 weeks of correct age as follows: 1) In all 
infants treated with mechanical ventilation, continuous positive airway pressure, or 
supplemental oxygen at FiO2 > 0.30, without additional testing; 2) If the FiO2 < 0.30, 
infants are to be gradually weaned to room air, in a timed stepwise fashion; those who 
cannot maintain an SaO2 ≥ 88% are diagnosed with BPD, unless they pass a timed, 
continuously monitored oxygen reduction test. An oxygen saturation 80% to 87% for 5 
minutes, or < 80% for 1 minute, indicates BPD. If all SaO2 measurements over 15 
minutes ≥ 96%, or if instead, all SaO2 measurements in a 60-minute period > 88%, the 
infant is deemed not to have BPD (Walsh et al., 2003).  
To evaluate the impact of the physiological definition on BPD rates, 1598 consecutively born 
preterm infants (birth weight 501–1249 g) in hospital at 36 weeks’ PMA were prospectively 
assessed and assigned an outcome using both the clinical and physiological definitions of 
BPD. The NICHD neonatal network centers demonstrated that many babies who, according 
to the nursing staff, required oxygen were able to maintain an SaO2 > 90% on room air. 
Though 560 (35%) had clinical BPD (oxygen use at 36 weeks), only 398 (25%) had 
physiological BPD (as defined above) (Walsh et al., 2004). 
2.3 Structural lung changes 
As described by Northway et al. (1967), the histological features of classical BPD included 
prominent interstitial fibrosis, alveolar overdistention alternating with regions of atelectasis, 
and airway abnormalities such as squamous metaplasia and excessive muscularization.  On 
the other hand, the “new” BPD shows histological features consistent with developmental 
arrest and impaired alveolar development (Husain et al., 1998): alveoli are fewer in number 
and larger in diameter than normal; the fibrosis, squamous metaplasia and excessive airway 
muscularization seen in classical BPD are conspicuously absent; airway and microvascular 
growth are affected. A short comparative study by Bhatt et al. (2001) found decreased levels 
of vascular endothelial growth factor (VEGF) and angiogenic receptors Flt-1 and Tie-2 in 
infants who died from BPD vs. from other causes. The authors concluded that the lungs 
from infants with BPD showed abnormal development of alveolar microvessels (abnormal 
placement in the alveolar septa) and that the capillaries were frequently dilated, changes 
attributable to low VEGF and associated receptors (Bhatt et al., 2000, 2001). Controls were 
five children born at term who died at a mean of 3.4  1.3 days, whereas the five BPD 
subjects were born at 27  2 weeks’ gestation, received FiO2 > 0.5 during 37  33 days, and 
died at 65  34 days. 
2.4 Epidemiology 
BPD remains the most prevalent and one of the most serious long-term sequelae of preterm 
birth (Fanaroff et al., 2007). There is considerable variation in reported rates, however, 
depending upon the centre. Among 4213 infants born in 2003 at 24–31 weeks’ gestation in 10 
different European regions, the rate of BPD (oxygen requirement at 36 weeks’ PMA) was 
anywhere from 10.5% to 21.5% (Zeitlin et al., 2008). 
A 2010 NICHD Neonatal Research Network report on neonatal outcomes of extremely 
preterm infants assessed 9575 infants born at extremely low gestational ages (22–28 weeks) 
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and very low birth weights (401–1500 g) at network centers between January 1, 2003 and 
December 31, 2007.  Including babies with mild BPD (oxygen therapy for 28 days but use of 
room air at 36 weeks), the incidence of BPD as determined by the severity-based definition 
was 68%; traditional definition, 42%; physiologic definition, 40% (Stoll et al., 2010). 
2.5 Demographic factors 
Factors linked to BPD include: 1) low gestational age at birth (Kraybill et al., 1989; Darlow 
& Horwood, 1992; Antonucci et al., 2004; Ambalavanan & Novak, 2003), 2) low birth 
weight (Darlow & Horwood, 1992; Hakulinenet al., 1988; Avery et al., 1987; Ambalavanan 
et al., 2008), 3) growth restriction (small for gestational age) (Durrmeyer X et al., 2011; Lal 
Mk et al., 2003; Zeitlin J et al., 2010), 4) male sex (Kraybill et al., 1989; Darlow & Horwood, 
1992; Ambalavanan & Novak, 2003; Avery et al., 1987), and 5) white race  (Avery et al., 
1987; Palta et al., 1991).  In a recent cohort, BPD affected 85% of infants born at 22 weeks’ 
gestation vs. 23% of those born at 28 weeks’ (Stoll et al., 2010). Furthermore, of the infants 
affected by BPD in a large American study which included over 9.5 million very low birth 
weight infants between 1993 and 2006, 59.3% were male while 40.7% were female (male : 
female ratio = 1.46 : 1) (Stroustrup & Trasande, 2010). 
2.6 Impact of perinatal lung injury later in life  
Preterm infants with BPD commonly develop impaired health, neurodevelopment, and 
quality of life later on in childhood. Often noted are:  1) increased risk of postneonatal 
mortality (Van Marter, 2009), 2) higher rates of rehospitalization (Jeng et al., 2008), 3) long-
term pulmonary impairments (Broström et al., 2010) such as asthma (Baraldi et al., 2009) and 
emphysema (Wong et al., 2008), 4) failure to thrive (Theile et al., 2011), and 5) cognitive 
impairment (Anderson & Doyle, 2006), cerebral palsy (Koo KY et al 2010; Majnemer et al., 
2000), and global neurodevelopmental deficits (Short EJ et al, 2003). 
3. The preterm lung: Set-up for injury 
Human lung development proceeds in five regulated stages: embryonic (3–7 weeks’ 
gestation), pseudoglandular (7–17 weeks’), canalicular (17–27 weeks’), saccular (28–36 
weeks’) and alveolar and microvascular maturation (36 weeks’ gestation to at least 2 years 
after birth). The lungs of preterm infants born at 24–28 weeks’ gestation are in the late 
canalicular or early saccular stages and therefore cannot support efficient gas exchange. 
Branching and expansion of air spaces to form saccules and thinning of mesenchyme occur 
later in gestation, as do the formation of alveoli and the synthesis of surfactant by type II 
alveolar cells which only commence in late gestation. Any injury to the lung at the early 
stages of development can potentially alter the developmental process, leading to long-term 
pulmonary sequelae (Chakraborty et al., 2010). 
Whereas fetal development is predicated on a hypoxic environment, at birth the oxidative 
load is sharply increased. At the same time, oxygen demands increase abruptly. The baby 
born at term easily adapts to this transition in most cases but for the preterm infant, the 
intra- to extra-uterine transition is not without risks. Among the reasons why the preterm 
infant is more likely to experience oxidative injury than more mature newborns and older 
children are the following: 1) intracellular defences against oxidative stress are still poorly 
developed; 2) the preterm infant is often, for various reasons, exposed to high 
concentrations of supplemental oxygen; and 3) the fetus and premature infant are also 
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susceptible to inflammation and infection that may lead to increased oxidative stress 
(Saugstad, 2010).  
It may therefore be instructive to look at some of the molecules implicated in oxidative stress, 
while drawing parallels with the corresponding processes in BPD. This added insight will 
contribute to delimiting specific sources of oxidant molecules that may contribute to the 
development of BPD, a topic we will explore later in the chapter in relation to BPD risk factors. 
4. Oxidative stress  
In utero, the arterial pressure of oxygen (PaO2) is close to 30 mm Hg. After birth, with the 
baby breathing in ambient air, the PaO2 rises to 75 mm Hg. This greater oxygen load 
increases the concentration of dissolved oxygen available for oxidative phosphorylation in 
the mitochondria, organelles that release 1-3% of oxygen in the form of reactive oxygen 
species (ROS).  
Inspired oxygen (O2) is a diatomic molecule with two free electrons (O-O). This molecule 
has the highest half-cell reduction potential (Ehc) in vivo (Ehc for the ½O2/H2O couple = 0.816 
V). Consequently, dissolved O2 readily accepts an electron () from donors such as 
polyunsaturated fatty acids or ascorbic acid, generating the free radical superoxide anion 
(O-O or O2−). This transformation of O2 into O2− is spontaneous, generating the 
oxidized form of vitamin C (dehydroascorbate, DHA) and/or the by-products of fatty acid 
oxidation (lipid peroxides, aldehydes such as malondialdehyde or 4-hydroxy-2-nonenal 
(HNE), or isoprostanes). The reaction may also be catalyzed by nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase.  Thus, the inspiration of diatomic oxygen leads 
to an increase in the cellular concentration of free radicals (O2−) as well as free O2, which 
will contribute to metabolic regulation by hydroxylation of several biologically active 
molecules. For instance, O2 is essential for the degradation of hypoxia-inducible factor-1 
(HIF-1; HIF-1 activates transcription of the gene encoding VEGF, an important growth 
factor for angiogenesis. This process is impaired in BPD (Husain et al., 1998; Bhatt et al., 
2000, 2001). Figure 1 shows a number of oxidative-reduction (redox) reactions of interest.  
4.1 Superoxide anion 
The dismutation of the superoxide anion (O2−) into O2 and H2O2 (2 O-O + 2H+ O-O 
+ HO-OH) may be either spontaneous or catalyzed by a superoxide dismutase (SOD). In 
preterm infants, the pulmonary activity of SOD is suspected to be immature. As reported by 
Lee Frank in several animal species (mice, hamster, rat, guinea pig), the pulmonary activity 
of SOD, catalase, and glutathione peroxidase are only 10-15% of that in term babies, in 
preterm newborns < 32 weeks of human-equivalent gestation (Frank & Sosenko, 1987a, 
1987b; Frank, 1991). As a result, the levels of O2− may be higher in preterm than term 
neonates. Furthermore, the oxidant property of O2− is not related to the attraction of an 
electron from a common antioxidant such as ascorbate, but to the donation of an electron to 
a free transition metal such as ferric iron (Fe3+) in a Haber-Weiss reaction (O2− + Fe3+   O2 
+ Fe2+).  The resulting ferrous ion (Fe2+) from this reaction reacts rapidly with hydrogen 
peroxide (H2O2) in a Fenton reaction to generate Fe3+, OH− and OH. This hydroxyl radical 
(OH) is among the most reactive of molecules, leading to the oxidation of proteins, lipids 
and DNAs. Therefore, high oxygen supplementation coupled with low SOD activity add to 
oxidative stress, and this may be evidenced by an increase in the by-products of lipid 
peroxidation (lipid peroxides, malondialdehyde, HNE, alkanes such as ethane and pentane, 
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and isoprostanes) and/or of protein oxidation (carbonyl compounds, o-dityrosine). 
Newborn infants receiving O2 supplementation have demonstrably elevated levels of 
markers of oxidative stress such as exhaled ethane and pentane (Nycyk et al., 1998; Pitkanen 
et al., 1990), serum HNE (Ogihara et al., 1999), F2a-isoprostanes in tracheal aspirate (Cotton 
et al., 1996) or in plasma (Ahola et al., 2004), protein-carbonyl in bronchoalveolar fluid 
(Gladstone & Levine et al., 1994) or o-dityrosine in urine (Kelly & Lubec, 1995; Lubec et al., 
1997). It has been suggested that some of these markers may be higher in the first few days 
of life in preterm infants who will develop BPD as compared to those who will not 
(Gladstone & Levine et al., 1994; Hodgman et al., 1969). Hence, reducing the O2− levels in 
preterm neonates has been a seductive approach to BPD prevention. Indeed, a randomized 
study of human recombinant SOD administered intratracheally in the first 24 hours to 
preterm infants at high risk (birth weight 600-1200g) has been associated with a lower 
incidence of respiratory illnesses such as wheezing, asthma and pulmonary infections 
(Davis et al., 1993; Davis et al., 2003).  
4.2 Hydrogen peroxide 
As noted in Figure 1, H2O2 is generated following high oxygen supplementation. Chemically, 
H2O2 is a relatively stable molecule that can diffuse passively through cell membranes. Its 
oxidation reactions occur in two ways, one by accepting an electron from ferrous iron (Fe2+) to 
generate the free radical hydroxyl (OH), the other by oxidizing sulfhydryl or thiol groups (R-
SH) on protein. By its high affinity for thiol, H2O2 is considered an important player in the 
regulation of several metabolic pathways (Winterbourn & Hampton, 2008). Of interest to BPD, 
H2O2 can activate nuclear factor kappa B (NF-kB) (Flohé et al., 1997; Haddad, 2002; Haddad & 
Land, 2000; Takada et al., 2003), upregulating the transcription of genes encoding pro-
inflammatory cytokines (Randell et al., 1990). H2O2 also contributes to the stability of HIF-1 
(Bonello et al., 2007; Chen Y Shi, 2008; Haddad, 2002; López-Lázaro, 2006; Simon, 2006), a 
transcription factor involved in angiogenesis. It is therefore important that the intracellular 
level of H2O2 be tightly regulated. 
The intracellular concentration of H2O2 depends on the balance between production from 
the dismutation of superoxide anions catalyzed by manganese superoxide dismutase 
(MnSOD) (Buettner et al., 2006), and detoxification by catalase and/or glutathione 
peroxidase. Catalase has a high catalytic activity but relative low affinity for H2O2 (Km of 1.1 
M) (Jones & Suggett, 1968), whereas glutathione peroxidase has a Km close to 1 M (Flohéa 
& Branda, 1969). With the exception of erythrocytes (Gaetani et al., 1996), catalase is present 
in peroxisomes and mitochondria. Glutathione peroxidase, however, is present in the 
cytosol, where it is an efficient regulator of the intracellular level of H2O2. Reduction of H2O2 
by glutathione peroxidase implies a conversion of glutathione (GSH) to its disulfide form 
(GSSG). The cell exerts tight control over the intracellular concentrations of GSH and GSSG 
in order to maintain the appropriate redox environment for the various cellular processes to 
occur efficiently. Indeed, the redox potential is a component of the Gibbs free energy 
equation that predicts the feasibility of a chemical reaction. Several biochemical pathways 
are dependent on the intracellular redox potential, including NF-B activation and HIF-1 
levels as discussed earlier (Bonello et al., 2007; Chen & Shi, 2008; Haddad et al., 2000; 
Haddad & Land, 2000; Land & Wilson, 2005; López-Lázaro, 2006; Roy et al., 2008). In the 
presence of a large peroxide load or sustained generation of peroxides, the formation of 
GSSG can exceed the capacity of glutathione reductase to recycle it into GSH, and the redox 
potential will change to a more oxidized state.  
 





Fig. 1. Relationship between oxidant molecules and endogenous antioxidant defences. 
Oxygen (O2) supplementation as well as hydrogen peroxide (H2O2) from parenteral 
nutrition can lead to modulation of: 1) transcription factors such as hypoxia-inducible 
factor-1 (HIF-1) and nuclear factor kappa B (NF-B), important players in the 
pathogenesis of BPD; 2) levels of oxidative stress markers (isoprostanes, peroxides, lipid 
aldehydes, alkanes); 3) activity of thiol-sensitive proteins (R-SH); and 4) redox potential of 
glutathione (GSH), as influenced by glutathione peroxidase (GPx) and the intracellular 
concentrations of reduced (GSH) and oxidized (GSSG) glutathione. 
 
Lung Diseases – Selected State of the Art Reviews 
 
492 
4.3 Redox potential of glutathione 
The redox potential is dependent of the concentration of GSH and GSSG according to the 
Nernst equation: ∆E =∆E°· (RT/nF)· log ([GSH]2/[GSSG]) (Schafer & Buettner, 2001). In cells 
extracted from the endotracheal aspirate of intubated newborns, the level of glutathione 
increases with gestational age and female sex, being lower in preterm and male infants 
(Lavoie & Chessex, 1997). The sex is a significant risk factor for BPD, as BPD affects more 
boys than girls (Ambalavanan et al., 2008; Ambalavanan & Novak, 2003; Darlow & 
Horwood, 1992; Kraybill et al., 1989; Stroustrup & Trasande, 2010). The low glutathione 
concentration measured in preterm newborns (Lavoie & Chessex, 1997) is associated with an 
oxidized redox potential. Low blood level of glutathione were also reported in preterm 
neonates with chronic lung disease (White et al., 1994). Recently, Chessex et al. (2010) 
demonstrated a correlation between BPD severity in preterm infants (26  1 weeks’ 
gestation) and blood redox potential measured one week after birth: the more oxidized the 
redox potential, more severe the disease. 
As previously reported (Schafer & Buettner, 2001), the redox potential acts as a switch for a 
number of metabolic pathways, inducing cellular proliferation, differentiation or death 
(apoptosis) (Figure 2). During organ development, cells must pass through the various cell 
cycle stages in order to allow for continued remodelling. This process is essential to proper 
lung development (Bruce et al., 1999; Luyet et al., 2000). Consequently, the redox potential 
must also cycle continuously (Figure 3). The proliferation phase is accompanied by a higher 
metabolic rate leading to increased generation of ROS. These ROS in turn favour a shift of the 
redox potential toward a more oxidized status, inducing the differentiation phase. 
Alternatively, the oxidized status may 1) induce apoptosis, which favours tissue remodelling, 
and 2) activate redox-sensitive factors inducing the transcription of genes that encode enzymes 
involved in glutathione synthesis and GSSG recycling (glutathione reductase). This last event 
will shift the redox potential toward a more reduced state, beginning a new cell cycle. 
 
Fig. 2. The redox environment influences metabolic processes. 
By modulation from a more reduced to a more oxidized state, the redox environment allows 
activation and inactivation of various metabolic processes controlling the cell cycle. A 
reduced state favours cellular proliferation whereas an oxidized state favours 
differentiation. A more oxidized state will also induce cell death by apoptosis.  
(Adapted from Schafer FQ et al., 2001) 
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The link between redox potential and BPD can be explained by an exacerbated apoptosis 
rate caused by an abnormally elevated redox potential (Luyet et al., 2000). Lung samples 
from premature baboons with BPD (Das et al., 2004) showed a large number of apoptotic 
events. In newborn guinea pigs given parenteral nutrition for 4 days, the alveolar count was 
20% lower when the nutritive solution was infused without light protection, peroxide 
concentration being higher in light-exposed solutions (Section 5.2 below) (Lavoie et al., 2004, 
2005, 2008). On histology, 30% of alveolar cells were in an apoptotic state (Lavoie et al., 
2004). During normal alveolar development, however, about 10% of cells die by apoptosis 
(Luyet et al., 2000), in order to thin the septa between alveoli for more efficient gas exchange 
(Bruce et al., 1999; Luyet et al., 2000).   
Various factors may contribute to a shift in redox potential to a more oxidized state (Figure 
3, dashed line). An induced or sustained oxidized status favours the apoptosis process, 
leading to a loss of tissue such as observed in BPD (Das et al., 2004; Lavoie et al., 2004, 2005, 
2008). In preterm infants, these factors are oxygen supplementation, parenteral nutrition 
(containing peroxides), and inflammation.  
 
Fig. 3. The redox environment as a function of time. 
A normal oscillation of the redox environment occurs over time, between a more reduced 
and a more oxidized state. As the environmental redox potential changes, pulmonary 
development is supported by cell proliferation, differentiation, and controlled apoptotic 
events. An excessively oxidized redox environment, such as that caused by oxidative stress, 
will favour an apoptotic phase, leading to loss of cells and impaired development. 
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5. Sources of oxidant molecules in BPD  
Oxygen supplementation and parenteral nutrition are exogenous sources of oxidant 
molecules affecting the preterm neonate. Inflammation, however, is an endogenous source 
of oxidants and its role is complex. Indeed, inflammation can either be a source or 
consequence of oxidative stress. In this section, we will analyze each of these sources for 
their potential role in BPD. 
5.1 Oxygen supplementation   
Oxygen supplementation increases ROS generation in the lungs. For this reason, and 
because of the potential effect of oxidative stress on the development of BPD, it has been 
hypothesized that high O2 concentration in inspired air is linked to the development of BPD 
in preterm neonates (Northway et al., 1967). This hypothesis is supported by animal studies. 
In rats, exposure to 95% O2 during the first week of life resulted in a 13% reduction in 
pulmonary alveolar surface area at 40 days (Randell et al., 1990). However, the impact of 
oxygen has recently been questioned. Although major clinical advances such as the use of 
surfactant and continuous positive airway pressure (CPAP) have led to a reduction in 
oxygen supplementation, their impact on lessening the incidence of BPD has been only 
about 3% per year between 1993 and 2006, for a global  reduction of 30% in 13 years 
(Stroustrup & Trasande, 2010).  This relatively weak contribution was confirmed by studies 
in newborn preterm baboons, where a reduction in the fraction of inspired oxygen (FiO2) 
from 80-100% to 21-50% had no significant impact on the levels of fibrosis and alveolar 
hypoplasia (Coalson et al., 1995, 1999). Similarly, a 2010 study of 1316 human infants born at 
less than 28 weeks’ gestation reported a non-significant effect of ventilation strategy leading 
to a lower oxygen saturation (85-89% versus 91-95%) on the incidence of BPD (SUPPORT 
Study Group, 2010). Furthermore, The use of high-dose antioxidants scavenging free 
radicals (vitamins C and E) did not have any protective effect against alveolar hypoplasia 
(Berger et al., 1998). Free radicals were therefore not the major player in BPD.  
If higher O2 in inspired air could lead to a greater cellular concentration of H2O2 that is not 
quenched by vitamins C or E, the apparently weak effect of oxygen supplementation on 
BPD development must be explainable by another source of oxidant molecules masking the 
impact of O2. It is noteworthy that the major risk factor for BPD is gestational age; the lower 
the age, the greater the incidence of BPD. Coincidentally, the more premature the infant, the 
greater is his dependence on parenteral nutrition. A 2011 study showed that preterm infants 
developing BPD received more parenteral than enteral nutrition (Wemhöner et al., 2011). In 
the various studies on BPD, including those in baboons, the gestation ages of the subjects 
were such that the infants likely required parenteral nutritive support, a major source of 
ROS and particularly of H2O2 (Laborie et al., 1998; Lavoie et al., 1997). In itself, parenteral 
nutrition may be sufficient to induce the development of BPD. In fact, however, it is highly 
probable that both parenteral nutrition and oxygen supplementation induce oxidative stress, 
by both increasing the intracellular concentration of H2O2 and modifying the redox potential 
of glutathione (Chessex et al., 2010).  
5.2 Parenteral nutrition   
Parenteral nutrition consists of the intravenous administration of a solution containing 
amino acids, dextrose, electrolytes, vitamins and lipids. Parenteral nutrition is essential for 
the nutritional support of the preterm infant, bypassing a gastrointestinal system whose 
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immaturity severely limits the natural feeding process. Although parenteral nutrition is 
sufficient to support growth in the child, the instability of the nutrients in solution favours 
the generation of undesirable molecules. The admixture of redox-sensitive elements such as 
amino acids (tryptophan, tyrosine and others), polyunsaturated fatty acids, and vitamin C, 
in the presence of a strong oxidizing molecule such as dissolved oxygen, will induce 
oxidation of the nutrients and the formation of their consequent derivatives. For instance, 
peroxidation of omega-6 polyunsaturated fatty acids will yield lipid hydroperoxides and 
HNE (Massarenti et al., 2004; Silvers et al., 2001), while vitamin C and dissolved oxygen will 
produce H2O2 (Laborie et al., 1998; Lavoie et al., 1997). As vitamin C is the most powerful 
antioxidant found in parenteral nutrition, the main source of peroxides in parenteral 
nutrition would appear to be the multivitamin preparation (Laborie et al., 1998; Lavoie et al., 
1997). Furthermore, this solution contains riboflavin, a photosensitive molecule. In the 
presence of light, photoexcited riboflavin catalyzes a peroxide-producing reaction (Laborie 
et al., 1998). The simple act of adequately shielding parenteral nutrition solutions from 
ambient light halved the concentration of peroxides in the infused solution (Chessex et al., 
2001; Laborie et al., 1998, 1999, 2000; Lavoie et al., 1997, 2007) as well as in the urine of 
preterm infants (Bassiouny et al., 2009; Chessex et al., 2001). Adequate photoprotection of 
parenteral nutrition has also been reported to reduce the incidence of chronic lung disease 
(Bassiouny et al., 2009) or BPD (Chessex et al., 2007) in premature infants.  
As administered in neonatal units, without adequate photoprotection, parenteral nutritive 
solutions are contaminated with several molecules having the potential to perturb the redox 
status of the lung, i.e. lipid hydroperoxides (Silvers et al., 2001), HNE (personal 
communication of Lavoie JC, 2011), ascorbylperoxide (Lavoie et al., 2004; Maghdessian et 
al., 2010), and H2O2 (Laborie et al., 1998; Lavoie et al., 1997; Silvers et al., 2001). All these 
molecules are detoxified by the glutathione system. Since glutathione levels are low in 
preterm infants (Lavoie & Chessex, 1997), these molecules can conceivably overwhelm the 
glutathione system, allowing the redox potential to shift toward an oxidized state. Infusion 
of parenteral nutrition without light protection for 4 days in newborn guinea pigs was 
associated with: 1) a loss of glutathione (Lavoie et al., 2000), 2) a more oxidized glutathione 
redox potential (Lavoie et al., 2008), and 3) a lower alveolar count (Lavoie et al., 2004, 2005, 
2008), as compared to animals infused with a fully photoprotected solution. A recent study 
demonstrated that the blood glutathione redox potential measured in 7-day-old preterm 
infants (26  1 weeks’ gestation) was correlated with the severity of BPD; a more oxidized 
status was measured in the most severe cases (Chessex et al., 2010). Therefore, current 
knowledge suggests that each oxidant molecule affecting the glutathione system, whether 
from oxygen supplementation or from parenteral nutrition, may contribute to the 
development of BPD.  
5.3 Inflammation 
The third major risk factor for BPD is inflammation, a significant source of ROS (Federico et 
al., 2007; Pereda et al., 2006). Several pro-inflammatory cytokines have been detected in 
aspirated fluids from infants with BPD, the concentration increasing as a function of assisted 
ventilation duration and level of oxygen supplementation (Bose et al., 2008). As previously 
demonstrated, exposure to high amounts of O2 favours the production of H2O2, a known 
activator of transcription factor NF-B (Flohé et al., 1997; Haddad, 2002; Haddad & Land, 
2000; Takada et al., 2003), which in turn upregulates the expression of several pro-
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inflammatory cytokine genes (Federico et al., 2007; Pereda et al., 2006). The oxygen-cytokine 
connection was further supported by research showing that oxygen supplementation 
induced an inflammatory response in preterm infants (Lavoie et al., 2010). The association 
between BPD and inflammation may therefore be explained by an initial oxidative stress 
followed by a local increase in H2O2 concentration. However, other researchers have argued 
that an inflammatory process independent of the variation in inspired oxygen concentration 
could also induce BPD, for example chorioamnionitis (Gien & Kinsella, 2011). Paananen R et 
al (2009) reported that elevated plasma concentrations of IL-6, a pro-inflammatory cytokine, 
and IL-10, an anti-inflammatory cytokine, on the first day of life were indicative of greater 
BPD risk, independently of previous exposure to chorioamnionitis (39% of the 128 preterm 
neonates in the cohort had had chorioamnionitis; incidence of BPD in cohort, 25%). The lack 
of correlation between an initial inflammatory process and BPD development was 
confirmed in 2010 in a study investigating the association between chorioamnionitis and 
BPD (Prendergast, et al., 2010). From the 71 preterm infants developing BPD, 41 had been 
exposed to chorioamnionitis and/or funisitis. Their results, however, showed a significant 
correlation between the severity of BPD and gestational age or birth weight. Thus, 
endogenous infection does not seem to be connected to the development of BPD while 
cytokines are, underlining a possible implication of oxidative stress early in life.  
6. Strategies for prevention/treatment 
Under the hypothesis that glutathione, by its very involvement in the cellular redox 
environment, could be a key player in BPD development, one strategy to prevent BPD 
development or reduce its severity would be to preserve or increase the intracellular 
concentration of glutathione. It is noteworthy that the low levels of glutathione observed in 
preterm infants (Lavoie & Chessex, 1997) are not due to a defective enzymatic process. 
Indeed, GSH synthesis is very active, even in newborns of 26 weeks’ gestation (Lavoie & 
Chessex, 1998). The defect comes rather from the immaturity of the cellular transport system 
of cysteine (Lavoie et al., 2002), an amino acid whose low intracellular availability limits the 
synthesis of glutathione (Deneke & Fanburg, 1989). This fact may explain the failure of 
intravenous administration of N-acetylcysteine to prevent the development of BPD in 
extremely low birth weight newborns (Ahola et al., 2003).  
If it is difficult to increase the intracellular concentration of glutathione, one must at least 
prevent its consumption by reducing oxidative stress. This can be partly achieved by 
monitoring blood oxygen saturation levels to prevent excessive oxygen supplementation. 
Prevention of inflammation will help as well. However, limiting peroxide contamination in 
parenteral nutrition is essential. Though photoprotection of the solution may be difficult to 
institute in the clinical setting, the process must be initiated in the pharmacy department at 
the time of compounding and continued until bedside. New nutritive strategies leading to 
improvements in the nutritive quality of parenteral products, reducing the oxidation of 
nutrients and preventing the generation of oxidant molecules, will have a positive impact on 
the incidence of BPD.    
7. Conclusions/perspectives 
Presently, no therapy exists for BPD (Gien & Kinsella, 2011) and its prevention is difficult. 
The etiology is multifactorial. This chapter focused on the part played by oxidative stress, in 
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particular the glutathione redox potential. While a number of oxidant sources can contribute 
to the shift in redox potential toward a more oxidized state, several BPD-related factors were 
found to have an impact, among them oxygen supplementation, parenteral nutrition, and 
inflammation. Modification of even one of these factors may decrease the incidence of BPD, 
but the best practice remains to administer a combination of new measures, as suggested by 
Geary C et al. (2008), including early use of surfactant and nasal continuous positive airway 
pressure for ventilatory support, as well as lowered oxygen saturation targets and better 
nutritive support. It is remarkable that all associations between biochemical markers and 
BPD have been observed with parameters measured in the first days of life (Ahola et al., 
2004; Geary et al., 2008; Gladstone & Levine, 1994; Lavoie et al., 2008; Ogihara et al., 1999; 
Pitkanen et al., 1990; Welty, 2001). The first week of life, in both infants and animal models, 
seems be a critical window during which all efforts to reduce oxidative stress must be 
pursued.  
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1. Introduction 
Preterm infants, especially the extremely preterm, require a large amount of support ex 
utero. They are often critically ill with greatly reduced chances of survival. Many die because 
of their overall immaturity with multiple organ systems that cannot adjust to extrauterine 
life, especially the lungs. Many die from their primary lung disease. The respiratory support 
they get from positive pressure ventilation almost always causes significant secondary lung 
injury.  
Over the previous decades partial liquid ventilation has been put forward as an adjunct form 
of respiratory support for especially immature lungs and severe lung disease: not only to 
provide a superior form of respiratory support but to deliver that support with reduced lung 
injury. Recent studies have renewed the hope that partial liquid ventilation has great potential 
to change the course of neonatal lung disease and respiratory morbidity. (Blassnig, 2009) 
Unfortunately, the extremely preterm infant is also at great risk of particular forms of brain 
injury (e.g., intraventricular haemorrhage, periventricular leucomalacia and other white 
matter injury). Disturbance of cerebral blood flow has been demonstrated to considerably 
increase the risk of these forms of brain injury. 
One of the concerns with using partial liquid ventilation in the extremely preterm infant is 
its affect on cerebral blood flow which could lead to brain injury, especially at the start of 
partial liquid ventilation during the initial dosing of perfluorocarbon into the lungs. Any 
benefits of partial liquid ventilation might be outweighed by an increased risk of brain 
injury and the subsequent devastating consequences.  
Before using partial liquid ventilation in human preterm infants it should be known to be 
safe with regard to its effects on cerebral blood flow during perfluorocarbon dosing. The 
effect of perfluorocarbon dosing at the start of partial liquid ventilation on cerebral blood 
flow can be mitigated to minimise or eliminate these adverse effects. 
2. The consequences of lung disease in the extremely preterm neonate 
2.1 Mortality 
The extremely preterm infant, born at less than 26 weeks gestational age, is at great risk of 
dying. The risk increases with decreasing gestational age. The majority of these infants die 
because of general immaturity (including extremely immature lungs) or lung disease. 
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Data are available from Australia and New Zealand. All babies that are admitted to a 
newborn nursery who were born at less than 32 completed weeks gestation, or weighed 
<1,500 grams at birth, or received assisted ventilation (mechanical ventilation), or received 
major surgery are registered with the Australian and New Zealand Neonatal Network 
(ANZNN). The ANZNN reports annually on all registered babies. (ANZNN, 2009)  The 
latest report of the ANZNN (ANZNN, 2009) is for births in 2006; of 339,271 live births there 
were 7,592 registered babies (2.2% of live births). There were 412 registered babies born at 
<26 weeks gestational age (5.4% of registered babies). Two thirds (276/412) survived to be 
discharged home – a mortality of 33%.  
The EPICure study (Wood, 2000) is a large population based study designed to reveal 
outcomes for extremely preterm infants. They enrolled all babies born at less than 26 weeks 
gestational age, from March 1995 to December 1995, who were admitted to a neonatal 
intensive care unit in the United Kingdom of Great Britain and Northern Ireland and the 
Republic of Ireland. These infants are deemed to be extremely immature and at the limits of 
viability. About sixty percent (60%) of these infants died before discharge from hospital and 
about 70% of those deaths had a respiratory cause. (Costeloe, 2000) In an Australian study 
from around the same period (1992-1996) at the Royal Women’s Hospital in Melbourne, 
about 28% of live born infants of 23 to 27 weeks gestational age died. Of those infants 
admitted to the intensive care nursery 60% of deaths had a respiratory cause. (Doyle, 1999) 
Recent data are available from the Royal Brisbane and Women's Hospital in Brisbane, 
Australia. From 2003-2007 inclusive there were 163 infants admitted of  less than 26 weeks 
gestational age: 58 (36%) died. Sixty-two percent (62%) of those deaths were either due to 
‘extreme prematurity’ or a direct respiratory cause. (Cartwright, 2003; Cartwright, 2004; 
Cartwright, 2005; Cartwright, 2006; Cartwright, 2007)  
2.2 Respiratory morbidity 
Lung immaturity and/or lung disease not only carries a high mortality in extremely 
preterm babies, but it also causes significant morbidity. This includes the requirement for 
respiratory support, air leak and neonatal chronic lung disease. Mechanical ventilation often 
causes significant secondary lung injury due to barotrauma and volutrauma. This makes the 
acute lung disease much worse and, along with extreme prematurity, is a major factor in the 
subsequent progression to chronic lung disease. Neonatal chronic lung disease consists of 
distortion of the lung architecture, disturbed lung growth and chronic inflammation of the 
small airways and the lung parenchyma. Most patients with neonatal chronic lung disease 
are born extremely preterm. Infants with chronic lung disease have significant morbidity 
which manifests as a requirement for prolonged respiratory support and oxygen therapy, as 
well as an increased hospital stay. Chronic lung disease is also a major cause of late 
mortality.  
Many extremely preterm infants need mechanical ventilation. About ninety percent (90%) of 
ANZNN registered babies in 2006 required some form of assisted ventilation. (ANZNN, 
2009) The mean length of time of assisted ventilation was 11 days. Most babies required 
respiratory support for either hyaline membrane disease or non-specific respiratory distress. 
Intubation and positive pressure mechanical ventilation was required by ninety-seven 
percent (97%) of babies born <26 weeks gestation. The most extreme form of acute  
lung injury in ventilated neonates is air leak (pneumothorax, pulmonary interstitial 
emphysema, pneumomediastinum); it occurred in eight percent (8%) of infants <26 weeks 
gestational age. 
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The ANZNN defines chronic lung disease as any registered baby born less than 32 weeks 
gestational age who needs assisted ventilation for their initial lung disease and continues to 
require some form of respiratory support or oxygen therapy at 36 weeks corrected 
gestational age. Of babies born less than 26 weeks gestational age, who survived to 36 weeks 
corrected gestational age, 55% had chronic lung disease. Four percent (4%) of surviving 
registered babies born less than 32 weeks gestational age required prolonged oxygen 
therapy and went home on oxygen treatment. (ANZNN, 2009) 
Local data from the Royal Brisbane and Women's Hospital (Cartwright, 2003; Cartwright, 
2004; Cartwright, 2005; Cartwright, 2006; Cartwright, 2007) from 2003 to 2007 inclusive for 
163 infants admitted of less than 26 weeks gestational age showed that: 
 99% were intubated and ventilated; 
 the mean length of time of ventilation was 36 days (2001-2007 data only); 
 27% had an air leak; 
 74% had chronic lung disease; and 
 16% went home on oxygen treatment. 
Three quarters (74%) of the EPICure cohort (Hennessy, 2008) had moderate to severe 
chronic lung disease; 36% went home on oxygen treatment. By two years of age almost two 
thirds of the cohort required hospital admission at least once for a respiratory illness. At six 
years many of the cohort had continuing respiratory symptoms, abnormal respiratory 
findings on physical examination and/or abnormal respiratory function tests. 
2.3 Non-respiratory morbidity 
Non-respiratory morbidity is very common in extremely preterm infants. This includes a 
number of different organ systems. The major morbidities include patent ductus arteriosus, 
necrotising enterocolitis, retinopathy of prematurity, intraventricular haemorrhage and 
periventricular leucomalacia.  
Extremely preterm infants that survive also require a prolonged hospital stay (even when 
this is not because of respiratory disease). The long-term sequelae of extreme prematurity 
can include adverse neurodevelopmental outcomes such as developmental delay, cognitive 
and learning impairment, cerebral palsy, blindness and deafness. 
Local data from the Royal Brisbane and Women’s Hospital from 2003 to 2007 inclusive 
(Cartwright, 2003; Cartwright, 2004; Cartwright, 2005; Cartwright, 2006; Cartwright, 2007) 
shows that of the 163 infants admitted of less than 26 weeks gestational age: 
 61% had a patent ductus arteriosus; 
 46% had an intraventricular haemorrhage and/or periventricular leucomalacia; 
 16% had a severe intraventricular haemorrhage; 
 57% had retinopathy of prematurity (20% had severe retinopathy of prematurity); and 
 the average length of stay in hospital was 127 days. 
2.4 Mechanical ventilation 
The management of lung disease in extreme preterm infants is predicate on the principle 
that respiratory support be provided until there is sufficient resolution of the lung disease 
and respiratory support is no longer required. Mechanical ventilation is a means of 
providing such support for babies with severe lung disease or extreme prematurity. 
Ventilation is provided to support gas exchange, i.e., oxygenation and carbon dioxide 
clearance.   
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The types of mechanical ventilation include- 
1. Conventional mechanical ventilation – pressure controlled, time-cycled ventilation, 
including: 
 intermittent positive pressure ventilation; 
 synchronised intermittent positive pressure ventilation; 
 volume-targeted ventilation. 
2. High frequency ventilation. 
3. Volume-controlled ventilation – rarely used in neonates. 
As can be seen from the above data the more usual forms of mechanical ventilation often 
don’t work (babies still die from their extremely immature lungs and lung disease) and 
often damage the lungs causing significant respiratory morbidity (lung injury and 
subsequent chronic lung disease). 
There is still a need for alternative forms of respiratory support that can provide ventilation 
and adequate gas exchange without damaging the lungs or put the infant at increased risk 
of brain injury.  
3. The risk of brain injury in the extremely preterm infant  
The developing brain is especially prone to injury and extremely preterm infants are at 
significant risk; this can result in long-term disability. (Vohr, 1996) The most common forms 
of brain injury arising in preterm infants are intraventricular haemorrhage, periventricular 
leukomalacia and other forms of white matter injury. Disturbance of cerebral blood flow 
have been demonstrated to substantially increase the risk of brain injury. 
The germinal matrix lies in the subependymal region at the floor of the lateral ventricle and 
this is the site of intraventricular haemorrhage. It is especially prone to both under perfusion 
and over perfusion. The vascular structure of this region predisposes to damage from 
ischaemia and later reperfusion and/or over perfusion with subsequent venous 
haemorrhage. (Takashima, 2009) With severe grades of intraventricular haemorrhage there 
is additional haemorrhage in the periventricular white matter; both focal injury and more 
diffuse white matter injury. The white matter is especially susceptible because of the 
vulnerability of the glia (especially premyelinating oligodendrocytes) which is gestational 
age dependant. Also the periventricular area has a blood supply which is immature and 
watershed. The white matter is also particularly prone to hypoperfusion. (Takashima, 2009; 
Volpe, 2009a; Volpe, 2009b) 
Given the vulnerability of the brain of the extremely preterm infant to both under and over 
perfusion it is not surprising that fluctuations of cerebral blood flow cause the most overt 
types of brain injury. (Ballabh, 2010; Perlman, 2009) Factors that lead to low cerebral blood 
flow also increase the risk of intraventricular haemorrhage and similarly those factors that 
lead to increased cerebral blood flow also increaese the risk of intraventricular haemorrhage. 
(Bassan, 2006) Periventricular leucomalacia can be easily produced in animal models of 
cerebral ischaemia. (Yoshioka, 1994; Ohyua, 1999) 
Increased cerebral blood flow velocity increases the incidence of intraventricular 
haemorrhage and extension of existing intraventricular haemorrhage. (Van Bel, 1987) Low 
cerebral blood flow states increase the risk of intraventricular haemorrhage. (Kluckow 2000;  
du Plessis, 2008) The strongest link exists with the development of intraventricular 
haemorrhage and more variability in cerebral blood flow. (Vohr, 1996; Van Bel,  1987; 
Mullaart; 1994, Kissack, 2004; Perlman, 1983; Takashima 1995) In the beagle pup model 
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rapid changes in cerebral perfusion easily produce subependymal haemorrhages 
indistinguishable from those seen in human preterm infants. (Ment, 1982) Keeping cerebral 
blood flow fluctuations to a minimum must be a prime aim when caring for extremely 
preterm infants to prevent intraventricular haemorrhage. (du Plessis, 2008; Wells, 1995) 
There are many factors that are known to alter cerebral blood flow in newborn infants (see 
Table 1). Because the preterm infant is more likely to have all the conditions listed in the left 
hand column of Table 1 it is not unreasonable to presume that fluctuations in cerebral blood 
flow are common particularly in the first few days of life. The preterm infant may also 
experience wide variations in cerebral blood flow because they do not have the normal 
autoregulation of cerebral blood flow. Thus periods of pressure-passive cerebral circulation 
are likely; the fluctuations in blood pressure that are common (Coughtrey, 1997) expose 
them to the extremes of cerebral blood flow and put them at risk of intraventricular 
haemorrhage. (du Plessis, 2008) 
 
Factor Effect 
Cerebral perfusion pressure 
 
- arterial BP 
 
- venous pressure 
increased perfusion pressure  increases CBF    
     … and vice versa 
- increased arterial pressure  increases CBF    
     … and vice versa 
- decreased venous pressure  increases CBF    
     … and vice versa 
PaCO2  increased PaCO2  increases CBF   … and vice versa 
PaO2 increased PaO2  increases CBF   … and vice versa 
Patent ductus arteriosus PDA with Left-to-Right shunt  decreases diastolic flow  
which  decreases CBF 
Hypoglycaemia decreased blood glucose  increases CBF 
Haemoglobin/blood viscosity increased viscosity  decreases CBF   … and vice versa 
Posthypoxic-ischaemic injury vaso-dilatation  increases CBF 
Brain metabolism/activity increased activity increases CBF   … and vice versa 
Autonomic nervous system increased parasympathetic drive  increases CBF   … 
and vice versa 
decreased sympathetic drive  increases CBF   … and 
vice versa 
Temperature mild-moderate hyperthermia  increases CBF 
hypothermia decreases CBF 
Table 1. Factors known to alter cerebral blood flow. (Perlman, 2009; Pryds, 1996; Ito, 2005; 
Vavilala, 2002; Greisen, 2005; Volpe, 1982; Leahy, 1980; Rahilly, 1980) (CBF – cerebral blood 
flow; BP – blood pressure; CVP – central venous pressure; PaCO2 – arterial carbon dioxide; 
PaO2 – arterial oxygen; PDA – patent ductus arteriosus) 
Many of the mechanisms listed in Table 1 put the extremely preterm infant at serious risk of 
significant cerebral blood flow alterations and intraventricular haemorrhage. Many 
respiratory problems or treatments are known to alter cerebral blood flow and/or increase 
the risk of intraventricular haemorrhage. These include: 
 intratracheal surfactant instillation (has been shown to increase or decrease cerebral 
blood flow velocity on Doppler ultrasound (Schipper, 1997; Saliba, 1994; Kaiser, 2004); 
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 asynchronous breathing mechanical ventilation (increases the variability of cerebral 
blood flow (Rennie, 1987); 
 endotracheal tube suction (has been shown to increase or decrease cerebral blood flow 
on near infrared spectroscopy (Limperopoulos, 2008;, Perlman, 1983; Kohlhauser, 2000); 
 endotracheal tube retaping increases cerebral blood flow on near infrared spectroscopy 
(Limperopoulos, 2008); 
 pneumothorax increases cerebral blood flow velocity on Doppler ultrasound, and 
increases the incidence of intraventricular haemorrhage. (Hill, 1982; Mehrabani, 1991) 
The alterations in cerebral blood flow during the administration surfactant are of particular 
concern because surfactant administration is comparable to the intratracheal administration 
of perfluorocarbon when starting partial liquid ventilation. Any perfluorocarbon 
administration effects on cerebral blood flow may increase the risk of brain injury in the 
extremely preterm infant. 
4. Liquid ventilation 
Extremely preterm infants with immature lungs and severe lung disease could benefit 
greatly from alternative forms of respiratory support. New techniques are required because 
conventional forms of mechanical ventilation often don’t work (babies still die from their 
extremely immature lungs and lung disease) and often damage the lungs causing significant 
respiratory morbidity (lung injury and subsequent chronic lung disease). 
Liquid ventilation has been touted as an alternative form of respiratory support for 
numerous and varied types of lung disease. Extremely preterm infants with immature lungs 
and severe lung disease could benefit greatly from the technique of partial liquid 
ventilation. Recent studies have renewed the promise that partial liquid ventilation has 
significant potential to alter the course of neonatal lung disease and respiratory morbidity. 
(Blassnig, 2009) 
4.1 History 
Artificial respiration using liquid ventilation in mammals was initially tried in mice in the 
1960s with solutions of saline in a hyperbaric environment. (Kylstra, 1962) Later 
experiments in the 1960s showed the successful use of fluorocarbons at atmospheric 
pressure for liquid ventilation in mice and cats. (Clark, 1966) At first experiments with 
perfluorocarbons were performed with immersion in perfluorocarbon liquid with 
spontaneously breathing animals or with gravity-assist bulk tidal flow of perfluorocarbon 
liquid. These techniques were not successful at removing sufficient carbon dioxide. (Kylstra, 
1966; Schoenfish, 1973; Shaffer, 1978) Over the ensuing decades the use of time-cycled, 
pressure-limited mechanical ventilators allowed the development of the method of total 
liquid ventilation. (Shaffer, 1975) Total liquid ventilation can maintain adequate gas 
exchange in animals. (Wolfson, 1990)  It has also been shown to improve lung function and 
gas exchange in experimental animal models of respiratory distress. (Shaffer, 1976; Shaffer, 
1984; Shaffer, 1983; Wolfson, 1992) In 1991 Fuhrman et al. (Fuhrman, 1991) introduced the 
method of perfluorocarbon associated gas exchange using functional residual capacity 
volumes of perfluorocarbon with conventional gas ventilation. This technique is now best 
known as partial liquid ventilation and it is this technique which is most promising for 
practical clinical application. 
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4.2 Partial liquid ventilation 
The technique of partial liquid ventilation entails pouring perfluorocarbon liquid into the 
endotracheal tube whilst ventilating the lung with gas ventilation (either conventional or 
high-frequency) continues. Customarily the starting volume of perfluorocarbon instilled 
into the lungs equals the estimated functional residual capacity and the perfluorocarbon is 
usually given slowly over 10 to 20 minutes. Repeated doses of perfluorocarbon are then 
given at intervals to keep a fluid level in the endotracheal tube at a positive end expiratory 
pressure (PEEP) of zero. Repeat doses are necessary because the functional residual capacity 
will increase as the liquid recruits collapsed alveoli, and to replace losses due to 
evaporation. Stopping partial liquid ventilation is achieved by ceasing further instillation of 
perfluorocarbon to allow it to evaporate into the expired gases. The technique is the same 
when used with high-frequency ventilation. 
Perfluorocarbon liquids are a group of chemicals that are formed from the fluorination of 
organic compounds such as alkanes. They are odourless and colourless, and are chemically 
and biologically inert. Perfluorocarbons are almost insoluble in lipid and insoluble in water. 
They are more dense than water and soft tissue. Perfluorocarbon liquids can dissolve more 
than 20 times the oxygen, and three times the carbon dioxide, than water. They have a low 
surface tension and low viscosity, and most evaporate faster than water. (Shaffer, 1992; 
Degraeuwe, 1995) 
The physical characteristics of perfluorocarbon liquids (see Table 2) determine the effects of 
partial liquid ventilation (Figure 1). During normal breathing and gas ventilation the inert 
gas nitrogen carries oxygen and carbon dioxide. During liquid ventilation perfluorocarbon 
replaces nitrogen as the carrier of oxygen and carbon dioxide. Perfluorocarbon liquids have 
a high oxygen carrying capacity and high solubility for carbon dioxide. (Shaffer, 1992; 
Meaney, 1997) The perfluorocarbon liquid is oxygenated and carbon dioxide removed by 
means of bulk tidal flow of gas provided by the gas ventilator. This occurs for either 
conventional or high frequency ventilation. The movement of perfluorocarbon in small 
peripheral airways is facilitated by its low viscosity. 
The surface tension of perfluorocarbon liquids is low, (Shaffer, 1992) at around 15 to 18 
millinewton per metre (mN/m). When the perfluorocarbon liquids goes into the lung the 
air/liquid alveolar interface (which in surfactant deficiency has a high surface tension of up 
to 50 mN/m (von Bismarck, 2007)) is abolished and surface tension decreases. This increases 
compliance and therefore alveolar recruitment improves. This allows the use of lower 
ventilator pressures and smaller tidal volumes; with reduction of barotrauma and volu-
trauma respectively. Perfluorocarbons do not disturb natural surfactant production (Cleary, 
1997) and they do not wash surfactant out of the lungs. (Rüfer, 1970; Modell, 1970) 
Compared to water and soft tissue perfluorocarbon liquids have a high density (Shaffer, 
1992) and will therefore mechanically recruit collapsed alveoli. This happens preferentially 
in the dependant portions of the lung therefore decreasing intra-pulmonary shunting by 
improving ventilation/perfusion matching. (Kelly, 1997)  
Partial liquid ventilation has been known to have some anti-inflammatory effects. These 
were thought to be due mainly to the less injurious nature of liquid ventilation. However, it 
is now clear that perfluorocarbons have some direct anti-inflammatory action on cells (such 
as alveolar macrophages). Also this direct anti-inflammatory effect goes further than the  
perfluorocarbons acting as a simple barrier. (Heard, 2000) There is direct inhibition of the 
inflammatory response of alveolar macrophages in contact with perfluorocarbon liquids. 
(Smith, 1995; Thomassen, 1997) A recent study has shown that the disruption of lung 
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development in newborn rats, caused by hyperoxia, can be prevented by a single daily dose 
of perfluorocarbon liquid into the lungs.  (Blassnig, 2009) 
 
 
Fig. 1. The mechanical effects of partial liquid ventilation on respiratory function. (Davies, 
2011) (PaCO2 – arterial carbon dioxide; PaO2 – arterial oxygen; PBF – pulmonary blood flow; 
PFC – perfluorocarbon; PIP – peak inspiratory pressure; Q – perfusion; V –ventilation) 
4.3 Animal studies 
Partial liquid ventilation has been touted as an alternative form of respiratory support for 
many types of lung disease because it improves gas exchange and lung function in the 
diseased and injured lung. Many animal studies using various models of lung injury and 
surfactant lack have shown improvement in oxygenation, carbon dioxide clearance and lung 
compliance. (Foust, 1996; Tutuncu, 1993; Smith, 1997a; Leach, 1993; Leach, 1995; Curtis, 
1994a; Curtis, 1994b) Partial liquid ventilation is more effective in improving gas exchange 
and lung function than surfactant alone. (Leach, 1995) There is significantly less damage on 
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lung histology to lungs after partial liquid ventilation. (Foust, 1996; Smith, 1997a) Lower 
peak inspiratory pressures can be used to achieve adequate tidal volumes. (Degraeuwe, 
1996) Partial liquid ventilation decreases intra-pulmonary shunting. (Zobel, 1996) Partial 
liquid ventilation increases oxygenation when combined with nitric oxide when treating 
pulmonary hypertension. (Zobel, 1996) 
Most of the above studies have shown benefits of partial liquid ventilation over a few hours. 
Two studies have shown that it is feasible to use partial liquid ventilation for longer periods. 
Neonatal piglets with normal lungs have been ventilated for 24 hours with stable ventilation 
and blood gases with no haemodynamic deterioration. (Salman, 1995) Newborn piglets with 
surfactant deficiency demonstrated improved oxygenation and lung histology with up to 20 
hours of partial liquid ventilation. (Smith, 1997a) 
 
 Saline FC-77 Perflubron 
Density 
(g/mL)* 1.0 1.78 1.93 
Kinematic viscosity 
(centistokes)* 1.0 0.8 1.10 
Vapour pressure 
(mmHg)† 47 85 11 
Surface tension 
(mN/m)* 72 15 18 
Oxygen solubility 
(mL/100 mL)* 3.0 50 53 
Carbon dioxide solubility 
(mL/100 mL) † 57 198 210 
Table 2. Physical properties of two perfluorocarbon liquids compared with saline.  
(* 25°C; †37°C) 
Partial liquid ventilation has also been used with high frequency ventilation. Animal studies 
investigating the effects of partial liquid ventilation with high frequency ventilation have 
shown the combined technique provides good gas exchange. (Smith, 1997a; Baden, 1997, 
Mrozek, 1998; Smith, 1997b; Sukumar, 1998) Smith et al. (Smith, 1997b) comparing various 
methods of high frequency partial liquid ventilation, showed that those forms of high 
frequency ventilation which allow volume recruiting manoeuvres, such as the addition of 
intermittent conventional breaths, gave superior gas exchange. It seems that, with the use of 
strategies aimed at maximal alveolar recruitment, high frequency partial liquid ventilation 
may not confer any additional benefit over high frequency ventilation alone. Davies et al. 
(Davies, 1999) demonstrated that if maximal recruitment is obtained with high frequency 
ventilation prior to starting high frequency partial liquid ventilation that the addition of 
partial liquid ventilation did not further improve oxygenation.  
4.4 Human studies 
4.4.1 Adult 
A Cochrane systematic review (Davies, 2004a) of partial liquid ventilation in adults with 
acute lung injury and acute respiratory distress syndrome found one randomised, 
controlled trial. (Hirschl, 2002) Another randomised, controlled trial has since been 
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published. (Kacmarek, 2006) There were no differences, in either study, in any clinically 
relevant outcomes in patients ventilated with partial liquid ventilation compared with 
conventional ventilation. 
4.4.2 Paediatric  
The Cochrane systematic review (Davies, 2004b), updated in 2009, of partial liquid 
ventilation in children with acute lung injury and acute respiratory distress syndrome found 
only one randomised, controlled trial as yet unpublished. (Fuhrman, 1998) This trial abstract 
report showed results from a clinical trial that was stopped early on paediatric acute 
respiratory distress syndrome (ARDS). The protocol underwent a number of changes during 
the trial which resulted in three different sets of inclusion criteria. The final set, with 
liberalised inclusion criteria, had an unexpected decrease in mortality in the control group 
so the trial was stopped to allow full data analysis to determine the safety of partial liquid 
ventilation in this group of patients. There were 182 patients enrolled (less than 20% of the 
target numbers) with an overall mortality of 24/91 (26%) in the partial liquid ventilation 
group and 18/91 (20%) in the conventional mechanical ventilation group. The authors 
concluded that partial liquid ventilation with perflubron was safe, however the trial was not 
powered to detect real differences in mortality and ventilator free days. 
4.4.3 Neonatal  
There have been several published reports of uncontrolled studies on the use of partial 
liquid ventilation in human neonates. (Meaney, 1997; Greenspan, 1989; Hirschl, 1995; 
Pranikoff, 1996; Garver, 1996; Leach, 1996; Bruch, 1997) 
Pranikoff et al. (Pranikoff, 1996) reported the use of partial liquid ventilation in four infants 
with congenital diaphragmatic hernia, all of whom were on extra-corporeal life support at 
the time. There was improved oxygenation and total lung compliance with haemodynamic 
stability and no acute adverse effects. 
Leach et al. (Leach, 1996) reported the use of partial liquid ventilation in 13 preterm infants 
from 24–33 weeks gestational age who had severe respiratory distress syndrome and failing 
conventional therapy. Ten infants had from 24 to 72 hours of partial liquid ventilation with 
improvement in oxygenation and lung compliance. Six of the 10 survived to 36 weeks 
corrected age. The partial liquid ventilation reportedly well tolerated without significant 
haemodynamic disturbance. 
Two randomised controlled trials have been started in newborn infants but both were 
stopped before reaching their targeted numbers. Both remain unpublished. Hirschl wrote in 
a review on liquid ventilation of a randomised, controlled trial comparing conventional 
mechanical ventilation with partial liquid ventilation in preterm infants with severe lung 
disease. (Hirschl, 2004) Twenty-four patients were recruited to the study: 8 of 13 (62%) in the 
partial liquid ventilation group survived and all in the conventional ventilation group 
survived. Hirschl wrote that “This study was placed on hold concomitant with 
discontinuation of the paediatric trial and has not been resumed.” (Hirschl, 2004)  In another 
review Field wrote of a randomised, controlled trial where partial liquid ventilation was 
used in mature infants with respiratory failure; he wrote that “Twenty-four subjects were 
randomized before recruitment was unexpectedly and inexplicably suspended. The results 
have never been published.” (Field, 2002) 
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5. Perfluorocarbon liquid instillation and the effect on cerebral blood flow 
As discussed above one of the concerns with the use of partial liquid ventilation in 
extremely preterm infants is its possible effect on cerebral blood flow and the potential to 
cause brain injury, especially during the initial dosing of perfluorocarbon into the lungs at 
the start of partial liquid ventilation. It may well be that any of the benefits of partial liquid 
ventilation are outweighed by an increase in the risk of brain injury. 
Davies et al (Davies, 2010a; Davies, 2010b) studied the effects of perfluorocarbon dosing, 
when initiating partial liquid ventilation, on haemodynamics and cortical cerebral blood 
flow in preterm lambs. They showed that compared with preterm lambs continuing to be 
ventilated with conventional gas mechanical ventilation, lambs that received a dose of 
tracheal perfluorocarbon liquid at the start of partial liquid ventilation had an increase in 
their cortical cerebral blood flow. This could not be reasonably explained by any related 
changes in haemodynamics or oxygenation. The lambs that had 30 mL/kg of tracheal 
perfluorocarbon had a minimal increase in arterial carbon dioxide over the 30 minute 
observation period, although arterial carbon dioxide was not measured continuously and 
the difference was not statistically significant. Overall, three different loading doses of 
perfluorocarbon liquid were studied: 20, 30 and 40 mL/kg. (Davies, 2010a; Davies, 2010b) 
There were no significant haemodynamic changes during perfluorocarbon dosing in any of 
the three different doses in preterm lambs; and whilst the cortical cerebral blood flow was 
increased in all three groups there was no difference between groups. 
Davies (Davies, 2011) reported further studies in a rabbit model designed to investigate the 
effects of different dosing strategies on cerebral blood flow. These studies confirmed that 
when the dose of perfluorocarbon was given into the trachea at the start of partial liquid 
ventilation cerebral blood flow increased. The cerebral blood flow increased regardless of 
the volume of the dose of perfluorocarbon; either 10 or 20 mL/kg. Furthermore, if the 
arterial carbon dioxide was closely monitored and the ventilation adjusted to maintain 
target arterial carbon dioxide, or volume-controlled ventilation was used, then there was no 
increase in cerebral blood flow. There was no significant advantage in varying the duration 
of administration of the dose of perfluorocarbon within the range from 10 to 20 minutes, 
although it is probably best to avoid giving the dose over 5 minutes or less. There was no 
benefit in giving the dose of perfluorocarbon through a secondary lumen at the distal tip of 
the endotracheal tube. With differences in cerebral blood flow there were also differences in 
some of the variables that may explain these differences. There were no statistically 
significant differences seen in arterial carbon dioxide. Although, on the two occasions where 
the differences in arterial carbon dioxide were almost statistically significant there were 
significant differences in either carotid flow or cortical cerebral blood flow or both. On one 
of those occasions the differences in pH were statistically significant and the changes in 
arterial carbon dioxide mirrored changes in pH, as would be usual. There were associations 
between increasing cerebral blood flow (or its variability) and factors measured that might 
explain those increases. In those situations where cerebral blood flow were increased there 
were also consistent increases in blood pressure and arterial carbon dioxide, and decreases 
in arterial oxygen. The increases in arterial carbon dioxide were associated with decreases in 
tidal volumes delivered during perfluorocarbon dosing. The most compelling reason that it 
was simply decreased tidal volumes that caused increased arterial carbon dioxide was that 
during those dosing strategies where the tidal volumes did not decrease (when using 
volume-controlled ventilation or closely targeting arterial carbon dioxide by adjusting peak 
inspiratory pressure) the arterial carbon dioxide did not increase. 
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Burkhardt et al (Burkhardt, 2002) report the only other study that investigated the effects of 
perfluorocarbon dosing on surrogate measures of cerebral blood flow: cerebral 
concentration of total and oxygenated haemoglobin using near infrared spectroscopy. The 
cerebral concentration of oxygenated haemoglobin decreased initially (at 1 minute) when 30 
mL/kg was given extremely rapidly (over about 40 seconds), with return to baseline by 3 
min and an increase after 5 min. There was no decrease with 30 mL/kg given slowly (over 
about 16 minutes) nor when 10 mL/kg was administered. The cerebral concentration of 
oxygenated haemoglobin and the total cerebral haemoglobin concentration increased when 30 
mL/kg of perfluorocarbon was given but not with 10 mL/kg. Similarly in both 30 mL/kg 
groups the arterial carbon dioxide increased and arterial oxygen decreased but not in the 10 
mL/kg group. There was no control group, therefore conclusions cannot be drawn about the 
effect of perfluorocarbon dosing compared with gas ventilation alone. The study design makes 
direct comparisons between the two volumes of perfluorocarbon given difficult because the 
doses were also given over different durations. Interpretation is also difficult as they did not 
measure cerebral blood flow directly, did not record and report real-time haemodynamic 
variables during the perfluorocarbon liquid dosing, and only reported changes in cerebral 
oxygenation at discrete time points. Burkhardt et al (Burkhardt, 2002) concluded that giving 
perfluorocarbon extremely rapidly (20-30 times faster than the fastest dosing studied by 
Davies (Davies, 2011)) is not recommended because of the decrease in cerebral blood flow (as 
determined by total cerebral haemoglobin concentration) during perfluorocarbon dosing. 
From the results of the above studies we can surmise that perfluorocarbon should best be 
administered whilst either monitoring arterial carbon dioxide continuously during 
perfluorocarbon dosing and keeping it under tight control or using volume-controlled 
ventilation. This will prevent any decrease in arterial blood pressure or oxygenation, or any 
increase in arterial carbon dioxide. This in turn will prevent any disturbance of cerebral 
blood flow. The lowest possible dose-volume of perfluorocarbon should be used (e.g., 10 
mL/kg or smaller, larger volumes may be acceptable but shouldn’t be given too fast), and 
the dose should not be given over 5 minutes or less. 
Given the availability of a suitable product, randomised controlled trials of partial liquid 
ventilation in neonates are both feasible and desirable. Now the design of such trials can 
incorporate some of the data from the studies summarised above and ensure that the dosing 
procedure is as safe as it can be for use in extremely preterm infants. 
6. Conclusions 
As is demonstrated by the above studies partial liquid ventilation has great potential to 
disturb cerebral blood flow and increase the risk of brain injury. If partial liquid ventilation 
is to be used in extremely preterm infants it should be safe. The best protection for the 
extremely preterm brain is to start partial liquid ventilation safely without disturbing 
cerebral blood flow. Given the potential for harm associated with perfluorocarbon dosing in 
the most susceptible of preterm infants it is encouraging to know that there are ways of 
giving perfluorocarbon that can mitigate any increase in cerebral blood flow. 
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1. Introduction 
Pulmonary edema (PE) remains one of the more common reasons for admission to the 
hospital. Pulmonary edema is either cardiac or non-cardiac. The cardiac causes of 
pulmonary edema occur because the cardiac pump function has failed and there is increased 
capillary hydrostatic pressure secondary to elevated pulmonary venous pressure. 
Cardiogenic pulmonary edema is the accumulation of fluid with a low-protein content in 
the lung interstitium and alveoli and occurs when the pulmonary venous and left atrial 
venous return exceeds left ventricular output. Most often this is due to left heart failure, 
cardiac valve disease, volume overload, kidney failure or cardiac tamponade. Non 
cardiogenic pulmonary edema (NCPE) is a condition that is associated with high morbidity 
and mortality. Pulmonary edema fluid accumulates in the lungs through damaged capillary 
endothelial cells and this leads to impaired gas exchange (oxygen and carbon dioxide) with 
hypoxia and respiratory failure. The best example of non-cardiogenic pulmonary edema is 
acute respiratory distress syndrome (ARDS) (Sartori et al, 2010). ARDS is a serious condition 
of hypoxia, bilateral lung infiltrates on chest roentgenogram with subsequent respiratory 
failure. The hallmark of ALI (acute lung injury)/ARDS on the cellular level is pulmonary 
capillary endothelial cell permeability and fluid leakage into the pulmonary parenchyma, 
followed by neutrophils, cytokines and an acute inflammatory response. It is associated 
with a high morbidity and 30-50% mortality. ARDS has multiple causes with the most 
common being sepsis or pneumonia, less common causes of ARDS with ensuing pulmonary 
edema are trauma or pancreatitis (Ware & Mathay, 2005). Other causes of NCPE in 
hospitalized patients are intravenous fluid with volume overload, neurogenic pulmonary 
edema, reperfusion pulmonary edema, re-expansion pulmonary edema, opiate overdose, 
salicylate toxicity. Less common, forms of NCPE are high altitude pulmonary edema 
(HAPE), immersion pulmonary edema and negative pressure pulmonary edema (NPPE).  
2. Increased permeability pulmonary edema 
NCPE causes direct injury to the lungs in several forms. Under normal conditions fluid 
outflow that occurs from the lung capillaries through tiny gaps in the vascular endothelial 
cell (EC) junction is removed from the interstitial space and returned to the circulation by 
the lymphatic system. Physiologically, the main forces regulating fluid balance in the lungs 
are the microvascular pressure of the capillaries. Fluid leaves the capillaries and enters the 
pulmonary interstitium in proportion to the net capillary hydrostatic pressure minus the net 
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osmotic pressure across the vessel wall. The formula for filtration across the pulmonary 
capillary semi-permeable membrane is  
Q=K-[CPmv-Ppmv)-(πmv-πpmv)] 
which is different from the systemic capillary fluid exchange. Q=net transvascular flow of 
fluid, K=membrane permeability, Pmv=hydrostatic pressure in the microvessels, 
Ppmv=hydrostatic pressure in the peri-microvascular interstitium, πmv=plasma protein 
osmotic pressure in the circulation, πpmv=protein osmotic pressure in the peri-
microvascular interstitium. This equation only reflects the known hydrostatic pressures 
without including the lymph hydrostatic pressure which has been studied but is unknown 
in relation to the Starling forces equation (Sartori et al, 2010). It is known that one of the 
main functions of the lymphatic system is to return plasma proteins from the interstitial 
tissue space to the bloodstream. Analyses of blood plasma and lymph have shown that all of 
the proteins that are found in the plasma are also found in the lymph although in lower 
concentrations (Ono et al, 2005). In normal circumstances, low pulmonary capillary 




Fig. 1. Representation of the pulmonary arterial and venous capillary barrier and lymphatic 
flow.  
Although hydrostatic pressures in the pulmonary arterial and venous system are known, 
the hydrostatic pressures of the interrelated pulmonary lymphatic system is unknown and 
largely unstudied. The illustration generously permitted by Dr. Davide Brunelli of Med-
ars.it. 
In some forms of NCPE such as ARDS disturbances of pulmonary capillary fluid balance 
and pulmonary permeability occur as a direct result of endotoxins and inflammation that 
cause disruption in the capillary EC barrier with barrier disruption and subsequent 
pulmonary venous congestion. As the volume excess initially enters the interstitium it is 
taken up by the lymphatic system to be returned to the vascular system. In normal 
circumstances the interstitial space can increase its volume by as much as 40% without 
resulting in pulmonary edema (Sartori et al, 2010). In pulmonary injury due to toxins or 
 
Non-Cardiogenic Pulmonary Edema 
 
527 
inflammation the fluid volume increase overwhelms the lymphatic drainage system and the 
hydrostatic forces become altered resulting in further injury to the pulmonary capillary 
endothelium. The result is persistent fluid accumulation that overwhelms the lymphatic 
drainage and tissue edema results. The final step occurs as the fluid volume overwhelms the 
hydrostatic forces and the excess fluid flows into the alveoli. The edema that is caused by 
the increasing fluid and vascular permeability is a hallmark of inflammation and tissue 
injury (Zimmerman & McIntyre, 2004). The edema formation can have severe consequences 
because the fluid and protein components in the edematous tissues and alveoli increase the 
diffusion barrier for oxygen and carbon dioxide with subsequent disruption of gas exchange 
thus precipitating hypoxia and respiratory failure. The rate of volume expansion is also a 
factor in pulmonary edema.  
Other forms of NCPE such as HAPE, immersion pulmonary edema and NPPE may occur 
due to greatly altered thoracic pressures and are thought to have a largely hydrostatic non-
inflammatory component (Fremont et al, 2007). The accelerated pulmonary edema that 
occurs with HAPE, immersion PE or NPPE is thought to be due to significant fluid shifts 
that come secondary to changes in intrathoracic pressure, and in the case of HAPE or 
immersion PE, possibly due to diminished atmospheric or oxygen inhalation pressures. 
Physiologically negative intrathoracic pressure is generated in the chest when a patient 
inspires against an obstructed airway. The rapid pressure change in the pulmonary venous 
circulation alters the transpulmonary fluid gradient. The increase in capillary hydrostatic 
pressure most likely causes capillary gap formation as well as transcellular fluid shifts. The 
fluid gradient is thus going from a high gradient to a low gradient. Although considered a 
second mechanism of the EC barrier disruption it is part of the capillary hydrostatic 
pressure. While it is unlikely that the rapidly resolved post obstructive PE and HAPE are of 
a different nature, it is more likely that all of the non-cardiogenic PE have the same 
hydrostatic mechanisms initially (Sartori et al, 2010 & Gantor et al, 2006). The NCPE in 
ARDS is ultimately a result of capillary permeability secondary to cellular damage, 
inflammatory cascades, and over inflation by mechanical ventilation resulting in endothelial 
permeability. The permeability from HAPE and scuba diving is not initiated by 
inflammation but rather stress failure occurring due to the increased pressures that occur at 
the capillary level in healthy subjects (Slade et al, 2001). The pulmonary capillary endothelial 
cell barrier is a semi-permeable membrane and is known to be an active biological interface 
between the blood and the surrounding tissue. The EC is a single layer of continuous 
endothelium lining the pulmonary capillaries and forms a single layer between blood and 
the pulmonary interstitium. The pulmonary capillaries have extremely thin walls to allow 
rapid exchange of respiratory gases across them (Costello et al, 1992).The endothelium 
modulates tone, growth, homeostasis and inflammation in the lungs and throughout the 
circulatory system (Ware & Matthay, 2005 & Umapathy et al, 2010). In NCPE due to diseases 
such as ARDS, the ensuing endotoxins and inflammatory markers induce capillary 
endothelial disarray and gap formations. This is followed by neutrophil chemotaxis, 
diapedesis and protein rich edema fluid leakage into the interstitial spaces. Inflammatory 
cascades are triggered and also enter into the interstitial milieu. As the capillary pressure 
increases there is damage of the capillary EC causing larger molecules such as proteins from 
the vascular space to flow into the interstitial space (Slade et al, 2001). NCPE in an ill patient 
with ARDS is a high protein pulmonary edema. The fluid/plasma ratio may be used to 
differentiate the etiology of pulmonary edema in NCPE and CPE. It is a measurement of the 
alveolar fluid, obtained by broncho- alveolar lavage (BAL), to the serum plasma during 
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acute pulmonary edema and has been shown in studies to be sensitive enough to 
differentiate a low protein fluid that results from CPE or NCPE in a patient without illness 
compared to a high protein ratio NCPE such as occurs with illness such as endotoxin 
induced ARDS (Fremont et al, 2001; Ware et al, 2010). The protein concentration in the 
pulmonary interstitium of ARDS exceeds 60% of the plasma value whereas the protein 
concentration in HAPE, reperfusion PE, neurogenic PE and other non ARDS causes is less 
than 45% (Fein et al, 1079 & Staub et al, 1967). The result is capillary injury with gap 
formation and high permeability of the EC barrier with an increase of protein rich edema 
fluid into the interstitial space. The resulting pulmonary interstitial protein remains elevated 
compared to circulating blood plasma. At this point there is no longer a “quick” resolution 
possible.  
 
Fig. 2. Schematic representation of the endothelial barrier in inflammatory pulmonary 
edema.  
NCPE causes direct injury to the lungs. The endothelial barrier is normally single layer of 
continuous endothelium lining the pulmonary capillaries. In ALI/ARDS the endotoxins 
recruited by the macrophages and neutrophils induce capillary endothelial disarray and gap 
formations. This is followed by neutrophil chemotaxis, diapedesis, proteases, cytokines and 
protein rich fluid into the interstitial spaces. 
3.  Neutrophils and molecular mechanisms in the endothelial and epithelial 
cell barrier in ALI/ARDS 
Neutrophils play an important role in the development of pulmonary edema associated 
with ALI/ARDS. It is well known that neutrophils are prevalent in ARDS pulmonary 
edema and are central to the pathogenesis (Bdeir et al, 2010). Initially pulmonary 
macrophages are activated and recruit circulating neutrophils to the pulmonary 
microvascular system and the injured capillaries. The interaction of the neutrophils and the 
endothelium is initiated by adhesion receptors and by soluble or membrane bound 
chemoattractants. Intercellular adhesion molecules-1 (ICAM-1) and other proteins are 
known to be present but the specific role of these molecules and proteins is unclear 
(Downey et al, 1999). Once the neutrophils become activated and move subsequently into 
the pulmonary parenchymal interstitium, they sequester and initiate an important 
component of the inflammatory response in endotoxin induced ALI/ARDS. This activation 
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and migration of neutrophils is a characteristic event in the progression of ALI and ARDS. 
Animal studies have shown that endothelial injury appears within minutes to hours after 
ALI initiation with resulting intercellular gaps of the EC. The EC gaps allow for 
permeability of fluid, neutrophils and cytokines into the pulmonary parenchymal space 
(Grommes & Soehnlein, 2011).  
The neutrophils that infiltrate the lungs and migrate into the airways express pro-
inflammatory cytokines such as TNF-α, IL-1β, IL-6 and contribute to both the endothelial 
and epithelial integrity disruption of the barriers (Bdeir et al, 2010; Grommes & Soehnlein, 
2011; Abraham, 2003). It has also been well documented that the percentage of neutrophils 
correlates directly with the alveolar-arterial PO2 difference in ALI/ARDS pulmonary edema 
(Weiland et al, 1986). Neutrophil sequestration is aided by chemotactic factors and by the 
adhesion molecules on both the neutrophils and capillary endothelial cells (Hasko et al, 
2006; Steinberg, 1994; Geerts et al, 2001). The activated neutrophils expressing IL-1β produce 
other pro-inflammatory cytokines after endotoxin administration. In fact, the removal of 
neutrophils after endotoxin administration almost entirely prevents an increase of IL-1β 
expression and attenuates endotoxin induced TNF-α. Neutrophils are the major source of 
IL-1β in murine models of the lung in ALI (Abraham, 2003). Another feature of the 
neutrophils that accumulate in the lung of murine models is increased activation of the 
transcriptional regulatory factor NF-кB. NF-кB is a protein complex that controls 
transcription of DNA and is involved in cellular responses to stimuli such as pulmonary 
edema due to ALI/ARDS. It is key in regulating the endotoxin induced immune response in 
neutrophils and produces increased amounts of pro-inflammatory cytokines whose 
transcription is dependent on NF-кB (Blackwell et al, 1996). Neutrophils also become an 
increasing liability in the edematous pulmonary interstitium as they release free radicals. 
The alveolar-capillary barrier is a very thin membrane allowing oxygen CO2 exchange for 
normal respiration. The major consequence of pulmonary edema is impaired gas exchange 
that interrupts the normal fluid exchange balance. The alveoli epithelium removes fluid by 
molecular mechanisms of sodium transport, however, the capillary endothelial barrier 
function has only incompletely defined pathways affecting the concurrent barrier 
disruption. Permeability of the EC in the capillaries with concurrent alveolar-capillary 
membrane damage and with leakage of fluid, neutrophils, proteases, cytokines and free 
radicals that all contribute to the ensuing pulmonary edema is a prominent feature of 
permeability edema and ALI/ARDS (Holter et al, 1986). The alveolar liquid clearance from 
the alveolus into the interstitium is based on active sodium transport largely through the 
highly regulated apical amiloride sensitive epithelial sodium channel complex (ENaC) with 
concomitant passive water transport and the Na+, K+ ATPase exchange (Elia et al, 2003; 
Folkesson & Matthay, 2006). The Na+, K+ ATPase exchange transports the alveolar liquid 
into the interstitium and ultimately into the lymphatic and blood vessels (Hamacher et al, 
2010; Lucas et al, 2009). However, these transport processes are often impaired in ALI or 
ARDS. 
It is likely that the induction of increased permeability of the pulmonary capillary bed is 
directly linked to reversible physical modifications of the pulmonary capillary endothelium 
(Kaner et al, 2000). The capillary endothelial regulation of endothelial permeability involves 
various pathways such as those involving reactive oxygen species (ROS), Rho GTPases, and 
tyrosine phosphorylation of junctional proteins all converge to regulate junctional 
permeability. They either affect the stability of junctional proteins or modulate their 
interactions (Lucas et al, 2009). The regulation of permeability at the junctions is mediated 
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by active communication between the proteins of the adherens junctions and the actin 
cytoskeleton. Actin mediated endothelial cell contraction is the result of myosin light chain 
(MLC) phosphorylation by MLC kinase (MLCK) in Ca2+/calmodulin- dependent manner. 
RhoA also potentiates MLC phosphorylation by inhibiting MLC phosphatase activity 
through its downstream effector Rho kinase (ROCK). As the actin/myosin driven 
contraction generates a contractile force it pulls VE-cadherin inward. This contraction will 
force VE-cadherin to dissociate from its adjacent partner causing endothelial gaps - the basic 
pathology in permeability pulmonary edema (Lucas et al, 2009).  
4. Serum Biomarkers in permeability edema and ARDS 
A complex progression of events is recognized in the development of permeability edema 
and ARDS but the exact nature of events is still an area of active study. A large variety of 
inflammatory mediators have been found to be elevated in ARDS including lung specific 
proteins, endotoxin binding proteins, tumor necrosis factor alpha (TNF-α), interleukins 
(ILs), chemokines and markers of endothelium activation such as adhesion molecules and 
von Willebrand factor antigen (VWF) (Tzouvelekis et al, 2005). A comprehensive review is 
beyond the scope of this article but some of the most widely known are discussed. There is 
an increased expression of the vascular endothelial growth factor VEGF gene in pulmonary 
edema. Although VEGF is widely expressed in the body, the highest level of expression in 
normal tissues is in the lung. Normally increased expression and angiogenesis is associated 
with lung tumors and has been studied as a target for therapy in lung cancer however VEGF 
also is known to stimulate actin stress fiber formation and new focal adhesions in 
endothelial cells suggesting a regulatory role in endothelial morphology (Kaner et al, 2000). 
A study by Kaner et al demonstrated that excess expression of VEGF within the murine lung 
was associated with increased permeability of pulmonary edema (Kaner et al, 2000). In 
addition to endotoxin effects on endothelial permeability there is strong evidence that 
cytokines such as tumor necrosis factor (TNF-α), interleukin (IL)-1β, IL-6, and IL-8 are 
associated with pulmonary edema. Shutte measured cytokine levels in patients with ARDS, 
severe pneumonia and cardiogenic pulmonary edema for comparison and found 
consistently higher levels of IL-8, IL-6 and TNF-α in the bronchoalveolar lavage fluid 
(BALF) and the serum of patients with ARDS and pneumonia compared to cardiogenic 
pulmonary edema (Schutte et al, 1996). Cytokines have various effects on activating 
endothelium inducing endothelial expression of adhesion molecules and leukocyte 
chemotaxis leading to a local inflammatory response in the lung. The cytokine, TNF-α 
induces macrophages and TH1 cells and activates ECs and macrophages (Braun et al, 2005). 
Studies have been conflicting as far as elevation of TNF-α in patients with ARDS pulmonary 
edema, for example, Bauer demonstrated that TNF-α concentrations were significantly 
higher in patients with ARDS than those of pneumonia or of the control subjects (Bauer et al, 
2000). Others, such as Hyers have found variability in the elevation of TNF-α, however, 
there is speculation that TNF-α is an acute phase cytokine and the timing of studies is 
important for its evaluation (Hyers, 1991). Although Bauer found that the TNF-α levels were 
significantly elevated it was also speculated that the elevation was more related to the 
severity of the lung disease and could not be extrapolated as a possible diagnostic marker 
for ARDS (Bauer et al, 2000). TNF-α is a known acute phase reactant and is also a cytokine 
involved in systemic inflammation. It is able to induce apoptotic cell death, inflammation, 
and inhibit tumorgenesis and viral replication. TNF-α is produced mainly by macrophages 
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but can also be produced by other cells including endothelial cells (Schutte et al, 1996). 
Large amounts of TNF-α are released in response to LPS endotoxin, bacterial products and 
IL-1. TNF- α works with IL-1 and IL-6 to produce actions on various organ systems (Schutte 
et al, 1996; Braun et al, 2005; Bauer et al, 2000). TNF-α also induces EC activation and barrier 
dysfunction both of which occur in the pathogenesis of pulmonary edema and ALI/ARDS. 
It can promote edema by TNF receptor dependent chemokine production and adhesion 
molecule expression and leads to neutrophil chemotaxis (Braun et al, 2005; Ward, 1996). It 
also causes a decrease in transendothelial electrical resistance across human pulmonary 
artery EC (HPAEC) (Petrache et al 2003). The pulmonary capillary EC have a balanced 
system between contracting and tethering forces that normally act to protect the EC barrier 
from paracellular gaps. The balancing forces depend on cytoskeletal components such as 
actin based microfilaments, intermediate filaments and microtubules. TNF-α causes 
contraction via the actin filaments and this results in the formation of gaps and EC 
permeability (Braun 2005). In pulmonary edema associated with ARDS, TNF-α can mediate 
acute inflammation and edema formation. It can also have a beneficial effect by increasing 
alveolar fluid clearance via an amiloride sensitive, cAMP independent mechanism to 
enhance alveolar fluid clearance. This is accomplished by binding to its receptors or 
activating Na+ channels in the epithelium (Fukuda et al, 2001). 
Other networks of cytokines regulate lung inflammation in lung injury and edema. 
Complement, C5a and or the membrane attack complex, C5b-9 can directly activate EC to 
up-regulate adhesion molecules (P-selectin) or act synergistically with TNF-α to up regulate 
I-CAM and E Selectin (Shutte et al, 1996 & Ward, 1996). IL-4 and IL-10 suppress TNF-α and 
can have a strong attenuating effect on TNF-α. Studies have shown that blocking IL-10 
increased TNF-α production, neutrophil recruitment and the intensity of lung inflammation 
(Ward, 1996). Although the role of cytokines in the pathogenesis of ARDS has been widely 
recognized, their importance in the clinical diagnosis has not been clearly defined. 
Recent studies have identified that the receptor for advanced glycation end products 
(RAGE) is activated by its ligands in many disorders including ALI/ARDS. RAGE and 
interaction with the high mobility group box-1 (HMGB-1)- one of its ligands- promotes local 
lung endothelial inflammation and evokes both local and systemic inflammation 
(Nakamura et al, 2011 & Wolfson et al, 2010). In vitro studies determined that RAGE is the 
primary receptor signaling HMGB-1 induced endothelial barrier disruption and endothelial 
gap formation in human pulmonary artery endothelial cells (Wolfson et al, 2010). Soluable 
RAGE (sRAGE) has also been noted in the plasma of patients with ARDS and it was 
investigated as a biomarker of severity and clinical outcomes in patients with ARDS. In 
addition sRAGE and HMGB-1 levels were elevated in non- survivors compared to survivors 
in ARDS (Nakamura et al, 2011). An analysis of biomarker levels in two randomized 
controlled trials of ventilator therapy for ALI was done and the biomarkers that were 
elevated were ICAM-1, von Willebrand factor, IL-8, soluble TNF receptor-1, and surfactant 
protein-D. It was concluded that combining three or more biomarkers may be useful for 
selecting a high risk ALI group of patients (Calfee et al, 2011). Biomarker identification of 
risk remains an area of intense research. 
5. Non-inflammatory NCPE 
Categories of NCPE that resolve more quickly than ARDS and NCPE due to infection, 
trauma or other medical illness are high altitude pulmonary edema (HAPE), Immersion 
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pulmonary edema (SCUBA diving and swimming) and negative pressure pulmonary 
edema (NPPE). Most commonly the non-inflammatory forms of NCPE occur in baseline 
healthy people although there may be a predilection to development of pulmonary edema 
in some people. However, there is no known way to predict who will develop pulmonary 
edema and who will not in the same circumstances. 
 
Fig. 3. Schematic representation of the endothelial barrier in Non-inflammatory Pulmonary 
Edema 
Non- inflammatory pulmonary edema may have an element of hemorrhage leading to a 
pink frothy tint but will not initially have an inflammatory secretion of cells. The pulmonary 
edema resolves quickly and the endothelial barrier is thought to accommodate hydrostatic 
changes that resolve quickly compared to toxin mediated changes that heal slowly and may 
develop fibrinous changes. 
6. HAPE 
HAPE is a life threatening form of NCPE that has a rapid onset in healthy people who 
venture to elevations above 8200feet. This occurs when the lower barometric pressures 
result in hypoxia, usually less than 90% SPO2 or 60 PaO2. Studies done at high altitude on 
patients who developed HAPE and compared to those who did not, have shown that 
pulmonary artery pressures are elevated and lead to a protein rich and mildly hemorrhagic 
edema. Leukocytes, cytokines, nitric oxide metabolites and eicosanoids are normal when 
compared to control subjects who did not develop HAPE (Swenson et al, 2002). The 
mechanism of the increased pulmonary vasoconstriction and resulting increased pulmonary 
pressures is not resolved. The mechanism is thought to be increased pulmonary and arterial 
capillary pressures second to hypoxic pulmonary vasoconstriction. Another effect is a non-
inflammatory increase in the permeability of the vascular endothelium. Some people are 
more susceptible to HAPE than others but the differentiating factors are not known. The 
most important treatment is to descend as soon as possible and provide oxygen therapy. 
Other treatments are Dexamethasone and nifedipine. Phosphodiesterase inhibitors are 
effective but the side effects worsen mountain sickness headaches (Maggiorini, 2010).  
7. Immersion PE  
Immersion PE that occurs in diving with self contained underwater breathing apparatus 
(SCUBA), and some triathlon athletes, combat swimmers (such as found in military 
missions) and breath hold divers is another type of non-inflammatory NCPE. Only about 1-
2% of immersion divers develop PE and studies have not shown clearly what makes some 
people susceptible. One study did show that women, hypertension, fish oil and asthma may 
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be factors that predispose to this condition (Miller III et al, 2010). The mechanism is poorly 
understood but reviews of cases have shown that the onset is rapid and that rapid 
improvement is also seen, similar to patients who develop HAPE (Slade et al, 2001). This 
observation lends credence to the probability that this is an acute but transient increase in 
pressure. The stress from the increased transalveolar pressure gradient that occurs with 
immersion is such that the non-cardiogenic capillary endothelium layer cell develops leaks 
(Slade et al, 2001). It has been shown that even asymptomatic dives result in an increased 
accumulation of extravascular lung water (Marinovic et al, 2010). They further 
demonstrated an increase in lung water, pulmonary artery pressure, NT-proBNP levels and 
decreased left ventricular contractility in healthy study volunteers who did not develop 
pulmonary edema. Immersion is known to increase preload and cold exposure increases 
both preload and afterload by vasoconstriction; it is possible that the changes could lead to 
damage in the pulmonary endothelium and lead to intrapulmonary redistribution of blood 
with regional overperfusion of some pulmonary capillaries and stress failure increasing 
capillary damage and permeability (Marinovic et al, 2010 & Pons et al, 1995). Hyperoxia and 
low tank pressures are other possible mechanisms that may damage the pulmonary 
endothelium and increase endothelial permeability the development of pulmonary edema 
in immersion PE. 
8. Negative pressure pulmonary edema  
Negative pressure pulmonary edema (NPPE) is pulmonary edema that occurs following an 
acute upper airway obstruction and may also be referred to as a post obstructive pulmonary 
edema. It often occurs in otherwise healthy patients. The most common cause is 
laryngospasm soon after extubation from an endo-tracheal intubation in about 0.1% in post 
anesthesia patients (Pathak et al, 2011). There are also case reports of NPPE after other 
causes such as foreign body, epiglottitis, tracheal secretions, upper airway tumors, obesity, 
obstructive sleep apnea, tumors (Fremont et al, 2007). Following an episode of obstruction of 
the airway there is a marked increase in negative intrathoracic pressure against the 
obstructed upper airway. The rapid increase in intrathoracic pressure causes a rise in 
venous return to the right heart, which increases pulmonary venous volume and pulmonary 
venous pressure which then increases the pulmonary capillary transmural pressure. 
Systemic pressures also rise due to catecholamine induced veno-constriction from anxiety, 
hypoxia and hypercarbia (Schwartz et al, 1999). Fremont et al have shown that the 
mechanism is due to hydrostatic changes with the fluid moving from high pressure in the 
pulmonary venous system to low pressure into the pulmonary interstitium and airspaces. 
Studies confirmed that the pulmonary edema fluid to plasma protein ratio were consistent 
with hydrostatic causes of acute fluid shifts and pulmonary edema. This causes an increase 
of blood flow (venous return) to the right heart increasing pulmonary venous pressure 
(Fremont et al, 2007). The treatment is resolving the obstruction, oxygen and either 
reintubation or if the patient is stable CPAP may be used. The issue is not volume overload 
and diuretics are not indicated (Kapoor, 2011). 
9. Clinical manifestation of non cardiogenic pulmonary edema 
Clinically non-cardiogenic pulmonary edema is a permeability edema. The Starling equation 
predicts that a change in permeability of the microvascular membrane will result in an 
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increase in the amount of fluid and protein that leaves the vascular space and enters the 
interstitial space. When the interstitial fluid increases in the interstitium then the outward 
movement continues and fluid enters the alveolar spaces through the tight junctions of the 
epithelium. Many entities are associated with permeability edema manifested as ARDS, the 
most common entities are sepsis, pneumonia, multiple blood transfusions, gastric 
aspiration, trauma, drug overdose and pancreatitis.  and others. Clinically NCPE prototype 
ALI/ARDS presents with progressive hypoxia and respiratory failure. Multi-organ failure is 
frequent and one of the reasons the mortality is so high. ARDS affects 200,000 people per 
year and has a mortality rate of 30-50%. This was initially described in the 1960s’ by Petty 
and Ashbaugh (Ashbaugh et al, 1967). The diagnosis is made by four clinical criteria, acute 
onset of bilateral chest infiltrates, hypoxia, no evidence of left atrial hypertension (or clinical 
manifestations indicating left heart failure) and a ratio of arterial oxygen to fraction of 
inspired oxygen (PaO2/FIO2 ratio) of 201-300 for ALI and less than 200 for ARDS (Bernard 
et al, 1994 & The Acute Respiratory Distress Syndrome Network, 2000). Due to the profound 
respiratory failure most patients require mechanical ventilation and care in the intensive 
care unit (ICU). The best therapeutic approach for ARDS permeability edema is to find and 
treat the cause. There is no pharmacological treatment for ARDS, the only “treatment” that 
has emerged since it was first described in 1971 is the ARDS-net trial protocol of low tidal 
volume mechanical ventilation. This is a strategy that is called “lung-protective ventilation”. 
The main benefit of lung-protective ventilation is to avoid further injury to the lungs from 
high tidal volumes often used for patients in the ICU as these large tidal volumes increase 
the injury and subsequently cause an increase in the permeability pulmonary edema in the 
injured lung. The standard tidal volumes used in ICU have been 10-15mg/kg for all 
mechanically ventilated patients, however, low tidal volumes of 6-8mg/kg are 
recommended for patients with ARDS. A mortality benefit was one of the primary outcomes 
demonstrated in the ARDS-net trial for patients with ARDS who are mechanically ventilated 
at these low tidal volumes (Matthay et al, 2002 & Marino 2007). Another aspect of NCPE and 
ARDS is heterogeneity of the lung parenchyma and the alveoli. The chest roentgenogram 
shows bilateral infiltrates that are difficult to distinguish from cardiogenic pulmonary 
edema and sometimes from pneumonia. The computed tomographic (CT) images are not 
necessarily diagnostic but in a patient with known ARDS shows that the lung edema and 
consolidation is not homogeneous but involves various lung regions, while other regions 
appear normal (Rouby et al, 2003). Alveolar over-distension from mechanical ventilation as 
well as repeated opening and collapse of the alveoli has been shown to cause lung injury 
initiating an increase in capillary stress and an increase in pro-inflammatory cytokine 
cascades (Matthay et al, 2002 & Slutsky &Tremblay, 1998). Hemodynamic evaluation of 
NCPE and ARDS requires careful ongoing evaluation, and may require monitoring cardiac 
filling pressures and cardiac output using a pulmonary artery catheter or currently, a non-
invasive evaluation is more likely to be used. Diuretic therapy is then tailored to achieve the 
lowest cardiac filling pressures that do not compromise cardiac output and systemic oxygen 
transport. The nature of the lung interstitial infiltration is an inflammatory process, so that 
diuretic therapy to remove fluid does not remove the inflammation. Fluid treatment versus 
diuresis is not necessarily the goal of treatment in NCPE secondary to ARDS (Marino, 2007). 
Ultimately the treatment is supportive care using the appropriate ventilator strategies, 
promoting oxygenation, and treating the multi organ failure that is often contributes to the 
mortality. Histologically in this acute phase of lung injury there is widespread interstitial 
and alveolar edema with an abundance of neutrophils, erythrocytes, macrophages, cell 
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debris, plasma proteins and strands of fibrin. At this phase there is injury to the capillary 
endothelium and denuding of the alveolar epithelium. If the patient survives this phase the 
pulmonary edema may completely resolve within a few months. Other patients with 
ALI/ARDS progress to a subacute phase over one to two weeks and may continue to have 
respiratory failure with hypoxia requiring mechanical ventilation. These patients develop 
fibrosis and capillary obliteration in the lungs, a condition called fibrosing alveolitis. These 
patients continue to progress with respiratory failure although they may recover from the 
initial event.  
Progress from bench to bedside is being made; the mortality from NCPE and ALI/ARDS 
has improved from the initial 60% or more to 30-50%. The establishment of the NIH ARDS 
Network for clinical trials has improved the quantity and quality of large multicenter 
clinical trials for ALI/ARDS patients. New research is continuing and tools such as genetic 
analysis, genomics and proteomics may offer more value for patients in the future. 
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1. Introduction 
High altitude pulmonary edema (HAPE) is a form of high altitude idiopathy that occurs in a 
minority of people upon either the first or subsequent exposure to high altitudes. It is 
triggered by a shortage of oxygen and certain other predisposing factors, all of which lead to 
a sudden increase in pulmonary arterial pressure, increase in lung blood volume, 
disturbance of pulmonary circulation, and leakage of fluid in microcirculation into the 
pulmonary interstitium and alveoli. The clinical symptoms of this condition include 
dyspnea and hacking cough. 
HAPE is a severe type of acute high altitude disease, typically occurring at altitudes above 
4,000 meters. However, cases have been reported at altitudes as low as 2,261 meters in 
Xining, China. HAPE is a rapid-onset condition that can progress and change quickly, 
especially during the first stage of high altitude exposure, usually within a week, peaking 
within three days. According to a report based on 332 cases, 63% of HAPE patients 
presented symptoms within three days, and the fastest onset was after only a few hours. 
HAPE occurs mostly in unacclimatized sea-level residents when they first ascend to high 
altitudes or acclimatized individuals ascending from lower to higher altitudes. It can also 
occur in long-term high altitude residents or high altitude natives undertaking excessive 
physical activities or in those who return to high altitudes after living in low-altitude areas 
for a period of time. HAPE patients can recover after short-term treatment and continue to 
stay at high altitudes. However, improper treatment may lead to negative effects. The 
incidence rate is closely related to the altitude, rapidity of exposure, season, the individual’s 
physical condition, and the intensity of activity. 
2. Epidemiology 
2.1 Incidence rate 
1. Population Incidence 
The incidence rate of HAPE varies significantly between China and the others country 
reports, for example it ranges between 0.15% and 9.9% in Chinese report. The incidence rate 
is higher in kids and teenagers than in adults. For instance, data collected from the Andes 
Mountain area of Peru reports that the incidence rate was 10% in children aged 2-12, 17% in 
teens aged 13-20, and 3% in adults over 21.  
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2. Hospitalization rate 
Due to the differences in location and population served, different treatment facilities have 
reported rather different hospitalization rate. The Menon hospital, at an altitude of 3,450 
meters, treated 101 HAPE patients over two years, accounting for 5-10% of all inpatients in 
the department of internal medicine; a hospital in Changdu (Tibetan), at an altitude of 3,200 
meters, treated 33 HAPE patients over 11 years, accounting for 0.37% of all inpatients in the 
internal medicine department and 6.28% of all inpatients with high altitude diseases; the 
General Hospital of the Tibet Military Region, at an altitude of 3,658 meters, treated 2,853 
HAPE patients from 1956 to 2005, accounting for 89.6% of all inpatients with high altitude 
diseases during the same time period. 
3. Age Distribution 
Reports from the Andes and Rocky Mountain areas show higher incidence in children, but 
occurrences in children below 2 years old are rare and the maximum age of all HAPE 
patients covered in these reports was found to be 53 years old. In the General Hospital of the 
Tibet Military Region, the youngest HAPE patient was 1 year old and the oldest one was 63 
years old. We think that HAPE can occur at any age, but children and young adults are 
more susceptible. 
4. Gender Differences 
HAPE can occur in both males and females. Many reports show higher incidence in males, 
mainly because more males travel to high altitude areas. In mountaineering and high altitude 
medical research teams, male participants are more common, hence a higher reported 
incidence of HAPE in males. Horrobin et al. mentioned that in Kenyan mountain areas there 
were many female mountaineers, none of whom developed HAPE. However Hultgren et al. 
reported that among 97 lifelong mountain residents, HAPE occurred mainly in females. 
5. Racial Differences 
It has been shown that there is no significant difference in HAPE incidence between 
Peruvian Indians and Caucasians in the plateau areas of Peru. However, some have 
suggested that the Sherpa of Nepal have a lower HAPE incidence than the Indians of Peru. 
They point out that the Indians have only inhabited the Andes for about 10,000 years, 
whereas the Sherpa, originally from the Tibetan Plateau, have lived in high altitude areas for 
several tens of thousands of years. Therefore, the Sherpa may be more adapted to high 
altitudes environment than Peruvian Indians. Our investigation found that, on the Tibetan 
Plateau, HAPE incidence in native Tibetans was lower than in Han immigrants. In the 923 
HAPE cases treated by the General Hospital of the Tibet Military Region over the past ten 
years, there was only one Tibetan patient. Recently we have retrospectively analyzed for 
severe acute mountain sickness of 3184 Inpatients cases in General Hospital of Tibet Military 
region Hospitalization from June 1956 to June 2005, and in which the incidence and clinical 
characteristics of native Tibetan plateau were analyzed.The results detected 24 cases of high 
altitude native Tibetan suffering severe cases of acute mountain sickness, high altitude 
pulmonary edema 21 cases and high altitude cerebral edema 3 cases in them, incidence of 
severe acute mountain sickness in native Tibetan population was 0.75% (24/3184). 
6. First and Repeated Exposure to High Altitudes 
Whether triggered by the patient’s first or a subsequent exposure to high altitude, HAPE onset 
usually takes place between one and seven days, but it can start as early as three hours or as 
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late as ten days after exposure. Occasionally, HAPE is triggered in high altitude residents by 
such factors as fatigue. For those who travel to high altitudes by plane, the typical time of 
HAPE onset is within three days. Data collected from Peru and the U.S. suggest that high 
altitude residents are likely to develop HAPE when returning to the plateau after spending 
typically one to three weeks on the plains. In Tibetan areas, HAPE tends to be triggered when 
residents spend typically three to six weeks on the plains before returning.  
7. Mode of Transportation to High Altitude Area 
Traveling to high altitude areas, whether on foot, by ground vehicle, or by airplane, can 
trigger HAPE. In recent years, as more people take airplane flights to the Tibetan Plateau, 
the number of HAPE patients who have arrived by plane has substantially increased. 
Among the 2,853 HAPE patients treated by the General Hospital of the Tibet Military 
Region between 1956 and 2005, 2,054 patients were traveled to Tibet by airplane. 
8. Occupation and Labor Intensity 
HAPE can occur in individuals of all occupations when they are exposed to high altitudes, 
but it is more common in those engaged in heavy physical labor. For instance, during the 
Qinghai-Tibet Highway, construction workers have a higher HAPE incidence than drivers, 
who in turn have a higher HAPE incidence than travelers taking rides. Those who are 
rapidly exposed to high altitudes and extreme fatigue are particularly susceptible to HAPE. 
Therefore, individuals engaged in physical activities at high altitudes, such as plateau 
mountaineering, alpine skiing, or traveling to high altitudes are all at risk for HAPE. In 
addition, HAPE is more likely to occur in young boys, as they tend to be more active and 
less willing to rest than young girls and adults.  
9. Season of Onset and Changes in Climate  
HAPE can occur in any season, but in general it is more common in the winter and spring. 
Earlier statistics from domestic show the onset of HAPE to be distributed mostly from 
November to March of the next year. More recent data suggest an increase in the prevalence 
of HAPE between January and October, mainly because there have been more people 
traveling to and from the plateau or engaging in high altitude activities during this period.  
10. Upper Respiratory Tract Infection and Acute mild mountain sickness 
Upper respiratory tract infection can also trigger HAPE. Among the 865 HAPE patients 
treated by a Tibetan hospital in Lhasa, 30% had already had a previous upper respiratory 
tract infection at the time of onset. It is suggested that upper respiratory tract infection may 
trigger HAPE because contracting an upper respiratory tract infection after reaching a high 
altitude substantially worsens the shortage of oxygen. 
A minority of those who show Acute mild mountain sickness (AMMS) may develop HAPE 
without prompt treatment. Among the 230 HAPE cases reported by a hospital in southern 
Xinjiang, 112 (47%) started out with AMMS. From this it can be concluded that, when 
developing acute or even minor AMMS or upper respiratory tract infection, one should rest 
and receive immediate treatment to prevent the condition from progressing to HAPE.  
11. Individual and Familial Susceptibility 
It has been reported that there are patients who develop severe HAPE more than two times, 
up to four times. Analysis on the 923 HAPE cases treated by a hospital in Lhasa showed that 
27% of the patients returning to high altitudes developed HAPE two or more times, two of 
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them even seven times. In our clinical experience we have seen one worker developing 
HAPE eight times. It is worth pointing out that some HAPE patients, when returning to 
high altitudes from the plain, may still develop HAPE again even if they take active 
measures to prevent it, such as bed rest, oxygen inhalation, and medicine. 
Some reports have shown that HAPE can co-occur in fathers and sons, brothers, and 
mothers and daughters. In Tibetan, Zhang reported HAPE occurring in three generations of 
one family, suggesting that familial and individual factors are involved in patients’ 
susceptibility to HAPE. Animal studies have also shown species and individual differences 
in susceptibility to HAPE. 
2.2 Fatality rate and cause of death 
1. Fatality Rate 
A collection of data showed that among 160 HAPE cases that occurred between 1958 and 
1965 in China, the fatality rate was 9.4%. In recent years, due to substantial improvements in 
medical conditions and the promptness of treatment, the fatality rate has decreased 
significantly. For instance, among the 923 cases of HAPE treated by the General Hospital of 
the Tibet Military Region in the northern Tibetan plateau, the fatality rate was 0.33%.  
2. Cause of Deaths 
When treated promptly, most HAPE patients can recover in three to five days. However, 
death still occurs occasionally, and the causes can be generally summarized as belonging to 
one of the following categories: 1) Delay in diagnosis or treatment due to poor 
transportation and substandard medical conditions in remote areas. 2) Deterioration of the 
patient’s general condition caused by undiagnosed and untreated  complications such as 
heart failure, shock, massive pulmonary embolism, severe lung infection, and cerebral 
encephaledema/encephalorrhagia. 3) Severe HAPE may cause instant death, and co-
occurring pulmonary embolisms or encephalorrhagia can also lead to death.  
In summary, the incidence of HAPE is closely related to factors such as the mode of 
transportation to high altitude regions, the rapidity of exposure to high altitudes, the 
altitude itself, the medical support received, and individual susceptibility. Fatigue, upper 
respiratory tract infection, and excessive mental stress are all important triggers of HAPE.  
HAPE mostly occurs at altitudes above 3,000 meters because there are more immigrants at 
these altitudes. HAPE is not clearly correlated with age or gender. With the increasing of 
knowledge on HAPE and improvements to medical conditions, the fatality rate of HAPE 
has become extremely low. 
3. Causes and predisposing factors 
HAPE is a disease that occurs at high altitudes, its main cause being scarcity of oxygen. All 
factors that aggravate oxygen shortage in the body lower the body’s tolerance to low oxygen 
levels, or add load to pulmonary circulation can trigger HAPE. The most common 
predisposing factors include cold, fatigue, and upper respiratory tract infection. 
1. Cold 
Cold is a basic feature of plateau weather. The temperature on the Tibetan Plateau is on 
average more than 20°C lower than the temperature at sea level on the same latitude. At 
night, wind blows downwards from the snow-covered mountaintops, further accelerating 
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the drop in body surface temperature and making the night at high altitudes especially cold. 
Under external conditions, extreme coldness accompanied by wind and snow, the body will 
speed up its metabolism and consume more oxygen. At the same time, sympathetic 
excitability will become elevated, increasing the venous blood return from the peripheral 
veins, especially those on the surface of the skin, increasing the load of pulmonary 
circulation. In addition, pulmonary arterioles contract, inducing or aggravating pulmonary 
hypertension and eventually triggering HAPE.  
2. Fatigue 
Physical labor can increase oxygen demand ten times. Physical labor further aggravates 
oxygen shortage. In addition, physical labor at high altitudes increases the release of 
catecholamine, and hyperventilation can cause respiratory alkalosis, decrease the 
concentration of PaCO2, and lead to venoconstriction in the systemic circulation and 
subsequent increases both in the cardiac output of the right side of the heart and in 
pulmonary blood volume. Physical labor may further increase the pulmonary arterial 
pressure and decrease the concentration of PaCO2. Those who engage in excessive mental 
labor may also be susceptible to HAPE due to bodily fatigue. 
3. Upper respiratory tract infection 
Upper respiratory tract infection often causes fever, which increases oxygen consumption. If 
complicated by bronchitis, causing coughing and an increase in bronchial secretions, it will 
affect pulmonary ventilation and cause damage to the alveolar epithelia, impeding the 
generation of surface-active substances. According to statistics from Lhasa, 30% of HAPE 
cases were triggered by upper respiratory tract infections; data from southern Xinjiang 
showed 29%.  
4. Excessive mental stress 
Mental stress, anxiety, and fear can increase the release of catecholamine, which in turn 
increases pulmonary arterial pressure and triggers HAPE. 
5. Rapidity of exposure to high altitudes 
Among those who quickly enter the plateau areas by ground vehicle or by plane without 
adaptation trainings, the incidence of HAPE is substantially higher than in those who come 
by slower means. This is because rapid exposure to high altitudes leads to acute oxygen 
shortage, in which the body does not have enough time to adapt and shows extremely poor 
tolerance to low oxygen levels. 
6. Sleep and hypnotic drugs 
During sleep, the horizontal position of the body increases pulmonary blood volume (500 
ml more than an upright position). The shallow breathing that takes place during sleep, 
especially the periodic or irregular breathing accompanied by temporary apnea can 
aggravate the oxygen shortage.  
The incidence of HAPE mainly depends on the altitude, temperature, and adaptability of the 
body. High altitudes, low temperatures, and failure to acclimate are three basic factors that 
trigger HAPE. Individuals may not develop HAPE when only one factor is present. With 
two factors, the incidence rate is still not high. However, when all three factors are present, 
one is much more likely to develop HAPE. The incidence rate will increase further if there 
are other coexisting conditions. Those who are exposed to high altitudes without a thorough 
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physical examination may have undetected organic cardiovascular diseases, organic 
diseases of the respiratory tract, liver, brain or kidney, malnutrition, or hypoproteinemia.  
4. Pathogenesis 
The incidence of HAPE is closely correlated with oxygen shortage at high altitudes. 
Currently, it is believed that the following processes are important: an excessive increase in 
the pulmonary arterial pressure, an increase in the permeability of the pulmonary 
capillaries, and impairment in alveolar epithelium water clearance. Among these three, an 
excessive increase in the pulmonary arterial pressure is the key link. 
4.1 Excessive increase in the pulmonary arterial pressure 
In 1904, Plumier et al. observed that low oxygen levels could lead to pulmonary 
hypertension. In 1964, Hultgnen performed right cardiac catheterization on four acute 
HAPE patients and found that in both the clinical and the recovery periods their pulmonary 
arterial pressures were significantly higher than that of control subjects at the same altitude, 
but their right arterial pressures, pulmonary venous pressures, and pulmonary capillary 
pressures were all essentially normal. There are several ways in which hypoxia that occurs 
at high altitudes can lead to pulmonary hypertension. 
1. Pulmonary vasoconstriction caused by hypoxia 
Hypoxic pulmonary vasoconstriction can redirect blood flow from low-oxygen alveolar 
regions to alveoli with higher oxygen content, which improves the ventilation/perfusion 
ratio and gaseous exchange, allows sufficient oxygenation of the blood, and increases 
arterial partial pressure of oxygen. However, pulmonary hypertension over a long period of 
time can also cause a series of pathophysiological changes and become an important 
pathologic basis of the initiation and development of HAPE. 
Studies on the mechanisms of hypoxic pulmonary vasoconstriction have demonstrated that, 
at low oxygen levels, the calcium concentration and transmembrane inflow of calcium ions 
in the pulmonary arterial smooth muscle cells are both significantly increased. As hypoxia 
the distribution of ions across the membranes of the pulmonary arterial smooth muscle cells, 
calcium and sodium ions flow into the cells and potassium ions flow out, causing the resting 
membrane potential to decrease, approaching its excitation threshold. This depolarization of 
the pulmonary arterial smooth muscle cells leads to increased reactivity of the pulmonary 
vessels and increased tension in the pulmonary arterioles and pulmonary arteriolar 
contraction. Some investigators believe that hypoxia directly changes the transmembrane 
potential of the pulmonary artery smooth muscle cells, leading to calcium ion inflow and 
decrease of excitation threshold of these cells, which then causes the smooth muscles of the 
arterioles to contract. In addition, vasoactive substances such as prostaglandin, 
thromboxane A2, angiotonin, and histamine may serve as regulators or synergists in hypoxic 
pulmonary vasoconstriction. However, persistent pulmonary hypertension caused by 
hypoxia may involve many vasoactive substances, the importance of each varying 
depending on the specific conditions. 
Hypoxic pulmonary vasoconstriction doubtlessly leads to pulmonary hypertension. As to 
how the pulmonary hypertension causes HAPE, currently there are three hypotheses. 
a. Regional maldistribution of blood flow. It has been proposed that when those who are 
sensitive to hypoxia at high altitudes are exposed to low-oxygen environments, their 
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muscle arterioles contract rigorously and precapillary resistance increases, while their 
non-muscle arterioles expand under pulmonary hypertension. The sudden increase in 
the hydrostatic pressure in the afflicted areas, plus other factors, can cause HAPE. As 
the changes described above occur in some but not all pulmonary arterioles and 
capillaries, the pathological changes manifested in the HAPE are usually regional, in 
accordance with the patchy distributions of edema in HAPE observed via X-ray. 
b. At high altitudes, as hypoxia leads to sudden increases in pulmonary arterial pressure, 
this high pressure in turn causes closed capillaries to instantly open. The abrupt 
increase in the capillary pressure then causes fluid to leak out.  
c. It has been proposed that fluid does not leak out through the capillaries but rather 
directly through the walls of pulmonary arterioles under the pulmonary hypertension 
caused by hypoxia. 
2. Increases in the resistance to pulmonary venous return 
The left ventricle is a relatively large, muscular organ that needs to overcome the high 
pressure and high resistance of systemic circulation to pump blood. At high altitudes, when 
oxygen shortage is minor, the body can employ a series of adaptive mechanisms on levels 
ranging from the systemic to the cellular to alleviate the damage to myocardia caused by 
hypoxia. However, when oxygen shortage is severe (such as may occur in cases of rapid 
ascent, excessive physical activity, and severe cold), there is no time for the body to set up 
these adaptive mechanisms of antihypoxia on the cellular level. In this case, hypoxia will 
cause direct damage to myocardia, especially those on the left side of the heart. Although 
left heart failure is not the main cause of HAPE, in clinical situations, cardiac agents have 
proven to be effective to a certain extent. Animal studies have also shown that compensation 
in heart function can significantly affect the progress of hypoxic pulmonary hypertension.  
When the myocardial damage induced by oxygen shortage exceeds a certain degree, the 
function of the left heart decompensates, causing an increase in the left ventricular end 
diastolic pressure (LVEDP) and in the left atrial pressure (LAP). This in turn boosts 
pulmonary hypertension and contributes further to the development of pulmonary edema. 
Pulmonary edema impedes gaseous exchange and oxygenation, and the resulting decrease 
in arterial partial pressure of oxygen further aggravates myocardial anoxia and damage. 
Increases in high altitude pulmonary blood volume cause an increase in the pulmonary 
venous resistance. 
3. Increases in pulmonary circulation blood volume 
Increases in pulmonary blood volume are another important factor that can elevate pressure 
in pulmonary circulation. It has been shown that 48-72 hours after healthy soldiers were 
airlifted from sea level to 3,658 meters, their pulmonary blood volumes increased by 82%. 
This is because oxygen shortage acts on the central nervous system and causes increased 
sympathetic excitability. Increased sympathetic excitability results in the large-scale release 
of catecholamines. At the same time, due to the increase in resistance in the peripheral 
vessels, the left ventricular load increases and cardiac output decreases while left atrial 
pressure increases. Pulmonary venous return is impeded, causing blood to fill the blood 
vessels of the lungs. The increased blood supply and reduced blood output in the 
pulmonary circulation increase pulmonary blood volume. The compensatory erythrocytosis 
and increase in both water and sodium retention caused by hypoxia increase blood volume 
in general, including pulmonary blood volume, which also leads to pulmonary edema.  
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4. Formation of micro-thrombi in the pulmonary vessels 
The formation of micro-thrombi in the pulmonary circulation is a pathological feature of 
HAPE. Autopsies of HAPE patients have found extensive blockages by thrombi in the 
pulmonary capillaries and some in the branches of the pulmonary veins and arteries, 
demonstrating that the formation of thrombi in the pulmonary vessels is relatively 
important to the pathogenesis of HAPE. Due to extensive micro-thrombus formation in the 
pulmonary capillaries and in other organs such as the brain, the liver, the spleen, the kidney, 
and the intestine, it has been suggested that hypoxic pulmonary hypertension results from 
abnormal coagulation and general thrombus blockage of the pulmonary capillaries.  
As to the mechanism by which micro-thrombi form in the pulmonary vessels, it is generally 
believed that as the levels of fibrinogen and anti-fibrinoclase released by the liver increase 
and levels of fibrinoclase activators released by the lung decrease, the resulting abnormal 
fibrinolysis is an important pathophysiological basis of the formation of micro-thrombi in 
the pulmonary vessels. Singh et al. proposed that hypoxia could lead to damage to the 
fibrinoclase system and that this damage might disturb the dynamic balance between the 
formation and dissolution of fibrin, causing fibrin to build up in the pulmonary vessels and 
hence cause the formation of micro-thrombi.  
Studies have shown that during the initial stages of HAPE, there are substantial increases in 
the level of platelet factor 3, and in the release of ADP, resulting in decreased platelet 
mobility. They have also found that, in HAPE patients, the levels of plasma 
immunoglobulins, including IgG, IgA, and IgM, all increase significantly. IgG and IgM can 
adhere to the surface of platelets and change their electrophoretic mobility, increasing 
platelet adhesivity and release of ADP. ADP can promote the utilizing of platelet factor 3, 
which further speeds up the coagulation process. Imbalances in cellular immune function 
cause immune complexes to build up. As the immune complexes activate blood coagulation 
factors, they further aggravate blood clotting in the blood vessels. The aforementioned 
weakening of the cellular immune function co-occurs with a decrease in the dissolution 
activity of fibrin. When the dissolution activity of fibrin improves, cellular immune function 
also recovers. In addition, recent studies have found that the magnesium content of 
erythrocytes and leukocytes increases significantly in healthy individuals who adapt well to 
high altitudes, but in HAPE patients it decreases significantly. Magnesium can alleviate 
coagulation by expanding blood vessels, stabilizing fibrinogen and platelets, and 
accelerating the dissolution of fibrin.  
4.2 Increases in the permeability of the pulmonary capillaries 
It has been reported that when dogs were placed at a simulated altitude of 6,401 meters, the 
flow of lymph in the right lymphatic duct increased. After inhaling pure oxygen, lymph 
flow decreased, the lymphatic duct expanded, but there was no sign of blockage. The causes 
of lymph flow increase included increased pressure and increased permeability resulting 
from pores opening in the walls of the lymphatic ducts in a low-pressure, low-oxygen 
environment. When the dogs’ arterial oxygen saturation dropped to 75% (corresponding to 
an altitude of 5,200 meters), the lymph flow began to increase. When the arterial oxygen 
saturation dropped to 52.5% (corresponding to an altitude of 6,100 meters), the lymph flow 
increased substantially. Once red blood cells enter the lymph, the capillaries are considered 
damaged. Schoene collected bronchoalveolar lavage fluid from HAPE patients in a lab at an 
altitude of 4,400 meters by branchofiberoscope. Component analysis showed elevated 
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protein content, even higher than that in the edema fluid collected from adult respiratory 
distress syndrome (ARDS) patients. All these directly demonstrate that HAPE results from 
the leakage of fluid, protein, and even blood formed elements caused by the increased 
permeability of the pulmonary capillaries, suggesting that HAPE is a type of protein-rich, 
high-permeability pulmonary edema. In 1991, West JB et al. successfully simulated the 
pathophysiological process of HAPE in the laboratory by increasing the pulmonary arterial 
pressure of laboratory animals. He observed that when the rabbits’ pulmonary capillary 
pressure reached 40 mmHg, the endothelia of the pulmonary capillaries and alveoli and 
sometimes even all the linings of the alveoli started to rupture.  
The mechanisms by which the pulmonary capillary permeability increases may include the 
following factors. 
1. Direct damage to the respiratory membrane structure 
According to studies, under emergency conditions involving hypoxia, the endochylema of 
the pulmonary capillary and alveolar endothelial cells become condensed, causing the cells 
to shrink, which in turn expands the intercellular space of the alveolar capillary membranes 
and increases their permeability.  
2. Decrease in secretion of alveolar surfactants 
The alveolar surfactant is a type of phospholipin secreted by alveolar epithelial type II cells. 
When the lung tissues experience shortages of oxygen and blood, the normal metabolism of 
the alveolar epithelial type II cells is disturbed, and the secretion of this substance decreases. 
In high altitude, secretion of this substance may decrease, causing the permeability of the 
barrier between the capillaries and lung tissues to increase, leading to HAPE.  
3. Increases in levels of acidic metabolites in local tissues 
The anaerobic metabolism increases and the acidic metabolites accumulate, causing the 
physicochemical properties of the adhesion substance between the capillary endothelial cells 
to change and the basilar membrane to denature, which eventually leads to increased 
capillary permeability. 
4. Respiratory tract infection 
Any respiratory tract infection can directly damage the pulmonary capillaries and tissues 
through inflammatory metabolites and bacterial toxins, increasing their permeability. It is 
already known that hypoxia can induce inflammatory reactions involving immunocytes and 
epithelial cells, and therefore it can be deduced that high altitude hypoxia may induce the 
secretion of inflammatory cytokines, causing HAPE by producing pulmonary extravasation. 
To understand the relationship between inflammation and the pathogenesis of HAPE, 
researchers measured the levels of several inflammation mediators under hypoxia, 
including interleukin-6 (IL-6), interleukin -1 receptor antibody (IL-1ra), and C reactive 
protein (CRP). The moderate increase of these inflammatory markers reflects the presence of 
general local inflammation and suggests that inflammation may be involved in the 
pathogenesis of HAPE. Another study measured continuously the level of NO, a marker of 
respiratory inflammation, in the expiratory air of human subjects, and found that at 4,359 
meters, the 13 subjects who were also HAPE patients among 28 subjects did not show trend 
of elevated NO levels during the clinical period, found the NO content in the expiratory air 
of subjects during their stay at high altitudes was 30% lower, indicating that respiratory 
tract infection does not precede HAPE. 
5.   Increases in plasma fibrinogen and the decreases in the dissolution activity of fibrin 
cause fibrin to accumulate in the pulmonary capillaries, forming thrombi that block them. 
This increases the permeability of the capillary walls. 
 
Lung Diseases – Selected State of the Art Reviews 
 
548 
4.3 Impairment of water clearance by the alveolar epithelium 
HAPE results from unbalanced fluid secretion and reabsorption in the alveoli. In particular, 
the amiloride-sensitive epithelial sodium channel (ENaC) is involved in 40-60% of the re-
absorption processes. It has also been found that 2 antagonist, which activates epithelial 
sodium channels (ENaC), also promotes water clearance in the lungs. In addition, in vitro 
studies have found that hypoxia inhibits Na+/K+-ATPase activity in alveolar epithelial type 
II cells as well as the co-transportation of Na, K, and Cl. This all suggests that hypoxia 
impedes the transmembrane re-absorption of water and sodium in epithelial cells. 
4.4 Increases in sympathetic excitability 
Studies have found that sympathectomy or blockage of cervical sympathetic nerves can 
eliminate HAPE. This suggests that the pathogenesis of HAPE is clearly related to 
sympathetic excitability. It has been found that the subjects’ sympathetic excitability 
instantly increased at 3,500 meters, reaching a peak value within 24-72 hours, which is 
exactly the period of time during which HAPE is most likely to occur.  
4.5 Individual susceptibility 
Given the same conditions, the incidence of HAPE shows differences along racial, individual, 
and age lines. A study reported that among the 43 patients with recurrent HAPE, thirty-two 
developed HAPE 2 times, seven 3 times, three 4 times, and one 6 times. This shows that 
individual susceptibility is one of the factors for the incidence of HAPE. When comparing 
HAPE patients to normal subjects, researchers have found that the chest circumferences and 
chest anteroposterior diameters of acute HAPE patients are both longer than those of controls. 
In addition, there are more circular muscle fibers on the pulmonary arteriolar walls of the 
acute HAPE patients. Individual differences in internal factors such as the tissue structure of 
the pulmonary vessels and immune function status may lead to individual differences in 
sensitivity, tolerance to hypoxia, and other steps of the pathogenesis of HAPE. 
In summary, the pathogenesis of HAPE is complex, involving many steps. Currently well-
accepted factors include the following: 
a. Hypoxia directly damages pulmonary capillary endothelial cells and expands or 
destroys the intercellular space, leading to general damage to the structure of the air-
blood barrier, which causes blood plasma to leak directly into the alveolar space. 
b. Hypoxia damages alveolar epithelial type II cells, diminishing their ability to secrete 
surfactants, leading to a decrease in alveolar surface tension, which causes the fluid and 
proteins in the pulmonary capillaries likely to leak out. 
c. Hypoxia prompts the alveoli to release cytokines such as histamine, serotonin, 
interleukin-1, interleukin-6, leukotriene E4, tumor necrosis factor, and C-reactive 
protein, causing capillary permeability to increase. 
d. Hypoxia prompts pulmonary arteriole constriction and an increase in vascular 
resistance, resulting in pulmonary hypertension. At the same time, sympathetic 
excitability increases and blood is redistributed, leading to an increase in pulmonary 
blood volume and body fluid retention, which causes capillary hydrostatic pressure to 
increase and fluid components to leak out, further aggravating HAPE. 
5. Pathological changes 
The pathological changes involved in HAPE mainly occur in the lungs. Visual inspections 
reveal increases in the volume, weight, and surface moisture of the two lungs and that the 
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peripulmonary membrane has become stretched, rubbery, and dark red in color. When 
pressed, pink spumous fluid streams to the surface. Under optical microscope, expansion of 
the pulmonary capillaries is observed, with red blood cells accumulating inside and 
bleeding around the vessels. The middle layers of the muscular pulmonary arterioles 
thicken, the elastic layers appear serrated, and the arterioles muscularize. The pulmonary 
arterioles are expanded and interrupted and capillary thrombi are formed. The bronchioles 
and alveoli present hyaline membranous edema, and the alveolar ducts become filled with 
blended protein fluid or cluttered red blood cells. The capillaries in the alveolar septum 
expand, with blood accumulating inside and forming thrombi. Under electron microscope, 
unformed edema fluid with low electron concentration is observed inside the pulmonary 
alveolar space. Red blood cells accumulate, the capillaries in the alveolar septum expand, 
the intercellular space between endothelial cells enlarges, and the endothelial cells swell. 
The number of pinocytotic vesicles and some vacuolated were increased. The alveolar 
epithelial type I and type II cells swell, shedding surface microvilli. The perinuclear space of 
the alveolar epithelial type II cells expands, and the laminated bodies in their cytoplasts 
increase in number and show vacuolization. 
6. Clinical manifestation 
Like those of other types of acute pulmonary edema, the clinical manifestation of HAPE 
includes dyspnea, cyanopathy, cough, the production of large amounts of white or pink 
spumous phlegm when coughing, and moist rales in one or both lungs. 
6.1 Symptoms 
At the early stage, the most common symptoms of HAPE include severe headache, dyspnea, 
palpitations, shortness of breath, chest tightness, chest pain, panic, extreme fatigue, 
weakness, persistent dry cough, worsened nighttime insomnia, pale complexion, and moist, 
cold skin. As the condition progresses, the above symptoms worsen, and patients may 
experience severe dyspnea, an inability to lie flat, and coughing out spumous phlegm, 
which is initially white or faint yellow in color and later turns pink, in some worse cases 
gushing out of the mouth and nose. Most patients display dysphoria while a minority 
experience hypersomnia, in some cases accompanied by altitude coma. 
6.2 Signs 
One distinctive sign of HAPE is moist pulmonary rales. In severe cases, moist rales can be 
heard in all regions of both lungs along with wheezing and phlegm. The cardiac sound is 
often masked. In mild cases, moist rales can be heard at the base of one or both lungs. Most 
patients display cyanosis in the lips, nail beds, and parts of the face. Due to dyspnea, 
patients often take bed rest in a semi-reclining position. About two thirds of patients 
experience fever, usually at 37.5-39oC. If body temperature persists over 38.5oC, it usually 
indicates complicating upper respiratory tract infection. Signs also include increased heart 
rate, loud or splitting P2, and grade 2-3 systolic murmur in the apex region of the heart. 
Some patients exhibit sulcus terminalis cordis expansion, possibly with diastolic gallop, 
jugular vein distention, hepatosplenomegaly, and edema complicated in some cases by 
cardiac insufficiency. Compared to other acute pulmonary edemas, HAPE has the following 
distinctive clinical features: 
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a. At early stages, HAPE patients only show symptoms of mild AMS, such as headache, 
dizziness, palpitations, insomnia, anorexia, and nausea. As these can be early 
symptoms of HAPE, they must be addressed with caution. Pulmonary auscultation 
may show normal results, but X-ray examination will reveal typical infiltrated shadows. 
b. In some patients, HAPE progresses very rapidly, with acute onset and severe 
symptoms. Patients experience extreme dyspnea, asphyxia, and rales in all lung 
regions, quickly reaching impending death status. They may exhibit bloody pleural 
fluid in one or both lungs before death. 
c. Patients tend to have high blood pressure, fine pulse, tachycardia, loud or splitting P2, 
and either a mild systolic murmur or diastolic gallop in the apex region of the heart. 
Only a few also experience right heart failure. 
d. Some patients mainly show neurological and psychiatric symptoms, which often 
include headache, vertigo, diplopia, vomiting, phrenitis, and irritation. A minority of 
patients exhibit symptoms of derangement, meningeal irritation, or even coma. Further 
examination typically reveals increased pressure in the cerebrospinal fluid and edema 
in the optic papilla. In these cases, encephaledema often co-occurs, as can be detected 
by encephalic CT or MRI examination.  
e. At the onset of HAPE, there is usually no fever, but some patients show low fever and 
intolerance to coldness.  
6.3 Diagnostic examination 
a. Hemogram: The leukocyte count is typically normal or mildly increased; about 40% 
patients have a count over 10000/mm3. The highest count recorded in our study was 
64000/mm3. The neutrophilic granulocyte count also increases mildly. If the leukocyte 
and neutrophilic granulocyte counts continue to rise, it usually indicates concurrent 
infection. 
b. X-rays: HAPE patients often show unilateral or bilateral flake-like or cloudy shadows 
centered at the porta pulmonis, mostly in the right lung. A minority of patients show 
large patchy or butterfly/batwing shadows. The apex regions of the lung are usually 
clear. At early stages, there is only thickening of the lung markings, also called 
pulmonary interstitial edema. 
c. Electrocardiography: Manifestations of HAPE on the electrocardiogram include nodal 
tachycardia, right axis deviation, right bundle branch blockage, sharply tented P waves 
or P pulmonale, T wave inversion, and ST segment depression. 
d. Blood gas: HAPE patients show substantial decreases in levels of PaO2 and SaO2, which 
are not only lower than those of healthy controls but also significantly lower than those 
of mild AMS patients.  
e. Pulmonary function: HAPE mainly features decreases in the expiratory flow rate or 
diffusion capacity. 
f. Hemodynamics: The pulmonary arterial pressure and resistance to the pulmonary 
artery are significantly increased. Left atrial pressure remains normal.  The pulmonary 
capillary wedge pressure and cardiac index remain normal or decrease slightly. 
7. Clinical classification 
Using clinical signs and symptoms and the results of diagnostic examination, HAPE can be 
classified into three types: mild, moderate, and severe. 
 
High Altitude Pulmonary Edema 
 
551 
1. Mild HAPE: Characterized by mild dyspnea, coughing, coughing out small amounts of 
spumous phlegm, focal moist rales at the base of one or both lungs, respiratory rate of 
20-30 breaths/minute, pulse rate under 100 beats/minute, bilateral thickening of lung 
markings, or cloudy spots at the base of the lungs visible on sternal X-ray. 
2. Moderate HAPE: Characterized by substantial dyspnea, chest pain, chest tightening, 
coughing out large amounts of white or pink spumous phlegm, moist rales at the base 
of both lungs spreading over other pulmonary regions, respiratory rate of 30-40 
breaths/minute, pulse rate of 110-120 beats/minute, bilateral thickening of lung 
markings, and flake-like or cloudy shadows at the base of the lungs visible on sternal X-
ray. 
3. Severe HAPE: Characterized by polypnea, panic, inability to lie flat, coughing out large 
amounts of pink spumous phlegm, severe cough, considerable blowing systolic 
murmur upon examination of the apex region of the heart or pulmonary valve area, 
moist rales sounding like boiling water in all pulmonary regions, bilaterally 
symmetrical cloudy shadows centered at the porta pulmonis or bilaterally symmetrical 
butterfly/batwing shadows visible on sternal X-ray, heart enlargement, clear 
protruding of the pulmonary trunk, and in some cases signs of heart failure including 
jugular vein distention, hepatomegaly, and edema in both lower extremities. 
8. Diagnosis and differential diagnosis 
8.1 Diagnosis and diagnostic criteria 
1. Clinical diagnostic criteria 
In China, the clinical diagnosis of HAPE is mostly based on the clinical diagnostic criteria 
recommended in 1995 by the Chinese Medical Association’s third national medicine 
academic seminar. These criteria have been approved by the International Society for 
Mountain Medicine. The criteria include the following: 
a. Upon recent exposure to high altitudes (usually considered to be 3,000 meters or more 
above sea level), the subject experiences dyspnea at rest, chest stress and tightening, 
cough, coughing out white or pink spumous phlegm, malaise, or decreased activity. 
b. There are unilateral or bilateral moist rales or wheezing sounds in the pulmonary field, 
central cyanosis, tachypnea, and tachycardia. 
c. X-ray shows unilateral or bilateral flake-like or cloudy infiltrated shadows centered at 
the porta pulmonis, often scattered and irregularly distributed but sometimes fused 
into a large patch. The podoid is normal in most cases, but sometimes signs of 
pulmonary hypertension and right heart enlargement can also be observed. 
d. Other cardiac and pulmonary diseases, such as myocardial infarction and heart failure are 
excluded by clinical and electrocardiographic examinations. Pneumonia is also excluded. 
e. Symptoms quickly improve after bed rest, oxygen inhalation treatment, or descending 
to a lower altitude, and signs shown by X-ray disappear within a short period of time. 
2. Criteria for early diagnosis 
As we gain a deeper knowledge of HAPE and accordingly improve both protective and 
therapeutic measures, clinically typical HAPE cases have become rare. If we continue to 
refer to the previous diagnostic criteria, it will be difficult to identify HAPE patients. For this 
reason, we carried out a study funded by the National Sci-Tech Support Plan and proposed 
the following as the criteria for early diagnosis of HAPE: 
 
Lung Diseases – Selected State of the Art Reviews 
 
552 
a. Upon recent exposure to high altitudes (usually considered to be 3,000 meters or more 
above sea level), the at-rest subject experiences palpitations, chest tightening, dyspnea, 
and coughing with or without small amounts of white spumous phlegm. 
b. There is local, unilateral or bilateral coarse breathing with or without focal moist rales. 
There is also central cyanosis, tachycardia (100 beats/minute), and tachypnea (24 
breaths/minute). 
c. Early routine X-ray examination shows a decrease in transmittance of the lungs, blurred 
or increased lung markings, and the presence of ground-glass opacity or small patchy 
shadows in the lung. CT scan shows increased number and thickening of lung 
markings, ground-glass opacity, nodular shadows, scattered or isolated alveolar edema 
on terminal bronchioles, and fine reticular shadows. 
d. Routine blood examination shows increases in the leukocyte count and the proportion 
of neutrophilic granulocytes. 
e. Arterial blood gas examination shows persistent hypoxemia accompanied by mild 
respiratory alkalosis. 
f. Electrocardiographic examination shows nodal tachycardia, clockwise rotation, sharply 
tented P waves, and so on. 
g. Ultrasonic cardiogram shows early, prominent, persistent pulmonary hypertension. 
h. All symptoms quickly improve after treatment such as bed rest, oxygen inhalation, 
decreasing pulmonary arterial pressure, and diuresis. 
It should be noted that criteria a-c must be met first. Conditions in d-h are then evaluated. 
The criteria are then combined collectively to produce an accurate early diagnosis. In clinical 
practice under aforementioned criteria, if we also refer to the severities of the condition and 
of the signs, the features and sizes of the shadows on the chest film, make proper diagnoses, 
and give prompt, effective, on-site treatment, it is completely possible that we will be able to 
keep early-stage HAPE under control. 
8.2 Differential diagnosis 
1. Adult respiratory distress syndrome 
a. Differences in the cause of disease: The fundamental cause of HAPE is oxygen shortage 
at high altitudes and low pressure leading to disturbed pulmonary circulation and body 
fluid maldistribution, of which oxygen shortage is the cause. ARDS is the secondary 
lesion of the lung tissues directly or indirectly caused by trauma or severe infection, in 
which oxygen shortage is the consequence. 
b. Differences in pathological changes: Both show high levels of permeability edema. 
However, HAPE features short duration, fibrosis of the interstitial tissues and alveolar 
walls, thickening of the interstitium, only mild hyperplasia in the epithelial cells of 
alveolar walls, and a full recovery without sequelae. ARDS may evolve into subacute 
and chronic conditions, such as alveolar wall fibrosis. Chronic patients may exhibit 
pathological changes in general bronchopneumonia, which can eventually lead to 
prominent fibrosis of the interstitium and the alveoli and the pathological changes of 
emphysema. 
c. Differences in reaction to oxygen inhalation: After treatments such as oxygen inhalation 
and measures that decrease pulmonary arterial pressure, most HAPE patients can 
quickly improve and recover in 2-7 days. Only in rare cases will patients die, usually 
due to a long delay before treatment, extreme severity of the condition, or complication 
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by adult respiratory distress syndrome. ARDS usually features more severity and a 
longer duration, often with hemosputum or hemorrhagic sputum and unilateral or 
focal tubular sound with few moist rales. Oxygen inhalation, even high-pressure 
oxygen inhalation and assisted respiration, is often not effective. The fatality rate is 
relatively high, usually between 40% and 70%. 
d. Differences in X-ray manifestations: HAPE often shows flake-like or cloudy shadows 
spreading outward from the porta pulmonis, mostly scattered at the middle and lower 
fields and rarely fused into large patch. The X-ray film of ARDS patients typically 
shows patchy shadow at the edges of the lungs, in server cases fused into a large patch. 
At the terminal stage, “white lung” is manifested, and the pulmonary shadows 
gradually disappear. 
2. High altitude pneumonia 
High altitude pneumonia and upper respiratory tract infection can trigger HAPE, and 
HAPE tends to be complicated by high altitude pneumonia. Therefore, we should carefully 
differentiate the two in both diagnosis and treatment. 
a. Differences in cause: HAPE is caused by hypoxia under low-oxygen, low-pressure 
conditions at high altitudes. High altitude pneumonia is pulmonary inflammation 
caused by bacteria, viruses, allergies, or inhalation of hazardous substances such as 
kerosene or gasoline. 
b. Differences in clinical manifestation: Both show increases in body temperature and 
hemogram. However, high altitude pneumonia usually has a rapid onset with chills 
and high fever. Body temperature reaches 39-40oC within hours and continues to rise, 
causing enecia. Both the leukocyte and the neutrophilic granulocyte counts increase 
significantly, reaching up to 20-30×109/L. Mostly neutrophilic granulocytes can reach 
more than 80%. There is also a left shift of nuclei, observable toxic granulations, and 
vacuoles in the cytoplasts. In comparison, HAPE patients usually do not have fever 
higher than 38.5oC, and their leukocyte and neutrophilic granulocyte counts only 
increase slightly. 
c. Differences in clinical signs: HAPE patients cough typical spumous hemosputum or 
pink spumous phlegm, which can gush out from mouth and nose when large amounts 
are present. High altitude pneumonia patients first cough mucus and then purulent or 
rusty sputum. 
d. Differences in X-ray manifestation: HAPE often shows either intense shadows with 
different densities, shapes, and sizes, or spotty, flake-like, cloudy shadows. Lesion 
margins of HAPE were blurred and not constrained by the interlobar fissures. The 
above signs are widely scattered in both lungs. High altitude pneumonia shows 
increased numbers of lung markings and decreased transmittance of the lung fields at 
early stages. Later spotty, flake-like shadows of different sizes can be observed, 
sometimes fused into patchy shadow, but usually limited to one pulmonary lobe or one 
pulmonary segment. 
9. Complications 
9.1 High Altitude Cerebral Edema 
High altitude cerebral edema (HACE) is a common complication of HAPE, as verified by 
clinical examinations, lab examinations, and autopsies. Because patients may have one or 
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both of these two diseases, we should take great caution in diagnosis and treatment. HAPE 
patients often show signs and symptoms such as headache, vomiting, hypersomnia, and 
coma, which relate to increased intracranial pressure and cerebral edema. Fundus 
examination sometimes shows papilledema and fundus hemorrhage, and lumbar puncture 
often shows increased cerebrospinal fluid pressure. Such cases merit special attention 
during diagnosis and treatment. 
Shortly after rapid exposure to a high altitude environment, blood within the body is 
redistributed via neural, fluid regulation. The vasomotion of the blood vessels in some 
organs undergo prominent changes resulting in large amounts blood moving to important 
organs, such as the lung, heart, and brain, ensuring their oxygen supply and normal 
function. However, if the blood flow volume, rate, and pressure in these organs become too 
high, disruption to microcirculation may occur. In particular, in the lung and brain, where 
low-pressure space is normally present, it can easily cause fluid to leak out into neighboring 
tissues, leading to edema. HAPE and HACE share some common pathogenesis, for the most 
part in the pathological changes in hemodynamics. HACE and HAPE may occur separately 
or jointly, sometimes in succession. Severe HAPE and large amounts of extravasation from 
the alveoli seriously impair oxygen uptake from the external environment, aggravating 
hypoxemia, which promotes the hemangiectasis of the cerebral blood-vessels via 
neuroendocrine regulation induced by severe hypoxia of the brain tissue. The resulting 
increase in cerebral blood flow and blood volume then further aggravates cerebral edema. 
However, HACE escalates the extravasation of pulmonary tissue and worsens HAPE via 
neural, fluid regulation. When HACE extends to the respiratory and cardiovascular centers 
of the medulla oblongata, respiration is inhibited and blood pressure drops, in severe cases 
leading to cerebral hernia, which can cause respiratory circulation failure or even sudden 
cardiac arrest，resulting in vicious circle. This is an important cause of death among 
patients with HAPE complicated by cerebral edema.  
9.2 Cerebral infarction 
Cerebral infarction is another common complication of HAPE, possibly induced by the 
following: 1) Acute erythrocytosis occurs due to excessive erythropoiesis triggered when the 
body is exposed to altitudes above a certain elevation. The compensatory erythrocytosis in 
the plasma leads to a significant increase in blood viscosity. Blood flow rate decreases and 
blood cells cluster together, resulting in increased contact between the platelets and the 
blood vessel walls, rendering the blood more likely to coagulate. 2) Wade et al. proposed 
that disturbances in cerebral circulation might play a major role in generating cerebral 
thrombosis. HAPE complicated with HACE is an important cause of disturbances in 
cerebral microcirculation, which slows down the blood flow and increases the blood 
viscosity of the patient, leading to cerebral thrombosis. 3) At high altitudes, the generation 
of blood coagulation factor in the plasma increases, creating a hypercoagulative condition. 
The blood of High altitude polycythemia (HAPC) patients is already in a hypercoagulative 
state, and second hyperfibrinolysis can easily occur. 4) HAPE patients have severe 
hypoxemia, which may result in damage to blood vessel endothelial cells. The above 
changes caused severe damage to the pulmonary capillary endothelial cells of HAPE 
patients, boosting platelet adhesion and activating the blood coagulation system, finally 
leading to cerebral thrombosis.   
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9.3 Multiple Organ Dysfunction Syndrome 
Patients with HAPE complicated by cerebral edema are prone to multiple organ dysfunction 
syndrome (MODS). Patients show symptoms including headache, chest tightness, shortness 
of breath, nausea, aggravated vomiting, and abnormal psychological behavior. Auscultation 
can reveal aggravated pulmonary rales; fundus  examination may show spotting or patchy 
bleeding in the retina and papilledema; there is gastrointestinal hemorrhage or fecal occult 
blood, hematuria, or proteinuria; chest X ray of most patients show enlarged hilar shadows, 
unilateral or bilateral cloudy shadows of uniform density in the lung field, in some cases 
fused into large, dense, patchy unilateral or bilateral shadows of uniform density; 
encephalic CT reveals decreased brain parenchymal density, narrowed bilateral cerebral 
ventricles, and the shallower, narrower sulci; laboratory examination will reveal increased 
leukocyte counts, often above 13.0×109/L, increased bleeding and clotting time, increased 
fibrinolytic activity, and increases in thromboxane B2, vWF, fibrinogen, tissue-type 
plasminogen activator and inhibitor in the plasma, increased levels of D-dimers, increased 
levels of alpha-granular membrane protein, significantly decreased levels of 6-keto-PGF1a 
and antithrombin III, and severe dysfunction of the coagulation and fibrolysis systems. 
AMS complicated by MODS has been underemphasized and the diagnostic yield has been 
low. Our investigation shows that 2.5% of AMS cases are complicated by MODS, which is 
considerable. We need to improve early diagnosis and early detection because early 
treatment is crucial in reducing the fatality rate of AMS complicated by MODS. 
10. Prevention and treatment 
10.1 Prevention 
1. Protection of susceptible populations from exposure to high altitudes 
Physical examinations, especially inspections of cardiac and pulmonary functions, should be 
performed on individuals who are about to travel to high altitude areas. Those with heart 
and/or lung ailments should be advised against exposure to high altitudes. 
2. Prevention of respiratory tract infection 
Individuals with respiratory tract infections are more susceptible to HAPE at high altitudes. 
Those who catch upper respiratory tract infections before planned trips to high altitude 
areas should first seek treatment and only make the trip after full recovery. Prior to high 
altitude exposure, one should perform cold resistance exercises. After arrival, one should 
take active measures to keep warm and prevent respiratory tract infection. 
3. Acclimatization to hypoxia 
Prior to high altitude exposure, one should receive hypoxic training using masks or hypoxic 
respirators to increase the body’s tolerance to hypoxia so as to promote high altitude 
acclimatization.  
When possible, one should ascend to higher altitudes gradually and multisteply rather than 
rapidly ascend to higher altitudes to avoid body damage. Before traveling to high altitude 
regions, individuals should familiarize themselves with the climate characteristics and 
geological environment of the area and familiarize themselves with preventative treatments 
for high altitude diseases. 
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4. Reduction and control of activity level 
During the first week of high-altitude exposure, one should take proper rest, reduce or 
avoid intense physical activity, avoid fatigue, and minimize oxygen consumption. Normal 
physical activity should be resumed only after the body is acclimatized to the hypoxic 
environment. 
5. Administration of prophylactic medicine 
a. Chinese traditional medicine  
There are four courses of Chinese traditional medicines that may serve to prevent 
HAPE: 
Compound codonopsis tablets: Take orally. Start 3 days before hypoxia exposure, 3-5 
tablets/dose, 3 doses each day. Continue for 5-7 days after hypoxia exposure. 
Ginseng and astragalus pollen tablets: Take orally. Start 3 days before high altitude 
exposure, 5 tablets/dose, 3 doses/day. Continue for 5-7 days after high altitude 
exposure. 
Rhodiola rosea oral solution: Take orally. Start 3 days before high altitude exposure, 10 
ml/dose, 3 doses/day. Continue for 5-7 days after high altitude exposure. 
Compound rhodiola capsules: Take orally. Start 3 days before high altitude exposure, 2 
capsules/dose, 3 doses/day, continue for 5-7 days after high altitude exposure. 
b. Glucocorticoid preparations 
Dexamethasone: Take orally. Start 1 day before high altitude exposure, 5 mg/dose, 3 
doses/day. Continue for 2 days after high altitude exposure. 
c. Carbonic anhydrase inhibitors 
Nephramid (a.k.a. acetazolamide): Take orally. Start 1 day before high altitude 
exposure, 250 mg/dose, 3 doses/day. Take for 2-3 days. 
Methazolamide (a.k.a. Ni Mu Ke Si): Take orally. Start 1 day before high altitude 
exposure, 25-50 mg/dose, 3 doses/day. Take for 2-3 days. 
d. Calcium antagonists 
Nifedipine: Take orally. Start 1 day before high altitude exposure, 10 mg/dose, 2 
doses/day or sublingual administration 10 mg/dose, 3 doses/day. Take for 1-3 days. 
e. Beta2- receptor stimulants 
Salbutamol: Inhale. Start 1 day before high altitude exposure, 125 g/dose, 2 
doses/day. Continue for 2-3 days after high altitude exposure. 
f. Phosphodiesterase inhibitors  
Sildenafil: Take orally. Start 1 day before high altitude exposure, 50 mg/dose, 3 
doses/day. Continue for 2-3 days after high altitude exposure. 
Tadalafil: Take orally. Start 1 day before high altitude exposure, 10 mg/dose, 1 
dose/day. Continue for 2-3 days after high altitude exposure. 
10.2 Treatment 
Accurate, effective early-stage treatment usually quickly improves symptoms. Therefore, 
early diagnosis and timely treatment are crucial to controlling the course of the disease and 
prognosis. 
1. Oxygen inhalation or hyperbaric oxygen therapy 
Oxygen inhalation can substantially decrease pulmonary arterial pressure in HAPE patients 
and quickly alleviate hypoxia and the series of clinical symptoms that it causes. HAPE 
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patients should in general use continuous administration of low-flow oxygen (4-6 
L/minute). For patients with severe hypoxia, high-flow continuous oxygen may be 
administrated (8-10 L/minute) but for no longer than 24 hours in order to avoid oxygen 
toxicity. If the symptoms include excessive spumous phlegm, an appropriate amount of 
alcohol may be added to the oxygen humidifying containers for froth suppression.  
Hyperbaric oxygen treatment can temporarily remove hypoxia for HAPE patients. Most 
patients show symptom improvement after 1-2 treatments and achieve recovery after 2-3 
treatments. However, for a minority of patients, HAPE signs and symptoms worsen after 
departure from the hyperbaric oxygen chamber, which can be associated with disease 
severity variance and individual difference. Therefore, when treating HAPE patients with 
hyperbaric oxygen therapy, caution should be taken to acknowledge individual variability 
and monitor the severity of the condition. 
2. Nitric oxide inhalation 
Inhalation of low-concentration nitric oxide can quickly, selectively alleviate the pulmonary 
hypertension caused by hypoxia. The inhalation method is as follows: Mix 10 ppm nitric 
oxide with pure air and inhale through a nasogastric feeding tube at 3-5 L/minute, 30-60 
minutes/treatment and 2-3 treatments/day. Patients with mild or moderate HAPE typically 
recover after 2-3 days. For severe HAPE patients, the duration and daily frequency of the 
inhalation treatments should be increased accordingly. 
Inhaled nitric oxide can be oxidized into NO2- and NO3- in high-oxygen environments and 
can accumulate in the blood, which will damage the blood cells. For this reason, when 
treating HAPE patients with nitric oxide, simultaneous inhalation of high concentration 
oxygen should be avoided. Animal studies have shown that the effects of inhaling 
concentrations of nitric oxide ranging from 5-80 ppm on decreasing pulmonary arterial 
pressure are statistically the same.  
3. Aminophylline 
Aminophylline is the drug of choice for standard HAPE treatment. It can quickly diminish 
pulmonary arterial and vena cava pressure and decrease right atrial venous return volume. 
It can also be cardiotonic, diuretic and a smooth muscle relaxant and can reduce resistance 
in the systemic circulation, improving the heart function. 
Regular dose: 0.25g diluted to 20ml 10-50% glucose, intravenously injected at an even speed. 
It can be repeated after 4-6 hours. For mild HAPE patients, administer 2 times/day. For 
severe patients, upgrade to 0.5g/administration, and increase the frequency of 
administration according to the severity. 
4. Anticholinergic agents 
Atropine and anisodamine can treat pulmonary vasospasms. They also decrease resistance 
in the pulmonary blood vessels, improve pulmonary microcirculation, keep pulmonary 
blood flow unimpeded, and prevent blood clotting and pulmonary thrombosis inside the 
blood vessels. 
Regular dose: Atropine 2-5 mg/0.5hour. Anisodamine (654-2) 20-40 mg/0.5 hour, 
intravenous drip. 
5. Dexamethasone 
Dexamethasone can be used in both treating and preventing HAPE. Regular dose: 10 mg, IV 
injection, 2 times/day for no more than 3 days. For patients with comorbid conditions such 
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as epilepsy, peptic ulcer, high blood pressure, or diabetes mellitus, dexamethasone should 
be taken with caution or contraindicated. 
6. Diuretics 
Nicorol: 10 mg IV injection, 1 dose/day; Nephramid: Take orally.250 mg/dose, 3 
doses/day; Drugs that alleviate pulmonary hypertension: nifedipine: 10-20 mg/dose orally 
or sublingually, 2 doses/day. Sodium nitroprusside: IV drip, 10-20 mg/dose. 
7. Cardiotonics 
Cedilanid: IV injection, 0.4-0.8 mg. Strophanthin K: IV injection, 0.125-0.5 mg. 
8. Sedatives 
Morphine hydrochloride: 5-10 mg, subcutaneous injection. In severe cases, dilute 5 mg to 20 ml 
10% glucose and administer IV injection. For some patients with anxiety symptoms, Valium 
may be used with caution, but its inhibitory effects on breathing should be monitored. 
9. Antibiotics 
HAPE is very likely to be complicated by pulmonary infection. When the two diseases co-
occur, each aggravates the other and the situation becomes difficult to control. In treating 
HAPE, broad-spectrum antibiotics are usually used to prevent and treat infection. Patients 
with mild symptoms should take broad-spectrum antibiotics (e.g. amoxicillin, norfloxacin, 
trimethoprim and sulphame-thoxazole etc.) orally for anti-infection purposes, and control 
the intake of sodium chloride to avoid worsening the HAPE. The commonly used antibiotics 
include the following: 
a. Amoxicillin: Take orally, 1g/dose, 3 doses/day. 
b. Norfloxacin: Take orally, 0.2g/dose, 3 doses/day. 
c. Trimethoprim and sulphame-thoxazole: Take orally, 1-2 tablets/dose, 2 doses/day, take 
orally. 
d. Levofloxacin: Take orally, 0.1-0.2 g/dose, 2 doses/day. 
e. Penicillin (still the first choice): 4,800,000-6,400,000 units diluted in 250-500 ml glucose 
or saline, IV drip, 1-2 times/day. Contraindicated in patients clinically significant  
allergy to penicillin. 
f. Ampicillin sodium/sulbactam sodium: For mild infections, 1.5g/day in 2-3 IM 
injections. For moderate infections, 4-9g/day in 3-4 IM injections. For severe infections 
9-12g/day in 2-3 IV drips.  
g. Cefamezin: 2g/dose, 3 doses/day, IV drip. 
h. Cefradine: 100-150 mg/kg/day, IV drip. 
i. Lincomycin hydrochloride: 0.6g/dose, 1-2 doses/day, IV drip. 
j. Ciprofloxacin Lactate: 0.2g/dose, 2 doses/day, IV drip. 
10. Decent to lower altitude 
When possible, patients should be quickly transferred to lower altitudes (below 3,000 
meters) for further treatment. After leaving the hypoxic environment, the elevated 
pulmonary arterial pressure can quickly return to normal levels and the series of symptoms 
caused by hypoxia quickly disappear. However, descent treatment is only applicable in less 
remote areas within a relatively short amount of time. In remote mountain areas where 
transportation conditions are extremely poor and continuous oxygen supplies cannot be 
guaranteed in transit, it is for the best to administer on-site treatment.  
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When transferring patients to lower altitudes, the following should be noted: 1) 
Transportation utilities: fast, stable transportation utilities are preferable, e.g. helicopter, 
truck, heavy medical vehicle, small ambulance. 2) Accompanying crew: there should be one 
doctor and one nurse, or at least one medical professional who can perform effective 
treatment through the transfer. 3) The patient in should assume a semireclining position 
during descent to keep the airway clear. 4) Patients with high altitude coma should assume 
a semireclining position. Head movement and vehicle pitching should be minimized to 
prevent cerebral hernia. 5) The driver should proceed slowly when road conditions are 
rough so that the patient’s position can remain relatively stable. 6) The accompanying crew 
should read and record vital signs and give effective treatment when needed. 7) If a patient 
passes away, the time and order of vital sign loss should be recorded and body position 
should respectfully be kept unchanged. 
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Mechanical Forces Impair  
Alveolar Ion Transport Processes –  
A Putative Mechanism Contributing to  
the Formation of Pulmonary Edema 
Martin Fronius 
Institute of Animal Physiology, Justus-Liebig-University Giessen 
Germany 
1. Introduction 
The aim of this chapter is to highlight the importance of transepithelial ion transport 
processes for lung function in general and to focus on the impact of mechanical forces on 
pulmonary ion transport in particular. Linking mechanical forces with pulmonary ion 
transport derives from the fact that the lung is a dynamic organ as well as from several 
studies providing evidence that the amount of mechanical forces as used during artificial 
ventilation correlates with mortality rates in patients with respiratory failure such as ALI 
(acute lung injury) and ARDS (acute respiratory distress syndrome) (ARDS Network 
Investigators, 2000). In these patients the formation of pulmonary edema is a characteristic 
symptom (Frank and Matthay, 2003; Ricard et al., 2003) and the basic rationale behind this 
is, that mechanical perturbations cause epithelial leakage in response to mechanically 
induced damage of the epithelial layer. This damage is suggested to be a major cause for the 
formation of pulmonary edema as well as the inability to reabsorb the edema fluid. 
However, little is known whether or not mechanical forces may directly interfere with 
pulmonary ion transport processes and this represents a putative mechanism that facilitates 
the formation of pulmonary edema – in addition to damages of the epithelial layer.  
2. Air breathing and pulmonary ion transport 
The water land transition of tetrapods represents a fundamental process within vertebrate 
evolution that was accompanied by the development of lungs as gas exchanging structures. 
The major advantage of air breathing is the almost infinite access to oxygen, although this 
bears also some risks. The gas-exchanging structures must be moistened to facilitate oxygen 
solubility and the architecture of these structures must be adapted to the requirement of 
efficient gas exchange by diffusion. These problems were basically fixed by invagination of 
the gas-exchanging surface, protecting them from desiccation and from mechanical damage. 
Therefore, invagination could be considered as a basic improvement allowing the 
development of a highly conserved architecture of the air blood barrier that can be found 
within all air-breathing vertebrates. This architecture is referred to as the “three ply design” 
(Maina and West, 2005). The three layers of the air-blood barrier are represented by the 
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pulmonary epithelium, the basal lamina and the endothelium that forms the pulmonary 
capillaries. Although invagination and the development of the three ply design fixed a lot of 
problems, other challenges arose. To ensure a constant supply of oxygen as well as a 
continuous replacement of the breathing medium, ventilation mechanisms were needed. This 
was achieved by different strategies within the different vertebrate classes. Early tetrapods and 
amphibians ventilate their lungs by a buccal pump (Brainerd and Owerkowicz, 2006). In 
higher vertebrates ventilation occurs by a costal pump (Roux, 2002) where the movement of 
the ribs ensures aspiration of air. But independent of the strategy how the exchange of the 
breathing medium is accomplished, the gas-exchanging surface is permanently exposed to 
pollutions and pathogens that are omnipresent in the air supplied to the lungs.  
It is also well known that the entire pulmonary epithelium is covered by a thin fluid layer 
(PLL: pulmonary liquid layer) (Daniels and Orgeig, 2003), that is of particular importance 
for the function of the lung. The PLL extends from the distal parts of the lung to the upper 
airways and consists of mucus, surfactant and periciliary fluid (Rubin, 2002) (Fig. 1). On the 
one hand the PLL is the first physical border that is exposed to the environment and the first 
line of host defense that absorbs pathogens. This is of particular importance in the airways, 
where the PLL is part of the innate immune system and crucial for protecting the host from 
the permanent exposure to pollutions and pathogens due to their removal by the 





















Fig. 1. Schematic drawing of the distal lung region. The distal lung is represented by 
respiratory bronchioles and terminal alveoli that are lined by a continuous layer of epithelial 
cells consisting of different cell types. The entire epithelium is further covered with a liquid 
film (PLL: pulmonary liquid layer) consisting of different layers. In the airways the PLL is 
composed from a liquid layer (periciliary fluid) and a layer of mucus and surfactant. In the 
alveolar regions the PLL consists of a liquid layer (alveolar fluid) and a surfactant layer.  
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On the other hand the height and volume of the PLL in the respiratory zone – primarily 
represented by the alveolar fluid – determines the distance of diffusion for the gases that is a 
limiting rate for the diffusion efficiency as defined by Fick’s law of diffusion. Thus, 
increased fluid content in the alveolar region decreases oxygenation of the blood (Matalon 
and O'Brodovich, 1999; Matthay et al., 2000). 
Therefore, the consistency as well as the volume of the PLL layer must be tightly regulated 
and controlled – in the airways as well as in the gas-exchanging region – to ensure effective 
host defense as well as effective gas exchange.  
This principle becomes evident regarding pulmonary diseases that are associated with 
inappropriate fluid balance in the lung. For example hyperabsorption of water from the 
airspace increases the viscosity of the PLL and this interferes with the removal of inhaled 
pathogens due to impaired mucociliary clearance as observed in patients with cystic fibrosis 
(Fig. 2A) (Widdicombe et al., 1985; Riordan et al., 1989; Matsui et al., 1998). In contrast, too 
much fluid in the lung impairs gas diffusion and this can be observed in patients with 
pulmonary edema (Figure 2B) (Sznajder, 2001; Hoschele and Mairbaurl, 2003).  
Thus, a defined content of water covering the pulmonary epithelia is a basic requirement for 
proper lung function and this depends on the development of appropriate ion transport 
















Fig. 2. Impaired epithelial fluid transport affects basic lung functions. A) Increased water 
reabsorption in the airways results in dehydration of the periciliary liquid layer (PCL) 
leading to an impaired mucociliary clearance and mucus accumulation within the airways. 
B) In the alveolar region an imbalance between fluid reabsorption and fluid infiltration leads 
to the formation of pulmonary edema that impairs the exchange of the breathing gases.  
2.1 Transepithelial Na+ and Cl– transport are the main pathways to control the water 
content in the lung 
Studying ion transport processes across pulmonary epithelia within the last decades 
improved our understanding how the fluid content in the lung is sustained. The basic 
principle of pulmonary water transport is ubiquitous – ions are transported across the 
epithelial layer and this generates transepithelial osmotic gradients that cause water 
diffusion across the epithelium (Sackin and Boulpaep, 1975). It is well accepted that 
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pulmonary epithelia are Na+ reabsorptive epithelia where active Na+ reabsorption 
represents the bulk of transepithelial ion transport. Na+ transport occurs via two steps: 1) 
Na+ ions are taken up through epithelial Na+ channels (ENaC) at the luminal side of the 
epithelial cells and are pumped out from the cells at the basolateral side by the 
Na+/K+ATPase. This process is suggested to be the principle mechanism for water 
reabsorption from the airspace into the body (Matthay et al., 2002). Another major 
component with significant impact on transepithelial water movement is represented by the 
transepithelial transport of Cl–. In the airways it is well accepted that Cl– is secreted via 
luminal Cl– channels (Smith et al., 1982; Willumsen et al., 1989; Chambers et al., 2007). 
However the particular role of Cl– channels Cl– in alveolar epithelial cells remains unclear 
since there is evidence that Cl– is secreted (McCray et al., 1993; Tizzano et al., 1994; Lazrak et 
al., 2002; Sommer et al., 2007), as well as absorbed (Fang et al., 2002; Fang et al., 2006). There 
are at least two different Cl– channels identified in the apical membrane of pulmonary 
epithelial cells – the Ca2+ dependent Cl– channel (TMEM16a) (Caputo et al., 2008; Schroeder 
et al., 2008; Yang et al., 2008) and the cAMP dependent CFTR Cl– channel (Riordan et al., 
1989; Welsh and Smith, 1993). In addition it might be noted that alveolar epithelial cells are 
characterized by a high water permeability (Folkesson et al., 1994; Dobbs et al., 1998) 
although the role of these proteins in pulmonary fluid handling is uncertain since no 
significant impact of aquaporins on alveolar clearance has been detected in transgenic 
(aquaporin deficient) animals (Verkman et al., 2000; Verkman, 2007).  
However, the crucial importance of defined and regulated ion transport processes in the lung 
to control the water content is beyond dispute, since this was impressively confirmed by 
several studies using transgenic animal models with impaired ion channel functions. For 
example deletion of the  ENaC subunit in mice leads to early death due to the inability to 
reabsorb the alveolar fluid from the lungs after birth (Hummler et al., 1996). Interestingly, 
rescuing  ENaC expression in transgenic mice that were derived from  ENaC deficient mice 
demonstrated that these animals expressed decreased levels of ENaC mRNA and that this 
resulted in an increased susceptibility to the formation of pulmonary edema (Olivier et al., 
2002). In addition overexpression of the ENaC subunit and hyperabsorption of Na+ is 
associated with impaired mucociliary clearance resulting in a phenotype that is characteristic 
for cystic fibrosis (Mall et al., 2004). Recent studies established that mutations in the CFTR gene 
of pigs resulted in a cystic fibrosis like lung disease (Rogers et al., 2008; Stoltz et al., 2010). 
3. Mechanical forces and breathing 
Ventilation of the lungs due to the movement of the chest is associated with the appearance 
of physical forces. These forces are pressure (force per area), strain (deformation e.g. 
reasoned by the impact of pressure) and shear stress (movement of fluid at the cellular 
surface) (Fig. 3) (Wirtz and Dobbs, 2000). It might also be considered that due to the 
complex anatomy of the gas exchanging area it is difficult to estimate the distinct forces 
acting on individual cells (Liu et al., 1999) and that the local appearance of forces can be 
influenced by parameters like surfactants, focal adhesion molecules, the contractile 
machinery of the cells as well as the activity of molecular motor proteins within the cells 
(Fredberg and Kamm, 2006).  
Although more or less all cell types within the lung are exposed to these physical stimuli the 
following section will focus on epithelial cells. Especially, the appearance and the reason for 
the stimuli as well as their impact on the pulmonary epithelial cells will be discussed. 
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Fig. 3. Breathing is associated with the appearance of physical forces. Airway epithelial cells 
are primarily exposed to shear forces that are reasoned by the airstream flowing passing the 
surface of the airways. In the alveolar region the main physical force is strain due to the 
positive and negative pressure that are reasoned by the movement of the chest. 
3.1 Pressure and strain in the lung 
The appearance of pressure is the consequence of the movement of the chest. During 
inspiration and expiration epithelial cells are exposed to negative and positive pressures. 
This pressure is defined as transpulmonary pressure and resembles the pressure difference 
between the pressure in the pleural space and the atmospheric pressure (Fredberg and 
Kamm, 2006). During inspiration at rest the inflating pressure is approx. 5 cm H2O and this 
can increase to approx. 30 cm H2O at deep inspirations (Fredberg and Kamm, 2006). In the 
lung the appearance of pressure will always cause deformation of the cells due to the 
delicate anatomy and morphology of the alveolar structure. Therefore, increasing pressure is 
always associated with the appearance of strain. From this point of view, it seems obvious to 
consider that strain rather than pressure is the adequate stimulus acting on epithelial cells as 
a consequence of the breathing movements (Liu et al., 1999).  
3.2 Shear stress in the lung 
In addition to strain, the luminal surface of the epithelial cells is exposed to shear stress. 
Shear stress is defined by the tangential movement of particles (e.g. air or fluid) at the 
surface between different physical compartments. In the airways shear stress is primarily 
caused by the oscillating airflow passing the surface of the airway epithelial cells (Tarran et 
al., 2006). In the distal lung regions shear stress is a consequence of the movement due to 
distention, where the epithelial cell represents one compartment that is distended and the 
fluid of the PLL represents a static component of another compartment. Thus a relative 
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movement of the epithelial cell (with respect to the fluid) will cause shear stress at the 
luminal surface of the cells.  
The next sections will focus on the impact of pressure and strain in particular on lung 
functions. 
3.3 Strain is crucial for several functions of epithelial cells 
It is well known that physical forces are important stimuli for distinct cellular functions of 
pulmonary epithelial cells (Fig. 4). An important indication for this is represented by the fact 
that development of the mammalian lung within the last third of gestation depends on 
breathing movements although the lungs are fluid filled (Kitterman, 1996). In animal models 
prevention of these breathing movements by spinal nerve sections resulted in retarded lung 
growth and development (Fewell et al., 1981). Further, in vitro studies demonstrated that 
distention of alveolar epithelial cells is an important trigger that affects alveolar cell 
differentiation. Mechanical distention of isolated and cultivated fetal alveolar cells promotes 
their differentiation to AT I cells whereas that lack of distention promotes the differentiation 














Fig. 4. Under normal breathing conditions mechanical stimuli are important for several 
functions of the lung.  
Besides affecting cell differentiation and lung development there is also evidence for the 
contribution of physical stress as a factor that mediates production and secretion of 
surfactant proteins by ATII cells (Edwards et al., 1999) as well as by cultured H441 cells 
(Sanchez-Esteban et al., 1998). There is also evidence that mechanical forces induce 
apoptosis in ATII cells (Edwards et al., 1999; Hammerschmidt et al., 2007). In addition, 
different signaling mediators and ATP in particular are released in response to mechanical 
stress (Homolya et al., 2000; Okada et al., 2006; Button et al., 2007). The release of ATP offers 
the possibility to initiate a variety of different cellular reactions by acting on multiple 
purinergic receptors – including P2X, P2Y and P1 receptors (Leipziger, 2003; Bucheimer and 
Linden, 2004; Barth and Kasper, 2009). The relevance of purinergic signaling has been 
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implicated by a study identifying alterations of transepithelial ion transport processes in 
airway epithelia in response to adenosine as a factor contributing to cystic fibrosis lung 
disease (Tarran et al., 2005; Tarran et al., 2006).  
3.4 Deleterious effects of mechanical forces in the lung 
Although, there is more than sufficient evidence that identifies mechanical stimuli as an 
important mediator for normal lung functions, a main reason for studying their effect in the 
lung arises from the hazardous effects that are caused by mechanical forces during artificial 
















Fig. 5. Effect of deleterious physical forces related to ventilator induced lung injury. This 
scheme was modified from (Frank and Matthay, 2003) and extended by the potential 
interference of mechanical stimuli with the activity of epithelial ion channels. This 
represents a yet unidentified mechanism to improve the understanding how mechanical 
forces contribute to the formation and probably maintenance of pulmonary edema. 
Artificial ventilation is a remedy of first choice for the treatment of patients with respiratory 
failure (e.g. acute lung injury (ALI); acute respiratory distress syndrome (ARDS)) (Ware and 
Matthay, 2000). However, the development of pulmonary edema due to fluid influxes into 
the airspace as well as the inability to resolve the edema fluid by decreased fluid 
reabsorption, is a major reason for the morbidity and mortality in these patients (Morty et 
al., 2007). The inability of the patients to resolve the edema fluid correlates with the 
mechanical ventilation duration times and mortality. High fluid clearance was associated 
with shorter durations of mechanical ventilation as well as with significantly decreased 
mortality rates (Sznajder, 2001; Ware and Matthay, 2001).  
Considering the important role of pulmonary ion transport processes as discussed above, it 
is obvious that pulmonary edema are somehow related to alterations of pulmonary ion 
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transport processes (Matthay, 2002). Although changes of ion transport processes do not 
have to be causative for the development of pulmonary edema – there is sufficient evidence 
demonstrating that artificial ventilation worsens the situation in ALI/ARDS patients. This 
phenomenon has been termed ventilator induced lung injury (VILI) (Ricard et al., 2003) and 
is attributed to inappropriate ventilation strategies and thus the appearance of extensive 
physical forces (Fig. 5) (Plataki and Hubmayr, 2010).  
This indication arises from the outcome of a multicenter trail study demonstrating a 
significantly reduced mortality in a group of patients that was ventilated with decreased 
tidal volumes (6 ml/kg) compared with high tidal volumes (12 ml/kg) (ARDS Network 
Investigators, 2000). Ventilation with decreased tidal volumes was also accompanied by the 
appearance of lower plateau pressures (ARDS Network Investigators, 2000) and this is 
associated with decreased mechanical forces.  
However, regarding the symptoms observed in patients with ALI, ARDS and VILI there is 
an obvious connection between artificial ventilation and the development of pulmonary 
edema. There are two possible explanations reasonable for the development of pulmonary 
edema related to artificial ventilation: 
1. Artificial ventilation causes ruptures and damages of the epithelial layer – enabling an 
uncontrolled influx of protein rich fluid into the airspace. 
2. Mechanical forces as appearing during ventilation directly interfere with pulmonary 
epithelial ion transport processes 
The first point has been extensively studied and there is no doubt that mechanical strain 
induced by artificial ventilation is a major reason for the development of pulmonary edema 
(Frank and Matthay, 2003). This is clearly indicated by the appearance of proteins in the 
edema fluid (Ware and Matthay, 2000). The second point is also obvious since a correlation 
between the ability to reabsorb alveolar fluid and the outcome of patients has been 
identified (Ware and Matthay, 2001). But for this instance, the mechanisms how artificial 
ventilation and thus mechanical forces interfere with ion transport processes are unknown.  
3.5 Tools for studying the impact of mechanical forces on pulmonary ion transport 
The first choice for studying functional epithelial ion transport is represented by 
electrophysiological Ussing chamber recordings. This technique was established by Hans 
Ussing during his studies on ion transport processes across the amphibian skin (Ussing and 
Zerahn, 1951). A major advantage as well as a prerequisite of this technique is the use of an 
intact epithelial layer consisting of differentiated polar cells. Although this technique is 
applicable for many freshly dissected epithelia including airway epithelia from mammals 
(Olver et al., 1975; Widdicombe and Welsh, 1980), the use of mammalian alveolar epithelium 
for elaborating this technique is not possible. This is due to the complex anatomy reasoned 
by miniaturization of the gas-exchanging region. Improved protocols and procedures for the 
isolation and cultivation of alveolar cells generally fixed this problem, but the use of isolated 
cells bears the risk of using cells with an artificial non-physiological phenotype. There is a 
bunch of studies published demonstrating that in isolated and cultivated cells the 
expression of ion transport proteins as well as their phenotype in terms of ion transport 
properties vary in dependence of the cultivation conditions used (Kunzelmann et al., 1996; 
Jain et al., 2001; Leroy et al., 2004; Dvorak et al., 2011). Further, these cells do not have their 
native surrounding (neighboring cells of different cell type, basal lamina etc.) that is 
important for the detection and transmission of forces. It remains also a challenge to expose 
these cultivated cells to defined physical forces (e.g. strain) to determine immediate changes 
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of ion transport processes because usually the cells are cultivated on rigid polyester or 
polycarbonate membranes.  
On the other hand pioneer studies addressing the function and relevance of pulmonary ion 
transport were performed on anaesthetized animals (Egan et al., 1976; Matthay et al., 1982). 
These studies identified the basic mechanisms of water and electrolyte transport by the 
alveolar epithelium. However, from such studies it is difficult to disentangle the particular 
ion conductances and to identify the specific ion transporting molecules that are involved in 
those processes.  
3.5.1 Using native lung preparations for studying the impact of strain on pulmonary 
epithelial ion transport  
Our lab has therefore established a native model for investigations of pulmonary ion 
transport. In accordance to Krogh’s principle (Krebs, 1975) we decided to use lung 
preparations derived from the South African Clawed Frog Xenopus laevis. The alveolar 
epithelium of the Xenopus lung consists of one cell type referred to as pneumocytes (Meban, 
1973). The anatomy and morphology of these cells is reminiscent to that of alveolar type I 
cells (Fischer et al., 1989), but they expose functional properties of alveolar type II cells as 
represented by the presence of lamellar bodies (Fischer et al., 1989). Most important, the 
Xenopus pneumocytes expose a Na+ reabsorptive phenotype (Fischer et al., 1989; Kim, 1990; 
Fronius et al., 2003). In addition, expression and function of the CFTR Cl– channel has been 
detected (Sommer et al., 2007). Recent studies identified the presence of the Na+/K+/2Cl– 
cotransporter, the function of a HCO3–/Cl– exchanger (Berger et al., 2010) and evidence for 
basolateral Cl– channels (Berger et al., 2011). Thus, the Xenopus pneumocytes exhibit the 
basic repertoire of ion channels and transporters that are supposed to be important in 
mediating the volume of the PLL.  
The main advantage of this amphibian organ is its relatively simple sac-like structure. This 
feature is a prerequisite for dissecting a preparation that is suitable for Ussing chamber 
recordings. Comparable studies with other native lung preparations from higher vertebrates 
– and mammals in particular - are not possible, because of the growing complexity and 
miniaturization of the gas-exchanging region. In addition to establishing the use of Xenopus 
lung preparations for electrophysiological recordings, an Ussing chamber was developed 
that enables the exposure of the mounted pulmonary epithelium to mechanical forces. 
Mechanical forces are applied via an increased hydrostatic pressure and this is achieved by 
changing the outflow-height from the compartments Fig. 6.  
4. Impact of strain on pulmonary ion transport in the Xenopus lung  
Although the connection between high tidal volumes and pulmonary edema has been well 
established, little is known whether or not the underlying mechanisms can be attributed – at 
least partly – to a direct interaction of the mechanical forces with ion transport processes. 
Studies have been published providing evidence that high volume ventilation resulted in a 
decreased Na+ transport due to a decreased Na+/K+-ATPase activity (Lecuona et al., 1999). 
Other studies demonstrated an increased Na+/K+-ATPase activity in response to cyclic 
stretch (Fisher and Margulies, 2002). Although these studies identified interference of strain 
with Na+/K+-ATPase activity, changes were observed hours after exposure to mechanical 
forces. So far little is known about a direct short-term effect of mechanical forces on ion 
transport processes in the lung. 
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Fig. 6. Drawing of the Ussing chamber used to study the effect of mechanical forces on 
pulmonary epithelial ion transport (modified from (Bogdan et al., 2008)). Mechanical forces 
were applied by increasing the water column (5 cm water column) of the outflow. Both 
chamber compartments (apical, basolateral) were continuously perfused and the 
transepithelial short-circuit current (ISC) and potential (VT) was permanently monitored (ti: 
mounted tissue).  
Using Xenopus lung preparations in combination with a customized Ussing chamber (Fig. 6) 
5 cm hydrostatic pressure was applied from the apical side to mechanically challenge the 
tissue. Application of hydrostatic pressure was accompanied by immediate changes of the 
measured transepithelial short-circuit current (ISC). The net effect induced by 5 cm H2O was 
characterized by a decreased transepithelial current (Bogdan et al., 2008). Interestingly, the 
application of 5 cm H2O from the basolateral side induced exactly the same response 
whereas the application of 5 cm H2O synchronously from the apical and basolateral side did 
not cause any effect of the ISC (Bogdan et al., 2008). These observations clearly demonstrate 
that the effective mechanical stimulus is strain and that it does not matter from which side 
the tissue is deflected.  
In this setup a decreased transepithelial ion current is an indication for a decreased net 
reabsorption of ions from the apical to the basolateral side of the epithelium. Further, a 
reduced ion reabsorption reasoned by changes in ion transport processes will also reduce 
the osmoticaly driven water reabsorption from the airspace. This means that the changes of 
ion transport in the pulmonary epithelium observed with hydrostatic pressure decrease 
water reabsorption from the airspace and this represents a mechanism to facilitate the 
development of pulmonary edema – without affecting the integrity of the epithelial barrier 
that was assessed by determining the transepithelial electrical resistance.  
4.1 Strain induces short-term activation of Na+, K+ and Cl– channels 
Further investigations using different ion channel inhibitors and substituting different ions 
from the perfusion solution revealed that the observed effect is reasoned by the activation of 
different ion channels and ion conductances resembled by: 
1. activation of amiloride-sensitive Na+ reabsorption 
2. activation of an apical Cl– secretion  
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3. activation of an apical K+ secretion  
Therefore, the inhibitory effect observed in the absence of drugs is an overlay of these three 
conductances (Fig. 7). Activation of Na+ reabsorption as well as an increase of Cl– secretion 
will produce an increase of the ISC. In contrast to this, activation of apical K+ channels will 
cause a decrease of the ISC. Since the net pressure effect is an inhibition of the ISC, the major 
response observed by the application of hydrostatic pressure is due to an activation of apical 
K+ channels. Accordingly, the inhibitory effect of hydrostatic pressure should be prevented 
(or reversed  activation of the ISC) following pre-incubation with K+ channel inhibitors. 
And indeed this is exactly what we observed (Bogdan et al., 2008). Further, it has been 
found that the pressure-induced effect was largely prevented by glibenclamide (Bogdan et 
al., 2008), a compound that is a high affinity inhibitor of ATP-sensitive K+ channels (KATP) 
(Nichols, 2006). Among other activating mechanisms, the activity of KATP channels is 
dependent on intracellular cyclic nucleotide levels and ATP in particular (Nichols, 2006). 
Interestingly, increased extracellular ATP concentrations were observed in response to the 
application of hydrostatic pressure and this represents a likely mechanism to explain our 
observations.  
KATP channels are octameric complexes consisting of four pore forming Kir (inward 
rectifying K+ channels) subunits and four associated SUR (sulfonylurea receptor) subunits 

















Fig. 7. Scheme illustrating the putative mechanism how hydrostatic pressure acts on 
epithelial ion transport processes in Xenopus lung epithelium (modified from Bogdan et al., 
2008). The entire process could be initiated by the release of ATP via a yet unknown 
mechanism (1). The decrease of intracellular ATP levels ([ATP]i) is likely to activate KATP 
channels (2). This will then cause the cell membrane potential to hyperpolarize (3) and 
subsequently facilitates the uptake of Na+ via apical Na+ channels (4) as well as the secretion 
of Cl– via apical Cl– channels. 
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membrane potential  (Nichols, 2006) and this in turn enables the possibility to influence the 
driving forces for other conductances such as Na+ and Cl–. From this point of view it might 
be suggested that strain is primarily transduced in activation of KATP channels and that this 
in addition influences secondarily Na+ and Cl– transport as we observe by the application of 
hydrostatic pressure on Xenopus lung epithelia. Interestingly, increased ATP levels are also 
observed in rats ventilated with injurious ventilation parameters. In those experiments the 
increase of extracellular ATP concentrations was not reasoned by cell damage or cell lysis 
(Rich et al., 2003). These observations together with our findings indicate that the release of 
ATP (by a yet unidentified mechanism) might play a key role concerning the activation of 
ion channels in response to mechanical forces.  
Last but not least it might be highlighted that the effect that was observed in response to the 
application of hydrostatic pressure (inhibition of the ISC) represents a mechanism that 
impairs ion reabsorption from the alveolar airspace. This will result in a decrease osmotic 
gradient across the epithelial layer and will subsequently cause a reduction of fluid 
reabsorption from the airspace. Thus, this is a likely mechanism that impairs the resolution 
of pulmonary edema or maybe represents a mechanism that – among other incidents – 
initiates the formation of pulmonary edema in response to strain as induced by artificial 
ventilation.  
5. Conclusions 
The fact that mechanical forces directly affect pulmonary epithelial ion transport is 
important for future therapeutic options. On the one hand it further confirms the 
observations that modified ventilation strategies with low pressures and reduced volumes 
are beneficial for the outcome of patients with respiratory failure that are admitted to 
artificial ventilation. Therefore, the development of new ventilation strategies should be 
considered with the background that a minimum of mechanical stress should be used 
because this decreases interference with ion transport processes and this will preserve the 
ability of the epithelium for effective ion and water reabsorption. 
On the other hand, it offers new therapeutic targets since we have evidence that K+ channels 
and KATP channels in particular play a major role in the response observed by increased 
hydrostatic pressure. In our experiments, the inhibition of these channels has been identified 
to largely abolish the mechanically induced activation of K+ channels and this would be 
beneficial to prevent the reduced ion transport absorption as that correlates with a 
decreased water reabsorption from the airspace. Another possibility in order to prevent the 
effects of strain on ion channels might be represented by the possibility to target the release 
of ATP, although the mechanisms of ATP release are still under debated.  
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1. Introduction 
In evaluating the respiratory system, many different tests are used and these can be divided 
into different categories based on the aspect of lung function they measure. Depending on 
availability and need, the tests can be complementary and yield results that allow deeper 
insight into respiratory function to understand disease processes and therapeutic 
interventions - both medical  and surgical. 
 
 
Table 1. The categories of pulmonary function testing  
Categories of Pulmonary Function Tests 
a. Airway Function 
- Simple spirometry ( VC, expiratory reserve volume {ERV}, 
inspiratory capacity {IC} ) 
- Forced vital capacity (FVC,  from which the Forced Expired 
Volume in the first second is derived- FEV1) 
- Maximal inspiratory / expiratory pressures (MIP / MEP) 
b. Lung volumes and ventilation 
- Function residual capacity (FRC) 
- Total lung capacity (TLC) 
- Residual Volume (RV) 
- RV / TLC ratio 
c. Diffusing Capacity Test 
- Single breath (breath holding) 
d. Blood gases and gas exchange tests 
- Blood gas analysis and blood oximetry 
- Pulse oximetry 
e. Cardiopulmonary exercise tests 
- Simple non-invasive tests 
- Tests with exhaled gas analyses 
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1.1 Spirometry & other related tests 
Spirometry is a physiological test that measures how an individual inhales or exhales 
volumes of air as a function of time. The primary signal measured may be volume or time. 
Spirometry is the pulmonary function test performed most often due to the large number of 
indications. “It is most often performed as a screening procedure because it may be the first 
test to indicate the presence of pulmonary disease”(Ruppel, 2009).  
 
 
Table 2. List of indications for spirometry (Ruppel, 2009) 
“Spirometry is recommended as the “gold standard” for the diagnosis of obstructive 
lung disease. However spirometry alone may not be sufficient enough to completely 
define the extent of disease, therapy response, preoperative risk, or level of impairment 
(Ruppel,2009)”.  
In view of the importance of spirometry in aiding an accurate diagnosis and monitoring 
changes that can be extremely subtle, a good quality spirometer is essential. As the machines 
become increasingly sophisticated and computerised, it is imperative that they meet the 
technical specifications so that are accurate and precise. These criteria are quite complex but 
are well laid out by the American Thoracic Society (ATS- Standardization of Spirometry, 
1994 Update). Thus in purchasing or utilising such a device it is crucial that one obtains the 
manufacturer’s guarantee that a reputable testing facility has checked that the spirometer 
meets and conforms with the ATS recommendations for accuracy and precision. Equally, a 
well trained pulmonary function technologist who understands the calibration and pitfalls 
of the testing can be invaluable. 
Indications for Spirometry 
a. Diagnose the presence / absence of lung disease. 
1. History of pulmonary symptoms (dyspnoea, wheezing, cough, 
phlegm production, orthopnoea) 
2.    Physical indicators ( decreased breath sounds, chest wall 
abnormalities) 
3.    Abnormal Laboratory findings ( Chest x-ray or CT studies) 
b. Quantify the extent of known disease on lung function 
1. Pulmonary disease (COPD, Asthma) 
2. Cardiac disease (Cardiac Failure) 
3. Neuromuscular disease (e.g. Guillain-Barrè syndrome) 
c. Measure effects of occupational / environmental exposures 
d. Determine beneficial / negative effects of therapy 
e. Assess risk for surgical procedures 
1. Lung resection 
2. Thoracic procedures 
3. Pulmonary rehabilitation 
f. Evaluate disability or impairment 
g. Epidemiologic or clinical research involving lung health or disease. 
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“The two most important measurements of spirometry are (1) forced vital capacity 
(FVC), which is the volume delivered during an expiration made as forcefully and 
completely as possible starting from full inspiration, and the (2) forced expiratory 
volume in one second (FEV1)  of an FVC manoeuvre (ATS/ERS,2005)”.  
Another variable derived from spirometry is the slow vital capacity (VC), which is the 
volume of gas measured from a slow, complete expiration after a maximal inspiration, 
without forced or rapid effort. The Inspiratory capacity (IC) and expiratory reserve volume 
(ERV) are subdivisions of the VC. The IC is the largest volume of gas that can be inspired 
from a resting expiratory level. ERV is the largest volume of gas that can be expired from the 
resting end-expiratory level. IC and ERV are used in the calculation of the residual volume 
(RV) and total lung capacity (TLC). The RV is the volume of gas remaining in the lungs at 
the end of maximal expiration regardless of the lung volume at which exhalation was 




Fig. 1. A schematic presentation of the lung volumes and capacities. 
 
Table 3. A list of contraindications to spirometry (Ruppel,2009). 
Contraindications to Spirometry 
- Myocardial infarction within the last month 
- Recent stroke, eye surgery, thoracic / abdominal surgery 
- Uncontrolled hypertension 
- Known aortic, thoracic, cerebral aneurysm 
- Recent pneumothorax 
- Relative contraindications: chest, abdominal, facial pain, 
headache, stress incontinence, dementia, confusion 
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2. Flow-volume loop 
This procedure is used to measure the FVC, FEV1 and other forced expiratory flow volumes. 
This test is dependent on patient effort.  
2.1 Significance and pathophysiology 
2.1.1 Forced Vital Capacity 
The FVC usually equals VC in healthy individuals and should be within 150ml of each 
other. The FVC and VC may differ if the patient’s effort is variable or if significant airway 
obstruction is present (FEV1 / FVC is less than 70%). The FVC may be lower than VC in 
patients with obstructive diseases as forced expiration can cause airway collapse. In these 
situations a slow VC (SVC) may be more accurate. 
Healthy adults can expire their FVC within 4-6 seconds. Healthy children and adolescents 
may exhale their FVC in less than 4 seconds. Patients with severe obstruction may require 15 
seconds or more to exhale completely.  
2.1.2 Forced expiratory volume in the first second (FEV1) 
FEV1 is reported as a volume, although it measures flow over a specific interval. FEV1 may 
be reduced in either obstructive or restrictive patterns. The FEV1 and FEV1 / FVC ratio are 
the most standardized indices of obstructive diseases. An obstructive defect is defined best 
by a reduced ratio. 
The severity of an obstructive disease may be gauged by the extent to which FEV1 is 
reduced. The ATS / ERS 2005 Task force suggests the following classifications of severity 
(Ruppel, 2005): 
 
Mild   FEV1 > 70% predicted 
Moderate  FEV1 = 60% - 69% predicted 
Moderately severe FEV1 = 50% -59% predicted 
Severe   FEV1 = 35% - 49% predicted 
Very severe  FEV1 < 35% of predicted 
Once the VC is below normal, a concomitant restrictive defect may also be present, and this 
can be determined by further measurement of volumes, in particular TLC. Restrictive 
processes such as fibrosis, oedema, and obesity may all cause a decrease in FEV1. Unlike the 
pattern seen in obstructive diseases, in which VC is preserved and FEV1 reduced, in 
restriction VC and FEV1 values are proportionally decreased. 
The FEV1 is the most widely used spirometric parameter, particularly for the assessment of 
airway obstruction. It is also used in conjunction with VC for simple screening, assessment 
of response to bronchodilators, and detection of exercise-induced bronchospasm. 
2.1.3 FEV1 / FVC ratio 
The normal ratio expressed as a percentage for healthy adults is between 75% - 85%. This 
value can decrease with age, presumably because of gradual loss of lung elasticity. 
Diagnosis of an obstructive pattern based on spirometry should focus on three primary 
variables: FVC, FEV1, and FEV1 / FVC.  
Examples of patterns seen in flow volume loops follow: The actual curve (with asterisks) is 
usually superimposed on the predicted as derived by the computer based on age, gender, 
height and ethnicity. 
 




            Normal curve   Obstructive curve       Restrictive curve 
2.2 Reversibility testing 
This is the determination of reversibility in airflow-limitation  with drug administration and 
is commonly undertaken as part of lung function testing. The choice of drug, dose and mode 
of delivery is a clinical decision depending on what the clinician wishes to learn from the 
test. The aim is to determine whether the patient’s lung function can be improved with 
therapy. 
The subject first undergoes baseline lung function testing, preferably with no prior drug 
therapy. According to the ATS/ERS 2005 guidelines, short-acting inhaled drugs should not 
be used 4hr prior to testing and long-acting β-agonist bronchodilators or oral aminophylline 
should be stopped 12hr prior to testing. Smoking should be avoided for an hour or more 
prior to testing as well as throughout the duration of the test procedure. 
2.2.1 Procedure (ATS/ERS, 2005) 
1. The subject performs  3 acceptable tests, with acceptable repeatability of the two highest 
FEV1, FVC and PEF as a baseline. 
2. The drug administered (100ug Salbutamol) is inhaled in one breath to TLC from a 
valved spacer device. The breath is then held for 5-10 s before the subject exhales.  
3. Three further doses of Salbutamol (total dose 400ug) are delivered at 30s intervals. 
4. Step 1 is repeated 10 – 15 min after administration of a short acting β2- agonists (and 30 
min after short-acting anticholinergic agents). 
2.2.2 Determination of reversibility 
A positive response to bronchodilator therapy is when either the FVC or the FEV1 of the 
post attempt improves by 12% and 200ml from the pre attempt. 
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2. BD response =    FVC post  –  FVC pre 100
1 1
  
2.2.3 Clinical significance 
Reversibility of airway obstruction is considered significant for increases of greater than 12% 
and 200ml for either the FEV1 or FVC. If the sGaw is assessed, an increase of 30%-40% is 
usually considered as significant. Some patients may show little or even no improvement in 
FEV1, but have a significant improvement in their sGaw. 
Increases greater than 50% in the FEV1 may occur in patients with asthma. Patients with 
chronic obstructive pulmonary diseases may show little improvement in their flows. Failure 
to show a significant improvement after inhaled bronchodilator therapy does not exclude a 
response. 
It has been erroneously extrapolated that reversibility testing can define a disease; this is not 
true ( Richter & Irusen, 2008). Asthma can be irreversible on spirometry ( especially when 
there is uncontrolled inflammation impairing bronchodilatation) and COPD can be 
spirometrically reversible in up to 50% of patients. ( In this respect, the absolute volume of 
improvement is more important as it is easy to get a significant percentage change when one 
starts with a low baseline.) 
3. Maximal inspiratory / expiratory pressure ( MIP & MEP) 
Forced manoeuvres during spirometry require the patient to give a maximal effort, yet it 
also requires that the patient should have normal muscle function. Muscle function is best 
assessed by measurement of maximal inspiratory and expiratory pressures. Maximal 
inspiratory pressure (MIP) is the lowest pressure developed during a forceful inspiration 
against an occluded airway. Maximal expiratory pressure (MEP) is the highest pressure 
that can be developed during a forceful expiratory effort against an occluded airway. 
3.1 Significance and pathophysiology 
MIP primarily measures inspiratory muscle strength. Healthy adults can generate 
inspiratory pressures greater than -50cmH2O in women, and -75 cmH2O in men (Ruppel, 
2009). Decreased MIP is seen in patients with neuromuscular disease or diseases involving 
the diaphragm, intercostals or accessory muscles. MIP may also be decreased in patients 
with hyperinflation as in emphysema. MIP is sometimes used to assess patient response to 
strength training of respiratory muscles. It is also used in the assessment of respiratory 
muscle function in patients who need ventilatory support. 
MEP measures the pressures generated during maximal expiration. Healthy adults can 
generate MEP values greater than 80 cmH2O in women and greater than 100 cmH2O in men 
(Ruppel, 2009). MEP may be decreased in patients with neuromuscular disorders, 
particularly those resulting in generalized muscle weakness.  
Reduced MEP often accompanies increased RV as seen in emphysema. A low MEP is 
associated with inability to cough effectively. 
Accurate measurement of MIP & MEP depends largely on patient effort. The best efforts 
should be reproducible within 20% or 10 cmH2O, whichever is greater. Widely varying 
pressures for either MIP or MEP should be assessed carefully before interpretation. 
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4. Body plethysmography  
The forces governing maximal airflow are the elastic recoil pressure of the lung and airway 
resistance upstream from the equal pressure point. Airway resistance (Raw) is the pressure 
difference per unit flow as gas flows into or out of the lungs. Raw is the difference between 
the mouth pressure and alveolar pressure, divided by flow at the mouth.  
Airway conductance (Gaw) is the flow generated per unit of pressure drop across the 
airways. Gaw is not commonly reported as it changes with lung volume. Instead, specific 
airway conductance (sGaw), which is Gaw divided by the lung volume at which the 
measurement was made, is usually reported (Ruppel, 2009).  
Spirometry may be performed with the patient in the plethysmograph. The 
pneumotachometer must be capable of accurately measuring the entire range of gas flows 
required.  
Spirometry, lung volumes, and airway resistance can all be obtained in a single sitting using 
plethysmography. 
4.1 The most common measurements made using a body plethysmograph are:  
- Airway resistance (Raw). 
- Lung Volumes: 
 VC= Volume measured from a maximal inspiration followed by a complete slow 
expiration. 
 FRC= It is the volume of air left in the lungs at the end of a quiet exhalation 
 IC = Maximal volume of air inspired from a resting expiratory level. 
 ERV= Maximal volume of air expired from a resting expiratory level 
 TGV= Is the absolute volume of gas in the thorax at any point in time and at any 
level of alveolar pressure 
 RV= Volume of air remaining in the lungs at the end of a maximal expiration. 
 TLC= Volume of gas that the lungs contain after maximal inspiration. 
 RV/TLC (must be in the range 20 – 35% in order to be normal) 
4.2 Important derivatives 
4.2.1 Thoracic Gas Volume (TGV) 
The TGV is a quick and accurate means of measuring lung volumes. It can be used in 
combination with simple spirometry to derive all lung volume compartments. The 
plethysmograph’s primary advantage is that it measures all gas in the thorax, whether in 
ventilatory communication with the atmosphere or not. 
4.2.1.1 Clinical Significance 
Normative data for TGV and pulmonary subdivisions allow definition of restrictive lung 
disease as distinct from obstructive, in the presence of a reduced VC. Definition of 
abnormally increased lung volumes in obstructive lung disease is a further appropriate 
clinical use of whole-body plethysmography. While lung volumes can be measured by gas 
dilution techniques, it is well known that dilution techniques measure only the volume of 
ventilated airspaces. Accordingly, when whole-body plethysmography is combined with 
dilution measures of lung volumes, the volume of trapped gas is estimated by the difference 
between FRCBox and dilutional FRCGas. 
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The ratio of FRCBox/FRCGas can be used as an index of gas trapping. This ratio is usually 
near 1.0 in patients with normal lungs, or even with restriction.  
Values greater than 1 indicate gas volumes detectable by the plethysmograph but hidden to 
the gas techniques. Care must be taken that lung volumes determined by the 2 methods are 
reliable before the values can be expressed as a ratio. This ratio has been used to evaluate 
candidates for lung volume reduction surgery (LVRS). Lung volume reduction attempts to 
directly reduce gas trapping by removal of unperfused lung tissue. Patients with bullous 
emphysema may have a litre or more difference in TLC (Total Lung Capacity) when the 
methods are compared. 
Some evidence suggests that in severe airway obstruction, FRC may actually be 
overestimated when the plethysmographic technique is used. This occurs primarily because 
PMouth may not equal alveolar pressure if the airways are severely obstructed. Rapid 
panting rates aggravate this inaccuracy. 
4.2.2 RAW  
Airway resistance (Raw) is the pressure difference per unit flow as gas flows into or out of 
the lungs. Raw is the difference between mouth pressure and alveolar pressure, divided by 
flow at the mouth. This pressure difference is caused primarily by the friction of gas 
molecules in contact with the airways. 
4.2.2.1 Clinical Significance 
The tracing labelled “(a)” displays a schematic sRaw loop in a normal patient during tidal 
breathing, which is shown after numerical software compensations to close the sRaw loop. 
Normal patients manifest a steep linear loop during tidal breathing without hysteresis. In 
contrast, during voluntary panting efforts, the upper and lower end portions of the loop 
may become slightly curvilinear.  
The curvilinearity is in the form of a very slight "S" shape, analogous to that shown in 
tracing “(d)”, but much less exaggerated. In normal patients during voluntary panting, the 
flattening of the sRaw loop at the upper right extremity (mid-inspiration) and at the lower 
left extremity (mid-expiration) of the loop are only barely visible, depending on the absolute 
value of flow rates achieved.  
Tracing “(b)” is typical of patients with large (central) airway constriction that is relatively 
uniform (and not a localized stenosis) and without significant small airway obstruction. This 
might be seen in a patient with mild asthma. 
It is well known that expiratory flow limitation and dynamic airway compression may occur 
during tidal breathing in COPD, and this contributes to the characteristic shape of the sRaw 
loop in tracing “(c)”. 
Tracing “(d)” shows the influence of a fixed or functional stenosis of the upper airways, for 
example laryngeal abnormality, or paralysis of one vocal cord. This type of "orifice" 
constriction manifests flow limitation during inspiration, such that, at sufficiently high 
flows, further increases in driving pressure do not result in any increase in airflow. This 
reflects localized upper airway obstruction, analogous to that which pertains in the maximal 
expiratory flow–volume curve. Thus, during forced expiration, when a critical driving 
pressure for expiratory airflow (intra-pleural pressure for forced expiration) is achieved, 
further increases in driving pressure do not cause any further increases in flow rate. A 
similar flow limitation may occur in the extra-thoracic airway during inspiration, as shown 
in the upper right portion of tracing “(d)”. 
 




Fig. 2. A schematic presentation of the flow / volume shift measuring Raw 
5. Functional Residual Capacity (FRC)  
The FRC is the volume of air left in the lungs at the end of a quiet exhalation. There are 2 
methods of measuring FRC which are (1) helium dilution and (2) the Nitrogen washout 
technique. 
5.1 Helium dilution 
The method for measuring lung volumes is based on the equilibration of gas in the lung 
with a known volume of gas containing helium. The test gas consists of air with added 
oxygen of 25–30%, but higher concentrations are acceptable. 
5.1.1 Measurement technique (ATS / ERS, 2005)  
Specific details of procedures will vary with different types of equipment and degrees of 
automation, but the basic procedure is as follows.  
1. The equipment should be turned on and allowed an adequate warm-up time. 
2. The equipment should be set up for testing, including calibration, according to 
manufacturer’s instructions. 
3. The patient should be asked if he/she has a perforated eardrum (if so, an earplug 
should be used). 
4. The patient is seated comfortably, with no need to remove dentures. The procedure is 
explained, emphasising the need to avoid leaks around the mouthpiece during the test 
and to use a nose clip. 
5. The patient breathes for  30–60 s on the mouthpiece to become accustomed to the 
apparatus and to ensure a stable end-tidal expiratory level.  
6. The patient is turned ‘‘in’’ (i.e. connected to the test gas) at the end of a normal tidal 
expiration.  
7. The patient is instructed to breathe regular tidal breaths.  
8. The O2 oxygen flow is adjusted to compensate for O2 consumption (significant errors in 
the calculation of FRC can result if O2 consumption is not adequately accounted for).  
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9. The helium concentration is noted every 15 s.  
10. Helium equilibration is considered to be complete when the change in helium 
concentration is, 0.02% for 30 s. The test rarely exceeds 10 min, even in patients with 
severe gas-exchange abnormalities [9].  
11. Once the helium equilibration is complete, the patient is turned ‘‘out’’ (i.e. disconnected 
from the test gas) of the system. If the measurements of ERV and IC are to be linked to 
the FRC measured, it should be ensured that the spirometer has an adequate volume for 
the full ERV and IVC manoeuvres (fig. 5).  
12. At least one technically satisfactory measurement should be obtained. Due to the extra 
costs and time in making multiple measurements, and the relatively good inter-day 
variability in adults, two or more measurements of FRCHe need to be made only when 
necessitated by clinical or research need . If only one measurement of FRCHe is made, 
caution should be used in the interpretation. For younger children, however, it is 
recommended that at least two technically satisfactory measurements be performed. If 
more than one measurement of FRCHe is carried out, the value reported for FRCHe 
should be the mean of technically acceptable results that agree within 10%. 
5.2 Nitrogen washout technique (ATS / ERS, 2005) 
This technique is based on washing out the N2 from the lungs, while the patient breathes 
100% O2. The initial alveolar N2 concentration and the amount of N2 washed out can then be 
used to calculate the lung volume at the start of washout. The technique originally utilized 
gas collections for a 7-min period, a period deemed adequate for washout of N2 from the 
lungs of healthy subjects. The measurement technique should adhere to the following steps: 
1. The equipment should be turned on and allowed an adequate warm-up time, with 
calibration as instructed by the manufacturer.  
2. The patient should be asked if he/she has a perforated eardrum (if so, an earplug 
should be used). 
3. The patient is seated comfortably, with no need to remove dentures. The procedure is 
explained, emphasizing the need to avoid leaks around the mouthpiece during the 
washout and using a nose clip. 
4. The patient breathes on the mouthpiece for 30–60 s to become accustomed to the 
apparatus, and to assure a stable end-tidal expiratory level.  
5. When breathing is stable and consistent with the end-tidal volume being at FRC, the 
patient is switched into the circuit so that 100% O2 is inspired instead of room air. 
6. The N2 concentration is monitored during the washout. A change in inspired N2 of .1% 
or sudden large increases in expiratory N2 concentrations indicate a leak; hence, the test 
should be stopped and repeated after a 15-min period of breathing room air.  
7. The washout is considered to be complete when the N2 concentration is, 1.5% for at 
least three successive breaths.  
8. At least one technically satisfactory measurement should be obtained. If additional 
washouts are performed, a waiting period of ≥ 15 min is recommended between 
trials. In patients with severe obstructive or bullous disease, the time between trials 
should be ≥ 1 h, if more than one measurement of FRCN2 is made, the value reported 
for FRCN2 should be the mean of technically acceptable results that agree within 10%. 
If only one measurement of FRCN2 is made, caution should be used in the 
interpretation. 
 




Fig. 3. A schematic presentation of the single breath DLCO manoeuvre 
6. Diffusing capacity (DLCO) 
6.1 Definition 
DLCO measures the transfer of a diffusion-limited gas (CO) across the alveoli capillary 
membranes. DLCO is reported in millilitres of CO/minute/ml of Mercury at STPD. 
6.2 Technique 
CO combines with Haemoglobin (Hb) approximately 210 times more readily than O2. In the 
presence of normal amounts of Hb and normal ventilator function, the primary limiting 
factor to diffusion of CO is the status of alveolocapillary membranes. 
Diffusing capacity can be affected by factors that change the membrane component, as well 
as by alterations in Hb and in the capillary blood volume. DLCO is used to assess the gas 
exchange ability of the lungs, specifically oxygenation of mixed venous blood. 
DLCO is used to evaluate pulmonary involvement in systemic diseases such as rheumatoid 
arthritis. DLCO measurements are often included in the evaluation of patients with 
obstructive lung disease such as emphysema. 
DLCO may be indicated to monitor changes in lung function induced by drugs used to treat 
cardiac arrhythmias as well as changes caused by chemo and radiation therapy for lung 
cancer.  
 
Indications for DLCO 
a. Evaluate or follow the progress of parenchymal lung diseases 
b. Evaluate pulmonary involvement in systemic diseases 
c. Evaluate obstructive lung disease 
- Follow progression of disease 
- Differentiate types of obstruction 
- Predict arterial desaturation during exercise in COPD 
d. Evaluate cardiovascular diseases 
e. Quantify disability associated with interstitial lung disease 
f. Evaluate pulmonary haemorrhage, polycythemia, or left to right shunts 
(Increased DLCO) 
Table 4. A list of DLCO indications (Ruppel, 2009) 
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The most commonly used method is the single-breath or breath-hold technique. The single-
breath method is also the most widely standardized. 
6.3 Significance and pathophysiology 
The expected DLCO value in a healthy patient varies directly with the patient’s lung 
volume. Women have slightly lower normal values, presumably because of smaller normal 
lung volumes. DLCO values can increase 2-3 times in healthy individuals during exercise in 
response to increased pulmonary capillary blood flow. 
DLCO is often decreased in restrictive lung diseases, particularly those associated with 
pulmonary fibrosis. Fibrotic changes in the lung parenchyma are associated with asbestosis, 
berylliosis, and silicosis. Idiopathic pulmonary fibrosis, sarcoidosis, SLE, scleroderma are 
associated with a decreased DLCO. Inhalation of toxic gases causes alveolitis and a decrease 
in DLCO values. 
A decrease in DLCO is more likely to be related to the loss of lung volume, alveolar surface 
area, or capillary bed than to thickening of the alveolocapillary membrane. DLCO also 
decrease when there is a loss of lung tissue or replacement of normal parenchyma by space 
occupying lesions such as tumours. DLCO may also be reduced in the presence of 
pulmonary oedema. 
Low resting DLCO (less than 50-60 % of predicted) may indicate the need for assessment of 
oxygenation during exercise. DLCO is directly related to lung volume (VA) in healthy 
individuals. DL / VA  relationship can be useful to differentiate whether decreased DLCO is 
the result of loss of lung volume or from some other causes. 
In obstruction, low DLCO without reduction in VA results in a low ratio. In a purely restrictive 
process, a decrease in DLCO reflects loss of VA and the DL / VA  ratio is preserved. 
Numerous other physiologic factors can influence the observed DLCO: 
- Hb and Hct, COHb 
- Alveolar PCO2 
- Pulmonary capillary blood volume 
- Body position 
- Altitude above sea level 
- Asthma and obesity 
6.4 Interpretive strategies (Ruppel, 2009) 
- If DLCO is less than the lower limit of normal (LLN) after appropriate corrections, it’s 
likely that a gas exchange abnormality exists. Evaluate   DL / VA  
- If DL / VA ratio is normal, reduced diffusing capacity is likely related to decreased lung 
volumes, parenchymal changes, pulmonary vascular disease or pulmonary 
hypertension. Consider clinical correlation. 
- If DL / VA ratio is decreased, reduced diffusing capacity is likely related to airway 
obstruction or increased dead space. Compare VA and TLC; a large difference suggests 
uneven distribution of ventilation. 
- If DLCO is increased after correction of Hb or altitude, consider possible causes of 
increased pulmonary blood volume, haemorrhage, obesity of left-to-right shunts. Also 
consider undiagnosed asthma. 
- If DLCO is less than 50% of predicted, consider additional tests such as blood gases, 
exercise desaturation study. 
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7. Blood gases 
Blood gas is the most basic test of lung function. Blood gas analysis is often done in 
conjunction with pulmonary function studies. Blood is drawn from a peripheral artery 
without being exposed to air (anaerobically). Blood gas analysis includes measurement of 
ph, pCO2, and pO2.  
The same specimen may be used for blood oximetry to measure total Hb, oxyhaemoglobin 
(O2Hb), carboxyhaemoglobin (COHb) and methaemoglobin (MetHb). Blood gas is the ideal 
measurement of pulmonary function because is assesses the two primary functions of the 
lung – oxygenation and carbon dioxide removal.  
7.1 Indications 
1. Evaluate adequacy of lung function 
2. Determine the need for supplementary oxygen 
3. Monitoring of ventilation  
4. Document the severity of progression of known pulmonary disease 
5. Provide data to correct or corroborate other pulmonary function measurements. 
7.2 3 Most important variables in a blood gas result: 
1. pH ( 7.35 – 7.45 ) 
2. pCO2 ( 4.67 – 6.00 kPa ) 
3. pO2 ( 10.00 – 13.33 kPa ) 
7.3 Significance and pathophysiology 
pH < 7.35   = Acidemia 
pH > 7.45   = Alkalemia 
Acid-base disorders arising from lung disease are often related to PCO2 and its transport as 
carbonic acid. 
 
- Acid-base disorders - 
 pH pCO2 pO2 
Metabolic acidosis ↓ N ↓ 
Metabolic alkalosis ↑ N ↑ 
Respiratory acidosis ↓ ↑ N 
Respiratory alkalosis ↑ ↓ N 
Compensatory Respiratory acidosis and metabolic  alkalosis N ↑ ↑ 
Compensatory Metabolic acidosis and respiratory alkalosis N ↓ ↓ 
Combined Metabolic and Respiratory acidosis ↓ ↑ ↓ 
Combined Metabolic and Respiratory alkalosis ↑ ↓ ↑ 
Table 5. Three helpful parameters in interpreting a blood-gas result (in the simple 
uncompensated state- Ruppel, 2009) 
pO2 is the pressure of O2 dissolved in blood. The amount of Hb and whether it is capable of 
binding O2 has only a minimal effect on pO2. Hypoxemia commonly results from 
inadequate or abnormal Hb. The severity of impaired oxygenation is indicated by the PaO2 
at rest. PaO2 is a good index of the lungs ‘ability to match pulmonary capillary blood flow 
with adequate ventilation. 
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Delivery of O2 to the tissues however depends on Hb concentration and cardiac output as 
well as adequate gas transfer in the lungs. Because most O2 transported is bound to Hb, 
there must be an adequate supply (12-15 g/dl) of functional Hb. 
8. Pulse oximetry 
SpO2 estimates SaO2 by analyzing absorption of light passing through a capillary bed, either 
by transmission or reflectance. Pulse oximetry is non-invasive. 
8.1 Interfering factors 
Motion artefact, shivering, bright ambient lightning, hypotension, low perfusion, 
hypothermia, vasoconstrictor drugs and dark skin pigmentation can confound. 
8.2 Significance and pathophysiology 
Most pulse oximeters are capable of accuracy of +/- 2% of actual saturation when SaO2 is 
above 90%. Other uses of pulse oximetry are: 
- Monitoring of O2 therapy  - Surgical procedures 
- Ventilatory support   - Sleep studies 
- Pulmonary / Cardiac rehabilitation - Cardiopulmonary exercise testing 
- Bronchoscopy 
Pulse oximetry may not be appropriate in all situations e.g. to evaluate hyperoxemia or acid-
base status in a patient, a blood gas analysis is required. Measurement of O2 delivery, which 
depends on Hb concentration, cannot be adequately assessed by pulse oximetry. 
9. Six minute walk test (6MWT) 
This is a simple exercise test used to assess the response to a medical or surgical 
intervention, but also been used to assess functional capacity as well as to estimate 
morbidity and mortality. This test doesn’t require any sophisticated equipment. 
  
INDICATIONS FOR THE SIX-MINUTE WALK TEST 
Pre-treatment and post treatment comparisons 
Lung transplantation / Resection 
Lung volume reduction surgery  
Pulmonary rehabilitation  
COPD  
Pulmonary hypertension 
Heart failure  
Cystic fibrosis  
Heart failure  
Peripheral vascular disease  
Predictor of morbidity and mortality 
Table 6. A list of indications for a six minute walk test (Ruppel, 2009) 
 




Unstable angina during the previous month  
Infarction during the previous month 
A resting heart rate of more than 120,  
Systolic blood pressure of more than 180 mm Hg,  
Diastolic blood pressure of more than 100 mm Hg. 
Table 7. A list of the contraindications of a six minute walk test (Ruppel, 2009) 
Reasons for immediately stopping a 6MWT include the following: 
1. chest pain,  
2. intolerable dyspnoea, 
3. leg cramps 
4. staggering  
5. diaphoresis 
6. pale or ashen appearance. 
Technicians must be trained to recognize these problems and the appropriate responses. If a 
test is stopped for any of these reasons, the patient should sit or lie supine as appropriate 
depending on the severity or the event and the technician’s assessment of the severity of the 
event and the risk of syncope.The following should be obtained based on the judgment of 
the technician: blood pressure, pulse rate, oxygen saturation, and a physician evaluation. 
Oxygen should be administered as appropriate. 
9.1 Equipment required 
1. Countdown timer (or stopwatch) 
2. Mechanical lap counter 
3. Two small cones to mark the turnaround points 
4. A chair that can be easily moved along the walking course 
5. Worksheets on a clipboard 
6. A source of oxygen 
7. Sphygmomanometer 
8. Telephone 
9. Automated electronic defibrillator 
9.2 Measurements (ATS / ERS 2002) 
1. Repeat testing should be performed about the same time of day to minimize intraday 
variability. 
2. A “warm-up” period before the test should not be performed. 
3. The patient should sit at rest in a chair, located near the starting position, for at least 10 
minutes before the test starts. During this time, check for contraindications, measure 
pulse and blood pressure, and make sure that clothing and shoes are appropriate. 
Complete the first portion of the worksheet  
4. Pulse oximetry is optional. If it is performed, measure and record baseline heart rate 
and oxygen saturation and follow manufacturer’s instructions to maximize the signal 
and to minimize motion artefact. Make sure the readings are stable before recording. 
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Note pulse regularity and whether the oximeter signal quality is acceptable. The 
rationale for measuring oxygen saturation is that although the distance is the primary 
outcome measure, improvement during serial evaluations may be manifest either by an 
increased distance or by reduced symptoms with the same distance walked. The SpO2 
should not be used for constant monitoring during the exercise. The technician must 
not walk with the patient to observe the SpO2. 
If worn during the walk, the pulse oximeter must be lightweight (less than 2 pounds), 
battery powered, and held in place (perhaps by a “fanny pack”) so that the patient does 
not have to hold or stabilize it and so that stride is not affected.  
5. Have the patient stand and rate their baseline dyspnoea and overall fatigue using the 
Borg scale  
6. Set the lap counter to zero and the timer to 6 minutes. Assemble all necessary equipment 
(lap counter, timer, clipboard, Borg Scale, worksheet) and move to the starting point. 
7. Instruct the patient as follows: 
“The object of this test is to walk as far as possible for 6 minutes. You will walk back 
and forth in this hallway. Six minutes is a long time to walk, so you will be exerting 
yourself. You will probably get out of breath or become exhausted. You are permitted 
to slow down, to stop, and to rest as necessary. You may lean against the wall while 
resting, but resume walking as soon as you are able. You will be walking back and forth 
around the cones. You should pivot briskly around the cones and continue back the 
other way without hesitation. Now I’m going to show you. Please watch the way I turn 
without hesitation.” Demonstrate by walking one lap yourself. Walk and pivot around 
a cone briskly. “Are you ready to do that? I am going to use this counter to keep track of 
the number of laps you complete. I will click it each time you turn around at this 
starting line. Remember that the object is to walk AS FAR AS POSSIBLE for 6 minutes, 
but don’t run or jog. Start now or whenever you are ready.” 
 
THE BORG SCALE 
0 Nothing at all 
0.5 Very, very slight (just noticeable) 
1 Very slight 
2 Slight (light) 
3 Moderate 
4 Somewhat severe 
5 Severe (heavy) 
6 
7 Very severe 
8 
9 
10 Very, very severe (maximal) 
Table 8. The Borg scale 
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At the beginning of the 6-minute exercise, show the scale to the patient and ask the 
patient this: “Please grade your level of shortness of breath using this scale.” Then ask 
this: “Please grade your level of fatigue using this scale.” At the end of the exercise, 
remind the patient of the breathing number that they chose before the exercise and ask 
the patient to grade their breathing level again. Then ask the patient to grade their level 
of fatigue, after reminding them of their grade before the exercise. 
8. Position the patient at the starting line. You should also stand near the starting line  
during the test. Do not walk with the patient. As soon as the patient starts to walk, start 
the timer. 
9. Do not talk to anyone during the walk. Use an even tone of voice when using the 
standard phrases of encouragement. Watch the patient. Do not get distracted and lose 
count of the laps. Each time the participant returns to the starting line, click the lap 
counter once (or mark the lap on the worksheet). Let the participant see you do it.  
10. Post-test: Record the post walk Borg dyspnoea and fatigue levels and ask this: “What, if 
anything, kept you from walking farther?” 
11. If using a pulse oximeter, measure SpO2 and pulse rate from the oximeter and then 
remove the sensor. 
12. Record the number of laps from the counter (or tick marks on the worksheet). 
13. Record the additional distance covered (the number of meters in the final partial lap) 
using the markers on the wall as distance guides. Calculate the total distance walked, 
rounding to the nearest meter, and record it on the worksheet.  
9.3 Interpretation 
Most 6MWTs will be done before and after intervention, and the primary question to be 
answered after both tests have been completed is whether the patient has experienced a 
clinically significant improvement. With a good quality-assurance program, with patients 
tested by the same technician, and after one or two practice tests, short-term reproducibility 
of the 6MWD is excellent. It is not known whether it is best for clinical purposes to express 
change in 6MWD as  
1. An absolute value, 
2. A percentage change, or 
3. A change in the percentage of predicted value. 
Until further research is available, we recommend that change in 6MWD be expressed as an 
absolute value (e.g., the patient walked 50 m farther). 
10. Stair climbing  
In a setting where corridor length is limited, but a few flights of stairs are available, the stair 
climb is an ideal test as a primary screening test to decide if a patient can undergo thoracic 
surgery or needs additional testing e.g. Cardio Pulmonary Exercise Testing. 
The stair climb as a test is easy to perform and easy to understand by patients as well as 
being safe. Minimal equipment and personnel is required. To do the test one instructs the 
patient to climb the flights of stairs at their fastest pace to a minimum ascent of +/- 20 metre.  
This climb is timed so as to calculate the speed of ascent, which correlates well with VO2max 
measured during cycle ergometry. It was shown that climbing at a speed of ascent of 
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≥15m/min to an elevation of 20 metres accurately predicted a VO2max ≥ 20ml/kg/min. 
(Koegeleneberg, 2009) 
11. Cardiopulmonary Exercise Testing (CPET) 
Cardiopulmonary exercise testing is used to define work limitations. Cardiopulmonary 
variables are assessed in relation to the workload. The patterns of change in any particular 
variable are then compared with the expected normal response. The primary indications for 
performing this test are dyspnoea and exertion, pain (especially angina) and fatigue. 
Exercise induces airway narrowing in the majority of patients with asthma. Exercise-
induced airway narrowing is called exercise- induced asthma (EIA) and exercise-induced 
bronchoconstriction (EIB). 
Other indications include: 
- Evaluation of exercise intolerance of level of fitness 
- Exercise evaluation for cardiac or pulmonary rehabilitation 
- Assess pre-operative risk, particularly lung resection or reduction. 
- Assess disability, particularly related to occupational lung disease 
- Evaluate therapeutic interventions such as heart or lung transplantation. 
Exercise testing can detect the following: 
- Presence and nature of ventilator limitation to work 
- Presence and nature of cardiovascular limitations to work 
- Extent of conditioning or de-conditioning 
- Maximal tolerable workload and safe levels of daily exercise 
- Extent of disability for rehabilitation purposes 
- O2 desaturation and appropriate levels of supplemental O2 therapy 
- Outcome measurement after a treatment plan. 
The preferred modes of exercise are the motor-driven treadmill with adjustable speed and 
grade or the electromagnetically braked cycle ergometer. Heart rate should be monitored 
from a three-lead electrocardiographic configuration as a minimum.  
Alternatively, a pulse oximeter or other device able to reliably determine heart rate may be 
used. For those at higher risk for coronary artery disease, a 12- lead ECG configuration is 
advisable. 
11.1 Treadmill protocol (ATS / ERS 1999) 
The treadmill speed and gradient are chosen to produce 4–6 min of exercise at near-
maximum targets with a total duration of exercise of 6–8 min. For children less than 12 yr of 
age, the time is usually 6 min; for older children and adults the time is usually 8 min. 
starting at a low speed and gradient, both are progressively advanced during the first 2–3 
min of exercise until the heart rate is 80–90% of the predicted maximum. Ventilation rather 
than heart rate can be used to monitor exercise intensity. Ventilation should reach 40–60% of 
the predicted maximum voluntary ventilation (MVV, estimated as FEV1 x 35). The degree of 
physical fitness and body weight will strongly influence the grade and speed necessary to 
obtain the desired heart rate. A reasonable procedure is to quickly advance to a rapid, but 
comfortable, speed and then raise the treadmill slope until the desired heart rate or 
ventilation is obtained.  
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For older children and adults 8 min of exercise is usually required to elicit EIB when dry air 
temperature is inhaled. A treadmill speed greater than 3 mph (about 4.5 km/h) and a 
gradient greater than 15% or an oxygen consumption of 35 ml/min/kg or greater will 
usually achieve the target ventilation or heart rate in young healthy subjects. Nomograms 
have been proposed to predict speed and grade that will elicit the desired heart rate, but 
they have not been extensively validated. It may be preferable to use nomograms relating 
oxygen consumption per kilogram to speed and slope of the treadmill. 
The test ends when the patient has exercised at the target ventilation or heart rate for at least 
4 min. This usually requires a total of 6–8 min of exercise. The test may be terminated by the 
patient at any time.  
11.1.1 Assessing the response 
Forced expiratory volume in 1 s (FEV1) is the primary outcome variable. Spirometry should 
be performed and evaluated as described earlier. One exception to ATS-recommended 
techniques for spirometry is allowed. If the only outcome variable to be used is the FEV1, the 
duration of the expiration may be limited to 2–3 s. In all cases it is important to vigorously 
coach the patient to inhale fully even in the presence of chest tightness. Incomplete 
inhalations will result in false reductions in FEV1. 
If vocal cord dysfunction or other possible causes of central airway obstruction are 
suspected, full inspiratory and expiratory flow–volume loops should be obtained. 
An appropriate post-exercise testing schedule is 5, 10, 15, 20, and 30 min after cessation of 
exercise. Some investigators include earlier measurements (1 and 3 min post-exercise) 
because severe EIB can sometimes be present at the cessation of exercise. Early recognition 
allows it to be dealt with promptly. If the FEV1 has returned from its nadir to the baseline 
level or greater, spirometry testing may be terminated at 20 min post exercise. A β-agonist 
bronchodilator may be administered at any time to reverse the bronchoconstrictive response 
if the patient experiences appreciable dyspnoea, or if the FEV1 has not recovered to within 
10% of baseline when the patient is ready to leave the laboratory. 
The presence of exercise-induced bronchoconstriction is defined by plotting FEV1 as a 
percentage of the pre-exercise baseline FEV1 at each post-exercise interval.  
A decrease below 90% of the baseline FEV1 (i.e., a 10% decrease) is a generally accepted 
abnormal response. Some authors suggest a value of 15% is more diagnostic of EIB, 
particularly if exercise has been performed in the field. 
12. Bronchial provocation testing 
Bronchial challenge testing is used to identify and characterize airway hyper-
responsiveness. Challenge test may be performed in patients with symptoms of 
bronchospasm who have normal pulmonary function studies or uncertain results of 
bronchodilator studies. It can also be used to assess changes in hyper-reactivity of the 
airways or to quantify its severity. 
Several commonly used provocative agents can be used to assess airway hyper reactivity. 
These include the following:  
- Methacoloine challenge (increase parasympathetic tone in bronchial smooth muscle) 
- Histamine challenge (trigger response producing bronchoconstriction) 
 




FEV1 is the variable most commonly used, although airway resistance and specific 
conductance can also be measured before and after testing. 
12.1 Dosing protocols (ATS /ERS 1999) 
1. Two-minute tidal breathing dosing protocol. 
2. Five-breath dosimeter protocol. 
a. Set up and check the dosimeter. 
b. Prepare the following five concentrations of methacholine in sterile vials; place 
them in a holder; and store them in a refrigerator.  
c. Remove the vials from the refrigerator 30 min before testing, so that the contents 
warm to room temperature before use. Insert 2.0 ml of the first concentration into 
the nebulizer, using a sterile syringe. The patient is seated throughout the test. 
d. Perform baseline spirometry. 
e. Briefly open the dosimeter solenoid to make sure the nebulizer is nebulising. 
f. Ask the patient to hold the nebulizer upright with the mouthpiece in his/her 
mouth. Watch the patient during the breathing manoeuvres to ensure that the 
inhalation and breath hold are correct and that the nebulizer is not tipped.  
g. At end exhalation during tidal breathing (functional residual capacity), instruct the 
patient to inhale slowly and deeply from the nebulizer. Trigger the dosimeter soon 
after the inhalation begins; dosimeters may do this automatically. Encourage the 
patient to continue inhaling slowly (about 5 s to complete the inhalation) and to 
hold the breath (at total lung capacity, TLC) for another 5 s. 
h. Repeat step g for a total of five inspiratory capacity inhalations. Take no more than 
a total of 2 min to perform these five inhalations. 
i. Measure the FEV1 at about 30 and 90 s after the fifth inhalation from the nebulizer. 
Obtain an acceptable-quality FEV1 at each time point. This may require repeated 
attempts. Perform no more than three or four manoeuvres after each dose. It 
should take no more than 3 min to perform these manoeuvres. To keep the 
cumulative effect of methacholine relatively constant, the time interval between the 
commencements of two subsequent concentrations should be kept to 5 min. 
j. At each dose, report the highest FEV1 from acceptable manoeuvres. 
k. If the FEV1 falls less than 20%, empty the nebulizer, shake it dry, and trigger the 
dosimeter once to dry the nebulizer nozzle. Add 2.0 ml of the next higher 
concentration, and repeat steps g–j. 
l. If the FEV1 falls more than 20% from baseline (or the highest concentration has 
been given), give no further methacholine, note signs and symptoms, administer 
inhaled albuterol, wait 10 min, and repeat the spirometry. 
12.2 Interpretive strategies 
1. Were there any factors present that could influence the result e.g. failure to withhold 
bronchodilators ? 
2. Respiratory infection? If so interpret cautiously or not at all. 
3. Were spirometric efforts repeatable and acceptable before and during the challenge? If 
not, interpret very cautiously or not at all. 
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4. For Metacholine or histamine challenge was there a 20% decrease after inhalant of 
dilatants. Is so, test result is positive. 
5. Was there a 20% decrease of FEV1 after inhalation of agonist? If so, test result is likely 
positive and PC20 should be used to categorize the degree of hyper responsiveness. 
6. Was there at least 35% decrease in SGaw (Preferably 50%)? If so, test result is likely 
positive 
7. Were there signs of airway hyper reactivity (coughing, wheezing or shortness of 
breath)? If so, test suggests bronchial hyper responsiveness 
8. Were the results borderline? If so, repeat the test. 
9. Were symptoms present despite little or no change in FEV1?  
10. Consider additional measurements such as SGaw or related conditions such as vocal 
cord dysfunction. 
13. Conclusion 
There are a variety of tests, both simple and sophisticated, that allow greater insights into 
respiratory disease, functional impairment and suitability for operative intervention. Some 
of the tests are more complicated to perform and both improvement and deterioration in 
respiratory status can be subtle. For these reasons strict quality control, in terms of 
appropriately validated equipment, standardisation and trained and experienced personnel 
are mandatory. To ensure excellent quality results good patient co-operation is required as 
well. Disregard for these precautions can lead to diagnostic confusion, misclassification of 
improvement and deterioration or unnecessary further interventions. These can be costly 
and also result in needless morbidity and mortality. Thus a full understanding of the tests, 
their appropriateness and  pitfalls can complement patient evaluation  and result in greater 
diagnostic certainty and patient management.  
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1. Introduction 
Lung microangiopathy is a little known negative influence of diabetes mellitus on the 
functioning of the lungs. In current medical practice lung microangiopathy is diagnosed by 
comparing two measurements of lung diffusing capacity – one with the subject standing 
and one with the subject lying. The necessity to take two measurements is inconvenient.  
In lung microangiopathy we observe a reduction of diffusing capacity, lung flow and 
volume. Diabetes is a chronic illness that can lead to diabetic angiopathy, a pathology of the 
blood vessels (arteries, veins and capillaries). There are two types of diabetic angiopathy: 
macroangiopathy (disease of the larger blood vessels) and microangiopathy (microvascular 
pathology). The examples of angiopathy include: neuropathy, nephropathy and retinopathy.  
Current knowledge regarding diabetic lung microangiopathy is limited. Histopathological 
examination of lung biopsy samples is not a conclusive test of the consequences of diabetes 
(Dalquen, 1999). Animal experiments and post-mortem examinations have disclosed the 
influence of diabetes on the lung capillaries and alveolar-capillary membranes (Kida et al, 
1993), (Kodolova et al, 1982) and (Popov& Simionescu, 1997). Histopathological tests have 
revealed the thickening of the alveolar and venous capillary walls (Matsubara& Hara, 1991) 
and (Weynand et al, 1999).  
Lung diffusing capacity measurements illustrate the state of alveolar-capillary barrier 
(Goldman, 2003). These are measurements of diffusion across the alveolar-capillary 
membrane. For diagnosing microangiopathy, the lung diffusing capacity is measured in two 
body positions: standing ( standingLD ) and lying on the back (
lying
LD ), (Strojek et al, 1993) and 
(Kuziemski et al, 2008). On account of the human anatomic structure, diffusing capacity 
depends on the body’s position. For healthy subjects the diffusing capacity increases in the 
reclined position, lying standingL LD D . The opposite is observed in the case of microangiopathic 
patients: the diffusing capacity decreases when the subject is lying lying standingL LD D . This is 
the result of blood vessel damage and alveolar thickening caused by diabetes (Kuziemski et 
al, 2009). Only the fact that diffusing capacity increases or decreases in a given position is 
important as far as microangiopathy diagnosis is concerned. 
Spirometry (measurement of the volume and flow of inhaled and exhaled air) is the most 
common pulmonary function test. It is helpful in diagnosing asthma, pulmonary fibrosis, 
cystic fibrosis, and COPD (Chronic Obstructive Pulmonary Disease). 
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Research (Goldman, 2003), (Kaminski, 2004) has shown that a single spirometry test does 
not provide sufficient information for a diagnosis of lung flow limitation and lung volume 
reduction caused by diabetes mellitus. Instead we need long-term observations of 
spirometry results to diagnose lung microangiopathy. Microangiopathy lung impairment is 
characterised by a decrease in spirometric parameters FVC  (the maximum volume of air 
that can be exhaled or inspired during a forced manoeuvre) and 1FEV  (the forced 
expiratory volume during the first second of expiration) (Davis et al, 2004), (Litonjua et al, 
2005), (Yeh et al, 2008). 
A later study (Kuziemski et al, 2009) proved that a single spirometric test is insufficient to 
identify lung microangiopathy on account of functional reserve breathing. The reserves 
compensate, to some extent, the lung dysfunction, and thus the negative effect of diabetes is 
concealed until the effect reaches a higher level of impairment.  
Since the direct measurements of pulmonary function are not conclusive and post-mortem 
autopsies do not serve the given patient, the diagnostics have to be based on such indirect 
results as spirometric measurements and modelling. It is probably also capable of revealing 
lung microangiopathy if the results are very carefully analysed. 
Perfusion computed tomography (pCT) is a diagnostic method that enables the imaging of 
the organ and tissue. This is a powerful tool for diagnosing perfusion of internal organs 
such as the brain, liver, pancreas, spleen, kidneys and lungs (Alonzi & Hoskin, 2006), 
(Blomley et al, 1993), (Cao, 2011), (Eichinger et al, 2010), (Kuziemski et al, 2011). The method 
enables quantitative evaluation of circulation by determining changes in tissue during the 
flow of a contrast agent in the blood vessels. Changes, when compared to a normal tissue, 
can indicate tissue pathology. Lung pCT measurements can help in the diagnosis of cystic 
fibrosis (Eichinger et al, 2010) and diabetes (Kuziemski et al, 2011). It can also help to 
differentiate benign pulmonary nodules from lung cancer (Alonsi & Hoskin, 2006). 
The technique of lung pCT involves the intravenous injection of a non-iodinated contrast 
agent and the sequential scanning of the diagnosed region of the chest. There are a number 
of pulmonary perfusion parameters, calculated pixel by pixel on the basis of raw CT data, 
which are next analysed in order to reveal differences between the normal and altered 
tissue. The most useful perfusion parameters are: blood volume (BV), blood flow (BF), mean 
transit time (MTT), time to peak (TTP) and permeability surface (PS) (Kuziemski et al, 2011). 
The diagnosis of pulmonary function has to be based on indirect results, such as diffusing 
capacity, spirometry and pCT because direct assessment is difficult.  
2. Materials 
The tests were performed on a group of 72 diabetics. People with cardiovascular disease and 
smokers were not included in this group.  
First the diabetics were tested for microangiopathy, by comparing diffusing capacity in 
standing and lying position, and on this basis they were split into two groups: 44angiopM   
and 28non angiopM   , with and without microangiopathy respectively.  
The spirometric tests were carried out on all the patients ( n-angiop no angiopM M M  ) to obtain 
the following spirometric parameters: 1FEV  (forced expiratory volume during the first 
second of expiration), FVC  (the maximum volume of air that can be exhaled or inspired 
during a forced manoeuvre), PEF  (peak expiratory flow), 50MEF  (maximal instantaneous 
forced expiratory flow where 50% of the FVC  remains to be expired), 75/25MEF  (maximal 
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mid-expiratory flow), IC  (inspiratory capacity) and 1%FEV FVC  (percentage relation of 
1FEV  to FVC ).  
The pCT test was performed on a group of 18 subjects: 10 diabetics and 8 non-diabetic 
volunteers. The local perfusion parameters BF  (blood flow), BV (blood volume), MTT  
(mean transit time) and PS  (permeability surface) were obtained in selected regions of 
interest (ROI) in the artery and parenchyma.  
The patients classified as suffering from microangiopathy had breathing impairment 
symptoms cause only by diabetes. They were all non-smokers and had not been diagnosed 
with any other acute or chronic respiratory disease.  
3. Diffusing capacity 
The quality of gas exchange in the lungs depends on the diffusing capacity 1[ ]LD mol s kPa
  . 
During the measurement of LD  (American Thoracic Society, 1995) a person takes a full 
inhalation of air mixed with small amounts of carbon monoxide and helium. The mixture is 
held in the lungs for a few seconds and then exhaled. The first part of the expired gas is 
discarded. The next portion, which includes gas from the alveoli, is collected. The LD  is 
determined by analyzing and comparing the concentrations of carbon monoxide and helium 
in the samples of the inhaled gas and the exhaled gas. The alveolar volume AV  is also 
determined in this test by using the single-breath helium dilution technique.  
3.1 The oxygen pathway model 
Fig. 1 shows oxygen diffusion. Oxygen transportation from the alveoli to erythrocytes, 
through the alveoli-capillary barrier, is presented as the flow 121  [ ]
-f g s . The blood 
saturation (0,1)S , (also given as (0,100%)S ) shows what part (percentage) of oxygen 
capacity (maximum amount of oxygen transported by the erythrocytes) is currently being 
transported in the blood. Poorly oxygenated blood enters the pulmonary artery and then, 
enriched in oxygen, flows out of the lung through the pulmonary vein. Lung arterial blood 
saturation AS  differs from lung venous blood saturation VS , A VS S . 
Flows 120[ ]f g s
  and 102[ ]f g s  represent the amount of oxygen in the blood flowing into 
the lung and flowing out of the lung. The oxygen diffusion model is: 
                 1 21 12 21 20 02 2
, 0
, 0
m t f t u t m
m t f t f t f t m
      

  (1) 
where the 1( )[ ]m t g  and 2( )[ ]m t g  are the 2O  masses in the alveoli and in the blood vessels 
respectively. The initial states 1(0)[ ]m g  and 2(0)[ ]m g  depend on oxygen partial pressure 
1(0) 13.32 [k ]P Pa , 2(0) 12.63 [ ]P kPa  and region volume 1 AV V , 4 32 10 [ ]V m , 
(Dalquen, 1999) ,West, 2008) and (Taylor et al, 1989). The alveolar volume 1 AV V  is 
measured during the diffusing capacity test. The relationship between the 2O  mass and the 
pressure is: 
2
( ) ( )i i O iP t RTm t M V , 1,2i  , where 1 1 [ ]- -R N m K  mol  is gas constant,  T  is 
absolute temperature and 
2
1[  ]OM g mol
  is the molecular mass. The mass diffusion, i.e. flow 
21( )f t  via the membrane is caused by the concentration gradient 1 2 0c c c    , where 
( ) ( )i i ic t m t V , 1,2i  : 
 




Fig. 1. The passage of oxygen from the airways to the lung vessels. The diffusing capacity 
LD  describes the condition of the alveoli-capillary barrier. The oxygen is bound in reversible 
bonds 8[ ]HbO with the haemoglobin in the lung vessels 
 1 221
1 2
( ) ( )( ) L
m t m tf t D R T
V V
       
 (2) 
The signal ( )u t  represents respiratory flow with the period pT , the delay time 0  [s]t  (the 
time the air passes through the airway to the alveoli) and the duty cycle d . The input 
amplitude 1[  ]g s  depends on the organism’s metabolic rate ( MR ), i.e. the organism’s need 
for oxygen.  
In medical practice, blood saturation S  gives the basic information concerning the quantity 
of oxygen transported from the lungs to all the other organs. The kinetics of oxygen 
association with haemoglobin is described in Hill’s equation (Khee-Shing, 2007): 











where 2( )P t  is oxygen partial pressure in the blood, 2.8n   is the Hill’s constant and 
101.2256 10  [1 ( ) ]nK Pa   is the association constant. The relationship between the 
endogenous inflow 20f  , the outflow 02f  and the organism’s need for oxygen MR  is as 
follows: 
 20 02( ) ( )f t f t MR   (4) 
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while the outflow 02f  depends on the blood velocity 
3 1[ ]m s  , maximum erythrocyte 
oxygen capacity 3[ ]mol m   and venous blood saturation ( )VS t  
    
202 V Of t S t M     (5) 
The elimination flow 02f , according to Hill’s equation, is: 











c R Tf t M c K m t
c M V
             
 (6) 
Taking into account (4), (5) and (6), the oxygen diffusion model is: 
                 1 1 1 2 2 1 12 1 1 2 2 2
, 0
, 0
m t p m t p m t u t m
m t p m t p m t MR m
           

  (7) 








            1 1 . 
The model parameters 1 1Lp D R T V    and 2 2Lp D R T V    can be estimated with the use 
of measurements 1,LD V  and physiological constants 2, ,R T V . 
The example measurements (lying body position),  3 35.42 10 [ ]non angiopAV m
   , 
 7 11.54 10 [ ]non angiopLD mol s Pa
     , 3 35.71 10 [ ]angiopAV m   and 
7 11.59 10 [ ]angiopLD mol s Pa
     together with the constants: 3 32 0.10 10  [ ]V m   (blood 
volume in lung capillary vessels), 293 [ ]T K  (absolute temperature) and 






[ , ] [5.6315 10 ,  3.3271]
[ , ] [6.2128 10 ,  3.9621]
angiop angiopangiop










The model parameter estimates have been calculated for all the 72M   patients. 
3.2 Statistical comparison of measurement and modelling results for 
microangiopathic and non- microangiopathic patients 
Measurements were made for two groups of diabetic patients: ones with diagnosed 
microangiopathy and others with no microangiopathy. Lung microangiopathy was 
identified when standing lyingL LD D . This examination also gives the alveoli volume 1AV V .  
The null hypothesis 0H  assumes that the mean values in both groups of patients are the 
same. Calculated ex post significance level p  is compared with ex ante significance level   
(test-T). If a test of statistical significance gives ex post significance level p , which is lower 
than the  , the null hypothesis is rejected, alternatively we no grounds to reject this 
hypothesis. Table 1 and Table 2 show a statistical comparison of spirometry measurements 
and model parameters obtained from microangiopathic and non-microangiopathic patients. 
The results presented in Table 1 ( lying lying  0 :  
angiop non angiop
L LH D D
 is rejected and the 
conclusion is: lying lying  angiop non angiopL LD D
 ) suggest the possibility of diagnosing 
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microangiopathy on the basis of lyingLD  only, instead of 
lying
LD  and 
standing
LD . The lack of 




Microangiopathic Non-microangiopathic Statistical 
significance 




LD  1.64 10-7 0.14 10-7 1.48 10-7 0.11 10-7 0.05p   
standing
AV  5.95 10-3 0.21 10-3 5.65 10-3 0.21 10-3 0.05p   
lying
LD  1.35 10-7 0.06 10-7 1.63 10-7 0.14 10-7 0.05p   
lying
AV  6.04 10-3 0.27 10-3 5.90 10-3 0.40 10-3 0.05p   
Table 1. Statistical comparison of LD  and AV . For 
lying
LD  ex post significance level is p  , 
0.05  . The null hypothesis lying lying  0 :  angiop non angiopL LH D D   concerning equality of mean 
diffusing capacity values in both groups was rejected. lyingLD  allows us to distinguish 
between patients with and without microangiopathy, while the rest do not.   
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 
level p  Mean value Standard deviation Mean value 
Standard 
deviation 
Measurements taken in standing body position 
1p  26.6176 10  20.4720 10  26.1900 10  20.2792 10  0.05p   
2p  3.9330 0.3447 3.5301 0.2730 0.05p   
Measurements taken in lying body position 
1p  5.4339 10-2 0.2233 10-2 6.5672 10-2 0.3139 10-2 0.01p   
2p  3.2427 0.1551 4.0981 0.3518 0.01p   
Table 2. Statistical comparison of 1p  and 2p . In the lying body position the ex post 
significance level  is p  , 0.01   and the 0H , concerning the equality of mean 
parameter values, is rejected. These parameters allow for a distinction to be made between 
patients with and without microangiopathy. 
Next, the null hypothesis 0
angiop non angiop
i iH p p
  , 1,2i   was tested (Table 2). The 
Kolmogorov-Smirnov test accepted the normality hypothesis concerning 1p  and 2p  at the 
significance level of 0.01p  . Therefore the mean values and standard deviations were 
calculated and the null hypothesis 0
angiop non angiop
i iH p p
   was tested.  
For 1p  and 2p , in lying body position, the ex post significance level p  , 0.01   and so 
the 0H  was rejected. These parameters enable a distinction to be made between patients 
with and without microangiopathy.  
In a standing body position ( 0.05p  ) the parameters 1p  and 2p  are not useful for 
microangiopathy diagnosis.  
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The results in Table 1 and Table 2 indicate the possibility of using a diagnostic test based on 
a single measurement lyingLD , and also on the basis of modelling results 1p .and 2p . 
3.3 Binary classification on the basis of diffusing capacity measurement and 
modelling 
Statistical analyses show that a single measurement lyingLD  and the model parameters 1p , 
2p  contain information concerning lung microangiopathy. The question remains as to 
whether or not such values can be used for binary classification. Binary classification is the 
classifying of the members of mixed group -angiop non angiopM M M   into two subgroups, 
angiopM  and non angiopM  , on the basis of whether or not they have microangiopathy. For this 
purpose an appropriate classification algorithm has to be chosen. 
To select the best potential classification algorithm, statistical measures, sensitivity and 
specificity (Panzer, Blach & Griner, 1991) were considered. Sensitivity Sens  is the ability of a 
test to detect a disease when it is really present. Specificity Spec  is the ability to confirm the 




True Positive False Negative




True Negative False Positive
   (9) 
The theoretically optimal prediction is: 100%Sens   ( all the sick patients were identified as 
sick) and  100%Spec   (none of the healthy patients was identified as sick).  
 
 
Fig. 2. Classification algorithms based on 1p  and 2p ; I) 2pM  are classified as 
microangiopathic and 
2pM M  are classified as non-microangiopathic, II) 1 2p pM M  are 
classified as microangiopathic and 
1 2
( )p pM M M   are classified as non-microangiopathic 
For binary classification the discrimination levels (boundaries, diagnostic thresholds) 
LDH , 
1pH  and 2pH  have to be calculated, respectively for LD , 1p  and 2p . The discrimination 
levels classify the test result as positive or as negative. The parameter value where 
maxSens Spec   was chosen as the parameter’s diagnostic threshold. 
Among different classification algorithms using 1p , 2p , 1pH  and 2pH  the best are the two 
shown in Fig. 2.  
 





Wide range of anthropometric 
features, 72M   (men and 
women, 21-69 y, 1.50-1.95m) 
Narrowed range of 
anthropometric features 
1 22M  (women, over 50 y, 
under 1.65 m) 
[%]Sens  [%]Spec  [%]Sens  [%]Spec  
I. 1 2,p p  50 84 62 87 
II. 2 1,p p  76 50 79 80 
lying
LD  33 61 62 71 
Table 3. Classification results obtained for entire group of 72M   subjects and for the group 
of 1 22M   women, over 50 y, under 1.65 m. The best results are underlined.  
Therefore the diagnostic procedure shown in Fig. 3 is recommend. 
 
 
Fig. 3. Diagnostic procedure with the use of lyingLD , 
lying
AV  measurements, constants R, T, 
2V  and calculated 1 2,  p p , 1pH  and 2pH . For binary classification the more conclusive 
algorithms I) (with respect to Spec ) and II) (with respect to Sens ) are recommended. 
The binary classification was performed for the 72M   subjects. The results were compared 
with already known medical diagnoses of 44 microangiopathic patients and 18 patients with 
no microangiopathy. Then the sensitivity and the specificity were calculated according to 
equations (8) and (9), (Table 3). The larger the Sens  and Spec , the better. It seems 
reasonable to assume that results larger than 75% are satisfactory. Therefore an algorithm 
should be selected to fulfil this requirement, and not every entry in Table 3 does. 
Diagnostic thresholds, calculated on the basis of 72M   measurement data, are: 
1
25.80 10pH
  , 
2
3.50pH   and -71.57 10LDH   . The best statistical measures obtained 
are: 76%Sens   (algorithm II) and 84%Spec   (algorithm I). The results for lyingLD , 
33%Sens   and 61%Spec  , are less than 75% and quite inadequate. 
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The thresholds established as common for the entire group did no take into account such 
important factors as age, height and gender. Therefore a subgroup 1 22M   was selected 
(women, over 50 years old and less than 1.65 m tall). Then the new diagnostic thresholds 
1
25.42 10pH
  , 
2
3.06pH  , -71.30 10LDH    and new Sens  and Spec  were calculated. As 
expected, both the new Sens  and Spec  were noticeably larger.  
The diagnostic procedure in Fig. 3 uses lyingLD  and 
lying
AV measurements, and R , T  and 2V  
physiological constants to calculate the 1p  and 2p  in a patient. Then algorithm I (with the 
most conclusive Sens ) and algorithm II (with the most conclusive Spec ) are applied 
together with 
1pH  and 2pH  diagnostic thresholds to obtain a binary classification result.  
This procedure produces one of two possible results: 1) high probability of lung 
microangiopathy or 2) high probability of no lung microangiopathy. This can serve as useful 
confirmation in a doctor’s diagnosis.  
The final decision is made by the doctor conducting the diagnosis, who can take into 
account this classification result along with other diagnostic data. 
4. Spirometry 
The most popular spirometry method is a dynamic one. The pneumotachometer (Miller, 
Harkinson&Brusasco, 2005) defines the volume ( ) [ ]V t l  and airflow 1( )[ ]Q t ls  during the 
inhalation and exhalation. The flow-volume curve ( )Q V  is received on the basis of the 
spirometry measurements of ( )V t  and ( )Q t . Specific ventilation manoeuvres are required 
in the spirometric test. The measurement is preceded by a period of quiet breathing–in and 
out (Fry, Hyatt, 1960). Next the maximal breath–in and the maximal forced breath–out 
manoeuvres are performed as the important parts of the spirometric test. 
The respiration parameters are defined on the basis of the volume–time curve ( )V t  and the 
flow–volume curves ( )Q V  (see Fig. 4 and Fig. 5), (Miller, Harkinson&Brusasco, 2005).  
In medical practice two terms, volume and capacity, are used. The difference between them 
is based on the assumption that volume refers to lung volumes, while capacity refers to 
different combinations of lung volumes, usually in relation to inhalation and exhalation.  
The relations between volumes and capacities are presented in equations (10). 
 TLC VC RV
TLC IC FRC
 
   (10) 
The following respiratory parameters have been defined:  [ ]TLC l  (Total Lung Capacity) is 
the volume of air in the lungs at the end of maximal inhalation;  [ ]VC l  (Vital Capacity) is 
the maximum volume of air that can be exhaled or inhaled during either a forced ( FVC ) or 
a slow (VC ) manoeuvre;  [ ]RV l  (Residual Volume) is the volume of air remaining in the 
lungs after the maximal exhalation;  [ ]IC l  (Inspiratory Capacity) is the maximal volume of 
air that can be inhaled from the resting expiratory level;  [ ]FRC l  (Functional Residual 
Capacity) is the volume of air in the lungs at the resting end-expiration.  
Also defined are the following respiratory parameters: 1  [ ]FEV l  the forced expiratory 
volume during the first second of expiration;   FET s  the forced expiratory time;  [ ]FIT s  
the forced inspiratory time; 1 [  ]PEF l s  (Peak Expiratory Flow) and 1 [  ]PIF l s  (Peak 
Inspiratory Flow) are respectively the maximal expiratory and the maximal inspiratory flow  
 





Fig. 4. The spirometry parameters defined on the basis of volume-time curve  V t . 
 
 
Fig. 5. The spirometric parameters defined on the basis of flow–volume curve  Q V . 
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rates achieved;   TPEF s  the time of maximal expiratory flow; 175 50 25, ,  [ ]-MEF MEF MEF l s  
maximal instantaneous forced expiratory flow where 75, 50, 25% of the FVC  remains to be 
expired; 175/25  [ ]
-MEF l s  is the maximal mid-expiratory flow and 1%FEV FVC  is the 
percentage relation of 1FEV  to FVC . 
The European Respiratory Society (Miller, Harkinson & Brusasco, 2005) has published the 
spirometric norms and the reference values for these spirometric parameters. The reference 
values of the respiration parameters, obtained for a representative healthy population, are 
used for the interpreting the spirometry data and making the diagnosis. The reference 
values depend on the patient’s anthropometric data, such as age, height and gender. In 
some medical cases (asthma, pulmonary fibrosis, cystic fibrosis and COPD) the spirometric 
parameter boundary values have already been defined. However, as far as lung 
microangiopathy is concerned, this has not yet been done.  
According to medical practice experience, lung microangiopathy is diagnosed on the basis 
of the following spirometric parameters: 1FEV , FVC , PEF , 50MEF , 75/25MEF , IC  and 
1%FEV FVC . These spirometric parameters were collected from the 72M   diabetic patients.  
However, a single spirometric test is not sufficient to diagnose the lung flow and volume 
reduction caused by microangiopathy; long term observation is necessary. Therefore one 
should consider an alternative method. By using the spirometric results in a statistical 
significance test, we can find the spirometric parameters that are most responsive to lung 
microangiopathy.  
4.1 Spirometric parameters. Statistical comparison of results for microangiopathic 
and non- microangiopathic patients 
Traditional spirometric parameters were tested for their ability to detect lung 
microangiopathy. The mean, standard deviation and the statistical significance level p  for 
spirometric parameters are presented in Table 4.  
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 











1FEV  2.970 0.699 2.919 0.832 0.05p   
FVC  4.245 0.911 4.015 1.245 0.05p   
PEF  9.175 1.545 11.621 1.914 0.05p   
50MEF  5.258 1.384 3.691 1.637 0.05p   
25/75MEF  2.896 1.051 2.853 1.206 0.05p   
IC  3.182 0.706 3.275 1.097 0.05p   
1%FEV FVC  70.731 7.482 73.621 8.880 0.05p   
Table 4. Statistical comparison of spirometric parameters for microangiopathic and non-
microangiopathic patients. In every case the ex post significance level p  , 0.05  , which 
means that 0H  concerning mean parameter value equality is not rejected. The parameters 
do not allow for a distinction to be made between patients with and without 
microangiopathy.  
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The parameters do not show statistical significance in detecting microangiopathy: ex post 
significance level p  is larger than ex ante significance level 0.05  , which confirms the 
null hypothesis concerning equality of mean values for both groups. Therefore, none of 
spirometric parameters are useful in diagnosing microangiopathy. 
4.2 Spirometry modelling 
The maximal breathing-in flow was modelled by means of the sine function. The forced 
breathing-out flow was finally mimicked using the gamma variate function (Askey R.A.& 
Roy R,2007) – after testing a large group of prospective regression functions, such as 
exponentials, polynomials, etc (Kalicka et al, 2007).  
The maximal inflow ( )inQ V  is modelled as follows: 
  ( ) sin ,  0in inQ V A V V FVC      (11) 
where 1 [  ]inA l s
  and 1 [ ]l   are model parameters and FVC  is the forced vital capacity.  
For modelling ( )outQ V  during the maximal outflow, the following gamma variate function 
is implemented: 
     ,  0b V aoutQ V K V e FVC V     (12) 
where 1[  ]K l s , b  and 1 [ ]a l  are model parameters. 
The model consists of the equations (11) and (12). The model parameters are arranged into 
vector [ ] [ , , , , ]i inp A K b a p ,  1 5i   . The parameter estimates were obtained using the 
least square procedure, according to the following: 
     max 2model meas meas
0
arg min , ,
V
V
Q V Q V

     
pp p y  (13) 
where meas meas 1 50 25/50[ ] [ , , , , , , % ]; 1 7jy FEV FVC PEF MEF MEF IC FEV FVC j   y  is vector 
of measurements and maxV FVC . The fitting procedure was executed separately to obtain 
,  inA   and ,  ,  K b a  based on the equations (11) and (12) respectively. 
The parameter vector [ , , , , ] [3.780 1.030 20.580 0.772 1.507]inA K b a , , , ,  p  is an example of 
the model identification results. This was obtained from a 59-year-old woman suffering 
from lung microangiopathy. The spirometric parameters obtained from the patient were: 
1 2.25FEV  , 2.84FVC  , 5.79PEF l s , 50 3.47MEF l s , 75/25 2.63MEF l s , 2.81IC   
and 1% 78.95%FEV FVC  . 
Calculations of [ , , , , ]inA K b ap  were performed for 72M   diabetic patients. Fig. 6 
shows an example of the model regression functions ( )inQ V  and ( )outQ V  drawn for the 
[ , , , , ]inA K b a p [3.780 1.030 20.580 0.772 1.507], , , , . In Fig. 6 the ( )Q V  spirometric test 
results have been added, for comparison.  
4.3 Statistical comparison of modelling results for microangiopathic and non- 
microangiopathic patients 
The mean parameter value and standard deviation were calculated separately for 
microangiopathic and non-microangiopathic patients (Table 5). The aim was to find out  
 





Fig. 6. An example result of the spirometric measurement and modelling of the flow–
volume curve ( )Q V . 
 
 
Microangiopathic Non-microangiopathic Statistical 
significance 









inA  5.92 1.72 5.88 2.20 0.05p   
  0.78 0.17 0.82 0.22 0.05p   
K  34.79 6.84 53.78 7.56 0.05p   
b  1.193 0.83 1.58 1.06 0.05p   
a  1.501 0.59 1.85 0.78 0.05p   
Table 5. Statistical comparison of model parameters for microangiopathic and non-
microangiopathic patients. For inA ,   and b , the ex post significance level was p  , 
0.05  , and thus the 0H , concerning mean parameter values equality, was not rejected – 
i.e. the parameters are not useful for diagnosis. However, parameters K  and a  are useful in 
distinguishing between patients with and without microangiopathy because the ex post 
significance level is p  , 0.05  . 
whether or not the model parameters are helpful in distinguishing between 
microangiopathic and non-microangiopathic patients. For this purpose the null hypothesis 
0
angiop non angiop
i iH p p
  , 1,..,5i   was tested. 
At first the normality hypothesis concerning the parameter estimates ip  was investigated, 
and the hypothesis was accepted (Kolmogorov-Smirnov test) at the significance level of 
0.05p  . Then the mean values and standard deviations (Table 5) were calculated and 
statistical test-T was performed. For K  and a  the ex post significance level p  , 0.05   
and 0H  is rejected. The two model parameters K  and a  allow for a distinction to be made 
between patients with and without microangiopathy.  
The remaining model parameters inA ,   and a  do not reveal the occurrence or absence of 
lung microangiopathy. 
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4.3 Binary classification on the basis of spirometric measurements and modelling 
Binary classification algorithms, based on the model parameters K  and a , were tested with 
discrimination levels KH  and aH . The discrimination levels were first established for all 
72M   subjects as 50.18KH   and 1.72aH  . These discrimination levels correspond to the 
K  and a  values for which maxSens Spec  . The 72M   subjects were now divided into 
two groups on the basis of these discrimination thresholds.  
Two algorithms, I and II (which gave the best results), were applied for binary classification. 
The algorithms are presented in Fig. 7. The binary classification decision was compared with 
previously known medical diagnoses, and then the Sens  and Spec  were calculated 
according to equations (8) and (9), (see Table 6).  
None of the tested algorithms could produce simultaneously a large Sens  and a large Spec . 
Algorithm II gave the best 82%Sens   and algorithm I gave the best 62%Spec  . Algorithm 
II accurately detected the majority of the microangiopathy cases ( 82%Sens  ), and only 
missed out on a few. Yet 50%Spec   means algorithm II identified only 50%  of the non-
microangiopathic patients as non-microangiopathic and gave too many false alarms. This is 
an unacceptable result. Somewhat better 62%Spec   was obtained with algorithm I but this 
was still not satisfactory. The most likely explanation for these poor results is the fact that 
the thresholds KH  and aH  are too general and do not take into consideration important 
anthropometric features. 
Therefore the range of anthropometric features was made more specific ( 1 22M   women, 
over 50 years old and under 1.65 m tall) and new diagnostic thresholds were calculated: 
48.11KH   and 1.68aH  . The new classification results are presented in Table 6. 
This more accurate choice of the diagnostic thresholds gave much better results. The 
100%Sens   means that algorithm II identified all the sick patients as sick. This excellent 
result has been obtained for the sample 1 22M   selected from the general population and 
therefore should be treated with care. An another sample may give a somewhat different 
result but the great improvement is obvious.  





Fig. 7. Classification algorithms based on a  and K ; I) KM  are classified as 
microangiopathic and KM M  are classified as non-microangiopathic, II) a KM M  are 
classified as microangiopathic and ( )a KM M M   are classified as non-microangiopathic 
 





Full range of anthropometric 
features, 72M   (men and 
women, 21-69 y, 1.50-1.95m) 
Limited range of anthropometric 
features 1 22M  (women, over 50 
y, under 1.65 m) 
[%]Sens  [%]Spec  [%]Sens  [%]Spec  
I. ,a K  64 62 87 83 
II. ,K a  82 50 100 80 
Table 6. Classification results obtained for entire group of 72M   subjects and for the 
subgroup 1 22M   of women over 50 years old and under 1.65 m. The best results are 
underlined.  
 
Fig. 8. Classification algorithms: I) KM  are classified as microangiopathic and KM M  as 
non-microangiopathic, II) a KM M  are classified as microangiopathic and ( )a KM M M   
as non-microangiopathic 
Applied with aH  and KH , algorithm I gives the best (most conclusive) Sens  classification 
result, while the algorithm II gives the best (most conclusive) Spec  result.  
This procedure gives one of two alternative results: 1) high probability of lung 
microangiopathy or 2) high probability of no lung microangiopathy. The final decision is 
made by the doctor.  
5. Perfusion computed tomography (pCT)  
Tests commonly used in clinical practice such as spirometry and lung diffusion capacity 
measurements are not considered precise enough to identify lung microangiopathy. There 
are very few publications in this field and most of them concern the decrease of diffusion 
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capacity in diabetics (Villa et al, 2004), (Goldman, 2003). Autopsies of patients who died of 
diabetes complications revealed a thickening in the basement membrane of alveolar 
capillaries and arterioles in the lungs as well as of the entire walls of pulmonary arterioles 
together with fibroblast proliferation (Weynand et al, 1999).  
Impaired gas exchange in pulmonary alveoli results in the progressive reduction of reserves 
in small pulmonary vessels. For this reason lung perfusion in regions of lung 
microangiopathy may be diminished. Computed tomography of chest perfusion allows 
imaging of pulmonary vessels and parenchyma and may be useful in diagnosing 
pulmonary microangiopathy (Kuziemski et al, 2011).  
5.1 Patients and study protocol 
A group of 10 never-smoking diabetic adults and a control group of 8 non-diabetic 
volunteers were chosen. All participants had a similar body mass index and none of them 
suffered any disease that affected pulmonary function. The mean time from when diabetes 
mellitus was first diagnosed was 15.5 years. Nephropathy was diagnosed in 3 diabetics, 
retinopathy in 6 and polyneuropathy in 4. The question was whether or not they also 
suffered from lung microangiopathy. In the control group lung and cardio-vascular diseases 
were not diagnosed. 
For all patients, spirometry and diffusing capacity tests were performed.  
For the pCT tests a 64-row CT scanner GE - Light Speed VCT (GE Healthcare USA) was 
used. Pulmonary perfusion was evaluated after the intravenous administration of 40 ml of 
contrast at the rate of 4 ml/s. CT images were taken with 1 s resolution in the period of 40 s 
of a selected lung section (4 cm thick layer situated 2 cm below carina). Within this 4 cm 
thick segment, three cross-sections, anterior, medium and posterior, 5 mm thick each, were 
selected at uniform distances from each other. 6 ROIs were chosen in each of the cross-
sections (18 ROIs in all, numbered ROI 3-ROI 20). The ROIs 3–20 were situated in the upper, 
medial and lower parts of the left and right lungs. The most vascularised areas of the lungs 
were left beyond the ROIs so as not to distort the evaluation of lung parenchyma.  
The pCT measurements were performed using standard CT Perfusion 4 (GE Healthcare 
USA). The following perfusion parameters were  calculated: 
- [ 100 ]BV ml g  - blood volume in 100g of lung tissue. 
- [ /100 /min]BF ml g - blood flow through 100g of lung tissue in 1 minute. 
- [min]MTT - mean transit time through the vascular system in selected region. 
- [ /100 /min]PS ml g - permeability surface, the permeability of blood from intravascular 
to extravascular space, observed in 100g of lung tissue during 1 min. 
5.2 pCT results  
The example results of pCT scans, obtained from a 62 year old diabetic male, are shown in 
Fig. 9 a), b), c) and d). Perfusion parameters BF , BV , MTT  and PS  were calculated and 
mapped out on the lung cross-section. Analysis was made of the pulmonary artery - ROI 1, 
which represents the arterial input function, i.e. the flow blood into the pulmonary system.  
In Fig. 9 the ROI 1 is marked with a circle. The calculated values of perfusion parameters 
(mean value for all pixels in the region and standard deviation of the mean) are displayed in 
the right lower corner of the scan.  
Table 7 shows mean perfusion parameters Avg and standard deviation Dev in the ROI 1. 
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As the table shows, the obtained permeability surface PS for the impermeable pulmonary 











Fig. 9. The pCT scans (a) blood flow BF , (b) blood volume BV , (c) mean transit time MTT  










Avg Dev Avg Dev Avg Dev Avg Dev 
509.9 20.64 48.06 3.48 5.65 0.30 0 0 
Table 7. Example results of perfusion parameters calculated as the mean values in the ROI 1 
marked in Fig. 9. The calculated standard deviations Dev illustrates the distribution of test 





Fig. 10. The PS maps  for (a) healthy subject and (b)  diabetic subject. For example, in ROI 13 
(right lower circle) 3.31PS   for the healthy subject and 79.80PS   for the diabetic subject. 
The measurements were obtained in the same location of the lung cross-section. 
Fig. 10 shows PS  maps obtained from a healthy patient and a diabetic patient. The 
qualitative comparison (amount of the red, permeable area) as well as the quantitative 
comparison (healthy patient 3.31PS   and diabetic patient 79.80PS  ) indicate damage to 
capillaries and pulmonary arterioles of the diabetic patient. 
All perfusion parameters were calculated in 18 ROIs (3-20) in the parenchyma to discover 
whether parameter values depend on the location of tested lung cross-section. Statistical 
analysis revealed no correlation between perfusion parameter value and ROI location in the 
upper central or lower part of the lungs (Kuziemski et al, 2011). Therefore mean perfusion 
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parameters were calculated for all 18 ROIs. The results are shown in Table 8 (Kuziemski et 
al, 2011). 
Here a noticeable increase was observed in the parenchyma perfusion parameter values of 
the diabetics with respect to control group, which may be due to diabetic mellitus.  
 
[ /100 /min]BF ml g Dev  [ /100 ]BV ml g Dev  [ /100 /min]PS ml g Dev  





















Table 8. Mean parameters  BF , BV  and PS  in the artery and parenchyma of the diabetics 
and of the control group. The calculated standard deviation Dev illustrates the distribution 
of test results in 18 ROIs (ROI 3 – 20, in upper, central and lower part of lungs) with respect 
to the mean of the eighteen results. No significant MTT differences were found.  
Chest perfusion CT allows imaging of lung vessels and parenchyma, which is essential in 
diagnosing pulmonary angiopathy. The analyzed results are very new and currently not all 
that numerous. While this does not allow for a complex statistical analysis, the above 
preliminary results indicate the great potential of pCT tests in diagnosing lung 
microangiopathy. 
5.3 Lung area extraction  
Each pCT image (see Fig. 9) consists of the body cross-section, including the lungs, essential 
for medical diagnosis, the rest of the body and the background, which is unnecessary for 
lung diagnostics but was nevertheless included in the perfusion map calculations.  
As computations of perfusion parameters involve complicated methods of signal processing, it 
is desirable that the distinction between diagnostically important regions (the lung cross-
section) and other areas (background and the rest of body cross-section) is conducted before 
the process starts. This shortens the time needed to obtain parametric maps by omitting data 
processing from the area outside the lungs. It can also help avoiding false lung malfunction 
diagnoses, which can occur when the automatic methods of pathological changes wrongly 
interpret signals from areas outside the lungs as abnormal lung signals. 
Literature describes many methods of lung area extraction from CT chest scans (Homma et 
al, 2009), (de Nunzio et al, 2011), (Vinhais & Campilho, 2006), (Zhou et al, 2004). Most 
methods are devoted to extracting the lung area from a single image. Some of these methods 
allow for neighbouring (upper and lower) slices to be analysed (Homma et al, 2009). 
The lung extraction presented here was obtained using the two-step procedure. The 
objective of the preliminary processing was to define the rough mask, i.e. the border within 
which the lung contour is always contained during the pCT test while the lungs are 
breathing and the heart is beating. The lung and heart region contour pixels are subjected to 
the greatest changes. This behaviour can be utilised to detect the contours. It can be achieved 





  (14) 
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where maxx , minx  and medianx  are respectively each pixel’s maximum, minimum and 




Fig. 11. Map VFM  of variability factor VF . The white areas are the most variable due to the 
breathing lungs and beating heart. 
Then the final lung mask was obtained with the use of morphological operators (dilation, 
erosion, closing and opening) to extract lung cross-sections from the chest pCT.  
Fig. 12 shows the BF , BV , MTT  and PS  maps of just the lungs, extracted using the mask. 
The lung mask was superimposed onto the calculated maps in Fig. 9. 
 
(a) (b) (c) (d) 
Fig. 12. Lung extraction. The pCT lung maps obtained for the scans in Fig. 9 - (a) blood flow 
BF , (b) blood volume BV , (c) mean transit time MTT  and (d) permeability surface PS . 
Visual comparison of Fig. 9 and  Fig. 12 shows just how much unnecessary computations 
are usually performed in areas outside the lungs. What is more, a clearly defined lung area 
allows for a much more accurate and reliable medical diagnosis. 
6. Conclusion  
Pulmonary diabetic microangiopathy has not yet been sufficiently studied and is difficult to 
diagnose. In clinical practice, lung microangiopathy is diagnosed by comparing two 
diffusing capacity measurements, taken with the patient standing up and lying down. Other 
methods to assist diagnosis of lung microangiopathy are needed. 
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The three methods presented here seem good enough to be competitive options to 
complement those currently used in medicine today. 
Diffusing capacity measurement and modelling allows for the development of a procedure 
to enhance the diagnostic process. This procedure is based on a single diffusing capacity 
measurement taken from a patient lying down, together with a model of oxygen diffusion 
from the alveoli to the blood. The model parameters, calculated using routine medical test 
results and physiological constants,  turned out to be useful for binary classification in lung 
microangiopathy diagnosis. Diagnostic thresholds were calculated. Next binary 
classification was performed, based on model parameters, and, for comparison, on the 
diffusing capacity test result. These results were compared with already known medical 
diagnoses. This allowed for the sensitivity and specificity to be calculated. The best binary 
classification results were 79%Sens   and 87%Spec  , when based on model parameters, 
and, when based on diffusing capacity measurements, 62%Sens   and 71%Spec  . These 
results show that for microangiopathy diagnosis the model parameters were more sensitive 
and more specific than the diffusing capacity measurements.  
The next method to be  examined for usefulness in lung microangiopathy diagnosis was 
spirometry. Statistical comparison of the spirometry parameters of microangiopathic and 
non-microangiopathic patients, revealed that such parameters do not allow for a distinction 
to be made between patients with and without microangiopathy. Therefore a spirometry 
model was developed and its parameters were tested for their ability to distinguish between 
microangiopathic and non-microangiopathic subjects. Two, out of five, model parameters 
were statistically significant and helpful in lung microangiopathy diagnosis. Diagnostic 
thresholds were calculated and binary classification was performed, based on the 
statistically significant model parameters. The best results were 100%Sens   and 
83%Spec  . 
Both diagnostic procedures, the one based on the diffusing capacity and the one based on 
spirometric measurements and modelling, produce one of two possible results: 1) high 
probability of lung microangiopathy or 2) high probability of no lung microangiopathy.  
Perfusion CT measurement seems to have considerable diagnostic potential with regard to 
lung microangiopathy. A study of lung tissue perfusion in diabetic patients in comparison 
with a group of healthy subjects showed an increase in the value of some parameters. These 
increased values may result from pulmonary microangiopathy. Further studies on the 
application of pCT in the detection of diabetes mellitus may not only improve diagnosis but 
also help us better understand pulmonary microangiopathy. 
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1. Introduction  
1.1 Overview on pneumoconioses 
Pneumoconiosis is an occupational lung disease caused by the exposure to dust. This section 
summarizes the generalities on pneumoconioses, including definitions, epidemiology and 
clinical manifestations of those occupational and environmental lung diseases. The most 
important step in the diagnosis of pneumoconiosis in to question the subject regarding 
specifics of the actual job and the minerals or materials involved in case of history of dust 
exposure. It is very important to seek a detailed account of workers’ past employment, too; 
as some pneumoconioses develop after only a brief but intense dust exposure.  
 Lately, many cases have been linked to environmental exposure to dust. This suggests that 
pneumoconiosis is no more a pathology exclusively related to work. Clinicians and 
epidemiologists should keep in mind the fact that cigarette smoking has a devastating 
impact of the health of dust-exposed individuals. Rates of cigarette smoking as high as 80% 
have been recorded among miners and other dust-exposed populations (Baum et al, 1998; 
Hammond et al, 1979). Asbestos-related diseases, silicosis and coal worker’s 
pneumoconiosis (CWP) are most predominant and widely investigated pneumoconioses. 
Pneumoconioses have relatively specific radiologic features that are not well-known to most 
physicians. Radiological imaging plays an important role in the diagnosis of those 
occupational lung diseases, including asbestos-related diseases, Silicosis and coal worker’s 
pneumoconiosis (Ngatu et al, 2010; Blum et al, 2008). This review is aimed at providing 
health care workers, especially clinicians, with basic and accurate knowledge on principal 
radiologic features often found on a pneumoconiotic chest radiograph that characterize each 
of the above mentioned lung diseases related to occupational or environmental exposure to 
dust. 
1.2 Asbestosis and other asbestos-related diseases (ARDs) 
1.2.1 Definitions and epidemiology 
Asbestosis refers to the pneumoconiosis caused by inhalation of asbestos fibers. It is 
characterized by a slowly progressive, diffuse pulmonary fibrosis. Asbestos is a fibrous 
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mineral whose specific properties have encouraged its use since ancient times, in particular 
for industrial applications since the 19th century (Tarres et al, 2009; American Thoracic 
Society [ATS], 2001). Few natural materials used in industry have been the subject of more 
epidemiological and pathological research than the fibrous mineral, asbestos. Asbestos 
fibers are divided into two categories based on fiber’s shape:  
- serpentine fibers (curly, long strands) of which chrisotile (white asbestos) is the most 
commercialized;  it accounts for more than 90 percent of the asbestos produced in the 
United States;  
- amphibole fibers (long and straight) which include amosite (brown asbestos), tremolite,  
crocidolite and  other types of asbestos. 
Of the different asbestos fibers used in industries, crocidolite (blue asbestos) is generally 
considered to be less toxic. The amphibole and amosite are reported to carry the greater risk 
of causing other asbestos-related diseases such as pleural plaque, mesothelioma and lung 
cancer. Exposed workers who have developed asbestosis are at risk of fatal complications 
(Wagner, 1997; Sichletidis et al, 2009; Mossman et al, 1990). 
In patients with asbestosis, the chest radiograph usually shows small bilateral parenchymal 
opacities with a multinodular or reticular pattern that may be associated with pleural 
abnormalities. However, in some individuals with histopathologic evidence of pulmonary 
fibrosis, no interstitial abnormalities are found on the chest radiographs (Larson et al, 2010; 
Kipen et al, 1987). Other asbestos-related disorders are: pleural plaques, mesothelioma, 
diffuse pleural fibrosis, rounded atelectasia, benign asbestos-related pleural effusion and 
chronic bronchitis. In the course of asbestosis development, other radiographic features such 
as honeycombing changes and ground-glass opacities can be seen on the radiograph; they 
are well visualized on computed tomography (CT) and high resolution computed 
tomography (HRCT) scans. 
It is estimated that approximately 27 millions workers in the United States received a 
significant exposure to asbestos during the middle of the last four decades of the twentieth 
century.  
Pleural disease is one of the characteristics of asbestos exposure. Pleural plaques are present 
in about 50 percent of asbestos exposed individuals and most commonly involve the parietal 
pleura, while involvement of the visceral pleura is scarce. The histological examination of 
pleural plaque specimens shows the presence of predominant acellular bandles of collagen 
(Yang et al, 2010).        
The prevalence of both pleural plaques and asbestosis is associated with “time since the first 
exposure” (TSFE) to asbestos, the “exposure intensity level”, the “duration or cumulative 
exposure” to asbestos. Meanwhile, time since the first exposure seems to be the best predictor for 
pleural plaques related to asbestos exposure, whereas cumulative exposure to asbestos is 
reported to be a major determinant for asbestosis (American Thoracic Society [ATS], 2004; 
Schart, 1991). In a study conducted in Finish construction, shipyards and asbestos industry 
workers by Koskinen and coworkers (1998), a strong relationship was found between pleural 
plaques and time since the first exposure to asbestos. A recent study by Paris et al. (2009) showed 
for the first time, in a multivariate analysis, strong and independent correlations between time 
since first exposure and pleural plaques, and between cumulative or level of exposure with both 
pleural plaques and asbestosis, indicating that time and dose parameters should be included 
in the definition of high-risk populations in screening programs. 
Malignant mesothelioma is an aggressive tumor that develops from the mesothelial cell of the 





The association between malignant mesothelioma and asbestos exposure has been well-known 
worldwide since the 1950s. Approximately, 90% of malignant mesothelioma cases are related 
to ealier exposure to asbestos and the risk of developing the disease is greater in case of 
exposure to the amphibole fibers in crocidolite and amosite, but serpentine fibers in chrysotile 
can also cause the disease with a relatively long latency period (30 years or more) (Fujimoto et 
al, 2010; Snashall et al, 2001). In Japan, one of the biggest consumers of asbestos in the last four 
decades of the twentieth century, the number of cases of malignant mesothelioma is shown to 
correlate with the amount of asbestos consumption and the country has been expected to 
confront an epidemic of asbestos-related malignancy (Suganuma et al, 2001; Takahashi, 1999). 
 The incidence of malignant pleural mesothelioma, an asbestos-related tumor, is increasing, 
with a median survival of seven to ten months; its clinical pattern usually involves 
substantial pain and dyspnea. The disease causes approximately 15,000 to 20,000 deaths per 
year worldwide (Pass et al, 2008).  
Lung cancer can be consecutive to asbestos exposure. Clinician’s search during risk 
assessment in patients with possible dust exposure may be hindered by the long latency 
period between the inhalation and the appearance clinical manifestions. In addition to its 
fibrogenic properties, asbestos is a first-level carcinogen and the most accepted oncological 
model is the dose-response without safety level (Rosell-Murphy et al, 2010; Goldberg et al, 
1999). According to some previous studies, smoking increases the risk of lung cancer in 
asbestos exposed individuals by 50 – 90 times more than non-smokers (Valavanidis et al, 
1996; Hartly et al, 2000).  
A variety of occupational and nonoccupational settings can be source of exposure to 
asbestos: 
- Manufacture of asbestos products 
- Thermal and fire insulation 
- Construction and demolition work 
- Shipbuilding and repair 
- Building maintenance and repair 
- Plumbers and gasfitters 




Since a while, there is an increasing number of reports on cases of asbestos-related diseases 
in workers whose occupations have not been traditionally on the lists of occupational health 
specialists. Asbestosis and pleural plaques have been found in dentists and mechanics in 
Europe and the United States. And in some cases, these asbestos-related abnormalities are of 
unusual source of exposure.  
Torbica and Krstev (2006) suggested that asbestos-related diseases in dentists might be 
linked to exposure to inorganic dust in the manufacturing of cobalt-chromium- 
molybdenum- based dental protheses. With the use of white asbestos-made lining material 
for casting rings in dentistry, dental technicians and dentists are potentially exposed to 
asbestos; and some cases of pleural plaques and malignant mesothelioma have been 
reported in a number of dentists after a relatively long period of work (35 to 45 years) (Choel 
et al, 2001; Reid et al, 1991; Sichletidis et at, 2009; Radi et al, 2002). 
Similarly, pneumoconiosis may occur in mechanics. Most motor vehicles, from passenger 
cars to heavy duty trucks, have disc brakes on the front wheels and drum brakes on the rear 
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wheels which help control their movement. Asbestos containing brake lining is generally 
found in those vehicles, ranging from 35% to 65% of chrysotile contents. Their repair or 
replacement can be a source of exposure to asbestos (Gilles, 2005; Paustnebach et al, 2004; 
Kakooei et al, 2004).  
According to previously published reports, the incidence of lung cancer and malignant 
mesothelioma in auto mechanics is higher than in the general population. In the Unites 
States, concentrations of airborne asbestos more than 300 times higher than the current 
permissible exposure limit (Occupational Safety and Health Agency, OSHA) of 0.1 fiber/cc 
were found (Levin et al, 1999; Lorimer et al, 1976; Rohl et al, 1976). 
1.2.2 Clinical manifestations of asbestos-related diseases 
For asbestosis, in general, the latency period between exposure and the appearance of 
symptoms is inversely proportional to the intensity of asbestos exposure. And the majority 
of patients remain asymptomatic for 20- 30 years after the first exposure, even though 
pleural plaque is present. The first symptom of asbestosis to appear is usually breathlessness 
with exertion. Dyspnea will follow as the disease progresses; however, cough, wheezing, 
sputum production are often present when the patient has a history of cigarette smoking. 
With the progression of the disease, the patient will develop bibasilar crackles heard mostly 
at the end of inspiration, and clubbing. Pleural disease occurs earlier mostly within 15 years 
since the initial exposure to asbestos (Epler et al, 1982; Paris et al, 2009). 
1.3 Silicosis 
1.3.1 Definition and epidemiology 
Silicosis is an interstitial pulmonary disease secondary to the inhalation of crystalline silica 
(silicon dioxide), usually in the form of quartz, and less commonly as cristobalite and 
tridymite. It is one of the world’s oldest known occupational diseases characterized by 
irreversible, progressive lung disease. Crystalline silica has long been considered as the toxic 
form of silica; however, very little was known about the toxicity of amorphous silica until 
the very recent toxicological and mechanistic study in animals by Constantini and cowokers 
that revealed the fact that both crystalline and amorphous (which has been regarded as non-
fibrogenic) silica are phagocytosed and are both toxic to alveolar macrophages and have 
similar pathway that lead to apoptosis. 
Silica, the second most abundant element that forms the quarter part of the earth’s crust, is 
an ubiquitous mineral in human environment. Thus, exposure to silicon dioxide and salts of 
silicic acid is a fact of life. However, intense exposure can lead to silicosis (Pascual et al, 
2011; Wagner, 1995; Constantini et al, 2011; Baum et al, 1998). Silica is also bound to other 
minerals; it is then called silicate. Silicates are used in some industries; they include asbestos, 
talc (Mg3S4O10 (OH)2), and kaoline (Al2Si2O5(OH)4) [Gamble, 1986]. 
New cases of Silicosis are annually recognized worldwide.  In the United States, up to 
200,000 miners and 1.7 million non-mining workers have experienced significant 
occupational exposure to inhaled silica; and every year the country register between 3600 
and 7300 new cases of Silicosis. The overall mortality attributable to Silicosis has decreased 
in the United states  thanks to the improvement of workplace protection, compared to that 
of 30 years ago (3000 deaths a year) [Rosenman et al, 2003; CDC, 2008; NIOSH, 1999]. 
Silicosis can occur in many industries and work settings with evident dust exposure such as: 






 Construction work, masonry. 
 Sandblasting 
 Foundry work 
 Ceramics, etc. 
The list is not complete; there are numerous other work sites with silica exposure, as free 
silica can be found anywhere. Mining and construction work that involve drilling, cutting, 
grinding or crushing the earth’s crust or rocks are associated with high level of silica 
exposure. In several developing countries, in Africa and Asia particularly, mining and 
minerals processing industries represent the main source of income. It is common to find 
employers who fail to provide necessary personal protective materials to workers, putting 
them at high risk of occupational lung disease such as silicosis.  
It is also obvious that, in some occupational settings, workers may be exposed to both silica 
and asbestos or other dust and develop what is called a mixed-dust pneumoconiosis (MDP). 
MDP is pathologically defined as an occupational lung disease that shows dust macules or 
mixed-dust fibrotic nodules, with or without silicotic nodules, in an individual with a history 
of exposure to mixed dust [Honma et al, 2004]. Radiologic features of MDP may include those 
related to exposure to silica and other fibrogenic duts such as silicates, metals, carbon.  
1.3.2 Clinical manifestations of Silicosis 
Clinical forms of Silicosis are described according to both their clinical and radiological 
manifestations. They are divided into: 
 Simple Silicosis 
 Acute Silicosis 
 Chronic silicosis 
 Accelerated silicosis 
Simple Silicosis is characterized by the presence of small (less than 10 mm in diameter) opacities 
that are rounded in general, on the chest radiograph, and mostly without symptoms. 
Acute Silicosis often occurs after weeks or a few years of an intense exposure to silica. The 
presence of silicotic nodules on the chest radiograph or computed tomography scan is the 
main radiologic manifestation. 
Chronic silicosis usually appears 10 – 30 years after the initial exposure to silica and develops 
slowly. This clinical form often share the same radiographic feature with simple Silicosis; 
but in some cases silicotic nodules may coalesce and form a large opacity which represent a 
progressive massive fibrosis (PMF). Both accelerated and chronic silicosis have similar 
radiographic features. The only trait that differentiates them is the interval between the 
exposure to silica dust and the development of the disease symptoms.  
Accelerated Silicosis occurs within ten years after initial exposure and is associated to high-
level exposure to silica. Both chronic and accelerated Silicosis may be asymptomatic with the 
patient having only an abnormal chest radiograph consistent with Silicosis. However, 
symptomatic patients would present with a chronic cough and dyspnea on exertion. Later, 
symptoms will become severe with the worsening of the radiographic abnormalities. 
Crackles, rhonchi and or wheeze may be present in some patients.  
The presence of large opacity or progressive massive fibrosis is always accompanied by the 
aggravation of patient’s status and respiratory impairment. The presence of emphysema, air 
trapping on chest radiograph may be observed (Munakata et al, 1985). Progressive massive 
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fibrosis (PMF) occurs when small rounded opacities enlarge progressively and coalesce to 
generate larger opacities (more than 10 mm in diameter). PMF, when it is present, its 
location is either the upper or the middle zone of the lung. 
Malignancy represents one of the complications of Silicosis.  The international Agency for 
Research on Cancer (IARC) determined in 1997 that there was evidence of carcinogenicity of 
crystalline silica (Scarselli et al, 2011). The relationship between silica exposure and lung 
cancer risk have been demonstrated in several studies. More than ten cohort studies have 
shown a standardized mortality ratio (SMR) between 1.37 and 3.70, and few reports showed 
stronger associations with highest risks and excess mortality from lung cancer among 
silicotics (Scarselli et al, 2011; Lacasse et al, 2005; Erren et a, 2009;Pelucchi et al, 2006). 
This suggests that clinicians should keep in mind the relationship between a workplace with 
exposure to silica dust and the development of lung cancer. Ignoring this fact may 
mistakenly lead the clinician towards a wrong diagnosis of the patient’s condition. 
1.4 Coal worker’s pneumoconiosis (CWP)  
1.4.1 Definition and epidemiology 
Coal worker’s pneumoconiosis is defined as an occupational lung disease caused by the 
deposition of coal mine dust in the lung parenchyma and the reaction of tissues to its 
presence. Coal mining has been used as a source of fuel for hundreds of years, and it still 
remains a major industry in countries such as the United States, France, Germany, Australia, 
China, India and South Africa. 
Recent researches suggest changes in terms of the epidemiology and clinical features of 
pneumoconiosis among underground coal miners that are characterized by an increase in 
the severity and rapid disease progression. Factors such as over-exposure to silica dust in 
coal mines, the increase in coal production and increasing hours of work are thought to be 
responsible of the current high prevalence and increased severity of the coal worker’s 
pneumoconiosis (CDC, 2007; Laney, 2009; Antao, 2005). 
Laney and Attfield’s more recent work, conducted in the Unites States, demonstrated the role of 
size of mine as another factor that contribute to the high prevalence and fatality of disease 
observed the last decades.  In their study, workers from small mines had a greater risk of coal 
worker’s pneumoconiosis and progressive massive fibrosis than their large mines counterparts. 
Smaller mining operations often have limited capital to upgrade safety equipment, and 
dedicated safety and personnel are less likely to be available to workers. This influences the 
implementation of dust monitoring and control activities in the mines (Laney & Attfield, 2010].  
1.4.2 Clinical forms of CWP 
CWP comprises two clinical forms: the simple and complicated Coal worker’s 
pneumoconiosis. Generally, simple CWP is not associated with symptoms. It is often 
characterized by a history of underground exposure of more than 10 years. As for silicosis, 
the early radiological features are small rounded opacities that first appear on upper lobes 
of the lung. 
In contrast, complicated CWP is associated with symptoms and a marked impairment of lung 
function. Shortness of breath, cough and sputum production are common symptoms (Caplan, 
1953). The pattern and severity of respiratory impairment in coal worker’s pneumoconiosis are 
related to the levels of coal mine dust exposure, geologic factors, exposure to other respiratory 





2. Classification of High Resolution Computed Tomography (HRCT) scans 
and chest radiographs of pneumoconioses  
2.1 Overview on the classification of pneumoconiotic HRCT scans 
The use of Computed Tomography (CT) has revolutionized the radiologic diagnosis of chest 
diseases as compared with conventional radiography. However, the ability of CT scanners to 
evaluate pulmonary parenchymal abnormalities is limited because of their resolving power. 
With the introduction of High-Resolution Computed Tomography (HRCT) techniques, it 
became possible to perform images of the lung with excellent spatial resolution, providing 
anatomic detail similar to that available from gross pathologic specimens (Kusaka et al., 2005). 
Thus, HRCT increases the specificity in the diagnosis of lung diseases, including 
pneumoconioses. In addition, the early diagnosis of these chronic diseases allows an early care 
and avoidance of further exposure to the hazardous dusts. For that reason, the proposed 
International Classification of HRCT of pneumoconiosis is used in some developed countries 
(such as Japan, Germany and Finland) in the screening and surveillance programs; however, 
its acceptance by international health institutions might take a time. 
The chest radiograph, which is easily accessible and cheaper, presently remains the unique 
internationally accepted diagnostic tool for pneumoconiosis. For this practical reason, in this 
chapter, we only present different parameters that are taken into account in the international 
classification of HRCT of pneumoconiosis. 
This section summarizes briefly the information on the proposed international classification 
of HRCT of pneumoconiosis. Though it is not yet accepted by the International Labor Office 
(ILO), clinicians should have in mind the existence of this tool which, sooner or later could 
be of use worldwide.  
The purpose of the international HRCT classification is to describe and code parenchymal 
and pleural manifestations of diffuse non-malignant occupational and environmental 
respiratory diseases. It is used for the screening (for early detection of pneumoconiosis) and 
surveillance and follow-up of the exposed individuals) (Kusaka et al., 2005).  
In asbestosis, the most common HRCT findings are centrilobular nodules on branching areas 
of high attenuation, and the thickened interlobular and intralobular lines, subpleural dot-like 
or curvilinear opacities and honeycombing predominantly distributed in the bases of the 
lungs. The interstitial fibrosis may also be manifested as traction bronchiectasis, honeycombing. 
On the other hand, in case of silicosis or CWP, the common characteristic radiologic features 
on HRCT scan are small opacities predominantly distributed in the upper zones of the lung 
and, sometimes, images of progressive massive fibrosis (large opacity) (Aberle et al., 1988; 
Akira et al., 2002).                                                           
The reading sheet used in the coding system for CT or HRCT films of pneumoconiosis has 
the following main parameters to be reported: film quality, parenchymal abnormalities 
(small opacities, large opacity, emphysema, honeycombing, inhomogenous attenuation of 
lung parenchyma, pleural abnormalities) ( Kusaka et al., 2005). 
- quality of the film:  four grades are considered, similarly to the ILO/ICRP (grade 1, 2, 3, 4; 
see ILO/ICRP). 
- parenchymal abnormalities: the absence (No) or presence (Yes) of small opacities (rounded 
or irregular) has to be reported on the reading sheet; their overall distribution is 
recorded in a grading system for each side (right, left), according to each zone of the 
thorax (upper [U], middle [M] or lower [L]). In addition, the severity of the disease is 
also reported as follows:  
0 = no definite opacities;  
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1=mild (present but only few small opacities);  
2=moderate (numerous small opacities);  
3=severe (very numerous small opacities and normal anatomical lung structure are poorly. 
A number of additional parenchymal abnormalities have to be checked:  
a. inhomogenous attenuation (absence [No] or presence [Yes] which may be due to the 
presence of ground glass opacities (GGO). When present on HRCT scan, the 
inhomogenous attenuation should be graded for each side and each zone for its extent 
as follows: 1=focal; 2=patchy; 3=diffuse. 
b. honeycombing (HC): absence (No) or presence (Yes);  
c. emphysema: absence (No) or presence (Yes) of emphysema has to be reported, and 
graded for right (R) and left (L) side, and for all zones as 1 (mild [up to 15% of area of 
one zone]), 2(moderate [15-30%]), 3(severe [more than 30%]). 
d. large opacity: absence (No) or presence (Yes). 
- pleural abnormalities: absence (No) or presence (Yes); two types of pleural abnormalities 
should be differentiated considering the CT appearance (parietal and visceral type). The 
parietal type refers to the flat thickening of the pleura, whereas the visceral type 
(diffuse pleural thickening) is associated with subpleural fibrosis or parenchymal bands 
(PB) and rounded atelectasis (RA). Their extent, width and location (medias- tinal, 
diaphragmatic,..) are also reported.  
- pleural calcifications: their absence (No) or presence (Yes) should also be reported on the 
reading sheet.  
Detailed information on the international classification of HRCT of pneumoconioses is 
available elsewhere (Kusaka et al., 2005). 
2.2 The ILO International Classification of chest Radiographs of Pneumoconiosis 
(ILO/ICRP) and ILO/WHO global program for the elimination of Silicosis (ILO/WHO 
GPES) 
The ILO 2000 International Classification of Radiographs of Pneumoconiosis (ILO/ ICRP) is 
used worldwide by experts to categorize conditions that are consistent with 
pneumoconiosis, with the use of a set of ILO standard films.  
This international classification system was created with the purpose of coding anterio-
posterior chest radiographs in a simple and reproducible manner; it provides a means for a 
systematic description and recording of radiographic abnormalities in the chest caused by 
the inhalation of dusts. It is useful in epidemiologic research, surveillance and medical 
checks of dust-exposed workers (Suganuma, 2001; International Labor Office [ILO], 2002). 
Chest radiographs of patients with silicosis, coal worker’s pneumoconiosis asbestosis and 
other asbestos-related diseases can be interpreted and classified the same way anywhere in 
the world using the ILO/ICRP system. In this section, basics on the principal radiologic 
features of pneumoconioses and their characteristics are summarized. In order to fully 
understand the system, a special training is of utmost importance. 
To classify a chest radiograph of a dust-exposed individual, there are four main points to be 
considered: 
- Technical quality; 
- presence (or absence) of parenchymal abnormalities consistent with pneumocoiosis; 
- presence (or absence) of pleural abnormalities 






Technical quality There are four grades:  
1. Good (grade 1);  
2. Acceptable, with no technical defect (grade 2); 
3. Acceptable, with some technical defect but still adequate for classification purposes 
(grade 3);  
4. Unacceptable for classification purposes (grade 4). 
A technical defect may be the presence of artifact, with poor contrast, under (light) or 
overexposed (dark) film or due to an improper position of the subject (overlapping of scapula, 
for example) or other defect. Artifacts can be interpreted as pathological abnormalities in case 
they mimic opacities, while the overlap of scapula (Fig. 1) can easily be interpreted as in-
profile or face on plaque. An abnormal feature related to the lung parenchyma or pleura may 
be present on the chest radiograph, but hidden by the overlapping scapula. When a chest 
radiograph is qualified as unreadable, it is necessary that another one be indicated. 
 
 
Fig. 1. Chest radiograph of poor quality showing overlapping scapula (white arrows) 
looking like pleural plaques on both right and left lung fields. 
[Courtesy of Prof. Dr. Yukinori Kusaka, Asian Intensive Reading of Pneumoconiosis radiographs 
(AIR PNEUMO)] 
2.2.1 Parenchymal abnormalities 
They include two types of opacities: small and large opacities. 
Small opacities are described by profusion, affected lung zones, the shape (rounded or 
irregular) and size.  
- Profusion refers to the concentration of small opacities in the affected zones of the lung; 
the are four categories of profusion (0, 1. 2, 3) and 12 sub-categories of profusion (0/-; 
0/0;  0/1; 1/1; 1/2; 2/1; 2/1; 2/2; 2/3; 3/2; 3/3; 3/+), where category 0 means the 
absence of small opacities or the presence of small opacities with a profusion lower than 
category 1, and category 3 has the highest profusion. 
To classify the dust-exposed individual’s chest radiograph, it has to be compared with the 
standard radiographs from ILO (known as ILO standard radiographs) which profusion 
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seems to be closer to that in the worker’s film. Standard radiographs provide examples of 
appearances classifiable as subcategory 0/0; 1/1; 2/2; 3/3.   
- Affected lung zone is the area the lung where small opacities are seen; each lung field is 
divided into three zones (upper, middle, lower) by horizontal lines. 
- Shape and size of small opacities are also recorded; for the shape, there are rounded and 
irregular (reticular) opacities. For small rounded opacities, there are three size ranges 
designated as p (diameter up to 1.5 mm), q (diameter exceeding 1.5 mm and up to 3 
mm), r (diameter exceeding 3mm and up to 10 mm). Similarly, for small irregular 
opacities, the three sizes are denoted by the letters s (opacities with a width up to 1.5 
mm), t (width exceeding 1.5mm and up to 3 mm), u (with a width exceeding 3mm and 
up to 10 mm). On each standard radiograph, the type of small opacities and their 
profusion are shown (for example: p/p, 2/2 which means ‘small opacities of p type and 
profusion 2/2). However, some chest radiographs may show both small rounded and 
irregular opacities; this often happens in case the worker was exposed to silica and 
asbestos, for example (mixed-dust pneumoconiosis). 
Large opacities are opacities whose longest diameter exceeds 10 mm. There are three 
categories of large opacities:  
- category A: one large opacity with longest dimension up to 50 mm, or several large 
opacities with the sum of their longest dimension not exceeding about 50 mm; 
- category B: longest diameter exceeding 50 mm, but not exceeding the equivalent area of 
the right upper zone; or several large opacities with the sum of their longest dimensions 
not exceeding the equivalent of the right upper zone (Fig. 2); 
- category C: one large opacity which exceeds the equivalent area of the right upper zone, 






Fig. 2. Silicotic chest radiograph showing a large opacity of category B (black arrows) on the right 
upper zone. Numerous rounded opacities (q type) are present in all zones of the lung field. 






Fig. 3. Chest radiograph showing calcified diaphragmatic pleural plaques (white arrows) 
and face-on plaques (blue arrows) bilaterally. In this film, pleural plaques can also be seen in 
other site (mediastinal region bilaterally). 
(Courtesy of Prof. Dr Yukinori Kusaka, AIR PNEUMO) 
 
 
Fig. 4. Chest radiograph showing an in-profile pleural plaque (arrows) in asbestos-exposed 
worker. 
(Courtesy of Dr Hisao Shida) 
2.2.2 Pleural abnormalities 
They comprise pleural plaques (localized pleural thickening), costophrenic angle obliteration and 
diffuse pleural thickening (DPT). 
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Pleural plaques may be located on the diaphragm, on the chest wall (in-profile or face-on 
plaques) and at other sites; they generally represent a thickening of the parietal pleura and 
are recoded as present or absent. 
Other details regarding the site (right or left lung), presence or absence of calcification, 
width and extent of the plaque are recorded. 
2.2.3 Costophrenic angle obliteration and diffuse pleural thickening 
Costophrenic angle obliteration is recoded as present or absent. However, with the ILO 
classification, diffuse pleural thickening extending up to the lateral chest wall is recorded only 
in case of an obliterated costophrenic angle. All details are summarized in a single chest 
radiograph reading sheet (ILO, 2002). 
The global program for the elimination of Silicosis (GPES) was adopted in 2003, Geneva, by 
a panel of experts in occupational health. It is aimed at establishing a wide international co-
operation so as to eliminate Silicosis by the year 2030 (World Health Organization [WHO], 
2003). GPES was established following recommendations of the twelfth session of the joint 
ILO/WHO Committee on occupational health in 1995, which indentified the global 
elimination of silicosis as a priority area for action in occupational health. The committee 
wanted countries to place it high on their agendas, with the belief that the experience gained 
through implementation of this program would provide a prevention model for other 
pneumoconioses and a proven system for the management of exposure to mineral dust. 
The GEPS has two different approaches; the primary prevention of Silicosis that emphasizes 
the control of silica hazard at source using engineered methods of dust control, while the 
secondary prevention includes surveillance of the work environment to assess the efficacy of 
the implemented measures for dust exposure control, exposure evaluation by assessing health 
risk for workers and surveillance of workers’ health for the early diagnosis of the disease.  
In most industrialized countries, following recommendation of the ILO/WHO Global 
Program for the Elimination of Silicosis, pneumoconiosis prevention programs have been 
initiated to protect workers from dust exposure and the actual trend of show a decrease in 
number of new cases. On the other hand, in the majority of developing countries millions of 
workers continue to be exposure to dust.  In order to reach the goal by 2030, each country 
should have its own national program. Unfortunately, the reality shows that there are still 
obstacles that might make it difficult to reach the GPES goal by 2030: one is the non 
adherence of some countries to the ILO/WHO program and, the insufficiency of qualified 
individuals in the interpretation of pneumoconiotic chest radiographs.  
Under the ILO/WHO GPES, experts focused manly on secondary prevention, upgrading 
skills of occupational physicians in developing countries in using the ILO 2000 Classification 
of Radiographs of Pneumoconiosis (ILO 2000 ICRP) and strengthening national Silicosis 
elimination programs (Luton, 2007).  
3. Short training on pneumoconiosis chest radiographs reading 
3.1 Objective 
The ILO classification system is an important tool for training occupational physicians in the 
diagnosis of pneumoconioses. Based on this ILO system, some countries have developed 
their own national program and produced necessary teaching materials. In the United 
States, the National Institute for Occupational Health (NIOSH) provides certification tests 





the B-readers system. And, since the year 2008, the Asian Intensive Reading of 
Pnemoconioses chest radiographs (AIR-PNEUMO) program started, organizing annual 
workshops and certification test for Asian countries and also Brazil. These programs 
contribute a lot for the achievement of the ILO/WHO Global Program for the Elimination of 
Silicosis, and also those dedicated to the elimination of asbestosis. 
However, the number of physicians who have required skills to interpret pneumoconiotic 
radiographs remains insignificant in many regions of the world, as participation to ILO 
training course by physicians is quite costly and, moreover, the absence of local trainers 
constitutes a real obstacle. Countries that do not yet get involved in the ILO/WHO program 
are numerous. Despite the existence of institution such Air-pneumo, NIOSH and others, the 
elimination of silicosis may not be achieved by the year 2030 without involvement of 
governments and health authorities of all nations. Providing basic knowledge on 
pneumoconiosis to clinicians and those who are about to graduate from medical school 
would also be helpful for the diagnosis of pneumoconiosis, particularly in regions where 
occupational or environmental exposure to dust represent a real public health issue. Here is 
presented a short training on pneumocnioses and the evaluation of its potential to improve 
physicians’ ability to detect main pneumoconiotic radiographic features on chest 
radiographs of dust-exposed individuals. 
3.2 Differentiating normal and pneumoconiotic radiographs 
Radiological imaging plays an important role in the diagnosis of pneumoconiosis. Although 
chest radiography has some limitations in terms of detecting earliest parenchymal and pleural 
abnormalities, it remains the most useful and universally accepted method for assessing 
pneumoconiosis; it is an easily accessible, cheap diagnostic tool (Takashima et al., 2007).  
On a normal chest radiograph (Fig. 5), there are anatomical structures that resemble 
abnormal features and may lead the reader to wrong interpretation. The presence of lymph   
 
 
Fig. 5. Normal chest radiograph showing normal anatomical features. Note the presence of 
opacities that represent lymph nodes and blood vessels. 
(Courtesy of Dr Hisao Shida) 
 




Fig. 6. Silicotic chest radiograph showing small rounded opacities of q type mostly, with 
involvement of all lung zones (upper, middle and lower zones). Coalescence of small 
rounded opacities is seen on the right upper zone. 
(Courtesy of Dr Hisao Shida) 
nodes, muscles (serratus anterior, oblique externus abdominis...), pleural fat’s shadow and 
normal cross-section or tangential views of blood vessels can be interpreted as opacities or  
pleural plaques related to pneumoconiosis, for example. This poses a challenge during chest 
radiograph reading process and may lead to misclassification of conditions consistent with 
pneumoconioses (Ngatu et al, 2010; Jinkai et al, 2008).   
For individuals who present with pneumoconiotic-like radiographic features, establishing 
the history of dust exposure is an important step towards the confirmation of the diagnosis. 
A silicotic or coal worker’s pneumoconiosis’ chest radiograph will often present small 
rounded opacities (opacities having a diameter up to 10 mm) as parenchymal abnormalities 
(Fig. 6). When they coalesce, small opacities form a large opacity (having a diameter > 10 
mm). In addition, a silicotic radiograph may also show calcified lymph nodes (eggshell 
calcifications). In silicosis, small opacities are first localized on the upper zone of the lung, 
then will progress towards the middle and lower zones. 
In contrast, a chest radiograph from an asbestosis patient will often present small irregular 
opacities (opacities having a longest dimension up to 10 mm) as parenchymal abnormalities 
(Fig. 7) and/or pleural plaque (s). Asbestosis small opacities appear on the lower zone of the 
lung, then later progress towards the middle and the upper lung zones. Other features may 
also be present such as diffuse pleural thickening, honeycombing changes.  
The table below summarizes frequently found pneumoconiotic radiographic features for 
mineral dust-exposed subjects: their localization according to the type of pneumoconiosis, 
and their shape and size for small opacities (Table 1). It is important to know that 
individuals exposed to both silica and asbestos may develop a “Mixed Dust Pneumoconiosis 
(MDP); the radiograph may show a combination of features of silica, asbestos or other 






Fig. 7. Chest radiograph of asbestos-exposed worker showing the presence of small irregular 
opacities (of “t” type primarily and “s” type secondarily), predominantly on lower and 
middle lung zones. The right upper lobe is also involved. The profusion is 2/3. In addition, 
diffuse pleural thickening (DPT) is evident on the right and in-profile plaque on the left; also 
note the abnormal cardiac size. The film quality is of grade 2 (scapula overlap). 













(category: A, B, C)
often present
may be present





First localisation Upper zone lower zone
may be present
 
Table 1. Summarized main radiographic findings related to silicosis and asbestos-related 
lung diseases 
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3.3 Implementation of the two-hour training session 
3.3.1 Participants and methods 
For the first reported training held in 2008, 102 Japanese physicians (72 males and 28 
females; 2 to 44 years of experience) having different background (preventive medicine, 
internal medicine, psychiatrists, surgery, pediatrics) from different cities within the country. 
Participants were invited to the 2008 training session held in Kochi and Ehime prefecture 
through the staff of Japanese medical corporations, and the training session was conducted 
by a NIOSH-B reader from Kochi University Medical School, Japan. 
We used three sets of chest radiographs were used, namely ILO/ICRP standard films, dust-
exposed workers’ chest radiographs and a set of twelve test films. ILO standard films were 
used to describe pneumoconiotic lung abnormalities (shape, size, profusion of small 
opacities; large opacities, pleural plaques) during the lecture. Dust-exposed workers’ chest 
radiographs, having different radiographic features of pneumoconioses, were provided by 
the Japan Pneumoconioses Study Group (JPSG). In order to read them, each film was put 
side by side with the ILO standard whose profusion, for example, seems to be close to that 
of the patient.  
Our intervention was aimed at improving inexperienced physicians’ skill in reading 
pneumo-coniotic chest radiographs. Participants had to listen to a pre-session talk to remind 
them the abnormalities to be checked on each of patients’ radiographs (before the main 
lecture); then, they take a pre-test as described in the protocol (Fig. 8). Each participant 
received a reading form that had a list of 12 radiograph numbers (from 1 to 12) and they had 
to check for the presence (Yes) or the absence (No) of parenchymal or pleural abnormalities 
consistent with pneumoconiosis (opacities and pleural plaques) for each chest radiograph. 
Classifying the radiographs using categories of profusion of small opacities, location, width 
or extent of pleural plaques was not indicated. The main lecture was given after the pre-test 
for two-hours; afterwards a post-test was organized using the same test films that were 



















reading skill befo re 




Fig. 8. Protocol of the intervention study  (CXR: chest radiograph; JPSG: Japan 
pneumoconiosis study group) 
3.3.2 Evaluation of physicians’ reading skill and observed results 
The reading forms were collected and managed by s staff who no relationship with any of 





(pre-test and post-test) results.   The difference in the physicians’ reading skill before and 
after the intervention was evaluated using McNemar’s chi-square test. 
The general trend was towards improvement in terms of physicians’ ability to detect 
pneumoconiotic parenchymal and pleural abnormalities on the test-radiographs. Regarding 
the dectection of the presence of pneumoconiotic small opacities, a significant increase in the 
specificity score  was observed, 65% in the pre-test and 73% in post-test (p<0.0001); whereas 
the sensitivity score remained high, 84% and 81% in pre- and post-test (p>0.05), respectively 
(Table 2). It is noticeable that the high sensitivity score in the pre-test was due to a high 
proportion of physicians who considered the normal radiographs to have pneumoconiotic 
opacities (false positive or over reading) in the pre-intervention test. The over reading of 
test radiographs was noticeable for the pre-intervention test for most of the readers. 
 
Lung abnormality  Sensitivity p Specificity p
pre-test            post-test pre-test     post-test
Small opacitity 84%                     81% 0.204 65%            73% <0.0001
Pleural plaque 46%                     60% <0.0001 77%            79% 0.3339
 
p: p-value by McNemar’s chi-square test. 
Table 2. Overall distribution of the sensitivity and specificity scores of the participants for 
detecting pneumoconiotic small opacities and pleural plaques on chest radiographs 
Group of readers Lung abnormality Sensitivity p Specificity p
pre-test   post-test pre-test   post-test
1. Internists Small opacity 83%          78% 0.208 67%           76% <0.01
Pleural plaque 41%          61% <0.0001 83%           80% 0.21
2. Other specialities Small opacity 85%          83% 0.546 63%           71% <0.01
Pleural plaque 50%          59% <0.05 72%           79% <0.05
 
p: p-value by McNemar’s chi-square test. 
Table 3. Distribution of sensitivity and specificity scores of readers for detecting 
pneumoconiotic abnormalities according to medical specialty. 
For pleural plaques, a marked increase in the sensitivity score was noted, 46% in pre-test 
and 60% in post-test (p<0.0001), while an improvement was also observed in the specificity 
score but not significantly (77% and 79% in pre and post-test, respectively) (p>0.05) as 
shown in Table 2. 
When compared according their medical specialties, a relatively similar reading skill 
improvement was observed between internists and physicians from working in other 
departments. Higher scores of sensitivity for the detection of small opacities and specificity 
for plaques were found in internists, and a similar trend was also noted in the group of 
physicians from other specialties in which a significant improvement of specificity score for 
pleural plaques was found (p<0.05) in the post-test (Table 3) (Ngatu et al, 2010). 
The lack of training for medical doctors in the diagnosis of occupational diseases is the main 
factor leading to the misdiagnosis of pneumoconiosis as either chronic bronchitis or 
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pulmonary tuberculosis (Murlidhar et al, 2005). One of the strong points of this training 
program is that, despite being carried out in relatively short time, it results in a noticeable 
improvement of physicians’ ability to detect pneumoconiotic parenchymal and pleural 
abnormalities. Popularizing such program may contribute to the early diagnosis of 
pneumoconioses, improve their prognosis and give chances of survival for individuals with 
lung diseases related to dust exposure. 
4. Conclusion 
This review article provides basic knowledge on pneumoconioses and a practical approach 
that may help physcians to diagnose occupational lung disorders related to exposure to 
mineral dust. Meanwhile, a training with demonstrations on the pneumoconiotic chest 
radiograph reading process is of utmost importance. Holding regular short period training 
courses for physicians, and even medical students who are about to graduate, focusing on 
main radiolographic features of lung parenchymal and pleural abnormalities related to 
occupational or environmental exposure to dust, with the use of typical ILO standard films, 
will contribute to improving their skill in the diagnosis of pneumoconioses.  
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1. Introduction 
The increasing population age, along with the prevalence of smoking and other 
environmental factors have contributed to a dramatic increase in the incidence of chronic 
pulmonary diseases with no known cures. Chronic obstructive pulmonary disease (COPD), 
lung cancer, and primary pulmonary hypertension are all conditions with well understood 
origins but few, if any therapeutic options. When taken in conjunction with the prevalence 
of genetic or poorly understood conditions such as cystic fibrosis (CF) and idiopathic 
pulmonary fibrosis (IPF) there is a large and growing cohort of patients that will eventually 
enter end-stage lung disease. The only currently available treatment option is lung 
transplantation which may potentially be extremely beneficial in terms of quality of life and 
life expectancy, although carries with it a vast array of considerations and complications. 
This chapter attempts to provide an account of the progress made in lung transplantation, 
complications associated with the procedure, current treatment for transplant associated 
conditions, and finally will discuss current research and possible future therapeutics.  
2. History of lung transplantation 
Lung transplantation remains the final therapeutic option for treatment of patients with 
diverse diagnoses of end stage lung disease. (Arcasoy and Kotloff 1999) This however, has 
not always been the case. It was only within the last three decades that the medical 
community achieved reproducible outcomes that translated into clinical improvement in the 
condition of the patient. Vladimir Demikhov is considered by some to be the founder of the 
field due to his work in animal models in the mid 20th century, but it wasn’t until 1963 that 
the first attempt at human lung transplantation occurred. (Cooper 1969; Hardy et al. 1963) 
This early trial was in a prisoner with both terminal lung cancer, and severe emphysema. 
Unfortunately, the patient died a mere 18 days post-transplantation. (Cooper 1969) It was 
almost another two decades before the first successful heart-lung transplantation was 
performed resulting in the multi-year survival of the recipient. This 1981 triumph was 
followed up by a group out of Toronto that proved once and for all that the one-time pipe 
dream of regular lung transplantation in humans was, in fact, a reality. (Cooper et al. 1987) 
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It was in the early 1990s that a comparative “transplant boom” began and has since leveled 
off to the approximately 2,700/year lung transplants performed worldwide today. (Orens 
and Garrity 2009) The relatively limited number (compared to other whole organ transplant 
procedures) of lung transplantations is a factor of limited supply of acceptable organs and 
ability to procure donor tissue. (Dilling and Glanville 2011) Unfortunately, it is because of 
this dearth of patients that few multi-center trials have been performed to assist in the 
investigation of better pre-, peri-, and post-operative techniques. However, with the increase 
in surgeries seen in the 1990s, serious efforts at reducing the risk factors associated with 
lung transplantation were initiated. 
3. Selection of candidates 
The majority of this chapter will deal with the complications and efforts to reduce them 
post-transplantation, but we will briefly touch on steps that have been implemented to 
reduce risk exposure prior to surgery. These preventative steps begin with a strict limitation 
on those who are eligible for transplant. Typically, individuals 55 and older are considered 
unsuitable for operation; although the mean age of recipients has been steadily increasing (it 
is currently over 50). (Dilling and Glanville 2011) Multiple organ failure, history of non-
compliance, active/recent cigarette smoking, and active cancer are all contraindications for 
enrolling a patient in the United Network for Organ Sharing (UNOS). (Maurer et al. 1998) 
One of the most important factors that clinicians must consider when evaluating a patient 
for transplantation is the infection state of the possible recipient. While most bacterial 
and/or viral colonizations are permissible, there are many transplant centers that refuse to 
operate on patients with unremitting infection with pan-resistant P. aeruginosa and B. cepacia.  
Even so, there is at least one group out of Canada that is willing to consider transplantation 
of this patient population. (Nash et al. 2010; Flume et al. 1994) Prior to 2005, the allocation of 
lungs in the United States was dependant solely on waiting time; those who had been on the 
list longer were given priority over newly enrolled patients. Unfortunately, this obviously 
created a selection bias against the acutely ill. In 2005 the Lung Allocation System 
underwent an overhaul, utilizing a Lung Allocation Score (LAS) to determine those patients 
that were both most in need of transplantation, and most likely to survive the surgery and 
excel in recovery. (Egan et al. 2006) The new LAS system includes a number of factors (age, 
6 minute walk test, forced vital capacity (FVC), body mass index (BMI), etc) to determine the 
patient’s predicted waitlist survival time. The LAS is equal to (Calculated 1 year survival 
benefit) – (Calculated 1 year waiting list survival). (Morton and Glanville 2009) Obviously, 
there are limitations to this type of allocation system; certain subjective metrics like 
functional status and diagnosis can affect the patient’s LAS, but the new method of lung 
allocation appears to have had a beneficial effect on median survival time post-
transplantation.  
4. Selection of donor organs 
4.1 Blood group matching and CMV status 
All of the evaluations discussed above are recipient-focused mechanisms designed to 
facilitate better outcomes in lung transplantation, but perhaps some of the most important 
protocols in place are related to obtaining the most viable donor organ available. There are 
several factors that contribute to the difficulty of procuring optimal lungs. Due to the 
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extremely limited time that lungs are able to endure ischemia (less than 6 hours), there is 
little opportunity to perform traditional human leukocyte antigen (HLA) matching. 
Physicians face an unfortunate catch-22; better HLA matching reduces incidence of chronic 
rejection, but increased ischemic time in turn leads to a higher propensity for rejection. 
(Brugiere et al. 2008) Blood groups, rather, are the primary method of histological matching, 
with consideration being given to size and cytomegalovirus (CMV) sero-status. However, 
this is somewhat disputed in a review of the heart-lung transplant patient population at 
Stanford. (Deuse et al. 2010) CMV sero-negative recipients are at a higher risk of developing 
CMV infection when miss-matched with sero-positive donors than those recipients that are 
already CMV sero-positive. CMV infection has shown to be immunomodulative; creating an 
increased risk of acute and chronic rejection, and infections. (Freeman 2009) Like other 
opportunistic infections, there is an increased risk of CMV disease with the use of 
immunosuppressive treatment, although CMV in turn increases the risk of rejection, 
defeating the intent of the immunosuppressive therapies. (Fishman et al. 2007) CMV 
infection is not only limited to lung transplant recipients and thus there have been 
significant efforts from all corners to establish a gold-standard of prevention and treatment 
for CMV disease in all transplant patients. In studies performed in kidney and liver 
recipients, investigators demonstrated a significant reduction in incidence of CMV disease 
and viremia, along with significant reduction in the number of opportunistic infections in 
patients treated with prophylactic valganciclovir. (Humar et al. 2010) Valganciclovir is 
currently considered the gold-standard in CMV prevention, but other DNA polymerase 
inhibitors, including ganciclovir and valacyclovir have been in use for several years with a 
smaller impact. (Zamora et al. 2004) Unfortunately, lung transplant recipients face a higher 
incidence of CMV infection than any other transplant patient population. This is for two 
primary reasons; first, CMV dormancy and recurrence have been shown to be higher in the 
lungs than anywhere else, and, unlike other whole organ transplant surgeries, there is a 
preponderance of lymphatic tissue transplanted with the lungs that contains further 
amounts of dormant virus. (Zamora, Davis, and Leonard 2005) 
4.2 Other donor factors 
Although blood group matching and CMV sero-status are two of the most important criteria 
when evaluating potential donor lungs, there are a multiple other factors surgeons must 
consider when assessing a possible donor organ. Traditionally it has been protocol to 
decline any lungs from donors positive for hepatitis B, even so, recent work has cracked 
open the door to this pool of donors, potentially increasing the donor pool and number of 
available organs. A 1-year longitudinal study showed no significant difference in survival of 
hepatitis B positive donor lung recipients compared to the hepatitis B sero-negative group. 
(Dhillon et al. 2009) The physicians must also take into account something as simple as time 
and distance when determining the possibility of performing the potentially life-altering 
operation. Lungs, like any other tissue, are susceptible to ischemia-reperfusion (IR) injury 
and the flood of damaging cytokines that go along with it. Primary graft dysfunction, which 
can occur in up to 20% of patients, has been directly attributed to IR injury. (Christie, Sager 
et al. 2005) In addition to this, the lungs are more readily affected by the abundance of fluids 
that are typically given in end of life situations. (Arcasoy and Kotloff 1999) Current thinking 
is that non-heart beating donors (NHBD) are ill suited for the harvesting of lungs due to the 
perceived damage that warm extended periods of ischemia would incur. This has been 
challenged, however by a group in Canada demonstrating no ill-adverse effects from the use 
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of this here-to-for off-limits pool of potential donor candidates. They state that there is an 
ameliorative effect on the levels of inflammatory cytokines present in these lungs which off 
sets the perceived ischemic damage. (Cypel et al. 2009)  
Donor age is another consideration that is factored in when considering possible 
transplantation. Not surprisingly, elevated donor age and increased ischemic times correlate 
with worse outcomes in transplant recipients. (Meyers and Patterson 2000) While not 
optimal, there is such a shortage of available donors, NHBDs over the age of 60 now 
represent over 10% of the NHBD donor population. (Ojo et al. 1999) There are several 
techniques available to try and optimize the donor lung, but most common are the use of 
vasopressin, and thyroid hormone. (Botha et al. 2008) Finally, brain dead (BD) donors 
represent a potential donor pool that presents its own unique set of possible complications. 
In animal models of BD, investigators observed a three fold increase in the blood volume in 
the pulmonary circulation within minutes after onset of BD. (Avlonitis et al. 2005) This, in 
concert with loss of sympathetic tone, contributes heavily to a rapid onset of pulmonary 
edema which in and of itself is enough to dissuade many surgeons from considering using the 
tissue. Furthermore, several groups have reported a significant increase in the concentrations 
of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis 
factor-alpha (TNFα). (Skrabal et al. 2005; Pratschke et al. 2000; Shohami et al. 1994) 
Additionally, the neutrophil chemokine, IL-8, has also been demonstrated to be elevated in the 
lungs of BD lung donors. (Fisher et al. 1999) Increased neutrophil burden has been strongly 
associated with increased matrix-metalloprotease activity and possible exposure of the auto-
antigen collagen V (Coll V). (Fisher et al. 2001; Hardison 2009) The exposure of Coll V directly 
correlates with the incidence of primary graft dysfunction. (Iwata et al. 2008)  
All of the considerations discussed contribute to the limited number of lung transplants that 
are performed each year, but the lack of family consent is by far the largest obstacle to 
available donor organs. (Spital 2005) Since it is unlikely that an automatic-enrollment system 
similar to other countries is likely, it is vital that the best efforts are made to elucidate the 
mechanisms behind the numerous and varied complications inherent in lung 
transplantation by both basic scientists and clinicians alike. The litany of assessments and 
interventions discussed thus far are all employed to attempt to prevent the plethora of post-
transplantation complications that can arise. The unfortunate reality is that while surgical 
techniques and medical therapeutics are far more advanced and elegant than when the 
initial forays in lung transplantation occurred, there is still ample room for improving the 
outcomes observed in lung transplant recipients. The remainder of this chapter will discuss 
post-transplantation complications, current therapies, recent research in the field, and the 
exciting possibilities for novel therapeutics that are on the horizon. 
5. Post transplantation complications 
Due to the myriad of risk factors associated with lung transplantation, it has one of the 
highest morbidity and mortality rates of any whole organ transplant procedure. (Trulock et 
al. 2007) Only recently has the mean survival time for transplant recipients risen to 5.7 years. 
(Ahmad, Shlobin, and Nathan 2011) There are four major causes of morbidity and mortality 
in all transplant recipients; primary allograft dysfunction, infection, acute rejection, and 
chronic rejection. These four primary causes are closely related; rather they exist on a 
spectrum with the incidence of chronic rejection (the most serious) rising with increasing 
occurrences of the PGD, infection and acute rejection.  
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5.1 Primary graft dysfunction 
5.1.1 Characterization and etiology 
Primary graft dysfunction (PGD) is defined as having a PaO2/Fi O2 of ≤ ~300 with 
radiographic infiltrates consistent with pulmonary edema. (Christie, Carby et al. 2005) PGD 
is further categorized into 3 gradations with Grades 1, 2 and 3 corresponding to PaO2/Fi O2 
greater than 300, between 200 and 300, and less than 200, respectively. Clinically, PGD is 
simply a unique form of acute lung injury (ALI), presenting within 72 hours post-surgery 
with replete pulmonary infiltrates/edema and impaired compliance. These guidelines for 
evaluating PGD were initially put forth in 2005 by the International Society for Heart and 
Lung Transplantation (ISHLT) Working Group on PGD and later confirmed by a 
retrospective study of approximately 400 lung transplant recipients. This study 
demonstrated that PGD grade 3 did indeed correlate with the worst mortality. (Prekker et 
al. 2006) PGD can affect up to 25% of patients and correlates with much higher levels of 
mortality in the first 30 days. (Christie et al. 2005) The precise cause(s) of PGD are still 
unknown, but it is widely accepted that ischemia-reperfusion (IR) injury plays a major role 
in initiating the destructive process. It is in the ischemic period that reactive oxygen species 
(ROS) are produced in large quantities and directly damage the pulmonary epithelium and 
endothelium. (Tasoulis et al. 2009; de Perrot et al. 2003) This influx of ROS incites a pro-
inflammatory cascade that activates both the innate and complement immune systems. 
(Carter, Gelman, and Kreisel 2008)  
5.1.2 Risk factors for PGD 
Advanced age of organ donors is strongly associated with increased incidence of PGD in 
lung transplant recipients. What is interesting is that no definitive studies have been 
performed that indicate that recipients’ age play any role in the development of PGD. (Barr 
et al. 2005; Christie et al. 2003) Additionally, race (African-American), sex (female), and 
smoking history are all donor-dependent risk factors in the development of PGD. (Lee and 
Christie 2009) No conclusive studies of transplant recipients have explicitly delineated 
whether indication for transplantation correlates with development but it appears that 
idiopathic pulmonary fibrosis confers at least some increased risk of PGD. (Barr et al. 2005) 
Pulmonary arterial hypertension (PAH) has emerged as the only clinically measureable 
metric that correlates with the development of primary graft dysfunction. While the precise 
pathway of PAH to PGD is as yet unknown, multiple studies have demonstrated the 
relationship. (Whitson et al. 2006)  
5.1.3 Treatment of PGD 
Although over-used to the point of being a cliché, the maxim “an ounce of prevention is 
worth a pound of cure” is distinctly applicable to the treatment of primary graft 
dysfunction. Increasing emphasis is being placed on improved preservation of the donor 
organ. The main weapon in the clinician’s arsenal of preservative techniques is induced 
hypothermia of the tissue. It has been demonstrated that by maintaining the organ at 4oC, 
the metabolic rate is drastically reduced compared to that of control temperature tissue. (de 
Perrot et al. 2005) Two methods of organ cooling are typically employed; core cooling and 
pulmonary arterial flush (PAF). (Okada and Kondo 2009) The core cooling method occurs 
prior to organ explantation and is initiated with cardio-pulmonary bypass to reduce the 
body temperature to ~14oC. Upon harvesting, the donor lungs are submerged in 4oC saline. 
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PAF is accomplished by instilling 60ml/kg into the pulmonary artery, there have been some 
recent studies investigating the effects of a dual flush with the addition of flushing the 
pulmonary veins as well. The hypothesis being that this would ensure the complete removal 
of micro-thrombi in the capillaries and result in a more equitable distribution of the 
preservative solution. (Struber et al. 2002) There are several different “recipes” of 
preservative solution but the first in wide use (Euro-Collins solution), with high a high K+ 
and low Na+ concentrations to mimic intracellular fluid, was originally developed for use in 
liver preservation. (Okada and Kondo 2009) Since then, more sophisticated preservation 
solutions have been developed and are in the process of being tested. The Okada group 
developed a solution termed extra-cellular phosphate buffered saline type 4 (Ep4) that 
included dextran 40. This solution was capable of preserving canine lungs for up to 96 hrs 
post-explantation. Dextran 40 appeared to exert an anti-coagulative effect, ostensibly by 
forming a protective coat on the endothelial surface. (Handa et al. 1989; Okada et al. 1997; 
Colombat et al. 2004)  
Sadly, if efforts to prevent the development of primary graft dysfunction fail, the similarity 
to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) results in little 
that the clinician can do other than provide supportive care. Due to the increased 
concentration of pro-inflammatory cytokines in the pulmonary circulation it is of vital 
importance that fluid administration is closely monitored to decrease the risk of fulminant 
edema. (Shargall et al. 2005) In addition to the vigilance given to the administration of fluids 
in PGD patients, ventilator settings can play a major role in outcomes of those individuals. A 
multicenter, randomized, controlled trial demonstrated that lower tidal volumes, combined 
with elevated positive end expiratory pressure (PEEP) were significantly protective in 
individuals with ARDS. The authors of the study hypothesize that this was due to the 
decreased alveolar damage in the hyper-compliant lungs. (Petrucci and Iacovelli 2003)  
5.1.4 Current research and future directions 
Much of the current research in this area is focused on the development of better 
therapeutics and the identification of biomarkers in PGD to provide a deeper knowledge of 
the genetic and biochemical forces that are integral in the genesis of the condition. With the 
recent advances made in high through-put proteomics and DNA micro-array technology 
there are ample platforms to rapidly pursue numerous avenues of investigation in great 
detail. 
5.1.4.1 Potential Biomarkers of PGD 
A 2006 study by Kaneda et al, utilizing quantitative real time polymerase chain reaction 
(qPCR) revealed that the IL-6/IL-10 ratio in the donor lung was predictive of 30 day 
mortality in the transplant recipient. (Kaneda et al. 2006) Luminex analysis of blood samples 
from 25 Grade 3 PGD patients and 25 Grade 0 control patients by Hoffman, et al revealed a 
vastly different chemokine profile in the two population’s plasma. Severe PGD patients had 
significantly elevated levels of monocyte chemotactic protein-1 (MCP1) and CXC motif 
ligand 10 (CXCL10) compared to controls. (Hoffman et al. 2009) The detection of novel 
biomarkers is not limited to new sophisticated techniques, more traditional approaches also 
have also yielded results. Indeed, a recent study by Diamond, et al, using a conventional 
“sandwich” enzyme linked immunosorbent assay (ELISA) provided evidence that increased 
Clara cell secretory protein 16 (CC16) was significantly associated with the development of 
PGD. (Diamond et al. 2011) There are numerous other studies that have produced a litany of 
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possible biomarkers (soluble receptor for advanced glycosylation end-products (sRAGE), 
soluble P-selectin, Protein C, etc.) for primary graft dysfunction and that may one day 
provide the key to its early detection and prevention. (Kawut et al. 2009; Christie et al. 2007; 
Christie et al. 2009)  
5.1.4.2 Novel/Future Therapeutics for PGD 
The goal of those developing novel therapeutics for PGD is the prevention of the condition 
itself. A multi-center, randomized, placebo controlled trial by Keshavjee, et al showed a 
protective effect in the use of soluble complement receptor-1 (sCR1) resulting in decreased 
time to extubation and a trend toward abbreviated intensive care unit (ICU) stays. (Keshavjee 
et al. 2005) In an intriguing study by Eriksson, and colleagues, induced hypothermia appeared 
to be beneficial in case studies of PGD patients and was recapitulated in an animal model. 
(Eriksson and Steen 1998; Eriksson et al. 1999) Significant forays into the use of inhaled Nitric 
Oxide (iNO) as a therapeutic agent have also been made in recent years. There have been 
discordant results, however as to the efficacy, ranging from no change in outcomes to a 
decreased incidence of severe PGD and diminished concentrations of IL-6 and IL-8 in plasma 
compared to controls. (Meade et al. 2003; Ardehali et al. 2001) Due to the prevalence of PGD in 
lung transplant recipients, and the comparative lack of knowledge regarding the pathogenesis 
of this condition, it is reasonable to expect considerable resources to continue to be directed 
toward the investigation and prevention of this syndrome. 
5.2 Infection 
5.2.1 Characterization and etiology 
Infection in post lung transplantation begins as any other infection, however with the host 
being in the unenviable position of possessing immune systems under active and permanent 
suppression, in addition to the mechanical and physiologic stress that is inherent to any 
major surgery. Infection is, in fact, the primary source of mortality in the first year post-
transplant and continues to be a significant source of morbidity and mortality for the 
remainder of the recipient’s life. (Corris and Christie 2008) Unlike all other solid organ 
transplants, the lungs are open to the external environment and all of the pathogens, both 
virulent and opportunistic, that entails. Furthermore, the denervation that is a necessary 
component of organ harvesting results in at least a temporary impairment in the cough 
reflex and thus diminished clearance. (Ahmad, Shlobin, and Nathan 2011) It is important to 
note that any infection, particularly recurrent infection, is a risk factor for the occurrence of 
rejection, both acute and chronic. Rapid identification of the pathogen and appropriate 
treatment is optimal to decrease morbidity and mortality in this patient population. 
5.2.2 Bacterial infection 
Bacterial infections are the most common type of infection in lung transplant recipients and 
occur in a bi-modal, temporal-dependant manner. Pulmonary bacterial infections are 
common both early, due to the previously mentioned impaired cough reflex and damaged 
lymphatic system, and late, as an element of chronic rejection. (Kramer et al. 1993) Due to 
the nature of the pre-transplant disease, those patients with cystic fibrosis (CF) are the most 
difficult to maintain in an infection free state. This is especially true in the individual with a 
single lung transplant due to the potential for colonization from the native lung. 
Interestingly, the CF patient population also has the best long-term results despite the 
proclivity towards infection. (Lease and Zaas 2010)  
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Pseudomonas aeruginosa is the most common bacterial organism isolated from the post-
transplant lung. (Kramer et al. 1993) This opportunistic infection has a higher incidence in 
CF patients and has been estimated to be responsible for up to 33% of pneumonias in all 
transplant recipients. (Aguilar-Guisado et al. 2007; Campos et al. 2008) P. aeruginosa airway 
infection prior to transplant does not appear to demonstrate a predictive relationship for 
chronic rejection. However, this is not the case for colonization in the post-operative period. 
(Botha et al. 2008; Vos et al. 2008) P. aeruginosa infection is not limited to pneumonias; the 
pathogen has been reported to be responsible for nearly half of all post-transplant infections. 
(Valentine et al. 2008)  
Mycobacterium is a designation indicating acid-fast bacteria that are capable of causing a 
wide range of diseases. Perhaps the most well known of these M. tuberculosis, has the robust 
cell wall that is a calling card of the classification, and helps to confer resistance to broad 
spectrum antibiotics. Although, not nearly as common as P. aeruginosa infection, M. 
tuberculosis colonization presents a unique set of treatment hurdles, especially in the 
presence of multi-drug resistant (MDR) strains. (Lee et al. 2003)  
Opportunistic infections, hospital-acquired infections, and resistant strains of bacteria are all 
significantly more common in lung transplant recipients than the general population. 
Staphylococci strains have demonstrated a propensity for antibiotic resistance and this is only 
magnified in the already immunosuppressed transplant patient. Specifically, S. aureus is the 
second most common organism isolated from the airway, with multi-drug resistant S. aureus 
(MRSA) being extremely difficult to treat due to its almost pan-resistant nature. (Kotloff and 
Thabut 2011)  
5.2.3 Treatment of bacterial infection 
The treatment of infection in lung transplant recipients is a challenging task due to the 
patients’ significant cocktail of immunosuppressive therapies. Many of these drugs, 
including cyclosporine and tacrolimus can be highly cross-reactive. There is unfortunately 
no “magic bullet” specific for transplant patients, the traditional regimen of broad spectrum 
antibiotics, with specific coverage for gram negative, acid-fast, etc. being added upon 
differential diagnosis.  
5.2.4 Fungal infection 
While colonization by widespread fungi such as Aspergillus and Candida is common, a much 
smaller percentage of patients will develop a clinically relevant fungal infection. (Singh 
2003) Aspergillus and Candida are by far the most common, with Cryptococcus species and 
other molds playing a much smaller role. (Neofytos et al. 2010) The presence of foreign 
material (sutures) in the airway anastomosis, in addition to the inherent risk with 
ventilation, increases the risk of fungal infection in post-operative transplant patients.  
5.2.5 Prevention/treatment of fungal infection 
Similar to the treatment of bacterial infections, the therapeutic approach to fungal infection 
in lung transplant patients is primarily unchanged from the normal treatment options in 
other patients. Treatment regimens will typically consist of aerosolized Amphotericin B in 
the acute post-operative period, with voriconazole and itraconazole prophylactic treatment 
extending for up to a year post-transplantation. (Ahmad, Shlobin, and Nathan 2011)  
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5.2.6 Viral infection 
As has previously been mentioned, the sero-status of cytomegalovirus (CMV) is an 
important factor in opting to transplant or harvest donor organs. CMV is by far the most 
common viral pathogen observed after lung transplant procedures, affecting at least a third 
of all patients. CMV usually presents with fever, exhaustion, and flu-like symptoms with 
associated leukopenia. (Snydman et al. 2011) Diagnosis of CMV syndrome is made with 
PCR evaluation of viral titers in peripheral blood. If CMV pneumonia is suspected, the 
definitive test must be performed on a biopsy specimen of the in tissue. (Kotton et al. 2010) 
CMV infection has been shown to predispose the patient to infection with other community 
acquired respiratory viruses (CARVs). (Sims and Blumberg 2011) 
In a recent three year longitudinal study, Kumar et al showed the presence of virulent 
strains of H1N1 influenza, adenovirus, flu A, flu B, and rhinovirus in over half of transplant 
recipients. (Kumar et al. 2010) Diagnosis of these viral infections has become much more 
straightforward with the advent of qPCR to provide rapid evaluation of viral titer loads in 
bronchoalveolar lavage (BAL) fluid of patients. Antibody based assays are also available to 
determine the infection state of an individual, although these may vary from center to 
center.  
5.2.7 Prevention/treatment of viral infection 
Intravenous (IV) ganciclovir and the oral pro-drug valganciclovir are given prophylactically 
for anywhere from 6 to 12 months post-transplant. (Jaksch et al. 2009) CMV prophylaxis is 
standard protocol for all patients regardless of center and has been shown to be effective in 
reducing the CMV syndrome. (Palmer et al. 2010) Treatment for CARVs is dependant upon 
specific diagnosis of pathogen and strain and can include zanamivir, amantidine, 
oseltamivir, etc. (Ison and Michaels 2009) Unlike CMV therapy, prolonged treatment with 
these anti-virals is contraindicated for fear of contributing to the development of resistance. 
5.3 Acute rejection 
5.3.1 Characterization/etiology of acute rejection 
Acute rejection (AR) presents clinically with non-specific symptoms including dyspnea, 
mild fever, malaise, cough, and leukocytosis. Although not present in all AR exacerbations, 
radiographic imaging may show mild pleural effusion, and interstitial opacities with a 
concurrent decline in oxygenation and spirometric measurements. (Millet et al. 1989; 
Otulana et al. 1990) AR is definitively diagnosed by BAL and TBB followed by histological 
analysis showing perivascular infiltrates. (Stewart et al. 2007) TBB may not always be 
possible due to patient status and thus AR is tentatively determined based upon clinical 
symptoms and radiologic evidence. Many transplant centers have post-transplant protocols 
that include routine monitoring by BAL which is also capable of confirming AR. (Chakinala 
et al. 2004) Most importantly, as indicated by the name, acute rejection is just that, a brief 
intermittent condition that is most often easily resolved with or without hospitalization. 
Acute rejection is an extremely common complication of lung transplant patients, occurring 
in as many as 90% of lung recipients over their lifespan. (Arcasoy 2004) The incidence of AR 
is highest within the first year post-transplant, afflicting approximately one third of all 
patients. (Christie et al.) It is difficult to determine precise results in these retrospective 
studies due to the fact that AR can be clinically silent, only detectable upon transbronchiole 
biopsy (TBB). (Hopkins et al. 2002) The precise etiology of AR is still unknown but stratified 
risk appears to be heavily weighted toward donor-dependent factors in the immediate post-
 
Lung Diseases – Selected State of the Art Reviews 
 
656 
operative period, with recipient-dependent factors playing the predominant role after the 
first year. HLA-B mismatching, increasing donor age, non-O donor blood type, and 
increasing body-surface area (most likely corresponding to elevated BMI) all correspond 
with increased AR incidence. With a recipient history of diabetes, and recent transplant 
accounting for recipient driven risk in the intermediate and late phase AR. (Mangi et al. 
2011) 
The International Society for Heart-Lung Transplantation (ISHLT) has delineated the 
standard nomenclature to describe the various gradations of AR based solely on histological 
findings. Grade A0 is the absence of AR, no cellular infiltrates and healthy lung 
parenchyma. Grade A1 is characterized by patchy mononuclear cell infiltrates in alveolar 
parenchyma. Grade A2 is described as having more prevalent lymphocytic infiltrates 
centered in the perivascular area with the presence of some activated macrophages and 
eosinophils. Grade A3 features dense perivascular infiltrates, significant eosinophil 
presence, with the first observation of neutrophils in the intra-alveolar space. Grade A4 
describes the finding of diffuse mononuclear infiltrates, pneumocyte damage, macrophage 
and neutrophil presence. (Stewart et al. 2007)  
5.3.2 Treatment of acute rejection 
Similar to many aspects of lung transplantation, treatment for AR varies dependant upon 
hospital setting with some centers opting to not treat AR considered to be <Grade A2. 
(Orens and Garrity 2009) In more severe cases however, conventional treatment consists of a 
hospital admission with a three day course of solumedrol followed by an oral prednisone 
taper. (Aboyoun et al. 2001; Yousem et al. 1994) Additional treatment with methotrexate, 
lymphoid irradiation, and antithymocyte globulin, among others, has been reported to be 
effective in alleviating the transient AR condition. (Hachem 2009)  
5.3.3 Biomarkers of acute rejection 
Although ISHLT has defined acute rejection based solely upon histological findings, there is 
significant effort to describe biomarkers specific to patients undergoing AR to better classify 
and determine treatment. A recent study by a group out of Copenhagen described elevated 
mRNA of the regulatory T cell (Treg) cytokine FoxP3, along with cytotoxic T cell-derived 
granzyme B in BAL fluid of patients in AR. (Madsen et al. 2010) A 2007 study by Lande et al 
describes the use of microarray analysis to observe relative gene expression levels of 
cytokines thought in be involved in acute rejection in the BAL fluid of AR patients. (Lande 
et al. 2007) 
5.3.4 Novel/future therapeutics of acute rejection 
Due to the incredible amounts of data generated by high through methods such as mass-
spectrometry-assisted proteomics and gene microarray analysis there have never been more 
targets identified for the design of targeted therapeutics in acute rejection. The use of animal 
models of acute rejection have also significantly improved the ability to design and test 
novel therapeutics for acute rejection allograft rejection in lung transplantation. 
Jung et al (2006) have developed a spontaneous model of acute rejection in rats by 
performing lung transplantation in a manner similar to that used in humans. By utilizing a 
small molecule, irreversible inhibitor of dipeptidylpeptidase IV (DPPIV/CD26) the 
investigators reduced the incidence of acute rejection, preserved lung function, and 
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maintained normal histological structure in rat lung transplantees. (Jung et al. 2006) They 
previously published that DPPIV/CD26 was elevated in plasma of rats undergoing AR after 
cardiac transplant and hypothesize that the pulmonary protective effect is due to reducing 
the co-stimulatory effect of DPPIV/CD26 on T cells. (Korom et al. 1997) In a similar model, a 
group out of Fukouka, Japan employed a Janus kinase 3 (Jak3) inhibitor to prevent the 
development of AR. Jak3 is located at a biochemical bottleneck in the pathway of T cell 
clonal expansion. Higuchi, et al demonstrated a dose-dependant inhibition of the 
development of acute rejection by the AG490 in the experimental population. (Higuchi et al. 
2005) 
Animal models are not the only avenue available to scientists to pursue better methods of 
treating and preventing acute rejection. Investigators at the University Clinics of Leipzig 
reported a reduction in the incidence of acute rejection with preemptive administration of 
the traditional therapeutic methylprednisone. By simply giving bolus doses 2 hours prior to 
incision and immediately prior to completion of the transplant procedure they observed a 
significant improvement in outcomes. (Bittner et al. 2010) 
Clearly this is not meant to be an exhaustive review of the potential novel therapeutics 
currently under development. We are merely presenting a representative sample indicating 
the myriad of pathways that are being studied to yield targeted countermeasures to acute 
rejection. 
5.4 Chronic rejection (bronchiolitis obliterans syndrome) 
5.4.1 Characterization/etiology of bronchiolitis obliterans syndrome 
Chronic rejection, clinically termed bronchiolitis obliterans syndrome (BOS), is the primary 
source of morbidity and mortality seen in the lung transplant patient population. (Bando et 
al. 1995; Stewart et al. 2007) Due to the nature of BOS, primarily occurring irregularly in the 
small airways, diagnosis by transbronchial biopsy is ineffective. (Chamberlain et al. 1994) 
Diagnosis of BOS is difficult due to its similarities with other post-transplant complications. 
There are no tests to specifically determine BOS, rather, it is a diagnosis of exclusion. A 
persistent, unexplainable drop in forced expiratory volume in one second (FEV1) (~80% of 
baseline) with accompanying decline in FEV25-75 (less than or equal to 75% of baseline) is 
defined as BOS stage 0. (Belperio et al. 2009; Estenne et al. 2002) BOS is staged 0-3 based 
upon progressive declines in percent of expected FEV1.  
BOS is unfortunately observed in over half of lung transplant patients who survive five 
years or more post-transplantation. (Bando et al. 1995) Chronic rejection initially presents 
clinically in a manner similar to that of other complications with dyspnea, cough, and 
progressive airway obstruction. (Estenne and Hertz 2002) X-ray analysis is often 
unremarkable, but computer assisted tomography (CT) may reveal air trapping and 
bronchiectasis. (Morrish et al. 1991) 
BOS is characterized pathologically by a prominent neutrophilic component with a definite 
increase in pulmonary fibrosis and extra-cellular remodeling. (Billings et al. 2002; Boehler 
and Estenne 2003) The BAL fluid of the majority of BOS patients reveals chronic pulmonary 
neutrophilia. Indeed, when >20% of cells are neutrophils in BAL fluid patients fail to 
survive past 7 years post-transplant. (Neurohr et al. 2009) Unlike acute rejection, where the 
cellular infiltrates are centered around the vasculature, in BOS, the cells are located 
primarily in and around the airways with a striking increase in cell number and activation 
level of leukocytes. (Vanaudenaerde et al. 2008) The causes of BOS are only partially 
understood with much unknown about the exact causative events that lead to disease. 
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5.4.2 Risk Factors for bronchiolitis obliterans syndrome 
What facts are known about the pathogenesis of BOS are the multiple risk factors that have 
been detailed via epidemiologic investigations. Both alloimmune and alloimmune-
independent factors appear to play principle roles in the development of BOS. (Knoop and 
Estenne 2006) Primary graft dysfunction, along with gastroesophageal reflux (GER), and 
infection are all nonalloimmune factors that are associated with occurrence of BOS. (Estenne 
and Hertz 2002) CMV infection resulting in disease has been reported to enhance the 
relative risk of developing BOS, although there are conflicting reports regarding this. 
(Belperio et al. 2009) Alloimmune factors closely associated with BOS are recurrent, or 
persistent AR, and HLA mismatching. (Palmer et al. 2002) 
5.4.3 Treatment of bronchiolitis obliterans syndrome 
Currently there are no demonstrated effective treatments for BOS. Most present strategies 
rely on augmenting immunosuppression with the use of corticosteroids, cyclosporine, 
methotrexate, etc. (Date et al. 1998; Dusmet et al. 1996; Iacono et al. 1996) These, however 
have been met with little success. The majority of existing treatment methods rely on 
unproven, anecdotal evidence with few multi-center, randomized, controlled trials. 
5.4.4 Current research and future directions in bronchiolitis obliterans syndrome 
Our previously published hypothesis regarding the onset of BOS is that there is some initial 
insult (infection by CMV or other pathogens, inflammatory damage due to recurrent AR, 
etc.) that awakens the adaptive immune system to over-ride the potent cocktail of 
immunosuppressive drugs present. The adaptive immune (Type 1, and Type 2 T cells) 
further damages the transplanted organ by responding to the foreign epitopes innately 
present in the donor lung. This repeated damage induces a persistent release of pro-
inflammatory cytokines that recruit neutrophils into the interstitium and airways where 
they remain and participate in a fibroproliferative and proteolytically destructive process. 
(Hardison et al. 2009) 
5.4.4.1 Potential Biomarkers in Bronchiolitis Obliterans Syndrome 
We, along with others, have reported on the activation of neutrophils by glutamate-leucine-
arginine positive (ELR+) CXC chemokines such as IL-8. (Xu et al. 2011; Chakrabarti and 
Patel 2005) Upon activation, neutrophils degranulate which releases potent proteases such 
as matrix metalloproteinase-8, -9, and prolyl endopeptidase. (Xu 2011, O’Reilly 2010) It has 
been well established that collagen fragments are chemotactic to neutrophils, and in 1995, 
Pfister et al. were able to determine the sequence, proline-glycine-proline (Pro-Gly-Pro, 
PGP) confers chemotactic potential to collagen breakdown products. (Pfister et al. 1995) In a 
2006 paper, our group demonstrated the mechanism by which PGP is able to attract 
neutrophils into tissue. PGP shares significant sequence and structural homology with 
almost all ELR+CXC chemokines, which act via CXC receptors 1 and 2 in human (CXCR1, 
CXCR2). We reported that PGP competes with the CXCR ligand, IL-8, for binding, causes 
chemotaxis in CXCR transfected cells and elicits a similar oxidative burst to IL-8 stimulation. 
(Weathington et al. 2006) Recently we have also published the step-wise manner in which it 
is produced. (Gaggar et al. 2008)  
MMP-8 and -9 are capable of initially digesting collagen but are incapable of performing the 
final cleavage to PGP and a second step is necessary for the matrikine’s production. Our lab 
demonstrated that the serine protease prolyl endopeptidase (PE) performs the final 
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proteolysis. (Gaggar et al. 2008) PE cleaves after a proline in a peptide of ~100 amino acids 
or less.  
We have reported the potential for PGP as a biomarker of disease in multiple chronic 
inflammatory lung diseases such as cystic fibrosis (CF), chronic obstructive pulmonary 
disease (COPD), and most relevant to this manuscript, BOS. (Gaggar et al. 2007; O'Reilly et 
al. 2009; Hardison et al. 2009) In matched BAL samples of patients obtained three months 
prior to, and concurrent with diagnosis of BOS, we described a temporal shift in the 
chemokine/matrikine profile. MMP-8, -9 and PE activities were increased in the samples 
collected at diagnosis of BOS compared to a transplant control population, and matched 
samples collected prior to confirmation of disease. By employing a previously published 
mass spectrometry technique, we detected measureable amounts of PGP in both pre- and 
post-diagnosis of BOS, however, there was a dramatic and significant increase in the levels 
observed in BAL fluid collected at the time of diagnosis. Through the use of neutralizing 
antibodies to IL-8 and PGP, first individually and then in concert, we demonstrated a shift 
from the relative importance of the classical PMN chemoattractant, IL-8, to the more novel 
molecule, PGP, upon diagnosis of BOS.  
Clearly PGP is not the only molecule with the potential to serve as a novel biomarker for 
BOS diagnosis. There is a litany of research underway on a wide variety of proteins and cell 
types that may potentially one day play a role in the more precise classification of this 
condition. Endothelin-1, mesenchymal stromal cells, and serum KL-6 (a glycoprotein) have 
all been published as possible markers of disease progression. (Salama et al. 2011; Badri et 
al. 2011; Haberman et al. 2010) 
5.4.4.2 Current Research in Bronchiolitis Obliterans Syndrome 
Perhaps the most exciting development in the quest for reliable preventative therapy for 
BOS has been the recent establishment of reproducible rodent models of BOS which closely 
mimic human disease. The most recent model described by Jungraithmayr, et al., utilizing 
single lung transplantation, is a vast improvement over the traditional tracheal transplant 
which had the obvious limitation of leaving the native lung in the rodent. (Jungraithmayr et 
al. 2010) The Swiss group reports that a T cell response and cytokine presence, similar to 
that of humans with BOS, was observed. Another group, from the University of Pittsburgh, 
has developed a human-mouse chimeric model of BOS in which the allograft and immune 
effector cells are of human origin. (Xue et al. 2011) They state that the formation of chimeric 
allogenic T cells, and the resulting infiltration into small human airways is definitive in 
delineating the role T cells play in the development of BOS. 
5.4.4.3 Future Therapeutics for Bronchiolitis Obliterans Syndrome 
This is, in part, a continuation of the previous section due to the experimental nature of 
some of the procedures/drugs described herein. As was previously discussed, there is an 
association of GER and BOS incidence. A study out of Duke University describes improved 
pulmonary function in patients who underwent proactive treatment for GER. Surgical 
fundoplication was performed to reduce the possibility of bile aspiration and potential 
damage to the airway. (Davis et al. 2003) Additionally, a retrospective study of transplant 
recipients with BOS identified a possible advantage of treatment with Azithromycin (Az), 
though the mechanism of action remains unclear. (Jain et al. 2010) Patients with a higher 
initial neutrophil burden responded better to the treatment and had better outcomes. What 
is most interesting is the fact that azithromycin is a macrolide antibiotic, a class known to be 
 
Lung Diseases – Selected State of the Art Reviews 
 
660 
inhibitors of matrix metalloproteinases. It is possible that Az is preventing the generation of 
PGP and thus relieving some of the neutrophil burden associated with BOS. 
A recent publication by our group in Science detailed a bi-functional enzyme, Leukotriene 
A4 Hydrolase (LTA4H), which serves to degrade PGP endogenously. This enzyme is 
present in both neutrophils and airway epithelium and is elevated in a mouse model of 
pulmonary infection and inflammation. (Snelgrove et al. 2010) Modulation of the activity of 
this important enzyme may provide a welcome opportunity to utilize patients’ own biology 
to help resolve some of the destructive chronic neutrophilic inflammation seen in BOS. We 
have also described two specific inhibitors of PGP, arginine-threonine-arginine (RTR), and 
an all “D” isomer of PGP (DD-PGP) that are potent in preventing the mechanism of action of 
PGP in vitro and in vivo. (Jackson et al. 2011; van Houwelingen et al. 2008) 
6. Conclusion 
Even though long-term survival of lung transplant recipients has improved over time, the 
overall mortality rate in lung transplantation remains significantly higher than any other 
whole organ transplant population. The relatively recent advent of a more appropriate 
organ allocation system, along with improved ability to preserve donor organs has 
increased the pool of available organs to all-time highs. Even so, the number of actual lungs 
harvested each year compared to the estimated viable donor lungs is a small fraction of 
what is possible. With continued advancement in animal models, and description of 
biomarkers of the various complications associated with transplantation, there has been 
marked, if gradual, improvements in the therapeutic armament clinicians have at their 
disposal. It may yet be that lung transplantation one day be viewed as an early intervention 
in progressive irreversible pulmonary conditions such as idiopathic pulmonary fibrosis and 
confer a permanent, rejuvenative improvement in the lifespan and quality of life of such 
patients. 
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1. Introduction 
Bronchial atresia is an interesting congenital abnormality because of  its variable appearance 
and its semblance to certain acquired diseases. It is characterized by a branching mass 
formed by mucus that dilates the proximal bronchi to the atretic segment. The distal lung to 
atresia can develop normally but it shows a paucity of blood vessels and is hyperinflated 
due to unidirectional collateral air drift through intraalveolar pores of Kohn, 
bronchoalveolar channels of Lambert and interbronchiolar pores of Martin from the adjacent 
normal lung. These collateral communications act as a check-valve mechanism allowing the 
air to enter but not to leave the distal lung. 
More than 150 cases of bronchial atresia have been reported since 1953, when it was first 
described by Ramsay & Byron. The exact mechanism that ends in bronchial atresia is still 
unknown, but there are two hypotheses about the pathogenesis which have in common that  
they should occur before birth because the bronchial pattern to the site of stenosis is entirely 
normal. Many of the most relevant case reports and published series of cases are reviewed 
in this chapter to update our knowledge of bronchial atresia. They have been obtained as the 
result of a bibliographical research at Pubmed; ninety five articles were found using the 
Medical Subject Headings (MeSH) thesaurus descriptors congenital and bronchial atresia. 
2. Pathogenesis 
Bronchial buds appear in the fifth week of gestation and then complete branching takes 
place in the sixteenth week. Although bronchial atresia is associated with a decreased 
amount of alveoli, the number of airways is not reduced. 
Congenital bronchial atresia pathogenesis is not completely understood, but there are two 
pathogenic hypotheses. The first one proposes that proliferating cells at the distal tip of the 
developing bud are disconnected from the normal branch at any time from the fifth to the 
sixteenth weeks by a still unknown agent (Bucher et al., 1961; Kuhn et al., 1992). 
The other one postulates that focal ischemic insults at the fifth week or later result in 
necrosis and obliteration of the already completed bronchus (Reid, 1977 or Waddell et al., 
1965). The experiment of Louw & Barnard (1955), in which they tied off a mesenteric arterial 
branch in puppies two weeks before birth, showed that atresia may result from a vascular 
occlusion and develop late in intra-uterine life. Their findings favour vascular occlusion 
rather than a failure of growth as the cause. 
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The pulmonary arterial development is closely associated with the developing lung bud. 
The primitive pulmonary artery is already present as a major branch and grows toward the 
lung bud. Subsequently, it gives off a branch to accompany each airway branch in the 
preacinar region. Pulmonary vascular abnormalities have been documented in bronchial 
atresia (Ko et al., 1998; Lacquet et al., 1971). 
3. Respiratory symptoms and epidemiology 
Bronchial atresia has a male predominance, with an estimated prevalence of 1.2 cases per 
100,000 males and 0.6 cases per 100,000 females - a male: female ratio of 2:1. 
About two thirds of the reported patients were asymptomatic before diagnosis and occurred 
as an incidental radiological discovery. It is usually diagnosed in the second or third decade 
of life, and the diagnosis is infrequent during childhood. One third of patients may present 
with cough, shortness of breath and recurrent infections and less frequently with refractory 
wheezing, haemoptysis, chest pain, or pneumothorax (Agarwal et al., 2005; Kameyama et 
al., 2006; Morikawa et al., 2005 (Table 1). 
 
Asymptomatic 58.00% 
Recurrent Infection 21.00% 
Dysnea 14.00% 
Coughing 6.00% 
Table 1. Frequency of symptoms from more to less frequent (Jederlinic et al., 1987). 
The bronchi involved in this congenital anomaly are the apico-posterior segment of left 
upper lobe, right upper lobe, right middle lobe and right lower lobe, in decreasing order of 
frequency (Acosta Gordillo et al., 2005; Psathakis et al., 2004). 
4. Imaging techniques for the diagnosis 
Currently clinicians have lot of many imaging techniques at their disposal for the 
investigation of patients with this congenital anomaly. 
4.1 Plain Chest Radiography 
The radiographic findings mirror the pathologic changes. 
On chest radiography the typical finding of a mucocele is that of a nodule or a shadow-like 
mass close to the hilum, with well-defined margins, presenting as a tubular, round, ovoid or 
branching structure (Sacristán Bou et al., 2010) (Fig 1). A mucocele with an air-fluid level is 
considered by some authors  as a variance of congenital bronchial atresia (Matsushima et al., 
2003). 
The branching bronchocele mimics a glove-finger shadow, but is not pathognomonic of 
bronchial atresia. 
It has been proposed that the impacted mucous can also liquefy producing the radiological 






Fig. 1. Polylobulated round mass near to the hilum in the right lower lobe (Sacristán Bou et 
al., 2010). 
infected and presents as a pneumonia, the walls of bronchoceles develop tiny breaks that 
enables the air to enter in its lumen (Psathakis et al., 2009; Rahalkar et al., 2005).  
Occasionally, the dilated bronchi may appear as purely air-filled, lucent bands of odd 
shapes (Nussbaumer-Ochsner & Kohler, 2011; Van Klaveren et al., 1992). 
The distal lung is always distended, forming the apex of a roughly triangular zone of 
hyperlucency of the lung parenchyma (due to oligoemia and hyperinflation). On 
radiography obtained at expiration, obstructive emphysema is obvious, however, the 
synchronous appearance of both the mucocele and lung hyperlucency is only seen in 69% of 
cases (Jederlinic et al., 1987). 
Sometimes bronchial atresia is associated with other congenital anomalies like pectum 
excavatum (Van Klaveren et al., 1992). 
4.2 Computed Tomography (CT) and High-Resolution Computed Tomography 
Computed tomography is the procedure of choice for the diagnosis and study of congenital 
bronchial atresia. 
The bronchocele presents as a round/ovoid/branching structure near the hilum, with or 
without a fluid level, without contrast enhancement and it exhibits a density between 10 to 
25 Hounsfield Units due to mucoid material. Computed tomography allows 
characterization of the lack of communication between the mucocele and hilum (Fig. 2). 
High resolution techniques can display the characteristic features of the mucocele, being 
more sensitive than the plain chest radiography to show oligaemia, reduced caliber of the 
pulmonary vessels, hyperinflation of the lung parenchyma (Fig. 2), small mucoceles 
invisible to conventional radiography, associated mass effect and even calcification (Kinsella 
et al., 1992 and Primetis et al., 2011). 
 




Fig 2. Polilobulated round mass located in the posterobasilar right subsegmental bronchi 
with a distal segmental area of radiolucency and lack of communication between the 
mucocele and hilum on high-resolution computed tomography (Sacristán Bou et al., 2010).  
4.3 Magnetic Resonance Imaging (MRI) 
MRI shows a very high signal intensity within the bronchocele on T1W and T2W modes due 
to mucoid contents; however, it cannot depict regional air-trapping (Matsushima et al., 2003) 
and it does not have the same sensivity as computed tomography to evaluate the lung 
parenchyma (Naidich et al., 1988). So this technique has a limited role in the diagnosis of 
congenital brochial atresia, although a small number of case reports have dealt specifically 
with differential diagnosis and have established its value.  
Magnetic resonance imaging seem to be useful for the evaluation of either anomalous 
vessels or fluid collections that are usually associated with pulmonary abnormalities (Cohen 
et al., 1987). 
5. Bronchoscopy 
Before the advent of computed tomography, the diagnosis of bronchial atresia was made by 
bronchography, which allowed confirmation of the atretic segmental bronchus showing 
non-filling of the involved bronchus. 
Flexible-bronchoscopy identifies blind-ending bronchi. In clinical practice however, any 
absence of a segmental or sub-segmental bronchus that is found by chance during 
bronchoscopy in the absence of the characteristic radiographic features may be considered 
as a normal anatomic variance of the bronchial tree rather than a bronchial atresia.  
In the majority of the cases therefore, congenital bronchial atresia remains a radiological 
diagnosis. 
Some authors suggest that similar findings could be found in other disorders as well, such 
as lung cancer or bronchial adenoma (Jeung et al., 2002; Woodring, 1990). The role of 
bronchoscopy is to exclude these disorders and demonstrate the patency of the central 





6. Lung function tests 
Pulmonary function tests do not aid in diagnosis. They are normal in comparison with the 
magnitude of the radiological abnormality. The most interesting point is the normal 
physiological dead space that implies air trapping in the emphysematous area as a result of 
collateral ventilation that causes the inflation. 
7. Differential diagnosis 
The singular finding of a dilated bronchus due to mucoid impaction (bronchocele) can be 
seen in a variety of conditions apart from bronchia atresia. It is important to differentiate 
between congenital and acquired causes of obstruction (Table 2). 
7.1 Congenital obstructive illnesses 
7.1.1 Lung Aplasia 
Pulmonary agenesis refers to undeveloped pulmonary vessels, bronchi, and parenchyma. It 
may be unilateral or bilateral. In unilateral aplasia, the remaining lung contains twice as 
much alveoli as normal, but has normal bronchi. Although aplasia does not have the same 
structures, it has a rudimentary bronchus. 
Pulmonary aplasia (agenesis) is thought to result from the negative effects that occur in the 
4th week of fetal life. Although its etiology is not fully understood, Vitamin A or folic acid 
deficiency or the use of salicylates may be responsible. The incidence in males and females 
and the occurrence of the anomaly in the right or left lung are about the same.  Hypoplasia 
and aplasia are often observed together with other malformations (diaphragm defects, 
kidney anomalies, extrapulmonary sequestration, muscular or skeletal system defects). 
Nearly one-third of the patients have congenital heart diseases. Although the most common 
is the atrial septal defect, ventricular septal defect, patent ductus arteriosus, or aorta 
coarctation can also be observed. Clinical findings change with the presence of comorbid 
anomalies and their severity. Recurrent infections can increase respiratory dysfunction. 
Although patients with unilateral lung aplasia (agenesis) are believed to die usually in the 
neonatal period, there are patients who live up to adulthood, some of whom are completely 
asymptomatic. In the diagnosis of this condition, methods such as contrast-enhanced CT, 
bronchography, bronchoscopy, pulmonary angiography, and magnetic resonance imaging 
are also employed. 
7.1.2 Congenital Lobar Emphysema 
A congenital lobar emphysema (CLE) refers to an over inflation of one or more lung lobes 
presumably due to various factors including a possible obstructive check valve mechanism 
at the bronchial level. It is more common in males and often detected in neonates or 
identified during in utero ultrasound. Anomalies are rather infrequent. Patients will 
typically have respiratory distress within the first 6 months of life. 
CLE almost always involves one lobe, with rates of occurrence as follows: 41% left upper 
lobe, 34% right middle lobe, 21% right upper lobe. Congenital lobar emphysema has two 
forms of presentation: hypoalveolar: fewer than the expected number of alveoli, and 
polyalveolar: greater than the expected number of alveoli. 
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There are many presumed mechanisms for progressive overdistension of a lobe including 
obstruction, cartilage deficiency, dysplasia, immaturity and idiopathic. It can be associated 
with cardiac anomalies such as: a ventricular septal defect, patent ductus arteriosus and 
tetralogy of Fallot. Congenital lobar emphysema appears in the immediate postpartum 
period. 
Radiography of the chest in anteroposterior and lateral projections identifies the involved 
lobe, the degree of involvement, and the effect on surrounding structures. If a decubitus 
position radiograph is obtained, the involved lung does not collapse. Computed 
tomography scanning can provide details about the involved lobe and its vascularity, as 
well as information about the remaining lung. MRI can be used as an adjunctive modality to 
evaluate vascular supply and distribution to the involved lobe but is not routinely 
employed. In congenital lobar emphysema, the abnormal lobe usually has a normal vascular 
supply. 
7.1.3 Congenital Cystic Adenomatoid Malformation (CAM) 
The first cystic adenomatoid malformation (CAM) was described as a distinct entity by 
Ch'in and Tang in 1949. CAM is a developmental hamartomatous abnormality of the lung, 
with adenomatoid proliferation of cysts resembling bronchioles. CAM represents 
approximately 25% of all congenital lung lesions (Colin et al., 2006). 
CAM is subdivided into three major types: 
 Type I lesions, the most common, are composed of 1 or more cysts measuring 2-10 cm 
in diameter. Larger cysts are often accompanied by smaller cysts, and their walls 
contain muscle, elastic, or fibrous tissue. Cysts are frequently lined by pseudostratified 
columnar epithelial cells, which occasionally produce mucin. Mucinogenic 
differentiation is unique to this subtype of CAM. 
 Type II lesions are characterized by small, relatively uniform cysts resembling 
bronchioles. These cysts are lined by cuboid-to-columnar epithelium and have a thin 
fibromuscular wall. The cysts generally measure 0.5-2 cm in diameter. 
 Type III lesions have the appearance of solid masses without obvious cyst formation 
although adenomatoid cysts can be detected microscopically. 
CAM receives its blood supply from pulmonary circulation and is not sequestered from the 
tracheobronchial tree. However, type II and III lesions can occasionally coexist with extralobar 
sequestration, and in such cases, they may receive a systemic arterial supply. CAM may also 
occur in combination with a polyalveolar lobe. This is a form of congenital emphysema with 
an increased number of alveoli with normal bronchi and pulmonary vasculature. CAM 
usually occurs early in fetal life, whereas the polyalveolar lobe occurs later. 
Prenatal ultrasonography is accurate in diagnosing CAM. Prenatally diagnosed lesions may 
be asymptomatic at birth (71%), and they have normal radiographic findings (57%). A 
concurrent sequestration may not be identified. Usually, radiographic findings are apparent 
in a symptomatic individual, but they may not be as apparent in an asymptomatic child. 
Most often, the diagnosis can be made by using plain radiographs. CT scans may be used for 
confirmation and when planning surgery. Overlapping CT features exist among cases of 





7.1.4 Bronchogenic cysts 
Bronchogenic  cysts are part of a spectrum of congenital abnormalities of the lung including 
pulmonary sequestration, congenital cystic adenomatoid malformation and congenital lobar 
hyperinflation (emphysema). There exists a predilection in all of them for the left upper lobe 
that could be due to the embryologic instability of this area (Sadler, 1990). 
Although relatively rare, cysts represent the most common lesion of the mediastinum. In 
infants and small children, these cysts can be life threatening when they compress vital 
structures. In particular, subcarinal cysts can pose life-threatening airway compromise. In 
infants, the initial presentation may be respiratory distress. More than one half of patients 
are asymptomatic. 
These are usually found using antenatal ultrasonography or routine chest radiography and 
during evaluations for gastro-intestinal or cardiac symptomatology. Bronchogenic cysts are 
the result of anomalous development of the ventral foregut; they are usually single but may 
be multiple and can be filled with fluid or mucus. They have been found all along the 
tracheoesophageal course, in perihilar or intraparenchymal sites, with a predilection for the 
area around the carina. Those in the mediastinum frequently attach to, but do not 
communicate with, the tracheobronchial tree. Bronchogenic cysts have also been described 
in more remote locations, including the interatrial septum, neck, abdomen, and 
retroperitoneal space. Chest pain and dysphagia are the most common symptoms in adults 
with bronchogenic cysts; in infants, symptoms are most often produced as a result of airway 
or esophageal compression. 
Bronchogenic cysts are usually an incidental finding, and differentiating them from other 
pathologic conditions is important. On conventional radiographs, the appearances of 
mediastinal or lung masses are nonspecific and should be evaluated further using computed 
tomography (CT) scanning or magnetic resonance imaging (MRI). Intrapulmonary cysts are 
difficult to diagnose and must usually be aspirated to confirm the diagnosis. 
7.1.5 Anomalous pulmonary venous return 
Abnormal development of the pulmonary veins may result in either partial or complete 
anomalous drainage back into the systemic venous circulation. Three major clinical patterns 
of total anomalous pulmonary venous return (TAPVR) are seen: severe pulmonary venous 
obstruction; early heart failure; mildly symptomatic or asymptomatic. 
7.1.6 Pulmonary sequestration 
Pulmonary sequestration is a cystic or solid mass composed of nonfunctioning primitive 
tissue that does not communicate with the tracheobronchial tree and has an anomalous 
systemic blood supply rather than the pulmonary circulation. In 15-20% of cases multiple 
feeding vessels may be present. The two forms of pulmonary sequestration are 
intrapulmonary, which is surrounded by normal lung tissue, and extrapulmonary, which 
has its own pleural investment. Demonstration of a dominant feeding vessel, usually from 
the aorta or its major vessels, and venous drainage to the pulmonary veins suggests the 
diagnosis. Other congenital malformations may be present. 
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Chest radiographs can provide a reasonable diagnostic clue to pulmonary sequestration. A 
mass in the posterobasal segment of the lung in young patients with recurrent, localized 
pulmonary infections is suggestive of pulmonary sequestration.  Computed tomography 
scanning, angiography, magnetic resonance imaging or bronchography may be helpful in 
excluding other diagnoses. CT scans have 90% accuracy in the diagnosis of pulmonary 
sequestration. Arteriography is helpful in differentiating the lesion from other abnormalities 
of the lung, such as pulmonary arteriovenous fistulae. Magnetic resonance angiography can 
provide information similar to that on CT scans. 
7.1.7 Cystic Fibrosis (CF) 
The name cystic fibrosis refers to the characteristic scarring (fibrosis) and cyst formation 
within the pancreas, first recognized in the 1930s. Difficulty breathing is the most serious 
symptom and results from frequent lung infections that are treated with, though not cured 
by, antibiotics and other medications. A multitude of other symptoms, including sinus 
infections, poor growth, diarrhea, and infertility result from the effects of CF in other parts 
of the body. 
CF is caused by a mutation in the gene for the protein: the cystic fibrosis transmembrane 
conductance regulator (CFTR). This gene is required to regulate the components of sweat, 
digestive juices, and mucus. Although most people without CF have two working copies of 
the CFTR gene, only one is needed to prevent cystic fibrosis. CF develops when neither gene 
works normally and therefore has autosomal recessive inheritance. 
Individuals with cystic fibrosis can be diagnosed before birth by genetic testing, or by a 
sweat test in early childhood. Ultimately, lung transplantation is often necessary as CF 
worsens. CF mainly affects the lungs, pancreas, liver, intestines, sinuses, and sex organs. 
7.2 Acquired obstructive illnesses 
7.2.1 Allergic bronchopulmonary aspergillosis (ABPA) 
Allergic bronchopulmonary aspergillosis (ABPA) can be classified as an eosinophilic 
hypersensitivity disease. It appears concomitantly in patients with long standing asthma, 
and occasionally in patients with cystic fibrosis.  Rarely, it can appear in patients with no 
other identifiable pulmonary illness. In general, patients are diagnosed before the age of 40 
years. 
Clinically, patients have atopic symptoms and they present with recurrent chest infection. A 
clinical staging system has been developed: Stage I Acute, Stage II Remission, Stage III 
Recurrent Exacerbation, Stage IV Steroid-Dependent Asthma and Stage V Pulmonary 
Fibrosis. 
Laboratory findings include elevated Aspergillus specific IgE, elevated precipitating IgG 
against Aspergillus, peripheral eosinophilia and positive skin test. 
In patients with ABPA radiological findings will be reversible after appropriate treatment or 
may show progression from multi-focal and non-segmental consolidations to pulmonary 





7.2.2 Other causes 
Bronchial obstruction may be due to many acquired conditions including inflammatory 
diseases (broncholithiasis and foreign body aspiration), benign neoplastic processes 
(bronchial hamartoma, lipoma, and papillomatosis) and malignancies (bronchogenic 
carcinoma, carcinoid tumor, and metastases) (Gipson et al., 2009; Wilson et al., 2009). They 
can even take place after a segmentectomy as a surgical complication (Okuda et al., 2006). 
All these situations can produce an appearance of a round, oval or branching (glove-finger 
shadow) type of bronchocele. Most of these conditions can be differentiated by appropriate 
history (as all will be symptomatic), the progressive nature of the disease, imaging 
techniques, bronchoscopy and biopsy. 
 




Cystic adenomatoid malformation 
Bronchogenic cysts 
Vascular anomalies: 
Anomalous pulmonary venous return 




Acquired obstructive illnesses Infectious diseases: 
Allergic bronchopulmonary aspergillosis (ABPA) 
Tuberculous bronchoestenosis 
Inflammatory diseases: 
Broncholithiasis, foreign body aspiration 
Benign neoplastic processes: 
Bronchial hamartoma, lipoma, papillomatosis. 
Malignancies: 




Table 2. The differential diagnosis of bronchial atresia. 
8. Treatment of bronchial atresia 
Treatment of bronchial atresia is controversial. The majority of patients are asymptomatic 
and therefore no treatment is necessary. It is currently felt that surgical excision should be 
reserved for patients with secondary complications to the atretic bronchus, such as infection 
or significant compromise of adjacent lung parenchyma. However, some physicians 
advocate performing surgery on all patients because a definitive diagnosis could only be 
made by exeresis of the lung (Cohen et al., 1987). Lobar resection and segmentectomy have 
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been used to preserve as much normal lung parenchyma as possible to maintain pulmonary 
function (Miyahara et al., 1999; Pamer et al., 2008). 
9. Prenatal bronchial atresia 
Antenatal ultrasonography can raise the suspicion of bronchial atresia in the prenatal period 
by the presence of a hyperechogenic mass at the hilum of the lung which corresponds to a 
mucocele (Kamata et al., 2003; McAlister et al., 1987). Those hyperechogenic lesions are 
more likely to regress compared with cystic or mixed lesions (Hadchouel et als. 2011a, 
2011b). 
The routine use of prenatal steroids for microcystic congenital cystic adenomatoid 
malformation seemed to enhance regression (Curran et al., 2010).  There are no documented 
cases on regression of bronchial or lobar bronchial atresia. Despite the lack of evidence, it 
would be advisable to follow an expectant management (Bonnefoy et al., 2011). 
10. Diagnostic algorithm 
 
Fig. 3. Diagnostic algorithm in suspected bronchial atresia. 
11. State of art during the last three years 
Due to a wave of new interest in bronchial atresia among clinicians, there have been many 
more articles and case descriptions published in the last three years than previously. The 





 In asymptomatic patients the bronchial atresia is usually found by chance on a 
radiographic image as described by Psathakis et al. (2009) and Sacristán Bou et al. 
(2010), or sometimes because a patient refers to a shoulder ache, as Hooker & 
Hendriksz (2011) show. 
 Nussbaumer-Ochsner & Kohler (2011) report a 31-year-old HIV-positive man who 
presented with a history of chronic dry cough. They describe the finger-in-glove sign, a 
radiographic feature that refers to mucoid impaction in central airways. 
 Some surgeons like Cappeliez et al. (2009) or Zribi et al. (2011) think that bronchial 
atresia may lead to infectious complications and, in the long term, to damage to the 
adjacent lung parenchyma. Therefore, a surgical resection may be necessary. The first 
group of surgeons reported their experience with three patients (two lobectomies and 
one segmentectomy) and the second group with six. 
 Niimi & Gotoh (2010) present the rare case of pneumothorax due to the perforation of 
bullae associated with congenital bronchial atresia in a 25-year-old woman that 
complained of right chest pain and shortness of breath. A lateral segmentectomy was 
successfully performed by thoracoscopy-assisted limited thoracotomy. Diagnosis of 
congenital bronchial atresia and subpleural bullae were confirmed by pathological 
examination. 
 Discioscio et al (2010), Shimizu et al (2010) and Siddiqui et al. (2011) describe several 
anomalies associated with bronchial atresia like anomalous pulmonary venous return, 
congenital cystic adenomatoid malformation or right-sided descending aorta. 
 Jung et al. (2011) published a case report of a woman with diagnosis of bronchial atresia in 
whom the conversion of epidural analgesia to epidural anesthesia for cesarean delivery 
failed during labor, needing the application of general anesthesia for a successful delivery. 
12. Conclusions 
Bronchial atresia is a congenital abnormality with characteristic radiological features: a 
nodule or a mass like a shadow close to the hilum, with well-defined margins, presenting as 
a tubular, round, ovoid or branching structure and distal oligaemia and hyperinflation. 
When it is required to do differential diagnosis over bronchial obstruction, bronchial atresia 
should be kept in mind. 
Knowledge of this condition in patients with suspected bronchial obstruction would avoid 
unnecessary surgery. Currently, surgical excision is reserved only for patients with 
secondary complications to the atretic bronchus. Most surgeons try to preserve as much 
normal lung parenchyma as possible to maintain pulmonary function, whilst others prefer 
to resect the atretic segment. 
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1. Introduction 
Congenital cystic adenomatoid malformation of the lung is a rare disease that shows 
multiple cystic lesions in pulmonary tissues in the development process. It was first 
described by Chin et al.1 in 1949 and its incidence is known to be 1:25,000 to 1:35,0002. With 
the development of prenatal diagnosis, this disease can be diagnosed in 60% and detected 
within 2 years because of such symptoms as respiratory distress by compression of 
surrounding lung tissues immediately after birth and repeated respiratory infections in 
infancy. Among adults, it is detected accidentally on X-ray or by such symptoms as 
pneumonia, pneumothorax, and hemoptysis. In Korea, the first case in a 28 year-old woman 
was reported by Geun-Heung Ki et al.3 in 1989. Since then, about 25 adult cases were 
reported until 2006.  
Atypical adenomatous hyperplasia is pathologically defined as the proliferation of atypical 
cuboidal or columnar cepithelial cells which are typically 5 mm or smaller in size along the 
alveolus or respiratory bronchiole4,5. In 1999, the WHO classified this disease as a 
precancerous lesion together with squamous dysplasia and diffuse idiopathic pulmonary 
neuroendocrine cell hyperplasia5. It is known to be found in about 12% of lung cancers and 
highly correlated with glandular cancer6. 
2. Case 
Patient: O-Back Kim, Female, 37 
Current case history: The patient had been treated in a private clinic due to purulent sputum 
and cough and hemoptysis which had started two weeks before transfer to our hospital.  
Past case history: The patient had been treated for hyperthyroidism from 1999 to 2003.  
Examination findings: Vital signs were stable. Chest examination detected reduced bilateral 
breathing sounds only. 
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Laboratory findings: The peripheral blood examination found 13.2 g/dL of hemoglobin, 
39.5 % of hematocrit, 5210 /mm3 of white blood cells (neutrophils 43%, lymphocytes 44.5%, 
monocytes 9.2%), and 255,000 /mm3 of platelets. The results of serum biochemical 
examination, hepatitis marker test, urinalysis, mycoplasma antigen test, and pulmonary 
function test were normal. The thyroid function test found minor hypothyroidism with 8.72 
nIU/ml of thyroid stimulating hormone (TSH), 0.894 ng/dl and 1.19ng/ml of free T4 and T3 
respectively. The results of the sputum culture and bronchial washing cytodiagnosis were 
also negative. The results of arterial blood gas analysis which was conducted in atmosphere 
were 7.407 of pH, 41.2 mmHg of carbon dioxide tension, 82.6 mmHg of oxygen tension, 25.4 
mEq/L of bicarbonates, and 96.2% of oxygen saturation. The tumor marker test result was 
also normal with 1.49 ng/mL of CEA and 1.57 ng/mL of cyfra 21-1. 
Chest radiology: The chest X-ray showed a 2.5cm cavitating lesion in the left upper zone. 
(Figure 1).  
 
Fig. 1. Chest PA shows cavitatory lesion in the left upper zone 
On the second day after hospitalization, the chest CT showed a diffuse ground glass 
appearance and cystic lesions that spread in a branching pattern were found in the left lung  
(Figure 2).  
Clinical progress: The patient received symptomatic therapy as there were no features of 
infection. The bronchial endoscopy did not reveal any lesions. The bronchoalveolar lavage 
fluid test found 82% of macrophages, 8% of neutrophils, 0.5% of eosinophils, and 9.5% of 
lymphocytes. Endobronchial lung biopsy was performed at the left lower lobe and only 
chronic inflammatory changes were noted. On the 9th day after hospitalization, a wedge 
resection of the top section of the left upper lobe was performed.  On the 20th day after 
hospitalization, the patient was discharged with no complications.  
Biopsy: The microscopic findings of the resected lung showed cystic lesions of various sizes.  
The cells covering them were diverse, including ciliated pseudostratified columnar cells, 
monolayer columnar cell, and cuboid cells, which corresponded to type 2 of the congenital 
cystic adenomatoid malformation(Figure 3).  
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Fig. 2. Chest CT shows diffuse ground glass opacity and multiple branching cystic lesion in 
left lung  
 
Fig. 3. The lining cells are pseudostratified ciliated columnar cells to columnar and cuboidal 
cells like bronchiolar epithelial cells (H&E, x100).  
As there were minor atypical nuclei locally and linear structures filled with mucus in the 
cytoplasm, it looked similar to the mucoid bronchioloalveolar carcinoma, but because their 
sizes were all smaller than 5mm, they were judged to be atypical adenomatous proliferation 
(Figure 4). 
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Fig. 4. Focal mucinous epithelial lesion with mild atypism is revealed in the intervening 
parenchyma (H&E, x200).  
Treatment and progress: After discharge, the patient was transferred to another hospital at 
her request; As it was checked, she was being followed up with chest CT every 3 months 
with no specific treatment.  
3. Discussion 
The congenital cystic adenomatoid malformation of the lung is very rare and its incidence is 
known to be 1:25,000 - 1:35,0002. The cause is not known, but two hypotheses have been 
suggested: cessation in the development of the lung tissues and no development of aveoli 
during the development process of the respiratory system7,8. The time when the 
malformation occurs is estimated to be between 5 and 6 weeks before the lobe divides and 
prechondrial tissues are formed in the bronchus. It has been reported that it causes stillborn 
and premature infants. Immediately after birth, respiratory distress is frequent in most 
cases, and as the baby grows, repeated infections and pneumothorax are more frequent than 
respiratory distress. Accompanying malformations include kidney growth failure, 
diaphragmatic hernia, jejunul atresia, and colon growth failure1. A histological characteristic 
is the arrangement of polyp-shaped cysts of various sizes in the bronchial epithelium or 
simple columnar epithelium with no cartilaginous tissues or inflammatory reaction.  Stoker 
et al. classified them based on size and pathological findings into type I (only a few large 
thick walled cyst), type II (numerous, evenly spaced cyst, less than 1cm), and type III (less 
numerous, firm and bulky masses) in 1977. In 1994, they re-classified them into 5 types 
based on bronchial invasion: type 0 (bronchial), type I (bronchial/bronchiolar), type II 
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(bronchiolar), type III (bronchiolar/alveolar), and type IV (peripheral). In 1994, they reported 
that type I was the most frequent at 50 - 70% and type III showed the worst prognosis. 
Radiographic diagnoses include chest X-ray test, CT, and prenatal ultrasonography. Among 
them, chest CT can observe lesions that contain cysts with multiple large and small thin walls. 
It must be differentiated from pneumonia accompanied by pneumatosis, pulmonary 
sequestration, congenital lobar emphysema, and bronchiectasis. Definite diagnosis is only 
possible by pathological tests. Some claim that it is associated with malignant tumors of the 
lung. There was a report of pulmonary rhabdomyosarcoma in 22-month old boy, and several 
papers reported the accompaniment of mucoid bronchioloalveolar carcinoma in adults and 
children3,9. Hence, Ioachimescu et al.9 recommended surgical removal even if there were no 
symptoms, because it may become malignant. 
 Pathological findings in this patient were accompanied by atypical adenomatous 
hyperplasia. Atypical adenomatous hyperplasia is pathologically defined as the 
proliferation of atypical cuboidal epithelial cells or columnar epithelial cells along the 
alveolus or respiratory bronchiole4. Their sizes are mostly 5 mm or smaller, although a size 
of 19mm has been reported. As it is difficult to differentiate from bronchioloalveolar 
carcinoma, one researcher suggested 5 mm as the reference size for differentiation. It occurs 
in up to 5% of normal people and is usually asymptomatic. It is known to develop in 2.9% of 
total population and increases to 10 - 23.2% in lung cancer 11,12,13,14,15. The recent diagnostic 
rate is increasing due to low dose chest CT as a lung cancer screening test. Although there 
are no specific CT findings, the most frequent finding are nodules with a good boundary 
accompanied by a ground glass apperance10. In 1999, the WHO classified this disease as a 
precancerous lesion together with squamous dysplasia and diffuse idiopathic pulmonary 
neuroendocrine cell hyperplasia5. Chapman et al.6 analyzed the pathological findings of 554 
patients with primary lung cancer and found that atypical adenomatous hyperplasia was 
accompanied in 67 cases (12.1%), and that the percentage of glandular cancer was the 
highest (glandular cancer 23.2%, giant cell undifferentiated cancer 12.5%, epithelial 
carcinoma 2.2%). There are many different opinions among pathologists and no established 
views on the differentiation level of atypical adenomatous hyperplasia, classification based 
on this, and its relationship with adenocarcinoma. However, there are some reports related 
to morphological changes of the nuclei, expression of Ki-67 and p53, and K-ras mutation, 
which are expected to be helpful for better investigation of the characteristics of atypical 
adenomatous hyperplasia as a precancerous lesion5,10. As there are no principles in therapy 
yet, careful follow-up is needed.  
Although there is controversy about the treatment of this patient, the authors believe that 
pneumonectomy of the left lung will be necessary because the patient has both congenital 
cystic adenomatoid malformation which can be accompanied by bronchioloalveolar 
carcinoma and atypical adenomatous hyperplasia which is a precancerous lesion.   
After a literature review, it is believed that this is the first case report of congenital cystic 
adenomatoid malformation accompanied by atypical adenomatous hyperplasia. 
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